

SCIENTIFIC REPORT 2024

CONTENTS

LETTER FROM THE SCIENTIFIC MANAGEMENT 5

1. INTRODUCTION 9

2. GOVERNING AND ADVISORY BODIES 13

3. ORGANIZATIONAL STRUCTURE 17

 3.1. SCIENTIFIC AREAS 19

 3.2. HUMAN RESOURCES 28

4. SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA 33

 4.1. SCIENTIFIC PRODUCTION. BIBLIOMETRIC INDICATORS 34

 4.2. CLINICAL PRACTICE GUIDELINES 40

 4.3. RESEARCH PROJECTS 47

 4.4. HUMAN RESOURCES 52

 4.5. RICORS, RETICS, INTERNATIONAL NETWORKS, AND ISCIII & CIBER PLATFORMS 59

 4.6. CLINICAL TRIALS 65

 4.7. INNOVATION AND TRANSFER 69

 4.8. CLINICAL PRACTICE GUIDELINES IMPLEMENTED IN HEALTHCARE CENTERS 76

5. RESEARCH AREAS AND GROUPS 81

 5.1. PRIORITY SCIENTIFIC AREAS 82

 5.2. RESEARCH GROUPS 99

6. FUNDING 255

7. EDUCATION 263

8. COMMUNICATIONS 273

9. COMMON RESEARCH SUPPORT SERVICES (ECAI) 281

ANNEXES

 PUBLICATIONS 316

 COMPETITIVE RESEARCH GRANTS IN 2024 526

 CLINICAL STUDIES ACTIVE IN 2024 604

LETTER FROM THE SCIENTIFIC MANAGEMENT

LETTER FROM THE SCIENTIFIC MANAGEMENT



This year, IBIMA has consolidated our multidisciplinary character and strengthened our commitment to care with the aim of directly transferring scientific advances to the improvement of healthcare. One example of this is the celebration of the Primary Care Day and Care Day, meeting points for the promotion of innovation in daily clinical practice.

IBIMA Plataforma BIONAND's plan, which is in its fifth edition in 2024, has become one of the most highly valued initiatives by the Institute's professionals. This program reflects our firm commitment to promoting scientific quality, the transfer of results, and the visibility of the work carried out by our research groups.

IBIMA Plataforma BIONAND's scientific production continues to grow, with more than 884 scientific articles (773 original works and 111 reviews) in JCR indexed journals and 32 clinical practice guidelines and consensus documents and an increasing percentage of open access publications (77% in total). This contributes to the impact and visibility of research, thus promoting scientific collaboration. In addition, the percentage of publications in Q1 journals has increased from 45% in 2023 to 65% in 2024.

In terms of funding, we have been awarded €32 million for health research projects, an increase of €2 million over 2023. During the fiscal year, 366 projects funded in regional, national, and international competitive calls for proposals were conducted and funding was obtained for 69 new projects.

In the international scope, we obtained €2.4 million in European calls for proposals and were awarded two new Marie Skłodowska-Curie Actions

(MSCA-PF) grants, reinforcing our commitment to attracting talent. In addition, we actively participate in 8 RICORS networks, 34 COST actions, 7 CIBER, and 4 platforms of the Carlos III Institute of Health.

Another strategic area that is experiencing clear growth is clinical trials. There were 1,286 active studies in 2024, an increase of 7% over the previous year.

This year has also been marked by the celebration of emblematic scientific, institutional, and social initiatives. These included the Farmaindustria Conference, the recognition obtained with the Unicaja Foundation Award for Innovation in Biomedicine and Health, and the II IBIMA Plataforma BIONAND Soccer Tournament which, together with the I Charity Run against Obesity, raised close to €30,000 to promote new research projects.

Our commitment to society has also materialized in outreach and open doors days. We have welcomed schoolchildren, professionals, patient associations, and biotechnology companies with the aim of bringing science closer to the public and involving them in the work carried out in our laboratories and scientific platforms.

In conclusion, 2024 has been a year of consolidation and growth for IBIMA Plataforma BIONAND. Thanks to our joint efforts, we continue to set new objectives and goals that will allow us to maintain our position as a benchmark health research institute with a cutting-edge, innovative approach that is focused on a real impact on people's health.

Francisco J. Tinahones Madueño
Scientific Director of IBIMA Plataforma BIONAND

INTRODUCTION

1



The following report summarizes the scientific activity conducted by the Biomedical Research Institute of Málaga and Nanomedicine Platform, IBIMA Plataforma BIONAND, in 2024.

The institute's **mission** is to **develop and promote a multidisciplinary scientific space** for R&D&i of excellence in the field of biomedicine and nanomedicine aimed at industrial transfer and the translation into clinical practice in Málaga. The institute is centered around the Regional and Virgen de la Victoria University Hospitals in Málaga together with primary care centers and University of Málaga biotechnology groups.

It is the institute's intention to **integrate** the talent, structures, and centers dedicated to biomedical research in order to promote scientific and technological **innovation, inspire** the research callings of new professionals, attract talent, and provide training.

The **vision** of IBIMA Plataforma BIONAND **as a biomedical research institute is to be a proactive and innovative organization, a national and European point of reference that aims to offer the best possible research at all times.** This vision means the institute is:

- Focused on the organization and structuring of the research system, with knowledge applied to health at the center of the system.
- Attentive to the reality that surrounds the institute in order to take advantage of the possibilities for development arising from the opportunities that surround it and to successfully face threats by joining European knowledge and development networks.
- Actively involved in achieving the sustainability of the system, characterized by quality, efficiency, and effectiveness.
- Willing to continuously incorporate innovation (social, organizational, and technological) as an element of efficiency and good results from the Institute.
- Integrated among all the agents involved in the health and research systems with its own identity that is in consonance with the rest of the agents.

The IBIMA Plataforma BIONAND has been accredited as a Health Research Institute by the Carlos III Institute of Health since January 15, 2015 and was reaccruited on January 15, 2025 according to Royal Decree 279/2016, of June 24. The legal ownership of the institute belongs to the Foundation for Health and Biomedicine Research in Málaga (FIMABIS).

GOVERNING AND ADVISORY BODIES

2

The governing bodies of the IBIMA Plataforma BIONAND institute are the Board of Directors and the Delegated Commission, as collegiate bodies, and the Scientific Directorate, Scientific Vice-Directorate, and Management as individual bodies. The advisory bodies of the institute are the External Scientific Committee, the Internal Scientific Committee, and the Senate.

In addition, various committees have been organized to ensure compliance with the plans and policies approved by the Board of Directors: **Training and Postgraduate Commission, Innovation Commission, Quality Commission, Infrastructure Commission, and Equality Commission.**

The IBIMA Plataforma BIONAND **Board of Directors** is the institute's highest governing body. Its nature and role are defined by the Collaboration Agreement between the Regional Ministry of Health and Consumer Affairs; the Regional Ministry of Economic Transformation, Industry, Knowledge, and Universities; the University of Málaga; the Andalusian Health Service; and the Andalusian Public Foundation FIMABIS for the conduct of biomedical research in Málaga that was signed on December 30, 2021. The Board of Directors comprises the following members:

- Two representatives from the Regional Ministry of Health and Consumer Affairs of the Autonomous Government of Andalusia.
- Two representatives from the Regional Ministry of Economic Transformation, Industry, Knowledge, and Universities of the Regional Government of Andalusia, one of which belongs to the Andalusian Health Service.
- Two representatives from the University of Málaga.

The Scientific Directorate, the Scientific Vice-Directorate, and the Management of the IBIMA Plataforma BIONAND as well as a representative of the Andalusian Public Foundation for Progress and Health, as the central research support and management entity of the Regional Ministry of Health and Consumer Affairs, will be non-voting members in order to coordinate with the general and sectoral strategies for research, development, and innovation.

The **Delegated Commission** is an entity aimed at providing the institute with greater agility in decision-making in the periods between Board of Directors meetings. It was created by virtue of a resolution of the Board of Directors dated 11/24/2014. It comprises the following members:

- A representative of the Regional Ministry of Health and Consumer Affairs of the Autonomous Government of Andalusia or, if applicable, the regional ministry with authority in health matters, designed by the person in charge of the regional ministry.
- A representative of the Regional Ministry of Universities, Research, and Innovation of the Autonomous Government of Andalusia or, if applicable, the regional ministry with authority in research matters, designed by the person in charge of the regional ministry.
- A representative of the University of Málaga appointed by the Dean of the University of Málaga.

The Scientific Directorate, the Scientific Vice-Directorate, and the Management of the IBIMA Plataforma BIONAND as well as a representative of the Andalusian Public Foundation for Progress and Health will be non-voting members.

The **External Scientific Committee** is an advisory body for the institute that oversees its scientific quality and advises the Scientific Directorate and the Board of Directors, with independent judgment and autonomy for decision-making. It is formed of highly qualified professionals with recognized experience in the field of research.

The External Scientific Committee was proposed and approved at the institute's first Board of Directors meeting in July 2012 and was updated in 2024. Current members include:

- **Carlos Diéguez González.** Full Professor of Physiology. University of Santiago de Compostela. Chair.
- **Mariano Esteban Rodríguez.** Department of Molecular and Cellular Biology. National Centre for Biotechnology (CSIC).
- **Rafael Bañares Cañizares.** Chief of the Gastrointestinal Medicine Department. Gregorio Marañón University General Hospital. Madrid. Former Scientific Director of the Gregorio Marañón Health Research Institute (2011-2015)
- **Pablo Lapunzina Badía.** Coordinator of the Institute of Medical and Molecular Genetics (INGEMM) of the La Paz University Hospital Research Institute (IdiPaz) and Scientific Director of CIBER-ER.
- **Eva Carmona Porquera.** Researcher at the Mayo Clinic. Rochester, Minnesota, USA.
- **María Vallet Regí.** Full Professor of Inorganic Chemistry and Director of the Department of Inorganic and Bioinorganic Chemistry, School of Pharmacy, Complutense University of Madrid.
- **Pilar Marco Colás.** Institute for Advanced Chemistry of Catalonia (IQAC, CSIC, Barcelona).
- **Jesús Jiménez Barbero.** Institute of Organic Chemistry of the CSIC and Scientific Director of the Center for Cooperative Research in Biosciences (CIC bioGUNE, Bilbao, Spain).
- **Laura Lechuga Gómez.** Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, and CIBER-BBN.
- **Lina Badimon.** Cardiovascular Research Center CSIC-ICCC, Santa Creu i Sant Pau Hospital, (CIC, Barcelona).
- **Luis García Ortiz.** Scientific Director of the Biomedical Research Institute of Salamanca (IBSAL), Primary Care Research Unit of Salamanca (APISAL).


The **Internal Scientific Committee** is an advisory body to the Scientific Directorate on all scientific and organizational matters at the institute. Its decisions are non-binding. It is constituted at the proposal of the Scientific Directorate and ratified by the Board of Directors. It includes the following members:

- Scientific Directorate of IBIMA Plataforma BIONAND.
- Scientific Vice-Directorate of IBIMA Plataforma BIONAND.
- Management of IBIMA Plataforma BIONAND.
- A representative from the Virgen de la Victoria University Hospital management and a representative from the Regional University Hospital of Málaga management.
- A representative from the University of Malaga.
- A representative from Primary Care.
- The coordinators of the IBIMA Plataforma BIONAND scientific areas.
- A representative from the Training and Postgraduate Commission.
- A representative from the Quality Commission.
- A representative from the postdoctoral researchers and a representative of the predoctoral researchers.
- A representative of the technical staff of the research support units.

ORGANIZATIONAL STRUCTURE

3

The IBIMA Plataforma BIONAND institute is divided into 2 research programs; 7 scientific areas, 2 of which are multidisciplinary; and one research unit. The organization chart is as follows:



3.1. SCIENTIFIC AREAS & RESEARCH UNITS

Preclinical and Clinical Research Program:

- Area 1. **Cardiovascular diseases, obesity, and diabetes. Environmental Determinants and Lifestyle.**
Coordinator. Ricardo Gómez Huelgas
Deputy Coordinator. M. Rosa Bernal López
- CIMO Onco-Hematology Unit
Coordinator. Melissa García Caballero
Deputy Coordinator. Elisa Matas Rico
- Area 3. **Neurosciences, Chronicity, Aging, and Health in Vulnerable Populations.**
Coordinator. Antonia Serrano Criado
Deputy Coordinator. Patricia Moreno Peral
- Area 4. **Autoimmune diseases, infectious diseases, inflammation, and allergies.**
Coordinator. Lina Mayorga Mayorga
Deputy Coordinator. Natalia Mena Vázquez

Nanomedicine Research Program:

- Area 7. **Nanodiagnostics.**
Coordinator. María Luisa García Martín
- Area 8. **Nanosystems and Advanced Therapies.**
Coordinator. Elena González Muñoz

and two multidisciplinary areas:

- Area 5. **Rare: Rare diseases.**
Coordinator. Raquel Yahyaoui Macias
Deputy Coordinator. Juan Antonio García Ranea
- Area 6. **Tech: Health Technology and Innovation Area.**
Coordinator. Antonio I. Cuesta Vargas
Deputy Coordinator. Francisco Ángel Moreno Dueñas

These areas comprise the 78 research groups that formed the Institute in 2024: 47 consolidated, 21 emerging, and 10 associated research groups from the different institutions that make up the IBIMA Plataforma BIONAND. In addition, 7 associated external groups participate.

The distribution of the groups by areas and categories is as follows:




Figure 1: Consolidated, emerging, and associated groups by scientific areas

The list of each research area and group with their Lead Researchers (LR) and Co-Lead Researchers (Co-LR) are as follows:

Area 1. Cardiovascular diseases, obesity, and diabetes. Environmental Determinants and Lifestyle.

Consolidated groups:

Code	LR/Co-LR	Group Name
A-01	LR Gabriel Oliveira Fuster Gabriel. Co-LR Javier Bermúdez Silva	ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY
A-02	LR Francisco Tinahones Madueño. Co-LR Manuel Macías González. Co-LR Isabel Moreno Indias	OBESITY, DIABETES, AND THEIR COMORBIDITIES: PREVENTION AND TREATMENT.
A-03	LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón	CARDIOVASCULAR RESEARCH FOR HEALTH
A-06	LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal	DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.

Code	LR/Co-LR	Group Name
A-07	LR José Antonio González Correa. Co-LR José Pedro de la Cruz Cortés	TRANSLATIONAL RESEARCH IN CARDIOVASCULAR DISEASE
A-09	LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares.	RESEARCH IN ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.
A-10	LR Julia Warnberg. Co-LR Napoleón Pérez Farinós	EPIDEMIOLOGY, PHYSICAL ACTIVITY, ACCELEROMETRY, and NUTRITION (EpiPHAAN).
A-17	LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero	ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.
A-19	LR Isabel Leiva Gea, Co-LR David Moreno Pérez, Co-LR Juan Pedro López-Siguero	MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP
A-21	LR José Luis Guerrero Orriach. Co-LR José Cruz Mañas	RESEARCH ON ORGAN PROTECTION IN THE PERIOPERATIVE PERIOD OF HEART SURGERY
A-23	LR. Mario Gutiérrez Bedmar. Co-LR Rosa López Gigosos	PREVENTIVE MEDICINE AND PUBLIC HEALTH

Emerging groups:

Code	LR/Co-LR	Group Name
AE-11	LR. Verónica López Jiménez. Co-LR Juana Alonso Titos.	NEPHROLOGY AND RENAL TRANSPLANTATION

Associated groups:

Code	LR/Co-LR	Group Name
AA-04	LR María Antonia Estecha Foncea	INTENSIVE CARE MEDICINE
AA-15	LR Cristobal Urbano Carrillo	HEART AND VASCULAR DISEASE
AA-20	LR Cipriano Viñas. Co-LR Antonio Jesús Núñez Montenegro	RESEARCH GROUP ON CARE IN MÁLAGA (INVESCUIDA)
AA-22	LR Eduardo Sánchez Guerrero	BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX HEALTH SYSTEM PROCESSES

External associated groups:

Code	LR/Co-LR	Group Name
AA-24	LR: Miguel Ángel García Ordóñez. Co-LR: Jesus Olmedo Llanes	VASCULAR RISK AND CHRONIC DISEASES
AA-25	Néstor Oliva Damaso	NEFROCONSULTOR

CIMO Onco-Hematology Unit

Consolidated groups:

Code	LR/Co-LR	Group Name
B-01	LR Emilio Alba Conejo	CLINICAL AND TRANSLATIONAL RESEARCH IN CANCER
B-04	LR Miguel Ángel Medina Torres	MOLECULAR BASIS OF BIOLOGICAL SYSTEMS (SIBIUMA)
B-05	LR Antonio Rueda Domínguez. Co-LR. Isabel Barragan Mallofret	TRANSLATIONAL RESEARCH IN CANCER IMMUNOTHERAPY AND EPIGENETICS
B-07	LR Javier Márquez Gómez. Co-LR José Manuel Matés Sánchez	CANCEROMICS
B-10	LR María Victoria de Gálvez Aranda. Co-LR Enrique Herrera Acosta	SKIN CANCER
B-11	LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico	TRANSLATIONAL RESEARCH GROUP IN GENITOURINARY TUMORS
B-12	LR José Manuel Jerez Aragonés	COMPUTATIONAL INTELLIGENCE IN BIOMEDICINE
B-22	LR: Manuel Cobo Dols. Co-LR Inmaculada Ales Diaz	EMERGING ANTITUMOR ADAPTATION THERAPIES

Emerging groups:

Code	LR/Co-LR	Group Name
BE-03	LR Francisco José López Jaime	HEMATOLOGY AND HEMOTHERAPY
BE-15	LR Isabel Hierro. Co-LR Rafael E. Carvia Ponsaillé	ANATOMICAL PATHOLOGY
BE-17	LR Jaime Gómez-Millán Barrachina. Co-LR María Jesús García Anaya	CLINICAL, MOLECULAR, AND TECHNOLOGICAL RESEARCH IN RADIOTHERAPEUTIC ONCOLOGY
BE-18	LR Melissa García Caballero	VASCULAR BIOLOGY, TUMOR MICROENVIRONMENT & TARGET DISCOVERY
BE-19	LR Miguel José Ruiz Gómez	RADIOBIOLOGY
BE-21	LR Regina García Delgado. Co-LR Alejandro Escamilla Sánchez	HEMATOLOGY AND IMMUNOLOGY
BE-23	LR: Miguel Ángel Berciano Guerrero. Co-LR Julia Alcaide García.	NEW HORIZONS FOR ONCOLOGY PATIENTS

Associated groups:

Code	LR/Co-LR	Group Name
BA-16	LR Adolfo Romero Ruiz	QUALITY AND SAFETY IN LABORATORY AND HEMATOLOGY CARE
BA-20	LR. Jorge Contreras Martínez	ONCOLOGY AND BENIGN PATHOLOGY

External associated groups:

Code	LR/Co-LR	Group Name
BA-14	LR Maximino Redondo Bautista. Co-LR Marilina García Aranda	TRANSLATIONAL RESEARCH GROUP IN CANCER AND OTHER PREVALENT CHRONIC DISEASES

Area 3. Neurosciences, Chronicity, Aging, and Health in vulnerable populations

Consolidated groups:

Code	LR/Co-LR	Group Name
C-01	LR Pedro Serrano Castro. Co-LR Guillermo Estivill. Co-LR Laura Leyva	NEUROIMMUNOLOGY AND NEUROINFLAMMATION
C-02	LR Juan Ángel Bellón Saameño. Co-LR Patricia Moreno Peral	MENTAL HEALTH, SERVICES, AND PRIMARY CARE (SAMSERAP).
C-03	LR José Guzmán Parra. Co-LR Jessica Goodman Casanova	BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP
C-05	LR Antonio J. Jiménez Lara	DEGENERATION AND REGENERATION OF THE CENTRAL NERVOUS SYSTEM
C-06	LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez	NEUROPSYCHOPHARMACOLOGY
C-07	LR José Ángel Narváez Bueno	BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES
C-08	LR Francisca Leiva Fernández. Co-LR: Antonio García Ruiz	MAEPAP. MULTIMORBIDITY, ADHERENCE, ECONOMIC EVALUATION, AND PALLIATIVE CARE IN PRIMARY CARE
C-09	LR Antonia Gutiérrez Pérez	NEUROPATHOLOGY OF ALZHEIMER’S DISEASE (NEUROAD)
C-11	LR María Carmen Ramírez Maestre	VULNERABILITY AND RESILIENCE TO CHRONIC PAIN: IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTION
C-12	LR Guadalupe Dávila Arias	COGNITIVE NEUROSCIENCE: APHASIA AND RELATED DISORDERS (UNCA)
C-13	LR José Miguel Morales Asencio	CHRONICITY, DEPENDENCY, CARE, AND HEALTH SERVICES
C-16	LR Ernesto González Mesa. Co-LR Jesús Salvador Jiménez López	MATERNAL-FETAL MEDICINE, EPIGENETICS, WOMEN’S HEALTH CONDITIONS, AND REPRODUCTIVE HEALTH RESEARCH GROUP

Emerging groups:

Code	LR/Co-LR	Group Name
CE-17.	LR. Carmen Ortiz García. Co-LR Ángela García de la Torre. Co-LR Begoña Mora Ordoñez	TECHNOLOGY AND INNOVATION IN EMERGENCY DEPARTMENTS AND HOSPITALIZATION
CE-18.	LR. Stella Martín de las Heras	FORENSIC MEDICINE, TOXICOLOGY, AND FORENSIC ODONTOLOGY
CE-20	LR Carlos Rocha de Lossada	OPHTHALMOLOGY
CE-21	LR: Marina García Gámez	FRAILITY, AGING, COMPLEX CHRONICITY, AND TEACHING.

Associated groups:

Code	LR/Co-LR	Group Name
CA-10.	LR Francisco J. López Gutiérrez	CAUSAL COGNITION GROUP

External associated groups:

Code	LR/Co-LR	Group Name
CA-14.	LR Maria Dolores Martín Escalante. Co-LR Julián Olalla Sierra	CHRONIC DISEASES AND AGING
CA-15.	LR Rafael Gómez García. Co-LR Pilar Barnestein Fonseca	PALLIATIVE CARE
CA-19.	LR. Antonia Fernández Luque. Co-LR Fernando Zubeldia Santoyo	DigCompSalud. Digital competence for lifelong learning

Area 4. Autoimmune diseases, infectious diseases, inflammation, and allergies.

Consolidated groups:

Code	LR/Co-LR	Group Name
D-01.	LR Jesús Santos González. Co-LR Rosario Palacios Muñoz	CLINICAL RESEARCH GROUP ON HIV INFECTION, ENDOVASCULAR INFECTION, AND BACTEREMIA
D-03.	LR Antonio Fernández Nebro. Co-LR Natalia Mena Vázquez	INFLAMMATORY AND AUTOIMMUNE DISEASES
D-04	LR María José Torres Jaén. Co-LR: Lina Mayorga Mayorga	ALLERGIC DISEASES TO DRUGS AND ALLERGENS
D-05	LR Raúl J. Andrade Bellido, Co-LR Eduardo Garcia Fuentes, Co-LR Mercedes Robles Díaz	HEPATOASTROENTEROLOGY, PHARMACOLOGY, AND TRANSLATIONAL CLINICAL THERAPEUTICS

Emerging groups:

Code	LR/Co-LR	Group Name
DE-02	LR José María Reguera	GROUP FOR THE STUDY OF INFECTIOUS DISEASES
DE-07	LR Manuel Enrique Herrera Gutierrez. Co-LR Emilio Curiel Balsera	INFLAMMATION IN CRITICALLY ILL PATIENTS
DE-08	LR Miguel Jiménez Pérez. Co-LR Julio Santoyo Santoyo	HEPATOASTROENTEROLOGY, ENDOSCOPY, AND GASTROINTESTINAL SURGERY
DE-09	LR Juan José Borrego García. Co-LR José Manuel Jiménez Guardeno	IMMUNE RESPONSE TO VIRAL INFECTIONS.
DE-10	LR Rafael Luque Aranda. Co-LR Carmen Alba Linero	OPHTHALMOLOGY

Associated groups:

Code	LR/Co-LR	Group Name
DA-06	LR Rosa García Portales	IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMID)

Area 5. IBIMA RARE. Multidisciplinary

Code	LR/Co-LR	Group Name
A-01	LR Gabriel Oliveira Fuster Gabriel. Co-LR Javier Bermúdez Silva	ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY
A-03	LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas. Co-LR Francisco Javier Pavón Morón	CARDIOVASCULAR RESEARCH FOR HEALTH
A-06	LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal	DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.
A-09	LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares.	RESEARCH IN ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.
A-17	LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero	ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.
A-19	LR Isabel Leiva Gea, Co-LR David Moreno Pérez, Co-LR Juan Pedro López-Siguero	MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP
AA-22	LR Eduardo Sánchez Guerrero	BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX HEALTH SYSTEM PROCESSES
B-04	LR Miguel Ángel Medina Torres	MOLECULAR BASIS OF BIOLOGICAL SYSTEMS (SIBIUMA)
B-11	LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico	TRANSLATIONAL RESEARCH GROUP IN GENITOURINARY TUMORS

Code	LR/Co-LR	Group Name
BE-21	LR Regina García Delgado. Co-LR Alejandro Escamilla Sánchez	HEMATOLOGY AND IMMUNOLOGY
C-01	LR Pedro Serrano Castro. Co-LR Guillermo Estivill, Co-LR Laura Leyva	NEUROIMMUNOLOGY AND NEUROINFLAMMATION
C-03	LR José Guzmán Parra. Co-LR Jessica Goodman Casanova	BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP
C-06	LR Fernando Rodríguez de Fonseca. Co-LR Antonia María Serrano Criado. Co-LR Juan Suárez Pérez	NEUROPSYCHOPHARMACOLOGY
C-07	LR José Ángel Narváez Bueno	BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES
FA-07	LR Antonio Leiva Gea	RESEARCH IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY
H-02	LR Iván Durán Jiménez. Co-LR Fabiana Csukasi	Laboratory of Skeletal Biomedicine/Laboratorio de Biomedicina del esqueleto

Area 6. IBIMA Tech: Health Technology and Innovation Area

Consolidated groups:

Code	LR/Co-LR	Group Name
F-02	LR Ezequiel López Rubio	COMPUTATIONAL INTELLIGENCE AND IMAGE ANALYSIS
F-03	LR Iñigo Molina Fernández	COMMUNICATIONS ENGINEERING
F-04	LR Javier González Jiménez. Co-LR Francisco Ángel Moreno Dueñas	MAPIR (MACHINE PERCEPTION AND INTELLIGENT ROBOTICS GROUP)
F-05	LR. Víctor Fernando Muñoz Martínez	MEDICAL ROBOTICS
F-09	LR Fernando Vidal Verdú	ELECTRONICS FOR INSTRUMENTATION AND SYSTEMS.
F-10	LR Ezequiel Pérez Inestrosa. Co-LR Francisco Nájera Albendín	BIOMIMETIC DENDRIMERS AND PHOTONIC LABORATORY
F-14	LR Antonio Ignacio Cuesta Vargas. Co-LR Ismael Navas Delgado	CLINIMETRICS IN PHYSICAL THERAPY
F-15	LR José F. Aldana Montes	DATA AND KNOWLEDGE MANAGEMENT, INTEGRATION, AND ANALYSIS (KHAOS)
F-19	LR José Ignacio Peláez Sánchez	ARTIFICIAL INTELLIGENCE AND SOCIAL RESEARCH

Emerging groups:

Code	LR/Co-LR	Group Name
FE-17	LR Raquel Cantero Téllez. Co-LR Javier García Orza	HandResearchTeam
FE-18	LR Lorena Aguilar Cano. Co-LR Francisco Luna Cabrera	REHABILITATION, INNOVATION, AND QUALITY OF LIFE
FE-20	LR Francisco Sendra Portero	ARTIFICIAL INTELLIGENCE IN MEDICAL IMAGING

Associated groups:

Code	LR/Co-LR	Group Name
FA-07	LR Antonio Leiva Gea	RESEARCH IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY
FA-08	LR Alfonso Gago Calderón	OTOTECH

External associated groups:

Code	LR/Co-LR	Group Name
FA-16	LR Enrique Guerado Parra	INNOVATIVE THERAPIES AND NEW TECHNOLOGIES IN THE MUSCULOSKELETAL SYSTEM

Area 7. Nanodiagnostics

Consolidated groups:

Code	LR/Co-LR	Group Name
G-01.	LR María Luisa García Martín	BIOMEDICAL MAGNETIC RESONANCE LABORATORY (BMRL)

Area 8. Nanosystems and advanced therapies

Consolidated groups:

Code	LR/Co-LR	Group Name
H-02	LR Iván Durán Jiménez. Co-LR Fabiana Csukasi	LABORATORY OF SKELETAL BIOMEDICINE/ LABORATORIO DE BIOMEDICINA DEL SKELETO
H-03	LR Jose María Pérez Pomares	DEVELOPMENT AND CARDIOVASCULAR DISEASE

Emerging groups:

Code	LR/Co-LR	Group Name
HE-01	LR Elena González Muñoz	CELL REPROGRAMMING (iPSCs) AND DISEASE CELL MODELS FOR BIOMEDICAL APPLICATIONS

The **objectives of the scientific areas** and their research groups are explained in the 2023-2027 strategic plan and in the cooperative scientific plan with the general objective of fostering synergies between the institute's research groups by promoting inter-institutional, inter-area, and intra-area collaboration.

The IBIMA Plataforma BIONAND areas have proposed the following specific objectives:

- Increase scientific production and the conduct of projects resulting from collaboration among the Institute's groups.
- Promote collaborative translational research with results close to the market.
- Comply with new strategies and policies on Open Science.

The extent to which the annual objectives have been met is measured every six months and submitted to the Board of Directors. The following sections of this report describe the results achieved for the year 2024.

3.2. HUMAN RESOURCES

In 2024, the IBIMA staff consisted of a total of 1,443 professionals, including researchers (1,214), support technicians (191), and managers (38).

DISTRIBUTION OF PERSONNEL BY GENDER




Figure 2: Number of professionals by category and gender in 2024

PERSONNEL BY CATEGORY




Figure 3: Percentage of professionals by category in 2024

In 2024, IBIMA Plataforma BIONAND implemented the actions planned according to its Human Resources Strategy for Researchers (HRS4R). The strategy was launched 2017 after obtaining the “HR Excellence in Human Resources” recognition awarded by the European Commission.



HR EXCELLENCE IN RESEARCH

IBIMA's HRS4R action plan is aligned with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers with the aim of improving the working and employment conditions of researchers with open, transparent, and merit-based recruitment and hiring practices.

The distribution of IBIMA Plataforma BIONAND personnel by gender and category and according to the European classification of research profiles R1 – R4 (<https://euraxess.ec.europa.eu/europe/career-development/training-researchers/research-profiles-descriptors>) is as follows:

IBIMA PERSONNEL




Figure 4: IBIMA Plataforma BIONAND personnel in 2024 by category (Euraxess) and gender

Of the 1,214 researchers who formed part of the Institute in 2024, 208 were R1 researchers, 173 were R2 researchers, 705 were R3 researchers, and 128 were R4 researchers, according to the European classification of research profiles. Of the total, 46% (561) were men and 54% (653) were women.




Figure 5: IBIMA Plataforma BIONAND researchers according to the European classification of researchers

Research group leaders (LR and/or Co-LR by gender):




Figure 7: Research group leaders (LR/Co-LR) by gender

In addition, 61% of researchers have clinical practice activity (figure 8).




Figure 8: Distribution of researchers according to clinical practice activity




Figure 6: IBIMA Plataforma BIONAND Researchers according to European classification of researchers and gender

The institute's management personnel are organized into **Research Support Units (RSU)**, whose functions include supporting the institute's scientific objectives through its managing entity FIMABIS:

- Advisory service for fundraising and establishing collaborations.
- Fund management service for R&I activities.
- International project advisory service.
- Clinical trials management service.
- Methodological and statistical support service.
- Advisory and management service for the protection, transfer, and dissemination of results.
- Communication to society and event coordination.
- Management of healthcare research centers and institutes linked to the Andalusian Public Healthcare System.



SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA

4.1. SCIENTIFIC PRODUCTION. BIBLIOMETRIC INDICATORS

To calculate the bibliometric indicators published in this report, only original research articles and review articles published in journals with an impact factor that are indexed in the 2023 edition of the Journal Citation Report (JCR), the most recent edition available at the time of writing this report, have been considered. All other types of documents, including editorial material, letters, meeting abstracts, erratum, and advance publications (in press online ahead of print and early access), have been excluded.

The evolution of overall scientific production from the IBIMA Plataforma BIONAND over the last 5 years is shown in the following figure. It includes the number of publications according to the type of document. An upward trend can be observed, with 884 publications from the institute in 2024: 773 original articles and 111 reviews.




Figure 9: Changes in the number of publications by document type in the last five years

The percentage of each type of document in 2024 is shown in the following figure. Original articles represent 87% of the institute's scientific production and the rest are review articles:




Figure 10: Percentage of publications by document type

On the other hand, regarding the position of the publications in the JCR subject category in which they are indexed, following figure shows the percentage of publications in first quartile (Q1) and first decile (D1) scientific journals in the last five years. A considerable increase in Q1 publications is observed, from 45% in 2023 to 65% in 2024.




Figure 11: Change in the percentage of first quartile (Q1) and first decile (D1) publications

The distribution of the number of publications by quartile is shown below. Of them, 88% were published in first quartile (Q1) and second quartile (Q2) journals.




Figure 12: Publications by quartiles

The percentage of Open Access publications in 2024, considering the gold, green, hybrid and bronze pathways, was 77%.

Leadership

Forty-six percent of scientific production was led by IBIMA Plataforma BIONAND researchers and researchers who contributed as first, last, or corresponding author, as shown in the following figure:




Figure 13: Percentage of publications led by IBIMA researchers.

Changes over the last five years in the percentage of publications led by institute researchers is shown below

PUBLICATIONS WITH FIRST AUTHORSHIP (FIRST, LAST, OR CORRESPONDING AUTHOR) BY IBIMA PLATAFORMA BIONAND INVESTIGATORS




Figure 14: Change in the percentage of publications led by IBIMA researchers in the last five years

Impact Factor

To calculating the Impact Factor (IF), only **original research articles and review articles** were considered. Collaborative publications among different groups and/or areas of the institute were only counted once for the overall calculation.

The Institute's cumulative impact factor in 2024 was 5,083 points. The changes over the last 5 years are shown in the following figure:




Figure 15: Changes in cumulative impact factor.

Collaborations

The following figure shows the percentage of publications by IBIMA Plataforma BIONAND researchers published in collaboration with other researchers from national institutions outside of Andalusia (national collaborations) and institutions of other nationalities (international).




Figure 16: Change in the percentage of scientific production according to national and international collaboration.

On the other hand, the percentage of publications from intra-institute collaborations among the different research groups and institutions that make up the IBIMA Plataforma BIONAND is shown in the following figure:




Figure 17: Percentage of publications produced in collaboration among groups and among institutions that make up the IBIMA Plataforma BIONAND.

Journals with IF >20 in which works were published in 2024

No. of Publications/Group	Source Title	IF
(3) B-01, BE-23	LANCET	98.4
(2) B-22	NEW ENGLAND JOURNAL OF MEDICINE	96.3
B-05	NATURE MEDICINE	58.7
(3) B-22, B-11	ANNALS OF ONCOLOGY	56.7
B-01	NATURE	50.5
B-01, B-22	JOURNAL OF CLINICAL ONCOLOGY	42.1
A-23	EUROPEAN HEART JOURNAL	38.1
AA-15	EUROPEAN HEART JOURNAL	38.1
DE-02	LANCET INFECTIOUS DISEASES	36.4
(2) A-03	CIRCULATION	35.6
(3) D-05	JOURNAL OF HEPATOLOGY	26.8
(2) A-03, AA-04	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	21.7
B-22	JOURNAL OF THORACIC ONCOLOGY	21.1
DE-02	LANCET MICROBE	20.9
D-03	ANNALS OF THE RHEUMATIC DISEASES	20.3

4.2. CLINICAL PRACTICE GUIDELINES

In 2024, 32 clinical practice guidelines and/or consensus documents on which institute researchers participated were published in JCR-indexed journals:

Groups	Authors	Article Title	Source Title	IF	Q/D	Publication Year
A-01	Zeng, XF; Varady, KA; Wang, XD; Targher, G; Byrne, CD; Tayyem, R; Latella, G; Bergheim, I; Valenzuela, R; George, J; Newberry, C; Zheng, JS; George, ES; Spearman, CW; Kontogianni, MD; Ristic-Medic, D; Peres, WAF; Depboylu, GY; Yang, WS; Chen, X; Rosqvist, F; Mantzoros, CS; Valenti, L; Yki-Järvinen, H; Mosca, A; Sookoian, S; Misra, A; Yilmaz, Y; Kim, W; Fouad, Y; Sebastiani, G; Wong, VWS; Åberg, F; Wong, YJ; Zhang, PH; Bermúdez-Silva, FJ; Ni, Y; Lupsor-Platon, M; Chan, WK; Méndez-Sánchez, N; Knekt, RJD; Alam, S; Treeprasertsuk, S; Wang, L; Du, ML; Zhang, TJ; Yu, ML; Zhang, HJ; Qi, XS; Liu, X; Pinyopornpanish, K; Fan, YC; Niu, KJ; Jimenez-Chillaron, JC; Zheng, MH	The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus	METABOLISM-CLINICAL AND EXPERIMENTAL	10.9	D1	2024
A-01	Restrepo, JMR; Pérez, IMR; de Luna, PPG; Cunill, JLP; López, FJV; Marin, MG; Doblas, CY; Ortega, AJM; Ramírez, JM; Morell, CL; Rojas, J; Ortiz, M; Corte, JOD; Colorado, MEM	Consensus on criteria and minimum data set for the referral of candidate patients for home enteral nutrition teleconsultation: TELENUT project	NUTRICION HOSPITALARIA	1.2	Q4	2024
A-01/A-02	Enríquez, AJ; Rabat-Restrepo, JM; Vilchez-López, FJ; Tenorio-Jiménez, C; García-Almeida, JM; Rocamora, JAI; Pereira-Cunill, JL; Ramírez, MJM; Molina-Puerta, MJ; Soria, JBM; Rebollo-Pérez, MI; Oliveira, G; García-Luna, PP	Practical Guidelines by the Andalusian Group for Nutrition Reflection and Investigation (GARIN) on Nutritional Management of Patients with Chronic Obstructive Pulmonary Disease: A Review	NUTRIENTS	4.8	Q1	2024

Groups	Authors	Article Title	Source Title	IF	Q/D	Publication Year
A-01/A-09/A-19	de las Heras, J; Almohalla, C; Blasco-Alonso, J; Bourbon, M; Couce, ML; López, MJD; Jiménez, MCG; Ortega, DG; González-Diéguez, L; Meavilla, S; Moreno-alvarez, A; Pastor-Rosado, J; Sánchez-Pintos, P; Serrano-Gonzalo, I; López, E; Valdivielso, P; Yahyaoui, R; Quintero, J	Practical Recommendations for the Diagnosis and Management of Lysosomal Acid Lipase Deficiency with a Focus on Wolman Disease	NUTRIENTS	4.8	Q1	2024
A-03	de Miguel-Díez, J; Villota, JN; Pérez, SS; Lorite, NM; Navarrete, BA; Jiménez, JFD; Soler-Cataluña, JJ; Figal, DP; Ecenarro, PS; Doblas, JJG	Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease	ARCHIVOS DE BRONCONEUMOLOGIA	8.7	D1	2024
A-03	Doblas, JJG; García-Moll, X; Freire, RB; Juanatey, CG; Morillas, M; Muñoz, AV; Escobar, C	Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting	FUTURE CARDIOLOGY	1.6	Q3	2024
A-06	Kreutz, R; Brunström, M; Burnier, M; Grassi, G; Januszewicz, A; Muiesan, ML; Tsioufis, K; de Pinho, RM; Albin, FL; Boivin, JM; Dumas, M; Nemcsik, J; Rodilla, E; Agabiti-Rosei, E; Algharably, EA; Agnelli, G; Benetos, A; Hitij, JB; Cifková, R; Cornelissen, V; Danser, AHJ; Delles, C; Huelgas, RG; Járαι, Z; Palatini, P; Pathak, A; Persu, A; Polonia, J; Sarafidis, P; Stergiou, G; Thomopoulos, C; Wanner, C; Weber, T; Williams, B; Kjeldsen, SE; Mancia, G	2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1	2024
A-09	Mostaza, JM; Pintó, X; Armario, P; Masana, L; Real, JT; Valdivielso, P; Arrobas-Velilla, T; Baeza-Trinidad, R; Calmarza, P; Cebollada, J; Civera-Andrés, M; Melero, JIC; Díaz-Díaz, JL; Espildora-Hernández, J; Pardo, JF; Guijarro, C; Jericó, C; Laclaustra, M; Lahoz, C; López-Miranda, J; Martínez-Hervás, S; Muñoz-Grijalvo, O; Páramo, JA; Pascual, V; Pedro-Boteta, J; Pérez-Martínez, P; Puze, J	SEA 2024 Standards for Global Control of Vascular Risk	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	2024

Groups	Authors	Article Title	Source Title	IF	Q/D	Publication Year
A-19	Cantinotti, M; Di Salvo, G; Voges, I; Raimondi, F; Greil, G; Garrido, AO; Bharucha, T; Grotenhuis, HB; Köstenberger, M; Bonnello, B; Miller, O; McMahon, CJ	Standardization in paediatric echocardiographic reporting and critical interpretation of measurements, functional parameters, and prediction scores: a clinical consensus statement of the European Association of Cardiovascular Imaging of the European Society of Cardiology and the Association for European Paediatric and Congenital Cardiology	EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING	6.7	D1	2024
A-19	Pedraz, LM; Cuadros, EN; Hernández, MB; Rueda, RMA; Saavedra-Lozano, J; Rey, CC	Diagnostic and therapeutic approach to spondylodiscitis in Spanish children through the RIOPed Network: Evaluation before and after the publication of the national consensus document	ANALES DE PEDIATRIA	1.5	Q2	2024
A-19	Barreda-Bonis, AC; Domingo, JMD; Galán-Gómez, E; Guillén-Navarro, E; Leiva-Gea, I; Riano-Galan, I	Expert consensus for the management of patients with achondroplasia in treatment with vosoritide	ANALES DE PEDIATRIA	1.5	Q2	2024
A-19/C-01	Arenas-Cabrera, C; Cabezudo-García, P; Calvo-Medina, R; Galeano-Bilbao, B; Martínez-Agredano, P; Ruiz-Giménez, J; Rodríguez-Uranga, JJ; Quiroga-Subirana, P	Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol	REVISTA DE NEUROLOGIA	0.8	Q4	2024

Groups	Authors	Article Title	Source Title	IF	Q/D	Publication Year
A-19/DE-02	Benito, N; Martinez-Pastor, JC; Lora-Tamayo, J; Ariza, J; Baeza, J; Belzunegui-Otano, J; Cobo, J; del-Toro, MD; Fontecha, CG; Font-Vizcarra, L; Horcajada, JP; Morata, L; Murillo, O; Nolla, JM; Nunez-Cuadros, E; Pigrau, C; Portillo, ME; Rodriguez-Pardo, D; Sobrino-Diaz, B; Saavedra-Lozano, J	Executive summary: Guidelines for the diagnosis and treatment of septic arthritis in adults and children, developed by the GEIO (SEIMC), SEIP and SECOT	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.6	Q3	2024
B-01	Manso, L; Ramchandani-Vaswani, A; Romero, I; Sánchez-Lorenzo, L; Bermejo-Pérez, MJ; Estévez-García, P; Fariña-Madrid, L; García, YG; Gil-Martin, M; Quindós, M	SEOM-GEICO Clinical Guidelines on cervical cancer (2023)	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	2024
B-10	Galván-Casas, C; Ortiz-Alvarez, J; Martínez-García, E; Corbacho-Monné, M	Spanish Academy of Dermatology and Venereology (AEDV) expert recommendations for the management of sexual transmitted parasitosis. Scabies, and pediculosis pubis	ACTAS DERMOSIFILIOGRAFICAS	3.8	Q1	2024
B-22	Ospina, AV; Nadal, SB; de la Cruz, JLCC; Larriba, JLG; Vidueira, IM; Sureda, BM; Nadal, E; Tranco, FH; Kindelan, AA; Morillo, E; Caro, RB; Barrera, JB; de Juan, VC; Rubio, JC; de Castro, J; Ramos, AC; Dols, MC; Gomez, M; Almanzar, S; Campelo, RG; Molla, AI; Sarceda, JRJ; Maestre, UJ; Castro, RL; Majem, M; Martinez-Marti, A; Tellez, EM; Lorente, DS; Provencio, M	Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	2024
BA-16	Muñoz, M; Aragón, S; Ballesteros, M; Bisbe-Vives, E; Jericó, C; Llamas-Sillero, P; Meijide-Míguez, HM; Rayó-Martin, E; Rodríguez-Suárez, MJ	Executive summary of the consensus document on the management of perioperative anemia in Spain	REVISTA CLINICA ESPANOLA	2.3	Q2	2024

Groups	Authors	Article Title	Source Title	IF	Q/D	Publication Year
BE-23	Marquez-Rodas, I; Couselo, EM; Moreno, JFR; Fernández, AMA; Guerrero, MAB; Balea, BC; Merino, LD; Arranz, EE; Castaño, AG; Jaime, AB	SEOM-GEM clinical guidelines for cutaneous melanoma (2023)	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	2024
BE-23	Pericay, C; Montagut, C; Reina, JJ; Melian, M; Alcaide, J; Tarazona, N; Ruiz-Casado, A; González-Flores, E; Graña, B; Grávalos, C	SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	2024
C-01	Meca-Lallana, JE; Yélamos, SM; Eichau, S; Llaneza, MA; Martínez, JM; Martínez, JP; Lallana, VM; Torres, AMA; Torres, EM; Rio, J; Calles, C; Luque, AA; Ramió-Torrentà, L; Sola, MEM; Prieto, JM; Ginés, MLM; Arroyo, R; Martínez, MAO; Ruiz, LB; Gutiérrez, MG; Zarranz, ARA; Sánchez-Seco, VG; Costa-Frossard, L; Pérez, MAH; Pascual, LL; Platas, MG; Oreja-Guevara, C	Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023	NEUROLOGIA	2.9	Q2	2024
C-13/D-03/FE-17	Ramos-Petersen, L; Reinoso-Cobo, A; Ortega-Avila, AB; Garcia-Campos, J; Bernal, JA; Cantero-Tellez, R; Martin-Martin, JM; Caliz-Caliz, R; Tejero, S; Cano-Garcia, L; Gijon-Nogueron, G	A clinical practice guideline for the management of the foot and ankle in rheumatoid arthritis	RHEUMATOLOGY INTERNATIONAL	3.2	Q2	2024
D-03	Castrejón, I; Cano, L; Cuadrado, MJ; Borrás, J; Galindo, M; Salman-Monte, TC; Amorós, C; Román, CS; Cabezas, I; Comellas, M; Muñoz, A	Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care	BMC RHEUMATOLOGY	2.1	Q3	2024
D-03	Rúa-Figueroa, I; Salman-Monte, T; Reigosa, JM; Izquierdo, M; Alvarez, E; Fernández-Nebro, A; Ivorra, JA; Penades, I; Beobide, J; Alén, J	Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus	REUMATOLOGIA CLINICA	1.2	Q4	2024

Groups	Authors	Article Title	Source Title	IF	Q/D	Publication Year
D-03	Alvaro, JMAG; Fontecha, PDD; Sánchez, JLA; Criado, AB; Cáliz, RC; Fernández, IC; Corominas, H; Puerta, JAG; Arijá, SM; Vázquez, NM; García, AO; Rodríguez, CP; Fernández, LS; Molina, JT	Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis	REUMATOLOGIA CLINICA	1.2	Q4	2024
D-04	Al-Shaikhly, T; Cox, A; Nowak-Wegrzyn, A; Cianferoni, A; Katelaris, C; Ebo, DG; Konstantinou, GN; Brucker, H; Yang, HJ; Protudjer, JLP; Boechat, JL; Yu, JE; Wang, J; Blatman, KSH; Blazowski, L; Anand, MP; Ramesh, M; Torres, MJ; Holbreich, M; Goodman, R; Wasserman, RL; Hopp, R; Sato, S; Skypala, I	An International Delphi Consensus on the Management of Pollen-Food Allergy Syndrome: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	8.2	D1	2024
D-04	Pascal, M; Edelman, SM; Nopp, A; Möbs, C; Geilenkeuser, WJ; Knol, EF; Ebo, DG; Mertens, C; Shamji, MH; Santos, AF; Patil, S; Eberlein, B; Mayorga, C; Hoffmann, HJ	EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance	ALLERGY	12.6	D1	2024
D-04	Torres, MI; Gil-Mata, S; Bognanni, A; Ferreira-da-Silva, R; Yepes-Nuñez, JJ; Lourenco-Silva, N; Cardoso-Fernandes, A; Ferreira, A; Ferreira-Cardoso, H; Portela, D; Teles, J; Kvedariene, V; Torres, MJ; Klimek, L; Pfaar, O; Brussino, L; Zuberbier, T; Fonseca, JA; Schunemann, H; Bousquet, J; Sousa-Pinto, B; Vieira, RJ	Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review With Meta-Analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	8.2	D1	2024
D-04	Martínez-Moragón, E; Ercoreca, IA; García, MM; Maldonado, FC; Lamas, MC; Vives, EC; Diz, CC; Díaz-Pérez, D; Gracia, IE; Gil, SG; González-Pérez, R; Mena, AH; Valverde, TH; Montaña, SJ; López-Carrasco, V; López, IM; Merino-Bohórquez, V; Moreno-Ancillo, A; Cabeza, ACM; Monte-Boquet, E; Revuelta-Herrero, JL; Sánchez-Cuellar, S	Patient-reported outcome measures in severe asthma: an expert consensus	JOURNAL OF ASTHMA	1.7	Q3	2024

Groups	Authors	Article Title	Source Title	IF	Q/D	Publication Year
D-05	Segovia-Zafra, A; Villanueva-Paz, M; Serras, AS; Matilla-Cabello, G; Bodoque-García, A; Zeo-Sánchez, DED; Niu, H; Alvarez-Alvarez, I; Sanz-Villanueva, L; Godec, S; Milisav, I; Bagnaninchi, P; Andrade, RJ; Lucena, MI; Fernández-Checa, JC; Cubero, FJ; Miranda, JP; Nelson, LJ	Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network	JOURNAL OF HEPATOLOGY	26.8	D1	2024
D-05	.Cohen, EB; Patwardhan, M; Raheja, R; Alpers, DH; Andrade, RJ; Avigan, MI; Lewis, JH; Rockey, DC; Chui, F; Iacob, AM; Linardi, CC; Regev, A; Shick, J; Lucena, MI	Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative	DRUG SAFETY	4	Q1	2024
DA-06	Barbadillo-Villanueva, S; del Aguila, VA; Robustillo-Cortés, MD; Gimeno-Gracia, M; Yáñez, ES; Hermenegildo-Caudevilla, M; Aznárez, HN; López, AL; Vicente, E; Monte-Boquet, E	Telematic interview in telepharmacy: consensus document for pharmacotherapeutic monitoring and informed drug delivery	FARMACIA HOSPITALARIA	1	Q4	2024
DE-08	Bilbao, I; Lladó, L; Cachero, A; Campos-Varela, I; Colmenero, J; del Hoyo, J; García, EF; Pajares, FG; Diéguez, LG; Grande, RG; Sánchez, AG; Oliveros, FH; Santos, JIH; Lorente, S; Mateos, RM; López, MJM; Alvarez, JLM; Codoceo, CM; Ferreiro, AO; Nieto, EO; Soler, MR; Cristóbal, MR; Oliver, LS; Labiano, MS; Martín, JMS; Traperó-Marugán, M; Varo, E; de la Rosa, G; Rodríguez-Perálvarez, ML	First consensus document of waiting list prioritization for liver transplantation by the Spanish Society of Liver Transplantation (SETH)	REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS	2.7	Q2	2024

4.3. RESEARCH PROJECTS

In 2024, 366 research projects funded in regional, national, and international competitive calls were conducted at IBIMA Plataforma BIONAND. Of these, 219 were projects managed directly by FIMABIS as the Institute's managing entity.



Figure 18: Active competitive research projects in 2024




Figure 19: Changes in active competitive research projects at IBIMA 2020–2024

Sixty-nine new competitive projects were awarded to IBIMA Plataforma BIONAND research groups, with a success rate of 30% (69 awarded/226 applied for).




Figure 20: Competitive research projects applied for and awarded in 2024

The following table shows the success rates in the main national and regional competitive calls for research projects:

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
NATIONAL	PRIVATE	SPANISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM	SENPE 2024 SCHOLARSHIPS AND AWARDS	4	4
		LA CAIXA FOUNDATION	CAIXAIMPULSE HEALTH INNOVATION 2023 CALL FOR PROPOSALS	1	
			HEALTH RESEARCH CALL FOR PROPOSALS 2025	1	
		GILEAD SCIENCES, S.L.U.	GILEAD BIOMEDICAL RESEARCH GRANTS 2024	1	
			GILEAD BIOMEDICAL RESEARCH GRANTS 2023		1

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
NATIONAL	PRIVATE		CALL FOR PROPOSALS FOR GILEAD GRANTS FOR HEPATITIS C MICROELIMINATION AND HEPATITIS D EPIDEMIOLOGY PROJECTS 2024	1	1
		SPANISH RARE DISEASES FEDERATION	CALL FOR FEDER FOUNDATION RESEARCH GRANTS 2024	1	
		SPANISH SOCIETY FOR ATHEROSCLEROSIS	RESEARCH GRANTS 2024	1	1
		RAMÓN ARECES FOUNDATION	GRANTS FOR HEALTH AND MATERIALS SCIENCE RESEARCH 2024	3	
		SPANISH ASSOCIATION AGAINST CANCER	AECC 2024 STRATEGIC PROJECTS		1
			AECC CHALLENGE 70% SURVIVAL 2024		1
		EUGENIO RODRIGUEZ PASCUAL FOUNDATION	BIOMEDICAL RESEARCH GRANTS 2024	3	
		OLGA TORRES FOUNDATION	POSTDOCTORAL FELLOWSHIP PROGRAM 2024	1	
		MAPFRE FOUNDATION	IGNACIO HERNANDO DE LARRAMENDI RESEARCH GRANTS 2024	2	
		ASTRAZENECA FARMACEUTICA ESPAÑA S.A.	CALL FOR YOUNG RESEARCHER AWARDS 2024	1	
		SPANISH CYSTIC FIBROSIS SOCIETY	RESEARCH GRANTS 2023		1
		L'OREAL S.A.	L'ORÉAL-UNESCO RESEARCH AWARDS FOR WOMEN IN SCIENCE 2024	1	
		GENERAL NURSING COUNCIL OF SPAIN	RESEARCH AWARDS 2024	1	
		SPANISH SOCIETY OF MEDICAL ONCOLOGY	GRANTS FOR PROJECTS ON NEW TECHNOLOGIES FOR THE STUDY AND CARE OF LONG-TERM CANCER SURVIVORS 2023		1
			RESEARCH PROJECT GRANTS FOR EMERGING GROUPS 2023		1
Total PRIVATE				22	12

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
NATIONAL	PUBLIC	CARLOS III INSTITUTE OF HEALTH	STRATEGIC ACTION IN HEALTH -HEALTH TECHNOLOGY DEVELOPMENT PROJECTS 2024	2	
			STRATEGIC ACTION IN HEALTH - CALL FOR INDEPENDENT CLINICAL RESEARCH PROJECTS 2024	1	
			STRATEGIC ACTION IN HEALTH - HEALTH R&D&I PROJECTS 2024	49	10
			STRATEGIC ACTION IN HEALTH -GRANTS FOR PRECISION PERSONALIZED MEDICINE RESEARCH PROJECTS 2022		3
			CALL FOR JOINT SCIENCE-HEALTHCARE MISSIONS IN PERSONALIZED PRECISION MEDICINE 2024	3	2
			CALL FOR JOINT SCIENCE-HEALTHCARE MISSIONS IN RARE DISEASES AND NEUROMUSCULAR CONDITIONS 2024	3	3
		Total CARLOS III INSTITUTE OF HEALTH		58	18
		STATE RESEARCH AGENCY	R&D&I PROJECTS - KNOWLEDGE GENERATION 2023	5	
			GRANTS FOR PUBLIC-PRIVATE PARTNERSHIP PROJECTS 2023	3	
			RAMÓN Y CAJAL GRANTS 2023	2	2
			GRANTS TO PROMOTE RESEARCH CONSOLIDATION 2023		3
		Total STATE RESEARCH AGENCY		10	5
		MINISTRY OF HEALTH	GRANTS FOR ADDICTION RESEARCH PROJECTS 2024	2	
		Total MINISTRY OF HEALTH		2	
		Total PUBLIC			70
Total NATIONAL			92	35	
REGIONAL	PRIVATE	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	SANCYD 2023-2024 SCHOLARSHIPS		3

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
REGIONAL	PRIVATE	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	SPAO GRANTS FOR RESEARCH IN PEDIATRICS 2024	1	1
		ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	SANCYD AWARDS 2024	4	4
		ANDALUSIAN COUNCIL OF COLLEGES OF PHYSICIANS	RESEARCH AWARD ON THE HEALTH BENEFITS OF OLIVE OIL 2024	1	1
		ANDALUSIAN SOCIETY OF MEDICAL ONCOLOGY	SAOM DR. MORENO NOGUEIRA GRANTS FOR TRANSLATIONAL RESEARCH PROJECTS 2022		1
		ANDALUSIAN FOUNDATION OF RHEUMATOLOGY	CALL FOR PROPOSALS FOR THE FAR RESEARCH GRANTS 2023		1
		ANDALUSIAN SOCIETY OF CARDIOLOGY	RESEARCH GRANTS FOR SINGLE-CENTER PROJECTS 2024	1	1
		Total PRIVATE		7	12
	PUBLIC	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	GENERAL HEALTH RESEARCH PROJECTS 2024	63	10
			PUBLIC-PRIVATE COLLABORATION RESEARCH AND INNOVATION PROJECTS 2024	2	
			FOSTERING KNOWLEDGE GENERATION IN THEMATIC AREAS OF EXCELLENCE IN BIOMEDICINE AND HEALTH SCIENCES THROUGH R&D&I 2024	1	
		Total REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS		66	10
		ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	CALL FOR RESEARCH AND INNOVATION PROJECTS IN THE FIELD OF PRIMARY CARE, COUNTY HOSPITALS, AND HIGH-COMPLEXITY HOSPITAL CENTERS OF ANDALUCIA (CHARES) 2024	3	3

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
REGIONAL	PRIVATE	Total ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.		3	3
		REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	GRANTS FOR THE CONDUCT OF RESEARCH PROJECTS BY AGENTS OF THE ANDALUSIAN KNOWLEDGE SYSTEM. LINE 2 -APPLIED RESEARCH AND EXPERIMENTAL DEVELOPMENT 2024	12	
		Total REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION		12	
	Total PUBLIC			81	13
	Total REGIONAL			88	25
TOTAL PROJECTS				180	60

4.4. HUMAN RESOURCES

In 2024, IBIMA Plataforma BIONAND had 181 active human resources grants funded in competitive calls.



Figure 21: Human resources grants active in 2024

The research personnel funded entirely or in part through competitive calls and research networks are as follows:

ENTITY	CALL/NETWORK	No. OF PERSONNEL FINANCED
ISCIII	i-PFIS	4
	JR	9
	MSI	9
	MSII	3
	PFIS	15
	RH	16
	SB	12
	MANAGEMENT TECH.	1
	INDIVIDUAL MSCA ACTIONS	1
Total ISCIII		70
AECC	AECC PREDOCTORAL GRANTS 2023	2
	JUNIOR CLINICIAN 2023	1
Total AECC		3
STATE RESEARCH AGENCY	TECHNICAL SUPPORT PERSONNEL	1
	PREDOCTORAL CONTRACTS FOR THE TRAINING OF DOCTORS 2021 - 2022	3
	RAMÓN Y CAJAL CONTRACTS	1
	GRANTS TO PROMOTE RESEARCH CONSOLIDATION 2023	3
Total STATE RESEARCH AGENCY		8
MINISTRY OF UNIVERSITIES	PREDOCTORAL CONTRACTS FOR UNIVERSITY PROFESSOR TRAINING (FPU)	2
Total MINISTRY OF UNIVERSITIES		2
EUROPEAN COMMISSION	MARIE SKŁODOWSKA-CURIE	1
Total EUROPEAN COMMISSION		1
Regional Ministry of Health and Consumer Affairs	Incorporation of Postdoctoral Researchers to Groups in the Health and Research Centers of the Andalusian Public Health System	4
Total Regional Ministry of Health and Consumer Affairs		4
REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	PAIDI - GRANTS FOR THE HIRING OF DOCTORAL RESEARCH PERSONNEL BY UNIVERSITIES AND PUBLIC RESEARCH ENTITIES	6
	HIRING OF PREDOCTORAL RESEARCH PERSONNEL IN TRAINING BY THE AGENTS OF THE ANDALUSIAN KNOWLEDGE SYSTEM 2021	2
Total REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION		38
ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH	PROMOTION OF THE INTERNATIONALIZATION OF R&I IN THE ANDALUSIAN PUBLIC HEALTHCARE SYSTEM: REINFORCEMENT OF SUPPORT STRUCTURES 2021	1
Total FPS		1

ENTITY	CALL/NETWORK	No. OF PERSONNEL FINANCED
REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	RESEARCH PROGRAM 2022	26
Total REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT		26
SAS	Action B. Clinical Researcher	4
	Renewal Action B Long-term reinforcement	5
	Action C. Nicolás Monardes	10
	Renewal of action C (Nicolás Monardes program)	10
	LINK OF TECHNICIANS TO SHARED RESEARCH SUPPORT STRUCTURES 2022.	1
	Renewal of technicians linked to Shared Research Support Structures (ECAIs)	7
Total SAS		37
PT20/00101	RNBB BIOBANKS	7
PT20/00127	Support for Independent Clinical Research and Clinical Trials Platform	5
RD21/0002/0008	Inflammatory Diseases Network	2
RD21/0009/0003	Research Network on Primary Care for Addictions	1
RD21/0016/0012	Research Network on Preventive Activities and Health Promotion in Primary Care	2
RD21/0002/0037	Chronic Disease and Transplant Network	1
RD21/0005/0012	Inflammatory Diseases Network	1
RD21/0016/0012	Research Network on Chronicity, Primary Care, and Health Promotion	5
RIC-0539-2018	NETWORK OF CLINICAL TRIALS ON METABOLISM: DIABETES, OBESITY, AND DYSLIPIDEMIA	3
RIC-0111-2019	ANDALUSIAN NETWORK FOR CLINICAL AND TRANSLATIONAL RESEARCH IN NEUROLOGY (NEURO-RECA)	3
PT23/00082	IBIMA Plataforma BIONAND Research Unit.	2
RD21-0016-0015	Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS). LR: Maximino Redondo Bautista	3
PT23/00049	Biobank and Biomodel Platform	2

What’s more, IBIMA Plataforma BIONAND has been granted 73 new resources out of a total of 166 applied for, which represents a success rate of 44%.




Figure 22: Human resources grants applied for and funded in 2024

The following table reflects the competitive HR grants awarded in national and regional calls in 2024 according to funding entity and grant type:

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
NATIONAL	PRIVATE	LA CAIXA FOUNDATION	POSTDOCTORAL JUNIOR LEADER-INCOMING 2024	2	
			POSTDOCTORAL JUNIOR LEADER-RETAINING 2024	1	
		SPANISH SOCIETY OF MEDICAL ONCOLOGY	RETURNING YOUNG RESEARCHER FELLOWSHIPS 2023		1
		RAMÓN ARECES FOUNDATION	GRANTS FOR THE COMPLETION OF DOCTORAL THESES IN LIFE AND MATERIALS SCIENCES 2024	5	
		SCIENTIFIC FOUNDATION OF THE SPANISH ASSOCIATION AGAINST CANCER	JUNIOR CLINICIAN IN THE AECC FIELD 2024		1

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
NATIONAL	PRIVATE		JUNIOR CLINICIAN IN THE AECC FIELD 2025	1	
			AECC SENIOR CLINICIAN 2025	1	
			AECC RESEARCHER 2025	3	
			AECC POSTDOCTORAL GRANTS 2025	1	
			AECC PREDOCTORAL GRANTS 2025	4	
		CRIS FOUNDATION FOR RESEARCH TO BEAT CANCER	CRIS PROGRAM OF EXCELLENCE 2024	1	
	Total PRIVATE			19	2
	PUBLIC	CARLOS III INSTITUTE OF HEALTH	STRATEGIC ACTION IN HEALTH - CONTRACTS FOR BIOINFORMATICS TECHNICIANS TO SUPPORT RESEARCH AT HEALTH RESEARCH INSTITUTES (IIS) 2024	1	
			STRATEGIC HEALTH ACTION -SARA BORRELL CONTRACTS 2023		1
			STRATEGIC HEALTH ACTION -SARA BORRELL CONTRACTS 2024	10	5
			STRATEGIC ACTION IN HEALTH - RÍO HORTEGA CONTRACTS 2024	14	8
			STRATEGIC ACTION IN HEALTH - MIGUEL SERVET CONTRACTS 2024	7	2
			STRATEGIC HEALTH ACTION -PFIS CONTRACTS: PREDOCTORAL CONTRACTS FOR HEALTH RESEARCH TRAINING 2024	10	5
			STRATEGIC ACTION IN HEALTH - i-PFIS CONTRACTS: DOCTORATES HEALTH RESEARCH INSTITUTES (IIS)- BUSINESSES IN HEALTH SCIENCES AND TECHNOLOGY 2024	1	
			STRATEGIC ACTION IN HEALTH - CONTRACTS FOR THE INTENSIFICATION OF RESEARCH ACTIVITY IN THE NATIONAL HEALTH SYSTEM (SNS) 2024	3	3
			STRATEGIC ACTION IN HEALTH - JUAN RODÉS CONTRACTS 2024	4	1
		Total CARLOS III INSTITUTE OF HEALTH		50	25

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
NATIONAL	PUBLIC	STATE RESEARCH AGENCY	GRANTS TO PROMOTE RESEARCH CONSOLIDATION 2023		3
			GRANTS TO PROMOTE RESEARCH CONSOLIDATION 2024	1	
			JUAN DE LA CIERVA GRANTS 2023	8	4
			GRANTS FOR TECHNICAL SUPPORT PERSONNEL (PTA) 2024	4	
			RAMÓN Y CAJAL GRANTS 2023	2	2
		Total STATE RESEARCH AGENCY		15	9
		MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES	PREDOCTORAL CONTRACTS FOR UNIVERSITY-VOCATIONAL EDUCATION PROFESSOR (FPU) 2023	1	
		Total MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES		1	
		Total PUBLIC		66	34
		Total NATIONAL		85	36
REGIONAL	PUBLIC	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	CALL FOR THE INCORPORATION OF POSTDOCTORAL RESEARCHERS TO GROUPS IN THE HEALTH AND RESEARCH CENTERS OF THE ANDALUSIAN PUBLIC HEALTH SYSTEM 2024	26	5
		Total REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS		26	5
		ANDALUSIAN HEALTH SERVICE	RENEWAL OF TECHNICIANS LINKED TO SHARED RESEARCH SUPPORT STRUCTURES 2024	2	2
			ACTION C. PROMOTION OF TRANSLATIONAL RESEARCH IN THE CUs (NICOLÁS MONARDES PROGRAM) 2023		4
			ACTION C. PROMOTION OF TRANSLATIONAL RESEARCH IN THE CUs (NICOLÁS MONARDES PROGRAM) 2024	2	

Scope	Nature of the call for proposals	Name of the Funding Entity	Call Name	Total Applied For	Total Awarded
REGIONAL	PUBLIC		ACTION A. ANNUAL REINFORCEMENT OF RESEARCH ACTIVITY IN THE CLINICAL UNITS OF THE ANDALUSIAN HEALTH SERVICE 2024	15	14
			ACTION B. INCORPORATION OF CLINICAL-RESEARCH PROFESSIONALS INTO ANDALUSIAN HEALTH SERVICE CLINICAL UNITS 2024	4	
			ACTION B. INCORPORATION OF CLINICAL-RESEARCH PROFESSIONALS INTO ANDALUSIAN HEALTH SERVICE CLINICAL UNITS 2023		4
			C PROGRAM 2024	4	
			MARÍA CASTELLANO ARROYO TRAINING AND RESEARCH PROGRAM -UMA 2024	2	2
			ACTION B RENEWAL - LONG-TERM REINFORCEMENT 2024	2	2
		Total ANDALUSIAN HEALTH SERVICE		31	28
		REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	LÍNEA 3: EMERGIA PROGRAM 2023	1	
			LINEA 2: GRANTS FOR HIRING DOCTORAL RESEARCH PERSONNEL BY AGENTS OF THE ANDALUSIAN KNOWLEDGE SYSTEM 2024	3	1
			LÍNEA 1: GRANTS FOR HIRING PREDOCTORAL RESEARCH PERSONNEL IN TRAINING BY THE AGENTS OF THE ANDALUSIAN KNOWLEDGE SYSTEM 2024	9	1
		Total REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION		13	2
		Total PUBLIC			70
	Total REGIONAL			70	35
TOTAL HR			155	71	

4.5. RICORS, RETICS, INTERNATIONAL NETWORKS, AND ISCIII AND CIBER PLATFORMS

RICORS:

AREA	NETWORK NAME	IBIMA PARTICIPATION	IBIMA LR	GROUP(S)
PRIMARY CARE, CHRONICITY, AND HEALTH PROMOTION	RESEARCH NETWORK ON PRIMARY CARE FOR ADDICTIONS (RIAPad) RD21/0009/0003	RESEARCH GROUP	Fernando Rodríguez de Fonseca	C-06
	RESEARCH NETWORK ON PRIMARY CARE FOR ADDICTIONS (RICAPPS) RD21/0016/0012	RESEARCH GROUP	Juan Ángel Bellón Saameño	C-02
	RICORS-SAMID: PRIMARY CARE INTERVENTIONS TO PREVENT MATERNAL AND CHILD CHRONIC DISEASES OF PERINATAL AND DEVELOPMENTAL ORIGIN RD21/0012	ASSOCIATED CLINICAL GROUP	Ernesto González Mesa	C-16
INFLAMMATION AND IMMUNOPATHOLOGY OF ORGANS AND SYSTEMS	INFLAMMATORY DISEASES RICORS-REI RD21/0002/0008	RESEARCH GROUP	María José Torres Jaén	D-04
	INFLAMMATORY DISEASES RICORS-REI RD21-0002-0037	RESEARCH GROUP	Antonio Fernández Nebro	D-03
	RICORS2040 (KIDNEY DISEASE) RD21-0005-0012	RESEARCH GROUP	Verónica López Jiménez	AE-11
CEREBRAL VASCULAR DISEASES	RICORS-ICTUS	ASSOCIATED CLINICAL GROUP	Carlos de la Cruz Cosme	A-09
ADVANCED THERAPIES	RICORS TERA V	COLLABORATING RESEARCHER	Antonio Rodríguez Acosta	ECAI-06

INTERNATIONAL NETWORKS

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
A-02	CA23151 (Medi-CaSE) - Mediterranean Cancer Screening and Early Diagnosis Network	NETWORK	EUROPEAN COMMISSION	MANUEL MACIAS GONZÁLEZ
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	NETWORK	EUROPEAN COMMISSION	ISABEL MORENO INDIAS/PATRICIA RUIZ LIMON/ CAROLINA GUTIÉRREZ REPISO
A-03	CA19101 (DE-PASS) -Determinants of Physical Activities in Settings	NETWORK	EUROPEAN COMMISSION	JORGE RODRIGUEZ CAPITAN
A-03	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03	CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03	CA20137 (VOICES) - Making Young Researchers' Voices Heard for Gender Equality	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-06	CA18216 (VascAgeNet) -Network for Research in Vascular Ageing	NETWORK	EUROPEAN COMMISSION	MARÍA ROSA BERNAL LÓPEZ
A-06	CA21147 (ENOTTA) - European Network on Optimizing Treatment with Therapeutic Antibodies in chronic inflammatory diseases	NETWORK	EUROPEAN COMMISSION	MARIA DEL MAR AYALA GUTIÉRREZ
A-19	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	NETWORK	EUROPEAN COMMISSION	ISABEL LEIVA GEA
A-19	CA19115 (HyperChildNET) - Network for blood pressure research in children and adolescents	NETWORK	EUROPEAN COMMISSION	VERONICA MARTINEZ RIVERA
A-19	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	NETWORK	EUROPEAN COMMISSION	PILAR SÁNCHEZ YAÑEZ

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
A-19	CA21168 (JIR-CLiPS) -Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	NETWORK	EUROPEAN COMMISSION	ROCIO GALINDO ZAVALA
A-21	CA21152 (INE-CSC) -Implementation Network Europe for Cancer Survivorship Care	NETWORK	EUROPEAN COMMISSION	AIDA RAIGÓN PONFERRADA
AA-20	CA19133 (FOSTREN) -Fostering and strengthening approaches to reducing coercion in European mental health services	NETWORK	EUROPEAN COMMISSION	DANIEL MORENO SANJUÁN
AA-20	CA19113 (TheERNSTGroup) -The European Researchers Network Working on Second Victims	NETWORK	EUROPEAN COMMISSION	DANIEL MORENO SANJUÁN
AA-22	CA18205 -WORCK Worlds of Related Coercions in Work	NETWORK	EUROPEAN COMMISSION	FRANCISCO JAVIER ALCALDE DE HOYOS
BE-18	CA21154 (TRANSLACORE)- Translational control in Cancer European Network	NETWORK	EUROPEAN COMMISSION	MELISSA GARCÍA CABALLERO
BE-18	CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer	NETWORK	EUROPEAN COMMISSION	MELISSA GARCÍA CABALLERO
C-01	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	NETWORK	EUROPEAN COMMISSION	BEATRIZ GARCIA DIAZ
C-03	CA19133 (FOSTREN) -Fostering and strengthening approaches to reducing coercion in European mental health services	NETWORK	EUROPEAN COMMISSION	JOSÉ GUZMAN PARRA
C-03	CA23153 (YouthDMH) - Digital Mental Health for Young People	NETWORK	EUROPEAN COMMISSION	JOSÉ GUZMAN PARRA/ JESSICA MARIAN GOODMAN CASANOVA
C-03	CA19101 (DE-PASS) -Determinants of Physical Activities in Settings	NETWORK	EUROPEAN COMMISSION	ANA BELEN PABA DOTES
C-03	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	NETWORK	EUROPEAN COMMISSION	GLORIA MARGARITA GUERRERO PERTÍÑEZ
C-06	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	NETWORK	EUROPEAN COMMISSION	ADRIANA CASTRO ZAVALA

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
C-06	CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development	NETWORK	EUROPEAN COMMISSION	ANTONIA SERRANO CRIADO
C-08	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	NETWORK	EUROPEAN COMMISSION	FRANCISCA LEIVA FERNÁNDEZ/ PILAR BARNESTEIN FONSECA
C-13	CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims	NETWORK	EUROPEAN COMMISSION	JOSÉ CARLOS CANCA SÁNCHEZ
C-13	CA19137 (PARQ): Sudden cardiac arrest prediction and resuscitation network: Improving the quality of care	NETWORK	EUROPEAN COMMISSION	EVA TIMONET ANDREU
C-13	CA21168 (JIR-CLiPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	NETWORK	EUROPEAN COMMISSION	EVA TIMONET ANDREU
C-13	CA21110 (NetwoArk) - Building an open European Network on OsteoArthritis research	NETWORK	EUROPEAN COMMISSION	EVA TIMONET ANDREU/ GABRIEL ANTONIO GIJON NOGUERON/ANA BELEN ORTEGA AVILA
C-16	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	NETWORK	EUROPEAN COMMISSION	ERNESTO GONZÁLEZ MESA/MARÍA FERNANDA LARA CABANÁS
C-16	CA21108 (NETSKINMODELS) -European Network for Skin Engineering and Modeling	NETWORK	EUROPEAN COMMISSION	MARÍA FERNANDA LARA CABANÁS
CE-18	CA22106 (MDVI): Migrant Disaster Victim Identification	NETWORK	EUROPEAN COMMISSION	STELLA MARTIN DE LAS HERAS
D-01	CA21164 (ADVANCE-TB) - Towards an improvement in diagnostics and treatment strategies for TB control	NETWORK	EUROPEAN COMMISSION	ISABEL ASCENSION PEREZ HERNANDEZ

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
D-04	CA18226 (ADOPT)-New approaches for the detection of pathogens and aeroallergens	NETWORK	EUROPEAN COMMISSION	IBON EGUILUZ GRACIA
D-04	CA18227 (COMFA) - The Core Outcome Measures for Food Allergy	NETWORK	EUROPEAN COMMISSION	CRISTOBALINA MAYORGA MAYORGA
D-05	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	NETWORK	EUROPEAN COMMISSION	CARLOS LOPEZ GOMEZ
DE-09	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	NETWORK	EUROPEAN COMMISSION	CARMEN MARÍA GONZÁLEZ DOMENECH
DE-09	CA20128 (PIMENTO) -Promoting Innovation of fermented foods	NETWORK	EUROPEAN COMMISSION	CARMEN MARÍA GONZÁLEZ DOMENECH
F-14	CA21152 (INE-CSC) -Implementation Network Europe for Cancer Survivorship Care	NETWORK	EUROPEAN COMMISSION	CRISTINA ROLDÁN JIMÉNEZ
F-15	CA19134 (DKG) -Distributed Knowledge Graphs	NETWORK	EUROPEAN COMMISSION	MARÍA DEL MAR ROLDÁN GARCÍA
FE-17	CA21110 (NetwoArk) - Building an open European Network on OsteoArthritis research	NETWORK	EUROPEAN COMMISSION	RAQUEL CANTERO TELLEZ
H-02	CA22170 (TENET) -TEndon Regeneration NETwork	NETWORK	EUROPEAN COMMISSION	IVAN DURAN JIMENEZ
HE-01	CA21151 (HAPLO-iPS) - GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS FROM HAPLO-SELECTED CORD BLOOD SAMPLES	NETWORK	EUROPEAN COMMISSION	MARIA ELENA GONZALEZ MUÑOZ
HE-01	CA20140 (CorEuStem) - The European Network for Stem Cell Core Facilities	NETWORK	EUROPEAN COMMISSION	MARIA ELENA GONZALEZ MUÑOZ

National ECRIN Hub -European Clinical Research Infrastructure Network **coordinator** Maribel Lucena

PARTICIPATION IN ISCIII PLATFORMS

Title	Subtype	Name of the Funding Entity	LR Name
PT23/00082 IBIMA BIONAND Platform Innovation Unit. Promotion of technological valorization, knowledge transfer, and consolidation of the industrial network.	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FERNANDO RODRÍGUEZ DE FONSECA
PT20/00101 - PT23/00049 Biobank and Biomodel Platform: the keystone to Precision Medicine: expansion, virtualization, and internationalization of the service. Generation of organoids	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FRANCISCO JOSÉ TINAHONES
PT20/00127 - PT23/00137 Clinical Research and Clinical Trials Unit, UICEC UICEC IBIMA Plataforma BIONAND. ISCIII Clinical Research Platform: Consolidation of its international projection, comprehensive management, collaboration, and transfer.	PLATFORM	CARLOS III INSTITUTE OF HEALTH	MARIA ISABEL LUCENA GONZÁLEZ
CERT22-00034. Networked State Consortium for the Development of Medicines for Advanced Therapies (CERTERA)	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FRANCISCO JOSÉ TINAHONES

PARTICIPATION OF GROUPS IN CIBER

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
A-01	CIBERDEM CB07/08/0019 Diabetes and Associated Metabolic Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	GEMMA ROJO MARTÍNEZ
A-02	CIBEROBN CB06/03/0018 Physiopathology of Obesity and Nutrition	CIBER	CARLOS III INSTITUTE OF HEALTH	FRANCISCO TINAHONES
A-03	CIBERCV CB16/11/00360 Cardiovascular Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	MANUEL FRANCISCO JIMÉNEZ NAVARRO
B-01	CIBERONC CB16/12/00481 Cancer	CIBER	CARLOS III INSTITUTE OF HEALTH	EMILIO ALBA CONEJO
B-04	CIBERER CB06/07/0046 Rare Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	JUAN ANTONIO GARCÍA RANEA
C-09	CIBERNED Neurodegenerative Diseases CB06/05/1116	CIBER	CARLOS III INSTITUTE OF HEALTH	ANTONIA GUTIÉRREZ PÉREZ
D-05	CIBEREHD CB07/04/2008 Liver and Gastrointestinal Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	RAÚL ANDRADE

4.6. CLINICAL TRIALS

In 2024, 1286 clinical studies were conducted at IBIMA and 246 new studies were signed:




Figure 23: Active Clinical Studies (Clinical Trials and Observational Studies) in 202




Figure 24: New Clinical Studies (Clinical Trials and Observational Studies) signed in 2024

Of the 1286 clinical studies conducted in 2024, 893 were clinical trials. Of the total of 246 new studies signed, 185 were new trials. The following figures show these active and new clinical trials according to their phase:




Figure 25: Active clinical trials in 2024




Figure 26: New clinical trials signed in 2024

Changes in the clinical trials and studies conducted at the institute during the last five years are as follows:




Figure 27: Changes in Active Clinical Trials and Observational Studies from 2020-2024

Changes in early phase (phases I and II) clinical trials conducted at the Institute in the last five years is shown below:




Figure 28: Changes in active early-phase clinical trials 2020–2024

The following figure shows changes in revenue for clinical trials conducted in the last five years:




Figure 29: Changes in clinical trial revenue 2020–2024

4.7. INNOVATION AND TRANSFER

Protection

This section summarizes the results of national and international patents and utility models applied for from 2020 to 2024 by researchers at the institute as well as the list of patents applied for in 2024 and granted from 2020 to 2024.

INDICATOR	2020	2021	2022	2023	2024
National patents and utility models	15	12	16	15	9
PCT, international extensions ¹	19	20	14	9	28

¹PCT: Requests for international extension through the Patent Cooperation Treaty procedure. International extensions of patent applications.

APPLICATIONS FOR PRIORITY PATENTS/UTILITY MODELS, INDUSTRIAL DESIGNS, AND INTELLECTUAL PROPERTY REGISTRATIONS IN 2024			
TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP
NANOSYSTEM CONDUCTION SYSTEM TO ADIPOSE TISSUE THROUGH THE CREATION OF A NEGATIVELY CHARGED FIELD	P202430047	01/19/2024	A-01
DIAGNOSTIC METHOD FOR PATIENTS WITH RHEUMATOID ARTHRITIS	P202430349	05/03/2024	D-03 A-02
EPITRANSCRIPTOMIC BIOMARKERS FOR THE EARLY DETECTION OF COLORECTAL CANCER	P202430572	07/08/2024	A-02
SULFONAMIDE DERIVATIVES FOR ALCOHOL USE DISORDER	P202430833	10/15/2024	C-06
LOWER EXTREMITY ORTHOPEDIC DEVICE	P202430204	03/21/2024	FE-17
CATIONIC CARBON DOTS PREPARATION, AND GENE DELIVERY METHODS AND SYSTEMS RELATED THERETO	P202430141	02/27/2024	HE-01
POSTBIOTIC PRODUCTS FROM SHEWANELLA PUTREFACIENS PDP11 AND PREPARATION METHODS AND USES THEREOF	P202430499	06/17/2024	A-03
GALANIN (1-15) AND FLUOXETINE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION	P202430590	07/12/2024	C-07
METHOD FOR PREDICTING THE PHENOTYPIC EFFECTS OF MOLECULAR AGENTS WITH THERAPEUTIC POTENTIAL	P202431096	12/24/2024	B-04

INTERNATIONAL PATENT APPLICATIONS (PCT) IN 2024			
TITLE	REFERENCE	APPLICATION DATE	GROUP IBIMA
BIOMARKERS OF METASTASIS IN ENDOMETRIAL CANCER	PCT/ ES2024/070268	05/03/2024	B-01
CNR1 AND GPR55 AS EARLY BIOMARKERS OF TYPE 1 DIABETES	PCT/ ES2024/070292	05/16/2024	A-01
A METHOD FOR THE EARLY DETECTION OF VOMITING BEHAVIOR IN PATIENTS WITH EATING DISORDERS	PCT/ EP2024/063842	05/20/2024	A-02
BIOMARKERS AND DIAGNOSTIC METHOD FOR MONOGENIC DIABETES IN YOUNG ADULT CARRIERS OF DELETERIOUS HNF1A ALLELES	PCT/ ES2024/070483	07/29/2024	A-01 Genomics ECAI
NANOSYSTEM CONDUCTION SYSTEM TO ADIPOSE TISSUE THROUGH THE CREATION OF A NEGATIVELY CHARGED FIELD	PCT/ ES2024/070605	10/04/2024	A-01
MURINE EXTRACELLULAR MATRIX AND ITS USE IN CELL CULTURES	PCT/ ES2024/070114	02/27/2024	H-03 ECAI ANIMAL EXPERIMENTATION AND ANIMAL HOUSING
ULTRASOUND PROBE HOLDING DEVICE FOR JOINTS	PCT/ ES2024/070228	04/15/2024	C-13
FLUORESCENT COMPOUNDS BASED ON SYMMETRICAL (BIS)STYRYLINDOLIUMS WITH TWO-PHOTON ABSORPTION PROPERTIES, PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE AND USE AS MITOCHONDRIAL IDENTIFIERS	PCT/ ES2024/070598	10/02/2024	F-10
CLAY FILTERING AND RECOVERY SYSTEM	PCT/ ES2024/070593	09/30/2024	F-05
COMPOUNDS WITH ANTIMICROBIAL ACTIVITY OBTAINED FROM MINERAL DUST	PCT/ ES2024/070594	09/30/2023	F-05
COMPOUNDS WITH ANTIMICROBIAL ACTIVITY	PCT/ ES2024/070595	09/30/2023	F-05
SURFACE GRATING COUPLER SUITABLE FOR PHOTONIC DEVICES, ASSOCIATED METHOD, AND ASSEMBLY WITH SURFACE GRATING COUPLER	PCT/ ES2024/070735	11/24/2024	F-03
HIGHLY DIRECTIONAL OPTICAL PLANAR DIFFRACTIVE DEVICE	PCT/ IB2024/061706	11/22/2024	F-03

INTERNATIONAL EXTENSIONS IN 2024			
TITLE	APPLICATION No.	APPLICATION DATE	IBIMA
LIGHTING DEVICE WITH ORIENTED LED DIODES	USA: 18/580.540	01/18/2024	B-10 FA-08
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	EP22830191.7	06/27/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	RUSSIA: 2024117832	06/27/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	GEORGIA: AP202216549	07/01/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	CHILE: 202401630	05/31/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	NEW ZEALAND NO. 811638	05/31/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	AU2022400255	05/31/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	US18/715308	05/31/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	CANADA 3,242,713	06/02/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	BR1120240109976	06/02/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	IRAN 140350140003001647	06/02/2024	C-01
COMBINATION OF BIOMARKERS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS	MEXICO MX/A/2024/006686	06/02/2024	C-01
CIRCNA PROFILE FOR PREDICTING IMMUNOTHERAPY RESPONSE IN CANCER PATIENTS	18/869.700	11/26/2024	B-01 B-02
CIRCNA PROFILE FOR PREDICTING IMMUNOTHERAPY RESPONSE IN CANCER PATIENTS	EP23811228.8	12/10/2024	B-01 B-02
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES THROUGH THE BIOELECTRIC EFFECT	EP23815357.1	12/27/2024	FA-16

PATENT APPLICATIONS GRANTED 2020–2024		
TITLE	APPLICATION No.	GROUP IBIMA
PARKINSON'S DISEASE AND RELATED NEURODEGENERATIVE AND/OR MOTOR DISORDERS.	P202130377	C-07 C-01 A-01
GENE EXPRESSION SIGNATURE AS A PROGNOSTIC MARKER OF RELAPSE IN PATIENTS WITH STAGE I NONSEMINOMATOUS TESTICULAR GERM CELL TUMORS	P202030506	B-01
INTEGRATED MODE CONVERTER AND MULTIPLEXER	SG11202002241S	F-03
SUB-WAVELENGTH PERIODIC WAVEGUIDE GRATING, MODAL ADAPTER, POWER DIVIDER, AND POLARIZATION DIVIDER THAT MAKE USE OF SAID WAVEGUIDE	P202030367	F-03
SINGLE-BEAM SIDE DEFLECTOR, MULTIPLEXER/DEMULTIPLEXER, AND OPTICAL ANTENNA FEEDING DEVICE THAT INCORPORATE THE DEFLECTOR, AND METHODS THAT USE THEM	P202031204	F-03
WALKING AID HANDLE EQUIPPED WITH GALVANIC SKIN RESPONSE (GSR) AND TEMPERATURE SENSORS	U202032693	F-09
WALKING AID HANDLE EQUIPPED WITH PULSE OXIMETER	U202032695	F-09
DEVICE FOR THE INSTILLATION OF GASES INTO A BODY CAVITY	U202031502	F-05
AORTIC OPENING GUIDE DEVICE FOR SUTURELESS PROSTHESIS IMPLANTATION	U202031652	F-05
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS	US 15/529.433	C-06
ROBUST, RAPIDLY MANUFACTURED ARTIFICIAL RESPIRATOR	U202030613	F-05
MICRORNA SIGNATURE AS AN INDICATOR OF RISK OF EARLY RECURRENCE IN PATIENTS WITH BREAST CANCER	US 15/125.714	B-01
RECOMBINANT PROTEIN AND USES IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS	EP 13856322.6	C-01 / D-04
WAVEGUIDE, WAVEGUIDE PRODUCTION METHOD AND POLARISATION SPLITTER USING SAID WAVEGUIDE	SG11202013094U	F-03
GAL (1-15) AND ANALOGUES THEREOF FOR USE IN THE PREVENTION AND/OR TREATMENT OF ALCOHOL-RELATED EFFECTS AND DISORDERS	US16757706	C-07
		C-01
INTEGRATED PHOTONIC BIOSENSOR WITH LAYER DISCRIMINATION CAPABILITY AND COHERENT READOUT SYSTEM: DEVICE, ASSEMBLY, AND METHODS ASSOCIATED WITH IT	P202230993	F-03
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES THROUGH THE BIOELECTRIC EFFECT	P202230480	FA-16
METHOD FOR PREDICTING OR PROGNOSTICATE RESPONSE TO TREATMENT OF MULTIPLE SCLEROSIS WITH INTERFERON BETA	EP19869444	C-01

Collaboration with industry

Below is a summary of the indicators of collaboration between the IBIMA Plataforma BIONAND and industry. This includes active licenses, collaborations managed by FIMABIS, and technology companies founded based on a technology developed at IBIMA Plataforma BIONAND from 2020–2024.

INDICATOR	2020	2021	2022	2023	2024
Active Licenses1	7	11	13	17	18
Collaborations2	16	16	17	19	17
SPIN-OFFS/START-UPS CREATED AND ACTIVE	1	2	3	3	3

(1) The number of license agreements, not the number of licensed patent families is counted; a single license may contain several families.

(2) Contracts/agreements for conducting collaborative R&D&I projects

LICENSED/TRANSFERRED PATENT FAMILIES		
TITLE	APPLICATION No.	GROUP
PPAR-ALPHA AGONISTS, DUAL AGONISTS, AND COMBINATIONS FOR THE TREATMENT OF ALCOHOL USE DISORDER	PCT/ES2019/070565 - P201830824 - P201830825	C-06
RECOMBINANT PROTEIN AND ITS USES IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS	ES2470816-US10393758-EP2930183	C-01
METHOD FOR PREDICTING OR FORECASTING THE RESPONSE TO THE TREATMENT OF MULTIPLE SCLEROSIS WITH BETA INTERFERON	PCT/ES2019/070660 - P201830953-US17281520-EP19869444.0	C-01
COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ALCOHOL USE DISORDERS	P201630447-PCT/ES2017/070225-EP160933084	C-06
USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME	PCT/ES2011/070875-US 14/977,413-EP11848650.5	C-03
EXTERNAL FIXATOR FOR PELVIC FRACTURES AND TENSIONER FOR OPENING THE FIXATOR	PCT/ES2013/000051-EP 13755839.1	FA-07
1,2,4-OXADIAZOLE DERIVATIVES	P201030093 - PCTES2011/070042	C-06
CLAVULANIC ACID COMPOSITION AND ITS DIAGNOSTIC USE IN ALLERGOLOGY	P200930781	D-04
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS	PCT/ES2015/070848	C-06

LICENSED/TRANSFERRED PATENT FAMILIES		
TITLE	APPLICATION No.	GROUP
INTEGRATED MODE CONVERTER AND MULTIPLEXER	PCT/EP2018/075753 US17837774	F-03
INTEGRATED POLARIZATION DIVIDER	P201830129 PCT/ES2019/070031	F-03
WAVEGUIDE, METHOD OF MANUFACTURING SAID WAVEGUIDE, AND POLARIZATION SPLITTER THAT MAKES USE OF SAID WAVEGUIDE	P201830653 PCT/ES2019/070452 EP19759632.3	F-03
BRICKED SUB-WAVELENGTH PERIODIC WAVEGUIDE, MODAL ADAPTER, POWER DIVIDER AND POLARISATION SPLITTER THAT USE SAID WAVEGUIDE	PCT/ES2021/070279 US17922350	F-03
MULTIMODE INTERFERENCE COUPLER AND METHOD FOR THE STRUCTURAL CONFIGURATION THEREOF	PCT/EP2009/061149 EP09782346.2 US13060341	F-03
MULTIVALENT HAPTEN CARRIER COMPLEXES WITH DENDRIMERS AS CARRIER PROTEIN EMULATORS	P200302737	F-10
INTEGRATED MODE CONVERTER AND MULTIPLEXER	P201731166, PCT/EP2018/075753	F-03
INTEGRATED PHOTONIC BIOSENSOR WITH LAYER DISCRIMINATION CAPABILITY AND COHERENT READOUT SYSTEM: DEVICE, ASSEMBLY, AND METHODS ASSOCIATED WITH IT	P202230993 PCT/ES2023/070688	F-03
SURFACE GRATING COUPLER SUITABLE FOR PHOTONIC DEVICES, ASSOCIATED METHOD, AND ASSEMBLY WITH SURFACE GRATING COUPLER	P202330970 PCT/ES2024/070735	F-03
IN VITRO METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF MULTIPLE SCLEROSIS	EP21383087.0 PCT/EP2022/084300 MX/a/2024/006686 CL202401630 BR112024010997-6 IR140350140003001647 US18715308 NZ811638 AU2022400255 EP22830191.7 RU2024117832 CA3242713 AP202216549	C-01

SPIN-OFFS/START-UPS CREATED AND ACTIVE	
GALEA Therapeutics	Research and development of drugs for the treatment of fatty liver disease and related diseases. Focusing on the disease's origin related to obesity and/or alcohol intake.
ALA Diagnostics	Development and marketing of in vitro diagnostic kits for highly prevalent diseases and/or unresolved medical needs.
Bioherent	Diagnosis of drug allergies through a system based on a photonic biosensor.

INNOVATIONS GENERATED IN 2024

EPIPREDICT

IBIMA Plataforma BIONAND Group: **TRANSLATIONAL RESEARCH IN CANCER IMMUNOTHERAPY AND EPIGENETICS (B-05)**

EPIPREDICT combines epigenetic markers analyzed with software in a liquid biopsy to predict patient response to immunotherapy treatment. This project is currently in TRL 5-6.

PROSAKI: Software that allows automated interpretation of clinical reports.

IBIMA Plataforma BIONAND Group: **Bioinformatics ECAI**

Prosaki is a software for medical use designed in R shiny and optimized to analyze common clinical documents such as admission and discharge summaries in order to detect changes in a patient's cardiac capacity, identifying possible improvements or deteriorations.

ACTIVE IDEAS

The Innovation and Technology Transfer Unit of IBIMA Plataforma BIONAND had 111 active ideas at different levels of technological maturity at the end of 2024. These ideas represent the collective effort of the Institute's research groups to generate knowledge with a potential impact on health and society.

Some 35% of the ideas are already on the market. They have been implemented in the healthcare system, licensed to third parties, or made available to the community through open resources such as bioinformatics or patient support tools.

On the other hand, almost 30% of the ideas are in the transfer phase. This implies that they have a result with the potential to be implemented in clinical practice, either directly or through agreements with external agents that continue their development.

In about 10% of cases, the ideas are in the development phase, with an active innovation or technology project underway. Many of these continue to progress, although they are already in the process of being transferred, which highlights the need to advance in parallel along both lines.

Almost 10% of the initiatives are under analysis, either studying their technical feasibility, patentability, or seeking funding to take the next step.

Lastly, 20% of the ideas are still in the data collection phase: the information needed to evaluate them and define their potential is still being gathered.

This mind map reflects IBIMA Plataforma BIONAND's commitment to the valuation of the knowledge generated with a focus on concrete results that improve people's health and strengthen collaboration with the business environment.




Figure 30: Active ideas

4.8. CLINICAL PRACTICE GUIDELINES IMPLEMENTED IN HEALTHCARE CENTERS

- **“Practical Guidelines by the Andalusian Group for Nutrition Reflection and Investigation (GARIN) on Nutritional Management of Patients with Chronic Obstructive Pulmonary Disease: A Review”,** NUTRIENTS. Enriquez, Alicia Justel; Rabat-Restrepo, Juana M.; Vilchez-Lopez, Francisco J.; Tenorio-Jimenez, Carmen; Garcia-Almeida, Jose M.; Rocamora, Jose-Antonio Irles; Pereira-Cunill, Jose L.; Ramirez, Maria J. Martinez; Molina-Puerta, Maria J.; Soria, Juan B. Molina; Rebollo-Perez, Maria I.; Oliveira, Gabriel; Garcia-Luna, Pedro P.
- **“Multidisciplinary Management of Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease”,** ARCHIVOS DE BRONCONEUMOLOGIA. de Miguel-Diez, Javier; Villota, Julio Nunez; Perez, Salud Santos; Lorite, Nicolas Manito; Navarrete, Bernardino Alcazar; Jimenez, Juan Francisco Delgado; Soler-Cataluna, Juan Jose; Figal, Domingo Pascual; Ecenarro, Patricia Sobradillo; Doblas, Juan Jose Gomez.
- **“Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting”,** FUTURE CARDIOLOGY. Doblas, Juan Jose Gomez; Garcia-Moll, Xavier; Freire, Ramon Bover; Juanatey, Carlos Gonzalez; Morillas, Miren; Munoz, Alfonso Valle; Escobar, Carlos.
- **“SEA 2024 Standards for Global Control of Vascular Risk”,** CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS. Mostaza, Jose Maria; Pinto, Xavier; Armario, Pedro; Masana, Luis; Real, Jose T.; Valdivielso, Pedro; Arrobas-Velilla, Teresa; Baeza-Trinidad, Ramon; Calmarza, Pilar; Cebollada, Jesus; Civera-Andres, Miguel; Melero, Jose I. Cuende; Diaz-Diaz, Jose L.; Espildora-Hernandez, Javier; Pardo, Jacinto Fernandez; Guijarro, Carlos; Jerico, Carles; Laclaustra, Martin; Lahoz, Carlos; Lopez-Miranda, Jose; Martinez-Hervas, Sergio; Muniz-Grijalvo, Ovidio; Paramo, Jose A.; Pascual, Vicente; Pedro-Boteta, Juan; Perez-Martinez, Pablo; Puzo, Jose.
- **“Practical Recommendations for the Diagnosis and Management of Lysosomal Acid Lipase Deficiency with a Focus on Wolman Disease”,** NUTRIENTS. de las Heras, Javier; Almohalla, Carolina; Blasco-Alonso, Javier; Bourbon, Mafalda; Couce, Maria-Luz; de Castro Lopez, Maria Jose; Garcia Jimenez, Ma Concepcion; Gil Ortega, David; Gonzalez-Dieguez, Luisa; Meavilla, Silvia; Moreno-alvarez, Ana; Pastor-Rosado, Jose;

Sanchez-Pintos, Paula; Serrano-Gonzalo, Irene; Lopez, Eduardo; Valdivielso, Pedro; Yahyaoui, Raquel; Quintero, Jesus.

- **“SEOM-GEICO Clinical Guidelines on cervical cancer”,** CLINICAL & TRANSLATIONAL ONCOLOGY. Manso, Luis; Ramchandani-Vaswani, Avinash; Romero, Ignacio; Sanchez-Lorenzo, Luisa; Bermejo-Perez, Maria Jose; Estevez-Garcia, Purificacion; Farina-Madrid, Lorena; Garcia, Yolanda Garcia; Gil-Martin, Marta; Quindos, Maria.
- **“Spanish Academy of Dermatology and Venereology (AEDV) expert recommendations for the management of sexual transmitted parasitosis. Scabies, and pediculosis pubis”,** ACTAS DERMOSIFILIOGRAFICAS. Galvan-Casas, C.; Ortiz-Alvarez, J.; Martinez-Garcia, E.; Corbacho-Monne, M.
- **“Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network”,** JOURNAL OF HEPATOLOGY. Segovia-Zafra, Antonio; Villanueva-Paz, Marina; Serras, Ana Sofia; Matilla-Cabello, Gonzalo; Bodoque-Garcia, Ana; Zeo-Sanche, Daniel E. Di; Niu, Hao; Alvarez-Alvarez, Ismael; Sanz-Villanueva, Laura; Godec, Sergej; Milisav, Irina; Bagnaninchi, Pierre; Andrade, Raul J.; Lucena, M. Isabel; Fernandez-Checa, Jose C.; Cubero, Francisco Javier; Miranda, Joana Paiva; Nelson, Leonard J.
- **“Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative”,** DRUG SAFETY. Cohen, Eric B.; Patwardhan, Meenal; Raheja, Ritu; Alpers, David H.; Andrade, Raul J.; Avigan, Mark I.; Lewis, James H.; Rockey, Don C.; Chui, Francis; Iacob, Alexandru M.; Linardi, Camila C.; Regev, Arie; Shick, Jesse; Lucena, Maribel I.
- **“Telematic interview in telepharmacy: consensus document for pharmacotherapeutic monitoring and informed drug delivery”,** FARMACIA HOSPITALARIA. Barbadillo-Villanueva, Sara; del Aguila, Vera Areas; Robustillo-Cortes, Maria de las Aguas; Gimeno-Gracia, Mercedes; Yanez, Elena Sanchez; Hermenegildo-Caudevilla, Marta; Aznarez, Herminia Navarro; Lopez, Alicia Lazaro; Vicente, Esther; Monte-Boquet, Emilio.
- **“The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus”,** METABOLISM-CLINICAL AND EXPERIMENTAL. Zeng, Xu-Fen; Varady, Krista A.; Wang, Xiang-Dong; Targher, Giovanni; Byrne, Christopher D.; Tayyem, Reema; Latella, Giovanni; Bergheim, Ina; Valenzuela, Rodrigo; George, Jacob; Newberry, Carolyn; Zheng, Ju-Sheng; George, Elena S.; Spearman, C. Wendy; Kontogianni, Meropi D.; Ristic-Medic, Danijela; Peres, Wilza Arantes Ferreira; Depboylu, Gamze Yurtdas; Yang, Wanshui; Chen, Xu; Rosqvist, Fredrik; Mantzoros, Christos S.; Valenti, Luca; Yki-Jaervinen, Hannele; Mosca, Antonella; Sookoian, Silvia; Misra, Anoop; Yilmaz, Yusuf; Kim, Won; Fouad, Yasser; Sebastiani, Giada; Wong, Vincent Wai-Sun; Aberg, Fredrik; Wong, Yu Jun; Zhang, Pianhong; Bermudez-Silva, Francisco-Javier; Ni, Yan; Lupsor-Platon, Monica; Chan, Wah Kheong; Mendez-Sanchez, Nahum; Knekt, Robert J. de; Alam, Shahinul; Treeprasertsuk, Sombat; Wang, Li; Du, Mulong; Zhang, Tiejun; Yu, Ming-Lung; Zhang, Huijie; Qi, Xingshun; Liu, Xin; Pinyopornpanish, Kanokwan; Fan, Yu-Chen; Niu, Kaijun; Jimenez-Chillaron, Josep C.; Zheng, Ming-Hua.
- **“Consensus on criteria and minimum data set for the referral of candidate patients for home enteral nutrition teleconsultation: TELENUT project”,** NUTRICION HOSPITALARIA. Restrepo, Juana Maria Rabat; Perez, Isabel M. Rebollo; de Luna, Pedro Pablo Garcia; Cunill, Jose Luis Pereira; Lopez, Francisco Javier Vilchez; Marin, Montserrat Gonzalo; Doblas, Carmen Yeste; Ortega, Antonio Jesus Martinez; Ramirez, Jose Martinez; Morell, Concha Losada; Rojas, Julio; Ortiz, Manuela; Corte, Joaquin Obando de la; Colorado, Maria Eulalia Macias.
- **“European Society of Hypertension clinical practice guidelines for the management of arterial hypertension”,** EUROPEAN JOURNAL OF INTERNAL MEDICINE. Kreutz, Reinhold; Brunstrom, Mattias; Burnier, Michel; Grassi, Guido; Januszewicz, Andrzej; Muiesan, Maria Lorenza; Tsioufis, Konstantinos; de Pinho, Rosa Maria; Albin, Fabio Lucio; Boivin, Jean-Marc; Doumas, Michalis; Nemcsik, Janos; Rodilla, Enrique; Agabiti-Rosei, Enrico; Algharably, Engi Abd Elhady; Agnelli, Giancarlo; Benetos, Athanase; Hitij, Jana Brguljan; Cifkova, Renata; Cornelissen, Veronique; Danser, A. H. Jan; Delles, Christian; Huelgas, Ricardo Gomez; Jarai, Zoltan; Palatini, Paolo; Pathak, Atul; Persu, Alexandre; Polonia, Jorge; Sarafidis, Pantelis; Stergiou, George; Thomopoulos, Costas; Wanner, Christoph; Weber, Thomas; Williams, Bryan; Kjeldsen, Sverre E.; Mancina, Giuseppe.

- **“Standardization in paediatric echocardiographic reporting and critical interpretation of measurements, functional parameters, and prediction scores: a clinical consensus statement of the European Association of Cardiovascular Imaging of the European Society of Cardiology and the Association for European Paediatric and Congenital Cardiology”, EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING.** Cantinotti, Massimiliano; Di Salvo, Giovanni; Voges, Inga; Raimondi, Francesca; Greil, Gerald; Garrido, Almudena Ortiz; Bharucha, Tara; Grotenhuis, Heynric B.; Koestenberger, Martin; Bonnello, Beatrice; Miller, Owen; McMahon, Colin J.
- **“Diagnostic and therapeutic approach to spondylodiscitis in Spanish children through the RIOPed Network: Evaluation before and after the publication of the national consensus document”, ANALES DE PEDIATRIA.** Pedraz, Laura Martin; Cuadros, Esmeralda Nunez; Hernandez, Maria Belen; Rueda, Rosa Maria Alcobendas; Saavedra-Lozano, Jesus; Rey, Cristina Calvo.
- **“Expert consensus for the management of patients with achondroplasia in treatment with vosoritide”, ANALES DE PEDIATRIA.** Barreda-Bonis, Ana-Coral; Domingo, Josep Maria de Bergua; Galan-Gomez, Enrique; Guillen-Navarro, Encarna; Leiva-Gea, Isabel; Riano-Galan, Isolina.
- **“Executive summary: Guidelines for the diagnosis and treatment of septic arthritis in adults and children, developed by the GEIO (SEIMC), SEIP and SECOT”, ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA.** Benito, Natividad; Martinez-Pastor, Juan Carlos; Lora-Tamayo, Jaime; Ariza, Javier; Baeza, Jose; Belzunegui-Otano, Joaquin; Cobo, Javier; del-Toro, Maria-Dolores; Fontecha, Cesar G.; Font-Vizcarra, Lluís; Horcajada, Juan P.; Morata, Laura; Murillo, Oscar; Nolla, Joan M.; Nunez-Cuadros, Esmeralda; Pigrau, Carlos; Portillo, Maria Eugenia; Rodriguez-Pardo, Dolores; Sobrino-Diaz, Beatriz; Saavedra-Lozano, Jesus.
- **“Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol”, REVISTA DE NEUROLOGIA.** Arenas-Cabrera, Carmen; Cabezudo-Garcia, Pablo; Calvo-Medina, Rocio; Galeano-Bilbao, Benito; Martinez-Agredano, Paula; Ruiz-Gimenez, Jesus; Rodriguez-Uranga, Juan J.; Quiroga-Subirana, Pablo.
- **“Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP”, CLINICAL & TRANSLATIONAL ONCOLOGY.** Ospina, Aylen Vanessa; Nadal, Sergio Bolufer; de la Cruz, Jose Luis Campo-Canaveral; Larriba, Jose Luis Gonzalez; Vidueira, Ivan Macia; Sureda, Bartomeu Massuti; Nadal, Ernest; Trancho, Florentino Hernando; Kindelan, Antonio Alvarez; Morillo, Edel Del Barco; Caro, Reyes Bernabe; Barrera, Joaquim Bosch; de Juan, Virginia Calvo; Rubio, Joaquin Casal; de Castro, Javier; Ramos, Angel Cilleruelo; Dols, Manuel Cobo; Gomez, Manuel Domine; Almanzar, Santiago Figueroa; Campelo, Rosario Garcia; Molla, Amelia Insa; Sarceda, Jose Ramon Jarabo; Maestre, Unai Jimenez; Castro, Rafael Lopez; Majem, Margarita; Martinez-Marti, Alex; Tellez, Elisabeth Martinez; Lorente, David Sanchez; Provencio, Mariano.
- **“SEOM-GEM clinical guidelines for cutaneous melanoma”, CLINICAL & TRANSLATIONAL ONCOLOGY.** Marquez-Rodas, Ivan; Couselo, Eva Munoz; Moreno, Juan F. Rodriguez; Fernandez, Ana Ma Arance; Guerrero, Miguel Angel Berciano; Balea, Begona Campos; Merino, Luis de la Cruz; Arranz, Enrique Espinosa; Castano, Almudena Garcia; Jaime, Alfonso Berrocal.
- **“SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer”, CLINICAL & TRANSLATIONAL ONCOLOGY.** Pericay, Carles; Montagut, Clara; Reina, Juan Jose; Melian, Marcos; Alcaide, Julia; Tarazona, Noelia; Ruiz-Casado, Ana; Gonzalez-Flores, Encarnacion; Grana, Begona; Gravalos, Cristina.
- **“Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023”, NEUROLOGIA.** Meca-Lallana, J. E.; Yelamos, S. Martinez; Eichau, S.; Llana, M. A.; Martinez, J. Martin; Martinez, J. Pena; Lallana, V. Meca; Torres, A. M. Alonso; Torres, E. Moral; Rio, J.; Calles, C.; Luque, A. Ares; Ramio-Torrenta, L.; Sola, M. E. Marzo; Prieto, J. M.; Gines, M. L. Martinez; Arroyo, R.; Martinez, M. A. Otano; Ruiz, L. Brieve; Gutierrez, M. Gomez; Zarranz, A. Rodriguez-Antiguedad; Sanchez-Seco, V. G.; Costa-Frossard, L.; Perez, M. A. Hernandez; Pascual, L. Landete; Platas, M. Gonzalez; Oreja-Guevara, C.
- **“Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care”, BMC RHEUMATOLOGY.** Castrejon, Isabel; Cano, Laura; Cuadrado, Maria Jose; Borrás, Joaquin; Galindo, Maria; Salman-Monte, Tarek C.; Amoros, Carlos; Roman, Carmen San; Cabezas, Isabel; Comellas, Marta; Munoz, Alejandro.
- **“Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus”, REUMATOLOGIA CLINICA.** Rua-Figueroa, Inigo; Carlos Salman-Monte, Tarek; Pego Reigosa, Jose Maria; Galindo Izquierdo, Maria; Diez Alvarez, Elvira; Fernandez-Nebro, Antonio; Roman Ivorra, Jose Andres; Calvo Penades, Inmaculada; Artaraz Beobide, Joseba; Calvo Alen, Jaime.
- **“Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis”, REUMATOLOGIA CLINICA.** Alvaro, Jose Maria alvaro-Gracia; Fontecha, Petra Diaz del Campo; Sanchez, Jose Luis Andreu; Criado, Alejandro Balsa; Caliz, Rafael Caliz; Fernandez, Isabel Castrejon; Corominas, Hector; Puerta, Jose A. Gomez; Arija, Sara Manrique; Vazquez, Natalia Mena; Garcia, Ana Ortiz; Rodriguez, Chamaida Plasencia; Fernandez, Lucia Silva; Molina, Jesus Tornero.
- **“An International Delphi Consensus on the Management of Pollen-Food Allergy Syndrome: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee”, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE.** Al-Shaikhly, Taha; Cox, Amanda; Nowak-Wegrzyn, Anna; Cianferoni, Antonella; Katelaris, Constance; Ebo, Didier G.; Konstantinou, George N.; Brucker, Hannelore; Yang, Hyeon-Jong; Protudjer, Jennifer L. P.; Boechat, Jose Laerte; Yu, Joyce E.; Wang, Julie; Blatman, Karen S. Hsu; Blazowski, Lukasz; Anand, Mahesh Padukudru; Ramesh, Manish; Torres, Maria J.; Holbreich, Mark; Goodman, Richard; Wasserman, Richard L.; Hopp, Russell; Sato, Sakura; Skypala, Isabel.
- **“Patient-reported outcome measures in severe asthma: an expert consensus”, JOURNAL OF ASTHMA.** Martinez-Moragon, Eva; Antepara Ercoreca, Ignacio; Munoz Garcia, Maria; Casas Maldonado, Francisco; Calvin Lamas, Marta; Chiner Vives, Eusebi; Crespo Diz, Carlos; Diaz-Perez, David; Eguiluz Gracia, Ibon; Garcia Gil, Sara; Gonzalez-Perez, Ruperto; Habernau Mena, Alicia; Hermida Valverde, Tamara; Jornet Montana, Sonia; Lopez-Carrasco, Valentin; Martinez Lopez, Iciar; Merino-Bohorquez, Vicente; Moreno-Ancillo, Alvaro; Minguez Cabeza, Ana Cristina; Monte-Boquet, Emilio; Revuelta-Herrero, Jose Luis; Sanchez-Cuellar, Silvia.
- **“EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance”, ALLERGY.** Pascal, M.; Edelman, S. M.; Nopp, A.; Moebs, C.; Geilenkeuser, W. J.; Knol, E. F.; Ebo, D. G.; Mertens, C.; Shamji, M. H.; Santos, A. F.; Patil, S.; Eberlein, B.; Mayorga, C.; Hoffmann, H. J.
- **“Allergic Rhinitis and its Impact on Asthma 2024 Guideline Panel. Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review with Meta-Analysis”, J. ALLERGY CLIN. IMMUNOL. PRACT.** Torres MI, Gil-Mata S, Bognanni A, Ferreira-da-Silva R, Yepes-Nuñez JJ, Lourenço-Silva N, Cardoso-Fernandes A, Ferreira A, Ferreira-Cardoso H, Portela D, Teles J, Kvedariene V, Torres MJ, Klimek L, Pfaar O, Brussino L, Zuberbier T, Fonseca JA, Schünemann H, Bousquet J, Sousa-Pinto B, Vieira RJ.
- **“First consensus document of waiting list prioritization for liver transplantation by the Spanish Society of Liver Transplantation (SETH)”, REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS.** Bilbao, Itxarone; Llado, Laura; Cachero, Alba; Campos-Varela, Isabel; Colmenero, Jordi; del Hoyo, Javier; Fabrega Garcia, Emilio; Garcia Pajares, Felix; Gonzalez Dieguez, Luisa; Gonzalez Grande, Rocio; Guibertau Sanchez, Ana; Hernandez Oliveros, Francisco; Herrero Santos, Jose Ignacio; Lorente, Sara; Martin Mateos, Rosa; Mesa Lopez, Maria Jose; Montero Alvarez, Jose Luis; Munoz Codoceo, Carolina; Otero Ferreira, Alejandra; Oton Nieto, Elena; Rodriguez Soler, Maria; Romero Cristobal, Mario; Sastre Oliver, Lidia; Senosiain Labiano, Maria; Sousa Martin, Jose Manuel; Trapero-Marugan, Maria; Varo, Evaristo; de la Rosa, Gloria; Rodriguez-Peralvarez, Manuel Luis.

The background is a solid teal color. Scattered across the page are several abstract, light blue, elongated shapes that resemble stylized leaves or petals. These shapes are oriented in various directions, some pointing towards the top right and others towards the bottom left.

RESEARCH AREAS AND GROUPS

5

5.1. PRIORITY SCIENTIFIC AREAS

SCIENTIFIC PRODUCTION

This section shows data on the scientific production of the IBIMA Plataforma BIONAND priority research areas in a disaggregated manner. Collaborative publications among different groups in the same area have only been considered once for the calculation. Area 5 (IBIMA Rare) is multidisciplinary and publications are not included since they are already included in the rest of the areas:




Figure 31: Cumulative and average impact factor by research areas




Figure 32: Percentage of publications in each area (original articles and reviews) compared to the institute as a whole




Figure 33: Percentage of publications ranked Q1 and D1 in their category (JCR) by area

ACTIVE PROJECTS




Figure 34: Active competitive research projects at the regional, national, and international level by scientific area/research units

The percentage of competitive research projects in 2024 conducted by each research area/unit is as follows:

Research Area	Total active research projects	% of total research projects
Area 1	108	30%
Onco-Hemat. Unit	45	12%
Area 3	93	25%
Area 4	67	18%
IBIMA Tech Area	38	10%
Area 8	18	5%

IBIMA Rare area is a multidisciplinary area of the IBIMA Plataforma BIONAND formed by groups that also belong to other areas. The area is not included in this last figure and table so as not to distort the total number of active projects.

CLINICAL TRIALS

The clinical trials conducted in each scientific area/research unit of the IBIMA Plataforma BIONAND during the past year are as follows:




Figure 35: Distribution of active clinical trials by research areas/unit

AREA 1. CARDIOVASCULAR DISEASES, OBESITY, AND DIABETES. ENVIRONMENTAL DETERMINANTS AND LIFESTYLE.

Coordinator: Ricardo Gómez Huelgas. Assistant Coordinator: Rosa Bernal López

Scientific Production




Figure 36: Number of publications, number of publications led, and Impact Factor of Area 1

Figure 37: Percentage of publications in Q1 and D1 from Area 1

Selection of the five most relevant publications in the area in 2024:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-01	Ozcariz, E; Guardiola, M; Amigó, N; Valdés, S; Oualla-Bachiri, W; Rehues, P; Rojo-Martinez, G; Ribalta, J	H-NMR metabolomics identifies three distinct metabolic profiles differentially associated with cardiometabolic risk in patients with obesity in the Di@bet.es cohort	CARDIOVASCULAR DIABETOLOGY	8.5	D1	2024
A-02	Linares-Pineda, TM; Fragoso-Bargas, N; Picón, MJ; Molina-Vega, M; Jenum, AK; Sletner, L; Lee-Odegård, S; Opsahl, JO; Moen, GH; Qvigstad, E; Prasad, RB; Birkeland, KI; Morcillo, S; Sommer, C	DNA methylation risk score for type 2 diabetes is associated with gestational diabetes	CARDIOVASCULAR DIABETOLOGY	8.5	D1	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-02	Herrera-Martínez, AD; Prior-Sánchez, I; Fernández-Soto, ML; García-Olivares, M; Novo-Rodríguez, C; González-Pacheco, M; Martínez-Ramírez, MJ; Carmona-Llanos, A; Jiménez-Sánchez, A; Muñoz-Jiménez, C; Torres-Flores, F; Fernández-Jiménez, R; Boughanem, H; del Galindo-Gallardo, MC; Luengo-Pérez, LM; Molina-Puerta, MJ; García-Almeida, JM	Improving the nutritional evaluation in head neck cancer patients using bioelectrical impedance analysis: Not only the phase angle matters	JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE	9.4	D1	2024
A-03	de Miguel-Díez, J; Villota, JN; Pérez, SS; Lorite, NM; Navarrete, BA; Jiménez, JFD; Soler-Cataluña, JJ; Figal, DP; Ecenarro, PS; Doblas, JJG	Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease	ARCHIVOS DE BRONCONEUMOLOGIA	8.7	D1	2024
A-03	Molina-Ramos, AI; Ruiz-Salas, A; Medina-Palomo, C; Becerra-Munoz, V; Rodriguez-Capitan, J; Romero-Cuevas, M; Carmona-Segovia, A; Fernandez-Lozano, I; Gomez-Doblas, JJ; Navarro, MJ; Pavon-Moron, FJ; Barrera-Cordero, A; Alzueta-Rodriguez, J	Index and Repeat Ablation for Atrial Fibrillation in Older versus Younger Patients: A Propensity-Score Matching Analysis	AGING AND DISEASE	7	D1	2024

108
Active research projects

184
Clinical trials

CIMO ONCO-HEMATOLOGY UNIT

Coordinator: Melissa García Caballero. Assistant Coordinator: Elisa Matas Rico

Scientific Production




Figure 38: No. publications, no. publications led, and Impact Factor from CIMO Onco-Hematology Unit




Figure 39: Percentage of Q1 and D1 publications from the CIMO Onco-Hematology Unit

Selection of the five most relevant publications from the Unit in 2024:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-01	Hinte, Laura C.; Castellano-Castillo, Daniel; Ghosh, Adhideb; Melrose, Kate; Gasser, Emanuel; Noe, Falko; Massier, Lucas; Dong, Hua; Sun, Wenfei; Hoffmann, Anne; Wolfrum, Christian; Ryden, Mikael; Mejhert, Niklas; Blueher, Matthias; von Meyenn, Ferdinand	Adipose tissue retains an epigenetic memory of obesity after weight loss	NATURE	50.5	D1	2024
B-01	Castellano-Castillo, D; Ramos-Molina, B; Frutos, MD; Arranz-Salas, I; Reyes-Engel, A; Queipo-Ortuño, MI; Cardona, F	RNA expression changes driven by altered epigenetics status related to NASH etiology	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	2024
B-04	Cordoba-Caballero, J; Perkins, JR; Garcia-Criado, F; Gallego, D; Navarro-Sánchez, A; Moreno-Estellés, M; Garcés, C; Bonet, F; Romá-Mateo, C; Toro, R; Perez, B; Sanz, P; Kohl, M; Rojano, E; Seoane, P; Ranea, JAG	Exploring miRNA-target gene pair detection in disease with coRmiT	BRIEFINGS IN BIOINFORMATICS	6.8	D1	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-04	Marrero, AD; Cárdenas, C; Castilla, L; Ortega-Vidal, J; Quesada, AR; Martínez-Poveda, B; Medina, MA	Antiangiogenic Potential of an Olive Oil Extract: Insights from a Proteomic Study	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY	5.7	D1	2024
B-01	Alba-Bernal, A; Godoy-Ortiz, A; Domínguez-Recio, ME; López-López, E; Quirós-Ortega, ME; Sánchez-Martín, V; Roldán-Díaz, MD; Jiménez-Rodríguez, B; Peralta-Linero, J; Bellagarza-García, E; Troyano-Ramos, L; Garrido-Ruiz, G; Hierro-Martín, MI; Vicioso, L; González-Ortiz, A; Linares-Valencia, N; Velasco-Suelto, J; Carbajosa, G; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Comino-Méndez, I; Alba, E	Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	NPJ BREAST CANCER	6.6	Q1	2024

Active Research Projects: 45

Clinical Trials: 522



Active research projects



Clinical trials

AREA 3. NEUROSCIENCES, CHRONICITY, AGING, AND HEALTH IN VULNERABLE POPULATIONS

Coordinator: Antonia Serrano Criado, Deputy Coordinator: Patricia Moreno Peral.

Scientific Production




Figure 40: No. publications, no. publications led, and Impact Factor from Area 3




Figure 41: Percentage of publications in Q1 and D1 from Area 3

Selection of the five most relevant publications in the area in 2024:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-01	Serrano-Castro, PJ; Ramírez-García, T; Cabezudo-Garcia, P; Garcia-Martin, G; De La Parra, J	Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study	CNS DRUGS	7.4	D1	2024
C-01	Ciano-Petersen, NL; Muñiz-Castrillo, S; Villagrán-García, M; Farina, A; Vogrig, A; Wucher, V; Do, L; Birzu, C; Goncalves, D; Flabeau, O; Duwicquet, C; Benard, A; Nicole, F; Rogemond, V; Picard, G; Joubert, B; Honnorat, J	Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma	NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION	8.3	D1	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-01	Aliaga-Gaspar, Pablo; Brichette-Mieg, Isabel; Fernandez-Arjona, MdM; Rodriguez-Bada, Jose Luis; Lopez-Moreno, Yolanda; Serrano-Castro, Pedro; Fernandez-Fernandez, Oscar; Ciano-Petersen, Nicolas Lundahl; Oliver-Martos, Begona	Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy.	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	2024
C-03	del Campo-avila, J; Ramos-Martín, J; Gómez-Sánchez-Lafuente, C; García-Pedrosa, J; García-Martín, S; Martínez-García, AI; Guzmán-Parra, J; Morales-Bueno, R; Moreno-Küstner, B	Data mining process to detect suicidal behaviour in out-of-hospital emergency departments	ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE	7.5	D1	2024
C-05	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	2024



Active research projects



Clinical trials

AREA 4. AUTOIMMUNE DISEASES, INFECTIOUS DISEASES, INFLAMMATION, AND ALLERGY.

Coordinator: Cristobalina Mayorga Mayorga, Adjunct Coordinator: Natalia Mena Vázquez

Scientific Production




Figure 42: No. publications, no. publications led, and Impact Factor from Area 4




Figure 43: Percentage of publications in Q1 and D1 from Area 4

Selection of the five most relevant publications in the area in 2024:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-05	Segovia-Zafra, A; Villanueva-Paz, M; Serras, AS; Matilla-Cabello, G; Bodoque-García, A; Zeo-Sánchez, DED; Niu, H; Alvarez-Alvarez, I; Sanz-Villanueva, L; Godec, S; Milisav, I; Bagnaninchi, P; Andrade, RJ; Lucena, MI; Fernández-Checa, JC; Cubero, FJ; Miranda, JP; Nelson, LJ	Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network	JOURNAL OF HEPATOLOGY	26.8	D1	2024
D-04	Cruz-Amaya, A; Martin-Astorga, MD; Lebron-Martín, C; Paris, JL; Céspedes, JA; Núñez, R; Torres, MJ; Aranda, CJ; Cañas, JA; Mayorga, C	Butyrate dietary supplementation promotes tolerant responses in a Pru p 3-anaphylactic mouse model	ALLERGY	12.6	D1	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-04	Mayorga, C; Çelik, GE; Pascal, M; Hoffmann, HJ; Eberlein, B; Torres, MJ; Brockow, K; Garvey, LH; Barbaud, A; Madrigal-Burgaleta, R; Caubet, JC; Ebo, DG	Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper	ALLERGY	12.6	D1	2024
D-04	Bavbek, S; Özdemir, SK; Bonadonna, P; Atanaskovic-Markovic, M; Barbaud, A; Brockow, K; Martinez, JL; Nakonechna, A; Pagani, M; Arcolaci, A; Lombardo, C; Torres, MJ	Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper	ALLERGY	12.6	D1	2024
D-04	Cespedes, JA; Fernandez-Santamaria, R; Bogas, G; Veguillas, AA; Dona, I; Salas, M; Labella, M; Duarte, TDF; Mayorga, C; Torres, MJ; Frecha, CA	LPS in combination with amoxicillin increases BAT sensitivity to amoxicillin IgE-mediated hypersensitivity	ALLERGY	12.6	D1	2024



Active research projects



Clinical trials

AREA 6. IBIMA TECH: HEALTH TECHNOLOGY AND INNOVATION.

Coordinator: Antonio Ignacio Cuesta Vargas. Assistant coordinator: Francisco Ángel Moreno Dueñas

Scientific Production




Figure 44: Number of publications, number of publications led, and Impact Factor for the IBIMA Tech Area




Figure 45: Percentage of publications in Q1 and D1 from the IBIMA Tech Area

Selection of the five most relevant publications in the area in 2024:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-15	Nematzadeh, H; García-Nieto, J; Aldana-Montes, JF; Navas-Delgado, I	Pattern recognition frequency-based feature selection with multi-objective discrete evolution strategy for high-dimensional medical datasets	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1	2024
F-15	Picornell, A; Hurtado, S; Antequera-Gómez, ML; Barba-González, C; Ruiz-Mata, R; de Gálvez-Montañez, E; Recio, M; Trigo, MD; Aldana-Montes, JF; Navas-Delgado, I	A deep learning LSTM-based approach for forecasting annual pollen curves: Olea and Urticaceae pollen types as a case study	COMPUTERS IN BIOLOGY AND MEDICINE	7	D1	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-15	Segura-Ortiz, Adrian; Garcia-Nieto, Jose; Aldana-Montes, Jose F; Navas-Delgado, Ismael	Multi-objective context-guided consensus of a massive array of techniques for the inference of Gene Regulatory Networks.	Computers in biology and medicine	7	D1	2024
FE-20	Sendra-Portero, F; Lorenzo-Alvarez, R; Rudolphi-Solero, T; Ruiz-Gómez, MJ	The Second Life Metaverse and Its Usefulness in Medical Education After a Quarter of a Century	JOURNAL OF MEDICAL INTERNET RESEARCH	5.8	D1	2024
F-14	Fuentes-Abolafio, IJ; Trinidad-Fernández, M; Ricci, M; Roldán-Jiménez, C; Gómez-Huelgas, R; Arjona-Caballero, JM; Escriche-Escuder, A; Bernal-López, MR; Pérez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic parameters related to functional capacity, fatigue, and breathlessness during the 6-min walk test in older adults with heart failure with preserved ejection fraction	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	2.9	D1	2024

38

Active research projects

6

Clinical trials

AREA 7. NANODIAGNOSTICS.

Coordinator: María Luisa García Martín

Scientific Production




Figure 46: Number of publications, number of publications led, and Impact Factor from Area 7.




Figure 47: Percentage of publications in Q1 and D1 in Area 7.

Selection of the five most relevant publications in the area in 2023:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Caro, C; Guzzi, C; Moral-Sánchez, I; Urbano-Gámez, JD; Beltrán, AM; García-Martín, ML	Smart Design of ZnFe and ZnFe@ Fe Nanoparticles for MRI-Tracked Magnetic Hyperthermia Therapy: Challenging Classical Theories of Nanoparticles Growth and Nanomagnetism	ADVANCED HEALTHCARE MATERIALS	10	D1	2024
G-01	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Gómez-González, E; Caro, C; Núñez, NO; González-Mancebo, D; Urbano-Gámez, JD; Garcia-Martin, ML; Ocaña, M	Sodium lanthanide tungstate-based nanoparticles as bimodal contrast agents for in vivo high-field MRI and CT imaging	JOURNAL OF MATERIALS CHEMISTRY B	6.1	Q1	2024
G-01	Gómez-González, E; Núñez, NO; Caro, C; García-Martín, ML; Becerro, AI; Ocaña, M	Lanthanide vanadate-based nanoparticles as multimodal T1 1-T2 T 2 MRI contrast agent and NIR luminescent imaging probe	JOURNAL OF ALLOYS AND COMPOUNDS	5.8	D1	2024
G-01	González-Mancebo, D; Becerro, AI; Caro, C; Gómez-González, E; Luisa, GMM; Ocaña, M	Nanoparticulated Bimodal Contrast Agent for Ultra-High-Field Magnetic Resonance Imaging and Spectral X-ray Computed Tomography	INORGANIC CHEMISTRY	4.3	Q1	2024



AREA 8. NANOSYSTEMS AND ADVANCED THERAPIES

Coordinator: Elena González Muñoz

Scientific Production




Figure 48: No. publications, no. publications led, and Impact Factor from Area 8

Figure 49: Percentage of publications in Q1 and D1 from Area 8

Selection of the five most relevant publications in the area in 2024:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
H-03	Cano, E; Schwarzkopf, J; Kanda, M; Lindberg, EL; Hollfinger, I; Pogontke, C; Braeuning, C; Fischer, C; Huebner, N; Gerhardt, H	Intramyocardial Sprouting Tip Cells Specify Coronary Arterialization	CIRCULATION RESEARCH	16.5	D1	2024
H-03	Yu, DQ; Ren, YD; Uesaka, M; Beavan, AJS; Muffato, M; Shen, JY; Li, YX; Sato, I; Wan, WT; Clark, JW; Keating, JN; Carlisle, EM; Dearden, RP; Giles, S; Randle, E; Sansom, RS; Feuda, R; Fleming, JF; Sugahara, F; Cummins, C; Patricio, M; Akanni, W; D'Aniello, S; Bertolucci, C; Irie, N; Alev, C; Sheng, GJ; de Mendoza, A; Maeso, I; Irimia, M; Fromm, B; Peterson, KJ; Das, S; Hirano, M; Rast, JP; Cooper, MD; Paps, J; Pisani, D; Kuratani, S; Martin, FJ; Wang, W; Donoghue, PCJ; Zhang, YE; Pascual-Anaya, J	Hagfish genome elucidates vertebrate whole-genome duplication events and their evolutionary consequences	NATURE ECOLOGY & EVOLUTION	14.1	D1	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Year
H-03	Pascual-Anaya, J; Donoghue, PCJ	Hagfish genome sequence sheds light on early vertebrate genome evolution	NATURE ECOLOGY & EVOLUTION	14.1	D1	2024
HE-01	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	2024
HE-01	Algarra, M; Gonzalez-Muñoz, E	Efficient and scalable gene delivery method with easily generated cationic carbon dots	BIOLOGICAL PROCEDURES ONLINE	3.7	Q2	2024



5.2. RESEARCH GROUPS

AREA 1. CARDIOVASCULAR DISEASES, OBESITY, AND DIABETES. ENVIRONMENTAL DETERMINANTS AND LIFESTYLE

CONSOLIDATED GROUPS

A-01. ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY
LR Gabriel Olveira Fuster Gabriel. Co-LR Javier Bermúdez Silva

Priority line of research: Obesity, diabetes, and clinical nutrition.

Other lines:

- 1. Obesity and translational diabetes: adipose tissue and beta cell metabolism:
 - Pathophysiology of the pancreatic islet in type 2 diabetes.
 - Prevention of type 2 diabetes and the inflammatory processes that underlie and precede so-called “beta-cell failure”
 - Role of angiogenesis in the regulation of adipose tissue expansion in relation to obesity and type 2 diabetes.
 - Role of angiogenic microRNAs in the regulation of white, brown, and beige adipose tissue functionality
 - Role of microbiota in obesity and type 2 diabetes
 - Study of the cause-effect relationship between obesity and mental illnesses
 - Thymic adipose tissue as a source of angiogenesis for blood vessel neogenesis in older adult subjects with ischemic heart disease.
- 2. New approaches in clinical-experimental research in diabetes and metabolism and clinical nutrition applied to chronic diseases:
 - Type 1 diabetes, new technology, biomarkers, and psychosociological approach
 - Clinical nutrition and dietetics applied to artificial nutrition
 - Surgical morbid obesity: clinical experimental models
 - Hypogonadism and glomerulopathy associated with obesity.
 - Clinical nutrition in chronic diseases (cystic fibrosis and bronchiectasis, cancer, and neurological diseases)
 - New methods for the assessment of nutritional status and their prognostic value
- 3. Epidemiology and risk factors for diabetes and related metabolic diseases
 - Epidemiology of diabetes mellitus, obesity, and related metabolic diseases in Spain and Andalusia (prevalence and incidence)

- Study of new prognostic ecological markers (environmental pollution) for hydrocarbon metabolism abnormalities.
- Study of biomarkers predictive of diabetes and metabolic diseases (e.g. mRNA, genetic, epigenetic, and biochemical biomarkers).
- Epidemiology of thyroid diseases in Spain and iodine deficiency disorders.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-01	Ozcariz, E; Guardiola, M; Amigó, N; Valdés, S; Oualla-Bachiri, W; Rehues, P; Rojo-Martinez, G; Ribalta, J	H-NMR metabolomics identifies three distinct metabolic profiles differentially associated with cardiometabolic risk in patients with obesity in the Di@bet.es cohort	CARDIOVASCULAR DIABETOLOGY	8.5	D1
A-01	Lhamyani, S; Gentile, AM; Mengual-Mesa, M; Grueso, E; Giráldez-Pérez, RM; Fernandez-Garcia, JC; Vega-Rioja, A; Clemente-Postigo, M; Pearson, JR; González-Mariscal, I; Oliveira, G; Bermudez-Silva, FJ; El Bekay, R	Au@16-pH-16/miR-21 mimic nanosystem: An efficient treatment for obesity through browning and thermogenesis induction	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1
A-01	Moreno-Pérez, O; Reyes-Garcia, R; Modrego-Pardo, I; Doulatram-Gamgaram, VK; Cases, CC; Guillen-Morote, C; Mendoza, NA; Tejera-Pérez, C; Cárdenas-Salas, J; Martínez-Fuster, S; Lardiés-Sánchez, B; Márquez-Pardo, R; Pinés, P; Fernández-García, JC	Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S-RWD)	DIABETES OBESITY & METABOLISM	5.4	Q1
A-01	Martínez-Montoro, JI; Martínez-Sánchez, MA; Balaguer-Román, A; Fernández-Ruiz, VE; Hernández-Barceló, JE; Ferrer-Gómez, M; Frutos, MD; Núñez-Sánchez, MA; Fernández-García, JC; Ramos-Molina, B	Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study	NUTRIENTS	4.8	Q1
A-01	Roman, DD; Almeida, JMG; Guerrero, DB; Rolo, GG; Martín, A; Martín, DP; García-Delgado, Y; Guirado-Peláez, P; Palmas, F; Pérez, CT; Olivares, MG; Jiménez, MM; Lesmes, IB; Teomiro, CMA; Baena, JMG; Romero, LAC; Prior-Sánchez, I; García-Luna, PP; Pacheco, MG; Martínez-Olmos, MA; Alabadi, B; Alcántara-Aragon, V; Milla, SP; Folgueras, TM; García, AM; Molina-Baena, B; Barragán, HR; Gómez, PRD; Fernández, MR; Portilla, AJ; López-Gómez, JJ; Martín, NP; Madrid, NM; Eguinoa, AZ; Fernández, CP; Guerrero, MJT; Aguado, MR; Gimeno, CV; Martínez, ADH; Rodríguez, MN; Hernández, NCI; Medina, MD; Navarro, IG; López, FJV; Fernández-Pombo, A; Oliveira, G	Ultrasound Cut-Off Values for Rectus Femoris for Detecting Sarcopenia in Patients with Nutritional Risk	NUTRIENTS	4.8	Q1

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
48	44%	75%	23%	256



Networks and Ciber:

CIBERDEM CB07/08/0019 Diabetes and Associated Metabolic Diseases (ISCIII)

Competitive HR contracts funded in 2024:

- 1 Sara Borrell Contract (ISCIII).
- 1 Río Hortega Contract (ISCIII).
- 1 PFIS Contract (ISCIII).
- 1 i-PFIS contract (ISCIII).
- 1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)
- 1 Contract for long-term reinforcement of the SAS (Action B).
- 4 Nicolás Monardes SAS contracts (Action C).

A-02. OBESITY, DIABETES, AND THEIR COMORBIDITIES: PREVENTION AND TREATMENT.
LR Francisco Tinahones Madueño. Co-LR Manuel Macias González. Co-LR Isabel Moreno Indias

Priority line of research: Study of metabolic diseases: diabetes and obesity

Other lines:

- 1. Gut microbiota, insulin resistance, and obesity.
- 2. Role of adipobiology in metabolic diseases.
- 3. Metabolic effect of bariatric surgery.
- 4. Environmental factors in the genesis of obesity and diabetes.
- 5. Novel cellular and molecular mechanisms of inflammation in metabolic diseases: obesity, diabetes, and cancer
- 6. Genetic and epigenetic factors in the prevention, progression, and treatment of diabetes.
- 7. PREDIMED PLUS study.
- 8. Dietetic-therapeutic approach to obesity: role of ketosis, intermittent fasting, physical exercise, and chronobiology.
- 9. Mitochondrial fitness in metabolic diseases.
- 10. Endocrine-metabolic complications of obesity: NFALD.
- 11. Hyperlipoproteinemia, insulin resistance, and atherosclerotic disease.
- 12. Analysis of biomarkers of response to a weight loss intervention.
- 13. Immunity of metabolic diseases.
- 14. Role of gestation and lactation in the onset of metabolic diseases

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-02	Herrera-Martínez, AD; Prior-Sánchez, I; Fernández-Soto, ML; García-Olivares, M; Novo-Rodríguez, C; González-Pacheco, M; Martínez-Ramírez, MJ; Carmona-Llanos, A; Jiménez-Sánchez, A; Muñoz-Jiménez, C; Torres-Flores, F; Fernández-Jiménez, R; Boughanem, H; del Galindo-Gallardo, MC; Luengo-Pérez, LM; Molina-Puerta, MJ; García-Almeida, JM	Improving the nutritional evaluation in head neck cancer patients using bioelectrical impedance analysis: Not only the phase angle matters	JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE	9.4	D1

Group	Authors	Article Title	Source Title	IF	Q/D
A-02	Linares-Pineda, TM; Fragoso-Bargas, N; Picón, MJ; Molina-Vega, M; Jenum, AK; Sletner, L; Lee-Odegård, S; Opsahl, JO; Moen, GH; Qvigstad, E; Prasad, RB; Birkeland, KI; Morcillo, S; Sommer, C	DNA methylation risk score for type 2 diabetes is associated with gestational diabetes	CARDIOVASCULAR DIABETOLOGY	8.5	D1
A-02	Rodríguez-Muñoz, A; Picón-César, MJ; Tinahones, FJ; Martínez-Montoro, J	Type 1 diabetes-related distress: Current implications in care	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1
A-02	Rodriguez-Muñoz, A; Martínez-Montoro, JI; Sojo-Rodriguez, B; Benitez-Porres, J; Carrillo-Albornoz-Gil, M; Carrasco-Fernandez, L; Subiri-Verdugo, A; Molina-Ramos, A; Cobos-Diaz, A; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Glycaemic Response to Acute Aerobic and Anaerobic Exercise Performed in the Morning or Afternoon in Healthy Subjects: A Crossover Trial	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1
A-02	Ruiz-Limón, P; Muralidharan, J; Gomez-Perez, AM; Murri, M; Vioque, J; Corella, D; Fito, M; Vidal, J; Salas-Salvadó, J; Torres-Collado, L; Coltell, O; Atzeni, A; Castañer, O; Bulló, M; Bernal-López, MR; Moreno-Indias, I; Tinahones, FJ	Physical activity shifts gut microbiota structure in aged subjects with overweight/obesity and metabolic syndrome	BIOLOGY OF SPORT	4.2	D1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
75	45%	84%	21%	386



Active projects



Clinical studies



Patents applied for

Networks and Ciber:

CA20128 (PIMENTO): Promoting Innovation of fermented foods (European Commission)
CA23151 (Medi-CaSE) -Mediterranean Cancer Screening and Early Diagnosis Network
CERT22/00034. Networked State Consortium for the Development of Medicines for Advanced Therapies
CIBEROBN CB06/03/0018 Physiopathology of Obesity and Nutrition (ISCIII)

Competitive HR contracts funded in 2024:

2 PFIS Contracts (ISCIII)
2 Río Hortega Contracts (ISCIII)
1 Juan Rodés Contracts (ISCIII)
3 Sara Borrell Contracts (ISCIII)
4 Miguel Servet I Contracts(ISCIII)
2 Miguel Servet II Contracts (ISCIII)
1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)
1 Contract for long-term reinforcement of the SAS (Action B).
3 Nicolás Monardes SAS contracts (Action C).

A-03. CARDIOVASCULAR RESEARCH FOR HEALTH

LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón

Lines of research:

- 1. Ischemic heart disease: New preventive, diagnostic, and therapeutic approaches.
- 2. Biomarkers and risk factors for cardiovascular disease.
- 3. Valvular and aortic diseases: Molecular and genetic bases.
- 4. Pulmonary hypertension and rare diseases.
- 5. Cardiometabolic diseases: sexual dimorphism and lifestyles.
- 6. Clinical and translational research in arrhythmias, cardiomyopathies, and heart failure.
- 7. New information and communication technology in cardiovascular research.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-03	de Miguel-Díez, J; Villota, JN; Pérez, SS; Lorite, NM; Navarrete, BA; Jiménez, JFD; Soler-Cataluña, JJ; Figal, DP; Ecenarro, PS; Doblas, JG	Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease	ARCHIVOS DE BRONCONEUMOLOGIA	8.7	D1
A-03	Molina-Ramos, AI; Ruiz-Salas, A; Medina-Palomo, C; Becerra-Munoz, V; Rodriguez-Capitan, J; Romero-Cuevas, M; Carmona-Segovia, A; Fernandez-Lozano, I; Gomez-Doblas, JJ; Navarro, MJ; Pavon-Moron, FJ; Barrera-Cordero, A; Alzueta-Rodriguez, J	Index and Repeat Ablation for Atrial Fibrillation in Older versus Younger Patients: A Propensity-Score Matching Analysis	AGING AND DISEASE	7	D1
A-03	Jiménez-López, R; Romero-Trejejo, JL; Fernández-Romero, L; Martín-Chaves, L; Romero-Cuevas, M; Molina-Ramos, AI; Sánchez-Quintero, MJ; Murri, M; Costa, F; Bodí, V; Gutiérrez-Bedmar, M; Rodríguez-Capitán, J; Pavón-Morón, FJ; Jiménez-Navarro, M	Differential Ophthalmological Profile in Patients with Coronary Artery Disease Coexisting with Type 2 Diabetes Mellitus: Elevated Tear Cytokine Concentrations	JOURNAL OF CLINICAL MEDICINE	3	Q1
A-03	Becerra-Muñoz, VM; Sáenz, JTG; Subías, PE	The importance of data in Pulmonary Arterial Hypertension: from international registries to Machine Learning	CLINICAL MEDICINE	2.6	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
A-03	Torres-Salomón, P; Rodriguez-Capitán, J; Molina-Cabello, MA; Thurnhofer-Hemsi, K; Costa, F; Sanchez-Fernández, PL; Muñoz-Muñoz, MA; Carmona-Segovia, AD; Romero-Cuevas, M; Pavón-Morón, FJ; Jiménez-Navarro, M	Exploring the Prognostic Impact of Non-Obstructive Coronary Artery Lesions through Machine Learning	APPLIED SCIENCES-BASEL	2.5	Q1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
71	31%	70%	23%	424



Active projects



Clinical studies



Patents applied for

Networks and Ciber:

CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (European Commission)
CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities (European Commission)
CA19101 (DE-PASS) -Determinants of Physical Activities in Settings (European Commission)
CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure (European Commission)
CA20137 (VOICES) -Making Young Researchers’ Voices Heard for Gender Equality (European Commission)
CIBERCV CB16/11/00360 Cardiovascular Diseases (ISCIII)

Competitive HR contracts funded in 2024:

1 ERC GRANT 2023 Contract (Juan Rodés Contract -ISCIII)
2 PFIS Contracts (ISCIII)
2 Río Hortega Contracts (ISCIII)
2 Juan Rodés Contracts (ISCIII)
1 Contract for the intensification of research activity in the SNS (ISCIII)
1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)
1 Nicolás Monardes SAS Contract (Action C).
1 Contract for the incorporation of postdoctoral researchers to groups in the health and research centers of the SSPA.

A-06. DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.
LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal López

Priority line of research: Diabetes, obesity, and other cardiovascular risk factors

Other lines:

- 1. Systemic Autoimmune Diseases
- 2. Chronic diseases Older Adult Diseases
- 3. Thromboembolic disease

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-06	Gómez-Huelgas, R; Dalekos, GN; Dicker, D; Montano, N	Internal medicine in the 21st century: Back to the future	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1
A-06	Vargas-Molina, S; Garcia-Sillero, M; Bonilla, DA; Petro, JL; Garcia-Romero, J; Benitez-Porres, J	The effect of the ketogenic diet on resistance training load management: a repeated-measures clinical trial in trained participants	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1
A-06	Fuentes-Abolafio, IJ; Ricci, M; Bernal-López, MR; Gómez-Huelgas, R; Cuesta-Vargas, AI; Pérez-Belmonte, LM	Relationship between quadriceps femoris echotexture biomarkers and muscle strength and physical function in older adults with heart failure with preserved ejection fraction	EXPERIMENTAL GERONTOLOGY	3.3	Q2
A-06	Campos, L; Viñas, MM; Gómez, J; Santos, L; Rayo, A; Valdez, PR; Gómez-Huelgas, R	Recommendations of the Spanish-Portuguese Internal Medicine services in the fight against climate change and environmental degradation.	REVISTA CLINICA ESPANOLA	2.3	Q2
A-06	Fuentes-Abolafio, IJ; Trinidad-Fernández, M; Ricci, M; Roldán-Jiménez, C; Gómez-Huelgas, R; Arjona-Caballero, JM; Escriche-Escuder, A; Bernal-López, MR; Pérez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic parameters related to functional capacity, fatigue, and breathlessness during the 6-min walk test in older adults with heart failure with preserved ejection fraction	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	2.9	D1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
21	48%	71%	48%	95



Active projects



Clinical studies

Networks:

CA18216 (VascAgeNet) - Network for Research in Vascular Ageing (European Commission)
CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases

Competitive HR contracts funded in 2024:

- 1 PFIS Contract (ISCIII)
- 2 Río Hortega Contracts (ISCIII)
- 1 Miguel Servet Contract (ISCIII)
- 1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)
- 1 Nicolás Monardes SAS Contract (Action C).

A-07. TRANSLATIONAL RESEARCH IN CARDIOVASCULAR DISEASE

LR José Antonio González Correa. Co-LR José Pedro de la Cruz Cortés

Priority line of research: Translational research on the effect of olive oil polyphenols on vascular inflammation and micro- and macroangiopathic complications in patients with type 2 diabetes

Other lines of research:

- Evaluation of biomarkers and risk factors related to the progression of diabetic retinopathy
- Evaluation of the level of response to antiplatelet therapy with acetylsalicylic acid in patients with type 2 diabetes in primary care
- Characterization of functional fractions of olives, formulation of new products, and analysis of their effects
- Intensification of pharmacovigilance activities through an organizational change and training intervention in a primary care clinical management unit (UGC)

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-07	Baños, JE; Blanco-Reina, E; Bellido-Estévez, I; Bosch, F; Cabello, MR; Cambra-Badii, I; Cruz, JPD; D’Ocón, P; Ivorra, MD; Ferrándiz, M; Gonzalez-Correa, JA; Martin-Montanez, E; Martos, F; Pavia, J; Sanz, E	Beyond lectures and practical courses: Teaching pharmacology using imaginative pedagogical tools	PHARMACOLOGICAL RESEARCH	9.1	D1
A-07	de la Cruz, JP; Iserte-Terrer, L; Rodríguez-Pérez, MD; Ortega-Hombrados, L; Sánchez-Tévar, AM; Arrebola-Ramírez, MM; Fernández-Prior, MA; Verdugo-Cabello, C; Espejo-Calvo, JA; González-Correa, JA	Effects of Some Olive Fruits-Derived Products on Oxidative Stress and Cardiovascular Biomarkers on Experimental Diabetes Mellitus	ANTIOXIDANTS	6	Q1
A-07	López-Villodres, JA; García-Díaz, B	Oligodendrocytes: the forgotten players of diabetes pathophysiology	NEURAL REGENERATION RESEARCH	5.9	Q1
A-07	de la Cruz, JP; Osuna-Esteban, L; Rodríguez-Pérez, MD; Ortega-Hombrados, L; Sánchez-Tévar, AM; Martín-Aurioles, E; Fernández-Prior, MA; Pérez-Burillo, S; Espejo-Calvo, JA; González-Correa, JA	Effect of a Triterpenoid-Rich Olive Oil on Chronic Kidney Disease in an Experimental Model of Diabetes Mellitus	NUTRIENTS	4.8	Q1
A-07	Gavilán, P; Gavilán, JC; Arnedo, R; Clavijo, E; Viciano, I; González-Correa, JA	Prediction model of hepatocellular carcinoma development in chronic hepatitis B virus infection in a Spanish cohort	CLINICAL MEDICINE	2.6	Q1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
5	80%	100%	20%	28



A-09. RESEARCH IN ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.
LR Pedro Valdivielso Felices. Co-LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares

Priority line of research: Diseases of plasma lipoprotein metabolism

Other lines:

- 1. Rare diseases. PXE, Turner, Familial Chylomicronemia Syndromes
- 2. Epidemiology, stratification, and prevention of cardiovascular risk
- 3. Use of PET/CT imaging, 3T MRI, and ultrasound in the evaluation of atherosclerotic disease
- 4. Cognitive Impairment, Alzheimer’s Disease, and Vascular Risk
- 5. Neurological Diseases and Vascular Risk

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-09	Bueno, JAR; Sánchez-Guijo, G; Ráez, PD; García-Arnes, JA; Garzón-Maldonado, FJ; Castro, VS; de la Cruz-Cosme, C; Alba-Linero, C; Gutiérrez-Bedmar, M; García-Casares, N	Effects of Type 2 Diabetes on the Neuropsychological Profile in Mild Cognitive Impairment	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2
A-09	Espildora-Hernández, J; Díaz-Antonio, T; Olmedo-Llanes, J; León, JZ; Rioja, J; Valdivielso, P; Sánchez-Chaparro, MA; Ariza, MJ	Clinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3
A-09	Ramos, CFL; Moral, I; Brotons, C; Aguado, LQ; Prieto, IC; Valdivielso, P; Chaparro, MAS	Validation of the IberScore model in a primary care population	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3
A-09	López-Téllez, A; Torres, JMR; Vázquez, EP; Fernández, MAB; López-Martí, H; Martínez, IZ; Fernández, CT; Vargas, MF; Pinos, MDD; Morant, JFP; González-Fajardo, JA; Felices, PV	Ultrasound screening for abdominal aortic aneurysm in primary care	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3
A-09	Alvarez-González, C; Espildora-Hernández, J; Sánchez-Chaparro, MA	Beyond hypercoagulability in celiac disease	HIPERTENSION Y RIESGO VASCULAR	1.2	Q4

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
21	33%	43%	5%	67



Active projects



Clinical studies

Networks:

RICORS-ICTUS, Cerebral Vascular Diseases (ISCIII)

A-10. EPIDEMIOLOGY, PHYSICAL ACTIVITY, ACCELEROMETRY, and NUTRITION (EpiPHAAN).
LR Julia Wärnberg. Co-LR Napoleón Pérez Farinós

Priority line:

Prevention of cardiovascular disease through Mediterranean diet, physical activity, and behavioral therapy (PREDIMED-Plus)

Other lines:

1. Objective measurement of physical activity and sleep through accelerometry.
2. Health promotion, healthy lifestyle habits. Nutritional epidemiology.
3. Childhood obesity and its determinants.
4. Epidemiology and prevention of non-communicable diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-10	Gavala-González, J; Real-Pérez, M; Benítez-García, L; Fernández-García, JC	Fixed-Seat Rowing versus Sliding-Seat Rowing: Effects on Physical Fitness in Breast Cancer Survivors	CANCERS	4.5	Q1
A-10	Cortes-Rodríguez, A; Alves-Gomes, L; Losa-Iglesias, ME; Gómez-Salgado, J; Becerro-de-Bengoa-Vallejo, R; Saavedra-García, MA; Montiel-Luque, A; López-López, D; Jiménez-Cebrián, AM	Impact of ankylosing spondylitis on foot health and quality of life: an observational case-control study	FRONTIERS IN MEDICINE	3.1	Q1
A-10	De-Miguel-Diez, J; Llamas-Saez, C; Vaquero, TS; Jiménez-García, R; López-de-Andrés, A; Carabantes-Alarcón, D; Carricondo, F; Romero-Gómez, B; Pérez-Farinos, N	Association between Asthma and Lower Levels of Physical Activity: Results of a Population-Based Case-Control Study in Spain	JOURNAL OF CLINICAL MEDICINE	3	Q1
A-10	Gil-Espinosa, FJ; López-Fernández, I; Cadenas-Sanchez, C; Burgueño, R	The perspectives of school principals in Spain: identifying professional competencies beyond their scope	SCHOOL LEADERSHIP & MANAGEMENT	2.8	Q1
A-10	Jiménez-Cebrián, AM; Ruiz-Sánchez, FJ; Losa-Iglesias, ME; Becerro-de-Bengoa-Vallejo, R; López-López, D; Montiel-Luque, A; de Labra, C; Saavedra-García, MA; Navarro-Flores, E	Relationship of foot pain with the increased risk of falls in patients with Parkinson's disease	JOURNAL OF FOOT AND ANKLE RESEARCH	2.5	Q1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
25	44%	80%	16%	98



A-17. ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.

LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero

Priority line of research: Etiology and pathophysiology of bicuspid aortic valve disease and congenital coronary artery anomalies

Other lines:

1. Animal models of atherosclerosis
2. Vascular growth: angiogenesis and arteriogenesis
3. Embryonic development of the cardiovascular system
4. Comparative anatomy and evolution of the cardiovascular system

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-17	López-Unzu, MA; Soto-Navarrete, MT; Sans-Coma, V; Fernández, B; Durán, AC	The myoarchitecture of the vertebrate cardiac ventricles: evolution The myoarchitecture of the vertebrate cardiac ventricles: evolution and classification and classification	JOURNAL OF EXPERIMENTAL BIOLOGY	2.8	Q2
A-17	Michelena, HI; della Corte, A; Evangelista, A; Maleszewski, JJ; Edwards, WD; Roman, MJ; Devereux, RB; Fernández, B; Asch, FM; Barker, AJ; Sierra, LM; de Kerchove, L; Fernandes, SM; Fedak, PWM; Girdauskas, E; Delgado, V; Abbara, S; Lansac, E; Prakash, SK; Bissell, MM; Popescu, BA; Hope, MD; Sitges, M; Thourani, VH; Pibarot, P; Chandrasekaran, K; Lancellotti, P; Borger, MA; Forrest, JK; Webb, J; Milewicz, DM; Makkar, R; Leon, MB; Sanders, SP; Markl, M; Ferrari, VA; Roberts, WC; Song, JK; Blanke, P; White, CS; Siu, S; Svensson, LG; Braverman, AC; Bavaria, J; Sundt, TM; El Khoury, G; de Paulis, R; Enriquez-Sarano, M; Bax, JJ; Otto, CM; Schäfers, HJ	Summary: International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes	ARCHIVOS DE CARDIOLOGIA DE MEXICO	0.7	Q4

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
2	50%			4



A-19. MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP

LR Isabel Leiva Gea, Co-LR David Moreno Pérez, Co-LR Juan Pedro López

Priority line of research: Microbiota in patients who have undergone an appendectomy, microbiota after ketogenic diet in refractory epilepsy, microbiota in immunodeficiencies, microbiota in critical patients.

Other lines:

1. Diabetes and technology
2. Epidemiology in diabetes
3. Growth
4. Obesity
5. Autoimmunity and inflammatory bowel disease
6. Neonatal cystic fibrosis screening
7. Bronchiolitis. Risk factors in the Bayesian model
8. Telehealth in complex chronic patients
9. Antibiotic resistance

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-19	Mesas-Aróstegui, MA; Hita-Contreras, F; López-Siguero, JP	A Therapeutic Proposal for Mini-Puberty in Male Infants with Hypogonadotropic Hypogonadism: A Retrospective Case Series	JOURNAL OF CLINICAL MEDICINE	3	Q1
A-19	Arroyo-Ruiz, R; Urbano-Ruiz, C; García-Berrocal, MB; Marcos-Vadillo, E; Isidoro-García, M; Martín-Alonso, MM; Bajo-Delgado, AF; Prieto-Matos, P; López-Siguero, JP	Clinical and Genetic Characterization of a Cohort of Small-for-Gestational-Age Patients: Cost-Effectiveness of Whole-Exome Sequencing and Effectiveness of Treatment with GH	JOURNAL OF CLINICAL MEDICINE	3	Q1
A-19	Perez, PO; Valero-Arredondo, I; Torcuato-Rubio, E; Herrador-López, M; Martín-Masot, R; Navas-López, VM	Nutritional Issues in Children with Dysphagia	NUTRIENTS	4.8	Q1
A-19	Olid-Cárdenas, MJ; Lendínez-Jurado, A; Monroy-Rodríguez, G; Gómez-Perea, A; Cano-Ortiz, A; Ariza-Jiménez, AB; García-Ruiz, A; Jiménez-Cuenca, P; Picón-César, MJ; Leiva-Gea, I	Real-World Use of Hybrid Closed-Loop Systems during Diabetes Camp: A Preliminary Study for Secure Configuration Strategies in Children and Adolescents	NUTRIENTS	4.8	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
A-19	Rodríguez-Belvis, MV; Palomino, L; Pujol-Muncunill, G; Martin-Masot, R; Benitez, EMi; Fernández-Lorenzo, AE; Moreno-Alvarez, A; Arias, MM; Montes, IH; Torres, JB; Navas-López, VM; de Carpi, JM; Ruf, AL; Blasco-Alonso, J; Torres, JB; Montraveta, M; Peña-Quintana, L; Rueda, NR; Martínez, AR; Arcos, GB; Vicente, CA; Millán, AMC; Donat, E; Cebrián, SF; Sánchez, NR; Torres-Peral, R; Crehuá-Gaudiza, E; Jiménez, AM; Casano, CJ; Santamaría, SV; González, AT; Garcia-Romero, R; Arnal, IR; Vega, MJB; Madurga, LE; Torres, NM; Martínez, VC; González-Vives, L; Pérez-Moneo, B; Mas, MLM; Alvarez, AMV; Herrero, LG; Izquierdo, EL; Marín, FJC; Cuiñas, MDB; Fernández, JMMD; Alonso, JRA; Esteban, EMA	Transcultural adaptation and validation of IMPACT-III and IMPACT-III-P in Spanish families: a multicenter study from SEGHNP	EUROPEAN JOURNAL OF PEDIATRICS	3	Q1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
43	35%	63%	21%	155



Active projects



Clinical studies

Networks:

CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence (European Commission)

CA19115 (HyperChildNET) - Network for blood pressure research in children and adolescents (European Commission)

CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections in adolescents (European Commission)

CA21168 (JIR-ClIPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies adolescents (European Commission)

RICORS PRIMARY CARE INTERVENTIONS TO PREVENT MATERNAL AND CHILD CHRONIC DISEASES OF PERINATAL AND DEVELOPMENTAL ORIGIN, Primary Care, Chronicity, and Health Promotion (ISCIII)

A-21. RESEARCH ON ORGAN PROTECTION IN THE PERIOPERATIVE PERIOD OF HEART SURGERY

LR José Luis Guerrero Orriach. Co-LR José Cruz Mañas

Priority line of research: Cardioprotection with halogenated compounds

Other lines:

- 1. Organ protection in heart surgery
- 2. Anesthesia and cancer
- 3. Opioid-free anesthesia

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-21	Guerrero-Orriach, JL; Carmona-Luque, MD; Muñoz, GQ; Capitán, MJR	miRNA Expression: I/R Cardiomyocyte and Sevoflurane	BIOMOLECULES	4.8	Q1
A-21	García-Montoto, F; Paz-Martín, D; Pestaña, D; Soro, M; Marcos-Vidal, JM; Badenes, R; de la Rica, AS; Bardi, T; Pérez-Carbonell, A; García, C; Cervantes, JA; Martínez, MP; Guerrero, JL; Lorente, JV; Veganzones, J; Murcia, M; Belda, FJ	Guidelines for inhaled sedation in the ICU	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION	0.9	Q3

Scientific production and research activity:

Articles	%Art. Leader.	% Q1	% D1	IF
2	50%	50%	0%	6



Active projects



Clinical studies

Networks:

CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care

Competitive HR contracts funded in 2024:

1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)

A-23. PREVENTIVE MEDICINE AND PUBLIC HEALTH
LR. Mario Gutiérrez Bedmar. Co-LR Rosa López Gigosos

Priority line of research: Preventive medicine and public health

Other lines:

- 1. Epidemiology and prevention of chronic diseases
- 2. Vaccines
- 3. International Health
- 4. Emerging diseases
- 5. Nosocomial infection
- 6. Pollution and environmental health
- 7. Occupational health
- 8. Immunosenescence

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
A-23	Domínguez-López, I; Lamuela-Raventos, RM; Razquin, C; Arancibia-Riveros, C; Galkina, P; Salas-Salvadó, J; Alonso-Gómez, AM; Fitó, M; Fiol, M; Lapetra, J; Gómez-Gracia, E; Sorli, JV; Ruiz-Canela, M; Castañer, O; Liang, LM; Serra-Majem, L; Hu, FB; Ros, E; Martinez-Gonzalez, MA; Estruch, R	Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial	EUROPEAN HEART JOURNAL	38.1	D1
A-23	Khoury, N; Martínez, MA; Nishi, SK; Martinez-Gonzalez, MA; Corella, D; Castañer, O; Martinez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, F; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, J; Pérez-Vega, KA; Garcia-Rios, A; Ortiz-Díaz, F; Gomez-Gracia, E; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Peña-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fito, M; Babio, N; Salas-Salvadó, J	Dietary intake of Perfluorooctanesulfonic acid (PFOS) and glucose homeostasis parameters in a non-diabetic senior population	ENVIRONMENT INTERNATIONAL	10.3	D1

Group	Authors	Article Title	Source Title	IF	Q/D
A-23	Murcia-Lesmes, D; Dominguez-Lopez, I; Laveriano-Santos, EP; Tresserra-Rimbau, A; Castro-Barquero, S; Estruch, R; Vazquez-Ruiz, Z; Ruiz-Canela, M; Razquin, C; Corella, D; Sorli, J; Salas-Salvado, J; Perez-Vega, KA; Gomez-Gracia, E; Lapetra, J; Aros, F; Fiol, M; Serra-Majem, L; Pinto, X; Ros, E; Lamuela-Raventos, RM	Association between tomato consumption and blood pressure in an older population at high cardiovascular risk: observational analysis of PREDIMED trial	EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY	8.6	D1
A-23	Fernández, MJL; Narejos, S; Castro, A; Echave-Sustaeta, JM; Forner, MJ; Arana-Arri, E; Molto, J; Bernad, L; Pérez-Caballero, R; Prado, JG; Raïch-Regué, D; Boreika, R; Izquierdo-Useros, N; Trinité, B; Blanco, J; Puig-Barberà, J; Martínez, SN	Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results	VACCINES	5.2	Q1
A-23	Farinas-Guerrero, Fernando; Villatoro, Antonio J; Martinez-Manzanares, Eduardo; Lopez-Gigosos, Rosa	Occurrence of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus pseudintermedius colonization among veterinarians in the province of Malaga, Spain.	Veterinary world	1.7	Q2

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
11	18%	82%	36%	93



Active projects



Clinical studies

EMERGING GROUPS

AE-11. NEPHROLOGY AND RENAL TRANSPLANTATION
LR Verónica López Jiménez. Co-LR Juana Alonso Titos.

Priority line of research: Strategies to reduce the main complications after renal transplantation (cardiovascular, metabolic, and infectious complications) and the evaluation of risk factors and transplant outcomes.

Other lines:

- 1. Cardiovascular disease and LVH in renal patients.
- 2. Post-transplant diabetes and chronic graft dysfunction.
- 3. Immunosuppressive strategies.
- 4. Survival analysis and predictive models of mortality in renal patients.
- 5. Renal senescence and Klotho expression.
- 6. Evaluation, management, and analysis of risk factors for infectious complications in solid organs after transplantation.
- 7. Analysis of new biomarkers of renal function, mainly chemokines in urine.
- 8. Analysis of lymphocyte subpopulations involved in cellular rejection by means of fine-needle aspiration (FNA) biopsy and flow cytometry.


Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
AE-11	Rivero, M; Fernández-Vidal, M; Sandino, J; Rico, RB; Moliz, C; Ruiz-Cabello, JE; Garcia-Galán, LC; González-García, C; Hernández-Velasco, P; Segura, J; Gutiérrez, E; Morales, E	Effect of Intravitreal Anti-Endothelial Growth Factor Agents on Renal Function in Patients With Diabetes Mellitus	KIDNEY INTERNATIONAL REPORTS	5.7	D1
AE-11	Montiel, AM; Ruiz-Esteban, P; Del Río, AD; Valdivielso, P; Chaparro, MAS; Oliveira, C	Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype	SCIENTIFIC REPORTS	3.8	Q1
AE-11	Montiel, AM; Ruiz-Esteban, P; Del Río, AD; Valdivielso, P; Chaparro, MAS; Oliveira, C	The effect of pulmonary rehabilitation on cardiovascular risk, oxidative stress and systemic inflammation in patients with COPD	RESPIRATORY MEDICINE	3.5	Q2

Group	Authors	Article Title	Source Title	IF	Q/D
AE-11	Gómez, MAM; Molina, MC; Fradejas, ML; Titos, JA; Alvarez, RD	Focal segmental glomerulosclerosis associated with undescribed mutation in the LMX1B gene	EUROPEAN JOURNAL OF MEDICAL GENETICS	1.6	Q4
AE-11	Perea-Ortega, L; Muñoz-Sánchez, A; León-Fradejas, M; Rojas, RT; Ruiz-Esteban, P; López-Jiménez, V	Rheumatoid arthritis and PLA2R-associated membranous nephropathy. Cause or coincidence?	CLINICAL CASE REPORTS	0.6	Q3

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
11	36%	45%	9%	33



Networks:

RICORS2040 (KIDNEY DISEASE), Inflammation and Immunopathology of Organs and Systems (ISCIII)

ASSOCIATED GROUPS

AA-04. INTENSIVE CARE MEDICINE
LR María Antonia Estecha Foncea

Lines of research:

- Care circuits and mortality
- Biotechnology in critically ill patients with multiple organ dysfunction syndrome
- Critical patient safety
- Organ and tissue donation
- Professional and user participation
- Care circuits and mortality
- Biotechnology in critically ill patients with multiple organ dysfunction syndrome
- Critical patient safety
- Organ and tissue donation
- Professional and user participation

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
AA-04	Almendro-Delia, M; Hernández-Meneses, B; Padilla-Rodríguez, G; Blanco-Ponce, E; Arboleda-Sánchez, JA; Rodríguez-Yáñez, JC; Soto-Blanco, JM; Fernández-García, I; Castillo-Caballero, JM; García-Rubira, JC; Hidalgo-Urbano, R	Timing of P2Y 12 Inhibitor Administration in Patients With STEMI Undergoing Primary PCI	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	21.7	D1
AA-04	Almendro-Delia, M; Padilla-Rodríguez, G; Hernández-Meneses, B; Blanco-Ponce, E; Arboleda-Sánchez, JA; Rodríguez-Yáñez, JC; Soto-Blanco, JM; Fernández-García, I; Castillo-Caballero, JM; García-Rubira, JC; Hidalgo-Urbano, R	Nonadherence to ticagrelor versus clopidogrel and clinical outcomes in patients with ACS. Results from the CREA-ARIAM registry	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
AA-04	Miró, O; Aguiló, S; Alquézar-Arbé, A; Fernández, C; Burillo, G; Martínez, SG; Larrull, MEM; Periago, ABB; Molinas, CLA; Falcón, CR; Dacosta, PB; Flores, RCC; Calzada, JN; Blesa, EMF; Martín, MAP; Requena, AC; Fuentes, L; Cortizo, IL; Garcinuño, PG; García, MB; Del Valle, PR; Campos, RB; Jiménez, VC; Cuñado, VA; Gutiérrez, OT; Reviriego, MDS; Roussel, M; del Castillo, JG	Overnight stay in Spanish emergency departments and mortality in older patients	INTERNAL AND EMERGENCY MEDICINE	3.2	Q1
AA-04	Alvarez-Marquez, AJ; Huet, J; Pérez-Villares, JM; Daga-Ruiz, D; Díaz-Aunión, C; de la Nuez, PC; Cuende, N	Meeting the Shortage of Human Cells and Tissues: The Andalusian Quality Assurance Programme for Tissue Donation	TRANSPLANT INTERNATIONAL	2.7	Q1
AA-04	Estella, A; Lagares, C; Furones, MJ; López, PM; Martín, NL; Estebáñez, B; García, JMG; Rubio, O; Tejedor, BV; Galarza, L; Navarro, MP; Camps, VL; Martín, MC; Montejo, JC; Avidan, A; Sprung, C	Limitation of life support treatments in Spanish Intensive Care Units: Analysis of the ETHICUS II study	MEDICINA INTENSIVA	2.7	Q2

Scientific production and research activity:

Articles	%Art. Leader.	% Q1	% D1	IF
5	0%	80%	20%	38



AA-15. HEART AND VASCULAR DISEASE
LR Cristobal Urbano Carrillo

Lines of research:

- 1. Cardiovascular epidemiology
- 2. Heart failure
- 3. Cardiac interventionism
- 4. Congenital heart diseases
- 5. Pre-transplant evaluation of solid organs.
- 6. Heart and kidney failure
- 7. Systems of processes and organizational methods

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
AA-15	Frank, D; Durand, E; Lauck, S; Muir, DF; Spence, M; Vasa-Nicotera, M; Wood, D; Saia, F; Urbano-Carrillo, CA; Bouchayer, D; Iliescu, VA; Etienne, CS; Leclercq, F; Auffret, V; Asmarats, L; Di Mario, C; Veugeois, A; Maly, J; Schober, A; Nombela-Franco, L; Werner, N; Gomez-Hospital, JA; Mascherbauer, J; Musumeci, G; Meneveau, N; Meurice, T; Mahfoud, F; De Marco, F; Seidler, T; Leuschner, F; Joly, P; Collet, JP; Vogt, F; Di Lorenzo, E; Kuhn, E; Disdier, VP; Hachaturyan, V; Lueske, CM; Rakova, R; Wesselink, W; Bramlage, P; Mccalmont, G	A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study	EUROPEAN HEART JOURNAL	38.1	D1
AA-15	van Nieuwkerk, AC; Aarts, HM; Hemelrijk, KI; Carrillo, CU; Tchétché, D; de Brito, FS Jr; Barbanti, M; Kornowski, R; Latib, A; D'Onofrio, A; Ribichini, F; Garcia-Blas, S; Dumonteil, N; Abizaid, A; Sartori, S; D'Errigo, P; Tarantini, G; Lunardi, M; Orvin, K; Pagnesi, M; Navarro, F; Dangas, G; Mehran, R; Delewi, R	Cerebrovascular Events in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation: A Pooled Patient-Level Study	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
AA-15	Moreno, R; Baptista, SB; Valencia, J; Gomez-Menchero, A; Bouisset, F; Ruiz-Arroyo, JR; Bento, A; Besutti, M; -Valero, SJ; Rivero-Santana, B; Olhmann, P; Santos, M; Vaquerizo, B; Cuissetm, T; Lemoine, J; Pinar, E; Fiarresga, A; Urbano, C; Marliere, S; Braga, C; Amat-Santos, I; Morgado, G; Sarnago, F; Telleria, M; Van Belle, E; Díaz-Fernandez, J; Borrego, JC; Amabile, N; Meneveau, N	OPTImized coronary interventions eXplain the bEst cliNical outcomEs (OPTI-XIENCE) study. Rationale and study design	CARDIOVASCULAR REVASCULARIZATION MEDICINE	2.1	Q3
AA-15	González-Gutiérrez, JC; Benito-González, T; Bosa-Ojeda, F; Freixa-Rofastes, X; Estevez-Loureiro, R; Pascual, I; Andraka-Ikazuriaga, L; Díez-Gil, JL; Urbano-Carrillo, C; Amat-Santos, IJ	Prognostic impact of vasopressor test in transcatheter edge-to-edge repair of secondary mitral regurgitation: The PETIT study	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS	2.1	Q3
AA-15	Tejerizo, FB; Sánchez, FC; Jurado-Román, A; Cruz-González, I; Alvarez-Fuente, M; Amat-Santos, IJ; Blasco, PB; Mata, RB; Carrasco, JI; Bellón, JMC; Fernández, MF; Gómez-Jaume, A; Gutiérrez-Barrios, A; Albert, BI; Montañés, LJ; Aguado, FGL; Lalaguna, LA; Segovia, RM; Pérez, MJN; Pineda, SO; Núñez, FR; Gila, JS; Sanz-Ruiz, R; Vázquez-Alvarez, ME; Argüelles, JIZ	Spanish cardiac catheterization in congenital heart diseases registry. Third official report from the ACI-SEC and the GTH-SECPCC (2022)	REC-INTERVENTIONAL CARDIOLOGY	1.2	Q4

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
7	14%	57%	14%	55



AA-20. RESEARCH GROUP ON CARE IN MÁLAGA (INVESCUIDA)
LR Cipriano Viñas. Co-LR Antonio Jesús Núñez Montenegro

Priority line of research: Attention to chronicity.

Other lines:

- 1. Care of patients with chronic wounds.
- 2. Complications associated with the use of vascular devices: phlebitis, bacteremia, thrombosis, etc. An innovation project funded in 2018 began to be implemented in 2019
- 3. Clinical practice guidelines for pressure ulcers in pediatrics and neonatology.
- 4. Care of ostomies.
- 5. Validation of the “ESCENDE” Tool (Developmentally Sensitive Neonatal Nursing Care Scale) to determine the level of care intensity in the neonatal intensive care unit
- 6. Prevention of infections in neonatal intensive care units
- 7. Psychological intervention in palliative care patients

Networks:

CA19133 (FOSTREN) - Fostering and strengthening approaches to reducing coercion in European mental health services (European Commission)
CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims (European Commission)

AA-22. BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX PROCESSES IN HEALTH SYSTEMS
LR Eduardo Sánchez Guerrero

Priority line of research: Syndemic constructs for the bio-psycho-social model (MBPS)

Other lines:

- 1. Semiotics, topography, functionality, and nosology (BPS System)
- 2. ICD-11 and ICF ontologies and Dual MBPS Diagnosis
- 3. MBPS modulation systems
- 4. Capabilities and potentialities. Determinants of health
- 5. Cultural and bioactive physiological configurators MBPS

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
AA-22	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Pérez-Panero, AJ; Pérez-Belloso, AJ; Martínez-Barrios, FJ; González-Sánchez, M	Development and validation of a new questionnaire for the assessment of patients with diabetic foot disease: The Diabetic Foot Questionnaire (DiaFootQ)	PRIMARY CARE DIABETES	2.6	Q1
AA-22	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-Cosme, C; Lara, JP	Early Occupational Therapy Intervention post-stroke (EOTIPS): A randomized controlled trial	PLOS ONE	2.9	Q1
AA-22	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-cosme, C; Lara, JP	Early Occupational Therapy Intervention Programme and Coping Strategies and Burden in Caregivers of People with Sub-Acute Stroke: A Randomised Controlled Trial	JOURNAL OF PERSONALIZED MEDICINE	3	Q1
AA-22	Seoane-Martín, ME; Cuesta-Barriuso, R; Rodríguez-Martínez, MC	Performance of instrumental activities of daily living in patients with haemophilic arthropathy. A cross-sectional cohort study	HAEMOPHILIA	3	Q2

Group	Authors	Article Title	Source Title	IF	Q/D
AA-22	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Gijon-Noguerón, G; Navarro-Flores, E; González-Sánchez, M	Validity and reliability of the English version of the Diabetic Foot Self-Care Questionnaire: a cross-cultural adaptation	FRONTIERS IN PUBLIC HEALTH	3	Q2

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
15	60%	60%	7%	43

Networks:

CA18205 -WORCK Worlds of Related Coercions in Work (European Commission)

EXTERNAL ASSOCIATED GROUPS

AA-24. VASCULAR RISK AND CHRONIC DISEASES
LR: Miguel Ángel García Ordóñez. Co-LR: Jesus Olmedo Llanes

Lines of research:


1. Vascular risk factors and cardiovascular disease
2. Type 2 diabetes mellitus
3. Hypertension
4. Dyslipidemia
5. Complex chronic diseases
6. Chronicity and frailty
7. Pluripathological patients

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
AA-24	Espíldora-Hernández, J; Díaz-Antonio, T; Olmedo-Llanes, J; León, JZ; Rioja, J; Valdivielso, P; Sánchez-Chaparro, MA; Ariza, MJ	Clinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3
AA-24	Trullàs, JC; Peláez, AI; Blázquez, J; Sánchez-Biosca, A; López-Reborio, ML; Salamanca-Bautista, P; Fernández-Rodríguez, JM; Vázquez-Ronda, MA; Dávila-Ramos, MF; Mendoza-Ruiz-De-Zuazu, H; Morales-Rull, JL; Olmedo-Llanes, J; Llacer, P; Conde-Martel, A	The significance of metabolic alkalosis on acute decompensated heart failure: the ALCALOTIC study	CLINICAL RESEARCH IN CARDIOLOGY	3.8	Q1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
2	0%	50%	0%	6



Networks:
CA20104 (PhysAgeNet) -Network on evidence-based physical activity in old age
CA22169 (EU-METAHEART) -European network to tackle METAbolic alterations in HEART failure

Competitive HR contracts funded in 2024:
1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.

AA-25. NEFROCONSULTOR

- Lines of research**
- 1. Referral to the nephrology department from non-specialized care
 - 2. Glomerular diseases, renal tubular dysfunction

Featured publications:

Articles	%Art. Led	% Q1	% D1	IF

CIMO Onco-Hematology Unit

CONSOLIDATED GROUPS

B-01. CLINICAL AND TRANSLATIONAL RESEARCH IN CANCER
LR Emilio Alba Conejo

- Lines of research:**
- 1. Clinical-translational research in breast, prostate, gynecological, digestive, and germ cell cancers.
 - 2. Translational research in the identification of epigenetic/genetic markers of early stages of cancer.
 - 3. Research in the use of new diagnostic techniques (liquid biopsy...) and markers.
 - 4. Research on the relationship between microbiota and cancer.
 - 5. Research using real world data.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
B-01	Hinte, Laura C.; Castellano-Castillo, Daniel; Ghosh, Adhideb; Melrose, Kate; Gasser, Emanuel; Noe, Falko; Massier, Lucas; Dong, Hua; Sun, Wenfei; Hoffmann, Anne; Wolfrum, Christian; Ryden, Mikael; Mejhert, Niklas; Blueher, Matthias; von Meyenn, Ferdinand	Adipose tissue retains an epigenetic memory of obesity after weight loss	NATURE	50.5	D1
B-01	Alba-Bernal, A; Godoy-Ortiz, A; Domínguez-Recio, ME; López-López, E; Quirós-Ortega, ME; Sánchez-Martín, V; Roldán-Díaz, MD; Jiménez-Rodríguez, B; Peralta-Linero, J; Bellagarza-García, E; Troyano-Ramos, L; Garrido-Ruiz, G; Hierro-Martín, MI; Vicioso, L; González-Ortiz, A; Linares-Valencia, N; Velasco-Suelto, J; Carbajosa, G; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Comino-Méndez, I; Alba, E	Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	NPJ BREAST CANCER	6.6	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
B-01	Laborda-Illanes, A; Aranega-Martín, L; Sánchez-Alcoholado, L; Boutrig, S; Plaza-Andrades, I; Peralta-Linero, J; Ruiz, GG; Pajares-Hachero, B; Alvarez, M; Alba, E; González-González, A; Queipo-Ortuño, MI	Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1
B-01	Zafra, J; Onieva, JL; Oliver, J; Garrido-Barros, M; González-Hernández, A; Martínez-Gálvez, B; Román, A; Ordóñez-Marmolejo, R; Pérez-Ruiz, E; Benítez, JC; Mesas, A; Vera, A; Chicas-Sett, R; Rueda-Domínguez, A; Barragán, I	Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1
B-01	Lendinez-Sanchez, G; Díaz-Redondo, T; Iglesias-Campos, M; Garrido-Almazán, L; Alba-Conejo, E; Rueda-Dominguez, A; Sanchez-Muñoz, A	Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature	FRONTIERS IN ONCOLOGY	3.5	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
38	29%	76%	32%	571



Active projects



Clinical studies



Patents applied for

Ciber:

CIBERONC CB16/12/00481 Cancer (ISCIII)

Competitive HR contracts funded in 2024:

1 PFIS Contract (ISCIII)

1 Sara Borrell Contract (ISCIII)

1 Contract for the Training of University Personnel -FPU.

1 Contract for Technical Support Staff from the Ministry of Science and Innovation.

1 Pre-doctoral contract from the Spanish Association Against Cancer

1 Grant for Returning Young Researchers from the Spanish Society of Medical Oncology.

1 Contract for long-term reinforcement of the SAS (Action B).

B-04. MOLECULAR BASES OF BIOLOGICAL SYSTEMS (SIBIUMA)

LR Miguel Ángel Medina Torres

Lines of research:

1. Angiogenesis and tumor microenvironment: Identification and characterization of angiogenesis modulators. Metabolism in the tumor microenvironment.
2. Metabolism of biogenic amines and polyamines in health and disease.
3. Bioinformatics and networks: Interactome, disease network, and drug modeling with predictive methods.
4. Bioinformatics workflows for automation of genomic analysis. Analysis of transposon expression in cancer.
5. Applications of lines 1-4 to rare diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
B-04	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1
B-04	Bandres-Ciga, S; Faghri, F; Majounie, E; Koretsky, MJ; Kim, J; Levine, KS; Leonard, H; Makarious, MB; Iwaki, H; Crea, PW; Hernandez, DG; Arepalli, S; Billingsley, K; Lohmann, K; Klein, C; Lubbe, SJ; Jabbari, E; Saffie-Awad, P; Narendra, D; Reyes-Palomares, A; Quinn, JP; Schulte, C; Morris, HR; Traynor, BJ; Scholz, SW; Houlden, H; Hardy, J; Dumanis, S; Riley, E; Blauwendraat, C; Singleton, A; Nalls, M; Jeff, J; Vitale, D	NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations	MOVEMENT DISORDERS	7.4	D1
B-04	Cordoba-Caballero, J; Perkins, JR; Garcia-Criado, F; Gallego, D; Navarro-Sánchez, A; Moreno-Estellés, M; Garcés, C; Bonet, F; Romá-Mateo, C; Toro, R; Perez, B; Sanz, P; Kohl, M; Rojano, E; Seoane, P; Ranea, JAG	Exploring miRNA-target gene pair detection in disease with coRmiT	BRIEFINGS IN BIOINFORMATICS	6.8	D1
B-04	Marrero, AD; Cárdenas, C; Castilla, L; Ortega-Vidal, J; Quesada, AR; Martinez-Poveda, B; Medina, MA	Antiangiogenic Potential of an Olive Oil Extract: Insights from a Proteomic Study	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY	5.7	D1

Group	Authors	Article Title	Source Title	IF	Q/D
B-04	Abdala-Díaz, RT; Casas-Arrojo, V; Castro-Varela, P; Riquelme, C; Carrillo, P; Medina, MA; Cárdenas, C; Becerra, J; Manríquez, CP	Immunomodulatory, Antioxidant, and Potential Anticancer Activity of the Polysaccharides of the Fungus Fomitiporia chilensis	MOLECULES	4.2	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
21	29%	71%	24%	99



Active projects



Patents applied for

Ciber:
CIBERER CB06/07/0046 Rare Diseases (ISCIII)

B-05. TRANSLATIONAL RESEARCH IN CANCER IMMUNOTHERAPY

LR Antonio Rueda Domínguez. Co-LR. Isabel Barragan Mallofret

Priority line of research: Oncology and hematology.

Other lines of research: Cancer immunotherapy.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
B-05	Desai, J; Alonso, G; Kim, SH; Cervantes, A; Karasic, T; Medina, L; Shacham-Shmueli, E; Cosman, R; Falcon, A; Gore, E; Guren, T; Massarelli, E; Jr, WHM; Paz-Ares, L; Prenen, H; Amatu, A; Cremolini, C; Kim, TW; Moreno, V; Ou, SH; Passardi, A; Sacher, A; Santoro, A; Stec, R; Ulahannan, S; Arbour, K; Lorusso, P; Luo, J; Patel, MR; Choi, Y; Shi, Z; Mandlekar, S; Lin, MT; Royer-Joo, S; Chang, J; Jun, T; Dharia, N; Schutzman, JL; Han, SW	Divarasib plus cetuximab in KRASG12C-positive colorectal cancer: a phase 1b trial	NATURE MEDICINE	58.7	D1
B-05	Velasco-Suelto, J; Gálvez-Carvajal, L; Comino-Méndez, I; Rueda-Domínguez, A	Hodgkin lymphoma and liquid biopsy: a story to be told	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	11.4	D1
B-05	Omotesho, QA; Escamilla, A; Perez-Ruiz, E; Frecha, CA; Rueda-Dominguez, A; Barragan, I	Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures	FRONTIERS IN IMMUNOLOGY	5.7	Q1
B-05	Zafra, J; Onieva, JL; Oliver, J; Garrido-Barros, M; González-Hernández, A; Martínez-Gálvez, B; Román, A; Ordóñez-Marmolejo, R; Pérez-Ruiz, E; Benítez, JC; Mesas, A; Vera, A; Chicas-Sett, R; Rueda-Domínguez, A; Barragán, I	Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
B-05	Guardamagna, M; Meyer, ML; Berciano-Guerrero, MA; Mesas-Ruiz, A; Cobo-Dols, M; Perez-Ruiz, E; Gonzalez, AC; Lavado-Valenzuela, R; Barragán, I; Oliver, J; Garrido-Aranda, A; Alvarez, M; Rueda-Dominguez, A; Queipo-Ortuño, MI; Conejo, EA; Benitez, JC	Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review	TRANSLATIONAL LUNG CANCER RESEARCH	4	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
18	22%	50%	17%	128



Active projects



Clinical studies



Patents applied for

Competitive HR contracts funded in 2024:

- 1 Juan de la Cierva Contract from the State Research Agency.
- 1 Contract to promote research consolidation from the State Research Agency.
- 1 Contract for the annual reinforcement of the research activity in the SAS clinical units
- 2 Nicolás Monardes SAS contracts (Action C).
- 1 Contract for research personnel in training, Agents of the Andalusian Knowledge System.

B-07. CANCEROMICS

LR Javier Márquez Gómez. Co-LR José Manuel Matés Sánchez

Priority line of research: Functional genomics and cancer proteomics

Other lines of research:

- Cellular and molecular bases of glutamate synthesis in brain
- New antitumor strategies and therapies based on glutaminase isoenzymes
- Transgenic animal models with amino acid metabolism deficits
- Heterologous expression of recombinant human proteins with therapeutic and biotechnological value

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
B-07	de los Santos-Jiménez, J; Campos-Sandoval, JA; Alonso, FJ; Márquez, J; Matés, JM	GLS and GLS2 Glutaminase Isoenzymes in the Antioxidant System of Cancer Cells	ANTIOXIDANTS	6	Q1
B-07	Guillén-Pérez, YM; Ortiz-Ruiz, MJ; Márquez, J; Pandiella, A; Esparís-Ogando, A	ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1
B-07	Ramírez, CC; Alméciga-Díaz, CJ; Martín-Rufián, M; Cárdenas-García, C; Espejo-Mojica, AJ; Lobo, C; Benincore, EP	A close-up view of the Hunter syndrome	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS	2.5	Q3

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
3	33%	67%	0%	13



Active projects

B-10. SKIN CANCER

LR María Victoria de Gálvez Aranda. Co-LR Enrique Herrera Acosta

Priority line of research: Research on the processes involved in the development of skin cancer and other diseases that arise from overexposure to solar radiation and research on prevention through the development of photoprotection tools.

Other lines:

- 1. Studies of the mechanisms involved in the development of skin cancer with a specific search for new prognostic factors as well as a therapeutic approach.
- 2. Research on the effects of biologic therapy on psoriasis and other dermatoses.
- 3. Analysis of the etiopathogenesis of photodermatosis for a comprehensive approach to prevention and treatment measures.
- 4. Research on the mechanisms involved in the generation of photoaging hyperpigmentation and a comprehensive approach to photoprotection strategies to prevent them.
- 5. Measurement of ultraviolet, visible, and IR solar and artificial radiation in order to generate algorithms for solar and artificial exposure that are safe and for preventive purposes.
- 6. Non-intrusive technology-based research on the analysis of sun damage to the skin and topical photoprotection tools.
- 7. Research on new topical photoprotectors based on natural substances.
- 8. Development of solar and artificial radiation measurement tools based on specific sensors and development of new technology for photodiagnosis and phototherapy.
- 9. Development of communication strategies for sun damage prevention.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	D
B-10	Lluch-Galcerá, JJ; Carrascosa, JM; González-Quesada, A; Rivera-Díaz, R; Sahuquillo-Torralba, A; Llamas-Velasco, M; Gómez-García, F; Herrera-Acosta, E; de la Cueva, P; Baniandrés-Rodríguez, O; Lopez-Estebaranz, JL; Belinchón, I; Ferrán, M; Mateu, A; Rodríguez, L; Riera-Monroig, J; Abalde-Pintos, MT; Carretero, G; García-Donoso, C; Pujol-Marco, C; Del Alcázar, E; Santamaría-Domínguez, C; Suárez-Pérez, JA; Nieto-Benito, LM; Ruiz-Genao, D; Salgado-Boquete, L; Descalzo, MA; García-Doval, I	Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry	BRITISH JOURNAL OF DERMATOLOGY	11	D1	1

Group	Authors	Article Title	Source Title	IF	Q/D	D
B-10	Munoz-Aceituno, E; Butrón-Bris, B; Ovejero-Benito, MC; Sahuquillo-Torralba, A; Rodríguez, OB; Herrera-Acosta, E; Rivera-Díaz, R; Ferran, M; Sanchez-Carazo, JL; Riera-Monroig, J; Pujol-Montcusí, J; Vidal, D; de la Cueva, P; García-Bustinduy, M; Ruiz-Villaverde, R; Ballescà, F; Llamas-Velasco, M; Navares, M; Palomar-Moreno, I; Sanchez-García, I; Garcia-Martínez, J; Novalbos, J; Zubiaur, P; Abad-Santos, F; Daudén-Tello, E; de la Fuente, H	Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	8.5	D1	1
B-10	Salas-Marquez, C; García, RB; Jiménez, JBR; Escribano, PC; Ruiz, FR	Development of a Questionnaire on Knowledge, Habits, and Attitudes on Sexually Transmitted Infections in Teenagers and Young Adults	ACTAS DERMO-SIFILOGRAFICAS	3.8	Q1	2
B-10	Aguilera, J; Bosch, RJ; de Galvez, MV	Discussion Abounds on the Potential Carcinogenic Risks Associated With the Use of UV Curing Lamps for Permanent Nail Polish	ACTAS DERMO-SIFILOGRAFICAS	3.8	Q1	2
B-10	Aguilera, J; Navarrete-de Gálvez, END; El Houssaini, A; Soto-Lara, F; Herrera-Ceballos, E; de Galvez, MV	The topical application of different galenic formulations can alter the thermographic images of skin: Limitations for public thermal screening on infection control situations	AMERICAN JOURNAL OF INFECTION CONTROL	3.8	Q1	2

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
14	14%	79%	14%	60



Active projects



Clinical studies



Patents applied for

B-11. GENITOURINARY ONCOLOGY TRANSLATIONAL RESEARCH GROUP

LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico

Priority line of research: Genetic and molecular epidemiology of genitourinary cancer

Other lines of research:

- 1. Development of new antineoplastic molecules in genitourinary tumors
- 2. Oncogenesis and taxonomy of genitourinary tumors
- 3. Prognostic and predictive biomarkers in genitourinary cancer
- 4. Advanced therapies in urologic oncology
- 5. Lysophosphatidic acid and autotaxin-mediated signaling in genitourinary tumors

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D
B-11	Olmos, D; Lorente, D; Alameda, D; Cattrini, C; Romero-Laorden, N; Lozano, R; Lopez-Casas, PP; Jambrina, A; Capone, C; Vanden Broecke, AM; Trevisan, M; Van Sanden, S; Juergens, A; Herrera-Imbroda, B; Castro, E	Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes	ANNALS OF ONCOLOGY	56.7	D1
B-11	Tombal, BF; Gomez-Veiga, F; Gomez-Ferrer, A; López-Campos, F; Ost, P; Roumeguere, TA; Herrera-Imbroda, B; D'Hondt, LA; Quivrin, M; Gontero, P; Villà, S; Khaled, H; Fournier, B; Musoro, J; Krzystyniak, J; Pretzenbacher, Y; Lorient, Y	A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)	EUROPEAN UROLOGY ONCOLOGY	8.3	D1
B-11	Romero-Laorden, N; Lorente, D; de Velasco, G; Lozano, R; Herrera, B; Puente, J; López, PP; Medina, A; Almagro, E; Gonzalez-Billalabeitia, E; Villa-Guzman, JC; González-del-Alba, A; Borrega, P; Láinez, N; Fernández-Freire, A; Hernández, A; Rodríguez-Vida, A; Chirivella, I; Fernandez-Parra, E; López-Campos, F; Pacheco, MI; Morales-Barrera, R; Fernández, O; Villatoro, R; Luque, R; Hernando, S; Castellano, DC; Castro, E; Olmos, D	Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study	EUROPEAN UROLOGY ONCOLOGY	8.3	D1

Group	Authors	Article Title	Source Title	IF	Q/D
B-11	Garcia-Flores, LA; De Vera, MTD; Pilo, J; Rego, A; Gomez-Casado, G; Arranz-Salas, I; Martín, IH; Alcaide, J; Torres, E; Ortega-Gomez, A; Boughanem, H; Macias-Gonzalez, MM	Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis	FRONTIERS IN IMMUNOLOGY	5.7	Q1
B-11	Correa, R; Vidal, N; Quesada-García, A; Marcos, R; del Toro, JM; Muñoz-Rodríguez, J	Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey	ACTAS UROLOGICAS ESPANOLAS	1.2	Q3

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
9	33%	89%	44%	105



Competitive HR contracts funded in 2024:

- 1 junior clinician of the Spanish Association Against Cancer (AECC)
- 1 grant for predoctoral contracts for the training of doctors from the State Research Agency.

B-12. COMPUTATIONAL INTELLIGENCE IN BIOMEDICINE

LR José Manuel Jerez Aragonés

Lines of research:

- 1. Clinical informatics
- 2. Clinical data mining
- 3. Clinical bioinformatics

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
B-12	Cámara, J; Troya, J; Montes-Torres, J; Jaime, FJ	Generative AI in the Software Modeling Classroom: An Experience Report With ChatGPT and Unified Modeling Language	IEEE SOFTWARE	3.3	Q2
B-12	Pedrero-Martin, Y; Falla, D; Rodriguez-Brazzarola, P; Torrontegui-Duarte, M; Fernandez-Sanchez, M; Jerez-Aragones, JM; Liew, BXW; Luque-Suarez, A	Prognostic Factors of Perceived Disability and Perceived Recovery After Whiplash	CLINICAL JOURNAL OF PAIN	2.6	Q2
B-12	Gallego, F; Veredas, FJ	Recognition and normalization of multilingual symptom entities using in-domain-adapted BERT models and classification layers	DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION	3.4	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
3	33%	33%	0%	9



B-22. EMERGING ANTITUMOR ADAPTATION THERAPIES

LR: Manuel Cobo Dols. Co-LR Inmaculada Ales Diaz

Lines of research:

- Biomarkers Immuno-oncology and precision medicine: Agnostic in non-cutaneous solid tumors

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
B-22	Cho, BC; Lu, S; Felip, E; Spira, AI; Girard, N; Lee, JS; Lee, SH; Ostapenko, Y; Danchaivijitr, P; Liu, BG; Alip, A; Korbenfeld, E; Dias, JM; Besse, B; Lee, KH; Xiong, HL; How, SH; Cheng, Y; Chang, GC; Yoshioka, H; Yang, JCH; Thomas, M; Nguyen, D; Ou, SHI; Mukhedkar, S; Prabhash, K; D'Arcangelo, M; Alatorre-Alexander, J; Limon, JCV; Alves, S; Stroyakovskiy, D; Peregudova, M; Sendur, MAN; Yazici, O; Califano, R; Calderon, VG; de Marinis, F; Passaro, A; Kim, SW; Gadgeel, SM; Xie, JH; Sun, T; Martinez, M; Ennis, M; Fennema, E; Daksh, M; Millington, D; Leconte, I; Iwasawa, R; Lorenzini, P; Baig, M; Shah, SJ; Bauml, JM; Shreeve, SM; Sethi, S; Knoblauch, RE; Hayashi, H	Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC	NEW ENGLAND JOURNAL OF MEDICINE	96.3	D1
B-22	Lu, S; Kato, T; Dong, XR; Ahn, MJ; Quang, L; Soparattanapaisarn, N; Inoue, T; Wang, CL; Huang, MJ; Yang, JCH; Cobo, M; Özgüroglu, M; Casarini, I; Khiem, DV; Sriuranpong, V; Cronemberger, E; Takahashi, T; Runglodvatana, Y; Chen, M; Huang, XN; Grainger, E; Ghiorghiu, D; van der Gronde, T; Ramalingam, SS	Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC	NEW ENGLAND JOURNAL OF MEDICINE	96.3	D1
B-22	Felip, E; Metro, G; Tan, DSW; Wolf, J; Mark, M; Boyer, M; Hughes, BGM; Bearz, A; Moro-Sibilot, D; Le, XN; Puente, J; Massuti, B; Tiedt, R; Wang, YY; Xu, C; Mardjuadi, FI; Cobo, M	Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer	LUNG CANCER	4.5	Q1
B-22	Provencio-Pulla, M; Pérez-Parente, D; Olson, S; Hasan, H; Balea, BC; Rodríguez-Abreu, D; Piqueras, MLB; Pal, N; Wilkinson, S; Vilas, E; Ruiz-Gracia, P; Cobo-Dols, M	Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2

Group	Authors	Article Title	Source Title	IF	Q/D
B-22	Lendinez-Sanchez, G; Diaz-Redondo, T; Campos, MI; Pelayo, JP; Pelayo, JMP; Muriel-López, C	ATM Variant as a Cause of Hereditary Cutaneous Melanoma in a Spanish Family: A case report.	CASE REPORTS IN ONCOLOGY	0.7	Q4

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
32	9%	72%	41%	557



Active projects



Clinical studies

EMERGING GROUPS

BE-03. HEMATOLOGY AND HEMOTHERAPY
LR Francisco José López Jaime

Priority line of research:

- Study of genetic/genomic profiles with an influence on the diagnosis, treatment, and survival of adult and pediatric patients with hematologic neoplasms. Individualized treatment and quality of life.

Other lines:

- Transplantation of hematopoietic stem cells in adult and pediatric patients:
 - Home-based hematopoietic stem cell transplantation and quality of life.
 - Study of variables involved in graft-versus-host disease.
 - Study of chimerism in allogeneic hematopoietic stem cell transplantation using new technologies (real-time PCR and digital PCR), prognostic implications, and prediction of relapse.
- CAR-T (Chimeric Antigen Receptor-T) cell therapy: efficacy and quality of life studies.
- Study of rare hematologic-based diseases: diagnosis and individualized treatment.
- Hemostasis and Thrombosis: Clinical and laboratory approach to new therapies for patients with hemophilia. Digital tools for the management and analysis of information in hemophilia. Immune thrombocytopenia. Thrombophilic states of genetic and acquired origin. Thrombosis in oncohematology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BE-03	Piemontese, S; Labopin, M; Choi, G; Broers, AEC; Peccatori, J; Meijer, E; Van Gorkom, G; Rovira, M; Cascon, MJP; Sica, S; Vydra, J; Kulagin, A; Spyridonidis, A; Nagler, A; Bazarbachi, A; Savani, B; Brissot, E; Sanz, J; Mohty, M; Ciceri, F	Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide	LEUKEMIA	12.8	D1
BE-03	Moreno, DF; Jiménez, C; Escalante, F; Askari, E; Castellanos-Alonso, M; Arnao, M; Heredia, A; Canales, MA; Alcalá, M; Bermúdez, A; Carreres, AS; Casanova, M; Palomera, L; Motlló, C; García-Sánchez, R; Rull, PR; García-Sanz, R; de Larrea, CF	Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry	HEMASPHERE	11.9	D1

Group	Authors	Article Title	Source Title	IF	Q/D
BE-03	Garderet, L; Gras, L; Koster, L; de Wreede, L; Montserrat, R; Vincent, L; Fenk, R; Karunanithi, K; Deeren, D; Kaufmann, M; Kuball, J; Ozdogu, H; Cascon, MJP; Passweg, J; Rye, A; Salmenniemi, U; Snowden, J; Hansen, CT; Leleu, X; Gastaud, L; Drozd-Sokolowska, J; Raj, K; Beksac, M; Schönland, S; Hayden, P; Mclornan, D	Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation	HAEMATOLOGICA	8.2	Q1
BE-03	Salas, MQ; Cascos, E; López-García, A; Pérez, E; Baile-González, M; Rodríguez, CM; Cascón, MJP; Luque, M; Esquirol, A; Fernando, IH; Peña-Muñoz, F; Ormtegi, IO; Marín, AJS; Fernández-Luis, S; Dominguez-García, JJ; Fernández, SV; Girón, MFD; Pinedo, LG; Garcia, L; González-Rodríguez, AP; Torrado, T; Filaferro, S; Cedillo, A; Orti, G; Chacón, MJ	Cardiac events after allo-HCT in patients with acute myeloid leukemia	BLOOD ADVANCES	7.4	Q1
BE-03	Bravo, AP; Bonilla, RP; Rebollar, DB; López-Jaime, FJ; Fernández-Bello, I	Successful immunosuppressive drug-free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report	CLINICAL CASE REPORTS	0.6	Q3

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
19	5%	79%	16%	99



BE-15. PATHOLOGICAL ANATOMY
LR Isabel Hierro. Co-LR Rafael E. Carvia Ponsaillé

Priority line of research: Anatomic pathological factors of prognostic value or decisive for the therapeutic approach in oncology

- Other lines:**
- Anatomic pathological studies of autoimmune, infectious, or inflammatory diseases with prognostic or therapeutic value.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BE-15	Carrillo-García, J; Hindi, N; Conceicao, M; Sala, MA; Ugalde, A; López-Pousa, A; Bagué, S; Sevilla, I; Vicioso, L; Ramos, R; Martínez-Trufero, J; Mateo, MCG; Cruz, J; Hernández-León, CN; Redondo, A; Mendiola, M; García, JM; Hernández, JE; Alvarez, R; Agra, C; de Juan-Ferré, A; Valverde, C; Cano, JM; de Sande, LM; Pérez-Fidalgo, JA; Lavernia, J; Marcilla, D; Gutiérrez, A; Moura, DS; Martín-Broto, J	Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor	EUROPEAN JOURNAL OF CANCER	7.6	Q1
BE-15	Cornejo-Pareja, I; Amiar, MR; Ocaña-Wilhelmi, L; Soler-Humanes, R; Arranz-Salas, I; Garrido-Sánchez, L; Gutiérrez-Repiso, C; Tinahones, FJ	Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism	JOURNAL OF GASTROENTEROLOGY	6.9	Q1
BE-15	Castellano-Castillo, D; Ramos-Molina, B; Frutos, MD; Arranz-Salas, I; Reyes-Engel, A; Queipo-Ortuño, MI; Cardona, F	RNA expression changes driven by altered epigenetics status related to NASH etiology	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1
BE-15	Alba-Bernal, A; Godoy-Ortiz, A; Domínguez-Recio, ME; López-López, E; Quirós-Ortega, ME; Sánchez-Martín, V; Roldán-Díaz, MD; Jiménez-Rodríguez, B; Peralta-Linero, J; Bellagarza-García, E; Troyano-Ramos, L; Garrido-Ruiz, G; Hierro-Martín, MI; Vicioso, L; González-Ortiz, A; Linares-Valencia, N; Velasco-Suelto, J; Carbajosa, G; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Comino-Méndez, I; Alba, E	Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	NPJ BREAST CANCER	6.6	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
BE-15	Garcia-Flores, LA; De Vera, MTD; Pilo, J; Rego, A; Gomez-Casado, G; Arranz-Salas, I; Martín, IH; Alcaide, J; Torres, E; Ortega-Gomez, A; Boughanem, H; Macias-Gonzalez, MM	Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis	FRONTIERS IN IMMUNOLOGY	5.7	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
9	22%	78%	11%	47

BE-17. CLINICAL, MOLECULAR, AND TECHNOLOGICAL RESEARCH IN RADIATION ONCOLOGY

LR Jaime Gómez-Millán Barrachina. Co-LR María Jesús García Anaya

Priority line of research: Prognostic and predictive factors of response to ionizing radiation in upper aerodigestive tract and gynecologic tumors.

Other lines:

1. New techniques in cancer treatment with radiotherapy Etiopathogenesis of mucositis
2. Immunologic factors associated with response in SBRT

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BE-17	Zafra, J; Onieva, JL; Oliver, J; Garrido-Barros, M; González-Hernández, A; Martínez-Gálvez, B; Román, A; Ordóñez-Marmolejo, R; Pérez-Ruiz, E; Benítez, JC; Mesas, A; Vera, A; Chicas-Sett, R; Rueda-Domínguez, A; Barragán, I	Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1
BE-17	Gómez-Aparicio, MA; López-Campos, F; Buchser, D; Lazo, A; Willisich, P; Ocanto, A; Sargos, P; Shelan, M; Couñago, F	Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?	CANCERS	4.5	Q1
BE-17	Calvo, A; Anaya, MJ; Guillot, SS; Romero, NM; Ocón, MJ; Carmona, J; Gómez-Millán, J; Ríos, IG	Ultrahypofractionation in postoperative radiotherapy for breast cancer: A single-institution retrospective cohort series	CANCER MEDICINE	2.9	Q2
BE-17	Rivas, D; de la Torre-luque, A; Moreno-Olmedo, E; Moreno, P; Suárez, V; Serradilla, A; Arregui, G; Alvarez, D; Sallabanda, M; Lazo, A; Núñez, MI; López, E	Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?	WORLD JOURNAL OF UROLOGY	2.8	Q2
BE-17	Rodríguez-Rodríguez, D; Sanz-Sánchez, CI; Cazorla-Ramos, OE	Cervical necrotizing fascitis of odontogenous origin. A case report	REVISTA ORL	0.1	Q4

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
6	50%	33%	0%	15



BE-18. VASCULAR BIOLOGY, TUMOR MICROENVIRONMENT & TARGET DISCOVERY
LR Melissa García Caballero

Priority line of research: Study of the tumor microenvironment, characterization of endothelial reprogramming, identification of new therapeutic targets, and development of new drugs

Other lines: Study of diseases that depend on deregulated lymph/angiogenesis

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BE-18	Bettinetti-Luque, M; Trujillo-Estrada, L; Garcia-Fuentes, E; Andreo-Lopez, J; Sanchez-Varo, R; Garrido-Sánchez, L; Gómez-Mediavilla, A; López, MG; Garcia-Caballero, M; Gutierrez, A; Baglietto-Vargas, D	Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease	BRITISH JOURNAL OF PHARMACOLOGY	6.8	D1
BE-18	de Zeeuw, P; Treps, L; García-Caballero, M; Harjes, U; Kalucka, J; De Legher, C; Brepoels, K; Peeters, K; Vinckier, S; Souffreau, J; Bouché, A; Taverna, F; Dehairs, J; Talebi, A; Ghesquiere, B; Swinnen, J; Schoonjans, L; Eelen, G; Dewerchin, M; Carmeliet, P	The gluconeogenesis enzyme PCK2 has a non-enzymatic role in proteostasis in endothelial cells	COMMUNICATIONS BIOLOGY	5.2	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
2	0%	100%	50%	12



Networks:

CA21154 (TRANSLACORE) - Translational control in Cancer European Network
CA21135 (IMMUNO-model) -Modelling immunotherapy response and toxicity in cancer

Competitive HR contracts funded in 2024:

1 Pre-doctoral contract with the Spanish Association Against Cancer

BE-19. RADIOBIOLOGY
LR Miguel José Ruiz Gómez

Lines of research:

- Molecular markers of antineoplastic drug resistance, radiation, and cellular aging
- Effect of electromagnetic fields. Evaluation of cell damage and mechanisms of repair and resistance.
- Molecular radiobiology
- Study of chronological and replicative cellular aging and its relationship with the effects and molecular mechanisms of resistance to drugs and physical agents
- Biological and environmental dosimetry

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BE-19	Sendra-Portero, F; Lorenzo-Alvarez, R; Rudolphi-Solero, T; Ruiz-Gómez, MJ	The Second Life Metaverse and Its Usefulness in Medical Education After a Quarter of a Century	JOURNAL OF MEDICAL INTERNET RESEARCH	5.8	D1
BE-19	Martín-Sierra, C; Bravo, MJ; Sáez, ME; De Rojas, I; Santos, M; Martín-Carmona, J; Corma-Gómez, A; González-Serna, A; Royo, JL; Pineda, JA; Rivero, A; Rivero-Juárez, A; Macías, J; Real, LM	The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations (GEHEP-012 study)	ANTIVIRAL RESEARCH	4.5	Q1
BE-19	Castro, AA; Pinos, DD; Utrilla, VS; del Campo, JAO; Portero, FS; Ruiz-Gómez, MJ	Update in imaging tests used for the localization of parathyroid pathology	RADIOLOGIA	1.1	Q3
BE-19	Rudolphi-Solero, T; Lorenzo-Alvarez, R; Domínguez-Pinos, D; Ruiz-Gómez, MJ; Sendra-Portero, F	An Interuniversity Competition for Medical Students to Learn Radiology in the Second Life Metaverse	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY	4	Q1
BE-19	Atencia-Jiménez, I; Balajee, AS; Ruiz-Gómez, MJ; Sendra-Portero, F; Montoro, A; Molina-Cabello, MA	Neural Network Ensemble to Detect Dicentric Chromosomes in Metaphase Images	APPLIED SCIENCES-BASEL	2.5	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
7	57%	71%	14%	26



BE-21. HEMATOLOGY AND IMMUNOLOGY

LR Regina García Delgado. Co-LR Alejandro Escamilla Sánchez

Lines of research:

- Multidisciplinary translational study to evaluate clinical, biological, and immunological profiles in patients with hematological malignancies.
- Lymphoproliferative neoplasms (NHL).
- Related myeloproliferative neoplasms (MPN).
- Precision medicine for hematological malignancies.
- Immunotherapy for hematological malignancies.
- New therapeutic targets for hematological malignancies.
- Tumor microenvironment and progression of hematologic malignancies.
- Translational research and knowledge transfer.
- Psycho-oncology and patient well-being.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BE-21	Moreno, DF; Jiménez, C; Escalante, F; Askari, E; Castellanos-Alonso, M; Arnao, M; Heredia, A; Canales, MA; Alcalá, M; Bermúdez, A; Carreres, AS; Casanova, M; Palomera, L; Motlló, C; García-Sánchez, R; Rull, PR; García-Sanz, R; de Larrea, CF	Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry	HEMASPHERE	11.9	D1
BE-21	Omotesho, QA; Escamilla, A; Perez-Ruiz, E; Frecha, CA; Rueda-Dominguez, A; Barragan, I	Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures	FRONTIERS IN IMMUNOLOGY	5.7	Q1
BE-21	Jiménez-Bárcenas, R; García-Donas-Gabaldón, G; Campos-Alvarez, RM; de Mora, MCFS; Luis-Navarro, J; Domínguez-Rodríguez, JF; Nieto-Hernández, MD; Sánchez-Bazán, I; Yera-Cobo, M; Cardesa-Cabrera, R; Jiménez-Gonzalo, FJ; Ruiz-Cobo, MA; Caparrós-Miranda, I; Entrena-Ureña, L; Jiménez, DF; Díaz-Canales, D; Moreno-Carrasco, G; Calderón-Cabrera, C; Núñez-Vazquez, RJ; Pedrote-Amador, B; Mingot-Castellano, ME	Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study	BRITISH JOURNAL OF HAEMATOLOGY	5.1	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
BE-21	Arrari, F; Ortiz-Flores, RM; Lhamyani, S; Garcia-Fuentes, E; Jabri, MA; Sebai, H; Bermudez-Silva, FJ	Protective Effects of Spirulina Against Lipid Micelles and Lipopolysaccharide-Induced Intestinal Epithelium Disruption in Caco-2 Cells: In Silico Molecular Docking Analysis of Phycocyanobilin	NUTRIENTS	4.8	Q1
BE-21	Flores, RMO; Cáceres, CS; Cortiñas, TI; Mejiba, SEG; Sasso, CV; Ramirez, DC; Domínguez, MAM	Exotoxins secreted by Clostridium septicum induce macrophage death: Implications for bacterial immune evasion mechanisms at infection sites	TOXICON	2.6	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
8	13%	63%	13%	38



Active projects



Clinical studies

BE-23. NEW HORIZONS FOR ONCOLOGY PATIENTS
LR: Miguel Ángel Berciano Guerrero / Co-LR Julia Alcaide García.

Lines of research:

- Translational research in cancer.
- Cell therapy in solid tumors.
- New drugs and strategies for cancer
- Cross-sectional and multidisciplinary research in oncology patients.
- Long-term cancer survivors.
- Artificial intelligence applied to medical oncology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BE-23	Vallejo Herrera, M J; Vallejo Herrera, V; Serrano Puche, F	Extraadrenal abdominal paraganglyoma: Review of the literature	MEDICINA DE FAMILIA-SEMERGEN	0.9	Q4
BE-23	Zamudio-Sánchez, A; Camarero-Gómez, P; Rodríguez-Manjón, E; Iglesias-Parra, MR; Gómez-Salgado, J; Romero, A	Needs and Expectations of Long-Term Cancer Survivors: Multi-Centre Study Protocol	JOURNAL OF PERSONALIZED MEDICINE	3	Q1
BE-23	Flechon, A; Morales-Barrera, R; Powles, T; Alva, A; Özgüroğlu, M; Csösz, T; Lorient, Y; Rodríguez-Vida, A; Géczi, L; Cheng, SY; Fradet, Y; Oudard, S; Vulsteke, C; Gunduz, S; Mamtani, R; Yu, EY; Pino, AM; Anido, U; Sendur, MAN; Gravis, G; Révész, J; Kostorov, V; Huillard, O; Ma, JS; Rajasagi, M; Vajdi, A; Lunceford, J; Cristescu, R; Imai, K; Moreno, BH; Matsubara, N	Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma	CLINICAL CANCER RESEARCH	10.4	D1
BE-23	Márquez-Rodas, I; Alvarez, A; Arance, A; Valduvico, I; Berciano-Guerrero, MA; Delgado, R; Soria, A; Campos, FL; Sánchez, P; Romero, JL; Martín-Liberal, J; Lucas, A; Díaz-Beveridge, R; Conde-Moreno, AJ; de la Gala, MDA; García-Castaño, A; Prada, PJ; Cao, MG; Puertas, E; Vidal, J; Foro, P; de la Rosa, CA; Corona, JA; Cerezuela-Fuentes, P; López, P; Luna, P; Aymar, N; Puértolas, T; Sanagustín, P; Berrocal, A	Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/ GEM1802 phase II study)	NEURO-ONCOLOGY	16.4	D1

Group	Authors	Article Title	Source Title	IF	Q/D
BE-23	Morris, MJ; Castellano, D; Herrmann, K; de Bono, JS; Shore, ND; Chi, KN; Crosby, M; Piulats, JM; Fléchon, A; Wei, XX; Mahammedi, H; Roubaud, G; Studentová, H; Nagarajah, J; Mellado, B; Montes-Pino, A; Kpamegan, E; Ghebremariam, S; Kreisl, TN; Wilke, C; Lehnhoff, K; Sartor, O; Fizazi, K	177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naïve patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial	LANCET	98.4	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
14	14%	57%	29%	169



Active projects



Clinical studies

ASSOCIATED GROUPS

BA-16. QUALITY AND SAFETY IN LABORATORY AND HEMATOLOGY CARE

LR Adolfo Romero Ruiz

Lines of research:

- 1. Clinical safety.
- 2. Pre-blood test.
- 3. Hematology.
- 4. Clinical analysis.
- 5. Care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BA-16	Peña-Montero, N; Linares-Pineda, TM; Fernández-Valero, A; Lima-Rubio, F; Fernández-Ramos, AM; Gutiérrez-Repiso, C; Suárez-Arana, M; Picón-César, MJ; Molina-Vega, M; Morcillo, S	Differences in DNA Methylation in Genes Involved in Vitamin D Metabolism Are Related to Insulin Requirement in Pregnant Women with Gestational Diabetes Mellitus	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1
	Romero-Arana, A; González-Rodríguez, MJ; Sánchez-Vega, P; Gómez-Salgado, J; Romero, A	Effectiveness of a self-management program for anticoagulated patients to improve their knowledge about treatment and time in therapeutic range	MEDICINE	1.4	Q2
	Muñoz, M; Aragón, S; Ballesteros, M; Bisbe-Vives, E; Jericó, C; Llamas-Sillero, P; Meijide-Míguez, HM; Rayó-Martin, E; Rodríguez-Suárez, MJ	Executive summary of the consensus document on the management of perioperative anemia in Spain	REVISTA CLINICA ESPANOLA	2.3	Q2
	Rodriguez-Muñoz, A; Martínez-Montoro, JI; Sojo-Rodriguez, B; Benitez-Porres, J; Carrillo-Albornoz-Gil, M; Carrasco-Fernandez, L; Subiri-Verdugo, A; Molina-Ramos, A; Cobos-Diaz, A; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Glycaemic Response to Acute Aerobic and Anaerobic Exercise Performed in the Morning or Afternoon in Healthy Subjects: A Crossover Trial	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1

Group	Authors	Article Title	Source Title	IF	Q/D
BA-16	Zamudio-Sánchez, A; Camarero-Gómez, P; Rodríguez-Manjón, E; Iglesias-Parra, MR; Gómez-Salgado, J; Romero, A	Needs and Expectations of Long-Term Cancer Survivors: Multi-Centre Study Protocol	JOURNAL OF PERSONALIZED MEDICINE	3	Q1

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
6	50%	50%	17%	18

BA-20. ONCOLOGY AND BENIGN PATHOLOGY

LR Jorge Contreras Martínez

Lines of research:

- 1. Priority line: Prostate tumors, head and neck tumors, brain tumors, breast tumors, pediatric and adolescent tumors, hyperthermia treatment
- 2. Other lines: Benign diseases (skin tumors, rheumatologic diseases). Degenerative diseases (Alzheimer’s disease)

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D
BA-20	Zamora, V; Garin, O; Suárez, JF; Gutiérrez, C; Guedea, F; Cabrera, P; Castells, M; Herruzo, I; Fumadó, L; Samper, P; Ferrer, C; Regis, L; Pont, A; Ferrer, M	Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures	CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY	2.7	Q2

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1	0%	0%	0%	3



EXTERNAL ASSOCIATED GROUPS

BA-14. TRANSLATIONAL RESEARCH GROUP IN CANCER AND OTHER PREVALENT CHRONIC DISEASES

LR Maximino Redondo Bautista. Co-LR Marilina García Aranda

Lines of research:

- Evaluation of health services in oncologic diseases
- Study of inhibitor of apoptosis proteins in cancer
- Study of biomarkers of immunoediting and response to immunotherapy in cancer and health outcomes attributable to said immunotherapy.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
BA-14	Varela-Moreno, E; Anarte-Ortiz, MT; Jodar-Sanchez, F; Garcia-Palacios, A; Monreal-Bartolome, A; Gili, M; García-Campayo, J; Mayoral-Cleries, F	Economic Evaluation of a Web Application Implemented in Primary Care for the Treatment of Depression in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial	JMIR MHEALTH AND UHEALTH	5.4	D1
BA-14	Barnestein-Fonseca, P; Guerrero-Pertiñez, G; Gúzman-Parra, J; Valera-Moreno, E; Mayoral-Cleries, F	Is it possible to diagnose therapeutic adherence in mild cognitive impairment and dementia patients in clinical practice?	FRONTIERS IN PHARMACOLOGY	4.4	Q1
BA-14	Abbad-Gomez, D; Domingo, L; Comas, M; Santia, P; Jansana, A; Poblador, B; Sanz, T; del Cura, I; Ibañez, B; Padilla, M; Redondo, M; Castells, X; Sala, M	Effect of comorbidity and multimorbidity on adherence to follow-up recommendations among long-term breast cancer survivors	MATURITAS	3.9	Q1
BA-14	Hernández-Herrador, M; Marilina, GA; Hortas, ML; Carrillo-Lucena, S; Caracuel, Z; Castilla-Alcalá, JA; Martin-García, D; Redondo, M	Clusterin expression and distribution in spermatozoa as predictor of male fertility	MOLECULAR REPRODUCTION AND DEVELOPMENT	2.7	Q2
BA-14	Fernández-Sánchez, F; Martín-Bautista, E; Rivas-Ruiz, F; Wu, WN; García-Aranda, M	Evaluation of the EasyNAT SARS-CoV-2 assay PCR test for the diagnosis of SARS-CoV-2 infection	JOURNAL OF VIROLOGICAL METHODS	2.2	Q3

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
10	70%	50%	10%	37.9



Active projects



Clinical studies

Networks:

CA21152 (INE-CSC) -Implementation Network Europe for Cancer Survivorship Care
CA21139 (IMPROVE) -3Rs concepts to improve the quality of biomedical science
CA21135 (IMMUNO-model) -Modelling immunotherapy response and toxicity in cancer
CA18240 (Adher N Rise) - ADHEsion GPCR Network: Research and Implementation Set the path for future Exploration
CA23119 (SENESCENCE2030) -Targeting Cell Senescence to Prevent Age-Related Diseases
Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS), RD21-0016-0015.

Competitive HR contracts funded in 2024:

1 Contract for the intensification of research activity in the SNS from the ISCIII.

Area 3. Neurosciences, Chronicity, Aging, and Health in Vulnerable Populations

CONSOLIDATED GROUPS

C-01. NEUROIMMUNOLOGY AND NEUROINFLAMMATION

Co-LR Pedro Serrano Castro, Co-LR Guillermo Estivill, Co-LR Laura Leyva

Priority lines of research:

- 1. Neuroimmunology of multiple sclerosis
- 2. Neuroinflammatory basis of epilepsy

Other lines:

- 1. Advanced therapies in neurological diseases.
- 2. Neuromodulation techniques of brain circuits.
- 3. Psychopharmacology applied in experimental models of diseases with a neuroinflammatory component: Stroke.
- 4. Personalized medicine in neurology and new therapeutic perspectives.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-01	Serrano-Castro, PJ; Ramírez-García, T; Cabezudo-García, P; García-Martin, G; De La Parra, J	Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study	CNS DRUGS	7.4	D1
C-01	López-Villodres, JA; García-Díaz, B	Oligodendroctyes: the forgotten players of diabetes pathophysiology	NEURAL REGENERATION RESEARCH	5.9	Q1
C-01	Ciano-Petersen, NL; Muñoz-Castrillo, S; Villagrán-García, M; Farina, A; Vogrig, A; Wucher, V; Do, L; Birzu, C; Goncalves, D; Flabeau, O; Duwicquet, C; Benard, A; Nicole, F; Rogemond, V; Picard, G; Joubert, B; Honnorat, J	Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma	NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION	8.3	D1

Group	Authors	Article Title	Source Title	IF	Q/D
C-01	Aliaga-Gaspar, Pablo; Brichette-Mieg, Isabel; Fernandez-Arjona, MdM; Rodriguez-Bada, Jose Luis; Lopez-Moreno, Yolanda; Serrano-Castro, Pedro; Fernandez-Fernandez, Oscar; Ciano-Petersen, Nicolas Lundahl; Oliver-Martos, Begona	Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy.	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1
C-01	Fernández-Arjona, MD; Navarro, JA; López-Gambero, AJ; de Ceglia, M; Rodríguez, M; Rubio, L; de Fonseca, FR; Barrios, V; Chowen, JA; Argente, J; Rivera, P; Suárez, J	Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments	BIOLOGY OF SEX DIFFERENCES	4.9	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
46	35%	54%	15%	191



Active projects



Clinical studies



Patents applied for

Networks:

CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (European Commission).

Competitive HR contracts funded in 2024:

- 1 PFIS Contract (ISCIII)
- 1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)
- 1 Contract for long-term reinforcement of the SAS (Action B).
- 1 Nicolás Monardes SAS Contract (Action C).

C-02. MENTAL HEALTH, SERVICES, AND PRIMARY CARE (SAMSERAP).

LR Juan Ángel Bellón Saameño. Co-LR Patricia Moreno Peral

Lines of research:

- Develop and validate risk algorithms to predict the onset of common mental illnesses.
- Design, develop, and evaluate innovative programs for the prevention of common mental illnesses.
- Generate evidence on the effectiveness, cost-effectiveness, and acceptance of prevention programs for common mental illnesses.
- Evaluate the implementation of programs for the prevention of common mental illnesses.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-02	Bellón, D; Rodriguez-Ayllon, M; Solis-Urra, P; Fernandez-Gamez, B; Olvera-Rojas, M; Coca-Pulido, A; Toval, A; Martín-Fuentes, I; Bakker, EA; Sclafani, A; Fernández-Ortega, J; Cabanas-Sánchez, V; Mora-Gonzalez, J; Gómez-Rio, M; Lubans, DR; Ortega, FB; Esteban-Cornejo, I	Associations between muscular strength and mental health in cognitively normal older adults: a cross-sectional study from the AGUEDA trial	INTERNATIONAL JOURNAL OF CLINICAL AND HEALTH PSYCHOLOGY	5.3	D1
C-02	Moreno-Peral, P; Conejo-Ceron, S; Wijnen, B; Lokkerbol, J; Fernandez, A; Smit, F; Bellon, JA	Health-Economic Evaluation of Psychological Interventions for Anxiety Prevention: A Systematic Review	PSYCHIATRIC SERVICES	3.3	Q1
C-02	Muñoz-Cobos, F; Aguiar-Leiva, VP; Argüello-Suárez, C; Colacicchi, P; Calleja-Cartón, LA; Leiva-Fernández, F	Validation of an Inhaled Therapy Beliefs Questionnaire in Patients with Chronic Obstructive Pulmonary Disease	JOURNAL OF CLINICAL MEDICINE	3	Q1
C-02	Martínez-Vispo, C; García-Huércano, C; Conejo-Cerón, S; Rodríguez-Morejón, A; Moreno-Peral, P	Personalized online intervention based on a risk algorithm for the universal prevention of anxiety disorders: Design and development of the prevANS intervention	DIGITAL HEALTH	2.9	Q2

Group	Authors	Article Title	Source Title	IF	Q/D
C-02	Taubner, S; Ioannou, Y; Saliba, A; Sales, CMD; Volkert, J; Protic, S; Adler, A; Barkauskiene, R; Conejo-Cerón, S; Di Giacomo, D; Mestre, JM; Moreno-Peral, P; Vieira, FM; Mota, CP; Henriques, MIRS; Rossberg, JI; Perdihi, TS; Schmidt, SJ; Zettl, M; Ulberg, R; Heinonen, E	Mediators of outcome in adolescent psychotherapy and their implications for theories and mechanisms of change: a systematic review	EUROPEAN CHILD & ADOLESCENT PSYCHIATRY	6	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
11	36%	82%	27%	46



Active projects



Clinical studies

Networks:

RICAPPS, Research Network on Primary Care for Addictions (ISCIII)

Competitive HR contracts funded in 2024:

- 1 PFIS Contract (ISCIII)
- 1 Sara Borrell Contract (ISCIII)
- 1 Contract the intensification of research activity in the SNS.
- 1 Pre-doctoral contract for university professor training from the Ministry of Universities.
- 1 Pre-doctoral contract for the training of doctors from the State Research Agency.
- 1 Pre-doctoral contract for research personnel in training for agents of the Andalusian Knowledge System.
- 1 Contract for research personnel in training for agents of the Andalusian Knowledge System.

C-03. BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP

LR Jose Guzmán Parra, Co-LR: Jessica Goodman Casanova

Priority line of research: Genetic psychiatry: analysis of genetic variables associated with the expression of the bipolar I and II phenotype in a cohort of families with high aggregation.

Other lines of research:

- Biomarkers and new therapeutic targets in general developmental disorders.
- Evaluation and use of new technology for healthy aging.
- Epidemiology and evaluation of mental health outcomes.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-03	del Campo-avila, J; Ramos-Martín, J; Gómez-Sánchez-Lafuente, C; García-Pedrosa, J; García-Martín, S; Martínez-García, AI; Guzmán-Parra, J; Morales-Bueno, R; Moreno-Küstner, B	Data mining process to detect suicidal behaviour in out-of-hospital emergency departments	ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE	7.5	D1
C-03	Varela-Moreno, E; Anarte-Ortiz, MT; Jodar-Sanchez, F; Garcia-Palacios, A; Monreal-Bartolome, A; Gili, M; García-Campayo, J; Mayoral-Cleries, F	Economic Evaluation of a Web Application Implemented in Primary Care for the Treatment of Depression in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial	JMIR MHEALTH AND UHEALTH	5.4	D1
C-03	García-Sastre, MM; Castro-Molina, FJ; Cabanillas, RC; Corrales, CS; Golmar, LJ; Román, JC; Serrano, CA	Psychotherapeutic nursing as Advanced Clinical Practice for the promotion of mental health in Spain	INTERNATIONAL NURSING REVIEW	3.8	D1
C-03	Barnestein-Fonseca, P; Guerrero-Pertiñez, G; Gúzman-Parra, J; Valera-Moreno, E; Mayoral-Cleries, F	Is it possible to diagnose therapeutic adherence in mild cognitive impairment and dementia patients in clinical practice?	FRONTIERS IN PHARMACOLOGY	4.4	Q1
C-03	Goodman-Casanova, JM; Coles, A; Cuesta-Lozano, D; Mayoral-Cleries, F	It's all about the journey! An online museum-based recovery-oriented art psychotherapy group	INTERNATIONAL JOURNAL OF ART THERAPY	2.3	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
19	63%	63%	32%	65



Active projects



Clinical studies

Networks:

- CA19101 (DE-PASS) -Determinants of Physical Activities in Settings (European Commission)
- CA19133 (FOSTREN) - Fostering and strengthening approaches to reducing coercion in European mental health services (European Commission)
- CA22114 (TREASURE) - Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development (European Commission)
- CA23153 (YouthDMH) -Digital Mental Health for Young People (European Commission)

Competitive HR contracts funded in 2024:

- 1 Río Hortega Contract (ISCIII)
- 1 Juan Rodés Contracts (ISCIII)
- 1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.
- 1 Contract for long-term reinforcement of the SAS (Action B).
- 1 Contract for the incorporation of clinical-research professionals to the clinical units of the Andalusian Health Service.
- 1 Contract for the incorporation of postdoctoral researchers to groups in the health and research centers of the SSPA.

C-05. DEGENERATION AND REGENERATION OF THE CENTRAL NERVOUS SYSTEM

LR Antonio J. Jiménez Lara

Lines of research:

- Experimental studies on possible stem cell therapies in the treatment of fetal-neonatal hydrocephalus
- Long-term conditioning of microglia

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-05	Rodríguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1
C-05	Navarro-Lobato, I; Masmudi-Martín, M; López-Aranda, MF; López-Téllez, JF; Delgado, G; Granados-Durán, P; Gaona-Romero, C; Carretero-Rey, M; Posadas, S; Quiros-Ortega, ME; Khan, ZU	Promotion of structural plasticity in area V2 of visual cortex prevents against object recognition memory deficits in aging and Alzheimer's disease rodents	NEURAL REGENERATION RESEARCH	5.9	Q1
C-05	Masmudi-Martín, M; Navarro-Lobato, I; Lopez-Aranda, MF; Quiros-Ortega, ME; Carretero-Rey, M; Garcia-Garrido, MF; Téllez, JFL; Jiménez-Recuerda, I; López, CAMDL; Khan, ZU	Brain areas interconnected to ventral pathway circuits are independently able to induce enhancement in object recognition memory and cause reversal in object recognition memory deficit	CNS NEUROSCIENCE & THERAPEUTICS	4.8	Q1
C-05	Rodríguez-Pérez, LM; López-de-San-Sebastián, J; de Diego, I; Smith, A; Roales-Buján, R; Jiménez, AJ; Paez-Gonzalez, P	A selective defect in the glial wedge as part of the neuroepithelium disruption in hydrocephalus development in the mouse hyh model is associated with complete corpus callosum dysgenesis	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2

Group	Authors	Article Title	Source Title	IF	Q/D
C-05	Hedrich, C; Patel, P; Haider, L; Taylor, T; Lau, E; Hook, R; Dorfer, C; Roessler, K; Stepien, N; Lippolis, MA; Schned, H; Koeller, C; Mayr, L; Azizi, AA; Peyrl, A; Lopez, BR; Lassaletta, A; Bennett, J; Gojo, J; Bartels, U	Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma	FRONTIERS IN ONCOLOGY	4	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
11	18%	45%	9%	40



Active projects

C-06. NEUROPSYCHOPHARMACOLOGY

LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez

Priority line of research: Study of the biological basis of the behavior and pathophysiology of highly prevalent degenerative diseases. These include addiction disorders (drug abuse), eating disorders (obesity, diabetes, dyslipidemia), Alzheimer’s disease, as well as anxiety and depression syndromes throughout their course and in disease models (psychiatric comorbidity).

Other lines:

- 1. Alcoholic and non-alcoholic steatohepatitis
- 2. Neuropsychopharmacology of neurodegenerative diseases (ischemia, Parkinson’s disease)
- 3. Metabolic programming during development and growth (obesity, diabetes)
- 4. Development of new therapeutic chemical entities or new indications for existing drugs.
- 5. Pharmacological evaluation of food for special medical purposes (FSMPs).

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-06	Melgar-Locatelli, S; Manas-Padilla, MC; Castro-Zavala, A; Rivera, P; Razola-Díaz, MD; Monje, FJ; Rodríguez-Pérez, C; Castilla-Ortega, E	Diet enriched with high-phenolic cocoa potentiates hippocampal brain-derived neurotrophic factor expression and neurogenesis in healthy adult mice with subtle effects on memory	FOOD & FUNCTION	5.1	Q1
C-06	Tovar, R; de Ceglia, M; Rodríguez-Pozo, M; Vargas, A; Gavito, A; Suárez, J; Boronat, A; de la Torre, R; de Fonseca, FR; Baixeras, E; Decara, J	Hydroxytyrosol Linoleoyl Ether Ameliorates Metabolic-Associated Fatty Liver Disease Symptoms in Obese Zucker Rats	ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE	5.1	Q1
C-06	Suárez, J; de Ceglia, M; Rodríguez-Pozo, M; Vargas, A; Santos, I; Melgar-Locatelli, S; Castro-Zavala, A; Castilla-Ortega, E; de Fonseca, FR; Decara, J; Rivera, P	Inhibition of Adult Neurogenesis in Male Mice after Repeated Exposure to Paracetamol Overdose	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1
C-06	Fernández-Arjona, MD; Navarro, JA; López-Gamero, AJ; de Ceglia, M; Rodríguez, M; Rubio, L; de Fonseca, FR; Barrios, V; Chowen, JA; Argente, J; Rivera, P; Suárez, J	Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments	BIOLOGY OF SEX DIFFERENCES	4.9	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
C-06	Gobbi, C; Sánchez-Marin, L; Flores-López, M; Medina-Vera, D; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-dependent effects of acute stress and alcohol exposure during adolescence on mRNA expression of brain signaling systems involved in reward and stress responses in young adult rats	BIOLOGY OF SEX DIFFERENCES	4.9	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
24	50%	75%	21%	113



Active projects



Clinical studies



Patents applied for

Networks:

CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infant development.

CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development.

RIAPAd, Research Network on Primary Care for Addictions, RD21/0009/0003 (ISCIII).

Competitive HR contracts funded in 2024:

2 Río Hortega Contracts (ISCIII)

1 i-PFIS contract (ISCIII)

1 Sara Borrell Contract (ISCIII)

2 Miguel Servet Contracts (ISCIII)

2 Nicolás Monardes SAS contracts (Action C).

1 Contract for doctoral research personnel for agents of the Andalusian Knowledge System.

1 Contract for doctoral research personnel by universities and public research entities.

C-07. BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES

LR José Ángel Narváez Bueno

Priority line of research:

Basic biomedical aspects of neurotransmission and regeneration in the central nervous system to aspects applied to clinical and therapeutic approaches to neuropsychiatric and neurodegenerative diseases from different approaches but which converge on the study of basic mechanisms that will allow for the development of new diagnostic and therapeutic tools for the treatment of these diseases.

Other lines:

1. Study the role of neuropeptides in key areas of the central nervous system (CNS) for the mediation of behavioral functions associated with anxiety, depression, and fear.
2. Analyze the functional interaction of the opioid and dopaminergic systems during opioid dependence in areas related to the learning and consolidation of addictive behavioral habits.
3. Delve deeper into the molecular and cellular bases involved (such as oxidative stress) in the genesis of neurodegenerative processes such as aging and Parkinson's disease and study the neuroprotective effects of IGF-II.
4. Early diagnosis, monitoring, and intervention in neurodegenerative and neuropsychiatric diseases and through autonomic and cognitive assessment techniques. Basic and applied aspects.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-07	Sánchez-Varo, R; López-Salas, A; Beltran-Casanueva, R; Díaz-Sánchez, E; Alvarez-Contino, JE; Barbancho-Fernández, MA; Serrano-Castro, P; Fuxe, K; Borroto-Escuela, DO; García-Casares, N; Narváez, M	Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions	BEHAVIORAL AND BRAIN FUNCTIONS	4.7	Q1
C-07	Borroto-Escuela, D; Serrano-Castro, P; Sánchez-Pérez, JA; Barbancho-Fernández, MA; Fuxe, K; Narváez, M	Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder	EXPERT OPINION ON THERAPEUTIC TARGETS	4.6	Q1
C-07	Arrabal-Gómez, C; Serrano-Castro, P; Sánchez-Pérez, JA; García-Casares, N; Fuxe, K; Borroto-Escuela, D; Narvaéz, M	Potential of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus	EXPERT OPINION ON THERAPEUTIC TARGETS	4.6	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
C-07	Beltran-casanueva, R; Hernández-García, A; Serrano-Castro, PJ; Sánchez-Pérez, JA; Barbancho-Fernández, MA; García-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Long-term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co-administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus	FASEB JOURNAL	4.4	Q1
C-07	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-cosme, C; Lara, JP	Early Occupational Therapy Intervention Programme and Coping Strategies and Burden in Caregivers of People with Sub-Acute Stroke: A Randomised Controlled Trial	JOURNAL OF PERSONALIZED MEDICINE	3	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
24	54%	75%	25%	103



Active projects



Patents applied for

Competitive HR contracts funded in 2024:

1 Contract for hiring doctoral research personnel for agents of the Andalusian Knowledge System.

C-08. MAEPAP. MULTIMORBIDITY, ADHERENCE, ECONOMIC EVALUATION, AND PALLIATIVE CARE IN PRIMARY CARE

LR Francisca Leiva Fernández, Co-LR: Antonio García Ruiz

Priority line of research: Research on clinical, educational, and economic aspects of multimorbidity, polymedication and treatment adherence in primary care

Other lines:

1. Identification of health professionals’ educational needs on multimorbidity and polymedication.
2. Evaluation of training interventions on multimorbidity, polymedication, and treatment adherence for health professionals.
3. Creation and validation of a questionnaire to assess the beliefs of patients with COPD on inhalation therapy.
4. Validation of the mental model of disease in patients with COPD in our setting.
5. Research on health outcomes (treatment adherence, quality of life, pulmonary function) in patients with COPD.
6. Evaluation of the effectiveness of educational interventions in patients with COPD to improve inhaler technique and treatment adherence.
7. Educational impact of a journal club on the acquisition of evidence-based medicine and nursing skills.
8. Evaluation and improvement of teaching quality in specialized health training.
9. Financial assessment of health technology (including drugs).
10. Drug management: from efficacy to efficiency by way of effectiveness.
11. Development of the IDC-Pal tool: Diagnostic Instrument for Complexity in Palliative Care (PC), in a shared-care model.
12. Development of a multidisciplinary care plan for the last days of life.
13. Validation and cultural adaptation of the “Conversation guide for serious illness.”
14. Research on volunteering in palliative care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-08	Varela-Moreno, E; Anarte-Ortiz, MT; Jodar-Sanchez, F; Garcia-Palacios, A; Monreal-Bartolome, A; Gili, M; García-Campayo, J; Mayoral-Cleries, F	Economic Evaluation of a Web Application Implemented in Primary Care for the Treatment of Depression in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial	JMIR MHEALTH AND UHEALTH	5.4	D1

Group	Authors	Article Title	Source Title	IF	Q/D
C-08	Hafez, G; Aarnio, E; Mucherino, S; Kamusheva, M; Qvarnström, M; Potocnjak, I; Treciokiene, I; Mihajlovic, J; Ekenberg, M; van Boven, JFM; Leiva-Fernández, F	Barriers and Unmet Educational Needs Regarding Implementation of Medication Adherence Management Across Europe: Insights from COST Action ENABLE	JOURNAL OF GENERAL INTERNAL MEDICINE	4.3	Q1
C-08	Kamusheva, M; Aarnio, E; Qvarnström, M; Hafez, G; Mucherino, S; Potocnjak, I; Treciokiene, I; Mihajlovic, J; Ekenberg, M; van Boven, JFM; Leiva-Fernandez, F	Pan-European survey on medication adherence management by healthcare professionals	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY	3.1	Q2
C-08	Muñoz-Cobos, F; Aguiar-Leiva, VP; Argüello-Suárez, C; Colacicchi, P; Calleja-Cartón, LA; Leiva-Fernández, F	Validation of an Inhaled Therapy Beliefs Questionnaire in Patients with Chronic Obstructive Pulmonary Disease	JOURNAL OF CLINICAL MEDICINE	3	Q1
C-08	Pozo, AH; Ortega, DT; Ruiz, AJG; Serrano, JE; Cobalea, ME; Soler, NGA	Approach to patients with diabetes and obesity in primary care	ATENCION PRIMARIA	1.8	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
15	33%	47%	7%	48



Networks:

CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence (European Commission)
RICAPPS, Research Network on Primary Care for Addictions (ISCIII)

C-09. NEUROPATHOLOGY OF ALZHEIMER’S DISEASE (NEUROAD)
LR Antonia Gutiérrez Pérez

Priority line of research: Neuroinflammation and glial response in Alzheimer’s disease

Other lines:

1. Decipher new pathogenic mechanisms involved in Alzheimer’s disease that will allow greater translational success to symptoms in humans. Impact of risk factors. Identification of biomarkers and therapeutic targets.
2. Develop new animal models of Alzheimer’s disease that better recapitulate human disease. Preclinical studies in *in vivo* models of new therapeutic strategies and evaluation of drugs.
3. Development of *in vitro* models of Alzheimer’s disease using patient-derived iPSCs. Studies of pathogenic mechanisms and evaluation of new drugs in human cellular platforms.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-09	Mora-Romero, B; Capelo-Carrasco, N; Pérez-Moreno, JJ; Alvarez-Vergara, MI; Trujillo-Estrada, L; Romero-Molina, C; Martinez-Marquez, E; Morano-Catalan, N; Vizuite, M; Lopez-Barneo, J; Nieto-Gonzalez, JL; Garcia-Junco-Clemente, P; Vitorica, J; Gutierrez, A; Macias, D; Rosales-Nieves, AE; Pascual, A	Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality	NATURE METABOLISM	19.2	D1
C-09	Sánchez-Varo, R; López-Salas, A; Beltran-Casanueva, R; Díaz-Sánchez, E; Alvarez-Contino, JE; Barbancho-Fernández, MA; Serrano-Castro, P; Fuxe, K; Borroto-Escuela, DO; García-Casares, N; Narváez, M	Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions	BEHAVIORAL AND BRAIN FUNCTIONS	4.7	Q1
C-09	Noriega-Prieto, JA; Maglio, LE; Perez-Domper, P; Dávila, JC; Gutiérrez, A; Torres-Alemán, I; de Sevilla, DF	Bidirectional modulation of synaptic transmission by insulin-like growth factor-I	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2
C-09	Baglietto-Vargas, D; Freude, KK; Garcia-Leon, JA	Animal and Cellular Models of Alzheimer’s Disease	BIOMEDICINES	3.9	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
C-09	García-Alberca, JM; de Rojas, I; Sanchez-Mejias, E; Garrido-Martín, D; Gonzalez-Palma, L; Jimenez, S; Pino-Angeles, A; Cruz-Gamero, JM; Mendoza, S; Alarcón-Martín, E; Muñoz-Castro, C; Real, LM; Tenao, JJ; Polvillo, R; Govantes, F; Lopez, A; Royo-Aguado, JL; Navarro, V; Gonzalez, I; Ruiz, M; Reyes-Engel, A; Gris, E; Bravo, MJ; Lopez-Gutierrez, L; Mejias-Ortega, M; De la Guía, P; de la Rica, ML; Ocejo, O; Torrecilla, J; Zafra, C; Nieto, MD; Urbano, C; Jiménez-Sánchez, R; Pareja, N; Luque, M; García-Peralta, M; Carrillejo, R; Furniet, MD; Rueda, L; Sánchez-Fernández, A; Mancilla, T; Peña, I; García-Casares, N; Moreno-Grau, S; Hernández, I; Montreal, L; Quintela, I; González-Pérez, A; Calero, M; Franco-Macías, E; Macías, J; Menéndez-González, M; Frank-García, A; Vilas, RH; Diez-Fairen, M; Lage, C; García-Madróna, S; García-González, P; Valero, S; Sotolongo-Grau, O; Pérez-Cordón, A; Rabano, A; Pastor, AA; Pastor, AB; Espinosa, A; Corma-Gómez, A; Montes, AM; Sanabria, A; Rodríguez, CM; Buiza-Rueda, D; Rodriguez-Rodriguez, E; Ortega, G; Alvarez, I; Allende, IR; Pineda, JA; Rosende-Roca, M; Sánchez-Arjona, MB; Fernández-Fuertes, M; Alegret, M; Roberto, N; del Ser, T; Garcia-Ribas, G; Sánchez-Juan, P; Pastor, P; Piñol-Ripoll, G; Bullido, MJ; Alvarez, V; Mir, P; Medina, M; Marquié, M; Sáez, ME; Carracedo, A; Laplana, M; Tomas-Gallardo, L; Orellana, A; Tarraga, L; Boada, M; Palazon, JF; Vitorica, J; Ruiz, A; Guigo, R; Gutierrez, A; Royo, JL	An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
6	50%	67%	50%	42



Active projects

Ciber:

CIBERNED Neurodegenerative Diseases CB06/05/1116 (ISCIII)

Competitive HR contracts funded in 2024:

1 Contract to promote research consolidation from the State Research Agency.

C-11. VULNERABILITY AND RESILIENCE TO CHRONIC PAIN: IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTION
LR María Carmen Ramírez Maestre

Priority line of research: Coping styles and strategies and vulnerability to pain: individual differences and implications for psychological intervention.

Other lines:

- 1. Variables psicosociales de vulnerabilidad y protección implicadas en el proceso de cronificación del dolor / *The role of psychosocial variables of vulnerability and protection in pain chronification.*
- 2. Patrones de actividad y gestión de metas/ *Patterns of activity and goal management strategies.*
- 3. Variables predictoras del abuso de opioides y medicación coadyuvante en los pacientes con dolor crónico no oncológico: desarrollo de una escala de detección y clasificación de riesgo / *Predictive variables of opioid and coadjuvant drug abuse in patients with chronic non-oncologic pain: Development of an instrument to assess and classify risk of abuse.*
- 4. Trastorno de estrés postraumático y dolor crónico como entidades comórbidas: análisis de factores transdiagnósticos / *Post-traumatic stress disorder and chronic pain as comorbid entities: Analysis of transdiagnostic factors.*

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-11	de la Vega, R; Sakulsriprasert, P; Miró, J; Jensen, MP	Optimizing Pain Intensity Assessment in Clinical Trials: How Many Ratings are Needed to Best Balance the Need for Validity and to Minimize Assessment Burden?	JOURNAL OF PAIN	4	Q1
C-11	Ramírez-Maestre, C; Barrado-Moreno, V; Esteve, R; Serrano-Ibañez, ER; de la Vega, R; Ruiz-Párraga, GT; Fernández-Baena, M; Jensen, MP; López-Martínez, AE	Vulnerability Factors, Adjustment, and Opioid Misuse in Chronic Noncancer Pain Individuals	JOURNAL OF PAIN	4	Q1
C-11	Esteve, R; Barrado-Moreno, V; Ramírez-Maestre, C; Serrano-Ibañez, ER; de la Vega, R; Ruiz-Parraga, GT; Sainero-Tirado, G; Baena, MF; Jensen, M; López-Martínez, AE	Psychological profiles and prescription opioid misuse, craving, and withdrawal in people with chronic pain	EUROPEAN JOURNAL OF PAIN	3.5	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
C-11	Huerta, I; Cumsille, P; Vergés, A; Gómez-Pérez, L	Bidirectional Relationship Between Intraindividual Changes in Behavioral Activation and Intraindividual Changes in Postpartum Depressive Symptoms: A Random Intercept Cross-Lagged Panel Model	JOURNAL OF PSYCHOPATHOLOGY AND CLINICAL SCIENCE	3.1	Q1
C-11	Esteve, R; Serrano-Ibañez, ER; Castillo-Real, S; Ramírez-Maestre, C; Lpóez-Martnález, AE	How do the activity patterns of people with chronic pain influence the empathic response of future health professionals: an experimental study	ADVANCES IN HEALTH SCIENCES EDUCATION	3	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
13	77%	62%	0%	41



C-12. COGNITIVE NEUROSCIENCE: APHASIA AND RELATED DISORDERS (UNCA)

LR Guadalupe Dávila Arias

Priority line of research: Post-stroke aphasia

Other lines:

- 1. Validation of diagnostic tests in aphasia and related cognitive and behavioral disorders
- 2. Design of therapeutic strategies for speech and language disorders
- 3. Language learning in healthy subjects and individuals with aphasia
- 4. Echo, imitation, contagion, and repetition and their importance in normal and pathological language.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-12	Dávila, G; Berthier, ML	Are pharmacotherapeutics effective for treating aphasia?	EXPERT REVIEW OF NEUROTHERAPEUTICS	3.4	Q2
C-12	Sala-Padro, J; de la Cruz-Puebla, M; Miró, J; Cucurell, D; López-Barroso, D; Vilà-Balló, A; Plans, G; Santurino, M; Falip, M; Rodríguez-Fornells, A; Camara, E	De novo depression following temporal lobe epilepsy surgery	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY	2.7	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
2	50%	0%	0%	6



C-13. CHRONICITY, DEPENDENCY, CARE, AND HEALTH SERVICES

LR José Miguel Morales Asencio

Priority line of research: Multidisciplinary models of care and interventions in individuals with chronic diseases and multimorbidity as well as in situations of dependency.

Other lines:

- 1. Health inequalities in the caregivers of individuals with multimorbidity and dependence.
- 2. Clinical safety in individuals with chronic disease, multimorbidity, and dependence.
- 3. Improving the effectiveness of health care for individuals with chronic diseases and their caregivers (methods and instruments for evidence-based healthcare, design and implementation of clinical practice guidelines).

The spectrum ranges from interventions and models of care for people with chronic pain or type II diabetes mellitus, prevention of adverse events in this population, development and analysis of services for individuals with multimorbidity (case management, transitional care, etc.), or the health impact of the role of family caregiver in the medium-and long-term, among other examples.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
C-13	Morales-Puerto, M; Ruiz-Díaz, M; Garcia-Mayor, S; León-Campos, A; Morales-Asencio, JM; Canca-Sánchez, JC; Gavira-Guerra, S; Toledo-Fernandez, C; Aranda-Gallardo, M	Spanish transcultural adaptation of the 4AT score for the evaluation of delirium in the emergency department: a prospective diagnostic test accuracy study	BMC NURSING	3.1	D1
C-13	Saucedo-Figueroa, MC; Morilla-Herrera, JC; Gálvez-González, M; Rivas-Ruiz, F; Nava-DelVal, A; San Alberto-Giraldo, M; Hierrezuelo-Martín, MJ; Gómez-Borrego, AB; Kaknani-Uttumchandani, S; Morales-Asencio, JM	Anchor-Based and Distributional Responsiveness of the Spanish Version of the Edinburgh Feeding Evaluation in Dementia Scale in Older People with Dementia: A Longitudinal Study	NUTRIENTS	4.8	Q1
C-13	Cervera-Garvi, P; Galan-Hurtado, MH; Marchena-Rodríguez, A; Chicharro-Luna, E; Guerra-Marmolejo, C; Diaz-Miguel, S; Ortega-Avila, AB	Transcultural Adaptation and Validation of the Spanish Version of the Visual Analogue Scale for the Foot and Ankle (VASFA)	JOURNAL OF CLINICAL MEDICINE	3	Q1
C-13	Alabau-Dasi, R; Dominguez-Maldonado, G; Ortega-Avila, AB; Gordillo-Fernandez, LM; Ortiz-Romero, M; Melchor-Rodríguez, JM; Gijon-Nogueron, G	Validation of Fixed Ultrasonography for Achilles Tendon Assessment: A Reliability Study	DIAGNOSTICS	3	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
C-13	Martinez-Rico, M; Gijon-Nogueron, G; Ortega-Avila, AB; Roche-Seruendo, LE; Climent-Pedrosa, A; Sanchis-Sales, E; Deschamps, K	Effect of Custom-Made Foot Orthotics on Multi-Segment Foot Kinematics and Kinetics in Individuals with Structural Hallux Limitus	SENSORS	3.4	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
30	60%	63%	17%	83



Active projects



Patents applied for

Networks:

CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims (European Commission)

CA19137 (PARQ): Sudden cardiac arrest prediction and resuscitation network: Improving the quality of care (European Commission)

CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research

CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies

Competitive HR contracts funded in 2024:

3 Contracts for the annual reinforcement of research activity in the clinical units of the SAS.

C-16. MATERNAL-FETAL MEDICINE, EPIGENETICS, WOMEN'S HEALTH CONDITIONS, AND REPRODUCTIVE HEALTH RESEARCH GROUP

LR Ernesto González Mesa. Co-LR Jesús Salvador Jiménez López

Priority line of research: Research in the field of reproductive health.

Other lines:

1. Perinatal exposure and psychoevolutionary development.
2. Prematurity, prognostic markers of fetal neurodevelopment, mood disorders in the perinatal period, multiple pregnancy, and reproductive pathology.

Featured publications:

Group	Authors	Author Full Names	Article Title	Source Title	IF	Q/D
C-16	Frías, LC; Peralta, CTL; Oliva, NS; Arana, MS; Marín, CC; López, JSJ	Frias, Lucia Castano; Tudela-Littleton Peralta, Carmen; Oliva, Natalia Segura; Arana, Maria Suarez; Marin, Celia Cuenca; Lopez, Jesus S. Jimenez	Case Series of Listeria monocytogenes in Pregnancy: Maternal-Foetal Complications and Clinical Management in Six Cases	MICROORGANISMS	4.1	Q2
C-16	Díaz-Mohedo, E; Carrillo-León, AL; Calvache-Mateo, A; Ptak, M; Romero-Franco, N; Carlos-Fernández, J	Diaz-Mohedo, Esther; Carrillo-Leon, Antonio L.; Calvache-Mateo, Andres; Ptak, Magdalena; Romero-Franco, Natalia; Carlos-Fernandez, Juan	App-Mohedo ® : A mobile app for the management of chronic pelvic pain. A design and development study	INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS	3.7	Q1
C-16	Blanco-Diaz, M; Vielva-Gomez, A; Legasa-Susperregui, M; Perez-Dominguez, B; Medrano-Sánchez, EM; Diaz-Mohedo, E	Blanco-Diaz, Maria; Vielva-Gomez, Ana; Legasa-Susperregui, Marina; Perez-Dominguez, Borja; Medrano-Sanchez, Esther M.; Diaz-Mohedo, Esther	Exploring Pelvic Symptom Dynamics in Relation to the Menstrual Cycle: Implications for Clinical Assessment and Management	JOURNAL OF PERSONALIZED MEDICINE	3	Q1
C-16	González-Cazorla, E; Brenes-Romero, AP; Sánchez-Gómez, MJ; Estévez-Ruiz, E; Díaz-Enjuto, A; Cantón-Cisneros, A; Lubián-López, D; Mozas-Moreno, J; González-Mesa, ES	Gonzalez-Cazorla, Ernesto; Brenes-Romero, Ana Pilar; Sanchez-Gomez, Maria Jose; Estevez-Ruiz, Elena; Diaz-Enjuto, Antonio; Canton-Cisneros, Ana; Lubian-Lopez, Daniel; Mozas-Moreno, Juan; Gonzalez-Mesa, Ernesto S.	Physical Activity in Work and Leisure Time during Pregnancy, and Its Influence on Maternal Health and Perinatal Outcomes	JOURNAL OF CLINICAL MEDICINE	3	Q1

Group	Authors	Author Full Names	Article Title	Source Title	IF	Q/D
C-16	Gómez-Castellano, M; Morente, LS; López-Zambrano, MA; de Miguel-Luken, V; Jiménez-López, JS	Gomez-Castellano, Manuel; Sabonet-Morente, Lorena; Lopez-Zambrano, Maria Alejandra; de Miguel-Luken, Veronica; Jimenez-Lopez, Jesus Salvador	Temporary clamping of the uterine arteries versus conventional technique for the prevention of postpartum hemorrhage during cesarean section: a randomized controlled trial study	BMC PREGNANCY AND CHILDBIRTH	2.8	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
19	47%	63%	11%	66



Active projects



Clinical trials

Networks:

CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development.

CA21108 (NETSKINMODELS) -European Network for Skin Engineering and Modeling.

RICORS Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin (ISCIII).

Competitive HR contracts funded in 2024:

1 Contract for the María Castellano Arroyo training and research program of the SAS.

1 Contract for doctoral research personnel for agents of the Andalusian Knowledge System.

EMERGING GROUPS

CE-17. TECHNOLOGY AND INNOVATION IN EMERGENCY DEPARTMENTS AND HOSPITALIZATION

LR. Carmen Ortiz García. Co-LR Ángela García de la Torre. Co-LR Begoña Mora Ordoñez

Priority line of research:

Safety and well-being in emergency department and hospitalization patient care

Other lines:

- 1. Development of shared healthcare scenarios and technical and organizational innovation
- 2. Detection of vital and social risk or prevention of health problems and their sequelae
- 3. Participation in the third-sector health system or associations of expatients/users

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
CE-17	Maroto-García, J; Mañez, M; Martínez-Escribano, A; Hachmaoui-Ridaoui, A; Ortiz, C; Abalos-García, C; González, I; de la Torre, AG; Ruiz-Galdón, M	A sex-dependent algorithm including kappa free light chain for multiple sclerosis diagnosis	SCANDINAVIAN JOURNAL OF IMMUNOLOGY	4.1	Q2

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1	0%	0%	0%	4



Clinical studies

CE-18. FORENSIC MEDICINE, TOXICOLOGY, AND FORENSIC ODONTOLOGY

LR. Stella Martín de las Heras

Priority line of research: Gender violence, forensic odontology, mineralized samples subjected to thermal stress, forensic toxicology

Other lines:

- Forensic genetics, medical ethics, training and education in medicine and health sciences

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
CE-18	Suárez, J; de Ceglia, M; Rodríguez-Pozo, M; Vargas, A; Santos, I; Melgar-Locatelli, S; Castro-Zavala, A; Castilla-Ortega, E; de Fonseca, FR; Decara, J; Rivera, P	Inhibition of Adult Neurogenesis in Male Mice after Repeated Exposure to Paracetamol Overdose	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1
CE-18	Fernández-Arjona, MD; Navarro, JA; López-Gambero, AJ; de Ceglia, M; Rodríguez, M; Rubio, L; de Fonseca, FR; Barrios, V; Chowen, JA; Argente, J; Rivera, P; Suárez, J	Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments	BIOLOGY OF SEX DIFFERENCES	4.9	Q1
CE-18	de Fonseca, FR; Medina-Paz, F; Sapozhnikov, M; Hurtado-Guerrero, I; Rubio, L; Martín-de-las-Heras, S; Requena-Ocaña, N; Flores-Lopez, M; Fernández-Arjona, MD; Rivera, P; Serrano, A; Serrano, P; Zapico, SC; Suárez, J	Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study	TOXICS	3.9	Q1
CE-18	Gutiérrez-Sánchez, D; López-Leiva, I; Martin-de-las-Heras, S; Rubio, L; Martín-Martín, J	Validation of the Collett-Lester fear of death scale in occupational therapy students: psychometric testing and implications for palliative care education	BMC PALLIATIVE CARE	2.5	Q2

Group	Authors	Article Title	Source Title	IF	Q/D
CE-18	Ramos-Cozar, SN; Martín-Masot, R; Rodríguez-Gallego, B; Rubio, L; Cabanillas-Moruno, JL; Navas-López, VM	Assessment of the length of sick leave in patients with inflammatory bowel disease	GASTROENTEROLOGIA Y HEPATOLOGIA	2.2	Q3

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
7	14%	57%	14%	26



Active projects

Networks:

CA22106 (MDVI): Migrant Disaster Victim Identification (European Commission)

CE-20. OPHTHALMOLOGY
LR Carlos Rocha de Lossada

Lines of research:

- Cornea.
- Retina.
- Uveitis.
- Pediatric ophthalmology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
CE-20	Schiano-Lomoriello, D; Abicca, I; Contento, L; Gabrielli, F; Alfonsi, C; Di Pietro, F; Papa, FT; Ballesteros-Sánchez, A; Sánchez-González, JM; Rocha-De-Lossada, C; Mazzotta, C; Giannaccare, G; Bonzano, C; Borroni, D	Infectious Keratitis: Characterization of Microbial Diversity through Species Richness and Shannon Diversity Index	BIOMOLECULES	4.8	Q1
	Zamorano-Martín, F; Chumaceiro, G; Navarro-Torres, P; Borroni, D; Urbanati, F; Molina, A; Paytuví-Gallart, A; Rocha-de-Lossada, C	A Comparative Analysis of the Ocular Microbiome: Insights into Healthy Eyes and Anophthalmic Sockets	MICROORGANISMS	4.1	Q2
CE-20	Francisco, ZM; Sara, MM; José-María, SG; Facundo, U; Carlos, RD; María, GL; Jessica, M; Carmen, AL; Santiago, OP; Carlos, SEJ	Standardized clinical evaluation of dry anophthalmic socket syndrome in a real-world approach	CONTACT LENS & ANTERIOR EYE	4.1	Q1
CE-20	Romano, V; Ferrara, M; Gatti, F; Airaldi, M; Borroni, D; Aragona, E; Rocha-de-lossada, C; Gabrielli, F; Papa, FT; Romano, MR; Calza, S; Semeraro, F	Topical Antiseptics in Minimizing Ocular Surface Bacterial Load Before Ophthalmic Surgery: A Randomized Controlled Trial	AMERICAN JOURNAL OF OPHTHALMOLOGY	4.1	Q1
CE-20	Alba-Linero, C; Garcia-Lorente, M; Rachwani-Anil, R; Luque-Aranda, G; Pérez-Cabeza, MI; Escudero, J	Treatment of orbital lymphatic malformation with oral sirolimus: a case report Malformação linfática orbital tratada com sirolimo oral: relato de caso	ARQUIVOS BRASILEIROS DE OFTALMOLOGIA	1.1	Q3

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
16	19%	50%	0%	49

CE-21. FRAILITY, AGING, COMPLEX CHRONICITY, AND TEACHING.
LR Marina García Gámez

Lines of research:

- Frailty Research.
- Research on population aging.
- Research on complex chronic diseases.
- Research in the field of health teaching.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
CE-21	Corral-Perez, J; Casals, C; avila-Cabeza-de-Vaca, L; Gonzalez-Mariscal, A; Mier, A; Espinar-Toledo, M; Soler, NGA; Vazquez-Sanchez, MA	Associations Between Physical Activity and Inactivity Levels on Physical Function and Sleep Parameters of Older Adults With Frailty Phenotype	JOURNAL OF APPLIED GERONTOLOGY	2.2	Q2
CE-21	Valero-Cantero, I; Vázquez-Sánchez, MA; Casals-Sánchez, JL; Espinar-Toledo, M; Corral-Pérez, J; Casals, C	Complementary Musical Intervention for Patients in Palliative Care in Spain: A Randomized Controlled Trial	HEALTHCARE	2.4	Q2
CE-21	Casals, C; Corral-Pérez, J; Avila-Cabeza-de-Vaca, L; González-Mariscal, A; Carrión-Velasco, Y; Rodríguez-Martínez, MC; Jiménez-Cebrián, AM; Vázquez-Sánchez, MA	Exploring the interplay of frailty, physical function, physical activity, nutritional status, and their association with quality of life and depressive symptoms in older adults with the frailty phenotype	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	3.6	Q1
CE-21	Corral-Pérez, J; Vázquez-Sánchez, MA; Casals-Sánchez, JL; Contreras-García, FJ; Costilla, M; Casals, C	A 6-month educational program improves sleep behaviour in community-dwelling frail older adults: A randomised controlled trial	SLEEP MEDICINE	3.8	Q1
CE-21	Corral-Pérez, J; Avila-Cabeza-de-Vaca, L; Valero-Cantero, I; González-Mariscal, A; Ponce-Gonzalez, JG; Vázquez-Sánchez, MA; Casals, C	Predictors of Urinary and Fecal Incontinence in Prefrail and Frail Older Adults: A Cross-Sectional Study of the FRAGSALUD Project	JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES	4.3	Q1

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
5	40%	60%	0%	16



ASSOCIATED GROUPS

CA-10. CAUSAL COGNITION GROUP
LR Francisco J. López Gutiérrez

Lines of research:

- 1. Associative learning mechanisms.
- 2. Learning systems involved in the acquisition and extinction of conditioned fear.
- 3. Cerebral bases of the reinforcement learning system.
- 4. Individual differences in reinforcement learning as a marker of vulnerability to anxiety disorders.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
CA-10	Cobos, PL; Quintero, MJ; Lopez, FJ; Luque, D; Ciria, LF; Moris, J	Intolerance of uncertainty does not significantly predict decisions about delayed, probabilistic rewards: A failure to replicate Luhmann, C. C., Ishida, K., & Hajcak, G. (2011)	PLOS ONE	2.9	Q1
CA-10	Quintero, MJ; López, FJ; Vadillo, MA; Morís, J	Occasional Reinforced Extinction as a Method for Relapse Prevention: A Critical Systematic Review and Future Directions	COGNITIVE THERAPY AND RESEARCH	2.9	Q1
CA-10	Balea, P; Molinero, S; Vadillo, MA; Luque, D	The Role of Selection History in the Learned Predictiveness Effect	JOURNAL OF EXPERIMENTAL PSYCHOLOGY-HUMAN PERCEPTION AND PERFORMANCE	2.1	Q2
CA-10	Beesley, T; Earl, L; Butler, H; Sharp, I; Jaceviciute, I; Luque, D	Contextual cuing survives an interruption from an endogenous cue for attention	ATTENTION PERCEPTION & PSYCHOPHYSICS	1.7	Q3
CA-10	Quintero, MJ; Morís, J; López, FJ	Evaluating the effects of counterconditioning, novelty-facilitated, and standard extinction on the spontaneous recovery of threat expectancy and conditioned stimulus valence	QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY	1.5	Q3

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
5	100%	40%	0%	11



EXTERNAL ASSOCIATED GROUPS

CA-14. CHRONIC DISEASES AND AGING
LR Maria Dolores Martin Escalante/Co-LR Julian Olalla Sierra

- Lines of research:
- 1. Chronic cardiovascular diseases
 - 2. Quality and evaluation of healthcare outcomes in chronic diseases and aging
 - 3. Infectious diseases

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
CA-14	Lorenzo-Hernández, E; Rivas-Ruiz, F; Del Arco-Jiménez, A	Consequences of the COVID-19 Pandemic on the Incidence, Management and Outcomes of Staphylococcus aureus Bacteraemia: Experience in a Spanish Hospital	PATHOGENS	3.3	Q2
CA-14	Espiga, FR; Delia, MA; Martínez, FC; Martín, DM; Serrano, FN; López, RQ	Delayed diagnosis and missed opportunities in the early detection of atrial fibrillation: a cross-sectional study	REVISTA CLINICA ESPANOLA	2.3	Q2
CA-14	Salas-Marquez, C; García, RB; Jiménez, JBR; Escribano, PC; Ruiz, FR	Development of a Questionnaire on Knowledge, Habits, and Attitudes on Sexually Transmitted Infections in Teenagers and Young Adults	ACTAS DERMO-SIFILOGRAFICAS	3.8	Q1
CA-14	Fernandez-Pereza, FJ; Fernandez-Morenoa, N; Soria-Lopez, E; Rodriguez-Gonzalez, FJ; Fernandez-Galeoteb, FJ; Lifante-Olivac, A; Ruiz-Hernandezc, C; Escalante-Quijaitec, E; Rivas-Ruizd, F	Granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: A useful therapeutic tool not just in ulcerative colitis but also in Crohn's disease	GASTROENTEROLOGIA Y HEPATOLOGIA	2.2	Q3
CA-14	de Lomas-Guerrero, JG; Jiménez-García, N; Fernández-Sánchezb, F; del Arco-Jiménez, A; Prada-Pardal, JL; de la Torre-lima, J	Missed opportunities in the early detection of HIV infection in patients with sexually transmitted infections: A real-life study	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.6	Q3

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
20	30%	45%	15%	96.4



Active projects



Clinical studies

Competitive HR contracts funded in 2024:

1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.

CA-15. PALLIATIVE CARE

LR Rafael Gómez García. Co-LR Pilar Barnestein Fonseca

Lines of research: Clinical, educational, and economic aspects of palliative care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q
CA-15	Barnestein-Fonseca, P; Guerrero-Pertíñez, G; Gúzman-Parra, J; Valera-Moreno, E; Mayoral-Cleries, F	Is it possible to diagnose therapeutic adherence in mild cognitive impairment and dementia patients in clinical practice?	FRONTIERS IN PHARMACOLOGY	4.4	Q1
CA-15	Muñoz-Cobos, F; Aguiar-Leiva, VP; Argüello-Suárez, C; Colacicchi, P; Calleja-Cartón, LA; Leiva-Fernández, F	Validation of an Inhaled Therapy Beliefs Questionnaire in Patients with Chronic Obstructive Pulmonary Disease	JOURNAL OF CLINICAL MEDICINE	3	Q1
CA-15	Tripodoro, VA; Veloso, VI; Martín, EV; Kodba-Ceh, H; Bakan, M; Rasmussen, BH; Zambrano, SC; Joshi, M; Hálfðánardóttir, SI; Asgeirsdóttir, GH; Romarheim, E; Haugen, DF; McGlinchey, T; Yildiz, B; Barnestein-Fonseca, P; Goossensen, A; Lunder, U; van der Heide, A	‘Someone must do it’: multiple views on family’s role in end-of-life care -an international qualitative study	PALLIATIVE CARE & SOCIAL PRACTICE	2.7	Q2
CA-15	Barnestein-Fonseca, P; Nebro-Gil, A; Aguiar-Leiva, VP; Víbora-Martín, E; Ruiz-Torreras, I; Martín-Rosello, ML; van der Heide, A; Tripodoro, V; Veloso, VI; Montilla, S; De Simone, GG; Goldraij, G; Boughey, M; Berger, M; Fischer, C; Simon, J; Voltz, R; Joshi, M; Strupp, J; Halfdanardottir, SI; Sigurdardottir, V; Yildiz, B; Korfage, IJ; Goossensen, A; van Zuylen, C; Geijteman, ECT; Allan, S; Haugen, DF; Iversen, GS; Lunder, U; Bakan, M; Kodba-Ceh, H; Fürst, CJ; Schelin, MEC; Eychmüller, S; Zambrano, SC; Ellershaw, J; Mason, S; McGlinchey, T; Smeding, R	Barriers and drivers of public engagement in palliative care, Scoping review	BMC PALLIATIVE CARE	2.5	Q2
CA-15	Carrasco-Zafra, MI; Ocaña-Riola, R; Gómez-Garcia, R; Martín-Roselló, ML; Blanco-Reina, E	Palliative sedation at the end of life: prevalence, characteristics and possible determinants	BMC PALLIATIVE CARE	2.5	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
6	33%	33%	0%	17.6

Networks:

CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence (European Commission)

CA-19. DIGCOMPSALUD. DIGITAL COMPETENCE FOR LIFELONG LEARNING

LR Antonia Fernandez Luque, Co-LR Fernando Zubeldia Santoyo

Lines of research:

- 1. Artificial intelligence in the study of older adults
- 2. Dependence and frailty
- 3. Improvements in health care

Other lines:

Digital competence, open science, educational technology, digital transformation, curriculum design, lifelong learning, virtual library, school for patients, health technology, open education, digital health.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
CA-19	Echevarria-Lucas, L; Senciales-Gonzalez, JM; Rodrigo-Comino, J	Analysing the Evidence of the Effects of Climate Change, Air Pollutants, and Occupational Factors in the Appearance of Cataracts	ENVIRONMENTS	3.5	Q2
CA-19	Fernández-Luque,AM; Ramírez-Montoya, MS	Health Professionals' Competencies in the Framework of Complexity: Digital Training Model for Education 4.0	REVISTA ESPAÑOLA DE DOCUMENTACION CIENTIFICA	1	Q3
CA-19	Caballero, T; Alonso, C; Baeza, ML; Baynova, K; Cabeza, J; Cortés, I; Oblitas, DE; Guilarte, M; Joral, A; Palomo, JJ; Jiménez, MAL; Virto, AM; Medrano, L; Boquet, EM; Navarro, M; Pérez, D; Martí, MJP; Foltz, SLS; Suero, C; Zamora, C	Hereditary angioedema in Spain: medical care and patient journey	ORPHANET JOURNAL OF RARE DISEASES	3.4	Q2
CA-19	Ramírez-Morros, A; Berenguera, A; Millaruelo, L; Buil-Cosiales, P; Garcia, CG; Cos, X; Lachica, LA; Artola, S; Millaruelo, JM; Mauricio, D; Franch-Nadal, J	Impact of Gender on Patient Experiences of Self-Management in Type 2 Diabetes: A Qualitative Study	PATIENT PREFERENCE AND ADHERENCE	2	Q2

Group	Authors	Article Title	Source Title	IF	Q/D
CA-19	Caballero, T; Alonso, C; Baeza, ML; Baynova, K; Cabeza, J; Cortés, I; Oblitas, DE; Guilarte, M; Joral, A; Palomo, JJ; Jiménez, MAL; Virto, AM; Medrano, L; Boquet, EM; Navarro, M; Pérez, D; Martí, MJP; Foltz, SLS; Suero, C; Zamora, C	Hereditary angioedema in Spain: medical care and patient journey	ORPHANET JOURNAL OF RARE DISEASES	3.4	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
6	17%	17%	0%	17



Area 4. Autoimmune diseases, infectious diseases, inflammation, and allergies.

CONSOLIDATED GROUPS

D-01. CLINICAL RESEARCH GROUP ON HIV INFECTION, ENDOVASCULAR INFECTION, AND BACTEREMIA
LR Jesús Santos González. Co-LR Rosario Moreno Palacios

- Priority line of research: HIV infection
- Other lines of research:
- 1. HIV/HCV infection
 - 2. Other sexually transmitted infections
 - 3. Endovascular infections and bacteremia
 - 4. Osteoarticular infections
 - 5. International health and imported infections

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
D-01	Gasca-Capote, C; Lian, XD; Gao, C; Roseto, IC; Jiménez-Léon, MR; Gladkov, G; Camacho-Sojo, MI; Perez-Gomez, A; Gallego, I; Lopez-Cortes, LE; Bachiller, S; Vitalle, J; Benhnia, MRE; Ostos, FJ; Collado-Romacho, AR; Santos, J; Palacios, R; Gomez-Ayerbe, C; Munoz-Medina, L; Ruiz-Sancho, A; Frias, M; Rivero-Juarez, A; Roca-Oporto, C; Hidalgo-Tenorio, C; Rull, A; Olalla, J; Lopez-Ruz, MA; Vidal, F; Vilades, C; Mastrangelo, A; Cavassini, M; Espinosa, N; Perreau, M; Peraire, J; Rivero, A; López-Cortes, LF; Lichterfeld, M; Yu, XG; Ruiz-Mateos, E	The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers	JOURNAL OF CLINICAL INVESTIGATION	13.3	D1
D-01	Corma-Gómez, A; Cabello, A; Orviz, E; Morante-Ruiz, M; Ayerdi, O; Al-Hayani, A; Muñoz-Gómez, A; De Los Santos, I; Gómez-Ayerbe, C; Rodrigo, D; Riestra, SDR; Reus-Bañuls, S; Silva-Klug, A; Galindo, MJ; Santos, M; Serrano-Fuentes, M; Faro-Míguez, N; Pérez-Camacho, I; Corona-Mata, D; Morano, L; López-Ruz, MA; Montero, M; Anaya-Baz, B; Merino, D; Castillo-Navarro, A; Pineda, JA; Macías, J	Long or complicated mpox in patients with uncontrolled HIV infection	JOURNAL OF MEDICAL VIROLOGY	6.8	D1

Group	Authors	Article Title	Source Title	IF	Q/D
D-01	Caballero-Gómez, J; Pereira, S; Rivero-Calle, I; Perez, AB; Viciano, I; Casares-Jiménez, M; Rios-Muñoz, L; Rivero-Juarez, A; Aguilera, A; Rivero, A	Acute Hepatitis in Children Due to Rat Hepatitis E Virus	JOURNAL OF PEDIATRICS	3.9	D1
D-01	Sequera-Arquelladas, S; Hidalgo-Tenorio, C; Lopez-Cortés, L; Gutiérrez, A; Santos, J; Téllez, F; Omar, M; Ferra-Murcia, S; Fernández, E; Javier, R; García-Vallecillos, C; Pasquau, J	DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain	VIRUSES-BASEL	3.8	Q2
D-01	Calderon-Parra, Jorge; Dominguez, Fernando; Gonzalez-Rico, Claudia; Arnaiz de Las Revillas, Francisco; Goenaga, Miguel Angel; Alvarez, I; Munoz, Patricia; Alonso, David; Rodriguez-Garcia, Raquel; Miro, Jose Maria; De Alarcon, Aristides; Antorrena, Isabel; Goikoetxea-Agirre, Josune; Moral-Escudero, Encarnacion; Ojeda-Burgos, Guillermo; Ramos-Martinez, Antonio	Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort.	Open forum infectious diseases	3.8	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
6	0%	67%	50%	34



Networks:

CA21164 (ADVANCE-TB) - Towards an improvement in diagnostics and treatment strategies for TB control.

D-03. INFLAMMATORY AND AUTOIMMUNE DISEASES

LR Antonio Fernández Nebro. Co-LR Natalia Mena Vázquez

Priority line of research: Immunologically mediated inflammatory diseases

Other lines:

- 1. Microbiota in inflammatory diseases
- 2. Cardiovascular risk in inflammatory diseases
- 3. Nursing care in osteoarticular diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
D-03	Mena-Vázquez, N; Redondo-Rodríguez, R; Rojas-Gimenez, M; Romero-Barco, CM; Fuego-Varela, C; Perez-Gómez, N; Añón-Oñate, I; Pérez, PC; García-Studer, A; Hidalgo-Conde, A; de los Ríos, RAD; Cabrera-César, E; Velloso-Feijoo, ML; Manrique-Arija, S; Calvo-Gutiérrez, J; Gandía-Martínez, M; Morales-Garrido, P; Godoy-Navarrete, FJ; Mouriño-Rodríguez, C; Espildora, F; Aguilar-Hurtado, MC; Fernández-Nebro, A	Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study	FRONTIERS IN IMMUNOLOGY	6	Q1
D-03	Mena-Vázquez, N; Ortiz-Márquez, F; Ramírez-García, T; Cabezudo-García, P; García-Studer, A; Mucientes-Ruiz, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Redondo-Rodríguez, R; Manrique-Arija, S; Cano-García, L; Serrano-Castro, PJ; Fernández-Nebro, A	Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis	RMD OPEN	5	Q1
D-03	Mucientes, A; Lisbona-Montañez, JM; Mena-Vázquez, N; Ruiz-Limón, P; Manrique-Arija, S; García-Studer, A; Ortiz-Márquez, F; Fernández-Nebro, A	Intestinal Dysbiosis, Tight Junction Proteins, and Inflammation in Rheumatoid Arthritis Patients: A Cross-Sectional Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5	Q1
D-03	Cano-García, L; Redondo-Rodríguez, R; Mena-Vázquez, N; Manrique-Arija, S; García-Studer, A; Ortiz-Marquez, F; Borregón-Garrido, P; Fernández-Nebro, A	Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study	BMJ OPEN	2	Q1
D-03	Cano-García, L; Manrique-Arija, S; Redondo-Rodríguez, R; Vera-Ruiz, M; Lisbona-Montañez, JM; Mucientes-Ruiz, A; García-Studer, A; Ortiz-Marquez, F; Mena-Vázquez, N; Fernández-Nebro, A	Impact of the COVID-19 pandemic on psychosocial health in rheumatic patients: A longitudinal study	REUMATOLOGIA CLINICA	1	Q4

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
21	24%	62%	14%	102



Active projects



Clinical studies



Patents applied for

Networks:

RICORS INFLAMMATORY DISEASES REI, RD21-0002-0037 (ISCIII)

Competitive HR contracts funded in 2024:

1 PFIS Contract (ISCIII)

1 Sara Borrell Contract (ISCIII)

1 Contract for the intensification of research activity in the SNS (ISCIII)

1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.

1 Contract for intensification of research activity from the Spanish Society of Rheumatology.

D-04. ALLERGIC DISEASES TO DRUGS AND ALLERGENS

LR María José Torres Jaén, Co-LR: Lina Mayorga Mayorga

Priority line of research: Study of allergic reactions

Other lines:

- 1. Study of the mechanisms involved and improvement in the diagnosis and treatment of allergic reactions to drugs.
- 2. Study of the mechanisms involved and improvement in the diagnosis and treatment of allergic reactions to food.
- 3. Study of the mechanisms involved and improvement in the diagnosis and treatment of allergic respiratory diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
D-04	Cruz-Amaya, A; Martin-Astorga, MD; Lebron-Martín, C; Paris, JL; Céspedes, JA; Núñez, R; Torres, MJ; Aranda, CJ; Cañas, JA; Mayorga, C	Butyrate dietary supplementation promotes tolerant responses in a Pru p 3-anaphylactic mouse model	ALLERGY	12.6	D1
D-04	Mayorga, C; Çelik, GE; Pascal, M; Hoffmann, HJ; Eberlein, B; Torres, MJ; Brockow, K; Garvey, LH; Barbaud, A; Madrigal-Burgaleta, R; Caubet, JC; Ebo, DG	Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper	ALLERGY	12.6	D1
D-04	Bavbek, S; Özdemir, SK; Bonadonna, P; Atanaskovic-Markovic, M; Barbaud, A; Brockow, K; Martinez, JL; Nakonechna, A; Pagani, M; Arcolaci, A; Lombardo, C; Torres, MJ	Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper	ALLERGY	12.6	D1
D-04	Céspedes, JA; Fernandez-Santamaria, R; Bogas, G; Veguillas, AA; Dona, I; Salas, M; Labella, M; Duarte, TDF; Mayorga, C; Torres, MJ; Frecha, CA	LPS in combination with amoxicillin increases BAT sensitivity to amoxicillin IgE-mediated hypersensitivity	ALLERGY	12.6	D1
D-04	Eguiluz-Gracia, I; Parkin, RV; Layhadi, JA; Palmer, E; Meng, X; Zhu, RF; Sahiner, U; Durham, SR; Torres, MJ; Mayorga, C; Rondon, C; Shamji, MH	Nasal allergen-neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis	ALLERGY	12.6	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
40	40%	90%	63%	364



Networks:

CA18226 (ADOPT)- New approaches for the detection of pathogens and aeroallergens (European Commission)
CA18227 (COMFA) -The Core Outcome Measures for Food Allergy (European Commission)
RICORS INFLAMMATORY DISEASES REI RD21/0002/0008 (ISCIII)

Competitive HR contracts funded in 2024:

1 MARIE SKLODOWSKA-CURIE Contract: POSTDOCTORAL FELLOWSHIPS - EUROPEAN FELLOWSHIPS (European Commission).
1 MARIE SKLODOWSKA-CURIE Contract: INDIVIDUAL FELLOWSHIPS- EUROPEAN FELLOWSHIPS (European Commission).
5 PFIS Contracts (ISCIII)
4 Río Hortega Contracts (ISCIII)
4 Juan Rodés Contracts (ISCIII)
2 Sara Borrell Contracts (ISCIII)
2 Ramón y Cajal Contracts from the State Research Agency.
1 Pre-doctoral contract for the training of doctors from the State Research Agency.
2 Contracts to promote research consolidation from the State Research Agency.
1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.
1 Contract for long-term reinforcement of the SAS (Action B).
2 Contracts for the incorporation of clinical-research professionals to the clinical units of the Andalusian Health Service.
3 Nicolás Monardes SAS contracts (Action C).

D-05. HEPATOGASTROENTEROLOGY, PHARMACOLOGY, AND TRANSLATIONAL CLINICAL THERAPEUTICS

LR Raúl J. Andrade Bellido, Co-LR Eduardo García Fuentes, Co-LR Mercedes Robles Díaz

Lines of research:

- 1. Epidemiological research, causality, and genetic factors and identification of biomarkers in hepatotoxicity.
- 2. Etiopathogenesis and new treatments in inflammatory bowel disease
- 3. Etiopathogenesis, clinical course, and noninvasive diagnosis in nonalcoholic fatty liver disease

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
D-05	Segovia-Zafra, A; Villanueva-Paz, M; Serras, AS; Matilla-Cabello, G; Bodoque-García, A; Zeo-Sánchez, DED; Niu, H; Alvarez-Alvarez, I; Sanz-Villanueva, L; Godec, S; Milisav, I; Bagnaninchi, P; Andrade, RJ; Lucena, MI; Fernández-Checa, JC; Cubero, FJ; Miranda, JP; Nelson, LJ	Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network	JOURNAL OF HEPATOLOGY	26.8	D1
D-05	Niu, H; Solis-Muñoz, P; García-Cortés, M; Sanabria-Cabrera, J; Robles-Díaz, M; Romero-Flores, R; Bonilla-Toyos, E; Ortega-Alonso, A; Pinazo-Bandera, JM; Cabello, MR; Bessone, F; Hernandez, N; Lucena, MI; Andrade, RJ; Medina-Caliz, I; Alvarez-Alvarez, I	Prior drug allergies are associated with worse outcome in patients with idiosyncratic drug-induced liver injury: A machine learning approach for risk stratification	PHARMACOLOGICAL RESEARCH	9.1	D1
D-05	Pinazo-Bandera, JM; Niu, H; Alvarez-Alvarez, I; Medina-Cáliz, I; Campo-Herrera, ED; Ortega-Alonso, A; Robles-Díaz, M; Hernández, N; Paraná, R; Nunes, V; Giralá, M; Bessone, F; Lucena, MI; Andrade, RJ; Cortés, MG	Rechallenge in idiosyncratic drug-induced liver injury: An analysis of cases in two large prospective registries according to existing definitions	PHARMACOLOGICAL RESEARCH	9.1	D1
D-05	Lucena, MI; Villanueva-Paz, M; Alvarez-Alvarez, I; Aithal, GP; Björnsson, ES; Cakan-Akdogan, G; Cubero, FJ; Esteves, F; Falcon-Perez, JM; Fromenty, B; Garcia-Ruiz, C; Grove, JI; Konu, O; Kranendonk, M; Kullak-Ublick, GA; Miranda, JP; Remesal-Doblado, A; Sancho-Bru, P; Nelsons, L; Andrade, RJ; Daly, AK; Fernandez-Checa, JC	Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet	PHARMACOLOGICAL RESEARCH	9.1	D1

Group	Authors	Article Title	Source Title	IF	Q/D
D-05	Cárdenas-Quesada, J; Mestre-Pintó, J; Maldonado, R; de Fonseca, FR; Torrens, M; Farré, M	Substance use disorders and cooperative research on addictions: Spanish approach as a model	PHARMACOLOGICAL RESEARCH	9.1	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
34	38%	76%	41%	269



Networks and Ciber:

CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities.
CERT22/00034. Networked State Consortium for the Development of Medicines for Advanced Therapies (CERTERA)
CIBEREHD CB07/04/2008 Liver and Digestive Diseases (ISCIII)

Competitive HR contracts funded in 2024:

- 1 i-PFIS Contract (ISCIII)
- 2 Río Hortega Contracts (ISCIII)
- 1 Juan Rodés Contract (ISCIII)
- 2 Sara Borrell Contracts (ISCIII)
- 3 Miguel Servet Contracts (ISCIII)
- 1 Pre-doctoral contract for the training of doctors from the State Research Agency.
- 1 Contract for university professor training from the Ministry of Science, Innovation, and Universities.
- 1 Intensification grant for researchers of the Spanish Foundation for the Study of the Liver.
- 1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.
- 1 Nicolás Monardes SAS Contract (Action C).
- 1 Contract for doctoral research personnel by universities and public research entities.

EMERGING GROUPS

DE-02. GROUP FOR THE STUDY OF INFECTIOUS DISEASES

LR José María Reguera

Priority line of research: HIV infection

Other lines:

- 1. Endovascular infection
- 2. Multidrug-resistant bacteria
- 3. Identification of NTM by means of MALDITOF

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
DE-02	López-Cortés, LE; Delgado-Valverde, M; Moreno-Mellado, E; Aguirre, JG; Carrión, LG; Vidal, MJB; Soria, LML; Pérez-Rodríguez, MT; Lamas, LM; de las Revillas, FA; Arminanzas, C; de Alegría-Puig, CR; Aguilar, PJ; Martínez-Rubio, MD; Sáez-Bejar, C; de las Cuevas, C; Martín-Aspas, A; Galán, F; Yuste, JR; Leiva-León, J; Bou, G; González, PC; Boix-Palop, L; Xercavins-Valls, M; Goenaga-Sánchez, MA; Anza, DV; Castón, JJ; Rufián, MR; Merino, E; Rodríguez, JC; Loeches, B; Cuervo, G; Laso, JMG; Plata, A; Cortés, SP; Mato, PL; Monzón, JLS; Rosso-Fernández, C; Bravo-Ferrer, J; Retamar-Gentil, P; Rodríguez-Baño, J	Efficacy and safety of a structured de-escalation from antipseudomonal β -lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial	LANCET INFECTIOUS DISEASES	36.4	D1
DE-02	Maldonado, N; López-Hernández, I; García-Montaner, A; López-Cortés, LE; Pérez-Crespo, PMM; Retamar-Gentil, P; Sousa-Domínguez, A; Goikoetxea, J; Pulido-Navazo, A; Labayru-Echeverría, C; Natera-Kindelán, C; Jover-Sáenz, A; del Arco-Jiménez, A; Armiñanzas-Castillo, C; Aller, AI; Fernández-Suárez, J; Marrodán-Ciordia, T; Boix-Palop, L; Smithson-Amat, A; Reguera-Iglesias, JM; Galán-Sánchez, F; Bahamonde, A; Calvo, JMS; Gea-Lázaro, I; Pérez-Camacho, I; Reyes-Bertos, A; Becerril-Carral, B; Rodríguez-Baño, J; Pascual, A	Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study	LANCET MICROBE	20.9	D1

Group	Authors	Article Title	Source Title	IF	Q/D
DE-02	Maldonado, N; López-Hernández, I; López-Cortés, LE; Pérez-Crespo, PMM; Retamar-Gentil, P; García-Montaner, A; Riestra, SD; Sousa-Domínguez, A; Goikoetxea, J; Pulido-Navazo, A; Ortíz, MD; Natera-Kindelán, C; Jover-Sáenz, A; del Arco-Jiménez, A; Armiñanzas-Castillo, C; Aller-García, AI; Fernández-Suárez, J; Marrodán-Ciordia, T; Boix-Palop, L; Smithson-Amat, A; Reguera-Iglesias, JM; Galán-Sánchez, F; Bahamonde, A; Sánchez-Calvo, JM; Gea-Lázaro, I; Pérez-Camacho, I; Reyes-Bertos, A; Becerril-Carral, B; Pascual, A; Rodríguez-Baño, J; and Rodríguez-Baño, J	Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study	CLINICAL MICROBIOLOGY AND INFECTION	10.9	D1
DE-02	Paniagua-García, M; Bravo-Ferrer, JM; Pérez-Galera, S; Kostyanev, T; de Kraker, MEA; Feifel, J; Palacios-Baena, ZR; Schotsman, J; Cantón, R; Daikos, GL; Carevic, B; Dragovac, G; Tan, LK; Raka, L; Hristea, A; Viale, P; Akova, M; Cano, A; Reguera, JM; Bartoloni, A; Florescu, SA; Benea, S; Bukarica, L; Asensio, A; Korten, V; Grundmann, H; Goossens, H; Bonten, MJ; Gutiérrez-Gutiérrez, B; Rodríguez-Baño, J	Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)	CLINICAL MICROBIOLOGY AND INFECTION	10.9	D1
DE-02	Fernandez-García, MD; Garcia-Ibañez, N; Camacho, J; Gutierrez, A; García, LS; Calvo, C; Moreno-Docón, A; Menasalvas, AI; Medina, A; Perez-Ruiz, M; Toboso, MCN; Munoz-Almagro, C; Launes, C; Berengua, C; Cabrerizo, M	Enhanced echovirus 11 genomic surveillance in neonatal infections in Spain following a European alert reveals new recombinant forms linked to severe cases, 2019 to 2023	EUROSURVEILLANCE	10	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
14	0%	86%	50%	131



DE-07. INFLAMMATION IN CRITICALLY ILL PATIENTS

LR Manuel Enrique Herrera Gutiérrez. Co-LR Emilio Curiel Balsera

Priority line of research: Study of the inflammatory response and treatment measures.

Other lines: Inflammatory response in different scenarios: Extracorporeal surgery, acute kidney disease, acute liver disease. Extracorporeal organ support. Ischemic heart disease. Ischemic/hemorrhagic brain disease.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D
DE-07	Reta-Pérez, O; Colmenero-Ruiz, M; Hernández-Socorro, CR; Saavedra, P; Maichle, SF; Portugal, E; Cerezo-Arias, M; Alés, LS; Martínez-Carmona, JF; Mateu-Campos, L; Lorenzo-Cárdenas, C; García-Miguélez, A; Sosa-Durr, M; San Martín-Bragado, M; Ruiz-Santana, S	Trophic Nutrition in ICU Patients Undergoing High-Flow Oxygen Therapy and/or Noninvasive Mechanical Ventilation: The Nutri-Trophic Study	NUTRIENTS	4.8	Q1
DE-07	Gordillo-Resina, M; Aranda-Martinez, C; Arias-Verdú, MD; Guerrero-López, F; Castillo-Lorente, E; Rodríguez-Rubio, D; Rivera-López, R; Rosa-Garrido, C; Gómez-Jiménez, FJ; Lafuente-Baraza, J; Aguilar-Alonso, E; Arráez-Sanchez, MA; Rivera-Fernández, R	Mortality, Functional Status, and Quality of Life after 5 Years of Patients Admitted to Critical Care for Spontaneous Intracerebral Hemorrhage	NEUROCRITICAL CARE	3.1	Q2
DE-07	Herrera-Linares, ME; Rico-Pérez, B; Yaffy, D; Fernández-Parra, R; Llanos, C; Parra-Martínez, C; Herrera-Gutiérrez, ME; Sanchis-Mora, S	Cadaveric study of the ultrasound-guided erector spinae plane block over the transverse process of the twelfth thoracic vertebra in dogs: Transversal vs longitudinal approach	VETERINARY JOURNAL	2.3	Q1
DE-07	Trasobares, NQ; González-Fernández, M; Barea-Mendoza, JA; Arias-Verdú, MD; Barrueco-Francioni, JE; Seller-Pérez, G; Molina-Collado, Z; Gonzalez-de Aledo, AL; Herrera-Gutiérrez, M; Riera, JASI	The Role of Immunomodulatory Therapy with Oxiris in COVID-19 with Renal Failure and Immune Dysfunction	BLOOD PURIFICATION	2.2	Q2
DE-07	Barrueco-Francioni, JE; Martinez-González, MC; Martínez-Carmona, JF; Benítez-Moreno, MP; Aragón-Gonzalez, C; Herrera-Gutiérrez, ME	ECMO in severe hypoxemia post liver transplant for hepatopulmonary syndrome	INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS	1.4	Q3

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
6	17%	33%	0%	16



Active projects



Clinical studies

DE-08. HEPATOGASTROENTEROLOGY, ENDOSCOPY, AND GASTROINTESTINAL SURGERY

LR Miguel Jiménez Pérez. Co-LR Julio Santoyo Santoyo

Priority line of research: Liver diseases: viral, metabolic, and toxic. Liver transplantation. Gastrointestinal oncology.

Other lines: Inflammatory bowel disease. Digestive endoscopy.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
DE-08	Serradilla-Martín, M; Villodre, C; Falgueras-Verdaguer, L; Zambudio-Carroll, N; Castell-Gómez, JT; Blas-Laina, JL; Borrego-Estella, V; Domingo-del-Pozo, C; García-Plaza, G; González-Rodríguez, FJ; Montalvá-Orón, EM; Moya-Herraiz, A; Paterna-López, S; Suárez-Muñoz, MA; Alkorta-Zuloaga, M; Blanco-Fernández, G; Dabàn-Collado, E; Gómez-Bravo, MA; Miotra-de-Llamas, JI; Rotellar, F; Sánchez-Pérez, B; Sanchez-Cabus, S; Pacheco-Sanchez, D; Rodríguez-Sanjuan, JC; Varona-Bosque, MA; Carrión-Alvarez, L; de la Serna-esteban, S; Dopazo, C; Martín-Pérez, E; Martínez-Cecilia, D; Castro-Santiago, MJ; Dorcaratto, D; Gutiérrez-Díaz, ML; Asencio-Pascual, JM; Burdio-Pinilla, F; Carracedo-Iglesias, R; Escartín-Arias, A; Ielpo, B; Rodríguez-Laiz, G; Valdivieso-López, A; De-Vicente-López, E; Alonso-Orduña, V; Ramia, JM	Feasibility and Short-Term Outcomes in Liver-First Approach: A Spanish Snapshot Study (the RENACI Project)	CANCERS	4.5	Q1
DE-08	Burgos, MM; Grande, RG; Ortega, SL; Leiva, IS; Lombardo, JD; Santoyo, JS; Pérez, MJ	Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence	BIOMEDICINES	3.9	Q1
DE-08	González, MB; Martín, RVO; Bermúdez, AIM; Pérez, MJ	Characterization of Inflammatory Bowel Disease in the Elderly According to Age of Onset	JOURNAL OF CLINICAL MEDICINE	3	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
DE-08	Reyes, MP; Pérez, BS; González, CS; Daga, JAP; Villalba, JS; Santoyo, JS	Implementation of an ERAS protocol on cirrhotic patients in liver resection: a cohort study	UPDATES IN SURGERY	2.4	Q1
DE-08	Aranda-Nárvaez, JM; Fernández-Galeano, P; Romacho-López, L; Cabrera-Serna, I; Titos-García, A; Mirón-Fernández, I; Santoyo-Santoyo, J	Improving early cholecystectomy rate in acute cholecystitis with an evidence-based local multidisciplinary protocol and a surgical audit: single-center experience through an Acute Care Surgery Division	LANGENBECKS ARCHIVES OF SURGERY	2.1	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
12	33%	75%	17%	49



Active projects



Clinical studies

Competitive HR contracts funded in 2024:

1 María Castellano Arroyo research and training contract from the SAS.

DE-09. IMMUNE RESPONSE TO VIRAL INFECTIONS.

LR Juan José Borrego García. Co-LR José Manuel Jiménez Guardado. Co-LR Ana María Ortega Prieto

Priority line of research: Study of the immune response to viral infections and the mechanisms of viral immunopathology.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D
DE-09	Borrego-Ruiz, A; Borrego, JJ	An updated overview on the relationship between human gut microbiome dysbiosis and psychiatric and psychological disorders	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	5.3	D1
DE-09	Leiva-Rebollo, R; Labella, AM; Gémez-Mata, J; Castro, D; Borrego, JJ	Fish Iridoviridae: infection, vaccination and immune response	VETERINARY RESEARCH	3.7	D1
DE-09	Ortega-Prieto, A; Jimenez-Guardado, JM	Interferon-stimulated genes and their antiviral activity against SARS-CoV-2	MBIO	5.1	Q1
DE-09	Borrego-Ruiz, A; Borrego, JJ	Nutritional and Microbial Strategies for Treating Acne, Alopecia, and Atopic Dermatitis	NUTRIENTS	4.8	Q1
DE-09	Borrego-Ruiz, A; Borrego, JJ	Microbial Dysbiosis in the Skin Microbiome and Its Psychological Consequences	MICROORGANISMS	4.1	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
13	77%	54%	23%	45



Active projects

Networks:

CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections.

CA20128 (PIMENTO) -Promoting Innovation of fermented foods

Competitive HR contracts funded in 2024:

1 Ramón y Cajal Contract from the State Research Agency.

1 contract for the incorporation of doctors from the University of Málaga.

DE-10. OPHTHALMOLOGY

LR Rafael Luque Aranda. Co-LR Carmen Alba Linero

Priority line of research: Autoimmune diseases, infectious diseases and ocular allergies

Other lines:

- 1. Ocular involvement in neurological diseases
- 2. Ocular involvement in cardiovascular disease

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D
DE-10	Francisco, ZM; Sara, MM; José-María, SG; Facundo, U; Carlos, RD; María, GL; Jessica, M; Carmen, AL; Santiago, OP; Carlos, SEJ	Standardized clinical evaluation of dry anophthalmic socket syndrome in a real-world approach	CONTACT LENS & ANTERIOR EYE	4.1	Q1
DE-10	Bueno, JAR; Sánchez-Guijo, G; Ráez, PD; García-Arnes, JA; Garzón-Maldonado, FJ; Castro, VS; de la Cruz-Cosme, C; Alba-Linero, C; Gutiérrez-Bedmar, M; García-Casares, N	Effects of Type 2 Diabetes on the Neuropsychological Profile in Mild Cognitive Impairment	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2
DE-10	Mesa-del-Castillo, P; Ugarte, IY; Bolarín, JM; Martínez, D; Montesinos, BL; González, HB; Penadés, IC; Pérez, LL; Clemente, D; Robledillo, JC; Ferrán, IV; Mancheño, BB; Plats, MR; Pedraz, LM; Linero, CA; Sevilla-Pérez, B; García-Serrano, JL; Mir-Perelló, MC; Druetta, N; Souto, A; Lopez-Lopez, F; Zarallo-Reales, C; Fidalgo, MJ; Fajardo, JS; Fontana, NP; Pablo, RD; Pinedo, MC; Fonollosa, A; Casano, VJ; García, JJM; Brandy, A; López, AG; Esteban-Ortega, M; Reinoso, T; Calzada-Hernández, J; Cardeñosa, AL; Martín, CG; Verdú, EM; Vidal, MPM; Martí, NQ; Alvarado, MC; De Inocencio, J; Alonso-Martín, B; Recuero-Díaz, S; Carreño, E; González, JCN; Ibares, L; de Salazar, JRG; Sevilla, JL	Childhood-Onset Non-Infectious Uveitis in the Biologic Era. Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings	OCULAR IMMUNOLOGY AND INFLAMMATION	2.6	Q2
DE-10	Urbinati, F; Rachwani-Anil, R; Martín, FZ; Aranda, GL; Gómez, JE	Total recovery of visual acuity in a pediatric patient with compressive optic neuropathy secondary to sphenoid sinus mucocoele	ARQUIVOS BRASILEIROS DE OFTALMOLOGIA	1.1	Q3

Group	Authors	Article Title	Source Title	IF	Q/D
DE-10	Alba-Linero, C; Garcia-Lorente, M; Rachwani-Anil, R; Luque-Aranda, G; Pérez-Cabeza, MI; Escudero, J	Treatment of orbital lymphatic malformation with oral sirolimus: a case report Malformação linfática orbital tratada com sirolimo oral: relato de caso	ARQUIVOS BRASILEIROS DE OFTALMOLOGIA	1.1	Q3

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
5	20%	20%	0%	12



Active projects



Clinical studies

ASSOCIATED GROUPS

DA-06. IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMID)
LR Rosa García Portales

Lines of research:

- 1. Comorbidity, prevalence and impact of immune-mediated inflammatory diseases.
- 2. Biotherapies and targeted therapies in rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies, and uveitis.
- 3. Pharmacogenetics.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D
DA-06	Muñoz-Barrera, L; Perez-Sanchez, C; Ortega-Castro, R; Corrales, S; Luque-Tevar, M; Cerdó, T; Sanchez-Pareja, I; Font, P; Lopez-Mejías, R; Calvo, J; Abalos-Aguilera, MC; Ruiz-Vilchez, D; Segui, P; Merlo, C; Perez-Venegas, J; Montesino, MDR; Rodriguez-Escalera, C; Barco, CR; Fernandez-Nebro, A; Vazque, NM; Marengo, JL; Montañes, JU; Godoy-Navarrete, J; Cabezas-Lucena, AM; Estevez, EC; Aguirre, MA; González-Gay, MA; Barbarroja, N; Escudero-Contreras, A; Lopez-Pedrer, C	Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs	BIOMEDICINE & PHARMACOTHER-APY	6.9	D1
DA-06	Pinto-Bonilla, R; Baeza-Noci, J; Blanco, CC; Gumbau, GJV; Fernández, RJ; Pascual-Pastor, M; Magamón, BG; Lamothe, BP; Pastor, CM; Aviñó, RI; Aguilar, EG; Saz-Leal, P	Real-world effectiveness and safety of combined calcium 600 mg and cholecalciferol 2000 IU for treating vitamin d deficiency: Results from a nationwide study with focus in osteoporosis	BONE REPORTS	2.1	Q3
DA-06	Espíldora-Hernández, J; Díaz-Antonio, T; Olmedo-Llanes, J; León, JZ; Rioja, J; Valdivielso, P; Sánchez-Chaparro, MA; Ariza, MJ	Clinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3

Group	Authors	Article Title	Source Title	IF	Q/D
DA-06	Barbadillo-Villanueva, S; del Aguila, VA; Robustillo-Cortés, MD; Gimeno-Gracia, M; Yáñez, ES; Hermenegildo-Caudevilla, M; Aznárez, HN; López, AL; Vicente, E; Monte-Boquet, E	Telematic interview in telepharmacy: consensus document for pharmacotherapeutic monitoring and informed drug delivery	FARMACIA HOSPITALARIA	1	Q4

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
4	0%	25%	25%	12



Area 6. IBIMA Tech: Health Technology and Innovation Area

F-02. COMPUTATIONAL INTELLIGENCE AND IMAGE ANALYSIS
LR Ezequiel López Rubio

Lines of research:

- 1. Neurocomputing.
- 2. Digital image analysis.
- 3. Intelligent decision support systems.
- 4. Computational learning.
- 5. Grouping analysis.
- 6. Decision making.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-02	Jiménez-Partinen, A; Molina-Cabello, MA; Thurnhofer-Hemsi, K; Palomo, EJ; Rodríguez-Capitán, J; Molina-Ramos, AI; Jiménez-Navarro, M	CADICA: A new dataset for coronary artery disease detection by using invasive coronary angiography	EXPERT SYSTEMS	3	Q2
F-02	Molina-Cabello, MA; Serrano-Angulo, J; Benito-Picazo, J; Thurnhofer-Hemsi, K	Grades and Learning Styles: New Software for Analyzing Correlations in a Longitudinal Study Across Different Branches of Knowledge and Years	APPLIED SCIENCES-BASEL	2.5	Q1
F-02	Khan, N; Elizondo, D; Deka, L; Molina-Cabello, MA	Natural Language Processing Tools and Workflows for Improving Research Processes	APPLIED SCIENCES-BASEL	2.5	Q1
F-02	Atencia-Jiménez, I; Balajee, AS; Ruiz-Gómez, MJ; Sendra-Portero, F; Montoro, A; Molina-Cabello, MA	Neural Network Ensemble to Detect Dicentric Chromosomes in Metaphase Images	APPLIED SCIENCES-BASEL	2.5	Q1
F-02	Nazzal, W; Thurnhofer-Hemsi, K; López-Rubio, E	Improving Medical Image Segmentation Using Test-Time Augmentation with MedSAM	MATHEMATICS	2.3	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
14	86%	50%	7%	45



Competitive HR contracts funded in 2024:

1 i-PFIS Contract (ISCIII)

F-03. COMMUNICATIONS ENGINEERING
LR Iñigo Molina Fernández

Lines of research:


- 1. R&D in telecommunication networks, systems, and services.
- 2. Signal processing in biomedicine.
- 3. e-Health.
- 4. Biosensors.
- 5. Applications of adaptive optics in ophthalmology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-03	Sánchez-Ramírez, A; Luque-González, JM; Wangüemert-Pérez, JG; Ortega-Moñux, A; Molina-Fernández, I	Comparing dielectric and plasmonic waveguides in a Mach-Zehnder architecture with coherent readout for sensing applications	OPTICS AND LASER TECHNOLOGY	4.6	Q1
F-03	Torres-Cubillo, A; Luque-González, JM; Sánchez-Postigo, A; Fernández-Gavela, A; Wangüemert-Pérez, JG; Molina-Fernández, I; Halir, R	High-Performance Bimodal Evanescent-Field Sensor With Coherent Phase Readout	JOURNAL OF LIGHTWAVE TECHNOLOGY	4.1	Q1
F-03	Fernández-Hinestrosa, A; Luque-González, JM; Cheben, P; Schmid, JH; Wang, SR; Wangüemert-Pérez, JG; Molina-Fernandez, I; Ortega-Moñux, A	Nanophotonic Bragg grating assisted Mach-Zehnder interferometers for O-band add-drop filters	SCIENTIFIC REPORTS	3.8	Q1
F-03	Torres-Cubillo, A; Sanchez-Postigo, A; Jagerska, J; Wanguemert-Perez, JG; Halir, R	Simultaneous measurement of refraction and absorption with an integrated near-infrared Mach-Zehnder interferometer	OPTICS AND LASER TECHNOLOGY	4.6	Q1
F-03	Sánchez-postigo, A; Ginel-moreno, P; Schmid, JH; Hadij-ElHouati, A; Ortega-moñux, A; Wanguemert-perez, JG; Halir, R; Cheben, P; Molina-fernández, I	Ultra-efficient surface grating couplers for chip-to-fiber and chip-to-free-space coupling based on single-beam radiation	OPTICS EXPRESS	3.2	Q2

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
9	67%	67%	0%	36



F-04. MAPIR (MACHINE PERCEPTION AND INTELLIGENT ROBOTICS GROUP)

LR Javier González Jiménez. Co-LR Francisco Ángel Moreno Dueñas

Priority line of research: Use of robotic technology to improve the independence of older adults in their homes

Other lines of research:

- 1. Development and research on robotic telepresence systems that allow for extending independent living and social interaction among older adults. This system is designed so that a family member, caregiver, or healthcare professional can virtually visit the user’s home, experiencing an interaction very similar to a conventional in-person visit.
- 2. Development of automatic, safe navigation systems in small settings as well as systems for friendly interaction among older adults with a certain degree of cognitive frailty who live alone in their homes. This interaction seeks to alleviate the feeling of loneliness by contributing to users’ independence and well-being.
- 3. Development and research on sensor networks and algorithms for sensing activity in the environment as well as physiological parameters of individuals (patients who are chronic, at risk, in rehabilitation, etc.) for the purpose of monitoring and control by public health professionals (doctors, nurses, social workers, etc.).

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-04	Garcia-Salguero, M; Gonzalez-Jimenez, J	Certifiable planar relative pose estimation with gravity prior	COMPUTER VISION AND IMAGE UNDERSTANDING	4.3	Q1
F-04	Garcia-Salguero, M; Dima, E; Mateus, A; Gonzalez-Jimenez, J	Fast Certifiable Algorithm for the Absolute Pose Estimation of a Camera\ast	SIAM JOURNAL ON IMAGING SCIENCES	2.1	Q1
F-04	Fernández-Madrigal, JA; Gómez-de-Gabriel, JM; Rey-Merchán, MD; López-Arquillos, A	Inferring Helmet Compliance on E-Scooters Using Bluetooth and Angle-of-Arrival (AoA) Technology	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.6	Q1
F-04	Jaenal, A; Ruiz-Sarmiento, JR; Gonzalez-Jimenez, J	MachNet, a general Deep Learning architecture for Predictive Maintenance within the industry 4.0 paradigm	ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE	7.5	D1
F-04	Ojeda, P; Monroy, J; Gonzalez-Jimenez, J	Robotic Gas Source Localization With Probabilistic Mapping and Online Dispersion Simulation	IEEE TRANSACTIONS ON ROBOTICS	9.4	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
5	100%	100%	40%	29



F-05. MEDICAL ROBOTICS
LR. Victor Fernando Muñoz Martínez

Priority line: Development of robotic assistants for laparoscopic surgery

Other lines:


- 1. Design of surgical robots.
- 2. Instrument movement control.
- 3. Automated surgical planning.
- 4. Fault-tolerant control architectures
- 5. Development of human-machine interfaces
- 6. Telesurgery
- 7. Medical devices
- 8. Digital twins

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-05	Galán-Cuenca, A; De Luis-Moura, D; Herrera-López, JM; Rollón, M; García-Morales, I; Muñoz, VF	Automated suture for a robotic platform to assist laparoscopic surgery	REVISTA IBEROAMERICANA DE AUTOMATICA E INFORMATICA INDUSTRIAL	1.1	Q4
F-05	Herrera-López, JM; Galán-Cuenca, A; García-Morales, I; Rollón, M; Rivas-Blanco, I; Muñoz, VF	Cyber-physical framework for laparoscopic surgery	REVISTA IBEROAMERICANA DE AUTOMATICA E INFORMATICA INDUSTRIAL	1.1	Q4
F-05	Rivas-Blanco, I; López-Casado, C; Herrera-López, JM; Cabrera-Villa, J; Pérez-del-Pulgar, CJ	Instrument Detection and Descriptive Gesture Segmentation on a Robotic Surgical Maneuvers Dataset	APPLIED SCIENCES-BASEL	2.5	Q1
F-05	Herrera-López, JM; Galán-Cuenca, A; Reina, AJ; García-Morales, I; Muñoz, VF	Laparoscopic Suture Gestures Recognition via Machine Learning: A Method for Validation of Kinematic Features Selection	IEEE ACCESS	3.4	Q2
F-05	Castilla-Arquillo, R; Mandow, A; Pérez-del-Pulgar, CJ; Alvarez-Llamas, C; Vadillo, JM; Laserna, J	Thermal Imagery for Rover Soil Assessment Using a Multipurpose Environmental Chamber Under Simulated Mars Conditions	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.6	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
5	100%	40%	0%	14



F-09. ELECTRONICS FOR INSTRUMENTATION AND SYSTEMS
LR Fernando Vidal Verdú.

- Lines of research:
- 1. Research in electronics and instrumentation
 - 2. Bioinformatics/Biomedicine
 - 3. Applications in rehabilitation and assistance systems
 - 4. Use of artificial intelligence techniques in diagnostic systems
 - 5. Identification of correlations between genetic data and diseases

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-09	Remache-Vinueza, B; Trujillo-León, A; Vidal-Verdú, F	A Comparative Investigation of Cutaneous Rabbit and Funneling Tactile Illusions for Implementation in Vibrotactile Displays	IEEE ACCESS	3.4	Q2
F-09	Tobar-Subía-Contento, LM; Mandow, A; Gómez-de-Gabriel, JM	Open On-Limb Robot Locomotion Mechanism with Spherical Rollers and Diameter Adaptation	MACHINES	2.1	Q2
F-09	Remache-Vinueza, B; Trujillo-León, A; Vidal-Verdú, F	Phantom sensation: Threshold and quality indicators of a tactile illusion of motion	DISPLAYS	3.7	Q1
F-09	Lora-Rivera, R; Oballe-Peinado, O; Trujillo-León, A; Vidal-Verdú, F	The Goertzel Algorithm for the Extraction of Texture Features	IEEE ROBOTICS AND AUTOMATION LETTERS	4.6	Q2
F-09	Tamimi, I; Gasca, M; Halbardier, A; Martín, S; Caballero, GM; Serrano, CL; Martín, E; Tamimi, F; González-Quevedo, D; de Quevedo, DG; Sobrino, B; Palop, B; Guerado, E; Lara, AP; Urdiales, C; de Gabriel, JMG	The treatment of bacterial biofilms cultivated on knee arthroplasty implants using the bioelectric effect	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY	4.3	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
6	83%	50%	0%	24



F-10. BIOMIMETIC DENDRIMERS AND PHOTONIC LABORATORY
LR Ezequiel Pérez-Inestrosa. Co-LR Francisco Nájera Albendín

Priority line of research: Preparation of dendrimeric structures to emulate multivalent bioactive macromolecules and visualize their interactions

- Other lines:
- 1. Synthesis of new suitably functionalized dendrimer and dendron systems.
 - 2. Preparation of solid supports (nanoparticles) for their functionalization with dendrimer systems.
 - 3. Synthesis of fluorescent markers for dendrimeric systems.
 - 4. Design and synthesis of sensors for biomedical information processing.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-10	Matamoras, E; Pérez, EMS; Light, ME; Cintas, P; Martínez, RF; Palacios, JC	A True Reverse Anomeric Effect Does Exist After All: A Hydrogen Bonding Stereocontrolling Effect in 2-Iminoaldoses	JOURNAL OF ORGANIC CHEMISTRY	3.4	Q1
F-10	Sosa-Gil, C; Matamoras, E; Cintas, P; Palacios, JC	Bifunctional Azido(thio)ureas from an O-Protected 2-Amino-2-deoxy-d-glucopyranose: Synthesis and Structural Analyses	MOLECULES	4.2	Q2
F-10	Pérez, EMS; Matamoras, E; Cintas, P; Palacios, JC	Exploring and Re-Assessing Reverse Anomeric Effect in 2-Iminoaldoses Derived from Mono- and Polynuclear Aromatic Aldehydes	MOLECULES	4.2	Q2
F-10	Matamoras, E; Light, ME; Cintas, P; Palacios, JC	From Potential Prebiotic Synthons to Useful Chiral Scaffolds: A Synthetic and Structural Reinvestigation of 2-Amino-Aldononitriles	MOLECULES	4.2	Q2
F-10	Calvo-Serrano, S; Matamoras, E; Céspedes, JA; Fernández-Santamaría, R; Gil-Ocaña, V; Perez-Inestrosa, E; Frecha, C; Montañez, MI; Vida, Y; Mayorga, C; Torres, MJ	New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen-Silica Nanoparticle Composites	PHARMACEUTICS	4.9	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
7	71%	43%	0%	33



Active projects



Patents applied for

Competitive HR contracts funded in 2024:

1 Contract to promote research consolidation from the State Research Agency.

F-14. CLINIMETRICS IN PHYSICAL THERAPY

LR Antonio Ignacio Cuesta Vargas

Priority line of research: Develop and validate instruments for clinical assessment and diagnosis that incorporate biomechanics, physiology, psychometrics, and clinical signs

Other lines:

1. Development, validation, and sensitivity to change of instruments for measuring outcomes in clinical sciences.
2. Physiology and biomechanics applied to musculoskeletal (dys)function. Preclinical studies.
3. Multimodal health promotion interventions in chronic conditions. Clinical studies.
4. Health solutions based on portable information and communication technologies. Telemedicine and mHealth. Translational studies and innovation.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-14	Pareja-Cano, A; Arjona, JM; Caulfield, B; Cuesta-Vargas, A	Parameterization of Biomechanical Variables through Inertial Measurement Units (IMUs) in Occasional Healthy Runners	SENSORS	3.4	Q2
F-14	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Gijon-Noguerón, G; Navarro-Flores, E; González-Sánchez, M	Validity and reliability of the English version of the Diabetic Foot Self-Care Questionnaire: a cross-cultural adaptation	FRONTIERS IN PUBLIC HEALTH	3	Q2
F-14	Fuentes-Abolafio, IJ; Trinidad-Fernández, M; Ricci, M; Roldán-Jiménez, C; Gómez-Huelgas, R; Arjona-Caballero, JM; Escriche-Escuder, A; Bernal-López, MR; Pérez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic parameters related to functional capacity, fatigue, and breathlessness during the 6-min walk test in older adults with heart failure with preserved ejection fraction	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	2.9	D1
F-14	Trinidad-Fernández, M; González-Molina, F; Roldán-Jiménez, C; Vaes, P; González-Sánchez, M; Cuesta-Vargas, AI	New learning technique based on real-time kinematic feedback from an inertial sensor for manual therapy in shoulder joint: a randomised trial	BMC MEDICAL EDUCATION	2.7	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
F-14	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Pérez-Panero, AJ; Pérez-Belloso, AJ; Martínez-Barrios, FJ; González-Sánchez, M	Development and validation of a new questionnaire for the assessment of patients with diabetic foot disease: The Diabetic Foot Questionnaire (DiaFootQ)	PRIMARY CARE DIABETES	2.6	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
27	67%	37%	19%	76



Networks:

CA21152 (INE-CSC) -Implementation Network Europe for Cancer Survivorship Care

F-15. DATA AND KNOWLEDGE MANAGEMENT, INTEGRATION, AND ANALYSIS (KHAOS)

LR José F. Aldana Montes, Co-LR Ismael Navas Delgado

Priority line of research: (Big) data analytics (management, integration, and analysis of data and big data)

Other lines:

- 1. Clinical data management
- 2. Electronic medical records

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-15	Nematzadeh, H; García-Nieto, J; Aldana-Montes, JF; Navas-Delgado, I	Pattern recognition frequency-based feature selection with multi-objective discrete evolution strategy for high-dimensional medical datasets	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1
F-15	Hurtado, S; Antequera-Gómez, ML; Barba-González, C; Picornell, A; Navas-Delgado, I	e-Science workflow: A semantic approach for airborne pollen prediction	KNOWLEDGE-BASED SYSTEMS	7.2	Q1
F-15	Nematzadeh, H; García-Nieto, J; Navas-Delgado, I; Aldana-Montes, JF	Feature selection using a classification error impurity algorithm and an adaptive genetic algorithm improved with an external repository	KNOWLEDGE-BASED SYSTEMS	7.2	Q1
F-15	Picornell, A; Hurtado, S; Antequera-Gómez, ML; Barba-González, C; Ruiz-Mata, R; de Gálvez-Montañez, E; Recio, M; Trigo, MD; Aldana-Montes, JF; Navas-Delgado, I	A deep learning LSTM-based approach for forecasting annual pollen curves: Olea and Urticaceae pollen types as a case study	COMPUTERS IN BIOLOGY AND MEDICINE	7	D1
F-15	Segura-Ortiz, Adrian; Garcia-Nieto, Jose; Aldana-Montes, Jose F; Navas-Delgado, Ismael	Multi-objective context-guided consensus of a massive array of techniques for the inference of Gene Regulatory Networks.	Computers in biology and medicine	7	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
7	100%	86%	43%	42



Networks:

CA19134 (DKG) -Distributed Knowledge Graphs

GROUP F-19. ARTIFICIAL INTELLIGENCE AND SOCIAL RESEARCH

LR José Ignacio Peláez Sánchez.

Priority lines of research:

- Artificial Intelligence
- Big Data
- Data Sciences
- Decision Making
- Opinion Mining
- Digital Society
- Sociology of the family
- Comparative Social Structure

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
F-19	Falgueras-Cano, J; Falgueras-Cano, JA; Moya, A	ECA, a Python tool to study the evolution of life	SOFTWARE IMPACTS	1.3	Q3
F-19	Falgueras-Cano, J; Falgueras-Cano, JA; Moya, A	The influence of stochastic fluctuations on population dynamics: An in-silico approach	ECOLOGICAL MODELLING	2.6	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
2	0%	0%	0%	4



EMERGING GROUPS

FE-17. HandResearchTeam
LR Raquel Cantero Téllez. Co-LR Javier García Orza

Priority line of research: Use of new technologies and innovative treatments for hand injuries.

Other lines: New treatments in the conservative and post-surgical approach to hand injuries. Wrist and hand proprioception. Thumb conditions. Psychological aspects of hand injuries. Influence of traumatic, neurological, and rheumatic hand injuries on activities of daily living. Biomechanical and anatomical foundations of hand conditions. Effectiveness of the use of orthoses for objective and functional improvement of the hand. Study of the hand in musicians.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
FE-17	Medina-Porqueres, I; Martin-Garcia, P; Sanz-De-Diego, S; Reyes-Eldblom, M; Moya-Torrecilla, F; Mondragon-Cortes, R; Rosado-Velazquez, D; Gomez-Caceres, A	Platelet-Rich Plasma Injections in Chronic Lateral Ankle Instability: A Case Series	BIOMEDICINES	3.9	Q1
FE-17	Castro, C; Salazar-Frías, D; Szot, A; Laffarga, L; Rodríguez-Bailón, M	Hazard prediction and risky decision-making by drivers affected by non-hemineglect strokes	TRANSPORTATION RESEARCH PART F-TRAFFIC PSYCHOLOGY AND BEHAVIOUR	3.5	Q1
FE-17	Villalobos-García, A; Cruz-Gambero, L; Ucero-Lozano, R; Valdes, K; Cantero-Téllez, R	Kinesiophobia and Its Correlation with Upper Limb and Hand Functionality Among Individuals with Wrist/ Hand Injury: A Cross-Sectional Study	JOURNAL OF CLINICAL MEDICINE	3	Q1
FE-17	Gomez-Caceres, A; Tamimi-Mariño, I; Martinez-Malo, FJ; Idiart-Charrier, RP; Vieitez-Riestra, I; Medina-Porqueres, I	Outcomes of Over the Top Anterior Cruciate Ligament Reconstruction Associated with a Lateral Extra-Articular Tenodesis in Children	JOURNAL OF CLINICAL MEDICINE	3	Q1
FE-17	Cervera-Garvi, P; Galan-Hurtado, MH; Ortega-Avila, AB; Marchena-Rodriguez, A; Lopezosa-Reca, E; Castillo-Dominguez, A; Diaz-Miguel, S	Measurement properties of the Foot Function Index (FFI) questionnaire: A systematic review	CLINICAL REHABILITATION	2.6	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
19	63%	63%	5%	48



Active projects



Patents applied for

Networks:

CA21110 (NetwOArk) -Building an open European Network on OsteoArthritis research

FE-18. REHABILITATION, INNOVATION, AND QUALITY OF LIFE
LR Irene de Torres García. Co-LR: Francisco Luna Cabrera

Priority line of research: Neurorehabilitation, digital health, and technological innovation.

Other lines:

- 1. Cardiac rehabilitation
- 2. Respiratory rehabilitation
- 3. Mobility aids
- 4. Promotion of physical exercise

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
FE-18	González-Quevedo, D; Fernández-Arroyabe, N; Moriel-Garceso, DJ; Martínez-Malo, FJ; Martín-García, F; Arenas-Ros, J; Zambrana-Vico, S; Puerta-Migueles, L; Sáez-Casado, M; Sánchez-García, A; Tamimi, I	Reverse total shoulder arthroplasty for proximal humerus fractures: Primary or delayed after failed treatment?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
1	0%	0%	0%	2



Active projects



Clinical studies

Group FE-20. ARTIFICIAL INTELLIGENCE IN MEDICAL IMAGING
LR Francisco Sendra Portero

Lines of research:

- Development and application of artificial intelligence (AI) tools that assist in diagnostic imaging in the segmentation and automatic quantification of brain volumes, diagnosis of otosclerosis, and evaluation of tumors in the cervicofacial area.
- Research on New AI Applications in Medical Imaging: Explore and develop new applications of AI in various areas of medical imaging, such as prostate MRI, breast imaging, and osteoarticular radiology.
- Education and Training in AI Applied to Radiology: Leverage our teaching experience to develop educational programs that prepare professionals in the effective use of AI tools in clinical practice.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
FE-20	Terrón, CL; Alvarez, RL; Portero, FS	A problem-based learning experience in a radiology rotation for sixth-year medical students	RADIOLOGIA	1.1	Q3
FE-20	Aung, NWA; Bayarri, MS; Portero, FS	End-of-degree projects in radiology in Spanish universities	RADIOLOGIA	1.1	Q3
FE-20	Sendra-Portero, F; Lorenzo-Alvarez, R; Rudolphi-Solero, T; Ruiz-Gómez, MJ	The Second Life Metaverse and Its Usefulness in Medical Education After a Quarter of a Century	JOURNAL OF MEDICAL INTERNET RESEARCH	5.8	D1
FE-20	Castro, AA; Pinos, DD; Utrilla, VS; del Campo, JAO; Portero, FS; Ruiz-Gómez, MJ	Update in imaging tests used for the localization of parathyroid pathology	RADIOLOGIA	1.1	Q3
FE-20	Khan, AY; Luque-Nieto, MA; Saleem, MI; Nava-Baro, E	X-Ray Image-Based Real-Time COVID-19 Diagnosis Using Deep Neural Networks (CXR-DNNs)	JOURNAL OF IMAGING	2.7	Q3

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
12	67%	50%	17%	37



Active projects

ASSOCIATED GROUPS

FA-07. RESEARCH IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY
LR Antonio Leiva Gea

Lines of research:


- Chondral injuries, new therapies in orthopedic surgery and traumatology
- Autologous chondrocyte implantation.
- Osteosynthesis.
- Biomechanical optimization of orthopedic surgery and traumatology procedures.
- Elongation of bone segments in dysplasias.
- Infection in orthopedic surgery and traumatology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
FA-07	Savarirayan, R; Irving, M; Wilcox, WR; Bacino, CA; Hoover-Fong, JE; Harmatz, P; Polgreen, LE; Mohnike, K; Prada, CE; Kubota, T; Arundel, P; Leiva-Gea, A; Rowell, R; Low, A; Sabir, I; Huntsman-Labed, A; Day, J	Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life	GENETICS IN MEDICINE	6.7	D1
FA-07	Boero, S; Vodopiutz, J; Maghnie, M; de Bergua, JM; Ginebreda, I; Kitoh, H; Langendoerfer, M; Leiva-Gea, A; Malone, J; McClure, P; Mindler, GT; Popkov, D; Rodl, R; Rosselli, P; Verdoni, F; Vilenskii, V; Huser, AJ	International expert opinion on the considerations for combining vosoritide and limb surgery: a modified Delphi study	ORPHANET JOURNAL OF RARE DISEASES	3.4	Q2
FA-07	Lombardo-Torre, M; Espejo-Reina, A; Sevillano-Pérez, E; Verdejo-Parrilla, M; Espejo-Reina, MJ; Espejo-Baena, A	Graft Reorientation and Lateral Extra-articular Tenodesis in Revision Surgery for Persistent Rotational Instability of a Verticalized Anterior Cruciate Ligament Graft	ARTHROSCOPY TECHNIQUES	1.2	Q3
FA-07	Gómez-Palomo, JM; Rodríguez-Delourme, I; García-Vera, JJ; Irizar-Jiménez, SS; Huertas-Segador, PJ; Montañez-Heredia, E	Medial patellofemoral ligament reconstruction with an extensor hallucis longus allograft: a retrospective study of 45 cases	ACTA ORTHOPAEDICA BELGICA	0.5	Q4

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
4	50%	25%	25%	12



FA-08. OTOTECH
LR Alfonso Gago Calderón

Lines of research:

1. Research and development of technological devices for otology. Implantable hearing aids
2. Evaluation of hearing treatment quality.

Featured publications:

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF



EXTERNAL ASSOCIATED GROUPS

FA-16. INNOVATIVE THERAPIES AND NEW TECHNOLOGIES IN THE MUSCULOSKELETAL SYSTEM

LR Enrique Guerado Parra

Lines of research:

- 1. Clinical research in orthopedic and traumatological surgery
- 2. Genomics in diseases of the musculoskeletal system
- 3. Cellular processes in osteogenesis

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
FA-16	Cano, JR; Bogallo, JM; Ramirez, A; Guerado, E	Immediate management of a stable patient with unstable pelvis	EFORT OPEN REVIEWS	4.3	D1
FA-16	Sevillano-Perez, E; Prado-Novoa, M; Postigo-Pozo, S; Peña-Trabalon, A; Guerado, E	L4 fixation is not necessary in L5-Iliac spinopelvic fixation after trauma, but coadjutant transilio-transsacral fixation is	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2
FA-16	González-Quevedo, D; Fernández-Arroyabe, N; Moriel-Garceso, DJ; Martínez-Malo, FJ; Martín-García, F; Arenas-Ros, J; Zambrana-Vico, S; Puerta-Miguel, L; Sáez-Casado, M; Sánchez-García, A; Tamimi, I	Reverse total shoulder arthroplasty for proximal humerus fractures: Primary or delayed after failed treatment?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2
FA-16	González-Quevedo, D; Rubia-Ortega, C; Sánchez-Delgado, A; Moriel-Garceso, D; Sánchez-Siles, JM; Bravo-Bardaji, M; Garcia-de-Quevedo, D; Tamimi, I	Secondary osteoporosis prevention: three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients	AGING CLINICAL AND EXPERIMENTAL RESEARCH	3.4	Q2
FA-16	Tamimi, I; Gasca, M; Halbardier, A; Martin, S; Caballero, GM; Serrano, CL; Martin, E; Tamimi, F; González-Quevedo, D; de Quevedo, DG; Sobrino, B; Palop, B; Guerado, E; Lara, AP; Urdiales, C; de Gabriel, JMG	The treatment of bacterial biofilms cultivated on knee arthroplasty implants using the bioelectric effect	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY	4.3	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
9	56%	33%	11%	25.5



Active projects



Patents applied for

Area 7. Nanodiagnostics

G-01. BIOMEDICAL MAGNETIC RESONANCE LABORATORY (BMRL)
LR María Luisa García Martín

Lines of research:

- 1. Development of multifunctional magnetic nanomaterials for tumor theranostics.
- 2. Magnetic resonance metabolomics of tissue and biofluid biopsies for the identification of diagnostic, prognostic, and treatment response biomarkers.

Other lines:

- 1. Magnetic nanoparticles as contrast agents for magnetic resonance imaging (MRI).
- 2. Magnetic nanoparticles for magnetic hyperthermia therapy.
- 3. Multifunctional nanomaterials for multimodal imaging and/or tumor therapy.
- 4. Magic angle spinning MRI metabolomics for breast and brain tumor biopsies.
- 5. Biofluid metabolomics using high-resolution MRI in multiple sclerosis and other autoimmune diseases.
- 6. Biofluid metabolomics using high resolution MRI in cancer.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
G-01	Caro, C; Guzzi, C; Moral-Sánchez, I; Urbano-Gámez, JD; Beltrán, AM; García-Martín, ML	Smart Design of ZnFe and ZnFe@Fe Nanoparticles for MRI-Tracked Magnetic Hyperthermia Therapy: Challenging Classical Theories of Nanoparticles Growth and Nanomagnetism	ADVANCED HEALTHCARE MATERIALS	10	D1
G-01	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1
G-01	Gómez-González, E; Caro, C; Núñez, NO; González-Mancebo, D; Urbano-Gámez, JD; Garcia-Martin, ML; Ocaña, M	Sodium lanthanide tungstate-based nanoparticles as bimodal contrast agents for in vivo high-field MRI and CT imaging	JOURNAL OF MATERIALS CHEMISTRY B	6.1	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
G-01	Gómez-González, E; Núñez, NO; Caro, C; García-Martín, ML; Becerro, AI; Ocaña, M	Lanthanide vanadate-based nanoparticles as multimodal T1 1-T2 T 2 MRI contrast agent and NIR luminescent imaging probe	JOURNAL OF ALLOYS AND COMPOUNDS	5.8	D1
G-01	González-Mancebo, D; Becerro, AI; Caro, C; Gómez-González, E; Luisa, GMM; Ocaña, M	Nanoparticulated Bimodal Contrast Agent for Ultra-High-Field Magnetic Resonance Imaging and Spectral X-ray Computed Tomography	INORGANIC CHEMISTRY	4.3	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
8	25%	88%	38%	45



Active projects

Area 8. Nanosystems and advanced therapies

H-02. SKELETAL BIOMEDICINE LABORATORY
LR Iván Durán Jiménez. Co-LR Fabiana Csukasi

Priority line of research: Precision medicine in skeletal diseases.

Other lines:

- 1. Study of disease mechanisms and precision therapies in skeletal dysplasias
- 2. Study of skeletal stem cell differentiation and metabolism
- 3. Development of a transcriptomic atlas of the skeleton
- 4. Gene therapy and gene editing aimed at bone diseases.
- 5. Study of the influence of cellular stress and inflammation on the skeleton
- 6. Skeletal tissue engineering. Development of biomaterials and organoids.
- 7. Therapies based on mesenchymal stem cell secretomes.
- 8. Use of zebrafish as a model for skeletal diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
H-02	Fernandez-Bastit, L; Cano-Terriza, D; Caballero-Gomez, J; Beato-Benitez, A; Fernandez, A; Garcia-Parraga, D; Domingo, M; Sierra, C; Canales, R; Borragan, S; de la Riva-fraga, M; Molina-Lopez, R; Cabezon, O; Puig-Ribas, M; Espunyes, J; Vazquez-Calero, DB; Vergara-Alert, J; Garcia-Bocanegra, I; Segales, J	Survey of severe acute respiratory syndrome coronavirus 2 in captive and free-ranging wildlife from Spain	VETERINARY RESEARCH	3.7	D1
H-02	Vega-Granados, K; Escobar-Ibarra, P; Palomino-Vizcaino, K; Cruz-Reyes, J; Valverde-Guillén, P; Latorre-Redoli, S; Caneda-Santiago, CT; Mari-Beffa, M; Romero-Sánchez, LB	Hexyltrimethylammonium ion enhances potential copper-chelating properties of ammonium thiomolybdate in an in vivo zebrafish model	ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS	3.8	Q1
H-02	Kot, A; Chun, C; Martin, JH; Wachtell, D; Hudson, D; Weis, M; Marks, H; Srivastava, S; Eyre, DR; Duran, I; Zieba, J; Krakow, D	Loss of the long form of Plod2 phenocopies contractures of Bruck syndrome-osteogenesis imperfecta	JOURNAL OF BONE AND MINERAL RESEARCH	5.1	Q1

Group	Authors	Article Title	Source Title	IF	Q/D
H-02	Figueroa, FL; Castro-Varela, P; Vega, J; Losantos, R; Peñín, B; López-Cóndor, L; Pacheco, MJ; Redoli, SL; Mari-Beffa, M; Abdala-Díaz, R; Sampedro, D	Novel synthetic UV screen compounds inspired in mycosporine-like amino acids (MAAs): Antioxidant capacity, photoprotective properties and toxicity	JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY	3.9	Q1
H-02	Moncayo-Donoso, MA; Garzón-Alvarado, DA; Visser, RR; Ratia, JB; Vaca-González, JJ; Duque, MRF	Effects Of Biophysical Stimuli On Osteogenic Differentiation Of Mesenchymal Stem Cells	BIOMEDICAL ENGINEERING-APPLICATIONS BASIS COMMUNICATIONS	0.6	Q4

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
5	0%	80%	20%	17



Networks:

CA22170 (TENET) - TEndon Regeneration NETwork
RD16/0011/0022 Cell Therapy Network - TerCel (ISCIII)

H-03. DEVELOPMENT AND CARDIOVASCULAR DISEASE

LR Jose María Pérez Pomares

Priority line of research: Study of the embryonic foundations of cardiovascular disease. Study of the cellular and molecular mechanisms of cardiovascular pathophysiology

Other lines:

- 1. Embryonic cardiovascular development.
- 2. Cardiovascular repair and regeneration.
- 3. Fibrosis in the context of cardiomyopathies.
- 4. Cardiovascular histopathology.
- 5. Differentiation of cardiovascular progenitor cells.
- 6. Vascular pathology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
H-03	Yu, DQ; Ren, YD; Uesaka, M; Beavan, AJS; Muffato, M; Shen, JY; Li, YX; Sato, I; Wan, WT; Clark, JW; Keating, JN; Carlisle, EM; Dearden, RP; Giles, S; Randle, E; Sansom, RS; Feuda, R; Fleming, JF; Sugahara, F; Cummins, C; Patricio, M; Akanni, W; D'Aniello, S; Bertolucci, C; Irie, N; Alev, C; Sheng, GJ; de Mendoza, A; Maeso, I; Irimia, M; Fromm, B; Peterson, KJ; Das, S; Hirano, M; Rast, JP; Cooper, MD; Paps, J; Pisani, D; Kuratani, S; Martin, FJ; Wang, W; Donoghue, PCJ; Zhang, YE; Pascual-Anaya, J	Hagfish genome elucidates vertebrate whole-genome duplication events and their evolutionary consequences	NATURE ECOLOGY & EVOLUTION	14.1	D1
H-03	Pascual-Anaya, J; Donoghue, PCJ	Hagfish genome sequence sheds light on early vertebrate genome evolution	NATURE ECOLOGY & EVOLUTION	14.1	D1
H-03	Cano, E; Schwarzkopf, J; Kanda, M; Lindberg, EL; Hollfinger, I; Pogontke, C; Braeuning, C; Fischer, C; Huebner, N; Gerhardt, H	Intramyocardial Sprouting Tip Cells Specify Coronary Arterialization	CIRCULATION RESEARCH	16.5	D1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
3	100%	100%	100%	45



Active projects



Patents applied for

EMERGING GROUP

HE-01. CELL REPROGRAMMING (iPSCs) AND CELL MODELS OF DISEASE FOR BIOMEDICAL APPLICATIONS

LR Elena González Muñoz

Priority line of research: Cellular reprogramming (iPSCs) and generation of cellular models of disease for biomedical applications.

Other lines: Regenerative medicine and personalized medicine

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D
HE-01	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1
HE-01	Algarra, M; Gonzalez-Muñoz, E	Efficient and scalable gene delivery method with easily generated cationic carbon dots	BIOLOGICAL PROCEDURES ONLINE	3.7	Q2
HE-01	Algarra, M; Soto, J; Pino-González, MS; Gonzalez-Munoz, E; Ducic, T	Multifunctionalized Carbon Dots as an Active Nanocarrier for Drug Delivery to the Glioblastoma Cell Line	ACS OMEGA	3.7	Q2
HE-01	Rodriguez, MDB; Muñoz, EG; Moore, T	Oligodendrocyte-specific expression of PSG8-AS1 suggests a role in myelination with prognostic value in oligodendroglioma	NON-CODING RNA RESEARCH	5.9	Q1

Scientific production and research activity

Articles	%Art. Led	% Q1	% D1	IF
4	25%	50%	25%	21



Active projects



Patents applied for

Networks:

- CA21151 (HAPLO-iPS) - Generation of Human Induced Pluripotent Stem Cells from Haplo-Selected Cord Blood Samples
- CA20140 (CorEuStem) - The European Network for Stem Cell Core Facilities

FUNDING

6

The following graph shows changes in the revenue obtained by IBIMA Plataforma BIONAND over the last 5 years. This revenue is the sum of competitive and non-competitive grants (donations, agreements, and service provision agreements) obtained by the Institute in addition to the invoicing generated by the clinical studies performed.




Figure 53: Changes in revenue obtained (2020–2024)

As seen in the figure, the revenue obtained by or awarded to IBIMA has increased or remained steady over the years. This indicates that the institute is an established project with a clear vocation for growth. It generates synergies that translate into sustained growth.




Figure 54: Changes in competitive versus non-competitive revenue (2020–2024)

Comparing competitive and non-competitive revenue obtained, it can be observed that both types of revenue have increased or remained steady, with similar figures for both revenue types. On analyzing expenditures, the proportion is the same, though non-competitive revenue was slightly lower, as shown in the following table for the 2024 fiscal year:




Figure 55: Revenue spent 2024: Competitive vs non-competitive

In turn, the following shows revenue spent broken down by its nature:

Description of funding body	Budget 2024	Spent 2024	%
Competitive	9,800,045	9,246,809	46%
Competitive Private Grants	387,436	446,070	2%
CSYC	564,336	199,373	1%
CUII	346,013	913,838	5%
FPS	97,000	56,330	0%
International EUROPEAN	831,533	555,863	3%
ISCIII	5,848,360	5,321,105	26%
MINISTRY OF ECONOMY, TRADE, AND BUSINESS	529,175	432,251	2%
MINISTRY OF EDUCATION AND VOCATIONAL TRAINING	34,821	22,764	0%
MINISTRY OF HEALTH, SOCIAL SERVICES, AND EQUALITY	45,050	39,830	0%
Other Revenue	3,061	17,337	0%
Other public bodies	0	22	0%
SAS	1,113,261	1,242,025	6%
Non-competitive	8,736,149	10,990,566	54%
CSYC	300,000	300,000	1%
CUII	300,000	300,000	1%
Donations/Agreements	1,177,550	1,198,975	6%
Clinical Studies	5,424,933	7,714,048	38%
Provision of Services	993,666	937,543	5%
SAS	120,000	120,000	1%
UMA	420,000	420,000	2%
Total, general	18,536,194	20,237,374	100%

Eighty-five percent of the resources are allocated to research and the rest to funding management and scientific structures:

REVENUE SPENT 2024: RESEARCH VERSUS STRUCTURES




Figure 56: Revenue spent 2024: Research versus Structures

Destination of funding	Budget 2024	Spent 2024	%
Structural	2,920,484	3,029,097	15%
Research	15,615,710	17,208,278	85%
Total	18,536,194	20,237,374	100%

The sources of funding for structural revenue are as follows:

Description of structural revenue	Budget 2024	Spent 2024	%
Competitive Private Grants	21,752	40,508	1%
CSYC	352,723	326,564	11%
CUII	326,051	427,822	14%
Donations/Agreements	107,050	108,631	4%
FPS	10,696	5,954	0%
International EUROPEAN	115,944	55,536	2%
ISCIII	787,717	878,186	29%
MINISTRY OF ECONOMY, TRADE, AND BUSINESS	125,568	60,476	2%
MINISTRY OF EDUCATION AND VOCATIONAL TRAINING	381	245	0%
MINISTRY OF HEALTH, SOCIAL SERVICES, AND EQUALITY	5,876	5,452	0%
Other Revenue	3,061	17,337	1%
Other public bodies	0	0	0%
Provision of Services	303,666	339,768	11%
SAS	340,000	342,615	11%
UMA	420,000	420,000	14%
Total	€2,920,484	€3,029,097	100%

The revenue that funds the structural expenses of IBIMA's budget are shown below:

Operating expenses	2024 BUDGET	12/31/2024	VAR	Funding source	Total
Personnel Expenditures	1,138,601	1,641,083	502,482	HR grants and cofunding	794,601
				Member contributions	846,482
Purchasing	382,205	104,886	359,822	Invoicing for services	104,886
External Services	953,079	1,070,455	-86,836	Indirect costs (OH)	847,259
				Member contributions	223,196
Central Services Operating Expenses (Structure Cost)	187,216	0	-223,120		
IBIMA Plataforma BIONAND Plan Grants	258,297	212,114	22,858	Invoicing for services	142,351
				Member contributions	70,321
Total Operating Expenses:	2,919,398	3,028,538	123,555	Total Operating Expenses:	3,029,097

The expenses of the profit and loss account are shown in the following chart:




Figure 57: Revenue spent 2024

Balance sheet of the managing entity:

ASSET	2024	2023
A) NON-CURRENT ASSETS	18,128,481	17,867,067
I. Intangible assets	1,143,717	1,033,702
III. Tangible assets	11,059,010	11,033,452
VI. Long-term financial investments	5,925,754	5,799,913
B) CURRENT ASSETS	57,028,306	47,924,354
II. Inventory	80,598	34,281
IV. Users and other debtors of the institute's activity	3,690,025	2,917,108
V. Trade debtors and other accounts receivable	11,195,738	8,387,766
VII. Short-term financial investments	37,509,732	25,970,796
VIII. Short-term accruals	35,266	28,228
IX. Cash and other cash equivalents	4,516,947	10,586,175
TOTAL ASSETS (A+B)	75,156,787	65,791,421

NET EQUITY AND LIABILITIES	2024	2023
A) NET EQUITY	14,293,911	14,254,388
A-1) Equity	1,148,566	1,148,568
I. Endowment/Social Fund	6,010	6,010
II. Reserves	1,142,556	776,688
IV. Fiscal year surplus	0	365,870
A-3) grants, donations, and bequests received	13,145,345	13,105,820
I. Grants	6,593,693	6,999,933
III. Donations and bequests	6,551,652	6,105,887
B) NON-CURRENT LIABILITIES	8,266,698	8,374,823
I. Long-term reserves	443,639	440,874
II. Long-term debts	7,823,059	7,933,949
C) CURRENT LIABILITIES	52,596,178	43,162,210
II. Short-term reserves	33,142	0
III. Short-term debts	28,065,974	23,030,882
VII. Trade creditors and other accounts payables	2,384,587	2,921,490
VIII. Short-term accruals	22,112,475	17,209,838
TOTAL NET EQUITY AND LIABILITIES (A+B+C)	75,156,787	65,791,421

EDUCATION

7

Doctoral Programs of the University of Málaga for the 2023–2024 school year, regulated by Royal Decree 99/2011 dated January 28, 2011 and modifications to Royal Decree 576/2023, dated July 4, 2023.

Biomedicine, Translational Research, and New Technologies in Health

Lines of Research:

- Cardiometabolic and Renal Disease Research
- Systemic Diseases
- Advances in Skin, Inflammatory, and Oncologic Disease Research
- Molecular Biology of Cancer. Its Importance in Diagnosis and Treatment
- Genomics Applied to Medicine
- Clinical and Experimental Pharmacology, New Therapies and Technologies
- Basic and Applied Neuroscience
- Clinical, Technological, and Experimental Research in Radiobiology, Medical Imaging, Hearing, and Vision.
- Epidemiology and Public Health
- Surgery, Obstetrics, and Gynecology.

Advanced Biotechnology

Lines of Research:

- Bioengineering and tissue regeneration
- Neurogenesis
- Glutamatergic neurotransmission
- Plant-pathogen interaction
- Plant biotechnology
- Improvement and biotechnology of fruit and vegetable species
- Biotechnology of aquatic systems
- Electrophysiology of aquatic plants

Cellular and Molecular Biology

Lines of Research:

- Molecular biology
- Systems biology
- Neurobiology
- Microbiology
- Developmental biology

Health Sciences

Lines of Research:

- Prevention of cardiovascular disease and obesity
- Chronicity, care, dependency, and evaluation of health and social-health services
- Clinimetrics and physical therapy
- Biomechanics and chronic musculoskeletal processes
- Mental and occupational health in social, health, and emergency contexts

Chemistry and Chemical Technologies. Materials and Nanotechnology

Lines of Research:

- Biochemistry and organic chemistry
- Chemical-physical methods in materials science and technology
- Functional materials
- Materials and processes for sustainability, energy, and the environment
- Chemical engineering and environmental technology

Psychology

Lines of Research:

- Biological underpinnings of behavior.
- Psychology of basic processes
- Methodological applications Methodology in Social and Health Sciences.
- Developmental and educational psychology
- Psychology of social intervention
- Clinical and health psychology
- Physical activity, performance, management, and health

Information Technology

Lines of Research:

- Software Engineering
- Security, Networks, and Embedded Systems
- Bioevolutionary and Bioinspired Algorithms
- Parallel Architectures and Algorithms
- Computational Intelligence
- Intelligent Systems

Master’s Degrees at the University of Málaga in the 2023–2024 academic year

Health Sciences

- Master’s degree in biomedical research on diabetes and obesity.
- Master’s degree in human microbiota: research, clinical practice, and health.
- Master’s degree in biomedical research: dialog between clinical practice and molecules.
- Interdisciplinary master’s degree in palliative care.
- Master’s degree in morphofunctional assessment of disease-related malnutrition.
- Master’s degree in physical therapy in pelvic floor dysfunction.
- Master’s degree in adult and pediatric critical care nursing.
- Master’s degree in emotional intelligence and positive psychology.

Other University Expert Certificates in which IBIMA Plataforma BIONAND researchers have participated are the following:

- Interdisciplinary University Expert Certificate in Palliative Care.
- University Expert Certificate in Ethics for Healthcare Professionals.
- University Expert Certificate in clinical research and clinical trials monitoring.
- University Expert Certificate in techniques and procedures in medical emergencies.
- University Expert Certificate in therapeutic exercise and functional rehabilitation in physical therapy.
- University Expert Certificate in child clinical neuropsychology.

DOCTORAL THESES

The following table lists the theses supervised by IBIMA Plataforma BIONAND researchers:

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
A-01	Ana Aragón González	HUMAN-DERIVED BLOOD-BRAIN BARRIER IN VITRO MODELS AS RELIABLE TOOLS FOR RESEARCH AND THERAPEUTICS	Yes	María Yolanda De Diego Otero	Inmaculada Bellido Estévez
A-02	Cristina García García	VALORACIÓN MORFOFUNCIONAL® DE LA DESNUTRICIÓN RELACIONADA CON LA ENFERMEDAD: CONCEPTUALIZACIÓN, VALIDACIÓN DE EXPERTOS, MANUAL CIENTÍFICO, IMPLEMENTACIÓN EN PRÁCTICA CLÍNICA HABITUAL (ESTUDIO ANYVIDA) Y ANÁLISIS DE LÍNEAS FUTURAS DE INVESTIGACIÓN	No	Jose Manuel García Almeida	Francisco J. Tinahones Madueño
A-02	José Ignacio Martínez Montoro	EFFECTOS DEL CONSUMO MODERADO DE BEBIDAS FERMENTADAS CON DISTINTO CONTENIDO EN POLIFENOLES EN LA MICROBIOTA INTESTINAL	No	Francisco J. Tinahones Madueño	Mora Murri Pierri
A-03	Paula Bardón De Tena	CARACTERIZACIÓN EPIDEMIOLÓGICA Y MOLECULAR DEL VIRUS DE LA HEPATITIS A	No	Silvana Teresa Tapia Paniagua	Encarnación Clavijo Frutos
A-03	Dina Medina Vera	EVALUACIÓN DEL EFECTO TERAPÉUTICO DEL D-PINITOL COMO MODIFICADOR MULTIFACÉTICO EN EL CURSO DE LA ENFERMEDAD DE ALZHEIMER	Yes	Fernando Rodríguez De Fonseca	Cristina Rosell Del Valle

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
A-03	Ana Guijarro Contreras	CALIDAD DE VIDA RELACIONADA CON LA SALUD, SATISFACCIÓN Y RESULTADOS TRAS MINIESTERNOTOMÍA FRENTE A ESTERNOTOMÍA COMPLETA EN SUSTITUCIÓN VALVULAR AÓRTICA. RANDOMIZED CLINICAL TRIAL. (CALIDAD-SVAo TRIAL).	No	Manuel Francisco Jiménez Navarro	Emiliano Andres Rodríguez Caulo
A-06	Salvador Vargas Molina	EFFECTOS DE LA DIETA CETOGÉNICA EN EL RENDIMIENTO, LA SALUD Y LA COMPOSICIÓN CORPORAL EN PARTICIPANTES ENTRENADOS EN FUERZA	No	Javier Benítez Porres	
A-07	Laura Santiago Corral	EFFECTO NEFROPROTECTO DE 3,4-DIHIDROXIFENILGLICOL E HIDROXITIRO SOL EN LA NEFROPATÍA DIABÉTICA EXPERIMENTAL	No	José Antonio González Correa	Jesús Miranda Páez
A-09	José Manuel Ramírez Torres	CARGA ATROSCLERÓTICA SUBCLÍNICA EN HIPERTENSOS NO DIABÉTICOS SEGUIDOS EN ATENCIÓN PRIMARIA. ESTUDIO TOBRAGIM	No	Pedro Valdivielso Felices	Miguel Ángel Barbancho Fernández
A-10	Juan Carlos Benavente Marín	IDENTIFICACIÓN DE ACTIVIDADES DE INTENSIDAD VIGOROSA CON ACELEROMETRÍA EN LA ACTIVIDAD FÍSICA DIARIA INFANTIL Y SU ASOCIACIÓN CON LAS CLASES DE EDUCACIÓN FÍSICA	No	Julia Wörnberg	Napoleón Pérez Farinós
A-19	Elena Godoy Molina	VALIDACIÓN DE UNA ESCALA PARA LA IDENTIFICACIÓN Y CLASIFICACIÓN DEL PACIENTE PEDIÁTRICO CRÓNICO COMPLEJO Y DESARROLLO DE UNA PLATAFORMA PARA LA PLANIFICACIÓN PERSONALIZADA DE CUIDADOS	No	Victor Manuel Navas López	Esmeralda Núñez Cuadros
A-23	Edith Mészáros Crow	LAS INTERVENCIONES PSICOSOCIALES REDUCEN EL CORTISOL EN PACIENTES CON CÁNCER DE MAMA	No	Mario Gutiérrez Bedmar	
AA-22	Ángela Repiso Guardoño	LA CEFALÉA TENSIONAL CRÓNICA Y SU RELACIÓN CON EL CRECIMIENTO CRANEOMANDIBULAR SEGÚN LA CEFALOMETRÍA DE BJÖRK JARABAK	No	Juan Antonio Armenta Peinado	Noelia Moreno Morales
AA-24	Rafael Campos Arjona	PRONÓSTICO DE LA CIRUGÍA DE REPARACIÓN MITRAL EN INSUFICIENCIA MITRAL FUNCIONAL	No	Jorge Rodríguez Capitán	Gemma Sánchez Espín

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
B-01	Alfonso Alba Bernal	NUEVAS ESTRATEGIAS PARA LA DETECCIÓN ULTRASENSIBLE DE COMPONENTES TUMORALES CIRCULANTES EN PACIENTES CON CÁNCER DE MAMA LOCALIZADO	No	Iñaki Comino Méndez	Emilio Alba Conejo
B-01	Aurora Laborda Illanes	NUEVOS BIOMARCADORES EN CÁNCER DE MAMA: MICROARNS, MICROBIOTA Y VÍA MELATONÉRGICA	Yes	M. Isabel Queipo Ortuño	Emilio Alba Conejo
B-05	María Garrido Barros	PRECISION IMMUNOTHERAPY IN METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT BLOCKADE THERAPY	Yes	María Isabel Barragán Mallofret	Elisabeth Pérez Ruiz
B-12	Guillermo López García	ADVANCING DEEP LEARNING SOLUTIONS IN THE ERA OF PRECISION MEDICINE: FROM OMICS DATA TO CLINICAL NARRATIVES	Yes	Francisco Javier Veredas Navarro	José Manuel Jerez Aragonés
C-01	Fabiola Ávila Gámiz	EJERCICIO FÍSICO Y ENTRENAMIENTO NEUROCOGNITIVO COMO FACTORES MODULADORES DE LAS ASOCIACIONES COCAÍNA- CONTEXTO: PAPEL DE LA NEUROGÉNESIS HIPOCAMPAL ADULTA	Yes	Luis Javier Santín Nuñez	David Ladrón De Guevara Miranda
C-06	Jesús Herrera Imbroda	ACILETANOLAMIDAS COMO BIOMARCADORES DE TRASTORNO POR USO DE SUSTANCIAS: INFLUENCIA DE LA MEDICACIÓN PSICOTRÓPICA	No	Fernando Rodríguez De Fonseca	Fermin Mayoral Cleries
C-06	María Flores López	EVALUACIÓN DEL SISTEMA DEL ÁCIDO LISOFOSFATÍDICO COMO POTENCIAL BIOMARCADOR EN LOS TRASTORNOS POR USO DE ALCOHOL Y COCAÍNA	Yes	Antonia M. Serrano Criado	Francisco Javier Pavón Morón
C-07	Marta González García	MECANISMOS SUPRAENCEFÁLICOS INVOLUCRADOS EN EL CONTROL DE LA ACTIVIDAD LARÍNGEA	Yes	Manuel Víctor López González	Marc Stefan Dawid Milner
C-13	Yolanda Pedrero Martín	INFLUENCIA DE LOS FACTORES PSICOSOCIALES SOBRE EL DOLOR Y DISCAPACIDAD EN PACIENTES CON LATIGAZO CERVICAL	No	Alejandro Luque Suarez	Jose Miguel Morales Asencio
C-16	Laura Baños Cándenas	IMPACTO PERINATAL DE LA METRORRAGIA DEL PRIMER TRIMESTRE	Yes	Ernesto González Mesa	Inmaculada Bellido Estévez

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
C-16	Cristina Espada González	DISEÑO Y APLICACIÓN DE UN MODELO DE SCORE PARA LA VALORACIÓN POSTQUIRÚRGICA DE LAS BANDAS LIBRES DE TENSIÓN TRANSOBTURATRIZ PARA LA INCONTINENCIA DE ORINA DE ESFUERZO.	Yes	Jesús Salvador Jiménez López	Ernesto González Mesa
D-04	Rafael Nuñez Serrano	ESTUDIOS ÓMICOS DE LA RESPUESTA DE TOLERANCIA INDUCIDA TRAS INMUNOTERAPIA ESPECÍFICA DE ALÉRGENO EN UN MODELO DE ANAFILAXIA A MELOCOTÓN	No	Lina Mayorga Mayorga	Francisca Gómez Pérez
D-05	José Mª Pinazo Bandera	RE-EXPOSICIÓN POSITIVA EN HEPATOTOXICIDAD: ANÁLISIS DE CASOS EN DOS REGISTROS PROSPECTIVOS SEGÚN DEFINICIONES EXISTENTES Y PROPUESTA DE NUEVA DEFINICIÓN	No	Miren García Cortés	Raul Jesus Andrade Bellido
D-05	Flores Martín Reyes	DIVERSIDAD BACTERIANA E IMPLICACIÓN DE LAS VESÍCULAS EXTRACELULARES FECALES EN LA ENFERMEDAD DE CROHN	Yes	Cristina Rodríguez Díaz	Eduardo García Fuentes
DE-08	Francisco J. León Díaz	ANÁLISIS DE LA PERFUSIÓN COMBINADA DE HISTIDINA- TRIPTÓFANO-KETOGLUTARATO Y SOLUCIÓN DE WISCONSIN EN EL TRASPLANTE HEPÁTICO	No	José Luis Fernández Aguilar	Julio Santoyo Santoyo
DE-08	Javier González Cano	LOS RESULTADOS PERIOPERATORIOS Y ONCOLÓGICOS DE UN PROGRAMA DE TRATAMIENTO DE LA OCLUSIÓN NEOPLÁSICA DE COLON IZQUIERDO CON STENT PUENTE Y COLECTOMÍA DE INTERVALO REALIZADA POR CIRUJANOS DE TRAUMA Y CIRUGÍA DE URGENCIAS SON EQUIPARABLES A LOS OBTENIDOS POR CIRUJANOS COLORRECTALES EN EL ÁMBITO ELECTIVO: EXPERIENCIA DE UN CENTRO DE TERCER NIVEL	No	José Manuel Aranda Narváez	Julio Santoyo Santoyo
DE-08	Rosa Pérez Rodríguez	INFLUENCIA DE LA PERFUSIÓN ABDOMINAL NORMOTERMICA -ASISTOLIA FRENTE A MUERTE ENCEFALICA-EN LOS RESULTADOS A CORTO Y MEDIO PLAZO EN EL TRASPLANTE HEPATICO	No	Belinda Sánchez Pérez	Julio Santoyo Santoyo

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
F-04	Andrés Galeote Luque	ADVANCES IN 3D RANGE SENSORS ODOMETRY FOR MOBILE ROBOTICS	Yes	José Raúl Ruiz Sarmiento	Javier González Jiménez
F-04	Mª de las Mercedes García Salguero	CERTIFIABLE ALGORITHMS FOR 3D COMPUTER VISION PROBLEMS	Yes	Javier González Jiménez	
H-03	Ernesto Marín Sedeño	EPICARDIAL DEVELOPMENT REVISITED: PROEPICARDIAL HETEROGENEITY	Yes	José María Pérez Pomares	Adrián Ruiz Villalba

IBIMA Plataforma BIONAND Educational Program

Educational activities organized by IBIMA in 2024:

- Course on science communication aimed at key non-scientific actors: “Researchers’ skills on communicating science to the public.”
- Do the new obesity drugs really work?
- Pint Of Science 2024.
- Leadership, Biomedical Research, and Clinical Context: Difficulties and Opportunities.
- How to start a biomedical research and teaching career at the university.
- From a research career to the pharmaceutical industry.
- Guidance and tips for preparing the data management plan for FIS projects.
- III Conference on Primary Care.
- II Conference on Nursing.
- IBIMA-RARE Conference.
- I HRUM R&D&I Conference.
- I Clinical Research Academy, Antequera.
- Farmaindustria Conference.
- XXIII Conferences on Advances in Hepatology 2024.
- Open-house for different educational centers
- Women in neuroscience. Sowing the seeds of the future.
- European Researchers’ Night 2024.
- International conferences of professionals in the field of allergy research: Role of B cells in immune tolerance to allergens, speaker: Mubeccel Akdis, and Epithelial barrier theory and development of allergic and autoimmune diseases, speaker: Ali Cezmi Akdis
- Talk: Large-scale implementation of polygenic risk scores for preventive health care.
- Single Cell Seminar.
- Seminar: Single Cell Seminars: SeekGene Technology.
- Seminario Stemcell ‘Unraveling the Potential of hPSC and hPSC-derived Models’.
- Genome & cellular regulation.

- 26th Edition of the online course on Good Clinical Practice Standards.
- XVII Edition of the online course on Good Laboratory Practices.
- Ethical and regulatory methodological aspects of clinical trials.
- Methodological, ethical, and regulatory aspects of research projects.
- Basic use of R.
- Introduction to cell-sorter organized by the Cultures ECAI.
- Genomic analysis interpretation course.
- Basic and advanced aspects of proteomics. Proteomics ECAI.
- Transcriptome analysis interpretation course.
- Course on interpretation of proteomic/metabolomic analysis.
- Basic statistics in biomedical research and research methodology.
- Advanced statistics in biomedical research and methodology.
- Clinical application of epigenomics. Epigenomic Epidemiology-Advanced Epigenomics: techniques and their application.
- Genomics ECAI. General information.
- Training session: Applications of the Nanoimaging, Flow Cytometry, and Histology ECAIs.
- IBIMA clinical research support conference.
- Data protection meeting (GDPR).
- Conference on Innovation and Technology Transfer.
- Innohealth-Innovation Conference.
- Introductory conference on the Chemsex phenomenon.
- II Conference on Endometriosis.
- Talk on the new Ethics Committee information system.
- Informational meetings about the MARIE SKLODOWSKA-CURIE – POSTDOCTORAL PROGRAM.
- First aid course.
- Immunological basis of immune-mediated gastrointestinal diseases and their therapeutic management.
- ‘MSCA-PF Candidate Search through the MSCA-NET Platform’ workshop.
- University Expert Certificate in Clinical Research and Clinical Trials Monitoring from the University of Málaga.
- Creation of a Research Protocol Workshop Course.
- World Health Day: “Health First.”

The background is a solid teal color. Scattered across the page are several abstract, elongated, leaf-like or petal-like shapes in a lighter shade of teal. These shapes are oriented in various directions, some pointing towards the top, some towards the bottom, and some towards the sides. They have a soft, blurred appearance, giving the impression of floating or falling.

COMMUNICATIONS

8


In 2024, IBIMA Plataforma BIONAND has strengthened its presence on social networks through an organic and professional strategy on Facebook, Instagram, LinkedIn, and X.

Sixty press releases were published in coordination with the Foundation for Progress and Health, the University of Málaga, and the Regional University Hospital of Málaga and Virgen de la Victoria University Hospital. A certain degree of impact on the media has been achieved, with more than 1,000 media mentions. The reach, interaction, and performance of the social media profiles, as well as the main repercussions in the written and digital press, are listed below.

IMPACT ON SOCIAL NETWORKS:


FACEBOOK:

- Total followers: 1,989
- Cumulative scope: 19,200
- Visualizations: 25,300
- Interactions with content: 1,812
- Clicks on the link: 186
- Visits to the profile: 6,281
- New followers: +119
- Most popular content: photos (82), videos (12), links (19), reels (7)




INSTAGRAM:

- Followers: +326
- Total views: 71,937 (100% organic content)
- Scope: 18,200
- Interactions: 1,348
- Visits to the profile: 4,474
- Clicks on the link: 197
- Publications made: 121
- Stories published: 177
- Best performing formats: 'Did you know?' publications, visual content from researchers, and informational content



LINKEDIN:

- Account active as of April 17, 2024
- Ongoing publications with institutional, scientific, and informative content
- Estimated total views: more than 160,000
- High average interaction rate (several peaks >10%)
- Accumulated clicks: over 5,000
- Reactions: more than 2,000
- Publications with high organic virality rate





X (TWITTER):

- Constant activity: 2 publications per week
- Current followers: 4,296
- Consolidated channel for rapid institutional communication

IMPACT ON THE MEDIA:

- Press releases issued: 60
- Press releases published on sspa.juntadeandalucia.es: 35
- Total media impact: 1,168 news items (digital and paper)
- Impacts in the written press: 95 direct references to IBIMA
- Impacts in Diario SUR: 57 news items
- Impacts in La Opinión de Málaga: 58 news items
- Impacts in Málaga Hoy: 58 news items
- Impacts in Europa Press: 125 news items
- Impacts in El País: 18 news items
- A total of 15 media interventions on a Youtube channel (IBIMA TV) mainly on two programs: Salud Ahora and Canalsur TV.
- Coordination with Progress and Health Foundation, UMA, and public hospitals in Málaga.

	TOTAL IMPACTS	IMPACTS ON PAPER MEDIA
IBIMA	1,168	95
BIONAND (WITHOUT IBIMA)	775	32
BIOMEDICAL RESEARCH INSTITUTE OF MÁLAGA, NOT IBIMA	1266	69
BIOMEDICAL INSTITUTE OF MALAGA	56	10
IBIMA BIONAND	804	33
BIOMEDICINE INSTITUTE OF MALAGA	255	18
IBIMA Plataforma BIONAND	29	762



Some of the most significant news items of 2024:

- Is air pollution identified as a risk factor in cardiovascular and metabolic diseases? <https://www.ciberisciii.es/noticias/identifican-la-contaminacion-atmosferica-como-factor-de-riesgo-en-enfermedades-cardiovasculares-y-del-metabolismo>
- ASAMMA Donation <https://www.laopiniondemalaga.es/malaga/2024/02/20/registran-cancer-mama-metastasis-malaga-98402256.html>
- Alianza ROCHE Conference <https://www.roche.es/actualidad/notas-prensa/2024/febrero/neurologia-alianza-andalucia-roche>
- IBIMA-Rare Rare Diseases Conference <https://www.uma.es/facultad-de-ciencias/eventos/x-jornada-interdisciplinar-sobre-avances-en-enfermedades-raras/>
- Press Release on gestational diabetes https://www.malagahoy.es/malaga/Investigadores-IBIMA-alternativa-inyecciones-insulina-diabetes-gestacional_0_1885912118.html
- Farmaindustria conference <https://www.lavanguardia.com/sociedad/20240424/9602540/fomentan-conocimiento-investigacion-biomedica-jovenes-agenciaslv20240424.html>
- Diabetes Award Francisco J. Tinahones <https://www.diariosur.es/malaga/catedratico-francisco-tinahones-premio-mejor-investigador-senior-diabetes-espana-20240412152239-nt.html>
- ASAMMA Donation https://www.malagahoy.es/malaga/ibima-investigacion-cancer-mama-metastasis-donacion_0_1905111341.html
- European leadership on DILI <https://www.europapress.es/esandalucia/malaga/noticia-investigadores-ibima-clinico-uma-lideran-nivel-europeo-abordaje-lesiones-hepaticas-inducidas-medicamentos-20240528123250.html>
- HRUM – IBIMA Plataforma BIONAND II Soccer Tournament <https://www.alhaurindelatorre.com/la-policia-nacional-campeona-del-segundo-torneo-de-futbol-7-en-beneficio-de-la-investigacion-organizado-por-el-hospital-regional-universitario-de-malaga-e-ibima-plataforma-bionand/>
- Presentation of the Unicaja Foundation Awards <https://www.laopiniondemalaga.es/malaga/2024/06/24/fundacion-unicaja-convoca-nuevo-premio-investigacion-104213362.html>
- IBIMA Plataforma BIONAND Board of Directors <https://www.diariosur.es/malaga/doctor-raul-andrade-nuevo-vicepresidente-cientifico-ibima-20240703194100-nt.html>
- Drug that reduces fat accumulation https://www.malagahoy.es/malaga/ibima-regional-malaga-uma-investigan-enfermedad-higado-graso_0_2002215679.html
- ELA Spain Collaboration Agreement <https://www.europapress.es/esandalucia/malaga/noticia-ibima-asociacion-europea-ela-espana-unen-fuerzas-impulsar-investigacion-leucodistrofias-20240903120349.html>
- Bleeding in patients with infarction and cancer <https://cadenaser.com/andalucia/2024/09/26/investigadores-de-ibima-y-clinico-descubren-nuevos-avances-en-prediccion-de-riesgo-de-sangrado-en-pacientes-con-infarto-y-cancer-ser-malaga/>
- Olive oil <https://www.europapress.es/esandalucia/malaga/noticia-demuestran-potencial-aceite-oliva-virgen-extra-frenar-creacion-nuevos-vasos-sanguineos-20241015103655.html>
- ACSA Accreditation for Phase I Clinical Trials at Virgen de la Victoria University Hospital of Málaga <https://www.diariosur.es/malaga/unidad-ensayos-clinicos-fase-ibima-malaga-convierte-20241106181806-vi.html>
- Inauguration of a facility for research on radiopharmaceuticals against cancer and obesity https://www.malagahoy.es/malaga/ibima-uma-inauguran-nueva-instalacion-investigacion-radiofarmacos_0_2003009614.html

COMMON RESEARCH SUPPORT SERVICES (ECAI)

The IBIMA Plataforma BIONAND spaces dedicated to research total 10,307 m². They are distributed between the Regional University Hospitals (General H., Maternal H., and Civil H.) and the Virgen de la Victoria University Hospital (including a space in the Valle del Guadalhorce Hospital), the Málaga-Guadalhorce Primary Care Healthcare District, and the University of Málaga, by virtue of agreements signed for the use of spaces and/or shared use, as well as the Málaga TechPark building.

The following is a description of the Shared Research Support Services (ECAIs for their initials in Spanish) that support the various research groups and are necessary for carrying out the institute's activity.

Shared Research Support Services (ECAI, for its initials in Spanish)

- **CLINICAL RESEARCH AND CLINICAL STUDIES** (7th floor of the Regional University Hospital of Málaga (HURM), Early Phase Units at the HUVV and HRUM).
- **METHODOLOGICAL AND STATISTICAL ADVISORY SERVICE**
- **GENOMICS** (node in the Malaga TechPark building, node in the IBIMA laboratory at the HUVV, and node on the 1st floor of the UMA Bioinnovation building at Málaga TechPark)
- **PROTEOMICS** (SCAI building of the UMA on the Teatinos Campus)
- **CELL THERAPY AND GMP ROOMS** (7th floor HURM)
- **BIOBANK** (basement of pavilions 5 and 6 of the Civil H.)
- **ANIMAL EXPERIMENTATION** (Málaga TechPark building and Animal Experimentation Center at the UMA, Teatinos Campus).
- **BIOINFORMATICS** (Malaga TechPark and UMA building, Bioinnovation building in the Málaga TechPark).
- **CELL BIOLOGY (CYTOMETRY AND CULTURES)** (Málaga TechPark building and laboratories 1, 2, and 3 in the hospitals)
- **NANOIMAGING** (Málaga TechPark building).
- **HISTOLOGY** (Málaga TechPark building).
- **CHEMISTRY** (Málaga TechPark building).

Common Research Spaces (Laboratories):

- Laboratory 1. Location: Civil Hospital (HRUM), basements of pavilions 2, 5, and 6.
- Laboratory 2. Location: Virgen de la Victoria University Hospital.
- Laboratory 3 or Regenerative Medicine Laboratory (LMR, for its initials in Spanish). Location: Basement of the HRUM Administration Wing.
- Phase I Clinical Trials Unit: Virgen de la Victoria University Hospital and the Regional University Hospital of Málaga.
- Phase II-III Clinical Trials Unit: Virgen de la Victoria University Hospital and the Regional University Hospital of Málaga.
- Laboratories of the Málaga TechPark building.

Common Research Spaces in the School of Medicine (Pharmacology Laboratory and Legal and Forensic Medicine Department Laboratory), School of Health Sciences (Experimental and Human Movement Laboratory), School of Sciences (BIO-267 Laboratory and the Cellular Biology, Animal and Plant Physiology, and Department of Organic Chemistry laboratories), School of Psychology (Basic Physiology and Psychobiology and Social Sciences Methodology Laboratory), and the Industrial Engineering Higher Technical School (3D printing for research support (LIPSI)), all located on the Teatinos Campus of the University of Málaga.

PRIMARY CARE research space: Two offices on the 2nd floor of the Civil Hospital.

CLINICAL STUDIES

We conduct research to contribute to improving citizens' health. Our commitment is shared with industry leaders, who rely on our institute to conduct their clinical trials thanks to the robustness of our healthcare system, the high level of training of our professionals, and our state-of-the-art infrastructure for the optimal execution of our clinical research activity.

Independent Clinical Research and Clinical Trials Unit (UICEC, for its initials in Spanish)

IBIMA Plataforma BIONAND's Clinical Research and Clinical Trials Unit is a multidisciplinary support structure for the research groups at the research institute—the Regional and Virgen de la Victoria University Hospitals of Málaga and primary care—to conduct clinical research studies.

The IBIMA UICEC forms part of the Spanish Clinical Research Network (SCReN) and partially funded by the Carlos III Institute of Health (PT23/00137). On the European level, SCReN forms part of ECRIN, the European Clinical Research Infrastructure Network. SCReN is a national hub and supports and manages international multicenter clinical trials.

Services:

- Methodological and regulatory scientific advising.
- Management and administrative processing.
- Coordination and scientific management of clinical research.
- Scientific management of clinical research.
- Performing studies: Pre-start-up of clinical trials, conduct, finalization, and close-out.
- Monitoring.
- Pharmacovigilance.

Coordinator: Ms. María Isabel Lucena González, Scientific Director of UICEC.

Personnel in 2024: 9 Professionals

Clinical Studies Unit of the Regional University Hospital of Málaga

The aim of the Clinical Studies Unit of the Regional University Hospital of Málaga is to foster and promote observational studies and national and international clinical trials at the center in order to generate knowledge and improve patient health.

Services:

- Technical and administrative support to promote and dynamize the management and conduct of clinical trials and commercial observational studies.
- Promote the research activity of the clinical units of both consolidated and emerging units.
- Increase the number of commercial, national, and international clinical studies.
- Resolution of incidents that hinder the conduct of clinical studies.
- Optimize contract management and metrics/timing.

Coordinator: Mr. Francisco Carabantes Ocón

Phase I Clinical Trials Unit

The Phase I Clinical Research Unit of the Regional University Hospital of Málaga is located on the first floor of Pavilion 1 of the Civil Hospital. It has a space measuring 340 m², distributed in a user reception area, a consultation room for extractions, a nursing station, four consultation rooms, a waiting room, and a day hospital.

Coordinator: Mr. Francisco Carabantes Ocón

Clinical Studies Unit of the Virgen de la Victoria University Hospital in Málaga

The aim of the Clinical Studies Unit of the Virgen de la Victoria University Hospital Málaga is to foster and promote national and international observational studies and clinical trials at the center in order to generate knowledge and improve patient health.

Services:

Technical and administrative support to promote and dynamize the management and conduct of clinical trials and commercial observational studies.

- Promote the research activity of the clinical units of both consolidated and emerging units.
- Increase the number of commercial, national, and international clinical studies.
- Resolution of incidents that hinder the conduct of clinical studies.
- Optimize contract management and metrics/timing.
- Manage the infrastructure of the Phase II/III clinical research assistance area.

Phase II/III clinical research care area

Area that measures more than 600 square meters for phase II and III clinical research. It has a total of ten consultation rooms, a samples collection room, a day hospital, and sample processing rooms.

Coordinator: Mr. Manuel F. Jiménez Navarro

Phase I Clinical Trials Unit

The Phase I Clinical Research Unit of the Virgen de la Victoria University Hospital can be directly accessed from outside the hospital. It has a user reception area, a consultation room for samples collection, a nursing station, two consultation rooms, a day hospital, and two double rooms.

As of July 2024, the unit complies with the definitive standards of the Early Phase Clinical Trials Unit Standards Manual, with advanced quality certification by the Andalusian Healthcare Quality Agency.

Coordinator: Mr. Javier García Corbacho.

Main results of the ECAI in 2024:

No. of active independent clinical trials	No. of new independent clinical trials	No. of new early phase (I-II) clinical trials	Revenue from clinical trials (€)
350	38	77	€12,491,242.40

Location: This platform is located on the first floor (Phase I Clinical Trials Unit) and on the 2nd floor (Phase II/III Clinical Research Care Area) of the Virgen de la Victoria University Hospital, the first floor of pavilion 1 of the Civil Hospital, and on the 7th floor of Pavilion A of the Regional University Hospital of Málaga.

METHODOLOGICAL AND STATISTICAL ADVISORY SERVICE

The aim of this research advisory unit for research groups is focused on fulfilling the full potential to generate data that are crucial to detect, solve, and prevent problems related to patients’ health. It offers specialized biomathematical support that adds rigor and takes special care in design, implementation, and analysis. It provides scientific support that bridges the gap between clinical and translational research.

Services:

- **Methodological and epidemiological advising:** Methodological advising and/or review of research protocols, analysis of the grounds for rejecting projects, review of scientific articles.
- **Statistical advising:** sampling and sample size calculation, descriptive analysis of data, inferential analysis (bivariate and multivariate), support in the use of free software for statistical data analysis (R-project), and review of scientific articles.
- **Advising to research groups:** gathering knowledge about the work conducted in the research groups to support starting lines of research or clinical innovation and identify and promote possible inter-unit, inter-center, and international collaborations. Support for groups’ research personnel in the exploitation of their data as well as in the dissemination of their experimental results in national and international forums. Advising for research groups on their research interests in order to define objectives and outline appropriate strategies to achieve them.
- **Educational activities:** education on research methodology, the use of free software for statistical data analysis, advanced statistics, preparation of a scientific manuscript for publication in peer-reviewed scientific journals, critical reading of scientific literature, and specific educational courses according to researchers’ needs.

Coordinator: Rita Pérez González

GENOMICS

Platform that facilitates sequencing services (DNA using the Sanger method, Ultrasequencing, and Pyrosequencing) and SNP genotyping. It also creates genetic reports of monogenic diabetes. It is accredited in good practices according to the ISO 1704 standard coordinated by the European Molecular Genetics Quality Network (EMQN), which it participates in annually.

The Genomics ECAI provides technical and methodological support for research projects for the use of data and statistics. It provides services in two ways:

- Internal service through temporary access for IBIMA Plataforma BIONAND researchers who need its infrastructure to conduct research projects funded by different programs.
- External services to public and private, national and international institutions.
- It is organized into two sections:
- Genotyping, sequencing, pyrosequencing, and miRNA expression section, which encompasses the largest percentage of the work requested.
- Biomarkers section, in which diagnostic, prognostic, progress, or treatment response biomarkers are identified. This section provides support to numerous projects. The ECAI is part of EATRIS (European Advanced Translational Research Infrastructure in Medicine).

This ECAI also includes the CIBER-IBIMA Metagenomics Platform, which provides microbiota analysis services to national CIBER researchers as well as to internal and external researchers who request it.

The following infrastructure, distributed in different lines, is available to provide the portfolio of services:

Nucleic acid extraction area
Fume extraction hood
Maxwell automated DNA extraction
QIAcube automated DNA extraction
NanoDrop 2000 C nanospectrophotometer
Qubit 4 Fluorometer
Biotek Synergy MX Fluorimeter
Nucleic acid amplification area:
Thermocyclers:
QIAamplifier 96, Qiagen
MyCycler gradient, Bio-Rad
Mastercycler gradient, Eppendorf
Veriti 96-Well Thermal Cyclers, Applied Biosystems
Real-time thermal cyclers:
CFX96 Real Time System, Bio-Rad
The LightCycler® 480 Instrument II, Roche Diagnostics
7500 Fast Real-Time PCR System, Thermo Fisher Scientific
Mx3005P qPCR real-time PCR, Agilent Stratagene
QuantStudio 6 Flex Real-Time PCR System
QuantStudio 12 Real-Time PCR System
Nucleic acid amplification area:
Pyrosequencing:
PyroMark Q96 ID, Qiagen
PyroMark Q48 Autoprep, Qiagen
Sanger sequencing:
Avant Genetic Analyzer 3130XL, Applied Biosystems
Next Generation Sequencing (NGS):
Ion Chef System
Ion GeneStudio S5 System

Scientific Coordinator: Dr. Isabel Moreno Indias

Personnel in 2024: 2 Technicians

Location: This platform’s main headquarters is located at the IBIMA Plataforma BIONAND building in Malaga TechPark. It also has spaces in the basement of Pavilion 5 of the Civil Hospital (Regional University Hospital of Málaga) and in the laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

PROTEOMICS

The main objective of this platform is to provide scientific and technical support and advising in the identification and characterization of proteins and other biomolecules, mainly through mass spectrometry techniques.

Services:

- Sample preparation:
 - Protein extraction.
 - Desalting and concentration of samples.
 - Peptide purification through RP-HPLC.
 - Manual and automated enzymatic digestion of proteins in gel and in solution.
 - Preparation of histological sections for MALDI-Imaging.
 - Sample preparation for MALDI-Imaging of colonies.
- Chromatography:
 - HPLC: High Performance Liquid Chromatography.
 - FPLC: Fast Protein Liquid Chromatography.
 - TLC: Thin-layer Chromatography.
- Mass spectrometry:
 - Determination of protein molecular masses.
 - Identification of proteins in purified samples and complex mixtures.
 - Relative protein quantification by: LFQ, TMT, SILAC.
 - Study of post-translational modifications.
 - Analysis of protein profiles.
 - Study of the spatial distribution and relative abundance of analytes in intact samples of animal or plant tissues through MALDI-Imaging.
 - Study of bacterial metabolite profiles in microbial colonies and/or biofilms through MALDI-Imaging.
- Immunoassays: simultaneous detection and quantification of different secreted proteins (cytokines, chemokines, growth factors, etc.) by means of immunoassays based on Luminex technology.

Main results in 2024:

- A total of 44 requests for analysis corresponding to different research projects were attended to.
- Ten scientific publications were contributed to.
- Seven contributions to scientific conferences were made.
- The completion of 1 Bachelor’s Degree Final Project (TFG), 6 Master’s Degree Theses (TFM), and 1 Doctoral Thesis were collaborated on.
- Six training and teaching support activities were conducted.
- Six scientific dissemination actions were carried out.
- Seventeen training actions were completed by the three department technicians.
- Two new techniques or services were added to the catalog of services.

Scientific articles:

1. Ramírez CC, Alméciga-Díaz CJ, Martín-Rufián M, Cárdenas-García C, Espejo-Mojica AJ, Lobo C, Benincore EP. A close-up view of the Hunter syndrome. *Biochemical and Biophysical Research Communications*. 2024;696:149490. <https://doi.org/10.1016/j.bbrc.2024.149490>.
2. Roberto T Abdala-Díaz, Virginia Casas-Arrojo, Maria Angeles Arrojo-Agudo, Sergey Dobretsov, et al. Antitumor and antioxidant activities of polysaccharides from the seaweed *Durvillaea antarctica*. *Chemical Biology & Drug Design*. 2024;103. <https://doi.org/10.1111/cbdd.14392>.
3. León-Rodríguez A, Grondona JM, Marín-Wong S, López-Aranda MF, López-Ávalos MD. Long-term reprogramming of primed microglia after moderate inhibition of CSF1R signaling. *Glia*. 2024;73(1):1–21.
4. Rafael Jiménez-López, José Lorenzo Romero-Trevejo, Lourdes Fernández-Romero, Laura Martín-Chaves, Miguel Romero-Cuevas, Ana Isabel Molina-Ramos, Mora Murri, Mario Gutiérrez-Bedmar, Jorge Rodríguez-Capitán, Francisco Javier Pavón-Morón, Manuel Jiménez-Navarro. Differential Ophthalmological Profile in Patients with Coronary Artery Disease Coexisting with Type 2 Diabetes Mellitus: Elevated Tear Cytokine Concentrations. *Journal of Clinical Medicine*. 2024;13(16):4906. <https://doi.org/10.3390/jcm13164906>.
5. Sandra Torres-Galván, María Flores-López, Enrique Ochoa, Nerea Requena-Ocaña, Pedro Araos, Jesús Herrera Imbroda, Roberto Muga, Antonia Serrano, Fernando Rodríguez de Fonseca, Francisco Javier Pavón-Morón, Gonzalo Haro, Nuria García-Marchena. Dysregulation of plasma growth factors and chemokines in cocaine use disorder: Implications for dual diagnosis with schizophrenia and antisocial personality disorder in an exploratory study. *Neuropsychobiology*. 2024;83(2):73–88. <https://doi.org/10.1159/000536265>.
6. Aliaga-Gaspar P, Brichette-Mieg I, Fernández-Arjona M, Rodríguez-Bada JL, López-Moreno Y, Serrano-Castro P, Fernández-Fernández O, Ciano-Petersen NL, Oliver-Martos B. Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy. *Biomedicine & Pharmacotherapy*. 2024;181:117678. <https://doi.org/10.1016/j.biopha.2024.117678>.
7. Domínguez-Maqueda M, Pérez-Gómez O, García-Márquez J, Espinosa-Ruiz C, Cuesta A, Esteban MÁ, Alarcón-López FJ, Cárdenas C, Tapia-Paniagua ST, Balebona MC, Moriñigo MÁ. Microalgae and cyanobacteria as microbial substrate and their influence on the potential postbiotic capability of a bacterial probiotic. *Microbial Biotechnology*. 2024;17(11):e70046. <https://doi.org/10.1111/1751-7915.70046>.
8. Abdala-Díaz RT, Casas-Arrojo V, Castro-Varela P, Pérez Manríquez C, Cárdenas C. Immunomodulatory, Antioxidant, and Potential Anticancer Activity of the Polysaccharides of the Fungus *Fomitiporia chilensis*. *Molecules*. 2024;29(15). <https://doi.org/10.3390/molecules29152145>.
9. Marrero AD, Cárdenas C, Castilla L, Ortega-Vidal J, Quesada AR, Martínez-Poveda B, Medina MA. Antiangiogenic Potential of an Olive Oil Extract: Insights from a Proteomic Study. *Journal of Agricultural and Food Chemistry*. 2024;72(23):13023–13038. <https://doi.org/10.1021/acs.jafc.4c01184>.
10. Rodríguez-Pérez LM, Ojeda-Pérez B, López-De-San-Sebastián J, Paez-González P, Cárdenas-García C. Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated with Germinal Matrix Hemorrhages. *Stroke*. 2024;55(4):1062–1074. <https://doi.org/10.1161/STROKEAHA.123.044543>.

Contributions to conferences:

1. Gómez-Casado G, González-Jiménez A, Tinahones FJ, González-Mesa E, Ortega-Gómez A. A new niche of neutrophils blends innate and adaptive immunity in breast milk. *Neutrophil 2024*, Ludwig-Maximilians-Universität, Munich, Germany. Participation: Poster.
2. Gómez-Casado G, Cantarero-Cuenca A, González-Jiménez A, Tinahones-Madueño FJ, González-Mesa E, Ortega-Gómez A. Breast milk constitutes a new niche of neutrophils with distinct proteomic and functional properties. *58th Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI)*, Barcelona, Spain. Participation: Poster.

3. López de San Sebastián J, Rodríguez-Pérez LM, Anguita-Guardia A, Jiménez-Lara AJ, Páez-González P. Human Mesenchymal Stem Cells and Its Exosomes in Posthemorrhagic Hydrocephalus: A Focus on Edema and Ependymal Repair. *SRHSB Conference 2024*, Society for Research into Hydrocephalus and Spina Bifida, Manchester, United Kingdom. Participation: Oral communication.
4. León-Rodríguez A, Grondona JM, Marín-Wong S, López-Aranda MF, López-Ávalos MD. Consequences of microglial priming within the hypothalamus. Pharmacologic modulation by CSF1 receptor inhibition. IV Thesis Talk Contest -Explain your Thesis, University of Málaga (Spain). Participation: Lecture.
5. León-Rodríguez A, Grondona JM, Marín-Wong S, López-Aranda MF, López-Ávalos MD. When less is more: reversal of conditioned microglia immune memory by partial inhibition of the CSF1R receptor. *V Follow-up Conference of the Advanced Biotechnology Doctoral Program*, University of Málaga (Spain). Participation: Lecture.
6. Martín-Chaves L. Apolipoproteins in plasma of patients proposed for cardiovascular surgery: sexual dimorphism and abnormalities associated with thoracic aortic aneurysm and bicuspid aortic valve. *SEC24 Conference on Cardiovascular Health*, Bilbao, Spain. October 2024. Participation: Oral communication.
7. Pozo-Vilumbrales B, Soto-Navarrete MT, Martín-Chaves L, López-Unzu MA, Pavón-Morón J, Rodríguez-Capitán J, Fernández B. Connecting the dots: molecular pathways in bicuspid aortopathy explored. *Frontiers in Cardiovascular Biomedicine (FCVB) 2024 – 7th Congress of the ESC Council on Basic Cardiovascular Science*, Amsterdam, The Netherlands. April 2024. *Cardiovascular Research*. 2024;120(S1):I167. <https://doi.org/10.1093/cvr/cvae088.134>. Participation: Poster.

Doctoral theses and academic papers (TFMs and TFGs):

Doctoral Thesis:

1. Infantes-López I. *Sexual differences in the psychoneurobiology and microbiome of stress-induced depression*. Doctorate, University of Málaga (Spain), December 2024.

Master's Thesis (TFM):

2. López de San Sebastián J. *Evaluation and testing of bone marrow-derived mesenchymal stem cell exosomes as treatment for posthaemorrhagic hydrocephalus*. Master's Thesis, Master's Degree in Cellular and Molecular Biology, Faculty of Sciences, University of Málaga, July 2024. Tutor: Patricia Páez González.
3. Conesa MI. *Validación de dos medios comerciales para la criopreservación de células madre mesenquimales (MSCs) utilizadas en la fabricación de medicamentos de terapias avanzadas*. Master's Thesis, University of Málaga, 2024.
4. Serrano García V. *Descubriendo los mecanismos moleculares subyacentes a la lipofuscinosis neuronal ceroida a través del análisis transcriptómico*. Master's Thesis, University of Málaga, 2024.
5. El Ismaili El Alaoui Barranco B. *Uso del pez cebra (Danio rerio) como modelo de estudio para enfermedades génicas*. Master's Thesis, University of Málaga, 2024.
6. Hernández Martínez A. *Diversidad evolutiva de miosinas cardíacas en vertebrados*. Master's Thesis, University of Málaga, 2024.

Final Degree Project (TFG):

Romero Márquez A. *El papel de las citoquinas y quimioquinas inflamatorias en la demencia vascular: una revisión de su impacto en la patogénesis y progresión*. Final Degree Project in Medicine, University of Málaga, 2023/2024 academic year. Tutor: Manuel Jiménez-Navarro. External collaborators: Dina Medina Vera, Francisco Javier Pavón Morón.

Training and teaching support activities:

1. Participation in *Training Sessions: Applications of the Genomics, Proteomics, and Bioinformatics ECAs*, organized by IBIMA Plataforma BIONAND. Held at the IBIMA Plataforma BIONAND Conference Room, September 25, 2024.
2. Participation as a speaker at the *IX Conference of the Spanish Proteomics Society (SEPROT)*, held from February 6 to 9, 2024.
3. Tutoring of an internship (300 hours) for a *Master's in Advanced Biotechnology* student, University of Málaga, 2024.
4. Tutoring of an internship (385 hours) for a student in the Advanced Vocational Training Course for Laboratory Analysis and Quality Control, IES Universidad Laboral (Málaga), 2024.
5. Theoretical class and practical visit for Bachelor's Degree in Health Engineering students in the subject *Genomics, Proteomics, and Metabolomics*. University of Málaga, Tuesday, May 21, 2024.
6. Theoretical class and practical visit for Bachelor's Degree in Health Engineering studies in the subject *Biotechnology*. University of Málaga, Monday, April 08, 2024.

Informational activities:

1. Participation in *Transfiere 2024, European Forum for Science, Technology, and Innovation*, held on March 20, 21, and 22, 2024 at the Trade Fairs and Congress Center of Málaga.
2. Unit participation in *Destino UMA 2024, XX Open Doors Day* at the University of Málaga, held on March 13, 14, and 15, 2024 at the University Sports Complex of the Teatinos Campus.
3. Unit participation in the *Aquí y Ahora* program on Canal Málaga, broadcasted on November 6, 2024.
4. Visit and discussion with the students of the *IES Science 2024* program, an initiative to promote an interest in research and spark students' vocation for science, March 15, 2024.
5. Visit and discussion with students in the Anatomic Pathology Laboratory course at Litoral High School, Malaga, December 12, 2024.
6. Visit and discussion with students at Portada Alta High School, Málaga, January 25, 2024.

Coordinator: Mr. Javier Marquez Gómez

Personnel in 2024: 3 Technicians

Location: This platform is located in the Proteomics Unit, 2nd floor of the SCAI building of the University of Málaga. Teatinos Campus.

CELL CULTURE AND CYTOMETRY

CELL CULTURE

The Cell Culture Unit provides the institute's research groups and other public or private institutions the possibility of culturing and maintaining cells (mainly murine and human), including both primary cultures and established cell lines, offering advising from specialized personnel and the conduct of assays with guaranteed flexibility and adaptation to specific requirements.

Services

GENERAL:

- Maintenance and disinfection of biosafety hoods.
- Maintenance and disinfection of incubators.
- Regular change of water in CO2 incubators.
- Maintenance and disinfection of thermostatic baths.
- Periodic analysis of mycoplasma contamination in incubators.
- Solid waste disposal and treatment and disposal of liquid waste.
- Equipment and facilities for the use of viral vectors in cell culture.
- Daily control of temperature and CO2 in incubators.
- Annual certification of cabins and incubators.

SPECIFIC:

- Advice on the acquisition and maintenance of cell lines.
- Cryopreservation of samples.
- Analysis of mycoplasma contamination.

Scientific Coordinator: Dr. Elena González Muñoz

Personnel in 2024: 1 Technician in charge , shared with the Animal Housing Unit.

Main results 2024:

- Service to 15 research groups under the terms of the services offered.
- Education and training on the correct use of the unit for the personnel of 17 research groups (39 users).
- User management using a calendar in Clustermarket as well as billing of services rendered to internal and external entities.
- Maintenance and verification services have been performed for the cabins in use.
- The technician has completed a Good Laboratory Practices course (IAVANTE FPS)

DISSEMINATION:

1. 9 Visits organized for high school and vocational training students.

CYTOMETRY

The main objective of this unit is to provide support for the conduct of research studies carried out by the different groups that form part of the Institute or other research centers through scientific advising, sample analysis, and presentation of results in the field of flow cytometry.

The unit's primary mission is to provide efficient, quality service in order to promote and carry out research.

The catalog of services includes, among others:

- Analysis of cell populations via fluorescence:
 - Identification of cell populations through intracellular or extracellular antigen labeling.
 - Cell viability, cell cycle, and apoptosis studies using vital dyes (Annexin-V/Propidium Iodide, TUNEL, mitochondrial membrane potential determination, sub-G0 peak detection, etc.).
 - Studies of oxidative stress using fluorescent probes.
 - Determination of cell proliferative index using labeled nucleoside analogs (BrdU).
 - Fluorescent protein-guided gene expression studies (GFP, YFP...).
 - Quantification of cytokines and other soluble proteins.
 - Intracellular Ca²⁺ mobilization studies.
- Spectral analysis: Provides the possibility to analyze up to 40 colors
- Cell sorting from single cells collected in tubes or plates

Scientific Coordinator: Dr. Elena González Muñoz

Personnel in 2024: 1 Technician specialized in cytometry and cell separation.

Main results 2024:

- Incorporation of new techniques and protocols according to user demand. Several cytometry panels, both spectral and conventional, have been designed and optimized to meet the requirements of the researchers' projects.
- The technique of cell separation via cytometry has been performed in the separating spectral cytometer at the request of users.
- Fourteen new users have requested services from the cytometry unit, including both independent users of the analyzer and users of the spectral cytometry and cell separation services offered by the specialist technician. Currently, the unit routinely provides services to 8 different IBIMA and UMA research units.
- Four users were trained to use the cytometer analyzer correctly and autonomously.
- Advising has been provided on experiment design and results analysis to different research groups that have requested it, both from IBIMA and from the UMA and companies.
- The software license acquired has been used and the users who have requested it have been advised on its use for analyzing cytometry data obtained from the unit's equipment.
- The contracting of maintenance services for the two cytometers in use has been negotiated and the conditions of contracting have been established. The corresponding maintenance visits have occurred.
- A course on Good Laboratory Practices (IAVANTE FPS) has been carried out

DISSEMINATION:

1. Introductory talk on the Cytometry Unit for IBIMA-BIONAND.
2. Several visits organized for high school and vocational training students, undergraduate biology students (University of Málaga), and representatives of other entities, as well as occasional visits by researchers from other institutions throughout the year.

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

CELL THERAPY AND GMP ROOMS

The institute's Cell Production Unit (CPU) has **three rooms authorized for the aseptic manufacture of advanced therapy drugs according to GMP** (Good Manufacturing Practices) **standards**. The facilities meet the quality and safety requirements for the aseptic manufacture of medicines according to the Spanish Agency of Medicines and Medical Devices (AEMPS) guidelines since 2012. It is part of the Andalusian Network for the Design and Translation of Advanced Therapies (RADyTTA), whose objective is to promote the development and application in clinical practice of the results obtained from research in the fields of cell, tissue, gene, and nanomedicine therapy.

In addition, through the RADyTTA, the unit belongs to the RICORS Network of Advanced Therapies (TERAV) and the Networked State Consortium for Advanced Therapies (CERTERA), which aims to establish the scientific collaborations necessary for the clinical development of safe and effective advanced academic therapies, and the coordination of networked technological structures that facilitate the translation of these therapies to the National Health System in order to facilitate their clinical translation and patients' access to them.

This unit is authorized by the Spanish Agency of Medicines and Medical Devices for the **manufacture of cell therapy drugs based on expanded adult mesenchymal adipose tissue-derived stem cells (ADSCs) for autologous or allogeneic use** as well as the conduct of the corresponding quality controls according to the European Pharmacopoeia (Ph. Eur) for use in clinical trials in diseases that do not have or do not adequately respond to conventional treatments, such as amyotrophic lateral sclerosis (ALS), structural fecal incontinence, acute cerebral infarction or stroke, and severe SARS-CoV-2 pneumonia.

In addition, it manufactures drugs for compassionate use procedures with prior authorization from the AEMPS for the following diseases:

- Graft-versus-host disease (GVHD)
- Neurological diseases: ALS, multiple sclerosis
- Fecal incontinence
- Severe SARS-CoV-2 pneumonia.
- Pediatric craniosynostosis

It pioneered the First External Quality Program in Advanced Therapies (www.ega-atmp.com), which aims to standardize and verify the quality of the tests and techniques used in the manufacture of advanced therapy drugs.

The ECAI is currently collaborating with the University of Málaga on the creation of a 3D bioprinting platform for the preclinical evaluation of customized implants manufactured by bioprinting for the surgical correction of critical cranio-maxillofacial defects in pediatric patients.

Services:

- Isolation of adult mesenchymal stem cells derived from adipose tissue, *in vitro* expansion to obtain the dose assigned according to protocol, and subsequent packaging.
- Quality controls for cell therapy trials.
- Environmental and surface microbiological control of facilities with ISO classification: air volumetrics, settle plates; surfaces using contact plates.
- Grading of thermal equipment: refrigerators, freezers, stoves, etc.
- Microbiological control testing of cellular products (Ph. Eur. 2.6.27), Mycoplasma (Ph. Eur. 2.6.7), endotoxins (Ph. Eur. 2.6.14), characterization of cellular products (Ph. Eur. 2.7.24), cell count and viability (Ph. Eur. 2.7.29), promotion of cell growth in culture and cell population doublings, genetic stability of ATMPs, cell recovery rate after thawing.
- Potency assay by estimating the immunosuppressive capacity of mesenchymal cells.
- Methodological, scientific, and technical advising on cell therapy clinical trials.
- Management, evaluation, and advising on trial documentation.
- Introductory education on cell therapy.
- External Quality Assurance Program in Advanced Therapies.
-

Coordinator: Dr. Antonio Rodríguez Acosta

Personnel in 2024: 3 Technicians

Main results 2024:

- In 2023, 30 batches of hAD-MSCs-based drugs were manufactured for compassionate use for patients with GVHD (allogeneic treatment).
- Quality control tests were performed the Grenoble Tissue Center (France) and for the Regional Transfusion Center of Málaga.
- Six batches of drugs were manufactured for a multicenter, randomized, double-blind, Phase IIb clinical trial to evaluate the safety and efficacy of intralesional administration of two doses of expanded allogenic adipose tissue-derived stem cells (ADSCs) conditioned in hyaluronic acid hydrogel as a treatment for patients with fecal incontinence.
- Since 2012, it has been actively collaborating with the RADyTTA, the Graduate School, and the University of Granada to offer a Master’s Degree in Manufacturing of Advanced Therapy Medicinal Products.
- Collaboration with the International University of Andalusia in the teaching of the Master’s Degree in Advanced Biotechnology.
- Personnel linked to the Unit participate as teachers and workplace tutors in the Cell Culture Specialization Course (Litoral High School).
- In 2024, teaching was done in the Expert Diploma in Clinical Research and Clinical Trials Monitoring (IBIMA/CIBER and SCReN Platform).
- It has become part of the EATRIS European platform and the ISCIII’s 3D Printing and Bioprinting HUB platform.
- It has joined the Networked State Consortium for Advanced Therapies (CERTERA).
- Participation in “A multicenter clinical trial with mesenchymal stromal cells in adult and pediatric patients with steroid-refractory acute GVHD to validate an immunomodulatory potency assay associated with treatment efficacy ICI23/00085.” Coordinating LR Rafael Duarte Palomino, Puerta del Hierro Hospital Foundation

- Dissemination activities conducted in 2024:
 - UMA divulga 2024 Conference.
 - ISCT Europe 2024 Conference regional meeting (Gothenburg, Sweden). 5 posters and 1 oral presentation:
 - Evaluation of virally inactivated human platelet lysates as a supplement for culture media in manufacturing of cell-based medicinal products (poster + speech).
 - Compassionate use of a cell therapy in patients with GVHD. An efficient model for patient access.
 - Evaluation of animal-free commercial media for cryopreservation of mesenchymal stem cells.
 - Standardization of the cryopreservation process used for allogeneic Mesenchymal Stem Cells-based products for clinical use.
 - A practical risk-based approach for the validation of a temperature monitoring system according to GMP Annex 11.
 - 27th Congress of the European Association for Cranio Maxillo Facial surgery. 1 poster:
 - Customized bioprinted implants for the surgical correction of critical-sized cranio-maxillofacial defects in pediatric patients.
 - Terav Network Annual Meeting. 1 collaboration poster:
 - The Cell Production Platform of the Advanced Therapies Network.

Location: This platform is located in the Cleanroom, 7th floor of Pavilion A of the Regional University Hospital of Málaga.

BIOBANK

One of the institute’s research support structures is the Provincial Biobank of Málaga, which in turn belongs to the Andalusian Public Health System Biobank. It is a unique biobank structure in terms of its potential and capacity for obtaining, transforming, preserving, and distributing samples for research purposes. It comprises 26 nodes located in SSPA (Andalusian Public Health Service) health centers. The Provincial Biobank of Málaga comprises 3 nodes: the Regional University Hospital of Málaga, the Virgen de la Victoria University Hospital, and the Costa del Sol Hospital in Marbella. It also has the support of the regional hospitals and the Axarquía, Ronda, and Antequera Hospitals.

It is registered and authorized by the competent authorities with file number B.0001601 dated 09/16/2020 and owned by the *Regional Ministry of Health and Families of the Regional Government of Andalusia (the Biobank of the Costa del Sol University Hospital, it has its own record, B.0000414, ownership: Costa del Sol Public Company, 12/03/2012, pending update)*, in accordance with the provisions of Article 13. Creation and Organization of the Andalusian Public Healthcare System Network Biobank according to **Decree 1/2013**, of January 8, regulating the authorization of the creation and operation of biobanks for biomedical research purposes, creating the Andalusian Biobank Registry and the Andalusian Public Healthcare System Biobank. The Provincial Biobank of Málaga was started 15 years ago. Since its inception, it has worked to become what it is today: a platform of services for provincial researchers, most of whom belong to the Institute, that allows users to carry out their projects with the assurance that the biobank guarantees that the ethical, legal, and technical requirements for biological samples and their associated data are met.

Services:

- Provision of samples and data for research projects.
- Provision of samples and data for clinical trials in collaboration with the Clinical Trials Platform of Málaga.
- Processing of samples.
- New: Organoid unit
- Preservation of samples at different temperatures.
- Technical, scientific, ethical, and quality advising on the collection, storage, and management of human samples in biomedical research.
- Files for diagnostic confirmation.
- Real-time web-based remote equipment monitoring.

Work is being done to optimize tasks according to employee’s positions, standardize procedures, improve the management of clinical care samples with primary care, improve services for clinical studies, and unify strategic lines.

The manners in which the biobank provides these services are:

- Requests for sample provision: activation of circuits for sample collection, delivery of samples or data, and their custody.
- Requests for custody: use of facilities for sample conservation.
- Requests for processing: processing of samples for researchers.

Scientific Director: Ms. María Luisa Hortas Nieto

Coordinator: Tatiana Díaz Córdoba

Personnel in 2024: 7 Technicians


Main results 2024:

Services provided to research projects:

2024	HRUM	HUVV	HUCS
New Donors	942	267	0
No. of initial samples registered	12531	15975	343
No. of new donations	3653	1094	186
No. of total samples distributed	8644	4642	4
No. of applications received	62	34	2
No. of CMUs attended to	16 (20)	12 (14)	10 (15)
No. of researchers	72	54	16

1. Sample collection and receipt.


NEW DONORS



Note 1: it should be noted that these datas are only counted when we can assign donors, i.e. they have signed the biobank informed consent form.


Note 2: The structure has grown compared to 2023

NEW DONATIONS



Note 1: The structure has grown very significantly compared to 2023


NUMBER OF INITIAL SAMPLES REGISTERED



Note 1: The structure has grown very significantly compared to 2023


2. Use, distribution, and tracking of bioresources

NUMBER OF TOTAL SAMPLES DISTRIBUTED




3. Requests

NUMBER OF TOTAL REQUESTS RECEIVED (LOCAL AND FROM THE NETWORK)



NUMBER OF REQUESTS RECEIVED BY TYPE OF REQUEST



Services provided to clinical trials:

	2020	2021	2022	2023	2024
No. of first visits attended to	65	60	70	77	68
No. of active trials (cumulative)	161	237	290	370	380
No. of requests attended to (samples for clinical trials)	725	790	634	658	706
No. of samples/blocks without samples	51	37	27	37	54
%	7.6	5.77	5.60	5.33	7.50
Mean biobank management time (days)	1.2	0.83	1.04	0.88	0.82
Mean actual response time (days)	1.9	1.37	1.65	1.35	1.28
Maximum actual response time (days)	6.8	5.75	4.75	5.17	5.1
No. of samples outside hospitals without the Málaga biobank	36	55	38	40	42
No. of samples from hospitals outside of Málaga	0	4	3	2	3
Number of complete blocks delivered	532	1013	905	2167	566
Number of times slices have been delivered	153	245	87	172	248
TOTAL	691	1258	992	2339	814
Express biopsies attended to	ND	ND	ND	84	104

Resources and infrastructure:

The biobank’s resources and infrastructure have increased significantly in the last 3 years, which shows that it is a consolidated unit with a clear vocation for expansion and growth, generating the synergies necessary for the ongoing development of the structure according to demand. In this sense, the institute continues to provide important support to this unit: it covers the costs of equipment maintenance and repair, commits to acquiring the necessary equipment for the structure, and provides its technicians with the necessary tools to advance in their professional careers.

At present, its facilities cover 346 m², of which 230 m² correspond to 4 cryopreservation rooms. The remainder is divided into 4 sample reception and registration areas and 3 processing laboratories. All of its locations have the necessary equipment for the transformation of biological sample and their conservation according to the standard operating procedures. The cryopreservation rooms have equipment for preserving samples at -196 °C (11), -80 °C (44), -20 °C, 4 °C (5), and room temperature (5). It features digital temperature monitoring, validation with an external probe, 24/7 alarm management, connection to a power generator, independent air conditioning and heating, CO2 and O2 detection, forced ventilation activation, etc.

In addition, there are internal and external maintenance plans for all available equipment as well as a comprehensive emergency plan. The sample processing laboratories are also equipped with IIA biological safety laminar flow cabinets (2), microtome, tissue safe, refrigerated centrifuges (2), and other laboratory equipment.

Invoicing for services:

Invoicing for services provided during the 2024 financial year was done entirely through the Andalusian Public Foundation for Progress and Health and totaled €39,786. Málaga represents 41.6% of the total income of the SSPA biobank, a total for the Andalusian Biobank of €95,616.32.

Research projects led and collaborations:

1. Principal LR Biobank (Francisco Tinahones Madueño). National Platform for Biobanks, Biomodels, and 3D Printing, PT23/00049, ISCIII. Total amount: €287,680. Duration: 3 years

Internalization of the structure:

The Biobank, Organoids, 3D Printing, and Animal Biomodel Platform provides services to IBIMA researchers to conduct their research activity in international and national networks. The international networks that IBIMA participates in are:

- European Biobanking research infrastructure (**BBMRI-ERIC**) (<https://www.bbmri-eric.eu>): European research infrastructure for biobanks, which brings together the main actors in the field of biobanks to promote biomedical research. This network offers a variety of services. It comprises a total of 20 countries as full members and 5 countries as observers, with Spain being an observer member since November 2021. In Málaga, work is performed in full alignment with the national and European strategy, forming part of this network of networks. The structure stands out in the objective dedicated to quality, co-leading one of the working groups (“Development of the UNE Guide for the implementation of ISO20387 for Biobanks”).
- European Infrastructure for Translational Medicine (**EATRIS**) (<https://eatris.eu>): European infrastructure formed by more than 80 cutting-edge translational medicine research institutes. It has 4 platforms; IBIMA participates in 2 of them: the Advanced Therapies Platform and the Biomarkers Platform, providing cutting-edge technologies and synergies to advance the development of innovative therapies, vaccines, and diagnostics. The platform collaborates by offering collections of samples and associated clinical data to the scientific community and promoting direct international collaborations. A member of the team has been selected for a training program within EATRIS Plus that aims to forge ties and exchange knowledge, the foundation of all collaborative networking.

Training and Research Activities:

Type	Number
3.1.-Training Provided	16
Training Received	22
3.2.-Communications at conferences	4
3.3.-Publications	1
3.4.-Participation in research projects	5
3.4.-Outreach activities	4

Among the training provided , the following are noteworthy:

- Workplace mentoring of a clinical analysis laboratory advanced vocational training student.
- Training of Litoral High School teachers for the dual degree “Specialization Course on Cell Cultures.”
- Participation as lecturer in **I Expert Diploma in Clinical Research and Clinical Trials Monitoring. 15.00 ECTS.** 2024-2025 school year. Participation in 1 commercial clinical trial.
- Participation in teaching for the **Master’s Degree in Biomedical Research on Diabetes and Obesity.** 60 ECTS credits. 2022-2023 school year. Participation in 1 commercial clinical trial.
- Online Clinical Session (Webinar): Biobank of the Andalusian Public Healthcare System in the clinical field. IAVANTE. 10/16/2024 III Ed.
- Online Course: “Management of samples for research” organized by the SSPA biobank, accredited by the Andalusian Healthcare Quality Agency (ACSA).

Conferences:

- Attendance of the Conference with the oral presentation: Europe Biobank Week 24 May 14-17 at The Hofburg in Vienna, Austria Strengthening Biobanks and Biorepositories: Collaborative approaches for a sustainable future:
 - “Clinical research development in healthcare centers with lack of resources: Biobanks as a key structure for their success.”
 - -“Organoid biobanks: Walking towards the future for a high-standing precision medicine.”
- ISBER 2024 Annual Meeting. Online. May 28-29, 2024:
 - “Exploring perspectives to facilitate communication between donors and biomedical research biobanks: A qualitative study.”
 - “Pediatric Collections in biobanks: Current challenges to bring advances in personalized medicine into pediatric medical care”

Dissemination activities:

As dissemination activities of the Biobank ECAI to the public, the following should be mentioned:

1. Participation in **the XII European Researchers’ Night 2024.**
2. **‘Cafés Conciencia’ as part of Science Week 2024,** to publicize the structure and the institute as well as to recruit donors for the Andalusian Registry of Donors for Research (REDMI).
3. Nursing students from the CESUR Institute were received during an **Open House** organized by the ECAI on the occasion of the International Day of Women and Girls in Science on February 9.
4. For tobacco-free day on May 29, a conference was organized at the company **OPPEPLUS** aimed at publicizing the general public in which the Biobank, the Registry of Donors for Research, the risks not leading a healthy life entails, and the IBIMA Plataforma Bionand Institute.

5. The biobank also participated in the **XI Conference of the Andalusian Sjögren’s Syndrome Association** with tabling for information dissemination and the recruitment of REDMI donors.

The structure and its services were also publicized to professionals in meetings organized with the hospital clinical management units and by participating as a speaker at:

- HUVV Cardiology UGC meeting on March 5:
- **“Ethical and legal aspects of the management and use of human biological samples in research projects.”**
- **I IBIMA Clinical Research Support Conference** held at the Hospital Materno Infantil on April 24.
- Finally, on December 19, the Biobank participated as one of the speakers at the conference organized by Novartis: **“Role of the coordinator/data entry in clinical research.”**

Other notable results:

- Adaptation of the Biobank Information System for clinical trials management.
- Its certification was renewed in 2024 according to the ISO 9001-2015 standard. The unit is certified under the UNE-EN ISO 9001:2015 Standard and participates in the creation of national guidelines for the UNE-EN ISO 20387 accreditation of biobanks, under the coordination of the national platform.
- Notable new services and innovations introduced include the creation and implementation of the **Donor Portal** , developed thanks to autonomous community funding received for this competitive public innovation project. This portal facilitates real-time citizen participation in biomedical research in an easy and accessible way. Donors can consult the results of the research projects they have participated in, manage their informed consent forms, and consult the availability of samples, among other options. The results of this project have been protected through an intellectual property registration. The project received the IBIMA Plataforma BIONAND 2022 Award for innovations transferred to clinical practice for the results obtained. The **Researcher’s Portal** was also created (Intellectual Property Registry FIMABIS-21008) in coordination with the SSPA biobank, which makes it possible to manage the entirety of an application online. In addition, the ECAI is working to better the website so as to improve user access to the platform.
- User satisfaction was greater than 8.5.

Location: This platform is located in Pavilion 5 in the basement of the Civil Hospital and in the Research Laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

ANIMAL EXPERIMENTATION (UMA)

Maintenance, breeding, and housing of the animals used in different experimental procedures in ongoing research projects.

Services offered:

- Acquisition of animal models.
- Mouse/rat breeding and maintenance, transgenic models.
- Technical support service for performing experimental procedures.
- Advising on regulatory requirements for animal experimentation.

- Facilities:
- Breeding unit for animals with an SPF biological barrier,
- Three laboratories for processing samples and preparing reagents.
- Service for booking and using facilities for animal surgical procedures.
- Service for booking and using facilities for performing behavioral studies.
- Advising:
- Service or advising on experimental and behavioral procedures.
- Service or advising for breeding and reproduction.
- Advising on animal welfare and standardization of animal models.
- Training:
- Training on basic experimental techniques.
- Use of experimental, surgical, and behavioral devices.

Coordinator: Mr. Ricardo González Carrascosa

Personnel in 2024: 2 caretaker technicians, 3 breeding and procedures technicians, 4 assistants, 1 team leader, and 1 administrative assistant.

Location: This platform is located in the University of Málaga Animal Experimentation building.

ANIMAL EXPERIMENTATION (PTA BUILDING)

The animal housing service in the IBIMA Plataforma BIONAND building is a research support service whose objective is to provide housing for experimental animals, facilities, material, equipment, and advising necessary for conducting pre-clinical trials on the technologies and products developed at the center both for research groups and companies. The service has the necessary facilities and equipment to work with rats, mice, and zebrafish.

Rodent housing services:

The rodent housing service was authorized by the Autonomous Government of Andalusia's Regional Ministry of Agriculture and Fisheries in 2013. It has the capacity to house 170 rats and 2200 mice, with the possibility of expanding this capacity.

Services offered:

- Housing of laboratory rats and mice.
- Centralized supply of animal feed, shavings, sawdust, cages, racks, feeding bottles, etc.
- Provision of special diets for specific physiological or pathological studies.
- Type II special biological waste management service.
- Maintenance and care of animals in special conditions (temperature, light, humidity, sterile environment, etc.) during the conduct of the experiments that require them.
- Technical support service for performing experimental procedures (animal handling, routes of administration, sample collection, etc.).
- Rat and mouse breeding and maintenance service.

Zebrafish housing services:

Zebrafish housing in the center was authorized by the Regional Ministry of Agriculture and Fisheries in 2014. It has capacity to hold around 2000 zebrafish in 2 racks with 50 tanks each, with the possibility of expanding this capacity in the future.

- Services offered:
- Zebrafish housing.
- Advising on zebrafish handling, linecrossing, growth, and development
- Maintenance of zebrafish *wild-type* lines.

The animal housing facility has its own Animal Experimentation Ethics Committee that includes 5 members responsible for evaluating all animal experimentation projects to be carried out in the center. Approval must be requested from the Regional Ministry of Agriculture, Fisheries, Water, and Rural Development.

Scientific Manager: Mr. José María Pérez Pomares

Personnel in 2024: 2 Technicians

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

BIOINFORMATICS

The Bioinformatics ECAI aims to serve as a research support unit, focusing especially on the methodological support of projects, the conduct of bioinformatics analyses, and the promotion of technological innovation.

Services:

- Database and clinical information collection system design.
- Review and advising on research projects. Improvements in methodology.
- Design of applications and specialized software for biomedical research.
- Management and advising on the REDCap data management platform that is integrated into the Andalusian Public Healthcare System and the University of Málaga.
- Omics analysis: proteomics, genomics, epigenomics, transcriptomics (coding and non-coding RNA, small RNA), microbiota.
- Mediation and advising for research groups for the creation of multidisciplinary projects. Search for potential collaborations.
- Automation of data processing and statistical analysis.
- Conduct of complex statistical analyses and use of machine learning and data mining techniques.
- Multiomics integration studies. (MixOmics)
- Design of data management plans and monitoring of FAIR principles.
- Prioritization of variants based on phenotypic information.
- Phenotypic quality assessment of patient and disease cohorts.
- Analysis for the prioritization of different small RNA species.
- Genome-Wide Association Study (**GWAs**) analysis.
- Copy number variation (**CNV**) analysis.

Novelties 2024:

5 new services have been added to the catalog:

- Application and integration of basic and advanced machine learning algorithms and statistical descriptors
- Application of new methodologies for differential expression analysis with interaction terms using DESeq2 and edgeR
- Cell deconvolution analysis using 450K methylation and EPIC data
- ATAC-seq chromatin accessibility studies
- Development of mobile applications in Dart.
 - The registration of a new technology patent has been processed.
 - Four specialized training courses were held
 - Two dissemination actions on REDcap were carried out.

Coordinator: Mr. Andrés González Jiménez


Personnel in 2024: 2 technicians, distributed as follows:

- 1 specialist technical coordinator
- 1 specialist bioinformatics technician.

Main results 2024:

No. of services provided	No. of services in collaboration with other ECAIs	Interprovincial collaborations	Participation in international networks	Groups contacted to offer services	Hours of training provided
80	2	2	4	31	26

Distribution of services provided by subject area



Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

This research support platform offers cytometry, cell culture, immunochemistry, and sample processing services as well as the sterilization of instruments and reagents.

Cytometry Service:

- Cellular immunophenotyping. Characterization of cell subpopulations, activation status, receptor expression, and cellular mediators
- Cell separator

Cell Culture Service:

- Preparation and aliquoting of specific antibiotics for culture media, inactivation, and storage of fetal bovine serum. Preparation of culture media as well as medium for freezing cells and pipette maintenance.
- Processing of different biological samples: cell separation by density gradient, obtaining serum and plasma.
- Obtaining and isolation of primary cultures and cell lines
- Lymphocyte isolation and labeling for cell proliferation studies
- Cell freezing

Immunochemistry Department:

- Immunoassays

It has full facilities for use by the different IBIMA Plataforma BIONAND research groups as well as for possible external users. There is a reservation system for equipment or services.

Coordinators: Ms. Cristobalina Mayorga, Mr. Manuel Macías, and Mr. Fernando Rodríguez de Fonseca.

Personnel in 2024: 3 Technicians

Location: This platform is located in pavilions 5 and 6 of the Civil Hospital, in the Regenerative Medicine laboratory of the Regional University Hospital of Málaga, and in the laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

HISTOLOGY

The main objective of this platform is to provide support and scientific-technical advising for the processing of histological samples in the field of biomedical research.

Services:

- Sample preparation:
 - Fixation using cryosubstitution and aldehydes
 - Embedding in paraffin, resin, or OCT
 - Histochemistry of basic stains
 - Immunohistochemistry for antibody tissue labeling

- Histological slices:
 - Using the EXaC hard section method
 - Using conventional paraffin microtomy
 - Using a cryostat for cryosections
- Image acquisition and processing:
 - Sample analysis advising
 - Automated image acquisition using a slide loader up to 40x in brightfield, darkfield, and polarization.
 - Fluorescence image acquisition.
 - Histomorphometry
 - Brightfield, fluorescence, or polarization image analysis.

Coordinator: Iván Durán

Personnel in 2024: 1 Technician

Main results 2024:

More than 100 conventional histology and EXaC projects, invoicing a total of €14,188.80, among which the following external projects stand out:

- Foundation for Health and Biomedicine Research in Málaga for the amount of €367.88.
- Foundation for Health Research Management of Seville for the amount of €2,804.00.
- Four non-IBIMA University of Málaga projects for amounts of €1,446.74, €1,979.07, €340.67, and €408.00.
- Biomedical Research Institute of Salamanca (IBSAL) for an amount of €79.20.
- Anapath Research SAU for an amount of €411.84.
- Networked Biomedical Research Center Consortium for an amount of €676.60.
- Jamones Segovia S.A. for an amount of €426.56.
- Celldrive 3D for an amount of €5,248.24.

DISSEMINATION:

IBIMA Plataforma BIONAND research conferences.

TEACHING SUPPORT:

On-demand personalized histology courses according to research projects.

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

NANOIMAGING UNIT

The Nanoimaging Unit has been designed and optimized to provide highly varied, integrated technological support for biomedical research, with a special emphases on research based on nanotechnology, offering advanced services to internal and external users. This facility is accredited as a Singular Scientific and Technological Infrastructure (ICTS), as a node of the ICTS NANBIOSIS.

The unit brings together a wide range of state-of-the-art technologies and is divided into five departments, all of which are staffed by technical specialists:

- **Small animal preclinical imaging service.** Small animal (preclinical) imaging is a vital tool in biomedical research that allows for studying biological processes and potential drugs in animal models using non-invasive methods. This service offers some of the most relevant preclinical imaging types: magnetic resonance imaging (MRI), in vivo bioluminescence and fluorescence imaging (In vivo Xtreme), nuclear imaging (PET/SPECT), and X-ray computed tomography (CT). These techniques are essential for the preclinical evaluation and characterization of new diagnostic and therapeutic agents. The combined use of these technologies and new highly specific imaging probes are the basis of molecular imaging.
- **Magnetic resonance imaging (MRI).** This service is equipped with two high-resolution NMR spectrometers: a 400 MHz NMR spectrometer for routine experiments and a spectrometer with a larger magnetic field, 600 MHz, dedicated to high-resolution magic angle NMR spectroscopy (HR-MAS) and conventional spectroscopy of samples that require greater sensitivity. It also has a TD-NMR analyzer for low-field magnetic relaxivity measurements (1.44 T).
- **Electron Microscopy.** The service offers access to conventional transmission electron microscopy (TEM), Cryo-TEM and Tomography, and high-resolution environmental scanning electron microscopy (SEM). In addition, the service has an outstanding infrastructure for preparing samples through cryo-immobilization. All equipment has been optimized for biological and nanomedical applications. Although biological and medical applications are the main objective of this service, it can also be used in other scientific and engineering fields, including quality control studies, failure analysis, etc.
- **Optical microscopy.** This facility houses an excellent range of optical microscopy facilities designed to support high quality biomedical research. The equipment includes conventional, confocal, multiphoton, and super-resolution microscopes as well as advanced processing software, such as IMARIS.
- **Magnetometry.** This service has a vibrating sample magnetometer (VSM) for characterizing the magnetic properties (magnetization, coercivity, magnetic susceptibility, hysteresis loop) of various materials, including ferromagnetic, paramagnetic, diamagnetic, and superparamagnetic materials.
- In October 2024, the start-up of a Radioactive Facility (IRA3243) comprising 4 rooms was authorized:
- **Molecular Nuclear Imaging.** The PET/SPECT/CT equipment is located here
- **Quality control and radiopharmacy.** For the production of new radiopharmaceuticals and their quality controls.
- **X-rays:** Room with an irradiator and In vivo Xtreme bioluminescence, fluorescence, and X-ray equipment
- **Radiochemistry.** For the radioactive labeling of molecules.

The equipment included in the different services of the unit is listed below:

1. SMALL ANIMAL PRECLINICAL IMAGING SERVICE:

- **Bruker MRI 9.4T:** Multinuclear imaging and spectroscopy system. Magnetic resonance imaging (MRI) is a very versatile technique that offers excellent morphological, functional, and physiological information. In addition, significant advances made over the past few years in the development of highly sensitive

contrast agents using nanotechnology approaches have brought MRI into the field of molecular imaging.

- **Bruker Albira SI:** Trimodal positron emission tomography, single-photon emission computed tomography, and X-ray computed tomography (PET/SPECT/CT) system. Positron emission tomography (PET) is a non-invasive diagnostic technique that allows for taking images of the animal's body that show the activity and metabolism of the body's organs. Radioactively-labeled substances that are distributed throughout the body are used. Single-photon emission computed tomography (SPECT) uses gamma rays that produce radioactive **isotopes**. These isotopes are introduced into the animal's body as part of biologically active molecules. The procedure is similar to that of **positron emission tomography** (PET), but in SPECT, it is the isotope that directly produces the gamma ray, while in PET, the isotope produces a **positron** which is then annihilated by an **electron** to produce the two gamma rays. These two gamma rays exit in opposite directions and their simultaneous detection makes it possible to locate the isotope in a more precise manner than in SPECT. However, SPECT is simpler because it can use isotopes that are easier to obtain and have a longer **half-life**.

Computed tomography (CT) allows for taking high-quality 3D imaging of preclinical animal models based on the reconstruction of 2D X-ray images captured at different angles. Albira uses dedicated beds for mice and rats with built-in anesthetic gas. Different image-capturing modes allow users to balance capture time and image quality. The Albira software package automates the reconstruction process, while the PMOD software that is included allows users to perform advanced analysis and export data to popular formats such as DICOM. It allows for the possibility of combining CT data with fluorescence.

- **Bruker In-Vivo Xtreme:** Multimodal imaging system for rats and mice, BRUKER. The In-Vivo Xtreme is a multimodal optical and X-ray system for small animal imaging designed to combine sensitivity, speed, and flexibility for the widest range of molecular imaging applications. Equipped with a high-performance 58 mm f/1.3 lens and a 4MP back-illuminated CCD camera, the In-Vivo Xtreme is suitable for demanding intravital bioluminescence and fluorescence imaging challenges.

2. MAGNETIC RESONANCE SERVICE:

- **Bruker Avance 600 MHz NMR spectrometer:** High resolution spectrometer equipped with Prodigy TCI liquid cryoprobe, TXI room temperature probe, and HR-MAS (high-resolution magic angle spinning) probe. In biomedicine, the use of liquid state NMR studies has expanded from classical metabolic studies that use enriched stable isotope tracers to more recent applications in biofluid metabolomics (urine, plasma, CSF). Solid-state NMR, HR-MAS, allows for obtaining high-resolution spectra from intact tissue, i.e. without the need for any metabolite extraction procedure. HR-MAS spectroscopy is widely used for metabolomic studies, especially in cancer research, in which the metabolic profile (metabolome) of tumor biopsies can be characterized using only a few milligrams of intact tissue (tissue biopsy). The HR-MAS technique can also be used to characterize the structure and elucidate partially insoluble compounds.
- **Bruker Ascend 400 MHz NMR spectrometer:** High resolution spectrometer equipped with a BBFO Plus probe optimized for the direct detection of X-nuclei in the ^{31}P to ^{15}N range. Liquid NMR is a fundamental tool in both chemistry and biomedical research. Its applications in chemistry range from the elucidation of small molecule structures to studies of protein-ligand interactions.
- **Bruker Minispec (TD-RMN):** This piece of equipment allows for measuring magnetic relaxation times, T1 and T2, at clinical fields, 1.44T. Relaxation measurements are fundamental in characterizing the magnetic compounds developed as MRI contrast agents.

3. OPTICAL MICROSCOPY SERVICE:

- **Zeiss LSM980 NLO Multiphoton Confocal Microscope:** Multiphoton confocal microscope with conventional and resonant scanning. Multiphoton (or two-photon) microscopy takes advantage of the

near-simultaneous absorption of two or more photons that act to excite a fluorescent molecule with the combined energy of both photons. In practice, this means that low-energy infrared light can be used to see fluorescent molecules that are normally excited by high-energy blue and ultraviolet light. Using this method, fluorescent molecules can be visualized at much greater depths than with conventional microscopy. Infrared light is also much less damaging to living tissue than UV or blue excitation, making it ideal for viewing model organisms or tissue explants. The Zeiss LSM 980 NLO microscope combines confocal and multiphoton modes in one machine and it can easily switch between different modes.

- **Leica HyD SP5 Confocal Microscope:** Confocal microscope with conventional and resonant scanning. Confocal laser scanning microscopy is a very popular technique that uses a combination of laser illumination and a mask through a pinhole to ensure that only focal plane fluorescence reaches the detector. This avoids the characteristic blurring typical of conventional fluorescence microscopy and allows images to be captured as detailed optical slices and then used to build 3D models. Confocal microscopy is one of the most versatile techniques available in optical microscopy.
- **Nikon Eclipse TIRF/N-STORM fluorescence microscope:** This conventional fluorescent microscope is equipped with incubators for timelapse studies on live samples. Fluorescence microscopy offers a wide range of tools to visualize microscopic events. For many purposes, conventional widefield fluorescence microscopy remains the best choice. The CCD detectors used for conventional microscopy are usually more sensitive than the photomultiplier tubes used in confocal microscopes. As the camera captures the entire field of view simultaneously, it also allows for faster imaging. Examples where conventional microscopy may be more appropriate include visualization of individual molecules, receptors, or small organisms, such as bacteria and yeasts. The TIRF (Total Internal Reflection Fluorescence) technique combines the sensitivity of conventional fluorescence with selective illumination to enhance the contrast of features in close proximity to the coverslip. In addition, this equipment allows for performing super-resolution spectroscopy based on STORM (STochastic Optical Reconstruction Microscopy). Historically, the intrinsic diffraction of light has made it difficult to use fluorescence to distinguish structures less than 200 nm away. Super-resolution microscopy refers to techniques that selectively activate fluorescent molecules to map their position up to 10 times more accurately than conventional fluorescent microscopy. The Nikon N-Storm system is capable of locating molecules with a resolution of up to 20 nm.
- **Basic Nikon Eclipse Ti fluorescence microscope:** Conventional fluorescence microscope with incubators for timelapse studies on live samples.
- **Perkin Elmer Operetta HCS (High-Content Screening) equipment:** High-content screening (HCS) attempts to bridge the gap between microscopy and cytometry by providing large amounts of statistically useful and phenotypically rich data. High-content screening combines automated microscopy with customizable algorithms capable of detecting and quantifying many different types of phenotypic information in fixed and live cells. The HCS Operetta combines the quality of a spinning disk confocal microscope with Harmony HCS software, which contains many common algorithms such as nuclei and cell detection as well as the ability to detect complex phenotypes automatically using machine learning.

4. ELECTRON MICROSCOPY SERVICE:

- **Thermo Scientific-FEI Tecnai G2 20 Twin Transmission Electron Microscope:** In addition to the conventional applications of transmission electron microscopy, this equipment allows for more advanced studies, such as tomography-ET, cryo-ET, cryo-tomography, and EDS (Energy-Dispersive X-ray Spectroscopy).
- **Thermo Scientific-FEI Quanta 250 FEG Scanning Electron Microscope:** One of the most notable features of this equipment is that it is equipped to perform studies in environmental mode, ESEM (environmental scanning electron microscopy), wet-STEM (scanning transmission electron microscopy), and EDS (energy dispersive X-ray spectroscopy).

5. MAGNETOMETRY DEPARTMENT

- **VAM Lake Shore Cryotronics 8604 Magnetometer:** With this equipment, magnetization measurements at room temperature and as a function of temperature (between 2 and 400 K), determination of magnetic transition temperatures (Curie, Neel) in the previous range, magnetic granulometry for studies of small metallic particles and magnetic oxides; cyclic measurements of hysteresis; permeability; coercivity for soft materials; permanent magnets up to magnetic fields of 7 Teslas; and obtaining magnetization curves after cooling with and without a field (FC/ZFC curves).

6. SAMPLE PREPARATION ROOMS:

Electron Microscopy Service:

- Vitrobot Mark IV from Thermo Scientific-FEI, for sample preparation in aqueous solution for cryo-ET.
- LEICA EM UC7 Ultramicrotome, with LEICA EM FC7 cryoultramicrotomy module.
- LEICA EM AFS2 low-temperature freeze substitution and sample inclusion equipment with a LEICA EM FSP automatic reagent dispensing system.
- LEICA EM HPM 100 high-pressure freeze fixation equipment
- LEICA EM SCD 500 high-vacuum sample coating and metal coating system
- Glass knife preparation equipment for cryo-ultramicrotomy, LEICA EM KMR3 (cutting) and LEICA EM MP (mounting for collecting slices)
- LEICA DM 1000 conventional optical microscope
- LEICA S4 E stereomicroscope with LEICA L2 illumination system
- Laboratory for embedding samples in resin (shared use laboratory)

Nuclear Magnetic Resonance Service:

- Class II biosafety hood
- Cold room (common use area)

7. RADIOACTIVE EQUIPMENT ROOMS:

- **Precision X-RAD 220XL irradiator.** Compact cabinet X-ray irradiator for higher energy irradiation studies, ideal for delivering high doses in biology and materials science. This system can be used to irradiate in vivo (rats and mice) and in vitro (cell cultures) models.

Scientific Manager: Dr. María Luisa García Martín

Coordinator: Dr. Mónica Feijóo Cuaresma

Personnel in 2024: 5 Technicians

Main results 2024:

- A total of 56 requests were responded to, with a total turnover of €68,700.
- Thirty-four training activities were carried out.
- Ten teaching support activities were carried out.
- The unit was cited in 14 scientific articles published in 2024.
- More than 35 users belonging to 25 research groups used the Nanoimaging Unit's services.

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

CHEMISTRY

The unit's mission is to provide services to researchers from the IBIMA Plataforma BIONAND and associated laboratories as well as to visitors from other research institutes. It also contributed to conducting research projects and promoting cooperation among groups.

This service offers infrastructure and equipment for the synthesis and physical and chemical characterization of molecules and nanomaterials as well as for the evaluation of their interaction with biological samples. The platform is equipped with:

- Particle Analyzer by Dynamic Light Scattering (DLS) Particle Analyzer Malvern Nano ZS90 ZetaSizer
- NTA, Nanoparticle Tracking Analysis
- Four-glove dry chamber
- Varian UV-Vis Absorption Spectrometer (CARY-100 BIO-MELT)
- PerkinElmer LS-55 Plate Fluorescence Spectrometer
- FT/IR Infrared Spectrometer Jasco PS-4000
- HPLC chromatograph with UV-Vis and refractive index detectors. JASCO LC-2000-PLUS
- FPLC chromatograph with UV-Vis and electrochemical detectors. JASCO UV-2075
- GPC WATERS chromatograph: gel permeation or molecular exclusion chromatograph with photo diode array UV-Vis spectrometry detector, refractive index detector, light scattering detector, and fraction collector.
- MBraun MB-SPS-800 5-solvent drying system
- Lan Technics Polarimeter
- Melting point meter
- Liberty Blue 2.0 Peptide Synthesizer
-

Scientific Manager: José Juan Reina

Location: IBIMA Plataforma BIONAND building in Málaga TechPark.

The IBIMA Plataforma BIONAND center has chemical synthesis laboratories duly equipped with safety cabins, rotary evaporators, safety cabinets, etc. The Chemistry Platform is located at IBIMA Plataforma BIONAND and comprises several facilities/spaces:

- General Chemistry Laboratory (floor 1)
- Chemistry Unit (floor -1).

Operation:

- User self-service (own use).
- You must log in to most equipment with a username/password.
- This requires prior user authorization by the person in charge of the unit (request by email) after confirming that the user has mastered and knows how to operate the equipment to be used.
- Access to the Chemistry Unit room requires authorization to enter with a card.



ANNEXES

PUBLICATIONS

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Chacón, P; Vega-Rioja, A; Doukkali, B; Rodriguez, ADV; Fernández-Delgado, L; Domínguez-Cereijo, L; Segura, C; Perez-Machuca, BM; Perkins, JR; El Bekay, R; Cornejo-García, JA; Hajji, N; Monteseirín, J; Rivas-Pérez, D	Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE	19.0	D1	Article	2024
A-01	Avendano, MS; Perdices-Lopez, C; Guerrero-Ruiz, Y; Ruiz-Pino, F; Rodriguez-Sanchez, AB; Sanchez-Tapia, MJ; Sobrino, V; Pineda, R; Barroso, A; Correa-Saez, A; Lara-Chica, M; Fernandez-Garcia, JC; Garcia-Redondo, AB; Hernanz, R; Ruiz-Cruz, M; Garcia-Galiano, D; Pitteloud, N; Calzado, MA; Briones, AM; Vazquez, MJ; Tena-Sempere, M	The evolutionary conserved miR-137/325 tandem mediates obesity-induced hypogonadism and metabolic comorbidities by repressing hypothalamic kisspeptin	METABOLISM-CLINICAL AND EXPERIMENTAL	11.0	D1	Article	2024
A-01	Zeng, XF; Varady, KA; Wang, XD; Targher, G; Byrne, CD; Tayyem, R; Latella, G; Bergheim, I; Valenzuela, R; George, J; Newberry, C; Zheng, JS; George, ES; Spearman, CW; Kontogianni, MD; Ristic-Medic, D; Peres, WAF; Depboylu, GY; Yang, WS; Chen, X; Rosqvist, F; Mantzoros, CS; Valenti, L; Yki-Järvinen, H; Mosca, A; Sookoian, S; Misra, A; Yilmaz, Y; Kim, W; Fouad, Y; Sebastiani, G; Wong, VWS; Åberg, F; Wong, YJ; Zhang, PH; Bermúdez-Silva, FJ; Ni, Y; Lupsor-Platon, M; Chan, WK; Méndez-Sánchez, N; Knekt, RJD; Alam, S; Treeprasertsuk, S; Wang, L; Du, ML; Zhang, TJ; Yu, ML; Zhang, HJ; Qi, XS; Liu, X; Pinyopornpanish, K; Fan, YC; Niu, KJ; Jimenez-Chillaron, JC; Zheng, MH	The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus	METABOLISM-CLINICAL AND EXPERIMENTAL	11.0	D1	Article	2024
A-01	Herrera-Martínez, AD; Prior-Sánchez, I; Fernández-Soto, ML; García-Olivares, M; Novo-Rodríguez, C; González-Pacheco, M; Martínez-Ramírez, MJ; Carmona-Llanos, A; Jiménez-Sánchez, A; Muñoz-Jiménez, C; Torres-Flores, F; Fernández-Jiménez, R; Boughanem, H; del Galindo-Gallardo, MC; Luengo-Pérez, LM; Molina-Puerta, MJ; García-Almeida, JM	Improving the nutritional evaluation in head neck cancer patients using bioelectrical impedance analysis: Not only the phase angle matters	JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE	9.4	D1	Article	2024
A-01	Rehues, P; Girona, J; Guardiola, M; Ozcariz, E; Amigó, N; Rosales, R; Esteban, Y; Banús, H; Gavalda-Alsina, G; González-Lleó, A; Rojo-Martínez, G; Ribalta, J	ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III	CARDIOVASCULAR DIABETOLOGY	8.5	D1	Article	2024
A-01	Ozcariz, E; Guardiola, M; Amigó, N; Valdés, S; Oualla-Bachiri, W; Rehues, P; Rojo-Martinez, G; Ribalta, J	H-NMR metabolomics identifies three distinct metabolic profiles differentially associated with cardiometabolic risk in patients with obesity in the Di@bet.es cohort	CARDIOVASCULAR DIABETOLOGY	8.5	D1	Article	2024
A-01	Wreven, E; de Adana, MSR; Hardiville, S; Gmyr, V; Kerr-Conte, J; Chetboun, M; Pasquetti, G; Delalleau, N; Thévenet, J; Coddeville, A; Herrera, MJV; Hinden, L; Espínola, ICB; Duro, MG; Salido, LS; Linares, F; Bermúdez-Silva, FJ; Tam, J; Bonner, C; Egan, JM; Oliveira, G; Colomo, N; Pattou, F; González-Mariscal, I	Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulinitis in humans	DIABETOLOGIA	8.4	D1	Article	2024
A-01	Lhamyani, S; Gentile, AM; Mengual-Mesa, M; Grueso, E; Giráldez-Pérez, RM; Fernandez-Garcia, JC; Vega-Rioja, A; Clemente-Postigo, M; Pearson, JR; González-Mariscal, I; Oliveira, G; Bermudez-Silva, FJ; El Bekay, R	Au@16-pH-16/miR-21 mimic nanosystem: An efficient treatment for obesity through browning and thermogenesis induction	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
A-01	Montero, E; Bujaldón, R; Montanya, E; Calle-Pascual, AL; Rojo-Martínez, G; Castaño, L; Franch-Nadal, J; Delgado, E; Chaves, F; Alonso, B; Sanz, M; Herrera, D	Cross-sectional association between severe periodontitis and diabetes mellitus: A nation-wide cohort study	JOURNAL OF CLINICAL PERIODONTOLOGY	5.8	D1	Article	2024
A-01	Varela-Moreno, E; Anarte-Ortiz, MT; Jodar-Sanchez, F; Garcia-Palacios, A; Monreal-Bartolome, A; Gili, M; García-Campayo, J; Mayoral-Cleries, F	Economic Evaluation of a Web Application Implemented in Primary Care for the Treatment of Depression in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial	JMIR MHEALTH AND UHEALTH	5.4	D1	Article	2024
A-01	El Janahi, S; Filali, M; Boudar, Z; Akhattab, A; El Jaoudi, R; Al Idrissi, N; Dini, N; Nejari, C; Yahyaoui, R; Lloyd-Puryear, MA; Ghazal, H	Newborn Screening for Six Primary Conditions in a Clinical Setting in Morocco	INTERNATIONAL JOURNAL OF NEONATAL SCREENING	4.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Aragón-González, A; Shaw, AC; Kok, JR; Roussel, FS; Souza, CD; Granger, SM; Vetter, T; de Diego, Y; Meyer, KC; Beal, SN; Shaw, PJ; Ferraiuolo, L	C9ORF72 patient-derived endothelial cells drive blood-brain barrier disruption and contribute to neurotoxicity	FLUIDS AND BARRIERS OF THE CNS	5.9	Q1	Article	2024
A-01	Quirós, C; Arranz, MTH; Amigó, J; Wägner, AM; Beato-Vibora, PI; Azriel-Mira, S; Climent, E; Soldevila, B; Barquiel, B; Colomo, N; Durán-Martínez, M; Corcoy, R; Codina, M; Díaz-Soto, G; Pardo, RM; Martínez-Brocca, MA; Roman, AR; López-Gallardo, G; Cuesta, M; Fernández, JG; Goya, M; Guedes, BV; Mathison, LCM; Perea, V	Real-World Evidence of Off-Label Use of Commercially Automated Insulin Delivery Systems Compared to Multiple Daily Insulin Injections in Pregnancies Complicated by Type 1 Diabetes	DIABETES TECHNOLOGY & THERAPEUTICS	5.7	Q1	Article	2024
A-01	Moreno-Pérez, O; Reyes-Garcia, R; Modrego-Pardo, I; Doulatram-Gamgaram, VK; Cases, CC; Guillen-Morote, C; Mendoza, NA; Tejera-Pérez, C; Cárdenas-Salas, J; Martínez-Fuster, S; Lardiés-Sánchez, B; Márquez-Pardo, R; Pinés, P; Fernández-García, JC	Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S-RWD)	DIABETES OBESITY & METABOLISM	5.4	Q1	Article	2024
A-01	Araujo-Castro, M; Biagetti, B; Torre, EM; Novoa-Testa, I; Cordido, F; Corrales, EP; Berrocal, VR; Guerrero-Pérez, F; Vicente, A; Percovich, JC; Centeno, RG; González, L; Garcia, MDO; Echarri, AI; Rodríguez, MDM; Novo-Rodríguez, C; Calatayud, M; Villar, R; Bernabéu, I; Alvarez-Escola, C; Valderrama, PB; Tenorio-Jiménez, C; Galiana, PA; Moreno, EV; Molero, IG; Iglesias, P; Blanco, C; De Lara, FVO; de Miguel, P; Mezquita, EL; Hanzu, F; Aldecoa, I; Lamas, C; Aznar, S; Aulinas, A; Calabrese, A; Gracia, P; Recio-Córdova, JM; Aviles, M; Asensio-Wandosel, D; Sampedro, M; Ruz-Caracuel, I; Camara, R; Paja, M; Fajardo-Montañana, C; Marazuela, M; Puig-Domingo, M	Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.0	Q1	Article	2024
A-01	Núñez-Sánchez, MA; Martínez-Sánchez, MA; Martínez-Montoro, JI; Balaguer-Román, A; Murcia-García, E; Fernández-Ruiz, VE; Ferrer-Gómez, M; Martínez-Cáceres, CM; Sledzinski, T; Frutos, MD; Hernández-Morante, JJ; Fernández-Garcia, JC; Queipo-Ortuno, MI; Ruiz-Alcaraz, AJ; Mika, A; Ramos-Molina, B	Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.0	Q1	Article	2024
A-01	Laborda-Illanes, A; Aranega-Martín, L; Sánchez-Alcoholado, L; Boutriq, S; Plaza-Andrades, I; Peralta-Linero, J; Ruiz, GG; Pajares-Hachero, B; Alvarez, M; Alba, E; González-González, A; Queipo-Ortuño, MI	Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
A-01	Sasso, CV; Lhamyani, S; Hevilla, F; Padial, M; Blanca, M; Barril, G; Jiménez-Salcedo, T; Martínez, ES; Nogueira, A; Lago-Sampedro, AM; Oliveira, G	Modulation of miR-29a and miR-29b Expression and Their Target Genes Related to Inflammation and Renal Fibrosis by an Oral Nutritional Supplement with Probiotics in Malnourished Hemodialysis Patients	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
A-01	Jiménez-Cortegana, C; López-Enríquez, S; Alba, G; Santa-María, C; Martín-Núñez, GM; Moreno-Ruiz, FJ; Valdés, S; García-Serrano, S; Rodríguez-Díaz, C; Ho-Plágaro, A; Fontalba-Romero, MI; García-Fuentes, E; Garrido-Sánchez, L; Sánchez-Margalet, V	The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver Function	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
A-01	Soria-Utrilla, V; Sánchez-Torralvo, FJ; Palmas-Candia, FX; Fernández-Jiménez, R; Mucarzel-Suarez-Arana, F; Guirado-Peláez, P; Oliveira, G; García-Almeida, JM; Burgos-Peláez, R	AI-Assisted Body Composition Assessment Using CT Imaging in Colorectal Cancer Patients: Predictive Capacity for Sarcopenia and Malnutrition Diagnosis	NUTRIENTS	4.8	Q1	Article	2024
A-01	Hevilla, F; Porras, N; Girón, MV; García-Olivares, M; Padial, M; Sánchez-Torralvo, FJ; Oliveira, C; Oliveira, G	Impact of Elexacaftor-Tezacaftor-Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study	NUTRIENTS	4.8	Q1	Article	2024
A-01	Sánchez-Torralvo, FJ; Pérez-del-Río, V; Vela, LIN; García-Olivares, M; Porras, N; Fernández, JA; Bardají, MFB; de Quevedo, DG; Oliveira, G	Phase Angle as a Predictor of Mortality in Older Patients with Hip Fracture	NUTRIENTS	4.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Lago-Sampedro, A; Oualla-Bachiri, W; García-Serrano, S; Maldonado-Araque, C; Valdés, S; Doulatram-Gamgaram, V; Oliveira, G; Delgado, E; Chaves, FJ; Castaño, L; Calle-Pascual, A; Franch-Nadal, J; Rojo-Martínez, G; García-Escobar, E	Protective Effect of High Adherence to Mediterranean Diet on the Risk of Incident Type-2 Diabetes in Subjects with MAFLD: The Di@bet.es Study	NUTRIENTS	4.8	Q1	Article	2024
A-01	Arrari, F; Ortiz-Flores, RM; Lhamyani, S; Garcia-Fuentes, E; Jabri, MA; Sebai, H; Bermudez-Silva, FJ	Protective Effects of Spirulina Against Lipid Micelles and Lipopolysaccharide-Induced Intestinal Epithelium Disruption in Caco-2 Cells: In Silico Molecular Docking Analysis of Phycocyanobilin	NUTRIENTS	4.8	Q1	Article	2024
A-01	Mateos, IC; de Lucas, MDG; Doulatram-Gamgaram, VK; Moreno-Moreno, P; Jimenez-Millan, AI; Botana-López, M; Merino-Torres, JF; Soto-González, A; Fernández-García, JC; Morales-Portillo, C	Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)	NUTRIENTS	4.8	Q1	Article	2024
A-01	Martínez-Montoro, JI; Martínez-Sánchez, MA; Balaguer-Román, A; Fernández-Ruiz, VE; Hernández-Barceló, JE; Ferrer-Gómez, M; Frutos, MD; Núñez-Sánchez, MA; Fernández-García, JC; Ramos-Molina, B	Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study	NUTRIENTS	4.8	Q1	Article	2024
A-01	Roman, DD; Almeida, JMG; Guerrero, DB; Rolo, GG; Martín, A; Martín, DP; García-Delgado, Y; Guirado-Peláez, P; Palmas, F; Pérez, CT; Olivares, MG; Jiménez, MM; Lesmes, IB; Teomiro, CMA; Baena, JMG; Romero, LAC; Prior-Sánchez, I; García-Luna, PP; Pacheco, MG; Martínez-Olmos, MA; Alabadí, B; Alcántara-Aragon, V; Milla, SP; Folgueras, TM; García, AM; Molina-Baena, B; Barragán, HR; Gómez, PRD; Fernández, MR; Portilla, AJ; López-Gómez, JJ; Martín, NP; Madrid, NM; Eguinoa, AZ; Fernández, CP; Guerrero, MJT; Aguado, MR; Gimeno, CV; Martínez, ADH; Rodríguez, MN; Hernández, NCI; Medina, MD; Navarro, IG; López, FJV; Fernández-Pombo, A; Oliveira, G	Ultrasound Cut-Off Values for Rectus Femoris for Detecting Sarcopenia in Patients with Nutritional Risk	NUTRIENTS	4.8	Q1	Article	2024
A-01	Fernández-Jiménez, R; García-Rey, S; Roque-Cuéllar, MC; Fernández-Soto, ML; García-Olivares, M; Novo-Rodríguez, M; González-Pacheco, M; Prior-Sánchez, I; Carmona-Llanos, A; Muñoz-Jiménez, C; Zarco-Rodríguez, FP; Miguel-Luengo, L; Boughanem, H; García-Luna, PP; García-Almeida, JM	Ultrasound Muscle Evaluation for Predicting the Prognosis of Patients with Head and Neck Cancer: A Large-Scale and Multicenter Prospective Study	NUTRIENTS	4.8	Q1	Article	2024
A-01	Enríquez, AJ; Rabat-Restrepo, JM; Vilchez-López, FJ; Tenorio-Jiménez, C; García-Almeida, JM; Rocamora, JAI; Pereira-Cunill, JL; Ramírez, MJM; Molina-Puerta, MJ; Soria, JBM; Rebollo-Pérez, MI; Oliveira, G; García-Luna, PP	Practical Guidelines by the Andalusian Group for Nutrition Reflection and Investigation (GARIN) on Nutritional Management of Patients with Chronic Obstructive Pulmonary Disease: A Review	NUTRIENTS	4.8	Q1	Review	2024
A-01	de las Heras, J; Almohalla, C; Blasco-Alonso, J; Bourbon, M; Couce, ML; López, MJD; Jiménez, MCG; Ortega, DG; González-Diéguez, L; Meavilla, S; Moreno-alvarez, A; Pastor-Rosado, J; Sánchez-Pintos, P; Serrano-Gonzalo, I; López, E; Valdivielso, P; Yahyaoui, R; Quintero, J	Practical Recommendations for the Diagnosis and Management of Lysosomal Acid Lipase Deficiency with a Focus on Wolman Disease	NUTRIENTS	4.8	Q1	Review	2024
A-01	Durán-Martínez, M; Azriel, S; Doulatram-Gamgaram, VK; Moreno-Pérez, O; Pines-Corrales, PJ; Tejera-Pérez, C; Merino-Torres, JF; Brito-Sanfiel, M; Chico, A; Marco, A; García-Fernández, E; Martínez-Montoro, JI	Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study	DIABETES & METABOLISM	4.6	Q1	Article	2024
A-01	Guirado-Peláez, P; Fernández-Jiménez, R; Sánchez-Torralvo, FJ; Suárez-Arana, FM; Palmas-Candia, FX; Vegas-Aguilar, I; Amaya-Campos, MD; Tamés, GM; Soria-Utrilla, V; Tinahones-Madueño, F; García-Almeida, JM; Burgos-Peláez, R; Oliveira, G	Multiparametric Approach to the Colorectal Cancer Phenotypes Integrating Morphofunctional Assessment and Computer Tomography	CANCERS	4.5	Q1	Article	2024
A-01	Vílchez-López, FJ; González-Pacheco, M; Fernández-Jiménez, R; Zarco-Martín, MT; Gonzalo-Marín, M; Cobo-Molinos, J; Carmona-Llanos, A; Muñoz-Garach, A; García-Luna, PP; Herrera-Martínez, AD; Zarco-Rodríguez, FP; Galindo-Gallardo, MD; Miguel-Luengo, L; Fernández-Soto, ML; García-Almeida, JM	Predictive Factors of the Degrees of Malnutrition According to GLIM Criteria in Head and Neck Cancer Patients: Valor Group	CANCERS	4.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Valdés, S; Doulatram-Gamgaram, V; Maldonado-Araque, C; Garcia-Escobar, E; Garcia-Serrano, S; Oualla-Bachiri, W; Garcia-Vivanco, M; Garrido, JL; Gil, V; Martin-Llorente, F; Calle-Pascual, A; Castaño, L; Delgado, E; Menéndez, E; Franch-Nadal, J; Gaztambide, S; Gírbés, J; Chaves, FJ; Galán-García, JL; Aguilera-Venegas, G; Vallvé, JC; Amigó, N; Guardiola, M; Ribalta, J; Rojo-Martínez, G	Association between exposure to air pollution and blood lipids in the general population of Spain	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	4.4	Q1	Article	2024
A-01	de Diego-Otero, Y; El Bekay, R; García-Guirado, F; Sánchez-Salido, L; Giráldez-Pérez, RM	Apocynin, a Selective NADPH Oxidase (Nox2) Inhibitor, Ameliorates Behavioural and Learning Deficits in the Fragile X Syndrome Mouse Model	BIOMEDICINES	3.9	Q1	Article	2024
A-01	Montiel, AM; Ruiz-Esteban, P; Del Rio, AD; Valdivielso, P; Chaparro, MAS; Olveira, C	Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype	SCIENTIFIC REPORTS	3.8	Q1	Article	2024
A-01	Araujo-Castro, M; Biagetti, B; Torre, EM; Novoa-Testa, I; Cordido, F; Pascual-Corrales, E; Berrocal, VR; Guerrero-Pérez, F; Vicente, A; Hualpa, JCP; García-Centeno, R; González-Fernández, L; García, MDO; Echarri, AI; Rodríguez, MDM; Novo-Rodríguez, C; Calatayud, M; Villar-Taibo, R; Bernabéu, I; Alvarez-Escola, C; Valderrama, PB; Tenorio-Jiménez, C; Galiana, PA; Venegas, E; González-Molero, I; Iglesias, P; Blanco-Carrera, C; De Lara, FVO; Novoa, PD; Mezquita, EL; Hanzu, FA; Aldecoa, I; Aznar, S; Lamas, C; Aulinas, A; Asla, Q; Gimeno, PG; Recio-Córdova, JM; Avilés-Pérez, MD; Asensio-Wandosell, D; Sampedro-Núñez, M; Cámara, R; Fano, MP; Ruz-Caracuel, I; Fajardo, C; Marazuela, M; Puig-Domingo, M	Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	ENDOCRINE-RELATED CANCER	4.1	Q2	Article	2024
A-01	Prior-Sánchez, I; Herrera-Martínez, AD; Zarco-Martín, MT; Fernández-Jiménez, R; Gonzalo-Marín, M; Muñoz-Garach, A; Vilchez-López, FJ; Cayón-Blanco, M; Villarrubia-Pozo, A; Muñoz-Jiménez, C; Zarco-Rodríguez, FP; Rabat-Restrepo, JM; Luengo-Pérez, LM; Boughanem, H; Martínez-Ramírez, MJ; García-Almeida, JM	Prognostic value of bioelectrical impedance analysis in head and neck cancer patients undergoing radiotherapy: a VALOR® study	FRONTIERS IN NUTRITION	4.0	Q2	Article	2024
A-01	Díez, JJ; Anda, E; Pérez-Corral, B; Paja, M; Alcázar, V; Sánchez-Ragnarsson, C; Orois, A; Romero-Lluch, AR; Sambo, M; Oleaga, A; Caballero, A; Alhambra, MR; Urquijo, V; Delgado-Lucio, AM; Fernández-García, JC; Kishore-Doulatram, V; Duenas-Disotuar, S; Martín, T; Peinado, M; Sastre, J	Incident comorbidities in patients with chronic hypoparathyroidism after thyroidectomy: a multicenter nationwide study	FRONTIERS IN ENDOCRINOLOGY	3.9	Q2	Article	2024
A-01	Menéndez-Torre, EL; Gutiérrez-Hurtado, A; Ollero, MD; Irigaray, A; Martín, P; Parra, P; González-Molero, I; Araujo-Castro, M; Idrobo, C; Moure, MD; Molina, AR; Biagetti, B; Iglesias, P; Paja, M; Villar-Taibo, R; Pena, A; Vicente, A; Guerrero-Pérez, F; Cordido, F; Aulinas, A; Mateu, M; Soto, A	Natural history and surgical outcomes of Rathke's cleft cysts: a Spanish multicenter study	FRONTIERS IN ENDOCRINOLOGY	3.9	Q2	Article	2024
A-01	Díez, JJ; Anda, E; Pérez-Corral, B; Paja, M; Alcazar, V; Sánchez-Ragnarsson, C; Orois, A; Romero-Lluch, AR; Sambo, M; Oleaga, A; Caballero, A; Alhambra, MR; Urquijo, V; Delgado-Lucio, AM; Fernández-García, JC; Doulatram-Gamgaram, VK; Dueñas-Disotuar, S; Martín, T; Peinado, M; Sastre, J	Prevalence of chronic postsurgical hypoparathyroidism not adequately controlled: an analysis of a nationwide cohort of 337 patients	FRONTIERS IN ENDOCRINOLOGY	3.9	Q2	Article	2024
A-01	Montiel, AM; Ruiz-Esteban, P; Del Río, AD; Valdivielso, P; Chaparro, MAS; Olveira, C	The effect of pulmonary rehabilitation on cardiovascular risk, oxidative stress and systemic inflammation in patients with COPD	RESPIRATORY MEDICINE	3.5	Q2	Article	2024
A-01	Pascual-Corrales, E; Biagetti, B; Marazuela, M; Asensio-Wandosel, D; Berrocal, VR; Echarri, AI; Novo-Rodríguez, C; Calatayud, M; Bernabéu, I; Alvarez-Escola, C; Tenorio-Jiménez, C; Molero, IG; Iglesias, P; Blanco, C; de Miguel, P; Mezquita, EL; Lamas, C; Aulinas, A; Gracia, P; Recio-Córdova, JM; Sampedro-Núñez, M; Paja, M; Rodríguez, MDM; Fajardo-Montañana, C; Cordido, F; Torre, EM; Percovich, JC; García-Centeno, R; Cámara, R; Hanzu, FA; Delgado, AV; Fernández, LG; Guerrero-Pérez, F; García-Agulló, MDO; Novoa-Testa, I; Villar-Taibo, R; Valderrama, PB; Galiana, PA; Moreno, EV; De Lara, FVO; Enseñat, J; Aznar, S; Asla, Q; Aviles-Pérez, MD; Puig-Domingo, M; Araujo-Castro, M	Glucose metabolism outcomes after pituitary surgery in patients with acromegaly	PITUITARY	3.3	Q2	Article	2024
A-01	Snoek, FJ; Anarte-Ortiz, MT; Anderbro, T; Cyranka, K; Hendrieckx, C; Hermanns, N; Indelicato, L; Mcguire, BE; Mocan, A; Nefs, G; Polonsky, WH; Stewart, R; Vallis, M	Roles and competencies of the clinical psychologist in adult diabetes care-A consensus report	DIABETIC MEDICINE	3.2	Q2	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Padial, M; Taylor, A; Sabatino, A; Piccoli, GB; Avesani, CM	From ultra-processed foods towards healthy eating for CKD patients: a proposal of educational infographics	JOURNAL OF NEPHROLOGY	2.7	Q2	Article	2024
A-01	Flores, RMO; Cáceres, CS; Cortiñas, TI; Mejiba, SEG; Sasso, CV; Ramirez, DC; Domínguez, MAM	Exotoxins secreted by Clostridium septicum induce macrophage death: Implications for bacterial immune evasion mechanisms at infection sites	TOXICON	2.6	Q2	Article	2024
A-01	Restrepo, JMR; Pérez, IMR; de Luna, PPG; Cunill, JLP; López, FJV; Marin, MG; Doblas, CY; Ortega, AJM; Ramírez, JM; Morell, CL; Rojas, J; Ortiz, M; Corte, JOD; Colorado, MEM	Consensus on criteria and minimum data set for the referral of candidate patients for home enteral nutrition teleconsultation: TELENUT project	NUTRICION HOSPITALARIA	1.2	Q4	Article	2024
A-01	Herrera, MJV; Herrera, VV; Ortega, AD; Guerrero, MJT	Radiological versus endoscopic gastrostomy in patients with amyotrophic lateral sclerosis	NUTRICION HOSPITALARIA	1.2	Q4	Article	2024
A-01	Rojo-Martinez, G; Escobar, EG	The quality of macronutrients and the risk of illness	NUTRICION HOSPITALARIA	1.2	Q4	Editorial Material	2024
A-01	Fuster, GO	The vision of a nutrition unit with management experience	NUTRICION HOSPITALARIA	1.2	Q4	Editorial Material	2024
A-01	Moreno Villares, Jose Manuel; Olveira Fuster, Gabriel	To compete against giants... and yet, it moves (eppur si mouve)	Nutricion hospitalaria	1.2	Q4	Editorial Material	2024
A-01	Olveira, G	Update on the consensus for hospital coding according to GLIM criteria: an approach adapted to hospital complexity	NUTRICION HOSPITALARIA	1.2	Q4	Editorial Material	2024
A-02	Beato-Víbor, PI; Chico, A; Moreno-Fernandez, J; Bellido-Castañeda, V; Nattero-Chávez, L; Picón-César, MJ; Martínez-Brocca, MA; Giménez-Alvarez, M; Aguilera-Hurtado, E; Climent-Biescas, E; Azriel-Mir, S; Rebollo-Román, A; Yoldi-Vergara, C; Pazos-Couselo, M; Alonso-Carril, N; Quirós, C	A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting	DIABETES CARE	15.0	D1	Article	2024
A-02	Kahn, SE; Deanfield, JE; Jeppesen, OK; Emerson, SS; Boesgaard, TW; Colhoun, HM; Kushner, RF; Lingvay, I; Burguera, B; Gajos, G; Horn, DB; Hramiak, IM; Jastreboff, AM; Kokkinos, A; Maeng, M; Matos, ALSA; Tinahones, FJ; Lincoff, AM; Ryan, DH	Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial	DIABETES CARE	15.0	D1	Article	2024
A-02	Khoury, N; Martínez, MA; Nishi, SK; Martinez-Gonzalez, MA; Corella, D; Castañer, O; Martinez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, F; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, J; Pérez-Vega, KA; Garcia-Rios, A; Ortiz-Díaz, F; Gomez-Gracia, E; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Peña-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fito, M; Babio, N; Salas-Salvadó, J	Dietary intake of Perfluorooctanesulfonic acid (PFOS) and glucose homeostasis parameters in a non-diabetic senior population	ENVIRONMENT INTERNATIONAL	10.0	D1	Article	2024
A-02	Rodriguez-Muñoz, A; Motahari-Rad, H; Martin-Chaves, L; Benitez-Porres, J; Rodriguez-Capitan, J; Gonzalez-Jimenez, A; Insenser, M; Tinahones, FJ; Murri, M	A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle	CURRENT OBESITY REPORTS	9.5	D1	Review	2024
A-02	Herrera-Martínez, AD; Prior-Sánchez, I; Fernández-Soto, ML; García-Olivares, M; Novo-Rodríguez, C; González-Pacheco, M; Martínez-Ramírez, MJ; Carmona-Llanos, A; Jiménez-Sánchez, A; Muñoz-Jiménez, C; Torres-Flores, F; Fernández-Jiménez, R; Boughanem, H; del Galindo-Gallardo, MC; Luengo-Pérez, LM; Molina-Puerta, MJ; García-Almeida, JM	Improving the nutritional evaluation in head neck cancer patients using bioelectrical impedance analysis: Not only the phase angle matters	JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE	9.4	D1	Article	2024
A-02	Linares-Pineda, TM; Fragoso-Bargas, N; Picón, MJ; Molina-Vega, M; Jenum, AK; Sletner, L; Lee-Odegård, S; Opsahl, JO; Moen, GH; Qvigstad, E; Prasad, RB; Birkeland, KI; Morcillo, S; Sommer, C	DNA methylation risk score for type 2 diabetes is associated with gestational diabetes	CARDIOVASCULAR DIABETOLOGY	8.5	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Alvarez-Alvarez, L; Rubín-García, M; Vitelli-Storelli, F; García, S; Bouzas, C; Martínez-González, MA; Corella, D; Salvadó, JS; Malcampo, M; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Fernández, CG; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; García-Arellano, A; Martínez, MA; Sorlí, J; Zomeno, MD; García-Rios, A; González-Palacios, S; Monserrat-Mesquida, M; Abete, I; Fernández, AC; Casas, R; Ibáñez, NC; Ugarriza, L; Bernal-López, MR; Bes-Rastrollo, M; Paz-Graniel, I; Asensio, EM; Fitó, M; Larriva, APA; Oncina-Cánovas, A; Vázquez, Z; de la Puente, MF; Pérez-Vega, A; Tur, JA; Martín-Sánchez, V	Effect of a nutritional intervention based on an energy-reduced Mediterranean diet on environmental impact	SCIENCE OF THE TOTAL ENVIRONMENT	8.2	D1	Article	2024
A-02	Lhamyani, S; Gentile, AM; Mengual-Mesa, M; Grueso, E; Giráldez-Pérez, RM; Fernandez-Garcia, JC; Vega-Rioja, A; Clemente-Postigo, M; Pearson, JR; González-Mariscal, I; Oliveira, G; Bermudez-Silva, FJ; El Bekay, R	<u>Au@16-pH-16/miR-21 mimic nanosystem: An efficient treatment for obesity through browning and thermogenesis induction</u>	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
A-02	Román, DD; Gómez, JC; García-Almeida, JM; Vallo, FG; Rolo, GG; Gómez, JLL; Tarazona-Santabalbina, FJ; Sanz-Paris, A	Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	6.9	D1	Review	2024
A-02	Bettinetti-Luque, M; Trujillo-Estrada, L; Garcia-Fuentes, E; Andreo-Lopez, J; Sanchez-Varo, R; Garrido-Sánchez, L; Gómez-Mediavilla, A; López, MG; Garcia-Caballero, M; Gutierrez, A; Baglietto-Vargas, D	Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease	BRITISH JOURNAL OF PHARMACOLOGY	6.8	D1	Review	2024
A-02	García-Gavilán, JF; Atzeni, A; Babio, N; Liang, LM; Belzer, C; Vioque, J; Corella, D; Fitó, M; Vidal, J; Moreno-Indias, I; Torres-Collado, L; Coltell, O; Toledo, E; Clish, C; Hernando, J; Yun, H; Hernández-Cacho, A; Jeanfavre, S; Dennis, C; Gómez-Pérez, AM; Martínez, MA; Ruiz-Canela, M; Tinahones, FJ; Hu, FB; Salas-Salvadó, J	Effect of 1-year lifestyle intervention with energy-reduced Mediterranean diet and physical activity promotion on the gut metabolome and microbiota: a randomized clinical trial	AMERICAN JOURNAL OF CLINICAL NUTRITION	6.5	D1	Article	2024
A-02	Shyam, S; Gómez-Martínez, C; Paz-Graniel, I; Gaforio, JJ; Martínez-González, MA; Corella, D; Fitó, M; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sánchez, VM; Pintó, X; Ramos, M; Vidal, J; Alcarria, MM; Daimiel, L; Ros, E; Fernandez-Aranda, F; Nishi, SK; Regata, OG; Toledo, E; Sorlí, JV; Castañer, O; Garcia-Rios, A; Valls-Enguix, R; Perez-Farinos, N; Zulet, MA; Rayó-Gago, E; Casas, R; Rivera-Izquierdo, M; Tojal-Sierra, L; Damas-Fuentes, M; Buil-Cosiales, P; Fernández-Carrion, R; Goday, A; Peña-Orihuela, PJ; Compañ-Gabucio, L; Diez-Espino, J; Tello, S; González-Pinto, A; de la O, V; Delgado-Rodríguez, M; Babio, N; Salas-Salvadó, J	Coronavirus disease 2019 is associated with long-term depressive symptoms in Spanish older adults with overweight/obesity and metabolic syndrome	PSYCHOLOGICAL MEDICINE	5.9	D1	Article	2024
A-02	Rodríguez-Muñoz, A; Picón-César, MJ; Tinahones, FJ; Martínez-Montoro, J	Type 1 diabetes-related distress: Current implications in care	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1	Article	2024
A-02	Rodríguez-Muñoz, A; Martínez-Montoro, JI; Sojo-Rodriguez, B; Benitez-Porres, J; Carrillo-Albornoz-Gil, M; Carrasco-Fernandez, L; Subiri-Verdugo, A; Molina-Ramos, A; Cobos-Díaz, A; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Glycaemic Response to Acute Aerobic and Anaerobic Exercise Performed in the Morning or Afternoon in Healthy Subjects: A Crossover Trial	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1	Article	2024
A-02	Ruiz-Limón, P; Muralidharan, J; Gomez-Perez, AM; Murri, M; Vioque, J; Corella, D; Fito, M; Vidal, J; Salas-Salvadó, J; Torres-Collado, L; Coltell, O; Atzeni, A; Castañer, O; Bulló, M; Bernal-López, MR; Moreno-Indias, I; Tinahones, FJ	Physical activity shifts gut microbiota structure in aged subjects with overweight/obesity and metabolic syndrome	BIOLOGY OF SPORT	4.2	D1	Article	2024
A-02	Hinojosa-Nogueira, D; Russo, MD; Navajas-Porras, B; Delgado-Osorio, A; Pérez-Burillo, S; La Grutta, S; Cilluffo, G; Malizia, V; de la Cueva, SP; Lauria, F; Rufián-Henares, JA	Associations between the prevalence of asthma and dietary exposure to food contaminants in children: CHASER study	WORLD JOURNAL OF PEDIATRICS	3.6	D1	Article	2024
A-02	Cornejo-Pareja, I; Amiar, MR; Ocaña-Wilhelmi, L; Soler-Humanes, R; Arranz-Salas, I; Garrido-Sánchez, L; Gutiérrez-Repiso, C; Tinahones, FJ	Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism	JOURNAL OF GASTROENTEROLOGY	6.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Boughanem, H; Pilo, J; García-Flores, LA; Arranz, I; Ramos-Fernandez, M; Ortega-Castan, M; Crujeiras, AB; Sandoval, J; Macias-Gonzalez, M	Identification of epigenetic silencing of the SFRP2 gene in colorectal cancer as a clinical biomarker and molecular significance	JOURNAL OF TRANSLATIONAL MEDICINE	6.1	Q1	Article	2024
A-02	Martínez-Montoro, JI; Martín-Núñez, GM; González-Jiménez, A; Garrido-Sánchez, L; Moreno-Indias, I; Tinahones, FJ	Interactions between the gut microbiome and DNA methylation patterns in blood and visceral adipose tissue in subjects with different metabolic characteristics	JOURNAL OF TRANSLATIONAL MEDICINE	6.1	Q1	Article	2024
A-02	Garcia-Flores, LA; De Vera, MTD; Pilo, J; Rego, A; Gomez-Casado, G; Arranz-Salas, I; Martín, IH; Alcaide, J; Torres, E; Ortega-Gomez, A; Boughanem, H; Macias-Gonzalez, MM	Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
A-02	Araujo-Castro, M; Fano, MP; González-Boillos, M; Pascual-Corrales, E; Ramírez, PP; Rojas-Marcos, PM; García-Cano, A; Ruiz-Sanchez, JG; Vicente, A; Gómez-Hoyos, E; Casterás, A; Puig-Perez, A; Sanz, IG; Recasens, M; San Millan, RB; César, MJP; Guardiola, PD; Perdomo, C; Manjón-Miguélez, L; Román, AR; Lázaro, CR; Recio, JM; Morales-Ruiz, M; Calatayud, M; López, NJ; Meneses, D; Nuñez, MS; Ribas, EM; Sánchez, AS; Diaz, CG; Lamas, C; Tous, MD; Serrano, J; Michalopoulou, T; Rodrigo, ST; Chamorro, RR; Aguila, FJ; Mateo, EMM; Gutiérrez-Medina, S; Hanzu, FA	Influence of smoking on cardiometabolic profile and surgical outcomes in patients with primary aldosteronism: a cohort study	EUROPEAN JOURNAL OF ENDOCRINOLOGY	5.3	Q1	Article	2024
A-02	Sampedro-Nunez, Miguel; Herrera-Martinez, Aura Dulcinea; Ibanez-Costa, Alejandro; Rivero-Cortes, Esther; Venegas, Eva; Robledo, Mercedes; Martinez-Hernandez, Rebeca; Garcia-Martinez, Araceli; Gil, Joan; Jorda, Mireia; Lopez-Fernandez, Judith; Gavilan, Inmaculada; Maraver, Silvia; Marques-Pamies, Montserrat; Camara, Rosa; Fajardo-Montanana, Carmen; Valassi, Elena; Dios, Elena; Aulinas, Anna; Biagetti, Betina; Alvarez Escola, Cristina; Araujo-Castro, Marta; Blanco, Concepcion; Paz, de Miguel; Villar-Taibo, Rocío; Alvarez, Clara V; Gaztambide, Sonia; Webb, Susan M; Castano, Luis; Bernabeu, Ignacio; Pico, Antonio; Galvez, Maria-Angeles; Soto-Moreno, Alfonso; Puig-Domingo, Manel; Castano, Justo P; Marazuela, Monica; Luque, Raul M	Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study.	European journal of endocrinology	5.3	Q1	Article	2024
A-02	Atzeni, A; Díaz-López, A; Cacho, AH; Babio, N; García-Gavilán, JF; Cornejo-Pareja, I; Belzer, C; Fitó, M; Tinahones, FJ; Salas-Salvadó, J	Gut microbiota dynamics and association with chronic kidney disease: A longitudinal study within the PREDIMED-Plus trial	LIFE SCIENCES	5.2	Q1	Article	2024
A-02	Mena-Vázquez, N; Ortiz-Márquez, F; Ramírez-García, T; Cabezudo-García, P; García-Studer, A; Mucientes-Ruiz, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Redondo-Rodríguez, R; Manrique-Arija, S; Cano-García, L; Serrano-Castro, PJ; Fernández-Nebro, A	Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis	RMD OPEN	5.1	Q1	Article	2024
A-02	Oliveras-Cañellas, N; Moreno-Navarrete, JM; Lorenzo, PM; Garrido-Sánchez, L; Becerril, S; Rangel, O; Latorre, J; Vargas, ED; Pardo, M; Valentí, V; Romero-Cabrera, JL; Oliva-Olivera, W; Silva, C; Diéguez, C; Villarroya, F; López, M; Crujeiras, AB; Seoane, LM; López-Miranda, J; Frühbeck, G; Tinahones, FJ; Fernández-Real, JM	Downregulated Adipose Tissue Expression of Browning Genes With Increased Environmental Temperatures	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.0	Q1	Article	2024
A-02	Núñez-Sánchez, MA; Martinez-Sánchez, MA; Martínez-Montoro, JI; Balaguer-Román, A; Murcia-García, E; Fernández-Ruiz, VE; Ferrer-Gómez, M; Martínez-Cáceres, CM; Sledzinski, T; Frutos, MD; Hernández-Morante, JJ; Fernández-Garcia, JC; Queipo-Ortuno, MI; Ruiz-Alcaraz, AJ; Mika, A; Ramos-Molina, B	Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.0	Q1	Article	2024
A-02	Peña-Montero, N; Linares-Pineda, TM; Fernández-Valero, A; Lima-Rubio, F; Fernández-Ramos, AM; Gutiérrez-Repiso, C; Suárez-Arana, M; Picón-César, MJ; Molina-Vega, M; Morcillo, S	Differences in DNA Methylation in Genes Involved in Vitamin D Metabolism Are Related to Insulin Requirement in Pregnant Women with Gestational Diabetes Mellitus	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
A-02	Mucientes, A; Lisbona-Montañez, JM; Mena-Vázquez, N; Ruiz-Limón, P; Manrique-Arija, S; García-Studer, A; Ortiz-Márquez, F; Fernández-Nebro, A	Intestinal Dysbiosis, Tight Junction Proteins, and Inflammation in Rheumatoid Arthritis Patients: A Cross-Sectional Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Jiménez-Cortegana, C; López-Enríquez, S; Alba, G; Santa-María, C; Martín-Núñez, GM; Moreno-Ruiz, FJ; Valdés, S; García-Serrano, S; Rodríguez-Díaz, C; Ho-Plágaro, A; Fontalba-Romero, MI; García-Fuentes, E; Garrido-Sánchez, L; Sánchez-Margalet, V	The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver Function	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
A-02	Gómez-Zorita, S; Proença, C; Fernández-Quintela, A; Moreno-Indias, I; Portillo, MP	Beneficial Effects of Xanthohumol on Metabolic Syndrome: Evidence from In Vitro and Animal Model Studies	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
A-02	Soria-Utrilla, V; Sánchez-Torralvo, FJ; Palmas-Candia, FX; Fernández-Jiménez, R; Mucarzel-Suarez-Arana, F; Guirado-Peláez, P; Oliveira, G; García-Almeida, JM; Burgos-Peláez, R	AI-Assisted Body Composition Assessment Using CT Imaging in Colorectal Cancer Patients: Predictive Capacity for Sarcopenia and Malnutrition Diagnosis	NUTRIENTS	4.8	Q1	Article	2024
A-02	Cantarero-Cuenca, A; Gonzalez-Jimenez, A; Martinez-Núñez, GM; Garrido-Sánchez, L; Ranea, JAG; Tinahones, FJ	Epigenetic profiles in blood and adipose tissue: identifying strong correlations in morbidly obese and non-obese patients	JOURNAL OF MOLECULAR MEDICINE-JMM	4.8	Q1	Article	2024
A-02	Hinojosa-Nogueira, D; Romero-Molina, D; González-Alzaga, B; Giménez-Asensio, MJ; Hernandez, AF; Navajas-Porras, B; Delgado-Osorio, A; Gomez-Martin, A; Pérez-Burillo, S; de la Cueva, S; Lacasaña, M; Rufián-Henares, JA	Evaluation of Polyphenol Intake in Pregnant Women from South-Eastern Spain and the Effect on Anthropometric Measures at Birth and Gestational Age	NUTRIENTS	4.8	Q1	Article	2024
A-02	Fernández-Jiménez, R; Sanmartín-Sánchez, A; Cabrera-César, E; Espíldora-Hernández, F; Vegas-Aguilar, I; Amaya-Campos, MD; Palmas-Candia, FX; Claro-Brandner, M; Olivares-Alcolea, J; Simón-Frapolli, VJ; Cornejo-Pareja, I; Guirado-Peláez, P; Vidal-Suárez, A; Sánchez-García, A; Murri, M; Garrido-Sánchez, L; Tinahones, FJ; Velasco-Garrido, JL; García-Almeida, JM	IA-Body Composition CT at T12 in Idiopathic Pulmonary Fibrosis: Diagnosing Sarcopenia and Correlating with Other Morphofunctional Assessment Techniques	NUTRIENTS	4.8	Q1	Article	2024
A-02	Gómez-Pérez, AM; Muñoz-Garach, A; Lasserrot-Cuadrado, A; Moreno-Indias, I; Tinahones, FJ	Microbiota Transplantation in Individuals with Type 2 Diabetes and a High Degree of Insulin Resistance	NUTRIENTS	4.8	Q1	Article	2024
A-02	Oncina-Cánovas, A; Compañ-Gabucio, L; Vioque, J; Ruiz-Canela, M; Corella, D; Salas-Salvadó, J; Fitó, M; Martínez, A; Alonso-Gómez, AM; Wärnberg, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Alvarez-Pérez, J; Bueno-Cavanillas, A; Tur, JA; Martín-Sánchez, V; Esteve-Luque, V; Delgado-Rodríguez, M; Ortiz-Ramos, M; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Razquin, C; Paz-Graniel, I; Sorlí, JV; Castañer, O; García-Rios, A; Torres-Collado, L; Fernández-Barceló, O; Zulet, MA; Rayó-Gago, E; Casas, R; Cano-Ibáñez, N; Tojal-Sierra, L; Simón-Frapolli, VJ; Carlos, S; Shyam, S; Fernández-Carrión, R; Goday, A; Torres-Peña, JD; González-Palacios, S; Eguaras, S; Babio, N; Zomeño, MD; García-de-la-Hera, M	More Adult Women than Men at High Cardiometabolic Risk Reported Worse Lifestyles and Self-Reported Health Status in the COVID-19 Lockdown	NUTRIENTS	4.8	Q1	Article	2024
A-02	Joaquín, C; Bretón, I; Bretón, MJO; Burgos, R; Bellido, D; Matía-Martín, P; Olmos, MAM; Zugasti, A; Riestra, M; Botella, F; Almeida, JMG	Nutritional and Morphofunctional Assessment of Post-ICU Patients with COVID-19 at Hospital Discharge: NutriEcoMuscle Study	NUTRIENTS	4.8	Q1	Article	2024
A-02	Marcos-Delgado, A; Martín-Sánchez, V; Martinez-Gonzalez, MA; Corella, D; Salas-Salvadó, J; Schröder, H; Martínez, A; Alonso-Gomez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Alvarez-Pérez, J; Bueno-Cavanillas, A; Cano-Ibáñez, N; Amezcua-Prieto, C; Hernández-Segura, N; Tur, JA; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Toledo, E; Garcidueñas-Fimbres, TE; Viaplana, J; Asensio, EM; Zomeño, MD; Garcia-Rios, A; Oncina-Cánovas, A; Barón-López, FJ; Pérez-Farinos, N; Sayon-Orea, C; Galmés-Panadés, AM; Casas, R; Tojal-Sierra, L; Gómez-Pérez, AM; Buil-Corsiales, P; García-Gavilán, JF; Ortega-Azorín, C; Castañer, O; Peña-Orihuela, PJ; González-Palacios, S; Babio, N; Fitó, M; Nieto, J	Objectively Measured Sleep Duration and Health-Related Quality of Life in Older Adults with Metabolic Syndrome: A One-Year Longitudinal Analysis of the PREDIMED-Plus Cohort	NUTRIENTS	4.8	Q1	Article	2024
A-02	Hinojosa-Nogueira, D; Subiri-Verdugo, A; Díaz-Perdigones, CM; Rodríguez-Muñoz, A; Vilches-Pérez, A; Mela, V; Tinahones, FJ; Moreno-Indias, I	Precision or Personalized Nutrition: A Bibliometric Analysis	NUTRIENTS	4.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Olid-Cárdenas, MJ; Lendínez-Jurado, A; Monroy-Rodríguez, G; Gómez-Perea, A; Cano-Ortiz, A; Ariza-Jiménez, AB; García-Ruiz, A; Jiménez-Cuenca, P; Picón-César, MJ; Leiva-Gea, I	Real-World Use of Hybrid Closed-Loop Systems during Diabetes Camp: A Preliminary Study for Secure Configuration Strategies in Children and Adolescents	NUTRIENTS	4.8	Q1	Article	2024
A-02	Martínez-Montoro, JI; Martínez-Sánchez, MA; Balaguer-Román, A; Fernández-Ruiz, VE; Hernández-Barceló, JE; Ferrer-Gómez, M; Frutos, MD; Núñez-Sánchez, MA; Fernández-García, JC; Ramos-Molina, B	Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study	NUTRIENTS	4.8	Q1	Article	2024
A-02	Roman, DD; Almeida, JMG; Guerrero, DB; Rolo, GG; Martín, A; Martín, DP; García-Delgado, Y; Guirado-Peláez, P; Palmas, F; Pérez, CT; Olivares, MG; Jiménez, MM; Lesmes, IB; Teomiro, CMA; Baena, JMG; Romero, LAC; Prior-Sánchez, I; García-Luna, PP; Pacheco, MG; Martínez-Olmos, MA; Alabadí, B; Alcántara-Aragon, V; Milla, SP; Folgueras, TM; García, AM; Molina-Baena, B; Barragán, HR; Gómez, PRD; Fernández, MR; Portilla, AJ; López-Gómez, JJ; Martín, NP; Madrid, NM; Eguinoa, AZ; Fernández, CP; Guerrero, MJT; Aguado, MR; Gimeno, CV; Martínez, ADH; Rodríguez, MN; Hernández, NCI; Medina, MD; Navarro, IG; López, FJV; Fernández-Pombo, A; Oliveira, G	Ultrasound Cut-Off Values for Rectus Femoris for Detecting Sarcopenia in Patients with Nutritional Risk	NUTRIENTS	4.8	Q1	Article	2024
A-02	Fernández-Jiménez, R; García-Rey, S; Roque-Cuéllar, MC; Fernández-Soto, ML; García-Olivares, M; Novo-Rodríguez, M; González-Pacheco, M; Prior-Sánchez, I; Carmona-Llanos, A; Muñoz-Jiménez, C; Zarco-Rodríguez, FP; Miguel-Luengo, L; Boughanem, H; García-Luna, PP; García-Almeida, JM	Ultrasound Muscle Evaluation for Predicting the Prognosis of Patients with Head and Neck Cancer: A Large-Scale and Multicenter Prospective Study	NUTRIENTS	4.8	Q1	Article	2024
A-02	Martínez-Montoro, JI; Arranz-Salas, I; Gutiérrez-Repiso, C; Sánchez-García, A; Ocana-Wilhelmi, L; Pinazo-Bandera, JM; Fernández-García, D; Munoz-Garach, A; Morales-García, D; Garcia-Cortes, M; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study	NUTRIENTS	4.8	Q1	Article	2024
A-02	Vargas-Molina, S; Murri, M; Gonzalez-Jimenez, A; Gómez-Urquiza, JL; Benítez-Porres, J	Effects of the Ketogenic Diet on Strength Performance in Trained Men and Women: A Systematic Review and Meta-Analysis	NUTRIENTS	4.8	Q1	Review	2024
A-02	Enríquez, AJ; Rabat-Restrepo, JM; Vilchez-López, FJ; Tenorio-Jiménez, C; García-Almeida, JM; Rocamora, JAI; Pereira-Cunill, JL; Ramírez, MJM; Molina-Puerta, MJ; Soria, JBM; Rebollo-Pérez, MI; Oliveira, G; García-Luna, PP	Practical Guidelines by the Andalusian Group for Nutrition Reflection and Investigation (GARIN) on Nutritional Management of Patients with Chronic Obstructive Pulmonary Disease: A Review	NUTRIENTS	4.8	Q1	Review	2024
A-02	Lopez-Pedrosa, JM; Camprubi-Robles, M; Guzman-Rolo, G; Lopez-Gonzalez, A; Garcia-Almeida, JM; Sanz-Paris, A; Rueda, R	The Vicious Cycle of Type 2 Diabetes Mellitus and Skeletal Muscle Atrophy: Clinical, Biochemical, and Nutritional Bases	NUTRIENTS	4.8	Q1	Review	2024
A-02	Durán-Martínez, M; Azriel, S; Doulatram-Gamgaram, VK; Moreno-Pérez, O; Pines-Corrales, PJ; Tejera-Pérez, C; Merino-Torres, JF; Brito-Sanfiel, M; Chico, A; Marco, A; García-Fernández, E; Martínez-Montoro, JI	Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study	DIABETES & METABOLISM	4.6	Q1	Article	2024
A-02	Doímguez-Lpóez, I; Galkina, P; Parilli-Moser, I; Arancibia-Riveros, C; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Malcampo, M; Martínez, JA; Tojal-Sierra, L; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Rubín-García, M; Pintó, X; Fernández-Aranda, F; Delgado-Rodríguez, M; Barabash-Bustelo, A; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Toledo, E; Atzeni, A; Asensio, EM; Vera, N; Garcia-Rios, A; Torres-Collado, L; Pérez-Farinós, N; Zulet, M; Chaplin, A; Casas, R; Martín-Peláez, S; Vaquero-Luna, J; Gómez-Pérez, AM; Vázquez-Ruiz, Z; Shyam, S; Ortega-Azorín, C; Talens, N; Peña-Orihuela, PJ; Oncina-Canovas, A; Diez-Espino, J; Babio, N; Fitó, M; Lamuela-Raventós, RM	Microbial Phenolic Metabolites Are Associated with Improved Cognitive Health	MOLECULAR NUTRITION & FOOD RESEARCH	4.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Guirado-Peláez, P; Fernández-Jiménez, R; Sánchez-Torralvo, FJ; Suárez-Arana, FM; Palmas-Candia, FX; Vegas-Aguilar, I; Amaya-Campos, MD; Tamés, GM; Soria-Utrilla, V; Tinahones-Madueño, F; García-Almeida, JM; Burgos-Peláez, R; Oliveira, G	Multiparametric Approach to the Colorectal Cancer Phenotypes Integrating Morphofunctional Assessment and Computer Tomography	CANCERS	4.5	Q1	Article	2024
A-02	Vílchez-López, FJ; González-Pacheco, M; Fernández-Jiménez, R; Zarco-Martín, MT; Gonzalo-Marín, M; Cobo-Molinos, J; Carmona-Llanos, A; Muñoz-Garach, A; García-Luna, PP; Herrera-Martínez, AD; Zarco-Rodríguez, FP; Galindo-Gallardo, MD; Miguel-Luengo, L; Fernández-Soto, ML; García-Almeida, JM	Predictive Factors of the Degrees of Malnutrition According to GLIM Criteria in Head and Neck Cancer Patients: Valor Group	CANCERS	4.5	Q1	Article	2024
A-02	Guardiola, M; Rehues, P; Amigó, N; Arrieta, F; Botana, M; Gimeno-Orna, JA; Girona, J; Martínez-Montoro, JI; Ortega, E; Pérez-Pérez, A; Sánchez-Margalet, V; Pedro-Botet, J; Ribalta, J	Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	4.4	Q1	Review	2024
A-02	Aguas-Ayesa, M; Yáñez-Esquiros, P; Perdomo, CM; Olazarán, L; Vegas-Aguilar, IM; García-Almeida, JM; Gómez-Ambrosi, J; Frühbeck, G	Revisiting the beyond BMI paradigm in excess weight diagnosis and management: A call to action	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	4.4	Q1	Review	2024
A-02	Pérez-Vega, KA; Lassale, C; Zomeño, MD; Castañer, O; Salas-Salvadó, J; Basterra-Gortari, FJ; Corella, D; Estruch, R; Ros, E; Tinahones, FJ; Blanchart, G; Malcampo, M; Muñoz-Aguayo, D; Schröder, H; Fitó, M; Hernáez, A	Breakfast energy intake and dietary quality and trajectories of cardiometabolic risk factors in older adults	JOURNAL OF NUTRITION HEALTH & AGING	4.3	Q1	Article	2024
A-02	Paz-Graniel, I; Valle-Hita, C; Babio, N; Serra-Majem, L; Vioque, J; Zomeño, MD; Corella, D; Pintó, X; Cano-Ibáñez, N; Tur, JA; Cuadrado-Soto, E; Martínez, JA; Díaz-López, A; Torres-Collado, L; Goday, A; Fernández-Carrión, R; Nissenshon, M; Riera-Mestre, A; Garrido-Garrido, E; Bouzas, C; Abete, I; Daimiel, L; Cornejo-Pareja, I; Vázquez-Ruiz, Z; Khoury, N; Pérez-Vega, KA; Salas-Salvadó, J	Long-term association between water intake and kidney function in a population at high cardiovascular risk	JOURNAL OF NUTRITION HEALTH & AGING	4.3	Q1	Article	2024
A-02	Popescu, ML; Rubín-García, M; Alvarez-Alvarez, L; Toledo, E; Corella, D; Salas-Salvadó, J; Pérez-Vega, KA; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Cano-Ibáñez, N; Tur, JA; Naveiro, R; Pintó, X; Delgado-Rodríguez, M; Ortiz-Ramos, M; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Vázquez-Ruiz, Z; Babio, N; Sorlí, J; Castañer, O; García-Rios, A; González-Palacios, S; Zulet, M; Konieczna, J; Casas, R; Maso-Guijarro, P; Tojal-Sierra, L; Gómez-Pérez, AM; Cenoz-Osinaga, JC; Valverde, I; Fernández-Carrión, R; Schröder, H; Larriva, APA; Torres-Collado, L; García-Arellano, A; Palau-Galindo, A; Fitó, M; Martín-Sánchez, V; Fernández-Villa, T	Sex-specific dietary patterns and their association with metabolic syndrome: Insights from a cross-sectional analysis	DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS	4.3	Q1	Article	2024
A-02	Nascimento, RDD; Rizzato, JS; Polezi, G; Boughanem, H; Williams, NG; Borguini, RG; Santiago, MCPD; Junior, MRM; Parry, L	Myrciaria jaboticaba Fruit Peel: Bioactive Composition as Determined by Distinct Harvest Seasons and In Vitro Anti-Cancer Activity	PLANTS-BASEL	4.0	Q1	Article	2024
A-02	Alvarez-Alvarez, L; Vitelli-Storelli, F; Rubín-García, M; García, S; Bouzas, C; Ruíz-Canela, M; Corella, D; Salas-Salvadó, J; Fitó, M; Martínez, JA; Tojal-Sierra, L; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; García-Fernández, C; Esteve-Luque, V; Delgado-Rodríguez, M; Torrego-Ellacuría, M; Vidal, J; Prieto, L; Daimiel, L; Casas, R; Arellano, AG; Shyam, S; González, JI; Castañer, O; García-Rios, A; Díaz, FO; Fernández, AC; Sánchez-Villegas, A; Morey, M; Cano-Ibáñez, N; Sorto-Sánchez, C; Bernal-López, MR; Bes-Rastrollo, M; Nishi, SK; Coltell, O; Zomeno, MD; Pena-Orihuela, PJ; Aparicio, D; Zulet, MA; Vázquez, Z; Babio, N; Perez, KA; Tur, JA; Martín-Sánchez,	Impact of mediterranean diet promotion on environmental sustainability: a longitudinal analysis	PUBLIC HEALTH	3.9	Q1	Article	2024
A-02	Konstanti, P; Gómez-Martínez, C; Muralidharan, J; Vioque, J; Corella, D; Fitó, M; Vidal, J; Tinahones, FJ; Torres-Collado, L; Coltell, O; Castañer, O; Moreno-Indias, I; Atzeni, A; Ruiz-Canela, M; Salas-Salvadó, J; Belzer, C	Faecal microbiota composition and impulsivity in a cohort of older adults with metabolic syndrome	SCIENTIFIC REPORTS	3.8	Q1	Article	2024
A-02	Robles-Mezcua, A; Aguado, NG; de la Rosa, APM; Cruzado-Alvarez, C; Rubio, CJ; Cabeza, AI; Gomez-Doblas, JJ; Jiménez-Navarro, MF; Pierri, MM; García-Pinilla, JM	Sex-based Differences in Heart Failure Biomarkers	CURRENT HEART FAILURE REPORTS	3.8	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Araujo-Castro, M; Fano, MP; González-Boillos, M; Pascual-Corrales, E; Rojas-Marcos, PM; García-Cano, A; Ruiz-Sanchez, JG; Vicente, A; Gómez-Hoyos, E; Casterás, A; Puig-Pérez, A; Sanz, IG; Recasens, M; San Millan, RB; César, MJ; Guardiola, PD; Perdomo, CM; Manjón-Miguélez, L; Román, AR; Lázaro, CR; Recio, JM; Morales-Ruiz, M; Calatayud, M; López, NJ; Meneses, D; Nuñez, MS; Ribas, EM; Sánchez, AS; Diaz, CG; Lamas, C; Tous, MD; Serrano, J; Michalopoulou, T; Rodrigo, ST; Chamorro, RR; Aguila, FJ; Mateo, EMM; Gutiérrez-Medina, S; Hanzu, FA; Ramírez, PP	Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry	JOURNAL OF HYPERTENSION	3.3	Q1	Article	2024
A-02	Kuchay, MS; Martínez-Montoro, JI	Editorial for MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes	JOURNAL OF MAGNETIC RESONANCE IMAGING	3.3	Q1	Editorial Material	2024
A-02	Jiménez-López, R; Romero-Trevejo, JL; Fernández-Romero, L; Martín-Chaves, L; Romero-Cuevas, M; Molina-Ramos, AI; Sánchez-Quintero, MJ; Murri, M; Costa, F; Bodí, V; Gutiérrez-Bedmar, M; Rodríguez-Capitán, J; Pavón-Morón, FJ; Jiménez-Navarro, M	Differential Ophthalmological Profile in Patients with Coronary Artery Disease Coexisting with Type 2 Diabetes Mellitus: Elevated Tear Cytokine Concentrations	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
A-02	Garrigós, M; Garrido, M; Ruiz-López, MJ; García-López, MJ; Veíga, J; Magallanes, S; Soriguer, R; Moreno-Indias, I; Figuerola, J; Martínez-de la Puente, J	Microbiota composition of Culex perexiguus mosquitoes during the West Nile virus outbreak in southern Spain	PLOS ONE	2.9	Q1	Article	2024
A-02	Prior-Sánchez, I; Herrera-Martínez, AD; Zarco-Martín, MT; Fernández-Jiménez, R; Gonzalo-Marín, M; Muñoz-Garach, A; Vilchez-López, FJ; Cayón-Blanco, M; Villarrubia-Pozo, A; Muñoz-Jiménez, C; Zarco-Rodríguez, FP; Rabat-Restrepo, JM; Luengo-Pérez, LM; Boughanem, H; Martínez-Ramírez, MJ; García-Almeida, JM	Prognostic value of bioelectrical impedance analysis in head and neck cancer patients undergoing radiotherapy: a VALOR® study	FRONTIERS IN NUTRITION	4.0	Q2	Article	2024
A-02	Fernández-Jiménez, R; Cabrera-Cesar, E; Sanmartín-Sánchez, A; Sánchez-Garcia, A; Espildora-Hernandez, F; Vegas-Aguilar, I; Amaya-Campos, MD; Guirado-Pelaez, P; Simon-Frapolli, V; Murri, M; Garrido-Sanchez, L; Piñel-Jimenez, L; Cano-Gamonoso, MB; López-García, J; Gémez-Rodríguez, B; Velasco-Garrido, JL; Tinahones, FJ; García-Almeida, JM	Rectus femoris cross sectional area and timed up and go test potential useful of as a predictor of sarcopenia and mortality in idiopathic pulmonary fibrosis	FRONTIERS IN NUTRITION	4.0	Q2	Article	2024
A-02	D'Elia, D; Zomer, A; Indias, IM; Bongcam-Rudloff, E; Bertelsen, RJ; Claesson, MJ	Editorial: Microbiome and machine learning, volume II	FRONTIERS IN MICROBIOLOGY	4.0	Q2	Editorial Material	2024
A-02	Baenas, I; Camacho-Barcia, L; Granero, R; Razquin, C; Corella, D; Gomez-Martinez, C; Castaner-Nino, O; Martinez, JA; Alonso-Gomez, AM; Waernberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Cano-Ibanez, N; Tur, JA; Martin-Sanchez, V; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Jimenez-Murcia, S; Dalsgaard, S; Garcia-Arellano, A; Babio, N; Sorli, JV; Lassale, C; Garcia-de-la-Hera, M; Gomez-Garcia, E; Zulet, MA; Konieczna, J; Martin-Pelaez, S; Tojal-Sierra, L; Basterra-Gortari, FJ; de las Heras-delgado, S; Portoles, O; Munoz-Perez, MA; Arenas-Larriva, AP; Compan-Gabucio, L; Eguaras, S; Shyam, S; Fito, M; Banos, RM; Salas-Salvado, J; Fernandez-Aranda, F	Association between type 2 diabetes and depressive symptoms after a 1-year follow-up in an older adult Mediterranean population	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION	3.9	Q2	Article	2024
A-02	Gómez-García, I; Ladehesa-Pineda, ML; Diaz-Tocados, JM; López-Medina, C; Abalos-Aguilera, MC; Ruiz-Vilches, D; Paz-Lopez, G; Gonzalez-Jimenez, A; Ranea, JAG; Escudero-Contreras, A; Moreno-Indias, I; Tinahones, FJ; Collantes-Estévez, E; Ruiz-Limón, P	Bone metabolism and inflammatory biomarkers in radiographic and non-radiographic axial spondyloarthritis patients: a comprehensive evaluation	FRONTIERS IN ENDOCRINOLOGY	3.9	Q2	Article	2024
A-02	Araujo-Castro, M; Parra, P; Rojas-Marcos, PM; Fano, MP; Boillos, M; Pascual-Corrales, E; Cano, AMG; Ruiz-Sanchez, JG; Delgado, AV; Hoyos, EG; Ferreira, R; Sanz, IG; Sala, MR; Millan, RBS; Cesar, MJP; Guardiola, PD; Perdomo, CM; Manjon-Miguélez, L; Centeno, RG; Román, AR; Gimeno, PG; Lazaro, CR; Morales-Ruiz, M; Calatayud, M; Collao, SAF; Meneses, D; Nuñez, MS; Quesada, VE; Ribas, EM; Sánchez, AS; Diaz, CG; Lámas, C; Tous, MD; Gotarredona, JS; Alevras, TM; Mateo, EMM; Hanzu, FA	Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism	FRONTIERS IN ENDOCRINOLOGY	3.9	Q2	Article	2024
A-02	Alvarez-Mancha, AI; Mancha-Doblas, I; Molina-Vega, M; Fernández-García, D; Gómez-Pérez, AM; Gallego-Domínguez, E; Ortega-Jiménez, MV; Hierro-Martín, I; Tinahones, FJ	Evolutionary analysis of indeterminate cytology and risk of malignancy in a thyroid nodule unit	EUROPEAN THYROID JOURNAL	3.5	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Ramirez, PP; Rojas-Marcos, PM; Fano, MP; Gonzalez-Boillos, M; Pascual-Corrales, E; Cano, AMG; Ruiz-Sanchez, JG; Delgado, AV; Hoyos, EG; Ferreira, R; Sanz, IG; Sala, MR; San Millan, RB; Cesar, MJP; Guardiola, PD; Perdomo, CM; Manjon-Miguel, L; Roman, AR; Lazaro, CR; Morales-Ruiz, M; Calatayud, M; Collao, SAF; Meneses, D; Sampedro-Nunez, MA; Ribas, EM; Sanchez, AS; Diaz, CG; Lamas, C; Guerrero-Vazquez, R; Tous, MD; Gotarredona, JS; Alevras, TM; Rodrigo, ST; Chamorro, RR; Aguila, FJ; Mateo, EMM; Hanzu, FA; Araujo-Castro, M	Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry	HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION	3.1	Q2	Article	2024
A-02	Ramirez, PP; Rojas-Marcos, PM; Fano, MP; Boillos, MG; Peris, BP; Pascual-Corrales, E; Cano, AMG; Ruiz-Sanchez, JG; Delgado, AV; Hoyos, EG; Ferreira, R; Sanz, IG; Sala, MR; San Millan, RB; Cesar, MJP; Guardiola, PD; Perdomo, CM; Manjon-Miguel, L; Centeno, RG; Percovich, JC; Roman, AR; Gimeno, PG; Lazaro, CR; Morales-Ruiz, M; Calatayud, M; Collao, SAF; Meneses, D; Nunez, MAS; Quesada, VE; Ribas, EM; Sanchez, AS; Diaz, CG; Lamas, C; Guerrero-Vazquez, R; Tous, MD; Gotarredona, JS; Alevras, TM; Mateo, EMM; Hanzu, FA; Araujo-Castro, M	Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register	ENDOCRINE	3.0	Q2	Article	2024
A-02	Herrera-Quintana, L; Vázquez-Lorente, H; Hinojosa-Nogueira, D; Plaza-Díaz, J	Relationship between Infant Feeding and the Microbiome: Implications for Allergies and Food Intolerances	CHILDREN-BASEL	2.0	Q2	Review	2024
A-02	Chico, A; Moreno-Fernández, J; Fernández-García, D; Solá, E	The Hybrid Closed-Loop System Tandem t:slim X2™ with Control-IQ Technology: Expert Recommendations for Better Management and Optimization	DIABETES THERAPY	2.8	Q3	Article	2024
A-02	Ferro-Gallego, P; Vila-Sanjurjo, A; Pereira, AKV; Perez, GP; Dominguez-Gerpe, L	Circular PCR as an efficient and precise umbrella of methods for the generation of circular dsDNA with staggered nicks: Mechanism and types	BIOLOGY METHODS & PROTOCOLS	2.5	Q3	Article	2024
A-02	Almeida, JMG; Pareja, IMC; Jiménez, RF; Pérez, YL; Garrido, MJ; Padin, CA; Alfaro-Martínez, JJ; Gosalbez, MDA; Pla, MA; Carril, VA; Artero, A; Cayón-Blanco, M; Olmedo, LAC; Pereg, LD; Perojo, ED; Muñoz-Alique, MD; García, PD; de Bobadilla-Pascual, BF; Soto, MLF; Tudanc, SF; Gascón, JMG; Irlés-Rocamora, JA; Rodríguez, LJ; Iglesias, OL; Callau, FL; García, GM; Marco-Alacid, C; Cobos, MP; Sierra, MEM; Gayos, LO; Alcolea, JO; Cunill, JLP; Alonso, OP; Pérez, MIR; Paloma, JMR; Rodríguez, JJS; Carreras, PS; Vizcaino, BV; Wu-Xiong, NY	Improving the nutritional care of oncology patients - Validation of a multidisciplinary protocol in the Spanish clinical setting	NUTRICION HOSPITALARIA	1.2	Q4	Article	2024
A-02	Bellido, D; García-Almeida, JM	Why should we incorporate the determination of phase angle by bioelectrical impedance into our routine practice in clinical nutrition?	NUTRICION HOSPITALARIA	1.2	Q4	Editorial Material	2024
A-03	Evangelista, A; Galian-Gay, L; Guala, A; Teixido-Tura, G; Calvo-Iglesias, F; Sevilla, T; Bermejo, J; Méndez, I; Sánchez, V; Carmona, JMR; Alegret, JM; Ferrer-Sistach, E; Saura, D; Ruiz-Muñoz, A; Dux-Santoy, L; Carmona, MA; Huguet, M; Cuellar-Calabria, H; Sao-Aviles, A; Ferreira-González, I; Rodríguez-Palomares, JF	Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial	CIRCULATION	36.0	D1	Article	2024
A-03	Rodés-Cabau, J; Ribeiro, HB; Mohammadi, S; Serra, V; Al-Atassi, T; Iñiguez, A; Vilalta, V; Nombela-Franco, L; Sánchez, JISD; Auffret, V; Forcillo, J; Conradi, L; Urena, M; Moris, C; Muñoz-Garcia, A; Paradis, JM; Dumont, E; Kalavrouziotis, D; Pomerantzeff, PM; Rosa, VEE; Lopes, MP; Sureda, C; Diaz, VAJ; Giuliani, C; Avvedimento, M; Pelletier-Beaumont, E; Pibarot, P	Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial	CIRCULATION	36.0	D1	Article	2024
A-03	Cabrera-Romero, E; Ochoa, JP; Barriales-Villa, R; Bermúdez-Jiménez, FJ; Climent-Payá, V; Zorio, E; Espinosa, MA; Gallego-Delgado, M; Navarro-Peñalver, M; Arana-Achaga, X; Piqueras-Flores, J; Espejo-Bares, V; Rodríguez-Palomares, JF; Lacuey-Lecumberri, G; López, J; Tiron, C; Peña-Peña, ML; García-Pinilla, JM; Lorca, R; Ripoll-Vera, T; Díez-López, C; Mogollon, MV; García-Alvarez, A; Martínez-Dolz, L; Brion, M; Larrañaga-Moreira, JM; Jiménez-Jáimez, J; García-Alvarez, MI; Vilches, S; Villacorta, E; Sabater-Molina, M; Solla-Ruiz, I; Royuela, A; Domínguez, F; Mirelis, JG; Garcia-Pavia, P	Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	22.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Almendro-Delia, M; López-Flores, L; Uribarri, A; Vedia, O; Blanco-Ponce, E; López-Flores, MD; Rivas-García, AP; Fernández-Cordón, C; Sionis, A; Martín-García, AC; Vazirani, R; Corbí-Pascual, M; Salamanca, J; Pérez-Castellanos, A; Martínez, M; Becerra, VM; Aritza-Conty, D; López-País, J; Guillén-Marzo, M; Lluch-Requerey, C; García-Rubira, JC; Núñez-Gil, IJ	Recovery of Left Ventricular Function and Long-Term Outcomes in Patients With Takotsubo	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	22.0	D1	Article	2024
A-03	Marcos, MC; de la Espriella, R; Comín-Colet, J; Zegri-Reiriz, I; Gracia, JR; Morales-Rull, JL; Llàcer, P; Díez-Villanueva, P; Jiménez-Marrero, S; Bagudá, JD; Cortés, CO; Restrepo-Córdoba, MA; Goirigolzarri-Artaza, J; García-Pinilla, JM; Barrios, E; Díaz, SD; Hernández, EM; Sanchez-Marteles, M; Núñez, J	Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: The SALT-HF trial	EUROPEAN JOURNAL OF HEART FAILURE	17.0	D1	Article	2024
A-03	Arteagoitia Bolumburu, Ander; Monteagudo Ruiz, Juan Manuel; Mahia, Patricia; Perez David, Esther; Gonzalez, Teresa; Sitges, Marta; Li, Chi-Hion; Alonso, David; Carrasco, Fernando; Luna Morales, Manuel; Adeba, Antonio; de la Hera, Jesus Maria; Zamorano, Jose Luis	Determinants of Tricuspid Regurgitation Progression and Its Implications for Adequate Management.	JACC-CARDIOVASCULAR IMAGING	13.0	D1	Article	2024
A-03	Echarte-Morales, J; Guerreiro, CE; Freixa, X; Arzamendi, D; Moñivas, V; Carrasco-Chinchilla, F; Pan, MN; Nombela-Franco, L; Pascual, I; Benito-González, T; Perez, R; Gómez-Blázquez, I; Amat-Santos, IJ; Cruz-González, I; Sánchez-Recalde, A; Alvarez, ABC; Barreiro-Perez, M; Sanchis, L; Caneiro-Queija, B; Li, CH; del Trigo, M; Martínez-Carmona, JD; Mesa, D; Jiménez, P; Avanzas, P; Cepas-Guillén, P; Estévez-Loureiro, R	Impact of Optimal Procedural Result After Transcatheter Edge-to-Edge Tricuspid Valve Repair Results From TRI-SPA Registry	JACC-CARDIOVASCULAR INTERVENTIONS	12.0	D1	Article	2024
A-03	Amat-Santos, IJ; García-Gómez, M; Avanzas, P; Jiménez-Díaz, V; Alonso-Briales, JH; Hernández, JMD; Sanz-Sánchez, J; Diarte-de Miguel, JA; Sánchez-Recalde, A; Nombela-Franco, L; Jiménez-Mazuecos, J; Serra, V; Nogales-Asensio, JM; García-Blas, S; Gómez-Menchero, A; del Valle, R; Déniz, CM; Al Houssaini, W; Veiga-Fernández, G; Díez-Gil, JL; Sánchez, JJ; Menéndez, JL; Fernández-Cordón, C; Gómez-Salvador, I; Bustamante-Munguira, J; Kedhi, E; Román, JAS	Surgical vs Transcatheter Treatment in Patients With Coronary Artery Disease and Severe Aortic Stenosis	JACC-CARDIOVASCULAR INTERVENTIONS	12.0	D1	Article	2024
A-03	Marquis-Gravel, G; Costa, F	DAPT After PCI in High Bleeding Risk Should Diabetes Influence Duration?	JACC-CARDIOVASCULAR INTERVENTIONS	12.0	D1	Editorial Material	2024
A-03	Rodriguez-Muñoz, A; Motahari-Rad, H; Martin-Chaves, L; Benitez-Porres, J; Rodriguez-Capitan, J; Gonzalez-Jimenez, A; Insenser, M; Tinahones, FJ; Murri, M	A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle	CURRENT OBESITY REPORTS	9.5	D1	Review	2024
A-03	de Miguel-Díez, J; Villota, JN; Pérez, SS; Lorite, NM; Navarrete, BA; Jiménez, JFD; Soler-Cataluña, JJ; Figal, DP; Ecenarro, PS; Doblas, JJG	Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease	ARCHIVOS DE BRONCONEUMOLOGIA	8.7	D1	Article	2024
A-03	de Miguel-Díez, J; Doblas, JJG	Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: Response to Additional Considerations	ARCHIVOS DE BRONCONEUMOLOGIA	8.7	D1	Editorial Material	2024
A-03	Ochoa, JP; Espinosa, MA; Gayan-Ordas, J; Fernández-Valledor, A; Gallego-Delgado, M; Tirón, C; Lozano-Ibañez, A; García-Pinilla, JM; Rodríguez-Palomares, JF; Larrañaga-Moreira, JM; Llamas-Gómez, H; Ripoll-Vera, T; Braza-Boïls, A; Vilches, S; Méndez, I; Bascompte-Claret, R; García-Alvarez, A; Villacorta, E; Fernandez-Lozano, I; Lara-Pezzi, E; Garcia-Pavia, P	Rare Genetic Variants in Young Adults Requiring Pacemaker Implantation	JACC-CLINICAL ELECTROPHYSIOLOGY	8.0	D1	Article	2024
A-03	Mateas, FR; Pérez, MA; López, FG; González, S; Camós, IA; Tragant, GG; Irrañitu, MR; Lozano, IF; Martínez, JG; Rodríguez, FJA	Magnetic resonance imaging in patients with cardiac implantable electronic devices: the RESONANCE Spanish registry	EUROPACE	7.9	D1	Article	2024
A-03	Molina-Ramos, AI; Ruiz-Salas, A; Medina-Palomo, C; Becerra-Munoz, V; Rodriguez-Capitan, J; Romero-Cuevas, M; Carmona-Segovia, A; Fernandez-Lozano, I; Gomez-Doblas, JJ; Navarro, MJ; Pavon-Moron, FJ; Barrera-Cordero, A; Alzueta-Rodríguez, J	Index and Repeat Ablation for Atrial Fibrillation in Older versus Younger Patients: A Propensity-Score Matching Analysis	AGING AND DISEASE	7.0	D1	Article	2024
A-03	Alegre-García, G; Segovia-Reyes, J; Rodríguez-Capitán, J; García-Rodríguez, L; Morcillo-Hidalgo, L; Gómez-Doblas, JJ; Jiménez-Navarro, MF	Massive Mitral Valve Prosthetic Thrombosis in a Patient Undergoing Nintedanib Treatment: A Challenging Case Highlighting the Role of Echocardiography	CIRCULATION-CARDIOVASCULAR IMAGING	6.5	D1	Editorial Material	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Santoro, F; Núñez-Gil, IJ; Viana-Llamas, MC; Alfonso-Rodríguez, E; Uribarri, A; Becerra-Muñoz, VM; Guzman, GF; Di Nunno, N; Lopez-Pais, J; Cerrato, E; Sinagra, G; Mapelli, M; Inciardi, RM; Specchia, C; Oriecuia, C; Brunetti, ND	Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1	Article	2024
A-03	Rodríguez-Muñoz, A; Martínez-Montoro, JI; Sojo-Rodriguez, B; Benitez-Porres, J; Carrillo-Albornoz-Gil, M; Carrasco-Fernandez, L; Subiri-Verdugo, A; Molina-Ramos, A; Cobos-Díaz, A; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Glycaemic Response to Acute Aerobic and Anaerobic Exercise Performed in the Morning or Afternoon in Healthy Subjects: A Crossover Trial	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1	Article	2024
A-03	Nazzal, W; Thurnhofer-Hemsi, K; López-Rubio, E	Improving Medical Image Segmentation Using Test-Time Augmentation with MedSAM	MATHEMATICS	2.3	D1	Article	2024
A-03	Núñez-Gil, IJ; Rodríguez-Caulo, EA; García-Cosío, MD; Piñón, M; Hoyo, FDD; Eixerés, A; Carrasco-Chinchilla, F; López-Menéndez, J; Pérez-Villacastín, J; Rodríguez-Roda, J	Cardiovascular surgery and cardiology, current status of two sister specialties in Spain: the CARDIOXCARDIO study	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Article	2024
A-03	Nuche, J; Ternacle, J; Avvedimento, M; Cheema, AN; Veiga-Fernández, G; Muñoz-García, AJ; Vilalta, V; Regueiro, A; Asmarats, L; del Trigo, M; Serra, V; Bonnet, G; Jonveaux, M; Esposito, G; Rezaei, E; de la Torre-Hernández, JM; Fernández-Nofrerías, E; Vidal, P; Gutiérrez-Alonso, L; Oteo, JF; Belahnech, Y; Mohammadi, S; Philippon, F; Modine, T; Mesnier, J; Rodés-Cabau, J	Incidence, predictors, and prognostic significance of impaired functional status early after transcatheter aortic valve replacement	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Article	2024
A-03	Marcos, MC; de la Espriella, R; Ordás, JG; Llàcer, P; Pomares, A; Fort, A; de Antonio, IP; Méndez, A; Blázquez-Bermejo, Z; Pérez, PC; Gracia, JR; Recio-Mayoral, A; Zegrí, I; Pinilla, JMG; Hernández, EM; Castro, A; Soler, MJ; Górriz, JL; Claret, RB; Fluvià-Brugués, P; Manzano, L; Núñez, J	Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Article	2024
A-03	Bagudá, JD; de Frutos, F; López-Vilella, R; Mallón, DC; Guzman-Bofarull, J; Blazquez-Bermejo, Z; Cobo-Belaustegui, M; Mitroi, C; Pastor-Pérez, FJ; Moliner-Abós, C; Rangel-Sousa, D; Díaz-Molina, B; Tobar-Ruiz, J; Gonzalez, NS; García-Pinilla, JM; Carmena, MDGC; Crespo-Leiro, MG; Dobarro, D; Almenar, L; Delgado-Jiménez, JF; Paredes-Galán, E; González-Vílchez, F; González-Costello, J	Repetitive ambulatory levosimendan as a bridge to heart transplantation	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Article	2024
A-03	Bastante, T; Arzamendi, D; Martín-Moreiras, J; Alvarez, ABC	Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023)	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Article	2024
A-03	Asensi, JO; Lozano, IF; Rodriguez, JA; Calvo, D	Spanish implantable cardioverter-defibrillator registry. 20th official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2023)	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Article	2024
A-03	Vivas, D; San Roman, A; Anguita, M; Fernández-Hidalgo, N; Fernández-Lozano, I; González-Juanatey, C; González, A; Parellada, M; Quintana, E; Ferreiro, JL; Avanzas, P; Andrea, R; Boraita, A; Calvo, D; Campuzano, R; Delgado, V; Dos Subirá, L; Doblas, JG; Momblan, MAM; Mazón, P; Figal, DP; Sanchis, J; Hernández, JMD; Vivas, D	Comments on the 2023 ESC guidelines for the management of endocarditis	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Editorial Material	2024
A-03	Ruiz, RC; Ramos, PM; Conde, AC; Alvarez, BC; Alvarez, CC; Díez-Villanueva, P; Olmo, RF; Freixa-Pamias, R; Martin, DM; Pérez, SM; Ferreiro, JL; Avanzas, P; Andrea, R; Boraita, A; Calvo, D; Campuzano, R; Delgado, V; Dos Subirá, L; Doblas, JG; Momblan, MAM; Mazón, P; Figal, DP; Sanchis, J; Hernández, JMD; Vivas, D	Comments on the 2023 ESC guidelines on cardiovascular disease in patients with diabetes	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Editorial Material	2024
A-03	Pascual-Figal, D; Manito-Lorite, N; Bayes-Genis, A; Calero-Molina, E; Cobo, M; Delgado, J; Gómez-Otero, I; Núñez-Villota, J; Recio, A; Ferreiro, JL; Avanzas, P; Andrea, R; Boraita, A; Calvo, D; Campuzano, R; Delgado, V; Dos Subirá, L; Doblas, JG; Momblan, MAM; Mazón, P; Sanchis, J; Hernández, JMD; Vivas, D	Comments on the 2023 update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Editorial Material	2024
A-03	Díaz-Francés, JA; Fernández-Rodríguez, JD; Thurnhofer-Hemsi, K; López-Rubio, E	Semi-Supervised Semantic Image Segmentation by Deep Diffusion Models and Generative Adversarial Networks	INTERNATIONAL JOURNAL OF NEURAL SYSTEMS	6.6	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Amor-Salamanca, A; Rodriguez, AS; Rasoul, H; Rodriguez-Palomares, JF; Moldovan, O; Hey, TM; Delgado, MG; Cuenca, DL; Campos, DD; Basurte-Elorz, MT; Macias-Ruiz, R; Canamero, MEF; Galvin, J; Quesada, RB; Romero, LD; Trujillo-Quintero, JP; Garcia-Cruz, LM; Cardenas-Reyes, I; Jimenez-Jaimez, J; Garcia-Hernandez, S; Valverde-Gomez, M; Gomez-Diaz, I; Freire, JL; Garcia-Pinilla, JM; Gimeno-Blanes, JR; Savattis, K; Garcia-Pavia, P; Ochoa, JP	Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction	CIRCULATION-GENOMIC AND PRECISION MEDICINE	6.0	Q1	Article	2024
A-03	Medina-Vera, D; López-Gambero, A; Navarro, JA; Sanjuan, C; Baixeras, E; Decara, J; de Fonseca, FR	Novel insights into D-Pinitol based therapies: a link between tau hyperphosphorylation and insulin resistance	NEURAL REGENERATION RESEARCH	5.9	Q1	Review	2024
A-03	Vila-Sanjuán, S; Nuñez-Gil, IJ; Vedia, O; Corbi-Pascual, M; Salamanca, J; Martinez-Selles, M; Blanco, E; Almendro-Delia, M; Pérez-Castellanos, A; Martin-Garcia, AC; Tomasino, M; Vazirani, R; Fernández-Cordón, C; Cambra, AD; Becerra-Muñoz, VM; Guillén, M; Reyes, JA; Uribarri, A	Left ventricular outflow tract obstruction in Takotsubo syndrome with cardiogenic shock: prognosis and treatment	HEART	5.1	Q1	Article	2024
A-03	Tomasino, M; Núñez-Gil, IJ; Martínez-Selles, M; Vedia, O; Corbí-Pascual, M; Salamanca, J; Blanco-Ponce, E; Cordón, CF; Almendro-Delia, M; Pérez-Castellanos, A; Martín-García, A; Vila-Sanjuán, S; Vazirani, R; Duran-Cambra, A; Becerra-Muñoz, VM; Guillén-Marzo, M; Uribarri, A	Cardiogenic Shock Complicating Takotsubo Syndrome: Sex-Related Differences	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5.0	Q1	Article	2024
A-03	Martinez-Morata, I; Domingo-Relloso, A; Zhang, Y; Fretts, AM; Pichler, G; Pinilla, JMG; Umans, JG; Cole, SA; Sun, YF; Shimbo, D; Navas-Acien, A; Devereux, RB	Heart Failure Risk Prediction in a Population With a High Burden of Diabetes: Evidence From the Strong Heart Study	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5.0	Q1	Article	2024
A-03	Amat-Santos, IJ; López-Otero, D; Nombela-Franco, L; Peral-Disdier, V; Gutiérrez-Ibañes, E; Jiménez-Díaz, V; Muñoz-García, A; Del Valle, R; Regueiro, A; Ibáñez, B; Romaguera, R; Ramón, CC; García, B; Sánchez, PL; Gómez-Herrero, J; Gonzalez-Juanatey, JR; Tirado-Conte, G; Fernández-Avilés, F; Raposeiras, S; Revilla-Orodea, A; López-Díaz, J; Gómez, I; Carrasco-Moraleja, M; San Román, JA	Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5.0	Q1	Article	2024
A-03	Gobbi, C; Sánchez-Marin, L; Flores-López, M; Medina-Vera, D; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-dependent effects of acute stress and alcohol exposure during adolescence on mRNA expression of brain signaling systems involved in reward and stress responses in young adult rats	BIOLOGY OF SEX DIFFERENCES	4.9	Q1	Article	2024
A-03	Ortega, M; Fábrega-García, MM; Molina-García, T; Gavara, J; de Dios, E; Pérez-Solé, N; Marcos-Garcés, V; Padilla-Esquivel, JJ; Diaz, A; Martinez-Dolz, L; Jimenez-Navarro, M; Rios-Navarro, C; Bodí, V; Ruiz-Saurí, A	Novel Fibrillar and Non-Fibrillar Collagens Involved in Fibrotic Scar Formation after Myocardial Infarction	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
A-03	Dominguez-Maqueda, M; Pérez-Gómez, O; García-Márquez, J; Espinosa-Ruíz, C; Cuesta, A; Esteban, MA; Alarcón-López, FJ; Cárdenas, C; Tapia-Paniagua, ST; Balebona, MC; Moriñigo, MA	Microalgae and cyanobacteria as microbial substrate and their influence on the potential postbiotic capability of a bacterial probiotic	MICROBIAL BIOTECHNOLOGY	4.8	Q1	Article	2024
A-03	Medina-Vera, D; López-Gambero, AJ; Verheul-Campos, J; Navarro, JA; Morelli, L; Galeano, P; Suárez, J; Sanjuan, C; Pacheco-Sánchez, B; Rivera, P; Pavon-Morón, FJ; Rosell-Valle, C; Fonseca, FRD	Therapeutic Efficacy of the Inositol D-Pinitol as a Multi-Faceted Disease Modifier in the 5xFAD Humanized Mouse Model of Alzheimer's Amyloidosis	NUTRIENTS	4.8	Q1	Article	2024
A-03	Llacer, P; Marcos, MC; de la Espriella, R; Ordás, JG; Zegri, I; Fort, A; Chavarri, AR; Mendez, A; Blázquez, Z; Pérez, PC; Gracia, JR; Fernández, C; Recio-Mayoral, A; Pomares, A; Pinilla, JMG; López-Ibor, JV; Castro, A; Soler, MJ; Górriz, JL; Claret, RB; Fluvíà, P; Manzano, L; Núñez, J	Congestion as a crucial factor determining albuminuria in patients with cardiorenal disease	CLINICAL KIDNEY JOURNAL	3.9	Q1	Article	2024
A-03	Fernandez-Aviles, C; Gonzalez-Manzanares, R; Ojeda, S; Castillo, JC; Robles-Mezcua, A; Anguita, M; Mesa, D; Pan, MN	Diagnostic and Therapeutic Approaches for Heart Failure in Long-Term Survivors of Childhood Cancer	BIOMEDICINES	3.9	Q1	Review	2024
A-03	Cerezo, IM; Herrada, EA; Fernández-Gracia, J; Sáez-Casado, MI; Martos-Sitcha, JA; Moriñigo, MA; Tapia-Paniagua, ST	Analyzing bacterial networks and interactions in skin and gills of Sparus aurata with microalgae-based additive feeding	SCIENTIFIC REPORTS	3.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Esteban-Fernández, A; Gómez-Otero, I; López-Fernández, S; Santamarta, MR; Pastor-Pérez, FJ; Fluvial-Brugués, P; Pérez-Rivera, JA; López, AL; García-Pinilla, JM; Palomas, JLB; Bonet, LA; Cobo-Marcos, M; Mateo, VM; Llergo, JT; Fernández, VA; Vives, CG; Bagudá, JD; Benedicto, AM; de Polavieja, JIM; Solla-Ruiz, I; Solé-González, E; Cardona, M; Olaetxea, JR; Cortés, CO; Dosantos, VM; López, AG; Amao, E; Sánchez, BC; Torres, EA; Carrillo, VG; García-Fuertes, D; Ridocci-Soriano, F	Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction	CLINICAL RESEARCH IN CARDIOLOGY	3.8	Q1	Article	2024
A-03	Pueyo, PP; Ruberte, EG; Ordás, JG; Blanco, LM; Figal, DP; Moreira, JML; Barrado, JJG; Calle, DG; Bonet, LA; Salinas, GLA; Pascual, MJC; Martín, MP; Llinares, JP; López, AD; Pérez, MB; Ocaña, FC; García, JB; Ortega, GM; Rodríguez, FD; Mateo, VM; Crespo, MC; Guzmán, MQ; Martínez, LJ; Viñas, JA; López, JR; Santos, SF; Martí, PR; Roy, LA; Polo, JCG; Pinilla, JMG; Vallverdú, MF; Bueno, L; Colomé, TS; Diz, FW	Vaccine-carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination	CLINICAL RESEARCH IN CARDIOLOGY	3.8	Q1	Article	2024
A-03	Robles-Mezcua, A; Aguado, NG; de la Rosa, APM; Cruzado-Alvarez, C; Rubio, CJ; Cabeza, AI; Gomez-Doblas, JJ; Jiménez-Navarro, MF; Pierri, MM; García-Pinilla, JM	Sex-based Differences in Heart Failure Biomarkers	CURRENT HEART FAILURE REPORTS	3.8	Q1	Review	2024
A-03	Dobarro, D; Raposeiras-Roubin, S; Almenar-Bonet, L; Sole-Gonzalez, E; Padilla-Lopez, M; Diez-Lopez, C; Castrodeza, J; Garcia-Cosio, MD; Cobo-Marcos, M; Tobar, J; Codina, P; Lopez-Fernandez, S; Pastor, F; Rangel-Sousa, D; Barge-Caballero, E; Diaz-Molina, B; Barrio-Rodriguez, A; Burgos-Palacios, V; alvarez-Garcia, J; Gonzalez-Fernandez, O; Grau-Sepulveda, A; Garcia-Pinilla, JM; Ruiz-Bustillo, S; Mendez-Fernandez, AB; Vaqueriza-Cubillo, D; Sagasti-Aboitiz, I; Rodriguez-Santamarta, M; Lozano-Bahamonde, A; Abecia, A; Gomez-Otero, I; Marzoa, R; Gonzalez-Babarro, E; Gomez-Bueno, M; Gonzalez-Costello, J	Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries	LIFE-BASEL	3.2	Q1	Article	2024
A-03	Jiménez-López, R; Romero-Trebejo, JL; Fernández-Romero, L; Martín-Chaves, L; Romero-Cuevas, M; Molina-Ramos, AI; Sánchez-Quintero, MJ; Murri, M; Costa, F; Bodí, V; Gutiérrez-Bedmar, M; Rodríguez-Capitán, J; Pavón-Morón, FJ; Jiménez-Navarro, M	Differential Ophthalmological Profile in Patients with Coronary Artery Disease Coexisting with Type 2 Diabetes Mellitus: Elevated Tear Cytokine Concentrations	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
A-03	Vazirani, R; Feltes, G; Hoyo, RSD; Viana-Llamas, MC; Raposeiras-Roubin, S; Romero, R; Alfonso-Rodriguez, E; Uribarri, A; Santoro, F; Becerra-Munoz, V; Pepe, M; Castro-Mejia, AF; Signes-Costa, J; Gonzalez, A; Marin, F; Lopez-Pais, J; Cerrato, E; Vazquez-Cancela, O; Espejo-Paeres, C; Masjuan, AL; Velicki, L; El-Battrawy, I; Ramakrishna, H; Fernandez-Ortiz, A; Nunez-Gil, IJ	Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes-Results from a Multi-Center International Prospective Registry (HOPE-2)	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
A-03	Costa, F; Jurado-Román, A; Carciotto, G; Becerra-Munoz, V; Márquez, DT; Götzinger, F; Cerrato, E; Misra, S; Spissu, M; Pavani, M; Mennuni, M; Chinchilla, FC; Dominguez-Franco, A; Muñoz-Garcia, A; Navarrete, RS; Varbella, F; Salinas-Sanguino, P; Secemsky, EA; Mahfoud, F; Micari, A; Alonso-Briales, JH; Navarro, MJ	Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024
A-03	Pallante, F; Costa, F; Ruiz, VG; Vizzari, G; Iannello, P; Teresi, L; Carciotto, G; Lo Giudice, S; Iuvara, G; Larterra, G; Regueiro, A; Giustino, G; Briales, JHA; Hernandez, JM; Barbanti, M; Micari, A; Patanè, F	Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024
A-03	Teresi, L; Trimarchi, G; Liotta, P; Restelli, D; Licordari, R; Carciotto, G; Francesco, C; Crea, P; Dattilo, G; Micari, A; Emdin, M; Berrueto, A; Di Bella, G	Electrocardiographic Patterns and Arrhythmias in Cardiac Amyloidosis: From Diagnosis to Therapeutic Management-A Narrative Review	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024
A-03	Licordari, R; Costa, F; Garcia-Ruiz, V; Mamas, MA; Marquis-Gravel, G; Hernandez, JMD; Doblas, JJG; Jimenez-Navarro, M; Rodríguez-Capitan, J; Urbano-Carrillo, C; Ortega-Paz, L; Piccolo, R; Versace, AG; Di Bella, G; Ando, G; Angiolillo, DJ; Valgimigli, M; Micari, A	The Evolving Field of Acute Coronary Syndrome Management: A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024
A-03	Gómez-Moyano, E; Pavón-Morón, J; Rodríguez-Capitán, J; Bardán-Rebollar, D; Ramos-Carrera, T; Villalobos-Sánchez, A; de Pedro, IP; Ruiz-García, FJ; Mora-Robles, J; López-Sampalo, A; Pérez-Velasco, MA; Bernal-López, MR; Gómez-Huelgas, R; Jiménez-Navarro, M; Romero-Cuevas, M; Costa, F; Trenas, A; Pérez-Belmonte, LM	The Role of Heparin in Postural Orthostatic Tachycardia Syndrome and Other Post-Acute Sequelae of COVID-19	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Bonilla-Palomas, JL; Anguita-Sánchez, M; Fernández-Pérez, C; Bernal-Sobrino, JL; García, M; Prado, N; Rosillo, N; Pérez-Villacastín, J; Gómez-Doblas, JJ; Elola-Somoza, FJ	Hospital admissions and outcomes for systolic and diastolic heart failure in Spain between 2016 and 2019: A population-based study	CLINICAL MEDICINE	2.6	Q1	Article	2024
A-03	Becerra-Muñoz, VM; Sáenz, JTG; Subías, PE	The importance of data in Pulmonary Arterial Hypertension: from international registries to Machine Learning	CLINICAL MEDICINE	2.6	Q1	Article	2024
A-03	Torres-Salomón, P; Rodríguez-Capitán, J; Molina-Cabello, MA; Thurnhofer-Hemsi, K; Costa, F; Sanchez-Fernández, PL; Muñoz-Muñoz, MA; Carmona-Segovia, AD; Romero-Cuevas, M; Pavón-Morón, FJ; Jiménez-Navarro, M	Exploring the Prognostic Impact of Non-Obstructive Coronary Artery Lesions through Machine Learning	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
A-03	Molina-Cabello, MA; Serrano-Angulo, J; Benito-Picazo, J; Thurnhofer-Hemsi, K	Grades and Learning Styles: New Software for Analyzing Correlations in a Longitudinal Study Across Different Branches of Knowledge and Years	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
A-03	Jiménez-Partinen, A; Thurnhofer-Hemsi, K; Rodríguez-Capitán, J; Molina-Ramos, AI; Palomo, EJ	Coronary Artery Disease Classification With Different Lesion Degree Ranges Based on Deep Learning	IEEE ACCESS	3.4	Q2	Article	2024
A-03	Marcos, MC; Comin-Colet, J; de la Espriella, R; Gracia, JR; Morales-Rull, JL; Zegri, I; Llacer, P; Díez-Villanueva, P; Jimenez-Marrero, S; Bagudá, JD; Cortés, CO; Goirigolzarri-Artaza, J; Garcia-Pinilla, JM; Barrios, E; Díaz, SD; Hernández, EM; Sanchez-Marteles, M; Nuñez, J	Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure	ESC HEART FAILURE	3.2	Q2	Article	2024
A-03	Bravo-Marqués, R; Becerra-Muñoz, V; Espíldora-Hernández, F; Recio-Mayoral, A	Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study	CLINICAL THERAPEUTICS	3.2	Q2	Article	2024
A-03	Jiménez-Partinen, A; Molina-Cabello, MA; Thurnhofer-Hemsi, K; Palomo, EJ; Rodríguez-Capitán, J; Molina-Ramos, AI; Jiménez-Navarro, M	CADICA: A new dataset for coronary artery disease detection by using invasive coronary angiography	EXPERT SYSTEMS	3.0	Q2	Article	2024
A-03	De Heredia, APLF; Ortiz, MR; Cabeza, AIP; Expósito, AD; Valenzuela, MIF; Bailén, MC; Cubiles, IAD; Vega, AM; Aguilar, MZ; Muñoz, MC; Manrique, TG; Llergo, JT; Granados, ALO; Fernández, JJS; Cadenas, JC; Rubio, DM	Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings	CURRENT PROBLEMS IN CARDIOLOGY	3.0	Q2	Review	2024
A-03	van Mierlo, RFR; Houben, VJG; Rikken, SAOF; Gómez-Doblas, JJ; Lozano-Torres, J; van 't Hof, AWJ	Cardiac (tele)rehabilitation in routine clinical practice for patients with coronary artery disease: protocol of the REHAB	FRONTIERS IN CARDIOVASCULAR MEDICINE	2.8	Q2	Article	2024
A-03	Melendo-Viu, M; Salguero-Bodes, R; Valverde-Gómez, M; Larrañaga-Moreira, JM; Barriales, R; Díez-Lopez, C; Freire, JL; Peña-Peña, ML; Pavia, PG; Ripoll, T; Climent-Payá, V; Delgado, MG; Zorio, E; Jimenez, FJB; García-Pinilla, JM; Fernández, IM; Sabater-Molina, M; Asensio, AP; Marchán-Lopez, A; Ynsaurriaga, FA; Bueno, H; Doza, JAP	Hypertrophic cardiomyopathy due to truncating variants in myosin binding protein C: a Spanish cohort	OPEN HEART	2.8	Q2	Article	2024
A-03	Alvarez-Ortega, CA; Guillén, CRS; Cordero, AB; Ramos, JET; Martínez-Alday, JD; Morales, CEG; González, AR; García-Alberola, A; Alvarez, LP; Osorio, AFD; Afosno, JSH; León, RC; Pérez, OC; Trucco, E; Peinado, RP	Repeat cryoablation as a redo procedure for atrial fibrillation ablation: Is it a good choice?	CARDIOLOGY JOURNAL	2.5	Q2	Article	2024
A-03	Manito, N; Cepeda-Rodrigo, JM; Farré, N; Orive, MC; Galve, E; Jiménez-Candil, J; García-Pinilla, JM; Sánchez, ESL; Rafols, C; Doblas, JGG	Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban	CLINICAL CARDIOLOGY	2.4	Q2	Article	2024
A-03	Vazirani, R; Blanco-Ponce, E; Delia, MA; Martín-Garcia, AC; Fernández-Cordón, C; Uribarri, A; Vedia, O; Sionis, A; Salamanca, J; Corbí-Pascual, M; Pérez-Castellanos, A; Martínez-Selles, M; Manuel-Becerra, V; Raposeiras-Roubin, S; Aritza-Conty, D; Lopez-País, J; Guillén-Marzo, M; Lluch-Requerey, C; Núñez-Gil, IJ	Peripartum Takotsubo Cardiomyopathy: A Review and Insights from a National Registry	JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE	2.4	Q2	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Barge-Caballero, E; Sieira-Hermida, J; Barge-Caballero, G; Couto-Mallón, D; Paniagua-Martín, MJ; Enríquez-Vázquez, D; Marcos-Rodríguez, PJ; Rodríguez-Capitán, J; Vázquez-Rodríguez, JM; Crespo-Leiroa, MG	Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure	REVISTA CLINICA ESPANOLA	2.3	Q2	Article	2024
A-03	Torres-Galván, S; Flores-López, M; Ochoa, E; Requena-Ocana, N; Araos, P; Herrera-Imbroda, J; Muga, R; Serrano, A; de Fonseca, FR; Pavón-Morón, FJ; Haro, G; García-Marchena, N	Dysregulation of Plasma Growth Factors and Chemokines in Cocaine Use Disorder: Implications for Dual Diagnosis with Schizophrenia and Antisocial Personality Disorder in an Exploratory Study	NEUROPSYCHOBIOLOGY	2.3	Q2	Article	2024
A-03	Romero-Arana, A; González-Rodríguez, MJ; Sánchez-Vega, P; Gómez-Salgado, J; Romero, A	Effectiveness of a self-management program for anticoagulated patients to improve their knowledge about treatment and time in therapeutic range	MEDICINE	1.4	Q2	Article	2024
A-03	Amat-Santos, IJ; Gómez-Herrero, J; Pinon, P; Nombela-Franco, L; Moreno, R; Munoz-García, AJ; Redondo, A; Gómez-Menchero, A; Gómez-Salvador, I; San Román, JA	Impact of commissural alignment on the hemodynamic performance of supra-annular self-expandable transcatheter aortic valves	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS	2.1	Q3	Article	2024
A-03	López-Téllez, A; Torres, JMR; Vázquez, EP; Fernández, MAB; López-Martí, H; Martínez, IZ; Fernández, CT; Vargas, MF; Pinos, MDD; Morant, JFP; González-Fajardo, JA; Felices, PV	Ultrasound screening for abdominal aortic aneurysm in primary care	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
A-03	Marín, F; Sánchez, MA; Lekuona, I; Fernández, MS; Barrios, V; Muñoz, CP; Cosín-Sales, J; Cabeza, AIP; Schilling, VR; Priu, CR; Orenes-Piñero, E; Esteve-Pastor, MA	Clinical profile and outcomes in very elderly patients with at-rial fibrillation anticoagulated with rivaroxaban: data from the EMIR study	JOURNAL OF GERIATRIC CARDIOLOGY	1.8	Q3	Article	2024
A-03	Doblas, JJG; García-Moll, X; Freire, RB; Juanatey, CG; Morillas, M; Muñoz, AV; Escobar, C	Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting	FUTURE CARDIOLOGY	1.6	Q3	Article	2024
A-03	Sagredo, MS; Elorriaga, AS; Méndez, SR; Paz, DV; Llanos, RA; García, CL; Quirós, A; García, EM; Recalde, AS; Alonso, JR; Ruiz-Poveda, FL; Irazusta, FJ; Redondo, A; Sequeiros, RAA; Rodríguez-Leor, O	Discordance between fractional flow reserve and nonhyperemic index with a fiber-optic pressure wire. READI EPIC-14	REC-INTERVENTIONAL CARDIOLOGY	1.2	Q4	Article	2024
A-03	Núñez-Gil, IJ; Rodríguez-Caulo, EA; García-Cosío, MD; Piñón, M; Díez-Del Hoyo, F; Eixerés, A; Carrasco-Chinchilla, F; López-Menéndez, J; Pérez-Villacastín, J; Rodríguez-Roda, J	Cardiovascular surgery and cardiology, current status of two sister specialties in Spain: the CARDIOXCARDIO study.	CIRUGIA CARDIOVASCULAR	0.3	Q4	Article	2024
A-03	Al Houssaini, W; Mataró, MJ; Rubio, L; Muñoz, R; Sanchez-Espin, G; Porras, C; Melero, JM	Isolated tricuspid surgery without aortic clamping through a right mini-thoracotomy	CIRUGIA CARDIOVASCULAR	0.3	Q4	Article	2024
A-06	Khoury, N; Martínez, MA; Nishi, SK; Martinez-Gonzalez, MA; Corella, D; Castañer, O; Martinez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, F; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, J; Pérez-Vega, KA; Garcia-Rios, A; Ortiz-Díaz, F; Gomez-Gracia, E; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Peña-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fito, M; Babio, N; Salas-Salvadó, J	Dietary intake of Perfluorooctanesulfonic acid (PFOS) and glucose homeostasis parameters in a non-diabetic senior population	ENVIRONMENT INTERNATIONAL	10.0	D1	Article	2024
A-06	Rodríguez-Muñoz, A; Motahari-Rad, H; Martin-Chaves, L; Benitez-Porres, J; Rodriguez-Capitan, J; Gonzalez-Jimenez, A; Insenser, M; Tinahones, FJ; Murri, M	A Systematic Review of Proteomics in Obesity: Unpacking the Molecular Puzzle	CURRENT OBESITY REPORTS	9.5	D1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-06	Alvarez-Alvarez, L; Rubín-García, M; Vitelli-Storelli, F; García, S; Bouzas, C; Martínez-González, MA; Corella, D; Salvadó, JS; Malcampo, M; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Fernández, CG; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; García-Arellano, A; Martínez, MA; Sorlí, J; Zomeno, MD; García-Rios, A; González-Palacios, S; Monserrat-Mesquida, M; Abete, I; Fernández, AC; Casas, R; Ibáñez, NC; Ugarriza, L; Bernal-López, MR; Bes-Rastrollo, M; Paz-Graniel, I; Asensio, EM; Fitó, M; Larriva, APA; Oncina-Cánovas, A; Vázquez, Z; de la Puente, MF; Pérez-Vega, A; Tur, JA; Martín-Sánchez, V	Effect of a nutritional intervention based on an energy-reduced Mediterranean diet on environmental impact	SCIENCE OF THE TOTAL ENVIRONMENT	8.2	D1	Article	2024
A-06	Kreutz, R; Brunström, M; Burnier, M; Grassi, G; Januszewic, A; Muiesan, ML; Tsioufis, K; de Pinho, RM; Albin, FL; Boivin, JM; Dumas, M; Nemcsik, J; Rodilla, E; Agabiti-Rosei, E; Algharably, EA; Agnelli, G; Benetos, A; Hitij, JB; Cífková, R; Cornelissen, V; Danser, AHJ; Delles, C; Huelgas, RG; Járαι, Z; Palatini, P; Pathak, A; Persu, A; Polonia, J; Sarafidis, P; Stergiou, G; Thomopoulos, C; Wanner, C; Weber, T; Williams, B; Kjeldsen, SE; Mancia, G	2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1	Article	2024
A-06	Lorido, JCA; Gomez, JC; Rodriguez, PV; Huelgas, RG; Silvente, CM; Lora, FJS; Ares, EI; Pelegrín, API; Hernández, OP; Ena, J	Glycemic control and prescription profiles in internal medicine inpatients: The role of frailty	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1	Article	2024
A-06	Gómez-Huelgas, R; Dalekos, GN; Dicker, D; Montano, N	Internal medicine in the 21st century: Back to the future	EUROPEAN JOURNAL OF INTERNAL MEDICINE	5.9	D1	Article	2024
A-06	Rodriguez-Muñoz, A; Martínez-Montoro, JI; Sojo-Rodriguez, B; Benitez-Porres, J; Carrillo-Albornoz-Gil, M; Carrasco-Fernandez, L; Subiri-Verdugo, A; Molina-Ramos, A; Cobos-Diaz, A; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Glycaemic Response to Acute Aerobic and Anaerobic Exercise Performed in the Morning or Afternoon in Healthy Subjects: A Crossover Trial	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1	Article	2024
A-06	Vargas-Molina, S; Garcia-Sillero, M; Bonilla, DA; Petro, JL; Garcia-Romero, J; Benitez-Porres, J	The effect of the ketogenic diet on resistance training load management: a repeated-measures clinical trial in trained participants	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1	Article	2024
A-06	Ruiz-Limón, P; Muralidharan, J; Gomez-Perez, AM; Murri, M; Vioque, J; Corella, D; Fito, M; Vidal, J; Salas-Salvadó, J; Torres-Collado, L; Coltell, O; Atzeni, A; Castañer, O; Bulló, M; Bernal-López, MR; Moreno-Indias, I; Tinahones, FJ	Physical activity shifts gut microbiota structure in aged subjects with overweight/obesity and metabolic syndrome	BIOLOGY OF SPORT	4.2	D1	Article	2024
A-06	Fuentes-Abolafio, IJ; Trinidad-Fernández, M; Ricci, M; Roldán-Jiménez, C; Gómez-Huelgas, R; Arjona-Caballero, JM; Escriche-Escuder, A; Bernal-López, MR; Pérez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic parameters related to functional capacity, fatigue, and breathlessness during the 6-min walk test in older adults with heart failure with preserved ejection fraction	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	2.9	D1	Article	2024
A-06	Vargas-Molina, S; Murri, M; Gonzalez-Jimenez, A; Gómez-Urquiza, JL; Benítez-Porres, J	Effects of the Ketogenic Diet on Strength Performance in Trained Men and Women: A Systematic Review and Meta-Analysis	NUTRIENTS	4.8	Q1	Review	2024
A-06	Alvarez-Alvarez, L; Vitelli-Storelli, F; Rubín-García, M; García, S; Bouzas, C; Ruíz-Canela, M; Corella, D; Salas-Salvadó, J; Fitó, M; Martinez, JA; Tojal-Sierra, L; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; García-Fernández, C; Esteve-Luque, V; Delgado-Rodríguez, M; Torrego-Ellacuría, M; Vidal, J; Prieto, L; Daimiel, L; Casas, R; Arellano, AG; Shyam, S; González, JI; Castañer, O; García-Rios, A; Díaz, FO; Fernández, AC; Sánchez-Villegas, A; Morey, M; Cano-Ibañez, N; Sorto-Sánchez, C; Bernal-López, MR; Bes-Rastrollo, M; Nishi, SK; Coltell, O; Zomeno, MD; Pena-Orihuela, PJ; Aparicio, D; Zulet, MA; Vázquez, Z; Babio, N; Perez, KA; Tur, JA; Martín-Sánchez,	Impact of mediterranean diet promotion on environmental sustainability: a longitudinal analysis	PUBLIC HEALTH	3.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-06	Ruiz-Irastorza, G; Paredes-Ruiz, D; Herrero-Galvan, M; Moreno-Torres, V; Hernandez-Negrin, H; Ruiz-Arruza, I; Leonard, C; Richez, C; Lazaro, E	Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort	ARTHRITIS CARE & RESEARCH	3.7	Q1	Article	2024
A-06	Ruiz-Irastorza, G; Paredes-Ruiz, D; Dueña-Bartolome, L; Hernandez-Negrin, H; Moreno-Torres, V; Richez, C; Lazaro, E	No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
A-06	Gómez-Moyano, E; Pavón-Morón, J; Rodríguez-Capitán, J; Bardán-Rebollar, D; Ramos-Carrera, T; Villalobos-Sánchez, A; de Pedro, IP; Ruiz-García, FJ; Mora-Robles, J; López-Sampalo, A; Pérez-Velasco, MA; Bernal-López, MR; Gómez-Huelgas, R; Jiménez-Navarro, M; Romero-Cuevas, M; Costa, F; Trenas, A; Pérez-Belmonte, LM	The Role of Heparin in Postural Orthostatic Tachycardia Syndrome and Other Post-Acute Sequelae of COVID-19	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024
A-06	Fuentes-Abolafio, IJ; Ricci, M; Bernal-López, MR; Gómez-Huelgas, R; Cuesta-Vargas, AI; Pérez-Belmonte, LM	Relationship between quadriceps femoris echotexture biomarkers and muscle strength and physical function in older adults with heart failure with preserved ejection fraction	EXPERIMENTAL GERONTOLOGY	3.3	Q2	Article	2024
A-06	Pietrantonio, F; Florczak, M; Kuhn, S; Kärberg, K; Leung, T; Sikorski, S; Criado, IS; Ruggeri, M; Signorini, A; Rosiello, F; Drago, C; Vinci, A; Barreto, V; Montano, N; Dicker, D; Huelgas, RG	Applications to augment patient care for Internal Medicine specialists: a position paper from the EFIM working group on telemedicine, innovative technologies & digital health	FRONTIERS IN PUBLIC HEALTH	3.0	Q2	Review	2024
A-06	Campos, L; Viñas, MM; Gómez, J; Santos, L; Rayo, A; Valdez, PR; Gómez-Huelgas, R	Recommendations of the Spanish-Portuguese Internal Medicine services in the fight against climate change and environmental degradation.	REVISTA CLINICA ESPANOLA	2.3	Q2	Article	2024
A-06	Sanz-Cánovas, J; Lendtínez-Sánchez, G; Prieto-Sánchez, E; Vicioso-Recio, L; Gutiérrez-Cardo, A; Izurrategui-Hidalgo, E; Palacios-Rodríguez, S; Peláez-Angulo, JM; Roperó-Luis, G; Pérez-de-Pedro, I; Gómez-Huelgas, R; Salgado-Ordóñez, F	Corticodependent and recurrent inflammatory pseudo tumor. Analysis of cases and review	AMERICAN JOURNAL OF THE MEDICAL SCIENCES	2.3	Q2	Review	2024
A-06	Funes, AK; Avena, V; Boarelli, P; Monclus, MA; Zoppino, DF; Saez-Lancellotti, TE; Fornes, MW	Cholesterol dynamics in rabbit liver: High-fat diet, olive oil, and synergistic dietary effects	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS	2.5	Q3	Article	2024
A-06	Belmonte, AP; Madrazo, M; Piles, L; Rubio-Rivas, M; Huerta, LD; Antúnez, MG; Caleyá, JFL; Fernández, FA; Gericó-Aseguinolaza, M; Fontan, PMP; Rhyman, N; Dehesa, MP; Cabrera, JLR; García, GMG; García-Casasola, G; Ruiz, ALI; Carrasco-Sánchez, FJ; Hernández, SM; Pérez, MDP; Castro, JL; Albornoz, JLSCD; Varona, JF; Gomez-Huelgas, R; Antón-Santos, JM; Lumbreras-Bermejo, C	Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study	CANADIAN JOURNAL OF RESPIRATORY THERAPY	1.0	Q4	Article	2024
A-07	Baños, JE; Blanco-Reina, E; Bellido-Estévez, I; Bosch, F; Cabello, MR; Cambra-Badii, I; Cruz, JPD; D'Ocón, P; Ivorra, MD; Ferrándiz, M; Gonzalez-Correa, JA; Martin-Montanez, E; Martos, F; Pavia, J; Sanz, E	Beyond lectures and practical courses: Teaching pharmacology using imaginative pedagogical tools	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
A-07	de la Cruz, JP; Iserte-Terrer, L; Rodríguez-Pérez, MD; Ortega-Hombrados, L; Sánchez-Tévar, AM; Arrebola-Ramírez, MM; Fernández-Prior, MA; Verdugo-Cabello, C; Espejo-Calvo, JA; González-Correa, JA	Effects of Some Olive Fruits-Derived Products on Oxidative Stress and Cardiovascular Biomarkers on Experimental Diabetes Mellitus	ANTIOXIDANTS	6.0	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-07	López-Villodres, JA; García-Díaz, B	Oligodendroctyes: the forgotten players of diabetes pathophysiology	NEURAL REGENERATION RESEARCH	5.9	Q1	Article	2024
A-07	de la Cruz, JP; Osuna-Esteban, L; Rodríguez-Pérez, MD; Ortega-Hombrados, L; Sánchez-Tévar, AM; Martín-Aurioles, E; Fernández-Prior, MA; Pérez-Burillo, S; Espejo-Calvo, JA; González-Correa, JA	Effect of a Triterpenoid-Rich Olive Oil on Chronic Kidney Disease in an Experimental Model of Diabetes Mellitus	NUTRIENTS	4.8	Q1	Article	2024
A-07	Gavilán, P; Gavilán, JC; Arnedo, R; Clavijo, E; Viciana, I; González-Correa, JA	Prediction model of hepatocellular carcinoma development in chronic hepatitis B virus infection in a Spanish cohort	CLINICAL MEDICINE	2.6	Q1	Article	2024
A-09	Valdivielso, P; Prieto, IC	Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen	MED	13.0	D1	Editorial Material	2024
A-09	Cabañero-Navalon, MD; Garcia-Bustos, V; Balastegui-Martin, H; Bracke, C; Mateu, L; Solanich, X; Carrillo-Linares, JL; Robles-Marhuenda, A; Puchades, F; Ballesta, AP; Lopez-Osle, N; Torralba-Cabeza, MA; Masdeu, AMB; Niño, JG; Gaya, NT; Castellanos, GP; Sánchez-Martínez, R; Barragán-Casas, JM; González-García, A; de la Peña, JLP; López-Wolf, D; Rufete, AM; Mora, AC; Moral, PM	The impact of immune dysregulation on the risk of malignancy in common variable immunodeficiency: insights from a multicenter study	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
A-09	de las Heras, J; Almohalla, C; Blasco-Alonso, J; Bourbon, M; Couce, ML; López, MJD; Jiménez, MCG; Ortega, DG; González-Diéguez, L; Meavilla, S; Moreno-alvarez, A; Pastor-Rosado, J; Sánchez-Pintos, P; Serrano-Gonzalo, I; López, E; Valdivielso, P; Yahyaoui, R; Quintero, J	Practical Recommendations for the Diagnosis and Management of Lysosomal Acid Lipase Deficiency with a Focus on Wolman Disease	NUTRIENTS	4.8	Q1	Review	2024
A-09	Sánchez-Varo, R; López-Salas, A; Beltran-Casanueva, R; Díaz-Sánchez, E; Alvarez-Contino, JE; Barbancho-Fernández, MA; Serrano-Castro, P; Fuxe, K; Borroto-Escuela, DO; García-Casares, N; Narváez, M	Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions	BEHAVIORAL AND BRAIN FUNCTIONS	4.7	Q1	Article	2024
A-09	Arrabal-Gómez, C; Serrano-Castro, P; Sánchez-Pérez, JA; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, D; Narvaéz, M	Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus	EXPERT OPINION ON THERAPEUTIC TARGETS	4.6	Q1	Article	2024
A-09	Beltran-casanueva, R; Hernández-García, A; Serrano-Castro, PJ; Sánchez-Pérez, JA; Barbancho-Fernández, MA; García-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Long-term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co-administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus	FASEB JOURNAL	4.4	Q1	Article	2024
A-09	Montiel, AM; Ruiz-Esteban, P; Del Rio, AD; Valdivielso, P; Chaparro, MAS; Oliveira, C	Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype	SCIENTIFIC REPORTS	3.8	Q1	Article	2024
A-09	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-cosme, C; Lara, JP	Early Occupational Therapy Intervention Programme and Coping Strategies and Burden in Caregivers of People with Sub-Acute Stroke: A Randomised Controlled Trial	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Article	2024
A-09	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-Cosme, C; Lara, JP	Early Occupational Therapy Intervention post-stroke (EOTIPS): A randomized controlled trial	PLOS ONE	2.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-09	Stewart, S; Seco-Meseguer, E; Diago-Sempere, E; Marín-Candón, A; Carmona, M; Estébanez, M; López-Fernández, LA; Imaz-Iglesia, I; Saiz, MDG; Laserna-Mendieta, EJ; Peiró, AM; Farré, M; Rodríguez-Jimenez, C; Saiz-Rodríguez, M; Sanabria-Cabrera, J; Rosas-Alonso, R; Abad-Santos, F; Pedrosa, L; Carcas, AJ; García, IG; Borobia, AM	Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial	BMJ OPEN	2.4	Q1	Article	2024
A-09	Beltran-Casanueva, R; Hernández-García, A; García, PD; Blanco-Reina, E; Serrano-Castro, P; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2	Article	2024
A-09	Ramos-Cazorla, P; Carazo-Barrios, L; Reyes-Bueno, JA; Sagües-Sesé, E; de Rojas-Leal, C; Barbancho, MA; Garzón-Maldonado, FJ; de la Cruz-cosme, C; García-Arnés, JA; García-Casares, N	Olfactory Dysfunction as a Biomarker for Early Diagnosis of Cognitive Impairment in Patients With Type 2 Diabetes: A Systematic Review	JOURNAL OF DIABETES RESEARCH	3.6	Q2	Review	2024
A-09	Montiel, AM; Ruiz-Esteban, P; Del Río, AD; Valdivielso, P; Chaparro, MAS; Olveira, C	The effect of pulmonary rehabilitation on cardiovascular risk, oxidative stress and systemic inflammation in patients with COPD	RESPIRATORY MEDICINE	3.5	Q2	Article	2024
A-09	García-Alberca, JM; de Rojas, I; Sanchez-Mejias, E; Garrido-Martín, D; Gonzalez-Palma, L; Jimenez, S; Pino-Angeles, A; Cruz-Gamero, JM; Mendoza, S; Alarcón-Martín, E; Muñoz-Castro, C; Real, LM; Tenao, JJ; Polvillo, R; Govantes, F; Lopez, A; Royo-Aguado, JL; Navarro, V; Gonzalez, I; Ruiz, M; Reyes-Engel, A; Gris, E; Bravo, MJ; Lopez-Gutierrez, L; Mejias-Ortega, M; De la Guía, P; de la Rica, ML; Ocejó, O; Torrecilla, J; Zafra, C; Nieto, MD; Urbano, C; Jiménez-Sánchez, R; Pareja, N; Luque, M; García-Peralta, M; Carrillejo, R; Furniet, MD; Rueda, L; Sánchez-Fernández, A; Mancilla, T; Peña, I; García-Casares, N; Moreno-Grau, S; Hernández, I; Montreal, L; Quintela, I; González-Pérez, A; Calero, M; Franco-Macías, E; Macías, J; Menéndez-González, M; Frank-García, A; Vilas, RH; Díez-Fairen, M; Lage, C; García-Madróna, S; García-González, P; Valero, S; Sotolongo-Grau, O; Pérez-Cordón, A; Rabano, A; Pastor, AA; Pastor, AB; Espinosa, A; Corma-Gómez, A; Montes, AM; Sanabria, A; Rodríguez, CM; Buiza-Rueda, D; Rodríguez-Rodríguez, E; Ortega, G; Alvarez, I; Allende, IR; Pineda, JA; Rosende-Roca, M; Sánchez-Arjona, MB; Fernández-Fuertes, M; Alegret, M; Roberto, N; del Ser, T; Garcia-Ribas, G; Sánchez-Juan, P; Pastor, P; Piñol-Ripoll, G; Bullido, MJ; Alvarez, V; Mir, P; Medina, M; Marquié, M; Sáez, ME; Carracedo, A; Laplana, M; Tomas-Gallardo, L; Orellana, A; Tarraga, L; Boada, M; Palazon, JF; Vitorica, J; Ruiz, A; Guigo, R; Gutierrez, A; Royo, JL	An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
A-09	Bueno, JAR; Sánchez-Guijo, G; Ráez, PD; García-Arnes, JA; Garzón-Maldonado, FJ; Castro, VS; de la Cruz-Cosme, C; Alba-Linero, C; Gutiérrez-Bedmar, M; García-Casares, N	Effects of Type 2 Diabetes on the Neuropsychological Profile in Mild Cognitive Impairment	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
A-09	Sanz-Cánovas, J; Lendtínez-Sánchez, G; Prieto-Sánchez, E; Vicioso-Recio, L; Gutiérrez-Cardo, A; Izurrategui-Hidalgo, E; Palacios-Rodríguez, S; Peláez-Angulo, JM; Roperó-Luis, G; Pérez-de-Pedro, I; Gómez-Huelgas, R; Salgado-Ordóñez, F	Corticodependent and recurrent inflammatory pseudo tumor. Analysis of cases and review	AMERICAN JOURNAL OF THE MEDICAL SCIENCES	2.3	Q2	Review	2024
A-09	Flores-Márquez, A; Moreno-Gutiérrez, JA; Chinchurreta-Capote, AM; Lorenzo-Soto, M; García-Casares, N	Optic Disc Swelling and Roth Spots Associated with Respiratory Failure	JOURNAL OF NEURO-OPHTHALMOLOGY	2.2	Q2	Editorial Material	2024
A-09	Espíldora-Hernández, J; Díaz-Antonio, T; Olmedo-Llanes, J; León, JZ; Rioja, J; Valdivielso, P; Sánchez-Chaparro, MA; Ariza, MJ	Clinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
A-09	Arrobas-Velilla, T; Ariza, MJ; Rico-Corral, MA; Valdiviels, P	Early detection of severe hypertriglyceridemia using teleconsultation in a clinical laboratory setting	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-09	Mostaza, JM; Pintó, X; Armario, P; Masana, L; Real, JT; Valdivielso, P; Arrobas-Velilla, T; Baeza-Trinidad, R; Calmarza, P; Cebollada, J; Civera-Andrés, M; Melero, JIC; Díaz-Díaz, JL; Espíldora-Hernández, J; Pardo, JF; Guijarro, C; Jericó, C; Laclaustra, M; Lahoz, C; López-Miranda, J; Martínez-Hervás, S; Muñoz-Grijalvo, O; Páramo, JA; Pascual, V; Pedro-Boteta, J; Pérez-Martínez, P; Puzo, J	SEA 2024 Standards for Global Control of Vascular Risk	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
A-09	López-Téllez, A; Torres, JMR; Vázquez, EP; Fernández, MAB; López-Martí, H; Martínez, IZ; Fernández, CT; Vargas, MF; Pinos, MDD; Morant, JFP; González-Fajardo, JA; Felices, PV	Ultrasound screening for abdominal aortic aneurysm in primary care	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
A-09	Ramos, CFL; Moral, I; Brotons, C; Aguado, LQ; Prieto, IC; Valdivielso, P; Chaparro, MAS	Validation of the IberScore model in a primary care population	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
A-09	Alvarez-González, C; Espildora-Hernández, J; Sánchez-Chaparro, MA	Beyond hypercoagulability in celiac disease	HIPERTENSION Y RIESGO VASCULAR	1.2	Q4	Article	2024
A-10	Khoury, N; Martínez, MA; Nishi, SK; Martinez-Gonzalez, MA; Corella, D; Castañer, O; Martinez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, F; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, J; Pérez-Vega, KA; Garcia-Rios, A; Ortiz-Díaz, F; Gomez-Gracia, E; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Peña-Orihuela, PJ; Signes-Pastor, AJ; García-Arellano, A; Fito, M; Babio, N; Salas-Salvadó, J	Dietary intake of Perfluorooctanesulfonic acid (PFOS) and glucose homeostasis parameters in a non-diabetic senior population	ENVIRONMENT INTERNATIONAL	10.0	D1	Article	2024
A-10	Alvarez-Alvarez, L; Rubín-García, M; Vitelli-Storelli, F; García, S; Bouzas, C; Martínez-González, MA; Corella, D; Salvadó, JS; Malcampo, M; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Fernández, CG; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; García-Arellano, A; Martínez, MA; Sorli, J; Zomeno, MD; García-Rios, A; González-Palacios, S; Monserrat-Mesquida, M; Abete, I; Fernández, AC; Casas, R; Ibáñez, NC; Ugarriza, L; Bernal-López, MR; Bes-Rastrollo, M; Paz-Graniel, I; Asensio, EM; Fitó, M; Larriva, APA; Oncina-Cánovas, A; Vázquez, Z; de la Puente, MF; Pérez-Vega, A; Tur, JA; Martín-Sánchez, V	Effect of a nutritional intervention based on an energy-reduced Mediterranean diet on environmental impact	SCIENCE OF THE TOTAL ENVIRONMENT	8.2	D1	Article	2024
A-10	Schröder, H; Juton, C; Goran, MI; Wärnberg, J; Osés, M; Gonzalez-Gross, M; Gusi, N; Aznar, S; Marin-Cascales, E; Gonzalez-Valeiro, M; Herrera-Ramos, E; Terrados, N; Tur, JA; Segú, M; Fitó, M; Ribas-Barba, L; Bautista-Castaño, I; Peña-Quintana, L; Berruezo, P; Benavente-Marín, JC; Labayen, I; Zapico, AG; Sánchez-Gómez, J; Jiménez-Zazo, F; Alcaraz, PE; Sevilla-Sanchez, M; Pulgar, S; Bouzas, C; Serra-Majem, L; Gómez, SF	Twenty-year trend in the prevalence of increased cardiometabolic risk, measured by abdominal obesity, among Spanish children and adolescents across body mass index categories	BMC MEDICINE	7.1	D1	Article	2024
A-10	Shyam, S; Gómez-Martínez, C; Paz-Graniel, I; Gaforio, JJ; Martínez-González, MA; Corella, D; Fitó, M; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sánchez, VM; Pintó, X; Ramos, M; Vidal, J; Alcarria, MM; Daimiel, L; Ros, E; Fernandez-Aranda, F; Nishi, SK; Regata, OG; Toledo, E; Sorli, JV; Castañer, O; Garcia-Rios, A; Valls-Enguix, R; Perez-Farinos, N; Zulet, MA; Rayó-Gago, E; Casas, R; Rivera-Izquierdo, M; Tojal-Sierra, L; Damas-Fuentes, M; Buil-Cosiales, P; Fernández-Carrion, R; Goday, A; Peña-Orihuela, PJ; Compañ-Gabucio, L; Diez-Espino, J; Tello, S; González-Pinto, A; de la O, V; Delgado-Rodríguez, M; Babio, N; Salas-Salvadó, J	Coronavirus disease 2019 is associated with long-term depressive symptoms in Spanish older adults with overweight/obesity and metabolic syndrome	PSYCHOLOGICAL MEDICINE	5.9	D1	Article	2024
A-10	Oncina-Cánovas, A; Compañ-Gabucio, L; Vioque, J; Ruiz-Canela, M; Corella, D; Salas-Salvadó, J; Fitó, M; Martínez, A; Alonso-Gómez, AM; Wärnberg, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Alvarez-Pérez, J; Bueno-Cavanillas, A; Tur, JA; Martín-Sánchez, V; Esteve-Luque, V; Delgado-Rodríguez, M; Ortiz-Ramos, M; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Razquin, C; Paz-Graniel, I; Sorli, JV; Castañer, O; García-Rios, A; Torres-Collado, L; Fernández-Barceló, O; Zulet, MA; Rayó-Gago, E; Casas, R; Cano-Ibáñez, N; Tojal-Sierra, L; Simón-Frapolli, VJ; Carlos, S; Shyam, S; Fernández-Carrión, R; Goday, A; Torres-Peña, JD; González-Palacios, S; Eguaras, S; Babio, N; Zomeño, MD; García-de-la-Hera, M	More Adult Women than Men at High Cardiometabolic Risk Reported Worse Lifestyles and Self-Reported Health Status in the COVID-19 Lockdown	NUTRIENTS	4.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Marcos-Delgado, A; Martín-Sánchez, V; Martinez-Gonzalez, MA; Corella, D; Salas-Salvadó, J; Schröder, H; Martínez, A; Alonso-Gomez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Alvarez-Pérez, J; Bueno-Cavanillas, A; Cano-Ibáñez, N; Amezcua-Prieto, C; Hernández-Segura, N; Tur, JA; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Toledo, E; Garcidueñas-Fimbres, TE; Viaplana, J; Asensio, EM; Zomeño, MD; García-Rios, A; Oncina-Cánovas, A; Barón-López, FJ; Pérez-Farinos, N; Sayon-Orea, C; Galmés-Panadés, AM; Casas, R; Tojal-Sierra, L; Gómez-Pérez, AM; Buil-Corsiales, P; García-Gavilán, JF; Ortega-Azorín, C; Castañer, O; Peña-Orihuela, PJ; González-Palacios, S; Babio, N; Fitó, M; Nieto, J	Objectively Measured Sleep Duration and Health-Related Quality of Life in Older Adults with Metabolic Syndrome: A One-Year Longitudinal Analysis of the PREDIMED-Plus Cohort	NUTRIENTS	4.8	Q1	Article	2024
A-10	Gavala-González, J; Real-Pérez, M; Benítez-García, L; Fernández-García, JC	Fixed-Seat Rowing versus Sliding-Seat Rowing: Effects on Physical Fitness in Breast Cancer Survivors	CANCERS	4.5	Q1	Article	2024
A-10	Doímguez-Lpóez, I; Galkina, P; Parilli-Moser, I; Arancibia-Riveros, C; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Malcampo, M; Martínez, JA; Tojal-Sierra, L; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Rubín-García, M; Pintó, X; Fernández-Aranda, F; Delgado-Rodríguez, M; Barabash-Bustelo, A; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Toledo, E; Atzeni, A; Asensio, EM; Vera, N; Garcia-Rios, A; Torres-Collado, L; Pérez-Farinós, N; Zulet, M; Chaplin, A; Casas, R; Martín-Peláez, S; Vaquero-Luna, J; Gómez-Pérez, AM; Vázquez-Ruiz, Z; Shyam, S; Ortega-Azorín, C; Talens, N; Peña-Orihuela, PJ; Oncina-Canovas, A; Diez-Espino, J; Babio, N; Fitó, M; Lamuela-Raventós, RM	Microbial Phenolic Metabolites Are Associated with Improved Cognitive Health	MOLECULAR NUTRITION & FOOD RESEARCH	4.5	Q1	Article	2024
A-10	Popescu, ML; Rubín-García, M; Alvarez-Alvarez, L; Toledo, E; Corella, D; Salas-Salvadó, J; Pérez-Vega, KA; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Cano-Ibáñez, N; Tur, JA; Naveiro, R; Pintó, X; Delgado-Rodríguez, M; Ortiz-Ramos, M; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Vázquez-Ruiz, Z; Babio, N; Sorlí, J; Castañer, O; García-Rios, A; González-Palacios, S; Zulet, M; Konieczna, J; Casas, R; Masso-Guijarro, P; Tojal-Sierra, L; Gómez-Pérez, AM; Cenoz-Osinaga, JC; Valverde, I; Fernández-Carrión, R; Schröder, H; Larriva, APA; Torres-Collado, L; García-Arellano, A; Palau-Galindo, A; Fitó, M; Martín-Sánchez, V; Fernández-Villa, T	Sex-specific dietary patterns and their association with metabolic syndrome: Insights from a cross-sectional analysis	DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS	4.3	Q1	Article	2024
A-10	Alvarez-Alvarez, L; Vitelli-Storelli, F; Rubín-García, M; García, S; Bouzas, C; Ruíz-Canela, M; Corella, D; Salas-Salvadó, J; Fitó, M; Martinez, JA; Tojal-Sierra, L; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; García-Fernández, C; Esteve-Luque, V; Delgado-Rodríguez, M; Torrego-Ellacuría, M; Vidal, J; Prieto, L; Daimiel, L; Casas, R; Arellano, AG; Shyam, S; González, JI; Castañer, O; García-Rios, A; Díaz, FO; Fernández, AC; Sánchez-Villegas, A; Morey, M; Cano-Ibañez, N; Sorto-Sánchez, C; Bernal-López, MR; Bes-Rastrollo, M; Nishi, SK; Coltell, O; Zomeno, MD; Pena-Orihuela, PJ; Aparicio, D; Zulet, MA; Vázquez, Z; Babio, N; Perez, KA; Tur, JA; Martín-Sánchez,	Impact of mediterranean diet promotion on environmental sustainability: a longitudinal analysis	PUBLIC HEALTH	3.9	Q1	Article	2024
A-10	Casals, C; Corral-Pérez, J; Avila-Cabeza-de-Vaca, L; González-Mariscal, A; Carrión-Velasco, Y; Rodríguez-Martínez, MC; Jiménez-Cebrián, AM; Vázquez-Sánchez, MA	Exploring the interplay of frailty, physical function, physical activity, nutritional status, and their association with quality of life and depressive symptoms in older adults with the frailty phenotype	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	3.6	Q1	Article	2024
A-10	Cortes-Rodríguez, A; Alves-Gomes, L; Losa-Iglesias, ME; Gómez-Salgado, J; Becerro-de-Bengoa-Vallejo, R; Saavedra-García, MA; Montiel-Luque, A; López-López, D; Jiménez-Cebrián, AM	Impact of ankylosing spondylitis on foot health and quality of life: an observational case-control study	FRONTIERS IN MEDICINE	3.1	Q1	Article	2024
A-10	De-Miguel-Diez, J; Llamas-Saez, C; Vaquero, TS; Jiménez-García, R; López-de-Andrés, A; Carabantes-Alarcón, D; Carricondo, F; Romero-Gómez, B; Pérez-Farinos, N	Association between Asthma and Lower Levels of Physical Activity: Results of a Population-Based Case-Control Study in Spain	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Aznar, S; Jimenez-Zazo, F; Romero-Blanco, C; Gómez, SF; Homs, C; Wärnberg, J; Medrano, M; Gusi, N; Gonzalez-Gross, M; Marín-Cascales, E; González-Valeiro, MA; Serra-Majem, L; Terrados, N; Tur, JA; Segu, M; Lassale, C; Colom-Fernández, A; Labayen, I; Sánchez-Gómez, J; Alcaraz, PE; Sevilla-Sanchez, M; Zapico, AG; Herrera-Ramos, E; Pulgar, S; Bibilonii, MD; Sistac, C; Schröder, H; Molina-García, J	Walkability and socio-economic status in relation to walking, playing and sports practice in a representative Spanish sample of youth: The PASOS study	PLOS ONE	2.9	Q1	Article	2024
A-10	Gil-Espinosa, FJ; López-Fernández, I; Cadenas-Sanchez, C; Burgueño, R	The perspectives of school principals in Spain: identifying professional competencies beyond their scope	SCHOOL LEADERSHIP & MANAGEMENT	2.8	Q1	Article	2024
A-10	Cortés-Rojas, R; Castellano-Ruiz, MI; Baeza-Medina, A; Gil-Espinosa, FJ; Alvarez-Salvago, F; Jiménez-García, JD	Associations of Physical Fitness with Cognitive Performance in Children Aged 7-12 Years: A Cross-Sectional Study	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
A-10	Gavala-González, J; Real-Pérez, M; Gamboa-González, J; Fernández-García, JC	Effects of Rowing on Cardiac Function in Breast Cancer Survivors: Sliding Seat Rowing vs. Fixed Seat Rowing	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
A-10	Gavala-González, J; Porras-García, ME; Fernández-García, JC; Real-Pérez, M	Effects of Specific Training Using a Rowing Ergometer on Sport Performance in Adolescents	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
A-10	Jiménez-Cebrián, AM; Ruiz-Sánchez, FJ; Losa-Iglesias, ME; Becerro-de-Bengoa-Vallejo, R; López-López, D; Montiel-Luque, A; de Labra, C; Saavedra-García, MA; Navarro-Flores, E	Relationship of foot pain with the increased risk of falls in patients with Parkinson's disease	JOURNAL OF FOOT AND ANKLE RESEARCH	2.5	Q1	Article	2024
A-10	López-Fernández, I; Gil-Espinosa, FJ; Burgueño, R; Calderón, A	Physical education teachers' reality and experience from teaching during a pandemic	SPORT EDUCATION AND SOCIETY	2.3	Q1	Article	2024
A-10	Baenas, I; Camacho-Barcia, L; Granero, R; Razquin, C; Corella, D; Gomez-Martinez, C; Castaner-Nino, O; Martinez, JA; Alonso-Gomez, AM; Waernberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Cano-Ibanez, N; Tur, JA; Martin-Sanchez, V; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Jimenez-Murcia, S; Dalsgaard, S; Garcia-Arellano, A; Babio, N; Sorli, JV; Lassale, C; Garcia-de-la-Hera, M; Gomez-Garcia, E; Zulet, MA; Konieczna, J; Martin-Pelaez, S; Tojal-Sierra, L; Basterra-Gortari, FJ; de las Heras-delgado, S; Portoles, O; Munoz-Perez, MA; Arenas-Larriva, AP; Compan-Gabucio, L; Eguaras, S; Shyam, S; Fito, M; Banos, RM; Salas-Salvado, J; Fernandez-Aranda, F	Association between type 2 diabetes and depressive symptoms after a 1-year follow-up in an older adult Mediterranean population	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION	3.9	Q2	Article	2024
A-10	Maestre-Miquel, C; Lopez-de-Andres, A; Perez-Farinos, N; Jimenez-Sierra, A; Benavente-Marin, JC; Lopez-Gonzalez, A; Vinuela-Sanchez, A; Jimenez-Garcia, R	Prevalence and Factors Related to Physical Activity in Spanish Adults with Obesity and Overweight: Analysis of the European Health Surveys for the Years 2014 and 2020	HEALTHCARE	2.4	Q2	Article	2024
A-10	Benavente-Marín, JC; Barón-López, FJ; Barcenilla, BG; Abril, GL; Aguirre, JMR; Pérez-Farinós, N; Wärnberg, J	Accelerometry-assessed daily physical activity and compliance with recommendations in Spanish children: importance of physical education classes and vigorous intensity	PEERJ	2.3	Q2	Article	2024
A-10	Benavente-Marín, JC; Barón-López, FJ; Barcenilla, BG; Abril, GL; Aguirre, JMR; Pérez-Farinós, N; Wärnberg, J	Adherence to the WHO recommendation of three weekly days of vigorous intensity activities in children: an accelerometry study of vigorous physical activity bouts	PEERJ	2.3	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Real-Pérez, M; Fernández-García, JC; Gavala-González, J	Influence of a physical exercise program based on rowing in the rehabilitation of women with breast cancer	SPORTIS-SCIENTIFIC TECHNICAL JOURNAL OF SCHOOL SPORT PHYSICAL EDUCATION AND PSYCHOMOTRICITY	0.7	Q3	Article	2024
A-17	López-Unzu, MA; Soto-Navarrete, MT; Sans-Coma, V; Fernández, B; Durán, AC	The myoarchitecture of the vertebrate cardiac ventricles: evolution The myoarchitecture of the vertebrate cardiac ventricles: evolution and classification and classification	JOURNAL OF EXPERIMENTAL BIOLOGY	2.8	Q2	Review	2024
A-17	Michelena, HI; della Corte, A; Evangelista, A; Maleszewski, JJ; Edwards, WD; Roman, MJ; Devereux, RB; Fernández, B; Asch, FM; Barker, AJ; Sierra, LM; de Kerchove, L; Fernandes, SM; Fedak, PWM; Girdauskas, E; Delgado, V; Abbara, S; Lansac, E; Prakash, SK; Bissell, MM; Popescu, BA; Hope, MD; Sitges, M; Thourani, VH; Pibarot, P; Chandrasekaran, K; Lancellotti, P; Borger, MA; Forrest, JK; Webb, J; Milewicz, DM; Makkar, R; Leon, MB; Sanders, SP; Markl, M; Ferrari, VA; Roberts, WC; Song, JK; Blanke, P; White, CS; Siu, S; Svensson, LG; Braverman, AC; Bavaria, J; Sundt, TM; El Khoury, G; de Paulis, R; Enriquez-Sarano, M; Bax, JJ; Otto, CM; Schäfers, HJ	Summary: International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes	ARCHIVOS DE CARDIOLOGIA DE MEXICO	0.7	Q4	Article	2024
A-19	Bellos, E; Santillo, D; Vantourout, P; Jackson, HR; Duret, A; Hearn, H; Seeleuthner, Y; Talouarn, E; Hodeib, S; Patel, H; Powell, O; Yeoh, S; Mustafa, S; Habgood-Coote, D; Nichols, S; Elorrieta, LE; D’Souza, G; Wright, VJ; Estrada-Rivadeneira, D; Tremoulet, AH; Dummer, KB; Netea, SA; Condino-Neto, A; Lau, YL; Cuadros, EN; Toubiana, J; Pena, MH; Rieux-Laucat, F; Luyt, CE; Haerynck, F; Mège, JL; Chakravorty, S; Haddad, E; Morin, MP; Akcan, ÖM; Keles, S; Emiroglu, M; Alkan, G; Öz, SKT; Bozdemir, SE; Morelle, G; Volokha, A; Kendir-Demirkol, Y; Sözeri, B; Coskuner, T; Yahsi, A; Gulhan, B; Kanik-Yukse, S; Bayhan, GI; Ozkaya-Parlakay, A; Yesilbas, O; Hatipoglu, N; Ozcelik, T; Belot, A; Chopin, E; Barlogis, V; Sevetoglu, E; Menentoglu, E; Aydin, ZGG; Bloomfield, M; AlKhater, SA; Cyrus, C; Stepanovskiy, Y; Bondarenko, A; Öz, FN; Polat, M; Fremuth, J; Lebl, J; Geraldo, A; Jouanguy, E; Carter, MJ; Wellman, P; Peters, M; de Diego, RP; Edwards, LA; Chiu, C; Noursadeghi, M; Bolze, A; Shimizu, C; Kaforou, M; Hamilton, MS; Herberg, JA; Schmitt, EG; Rodriguez-Palmero, A; Pujol, A; Kim, J; Cobat, A; Abel, L; Zhang, SY; Casanova, JL; Kuijpers, TW; Burns, JC; Levin, M; Hayday, AC; Sancho-Shimizu, V	Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C)	JOURNAL OF EXPERIMENTAL MEDICINE	13.0	D1	Article	2024
A-19	Suarez, RG; Guruprasad, N; Tata, G; Zhang, ZX; Focht, G; McClement, D; Navas-López, VM; Koletzko, S; Griffiths, AM; Ledder, O; de Ridder, L; Wishart, D; Nichols, B; Gerasimidis, K; Turner, D; Wine, E	Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease	JOURNAL OF CROHNS & COLITIS	8.3	D1	Article	2024
A-19	Argiz, L; Valsami-Fokianos, M; Arasi, S; Barni, S; Boscia, S; Bracaglia, G; Bracamonte, T; Carballeira, I; Dinardo, G; Echeverria, L; Garcia, E; Garcia-Magan, C; Gomez-Rial, J; Gonzalez-Delgado, P; Fiocchi, A; Garriga, T; Ibrahim, T; Infante, S; Machinena, A; Mangone, G; Mori, F; Moure, JD; O’Valle, V; Pascal, M; Pecora, V; Prieto, A; Quevedo, S; Salas, A; Vazquez-Cortes, S; Vila, L; Martinon-Torres, F; Gomez-Carballa, A; Boyle, RJ; Vazquez-Ortiz, M	Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein-Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	8.2	D1	Article	2024
A-19	Rodríguez-Molino, P; Tebruegge, M; Noguera-Julian, A; Neth, O; Fidler, K; Brinkmann, F; Sainz, T; Ivaskeviciene, I; Ritz, N; Brito, MJ; Silva, TM; Chechenieva, V; Serdiuk, M; Lancelli, L; Russo, C; Soler-García, A; Navarro, ML; Krueger, R; Feiterna-Sperling, C; Starshinova, A; Hiteva, A; Hoffmann, A; Kalibatas, P; Lo Vecchio, A; Scarano, SM; Bustillo, M; Gamero, DB; Espiau, M; Buonsenso, D; Falcón, L; Turnbull, L; Colino, E; Rueda, S; Buxbaum, C; Carazo, B; Alvarez, C; Dapena, M; Piqueras, A; Velizarova, S; Ozere, I; Götzinger, F; Pareja, M; Llanos, MIG; Soto, B; Martín, SR; Korta, JJ; Pérez-Gorricho, B; Herranz, M; Hernández-Bartolomé, A; Díaz-Almirón, M; Vasconcelos, MK; Ferreras-Antolín, L; Santiago-García, B	Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study	CLINICAL INFECTIOUS DISEASES	8.2	D1	Article	2024
A-19	Salvador-Martín, S; Rubbini, G; Velloso, P; Zapata-Cobo, P; Velasco, M; Palomino, LM; Clemente, S; Segarra, O; Moreno-Alvarez, A; Fernández-Lorenzo, A; Pérez-Moneo, B; Montraveta, M; Sánchez, C; Tolín, M; Loverdos, I; Fobelo, MJ; Navas-López, VM; Magallares, L; García-Romero, R; Torres-Peral, R; Rodríguez, A; Bossacoma, F; Merino-Bohórquez, V; Salcedo, E; Alvarez, R; Dopazo, A; Sanjurjo-Sáez, M; López-Fernández, LA	Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-19	Castellano-Castillo, D; Ramos-Molina, B; Frutos, MD; Arranz-Salas, I; Reyes-Engel, A; Queipo-Ortuño, MI; Cardona, F	RNA expression changes driven by altered epigenetics status related to NASH etiology	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
A-19	Cantinotti, M; Di Salvo, G; Voges, I; Raimondi, F; Greil, G; Garrido, AO; Bharucha, T; Grotenhuis, HB; Köstenberger, M; Bonnello, B; Miller, O; McMahon, CJ	Standardization in paediatric echocardiographic reporting and critical interpretation of measurements, functional parameters, and prediction scores: a clinical consensus statement of the European Association of Cardiovascular Imaging of the European Society of Cardiology and the Association for European Paediatric and Congenital Cardiology	EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING	6.7	D1	Article	2024
A-19	Moral, L; Toral, T; Muñoz, C; Marco, N; García-Avilés, B; Murcia, L; Forníes, MJ; González, MC; Canals, F; Bragado, E; Olmos, JM; García-Magán, C; González, JDM; Cortes, N; Giménez, M; Gómez, C; Rodríguez, AB; Moreno, A; Lucas, JM; Quevedo, S; Blasco, C; Aliaga, Y	Direct oral challenge for immediate and non-immediate beta-lactam allergy in children: A real-world multicenter study	PEDIATRIC ALLERGY AND IMMUNOLOGY	4.3	D1	Article	2024
A-19	Rodriguez-Fernandez, R; Xu, ZH; Moreno-Galdó, A; Sardón, O; Rubi, T; Castillo-Corullón, S; Torres, A; Corcuera, P; Callejón, AC; Perez, G; Cortell, I; Rovira-Amigo, S; Pastor-Vivero, MD; Mondejar-Lopez, P; Perez-Frias, J; Velasco, V; Torres-Borrego, J; Figuerola, J; Blázquez, OD; Garcia-Hernandez, G; Tang, L; Mejias, A; Ramilo, O	Longitudinal transcriptional immune profiles and persistent wheezing in moderate-to-late preterm infants	PEDIATRIC ALLERGY AND IMMUNOLOGY	4.3	D1	Article	2024
A-19	Safi, S; Hjortdal, VE; Gewillig, M; Miller, O; Abumehdi, MR; Cantinotti, M; Grotenhuis, H; Raimondi, F; Garrido, AO; Roest, A; Sunnegårdh, J; Saleats, T; Brun, H; Pärna, H; Nolan, O; Rotés, AS; Deri, A; De Wolf, D; Herberg, U; Liuba, P; Möller, T; Oskarsson, G; Rebonato, M; Helbing, WA; Doros, G; Muntean, I; Ojala, T; Lubaua, I; Bhat, M; Wacker, J; Bonello, B; Ramcharan, T; Greil, G; Sendzikaite, S; Bonnet, D; Marek, J; Voges, I; McMahon, CJ	Lymphatic Disorder Management in Pediatric Patients With Congenital Heart Disease in European Pediatric Cardiology Centers: Current Status, Disparities, and Future Considerations	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5.0	Q1	Article	2024
A-19	Perez, PO; Valero-Arredondo, I; Torcuato-Rubio, E; Herrador-López, M; Martín-Masot, R; Navas-López, VM	Nutritional Issues in Children with Dysphagia	NUTRIENTS	4.8	Q1	Article	2024
A-19	Olid-Cárdenas, MJ; Lendínez-Jurado, A; Monroy-Rodríguez, G; Gómez-Perea, A; Cano-Ortiz, A; Ariza-Jiménez, AB; García-Ruiz, A; Jiménez-Cuenca, P; Picón-César, MJ; Leiva-Gea, I	Real-World Use of Hybrid Closed-Loop Systems during Diabetes Camp: A Preliminary Study for Secure Configuration Strategies in Children and Adolescents	NUTRIENTS	4.8	Q1	Article	2024
A-19	de las Heras, J; Almohalla, C; Blasco-Alonso, J; Bourbon, M; Couce, ML; López, MJD; Jiménez, MCG; Ortega, DG; González-Diéguez, L; Meavilla, S; Moreno-alvarez, A; Pastor-Rosado, J; Sánchez-Pintos, P; Serrano-Gonzalo, I; López, E; Valdivielso, P; Yahyaoui, R; Quintero, J	Practical Recommendations for the Diagnosis and Management of Lysosomal Acid Lipase Deficiency with a Focus on Wolman Disease	NUTRIENTS	4.8	Q1	Review	2024
A-19	Ribeiro-Constante, J; Tristán-Noguero, A; Calvo, FFM; Ibañez-Mico, S; Segura, JLP; Ramos-Fernández, JM; Chicano, MDM; Leon, RC; Insuga, VS; Alguacil, EG; Davila, CV; Fernández-Jaén, A; Plans, L; Camacho, A; Visa-Reñé, N; Blazquez, MDMT; Paredes-Carmona, F; Marti-Carrera, I; Hernández-Fabián, A; Davi, MT; Sanchez, MC; Herraiz, LC; Pita, PF; Gonzalez, TB; O'Callaghan, M; Santa Polonia, FFI; Cazorla, MR; Lucas, MTF; González-Meneses, A; Sala-Coromina, J; Macaya, A; Lasa-Aranzasti, A; Cueto-González, AM; Parraga, FV; Plana, JC; Serrano, M; Alonso, X; Del Castillo-Berges, D; Schwartz-Palleja, M; Illescas, S; Camacho, AR; Capdevila, OS; García-Cazorla, A; Bayés, A; Alonso-Colmenero, I	Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathy	FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY	4.6	Q1	Article	2024
A-19	Ledder, O; Dolinger, M; Dubinsky, MC; Stein, R; Vellanki, S; Buckuk, R; Fatima, A; Suskind, DL; Scarlett, J; Röser, D; Shouval, DS; Meyer, G; Rios, ZM; Pujol-Muncunill, G; Lozano, A; Kolho, KL; Rohani, P; Hussey, S; de Mejj, T; Ayers, T; Navas-López, VM; Turner, D; Tzivinikos, C	Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience	INFLAMMATORY BOWEL DISEASES	4.5	Q1	Article	2024
A-19	Marín, MJD; Ormazábal, IG; Gimeno-Navarro, A; Alvarez-Fuente, M; López-Ortego, P; Avila-Alvarez, A; Gómez, LA; González-Menchen, C; de Lera, CL; Balseiro, ML; Gutiérrez, LM; Frajilich, GM; Orellana, MR; García, NS; Delgado, AP; Torres, MV	Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up	CYTOTHERAPY	3.7	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-19	Castellano-Castillo, D; Núñez-Sánchez, MA; Balaguer-Román, A; Martínez-Sánchez, MA; Fernández-Ruiz, VE; Ferrer-Gómez, M; Martínez, CM; Frutos, MD; Queipo-Ortuño, MI; Cardona, F; Ramos-Molina, B	The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes	SURGERY FOR OBESITY AND RELATED DISEASES	3.5	Q1	Article	2024
A-19	Cohen, S; Rolandsdotter, H; Kolho, KL; Turner, D; Tzivinikos, C; Bramuzzo, M; Pujol-Muncunill, G; Scarallo, L; Urlep, D; Rinawi, F; Granot, M; Kang, B; Longueville, Y; Rodriguez-Belvis, MV; Weintraub, Y; Navas-Lopez, VM; Yerushalmy-Feler, A	Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN	PEDIATRIC DRUGS	3.4	Q1	Article	2024
A-19	Mesas-Aróstegui, MA; Hita-Contreras, F; López-Siguero, JP	A Therapeutic Proposal for Mini-Puberty in Male Infants with Hypogonadotropic Hypogonadism: A Retrospective Case Series	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
A-19	Arroyo-Ruiz, R; Urbano-Ruiz, C; García-Berrocal, MB; Marcos-Vadillo, E; Isidoro-García, M; Martín-Alonso, MM; Bajo-Delgado, AF; Prieto-Matos, P; López-Siguero, JP	Clinical and Genetic Characterization of a Cohort of Small-for-Gestational-Age Patients: Cost-Effectiveness of Whole-Exome Sequencing and Effectiveness of Treatment with GH	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
A-19	Germán-Díaz, M; Alcolea, A; Cabello, V; Blasco-Alonso, J; Rodríguez, A; Galera, R; García-Romero, R; Romero, C; González-Sacristán, R; Redecillas-Ferreiro, S; Moreno-Villares, JM; Ramos-Boluda, E	Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study	EUROPEAN JOURNAL OF PEDIATRICS	3.0	Q1	Article	2024
A-19	Clemente, D; Cuadros, EN; Lovillo, MC; Hernández, JC; Martín, SG; Silveira, LF; Cruz, MJL; Tagarro, A; Rueda, RMA; López, AL; Aritziturri, MS; Calvo, C	Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections	EUROPEAN JOURNAL OF PEDIATRICS	3.0	Q1	Article	2024
A-19	Pujol-Muncunill, G; Navas-López, VM; Ledder, O; Cohen, S; Lekar, M; Turner, D; Kolho, KL; Levine, A; Croft, NM; Bronsky, J; Shouval, DS; Assa, A; Harris, R; Kiparissi, F; Aloï, M; Afzal, NA; Tzivinikos, C; Barrio, J; Norden, C; Vega, MJB; Buderus, S; de Valderrama, AF; de Ridder, L; García-Romero, R; Medina, E; Sánchez, C; Velasco, M; Vicente, S; Wilson, DC; Naik, S; Hradsky, O; Cococcioni, L; Martin-de-Carpi, J	STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN	EUROPEAN JOURNAL OF PEDIATRICS	3.0	Q1	Article	2024
A-19	Rodríguez-Belvis, MV; Palomino, L; Pujol-Muncunill, G; Martin-Masot, R; Benitez, EMí; Fernández-Lorenzo, AE; Moreno-Alvarez, A; Arias, MM; Montes, IH; Torres, JB; Navas-López, VM; de Carpi, JM; Ruf, AL; Blasco-Alonso, J; Torres, JB; Montraveta, M; Peña-Quintana, L; Rueda, NR; Martínez, AR; Arcos, GB; Vicente, CA; Millán, AMC; Donat, E; Cebrián, SF; Sánchez, CS; Loverdos, I; Cantón, OS; Castellano, NR; Torres-Peral, R; Crehuá-Gaudiza, E; Jiménez, AM; Casano, CJ; Santamaría, SV; González, AT; Garcia-Romero, R; Arnal, IR; Vega, MJB; Madurga, LE; Torres, NM; Martínez, VC; González-Vives, L; Pérez-Moneo, B; Mas, MLM; Alvarez, AMV; Herrero, LG; Izquierdo, EL; Marín, FJC; Cuiñas, MDB; Fernández, JMMD; Alonso, JRA; Esteban, EMA	Transcultural adaptation and validation of IMPACT-III and IMPACT-III-P in Spanish families: a multicenter study from SEGHP	EUROPEAN JOURNAL OF PEDIATRICS	3.0	Q1	Article	2024
A-19	Carriquí-Arenas, S; Mosquera, JM; Quesada-Masachs, E; López, M; Clemente, D; Boteanu, A; Udaondo, C; de Inocencio, J; Nieto, JC; Riancho, L; Núñez, E; Sánchez-Manubens, J; Lirola, MJ; Roldán, R; Camacho, M; Martínez, M; Medrano, M; Alcañiz, P; Antón, J; Iglesias, E	Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry	PEDIATRIC RHEUMATOLOGY	2.8	Q1	Article	2024
A-19	Cárdenes, CL; Sanchez-Cañete, AM; Santamaría, SV; Galindo, CG; Sanz, NM; González, AT; Castro, EB; Tirado, AM; Garcia, MG; Rozas, ML; Riesgo, TR; Beltrán, MA; Martínez, JG; González, MS; Romero, RG; Hernández, D; Codoceo, MM; Fernández, CM; Gómez, CT; Rubio, ET; Pérez, PO; Eseverri, IL; Volpe, CG; Lobato, ES; Rivada, AM; Millan, ARC; Castillo, RDB; San Nicolás, SS; Hurtado, MM; Gaudiza, EC; Martínez, IMM; Jiménez, DG	Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis	PEDIATRIC PULMONOLOGY	2.7	Q1	Article	2024
A-19	Rodríguez-Belvis, Mí; Palomino, L; Muncunill, GP; Martin-Masot, R; Codoceo, RAM; Torres, JB; López, VMN; de Carpi, JM	Impact of pediatric inflammatory bowel disease on caregivers' work productivity: A multicenter study by the SEGHP	JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION	2.4	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-19	Gómez-Peralta, F; Leiva-Gea, I; Duque, N; Artime, E; de Santos, MR	Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review	ADVANCES IN THERAPY	3.4	Q2	Review	2024
A-19	Pérez-Ardanaz, B; Gutierrez-Rodríguez, L; Pelaez-Cantero, MJ; Morales-Asencio, JM; Gómez-González, A; García-Piñero, JM; Lupiañez-Perez, I	Healthcare service use for children with chronic complex diseases: A longitudinal six-year follow-up study	JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES	2.1	Q2	Article	2024
A-19	Pedraz, LM; Cuadros, EN; Hernández, MB; Rueda, RMA; Saavedra-Lozano, J; Rey, CC	Diagnostic and therapeutic approach to spondylodiscitis in Spanish children through the RIOPed Network: Evaluation before and after the publication of the national consensus document	ANALES DE PEDIATRIA	1.5	Q2	Article	2024
A-19	Barreda-Bonis, AC; Domingo, JMD; Galán-Gómez, E; Guillén-Navarro, E; Leiva-Gea, I; Riano-Galan, I	Expert consensus for the management of patients with achondroplasia in treatment with vosoritide	ANALES DE PEDIATRIA	1.5	Q2	Article	2024
A-19	Rubio, MN; Casano, CJ; López, MS; Herrera, AR; Casado, MAL; Navas-López, VM; Miravet, VV	Paediatric endoscopy in Spain: Current situation and recent developments	ANALES DE PEDIATRIA	1.5	Q2	Article	2024
A-19	Hidalgo, EH; Camacho, VR; González, LA; Alonso, JMC	Necrotizing fasciitis and streptococcal toxic shock	ANALES DE PEDIATRIA	1.5	Q2	Editorial Material	2024
A-19	González, LA; Peñaranda, NAD; Fernández, JMR; Alonso, JMC	Post-infective transverse myelitis following Streptococcus pyogenes meningitis	ANALES DE PEDIATRIA	1.5	Q2	Editorial Material	2024
A-19	Benito, N; Martinez-Pastor, JC; Lora-Tamayo, J; Ariza, J; Baeza, J; Belzunegui-Otano, J; Cobo, J; del-Toro, MD; Fontecha, CG; Font-Vizcarra, L; Horcajada, JP; Morata, L; Murillo, O; Nolla, JM; Nunez-Cuadros, E; Pigrau, C; Portillo, ME; Rodriguez-Pardo, D; Sobrino-Diaz, B; Saavedra-Lozano, J	Executive summary: Guidelines for the diagnosis and treatment of septic arthritis in adults and children, developed by the GEIO (SEIMC), SEIP and SECOT	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.6	Q3	Article	2024
A-19	Ramos-Cozar, SN; Martín-Masot, R; Rodríguez-Gallego, B; Rubio, L; Cabanillas-Moruno, JL; Navas-López, VM	Assessment of the length of sick leave in patients with inflammatory bowel disease	GASTROENTEROLOGIA Y HEPATOLOGIA	2.2	Q3	Article	2024
A-19	López-Téllez, A; Torres, JMR; Vázquez, EP; Fernández, MAB; López-Martí, H; Martínez, IZ; Fernández, CT; Vargas, MF; Pinos, MDD; Morant, JFP; González-Fajardo, JA; Felices, PV	Ultrasound screening for abdominal aortic aneurysm in primary care	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
A-19	Cantero, MJP; Asencio, JMM; Plantagenet-Whyte, FP; Carmona, ML; Antonelli, MR; Bigatá, TG; Alba, RM	Sedation in pediatric palliative care: The role of pediatric palliative care teams	PALLIATIVE & SUPPORTIVE CARE	1.9	Q3	Article	2024
A-19	Cantinotti, M; Voges, I; Miller, O; Raimondi, F; Grotenhuis, H; Bharucha, T; Garrido, AO; Valsangiacomo, E; Roest, A; Sunnegardh, J; Salaets, T; Brun, H; Khraiche, D; Jossif, A; Schokking, M; Sabate-Rotes, A; Meyer-Szary, J; Deri, A; Koopman, L; Herberg, U; Sarvaas, GD; Leskinen, M; Tchana, B; Ten Harkel, ADJ; Ödemis, E; Morrison, L; Steimetz, M; Laser, KT; Doros, G; Bellshan-Revell, H; Muntean, I; Anagostopoulou, A; Alpman, MS; Hunter, L; Ojala, T; Bhat, M; Olejnik, P; Wacker, J; Bonello, B; Ramcharan, T; Greil, G; Marek, J; DiSalvo, G; McMahon, CJ	Organisation of paediatric echocardiography laboratories and governance of echocardiography services and training in Europe: current status, disparities, and potential solutions. A survey from the Association for European Paediatric and Congenital Cardiology (AEPC) imaging working group	CARDIOLOGY IN THE YOUNG	0.9	Q3	Article	2024
A-19	del Arco-Guzmán, N; Lobato-López, S; Calvo-Medina, R; Vera-Medialdea, R; Ruiz-Pérez, C; Ramos-Fernández, JM	RYR1 myopathies in childhood: phenotype-genotype correlation and incidence	REVISTA DE NEUROLOGIA	0.8	Q4	Article	2024
A-19	Ramos-Fernández, JM; Cano-Martínez, M; Martínez-Leon, MI	Magnetic resonance images of onset and evolution of a child with a new genetic variant of evanescent leukodystrophy	REVISTA DE NEUROLOGIA	0.8	Q4	Editorial Material	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-19	Arenas-Cabrera, C; Cabezudo-García, P; Calvo-Medina, R; Galeano-Bilbao, B; Martínez-Agredano, P; Ruiz-Giménez, J; Rodríguez-Uranga, JJ; Quiroga-Subirana, P	Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol	REVISTA DE NEUROLOGIA	0.8	Q4	Review	2024
A-19	Carrasco, AS; Cantero, MJP; Piñero, JMG; Rodriguez, AM	Experience of caregivers and healthcare professionals using a telemedicine programme in a paediatric palliative care unit	INTERNATIONAL JOURNAL OF PALLIATIVE NURSING	0.7	Q4	Article	2024
A-19	Rodríguez-Belvis, MV; Palomino, L; Pujol-Muncunill, G; Martin-Masot, R; Torres, JB; Navas-López, VM; de Carpi, JM	Cross-cultural adaptation and validation of Work Productivity and Activity Impairment questionnaires for caregivers of patients with pediatric inflammatory bowel disease in Spain. A multicenter study	ARCHIVOS ARGENTINOS DE PEDIATRIA	0.7	Q4	Article	2024
A-19	García-Durán, C; Saralegui, C; Romeu, E; Hernández, ML; Maruri, A; Bastón-Paz, N; Lamas, A; Vicente, S; Perez-Ruiz, E; Delgado, I; Luna-Paredes, C; Caballero, JD; Zamora, J; Monteoliva, L; Del Campo, R; Gil, C	Human gut microbiota analysis of cystic fibrosis infants using metaproteomics	MICROBIOLOGY RESOURCE ANNOUNCEMENTS	0.7	Q4	Article	2024
A-19	Chinchilla-Alarcón, T; Yunquera-Romero, L; Fernández-Cuerva, C; Gallego-Fernandez, C; Núñez-Cuadros, E	Medication reconciliation during hospitalization in polymedicated pediatric patients: Perspective of the hospital pharmacist	PHARMACEUTICAL CARE ESPANA	0.5	Q4	Article	2024
A-21	Guerrero-Orriach, JL; Carmona-Luque, MD; Muñoz, GQ; Capitán, MJR	miRNA Expression: I/R Cardiomyocyte and Sevoflurane	BIOMOLECULES	4.8	Q1	Article	2024
A-21	García-Montoto, F; Paz-Martín, D; Pestaña, D; Soro, M; Marcos-Vidal, JM; Badenes, R; de la Rica, AS; Bardi, T; Pérez-Carbonell, A; García, C; Cervantes, JA; Martínez, MP; Guerrero, JL; Lorente, JV; Veganzones, J; Murcia, M; Belda, FJ	Guidelines for inhaled sedation in the ICU	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION	0.9	Q3	Article	2024
A-23	Domínguez-López, I; Lamuela-Raventos, RM; Razquin, C; Arancibia-Riveros, C; Galkina, P; Salas-Salvadó, J; Alonso-Gómez, AM; Fitó, M; Fiol, M; Lapetra, J; Gómez-Gracia, E; Sorli, JV; Ruiz-Canela, M; Castañer, O; Liang, LM; Serra-Majem, L; Hu, FB; Ros, E; Martinez-Gonzalez, MA; Estruch, R	Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial	EUROPEAN HEART JOURNAL	38.0	D1	Article	2024
A-23	Khoury, N; Martínez, MA; Nishi, SK; Martinez-Gonzalez, MA; Corella, D; Castañer, O; Martinez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, F; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, J; Pérez-Vega, KA; Garcia-Rios, A; Ortiz-Díaz, F; Gomez-Gracia, E; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Peña-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fito, M; Babio, N; Salas-Salvadó, J	Dietary intake of Perfluorooctanesulfonic acid (PFOS) and glucose homeostasis parameters in a non-diabetic senior population	ENVIRONMENT INTERNATIONAL	10.0	D1	Article	2024
A-23	Murcia-Lesmes, D; Dominguez-Lopez, I; Laveriano-Santos, EP; Tresserra-Rimbau, A; Castro-Barquero, S; Estruch, R; Vazquez-Ruiz, Z; Ruiz-Canela, M; Razquin, C; Corella, D; Sorli, J; Salas-Salvado, J; Perez-Vega, KA; Gomez-Gracia, E; Lapetra, J; Aros, F; Fiol, M; Serra-Majem, L; Pinto, X; Ros, E; Lamuela-Raventos, RM	Association between tomato consumption and blood pressure in an older population at high cardiovascular risk: observational analysis of PREDIMED trial	EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY	8.6	D1	Article	2024
A-23	Margara-Escudero, HJ; Paz-Graniel, I; García-Gavilán, J; Ruiz-Canela, M; Sun, Q; Clish, CB; Toledo, E; Corella, D; Estruch, R; Ros, E; Castañer, O; Arós, F; Fiol, M; Guasch-Ferré, M; Lapetra, J; Razquin, C; Dennis, C; Deik, A; Li, J; Gómez-Gracia, E; Babio, N; Martínez-González, MA; Hu, FB; Salas-Salvadó, J	Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease	CARDIOVASCULAR DIABETOLOGY	8.5	D1	Article	2024
A-23	Fernández, MJL; Narejos, S; Castro, A; Echave-Sustaeta, JM; Forner, MJ; Arana-Arri, E; Molto, J; Bernad, L; Pérez-Caballero, R; Prado, JG; Raïch-Regué, D; Boreika, R; Izquierdo-Useros, N; Trinité, B; Blanco, J; Puig-Barberà, J; Martínez, SN	Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results	VACCINES	5.2	Q1	Article	2024
A-23	Lozano-Lorca, M; Muñoz-Bravo, C; Barrios-Rodríguez, R; Castillo-Hermoso, MA; Kouiti, M; Torres, CGP; Jimenez-Moleón, JJ; Olmedo-Requena, R	Dietary and Smoking Acrylamide and Prostate Cancer Risk: CAPLIFE Study	NUTRIENTS	4.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-23	Hernando-Redondo, J; Malcampo, M; Pérez-Vega, KA; Paz-Graniel, I; Martínez-González, MA; Corella, D; Estruch, R; Salas-Salvadó, J; Pintó, X; Arós, F; Bautista-Castaño, I; Romaguera, D; Lapetra, J; Ros, E; Cueto-Galán, R; Fitó, M; Castañer, O	Mediterranean Diet Modulation of Neuroinflammation-Related Genes in Elderly Adults at High Cardiovascular Risk	NUTRIENTS	4.8	Q1	Article	2024
A-23	García-Márques, J; Alvarez-Torres, D; Cerezo, IM; Domínguez-Maqueda, M; Acién, G; Alarcón-López, FJ; Figueroa, FL; Martinez-Manzanares, E; Abdala-Díaz, RT; Béjar, J; Arijó, S	Effects of Chlorella fusca-supplemented diet on intestinal microbiota and gene expression related to metabolism, stress, and immune response in Chelon labrosus	ALGAL RESEARCH-BIOMASS BIOFUELS AND BIOPRODUCTS	4.6	Q1	Article	2024
A-23	Jiménez-López, R; Romero-Trevejo, JL; Fernández-Romero, L; Martín-Chaves, L; Romero-Cuevas, M; Molina-Ramos, AI; Sánchez-Quintero, MJ; Murri, M; Costa, F; Bodí, V; Gutiérrez-Bedmar, M; Rodríguez-Capitán, J; Pavón-Morón, FJ; Jiménez-Navarro, M	Differential Ophthalmological Profile in Patients with Coronary Artery Disease Coexisting with Type 2 Diabetes Mellitus: Elevated Tear Cytokine Concentrations	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
A-23	Bueno, JAR; Sánchez-Guijo, G; Ráez, PD; García-Arnes, JA; Garzón-Maldonado, FJ; Castro, VS; de la Cruz-Cosme, C; Alba-Linero, C; Gutiérrez-Bedmar, M; García-Casares, N	Effects of Type 2 Diabetes on the Neuropsychological Profile in Mild Cognitive Impairment	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
A-23	Farinas-Guerrero, Fernando; Villatoro, Antonio J; Martinez-Manzanares, Eduardo; Lopez-Gigosos, Rosa	Occurrence of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus pseudintermedius colonization among veterinarians in the province of Malaga, Spain.	Veterinary world	1.7	Q2	Article	2024
AA-04	Almendro-Delia, M; Hernández-Meneses, B; Padilla-Rodríguez, G; Blanco-Ponce, E; Arboleda-Sánchez, JA; Rodríguez-Yáñez, JC; Soto-Blanco, JM; Fernández-García, I; Castillo-Caballero, JM; García-Rubira, JC; Hidalgo-Urbano, R	Timing of P2Y 12 Inhibitor Administration in Patients With STEMI Undergoing Primary PCI	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	22.0	D1	Article	2024
AA-04	Almendro-Delia, M; Padilla-Rodríguez, G; Hernández-Meneses, B; Blanco-Ponce, E; Arboleda-Sánchez, JA; Rodríguez-Yáñez, JC; Soto-Blanco, JM; Fernández-García, I; Castillo-Caballero, JM; García-Rubira, JC; Hidalgo-Urbano, R	Nonadherence to ticagrelor versus clopidogrel and clinical outcomes in patients with ACS. Results from the CREA-ARIAM registry	REVISTA ESPANOLA DE CARDIOLOGIA	7.2	Q1	Article	2024
AA-04	Miró, O; Aguiló, S; Alquézar-Arbé, A; Fernández, C; Burillo, G; Martínez, SG; Larrull, MEM; Periago, ABB; Molinas, CLA; Falcón, CR; Dacosta, PB; Flores, RCC; Calzada, JN; Blesa, EMF; Martín, MAP; Requena, AC; Fuentes, L; Cortizo, IL; Garcinuño, PG; García, MB; Del Valle, PR; Campos, RB; Jiménez, VC; Cuñado, VA; Gutiérrez, OT; Reviriego, MDS; Roussel, M; del Castillo, JG	Overnight stay in Spanish emergency departments and mortality in older patients	INTERNAL AND EMERGENCY MEDICINE	3.2	Q1	Article	2024
AA-04	Alvarez-Marquez, AJ; Huet, J; Pérez-Villares, JM; Daga-Ruiz, D; Diaz-Aunión, C; de la Nuez, PC; Cuende, N	Meeting the Shortage of Human Cells and Tissues: The Andalusian Quality Assurance Programme for Tissue Donation	TRANSPLANT INTERNATIONAL	2.7	Q1	Article	2024
AA-04	Estella, A; Lagares, C; Furones, MJ; López, PM; Martín, NL; Estebáñez, B; García, JMG; Rubio, O; Tejedor, BV; Galarza, L; Navarro, MP; Camps, VL; Martín, MC; Montejo, JC; Avidan, A; Sprung, C	Limitation of life support treatments in Spanish Intensive Care Units: Analysis of the ETHICUS II study	MEDICINA INTENSIVA	2.7	Q2	Article	2024
AA-15	Frank, D; Durand, E; Lauck, S; Muir, DF; Spence, M; Vasa-Nicotera, M; Wood, D; Saia, F; Urbano-Carrillo, CA; Bouchayer, D; Iliescu, VA; Etienne, CS; Leclercq, F; Auffret, V; Asmarats, L; Di Mario, C; Veugeois, A; Maly, J; Schober, A; Nombela-Franco, L; Werner, N; Gomez-Hospital, JA; Mascherbauer, J; Musumeci, G; Meneveau, N; Meurice, T; Mahfoud, F; De Marco, F; Seidler, T; Leuschner, F; Joly, P; Collet, JP; Vogt, F; Di Lorenzo, E; Kuhn, E; Disdier, VP; Hachaturyan, V; Lueske, CM; Rakova, R; Wesselink, W; Bramlage, P; Mccalmon, G	A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study	EUROPEAN HEART JOURNAL	38.0	D1	Article	2024
AA-15	van Nieuwkerk, AC; Aarts, HM; Hemelrijk, KI; Carrillo, CU; Tchétché, D; de Brito, FS Jr; Barbanti, M; Kornowski, R; Latib, A; D'Onofrio, A; Ribichini, F; Garcia-Blas, S; Dumonteil, N; Abizaid, A; Sartori, S; D'Errigo, P; Tarantini, G; Lunardi, M; Orvin, K; Pagnesi, M; Navarro, F; Dangas, G; Mehran, R; Delewi, R	Cerebrovascular Events in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation: A Pooled Patient-Level Study	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5.0	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AA-15	Licordari, R; Costa, F; Garcia-Ruiz, V; Mamas, MA; Marquis-Gravel, G; Hernandez, JMD; Doblas, JG; Jimenez-Navarro, M; Rodríguez-Capitan, J; Urbano-Carrillo, C; Ortega-Paz, L; Piccolo, R; Versace, AG; Di Bella, G; Ando, G; Angiolillo, DJ; Valgimigli, M; Micari, A	The Evolving Field of Acute Coronary Syndrome Management: A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024
AA-15	Gómez-Moyano, E; Pavón-Morón, J; Rodríguez-Capitán, J; Bardán-Rebollar, D; Ramos-Carrera, T; Villalobos-Sánchez, A; de Pedro, IP; Ruiz-García, FJ; Mora-Robles, J; López-Sampalo, A; Pérez-Velasco, MA; Bernal-López, MR; Gómez-Huelgas, R; Jiménez-Navarro, M; Romero-Cuevas, M; Costa, F; Trenas, A; Pérez-Belmonte, LM	The Role of Heparin in Postural Orthostatic Tachycardia Syndrome and Other Post-Acute Sequelae of COVID-19	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Review	2024
AA-15	Marín, SG; del Puerto, MAR; Carrillo, CAU	Giant atrial mixoma in the right atrium	CLINICAL MEDICINE	2.6	Q1	Editorial Material	2024
AA-15	Moreno, R; Baptista, SB; Valencia, J; Gomez-Menchero, A; Bouisset, F; Ruiz-Arroyo, JR; Bento, A; Besutti, M; -Valero, SJ; Rivero-Santana, B; Olhmann, P; Santos, M; Vaquerizo, B; Cuissetm, T; Lemoine, J; Pinar, E; Fiarresga, A; Urbano, C; Marliere, S; Braga, C; Amat-Santos, I; Morgado, G; Sarnago, F; Telleria, M; Van Belle, E; Díaz-Fernandez, J; Borrego, JC; Amabile, N; Meneveau, N	OPTImized coronary interventions eXplain the bEst cliNical outcomEs (OPTI-XIENCE) study. Rationale and study design	CARDIOVASCULAR REVASCULARIZATION MEDICINE	2.1	Q3	Article	2024
AA-15	González-Gutiérrez, JC; Benito-González, T; Bosa-Ojeda, F; Freixa-Rofastes, X; Estevez-Loureiro, R; Pascual, I; Andraha-Ikazuriaga, L; Díez-Gil, JL; Urbano-Carrillo, C; Amat-Santos, IJ	Prognostic impact of vasopressor test in transcatheter edge-to-edge repair of secondary mitral regurgitation: The PETIT study	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS	2.1	Q3	Article	2024
AA-15	González-Lozano, J; Ballesteros, G; Cano, J; Osorio, D; Urbano, C	Endocardial substrate of ventricular tachycardia in an adult patient with congenitally corrected transposition of great arteries without surgical repair	PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY	1.7	Q3	Editorial Material	2024
AA-15	Tejerizo, FB; Sánchez, FC; Jurado-Román, A; Cruz-González, I; Alvarez-Fuente, M; Amat-Santos, IJ; Blasco, PB; Mata, RB; Carrasco, JI; Bellón, JMC; Fernández, MF; Gómez-Jaume, A; Gutiérrez-Barrios, A; Albert, BI; Montañés, LJ; Aguado, FGL; Lalaguna, LA; Segovia, RM; Pérez, MJN; Pineda, SO; Núñez, FR; Gila, JS; Sanz-Ruiz, R; Vázquez-Alvarez, ME; Argüelles, JIZ	Spanish cardiac catheterization in congenital heart diseases registry. Third official report from the ACI-SEC and the GTH-SECPCC (2022)	REC-INTERVENTIONAL CARDIOLOGY	1.2	Q4	Article	2024
AA-22	del-Rosal-Jurado, A; González-Sánchez, M; Cuesta-Vargas, AI	Effect of therapeutic exercise on peak oxygen consumption in oncological population: a systematic review with meta-analysis	SUPPORTIVE CARE IN CANCER	2.8	D1	Review	2024
AA-22	Casals, C; Corral-Pérez, J; Avila-Cabeza-de-Vaca, L; González-Mariscal, A; Carrión-Velasco, Y; Rodríguez-Martínez, MC; Jiménez-Cebrián, AM; Vázquez-Sánchez, MA	Exploring the interplay of frailty, physical function, physical activity, nutritional status, and their association with quality of life and depressive symptoms in older adults with the frailty phenotype	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	3.6	Q1	Article	2024
AA-22	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-cosme, C; Lara, JP	Early Occupational Therapy Intervention Programme and Coping Strategies and Burden in Caregivers of People with Sub-Acute Stroke: A Randomised Controlled Trial	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Article	2024
AA-22	Palomo-Carrion, R; Romy-Barrero, H; Pinero-Pinto, E; Romero-Galisteo, RP; Coello-Villalon, M; Ferri-Morales, A; Lopez-Munoz, P; Lirio-Romero, C	Feasibility of Home-Based Early Infant Hybrid Therapy in Children with Unilateral Cerebral Palsy	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
AA-22	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-Cosme, C; Lara, JP	Early Occupational Therapy Intervention post-stroke (EOTIPS): A randomized controlled trial	PLOS ONE	2.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AA-22	Trinidad-Fernández, M; González-Molina, F; Roldán-Jiménez, C; Vaes, P; González-Sánchez, M; Cuesta-Vargas, AI	New learning technique based on real-time kinematic feedback from an inertial sensor for manual therapy in shoulder joint: a randomised trial	BMC MEDICAL EDUCATION	2.7	Q1	Article	2024
AA-22	Martínez-Cal, J; Sandoval-Hernández, I; Ropero-Padilla, C; Rodriguez-Arrastia, M; González-Sánchez, M; Molina-Torres, G	An escape room game-based innovation for the assessment of physiotherapy students: A qualitative study	STUDIES IN EDUCATIONAL EVALUATION	2.6	Q1	Article	2024
AA-22	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Pérez-Panero, AJ; Pérez-Belloso, AJ; Martínez-Barrios, FJ; González-Sánchez, M	Development and validation of a new questionnaire for the assessment of patients with diabetic foot disease: The Diabetic Foot Questionnaire (DiaFootQ)	PRIMARY CARE DIABETES	2.6	Q1	Article	2024
AA-22	Matias-Soto, J; Pineda-Galan, C; Martin-Sanchez, AI; Gonzalez-Mesa, JM; Aguayo-Alves, A; Luque-Suarez, A	Unveiling relevant emotions, cognitions, and behaviours from the viewpoint of people with chronic low back pain: A qualitative study with patient involvement	MUSCULOSKELETAL SCIENCE AND PRACTICE	2.2	Q1	Article	2024
AA-22	Carrasco-Vega, E; Guiducci, S; Nacci, F; Randone, SB; Bevilacqua, C; Gonzalez-Sanchez, M; Baarni, L	Efficacy of physiotherapy treatment in the medium and long term in adults with fibromyalgia: an umbrella of systematic reviews	CLINICAL AND EXPERIMENTAL RHEUMATOLOGY	3.4	Q2	Review	2024
AA-22	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Gijon-Noguerón, G; Navarro-Flores, E; González-Sánchez, M	Validity and reliability of the English version of the Diabetic Foot Self-Care Questionnaire: a cross-cultural adaptation	FRONTIERS IN PUBLIC HEALTH	3.0	Q2	Article	2024
AA-22	Seoane-Martín, ME; Cuesta-Barriuso, R; Rodríguez-Martínez, MC	Performance of instrumental activities of daily living in patients with haemophilic arthropathy. A cross-sectional cohort study	HAEMOPHILIA	3.0	Q2	Article	2024
AA-22	Seoane-Martín, ME; Cuesta-Barriuso, R; Rodríguez-Martínez, MC	Occupational therapy in the management of haemophilia patients: A scoping review	HAEMOPHILIA	3.0	Q2	Review	2024
AA-22	Pimentel-Ponce, M; Romero-Galisteo, RP; Palomo-Carrión, R; Pinero-Pinto, E; Merchán-Baeza, JA; Ruiz-Muñoz, M; Oliver-Pece, J; González-Sánchez, M	Gamification and neurological motor rehabilitation in children and adolescents: A systematic review	NEUROLOGIA	2.9	Q2	Review	2024
AA-22	Mérida-López, S; Quintana-Orts, C; Pekaar, KA; Pineda-Galán, C; Extremera, N	Knowing is half the battle: Regulating and appraising emotions co-protect from suicidal ideation	DEATH STUDIES	2.1	Q2	Article	2024
AE-11	Rivero, M; Fernández-Vidal, M; Sandino, J; Rico, RB; Moliz, C; Ruiz-Cabello, JE; Garcia-Galán, LC; González-García, C; Hernández-Velasco, P; Segura, J; Gutiérrez, E; Morales, E	Effect of Intravitreal Anti-Endothelial Growth Factor Agents on Renal Function in Patients With Diabetes Mellitus	KIDNEY INTERNATIONAL REPORTS	5.7	D1	Article	2024
AE-11	Sasso, CV; Lhamyani, S; Hevilla, F; Padial, M; Blanca, M; Barril, G; Jiménez-Salcedo, T; Martínez, ES; Nogueira, A; Lago-Sampedro, AM; Oliveira, G	Modulation of miR-29a and miR-29b Expression and Their Target Genes Related to Inflammation and Renal Fibrosis by an Oral Nutritional Supplement with Probiotics in Malnourished Hemodialysis Patients	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
AE-11	Rodrigo, E; Quintana, LF; Vázquez-Sánchez, T; Sánchez-Fructuoso, A; Buxeda, A; Gavela, E; Cazorla, JM; Cabello, S; Beneyto, I; López-Oliva, MO; Diekmann, F; Gómez-Ortega, JM; Romero, NC; Pérez-Sáez, MJ; Sancho, A; Mazuecos, A; Espí-Reig, J; Jiménez, C; Hernández, D	Tubulo-interstitial inflammation increases the risk of graft loss after the recurrence of IgA nephropathy	CLINICAL KIDNEY JOURNAL	3.9	Q1	Article	2024
AE-11	Montiel, AM; Ruiz-Esteban, P; Del Rio, AD; Valdivielso, P; Chaparro, MAS; Oliveira, C	Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype	SCIENTIFIC REPORTS	3.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AE-11	Valdivia, MAP; Arbizu, JC; Barreña, DP; de la Nuez, PC; Jiménez, VL; Benot, AR; Blanca, AM; Guindo, MCD; Blanco, GB; Govantes, MAG; Pérez, RB; Castilla, JLR	Predicting Kidney Transplantation Outcomes from Donor and Recipient Characteristics at Time Zero: Development of a Mobile Application for Nephrologists	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
AE-11	Montiel, AM; Ruiz-Esteban, P; Del Río, AD; Valdivielso, P; Chaparro, MAS; Oliveira, C	The effect of pulmonary rehabilitation on cardiovascular risk, oxidative stress and systemic inflammation in patients with COPD	RESPIRATORY MEDICINE	3.5	Q2	Article	2024
AE-11	Sanz-Cánovas, J; Lendtínez-Sánchez, G; Prieto-Sánchez, E; Vicioso-Recio, L; Gutiérrez-Cardo, A; Izurrategui-Hidalgo, E; Palacios-Rodríguez, S; Peláez-Angulo, JM; Roperó-Luis, G; Pérez-de-Pedro, I; Gómez-Huelgas, R; Salgado-Ordóñez, F	Corticodependent and recurrent inflammatory pseudo tumor. Analysis of cases and review	AMERICAN JOURNAL OF THE MEDICAL SCIENCES	2.3	Q2	Review	2024
AE-11	Armas-Padrón, AM; Sicilia-Sosvilla, M; Ruiz-Esteban, P; Torres, A; Hernández, D	Cardiovascular health and target end-organ damage and comorbidities in hypertensive patients from a Spanish primary care urban population	NEFROLOGIA	2.0	Q2	Article	2024
AE-11	Perea-Ortega, L; Muñoz-Sánchez, A; León-Fradejas, M; Rojas, RT; Ruiz-Esteban, P; López-Jiménez, V	Rheumatoid arthritis and PLA2R-associated mebranous nephropathy. Cause or coincidence?	CLINICAL CASE REPORTS	0.6	Q3	Article	2024
AE-11	Gómez, MAM; Molina, MC; Fradejas, ML; Titos, JA; Alvarez, RD	Focal segmental glomerulosclerosis associated with undescribed mutation in the LMX1B gene	EUROPEAN JOURNAL OF MEDICAL GENETICS	1.6	Q4	Article	2024
AE-11	Martin-Gómez, MA; Torres, AR; Hernández, ME; Mendoza, ML; Sánchez, JMS; Armada, MM; Suarez, IM; Rubio, JLC; Castellano, MMC; Pintado, JCA; Marín, ACB; Esteban, MDM; Guerra, LC; Garrido, ED	Mortality and cardiovascular risk in vasculitis ANCA. Importance of hypertension and renal function. Experience from southern Spain	HIPERTENSION Y RIESGO VASCULAR	1.2	Q4	Article	2024
B-01	Pérez-García, JM; Cortés, J; Ruiz-Borrego, M; Colleoni, M; Stradella, A; Bermejo, B; Dalenc, F; Escrivá-de-Romaní, S; Martínez, LC; Ribelles, N; Marmé, F; Cortés, A; Albacar, C; Gebhart, G; Prat, A; Kerrou, K; Schmid, P; Braga, S; Di Cosimo, S; Gion, M; Antonarelli, G; Popa, C; Szostak, E; Alcalá-López, D; Gener, P; Rodríguez-Morató, J; Mina, L; Sampayo-Cordero, M; Llombart-Cussac, A	3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial	LANCET	98.0	D1	Article	2024
B-01	Oaknin, A; Gladieff, L; Martínez-García, J; Villacampa, G; Takekuma, M; De Giorgi, U; Lindemann, K; Woelber, L; Colombo, N; Duska, L; Leary, A; Godoy-Ortiz, A; Nishio, S; Angelergues, A; Rubio, MJ; Fariñas-Madrid, L; Yamaguchi, S; Lorusso, D; Ray-Coquard, I; Manso, L; Joly, F; Alarcón, J; Follana, P; Romero, I; Lebreton, C; Pérez-Fidalgo, JA; Yunokawa, M; Dahlstrand, H; D'Hondt, V; Randall, L	Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial	LANCET	98.0	D1	Article	2024
B-01	Hinte, LC; Castellano-Castillo, D; Ghosh, A; Melrose, K; Gasser, E; Noé, F; Massier, L; Dong, H; Sun, W; Hoffmann, A; Wolfrum, C; Rydén, M; Mejhert, N; Blüher, M; von Meyenn, F	Adipose tissue retains an epigenetic memory of obesity after weight loss	NATURE	51.0	D1	Article	2024
B-01	González-Martín, A; Rubio, MJ; Heitz, F; Christensen, RD; Colombo, N; Van Gorp, T; Romeo, M; Ray-Coquard, I; Gaba, L; Leary, A; De Sande, LM; Lebreton, C; Redondo, A; Fabbro, M; Ginesta, MPB; Follana, P; Pérez-Fidalgo, JA; Rodrigues, M; Santaballa, A; Sabatier, R; Bermejo-Pérez, MJ; Lotz, JP; Pardo, B; Marquina, G; Sánchez-Lorenzo, L; Quindós, M; Estévez-García, P; Alía, EG; Manso, L; Casado, V; Kommos, S; Tognon, G; Henry, S; Bruchim, I; Oaknin, A; Selle, F	Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial	JOURNAL OF CLINICAL ONCOLOGY	42.0	D1	Article	2024
B-01	Riesco-Martinez, MC; Capdevila, J; Alonso, V; Jimenez-Fonseca, P; Teule, A; Grande, E; Sevilla, I; Benavent, M; Alonso-Gordoa, T; Custodio, A; Anton-Pascual, B; Hernando, J; Polo, E; Castillo-Trujillo, OA; Lamas-Paz, A; Teijo, A; Rodriguez-Gil, Y; Soldevilla, B; Garcia-Carbonero, R	Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)	NATURE COMMUNICATIONS	15.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-01	Santana-Hernández, S; Suarez-Olmos, J; Servitja, S; Berenguer-Molins, P; Costa-Garcia, M; Comerma, L; Rea, A; Perera-Bel, J; Menendez, S; Arpi, O; Bermejo, B; Martínez, MT; Cejalvo, JM; Comino-Méndez, I; Pascual, J; Alba, E; López-Botet, M; Rojo, F; Rovira, A; Albanell, J; Muntasell, A	NK cell-triggered CCL5/IFN γ -CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	11.0	D1	Article	2024
B-01	Velasco-Suelto, J; Gálvez-Carvajal, L; Comino-Méndez, I; Rueda-Domínguez, A	Hodgkin lymphoma and liquid biopsy: a story to be told	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	11.0	D1	Review	2024
B-01	Quintela-Fandino, M; Bermejo, B; Zamora, E; Moreno, F; García-Saenz, JA; Pernas, S; Martínez-Jañez, N; Jiménez, D; Adrover, E; de Andrés, R; Mourón, S; Bueno, MJ; Manso, L; Viñas, G; Alba, E; Llombart-Cussac, A; Cortés, J; Tebar, C; Roe, DJ; Grant, A; Watson, A; Colomer, R; Mouneimne, G	High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer	CLINICAL CANCER RESEARCH	10.0	D1	Article	2024
B-01	Gebhart, G; Keyaerts, M; Guiot, T; Flamen, P; Ruiz-Borrego, M; Stradella, A; Bermejo, B; Escriva-de-Romani, S; Martínez, LC; Ribelles, N; Fernandez-Abad, M; Albacar, C; Colleoni, M; Garrigos, L; de Frutos, MA; Dalenc, F; Prat, A; Marmé, F; Schmid, P; Kerrou, K; Braga, S; Gener, P; Sampayo-Cordero, M; Cortés, J; Pérez-García, JM; Llombart-Cussac, A	Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial	JOURNAL OF NUCLEAR MEDICINE	9.1	D1	Article	2024
B-01	Castellano-Castillo, D; Ramos-Molina, B; Frutos, MD; Arranz-Salas, I; Reyes-Engel, A; Queipo-Ortuño, MI; Cardona, F	RNA expression changes driven by altered epigenetics status related to NASH etiology	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
B-01	Cortés, A; López-Miranda, E; Fernández-Ortega, A; Carañana, V; Servitja, S; Urruticoechea, A; Lema-Roso, L; Márquez, A; Lazaris, A; Alcalá-López, D; Mina, L; Gener, P; Rodríguez-Morató, J; Antonarellij, G; Llombart-Cussac, A; Pérez-García, J; Cortés, J	Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study	BREAST	5.7	D1	Article	2024
B-01	Carrillo-García, J; Hindi, N; Conceicao, M; Sala, MA; Ugalde, A; López-Pousa, A; Bagué, S; Sevilla, I; Vicioso, L; Ramos, R; Martínez-Trufero, J; Mateo, MCG; Cruz, J; Hernández-León, CN; Redondo, A; Mendiola, M; García, JM; Hernández, JE; Alvarez, R; Agra, C; de Juan-Ferré, A; Valverde, C; Cano, JM; de Sande, LM; Pérez-Fidalgo, JA; Lavernia, J; Marcilla, D; Gutiérrez, A; Moura, DS; Martín-Broto, J	Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor	EUROPEAN JOURNAL OF CANCER	7.6	Q1	Article	2024
B-01	Guerrero-Zotano, A; Pérez-García, JM; Ruiz-Borrego, M; Bermejo, B; Gil-Gil, M; de la Haba, J; Conejo, EA; Quiroga, ; Carañana, ; Urruticoechea, A; Morales, S; Bellet, M; Antón, A; Fernández-Abad, M; Sánchez-Rovira, P; Calabuig, L; Pérez-Escuredo, J; Sampayo-Cordero, M; Cortés, J; Llombart-Cussac, A	Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥ 18 : DxCARTES study	ESMO OPEN	7.1	Q1	Article	2024
B-01	Alba-Bernal, A; Godoy-Ortiz, A; Domínguez-Recio, ME; López-López, E; Quirós-Ortega, ME; Sánchez-Martín, V; Roldán-Díaz, MD; Jiménez-Rodríguez, B; Peralta-Linero, J; Bellagarza-García, E; Troyano-Ramos, L; Garrido-Ruiz, G; Hierro-Martín, MI; Vicioso, L; González-Ortiz, A; Linares-Valencia, N; Velasco-Suelto, J; Carbajosa, G; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Comino-Méndez, I; Alba, E	Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	NPJ BREAST CANCER	6.6	Q1	Article	2024
B-01	Pernas, S; Sanfeliu, E; Villacampa, G; Salvador, J; Perello, A; Gonzalez, X; Jimenez, B; Merino, M; Palacios, P; Pascual, T; Alba, E; Villanueva, L; Chillara, S; Ferrero-Cafiero, JM; Galvan, P; Prat, A; Ciruelos, E	Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy	NPJ BREAST CANCER	6.6	Q1	Article	2024
B-01	Navarro-Lobato, I; Masmudi-Martín, M; López-Aranda, MF; López-Téllez, JF; Delgado, G; Granados-Durán, P; Gaona-Romero, C; Carretero-Rey, M; Posadas, S; Quiros-Ortega, ME; Khan, ZU	Promotion of structural plasticity in area V2 of visual cortex prevents against object recognition memory deficits in aging and Alzheimer's disease rodents	NEURAL REGENERATION RESEARCH	5.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-01	Hontecillas-Prieto, L; García-Domínguez, DJ; Palazón-Carrión, N; García-Sancho, AM; Nogales-Fernández, E; Jiménez-Cortegana, C; Sánchez-León, ML; Silva-Romeiro, S; Flores-Campos, R; Carnicero-González, F; Ríos-Herranz, E; de la Cruz-vicente, F; Rodríguez-García, G; Fernández-Alvarez, R; Martínez-Banaclocha, N; Gumà-Padrò, J; Gómez-Codina, J; Salar-Silvestre, A; Rodríguez-Abreu, D; Gálvez-Carvajal, L; Labrador, J; Guirado-Risueño, M; Provencio-Pulla, M; Sánchez-Beato, M; Marylene, L; Alvaro-Naranjo, T; Casanova-Espinosa, M; Rueda-Domínguez, A; Sánchez-Margalet, V; de la Cruz-merino, L	CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
B-01	Garcia-Flores, LA; De Vera, MTD; Pilo, J; Rego, A; Gomez-Casado, G; Arranz-Salas, I; Martín, IH; Alcaide, J; Torres, E; Ortega-Gomez, A; Boughanem, H; Macias-Gonzalez, MM	Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
B-01	Núñez-Sánchez, MA; Martinez-Sánchez, MA; Martínez-Montoro, JI; Balaguer-Román, A; Murcia-García, E; Fernández-Ruiz, VE; Ferrer-Gómez, M; Martínez-Cáceres, CM; Sledzinski, T; Frutos, MD; Hernández-Morante, JJ; Fernández-García, JC; Queipo-Ortuno, MI; Ruiz-Alcaraz, AJ; Mika, A; Ramos-Molina, B	Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.0	Q1	Article	2024
B-01	Laborda-Illanes, A; Aranega-Martín, L; Sánchez-Alcoholado, L; Boutriq, S; Plaza-Andrades, I; Peralta-Linero, J; Ruiz, GG; Pajares-Hachero, B; Alvarez, M; Alba, E; González-González, A; Queipo-Ortuño, MI	Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
B-01	Zafra, J; Onieva, JL; Oliver, J; Garrido-Barros, M; González-Hernández, A; Martínez-Gálvez, B; Román, A; Ordóñez-Marmolejo, R; Pérez-Ruiz, E; Benítez, JC; Mesas, A; Vera, A; Chicas-Sett, R; Rueda-Domínguez, A; Barragán, I	Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
B-01	Masmudi-Martín, M; Navarro-Lobato, I; Lopez-Aranda, MF; Quiros-Ortega, ME; Carretero-Rey, M; Garcia-Garrido, MF; Téllez, JFL; Jiménez-Recuerda, I; López, CAMDL; Khan, ZU	Brain areas interconnected to ventral pathway circuits are independently able to induce enhancement in object recognition memory and cause reversal in object recognition memory deficit	CNS NEUROSCIENCE & THERAPEUTICS	4.8	Q1	Article	2024
B-01	Cantarero-Cuenca, A; Gonzalez-Jimenez, A; Martinez-Núñez, GM; Garrido-Sánchez, L; Ranea, JAG; Tinahones, FJ	Epigenetic profiles in blood and adipose tissue: identifying strong correlations in morbidly obese and non-obese patients	JOURNAL OF MOLECULAR MEDICINE-JMM	4.8	Q1	Article	2024
B-01	Gámez-Casado, S; Rodríguez-Perez, L; Bandera-López, C; Mesas-Ruiz, A; Campini-Bermejo, A; Bernal-Gómez, M; Zalabardo-Aguilar, M; Calvete-Candenas, J; Martínez-Bernal, G; Atienza-Cuevas, L; García-Rojo, M; Benitez-Rodríguez, E; Pajares-Hachero, B; Bermejo-Pérez, MJ; Baena-Cañada, JM	Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality	CANCERS	4.5	Q1	Article	2024
B-01	Perez-Navarro, E; Conteduca, V; Funes, JM; Dominguez, JI; Martin-Serrano, M; Cremaschi, P; Fernandez-Perez, M; Gordoa, TA; Font, A; Vázquez-Estévez, S; González-del-Alba, A; Wetterskog, D; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, M; Climent, M; Duran, I; Gallardo, E; Sanchez, A; Santander, C; Sáez, M; Puente, J; Tudela, J; Marinas, C; López-Andreo, M; Castellano, D; Attard, G; Grande, E; Rosino, A; Botia, JA; Palma-Mendez, J; De Giorgi, U; Gonzalez-Billalabeitia, E	Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer	CANCERS	4.5	Q1	Article	2024
B-01	Guardamagna, M; Meyer, ML; Berciano-Guerrero, MA; Mesas-Ruiz, A; Cobo-Dols, M; Perez-Ruiz, E; Gonzalez, AC; Lavado-Valenzuela, R; Barragán, I; Oliver, J; Garrido-Aranda, A; Alvarez, M; Rueda-Dominguez, A; Queipo-Ortuño, MI; Conejo, EA; Benitez, JC	Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review	TRANSLATIONAL LUNG CANCER RESEARCH	4.0	Q1	Review	2024
B-01	Castellano-Castillo, D; Núñez-Sánchez, MA; Balaguer-Román, A; Martínez-Sánchez, MA; Fernández-Ruiz, VE; Ferrer-Gómez, M; Martínez, CM; Frutos, MD; Queipo-Ortuño, MI; Cardona, F; Ramos-Molina, B	The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes	SURGERY FOR OBESITY AND RELATED DISEASES	3.5	Q1	Article	2024
B-01	Barbadilla, TC; Pérez, MA; Cuadra, JDP; de Vera, MTD; Alberca-del Arco, F; Muñoz, IG; de la Blanca, RSP; Herrera-Imbroda, B; Matas-Rico, E; Martín, MIH	The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer	DIAGNOSTICS	3.0	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-01	Lendinez-Sanchez, G; Diaz-Redondo, T; Iglesias-Campos, M; Garrido-Almazán, L; Alba-Conejo, E; Rueda-Dominguez, A; Sanchez-Muñoz, A	Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature	FRONTIERS IN ONCOLOGY	3.5	Q2	Article	2024
B-01	Sánchez-Martín, V; López-López, E; Reguero-Paredes, D; Godoy-Ortiz, A; Domínguez-Recio, ME; Jiménez-Rodríguez, B; Alba-Bernal, A; Quirós-Ortega, ME; Roldán-Díaz, MD; Velasco-Suelto, J; Linares-Valencia, N; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Alba, E; Comino-Méndez, I	Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients	CLINICA CHIMICA ACTA	3.2	Q2	Article	2024
B-01	Ribelles, N; Pascual, J; Galvez-Carvajal, L; Ruiz-Medina, S; Garcia-Corbacho, J; Benitez, JC; Dominguez-Recio, ME; Torres, E; Oliva, L; Zalabardo, M; Rueda, A; Alba, E	Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study	JCO GLOBAL ONCOLOGY	3.2	Q2	Article	2024
B-01	de la Haba-Rodríguez, JR; Mínguez, P; Rojo, F; Martín, M; Alba, E; Servitja, S; Prat, A; Pérez-Fidalgo, JA; Gavilá, J; Morales, C; Rodriguez-Lescure, A; Herrero, C; Peña-Enriquez, R; Herranz, J; Hernando, C; Hernández-Blanquisset, A; Guil-Luna, S; Martinez, MT; Blanch, S; Caballero, R; Martín, N; Pollán, M; Guerrero-Zotano, A; Bermejo, B	Gestational breast cancer: distinctive molecular and clinico-epidemiological features	JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA	3.0	Q2	Article	2024
B-01	De Heredia, APLF; Ortiz, MR; Cabeza, AIP; Expósito, AD; Valenzuela, MIF; Bailén, MC; Cubiles, IAD; Vega, AM; Aguilar, MZ; Muñoz, MC; Manrique, TG; Llergo, JT; Granados, ALO; Fernández, JJS; Cadenas, JC; Rubio, DM	Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings	CURRENT PROBLEMS IN CARDIOLOGY	3.0	Q2	Review	2024
B-01	Manso, L; Ramchandani-Vaswani, A; Romero, I; Sánchez-Lorenzo, L; Bermejo-Pérez, MJ; Estévez-García, P; Fariña-Madrid, L; García, YG; Gil-Martin, M; Quindós, M	SEOM-GEICO Clinical Guidelines on cervical cancer (2023)	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024
B-01	Sanchez-Beato, M; Méndez, M; Guirado, M; Pedrosa, L; Sequero, S; Yanguas-Casás, N; de la Cruz-merino, L; Gálvez, L; Llanos, M; Garcia, JF; Provencio, M	A genetic profiling guideline to support diagnosis and clinical management of lymphomas	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Review	2024
B-01	Belotte, J; Felicetti, B; Baines, AJ; YoussefAgha, A; Rojas-Espaillet, L; Ortiz, AG; Provencher, D; Vazquez, RM; Cortijo, LG; Zeng, X	Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial	TRIALS	2.0	Q3	Article	2024
B-01	Lendinez-Sanchez, G; Diaz-Redondo, T; Campos, MI; Pelayo, JP; Pelayo, JMP; Muriel-López, C	ATM Variant as a Cause of Hereditary Cutaneous Melanoma in a Spanish Family: A case report.	CASE REPORTS IN ONCOLOGY	0.7	Q4	Article	2024
B-04	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	Article	2024
B-04	Bandres-Ciga, S; Faghri, F; Majounie, E; Koretsky, MJ; Kim, J; Levine, KS; Leonard, H; Makarious, MB; Iwaki, H; Crea, PW; Hernandez, DG; Arepalli, S; Billingsley, K; Lohmann, K; Klein, C; Lubbe, SJ; Jabbari, E; Saffie-Awad, P; Narendra, D; Reyes-Palomares, A; Quinn, JP; Schulte, C; Morris, HR; Traynor, BJ; Scholz, SW; Houlden, H; Hardy, J; Dumanis, S; Riley, E; Blauwendraat, C; Singleton, A; Nalls, M; Jeff, J; Vitale, D	NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations	MOVEMENT DISORDERS	7.4	D1	Article	2024
B-04	Cordoba-Caballero, J; Perkins, JR; Garcia-Criado, F; Gallego, D; Navarro-Sánchez, A; Moreno-Estellés, M; Garcés, C; Bonet, F; Romá-Mateo, C; Toro, R; Perez, B; Sanz, P; Kohl, M; Rojano, E; Seoane, P; Ranea, JAG	Exploring miRNA-target gene pair detection in disease with coRmiT	BRIEFINGS IN BIOINFORMATICS	6.8	D1	Article	2024
B-04	Marrero, AD; Cárdenas, C; Castilla, L; Ortega-Vidal, J; Quesada, AR; Martinez-Poveda, B; Medina, MA	Antiangiogenic Potential of an Olive Oil Extract: Insights from a Proteomic Study	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY	5.7	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-04	Gayo, P; Berbel, C; Gómez-Maldonado, J; Claros, MG; Manchado, M	Phenotypic features, transcriptomic signatures and genomic regions associated with body ellipticity in the flatfish Senegalese sole	AQUACULTURE	3.9	D1	Article	2024
B-04	Daga, N; Servaas, NH; Kisand, K; Moonen, D; Arnold, C; Reyes-Palomares, A; Kaleviste, E; Kingo, K; Kuuse, R; Ulst, K; Steinmetz, L; Peterson, P; Nakic, N; Zaugg, JB	Integration of genetic and chromatin modification data pinpoints autoimmune-specific remodeling of enhancer landscape in CD4+ T cells	CELL REPORTS	7.5	Q1	Article	2024
B-04	Flook, M; Rojano, E; Gallego-Martinez, A; Escalera-Balsera, A; Perez-Carpena, P; Moleon, MD; Gonzalez-Aguado, R; de Jesus, VR; Dominguez-Durán, E; Frejo, L; Ranea, JAG; Lopez-Escamez, JA	Cytokine profiling and transcriptomics in mononuclear cells define immune variants in Meniere Disease	GENES AND IMMUNITY	5.0	Q1	Article	2024
B-04	Urbano-Gámez, JD; Guzzi, C; Bernal, M; Solivera, J; Martínez-Zubiaurre, I; Caro, C; García-Martín, ML	Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
B-04	Cantarero-Cuenca, A; Gonzalez-Jimenez, A; Martinez-Núñez, GM; Garrido-Sánchez, L; Ranea, JAG; Tinahones, FJ	Epigenetic profiles in blood and adipose tissue: identifying strong correlations in morbidly obese and non-obese patients	JOURNAL OF MOLECULAR MEDICINE-JMM	4.8	Q1	Article	2024
B-04	Dominguez-Maqueda, M; Pérez-Gómez, O; García-Márquez, J; Espinosa-Ruiz, C; Cuesta, A; Esteban, MA; Alarcón-López, FJ; Cárdenas, C; Tapia-Paniagua, ST; Balebona, MC; Moriñigo, MA	Microalgae and cyanobacteria as microbial substrate and their influence on the potential postbiotic capability of a bacterial probiotic	MICROBIAL BIOTECHNOLOGY	4.8	Q1	Article	2024
B-04	Marrero, AD; Quesada, AR; Martinez-Poveda, B; Medina, MA	Anti-Cancer, Anti-Angiogenic, and Anti-Atherogenic Potential of Key Phenolic Compounds from Virgin Olive Oil	NUTRIENTS	4.8	Q1	Review	2024
B-04	Lucena-Padros, H; Bravo-Gil, N; Tous, C; Rojano, E; Seoane-Zonjic, P; Fernández, RM; Ranea, JAG; Antiñolo, G; Borrego, S	Bioinformatics Prediction for Network-Based Integrative Multi-Omics Expression Data Analysis in Hirschsprung Disease	BIOMOLECULES	4.8	Q1	Article	2024
B-04	Gallego, D; Serrano, M; Cordoba-Caballero, J; Gámez, A; Seoane, P; Perkins, JR; Ranea, JAG; Pérez, B	Transcriptomic analysis identifies dysregulated pathways and therapeutic targets in PMM2-CDG	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE	4.2	Q1	Article	2024
B-04	Bonet, F; Campuzano, O; Cordoba-Caballero, J; Alcalde, M; Sarquella-Brugada, G; Braza-Boils, A; Brugada, R; Hernandez-Torres, F; Quezada-Feijoo, M; Ramos, M; Mangas, A; Ranea, JAG; Toro, R	Role of miRNA-mRNA Interactome in Pathophysiology of Arrhythmogenic Cardiomyopathy	BIOMEDICINES	3.9	Q1	Article	2024
B-04	Novoa, J; López-Ibáñez, J; Chagoyen, M; Ranea, JAG; Pazos, F	CoMentG: comprehensive retrieval of generic relationships between biomedical concepts from the scientific literature	DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION	3.4	Q1	Article	2024
B-04	Abdala-Díaz, RT; Casas-Arrojo, V; Castro-Varela, P; Riquelme, C; Carrillo, P; Medina, MA; Cárdenas, C; Becerra, J; Manríquez, CP	Immunomodulatory, Antioxidant, and Potential Anticancer Activity of the Polysaccharides of the Fungus Fomitiporia chilensis	MOLECULES	4.2	Q2	Article	2024
B-04	Gómez-García, I; Ladehesa-Pineda, ML; Diaz-Tocados, JM; López-Medina, C; Abalos-Aguilera, MC; Ruiz-Vilches, D; Paz-Lopez, G; Gonzalez-Jimenez, A; Ranea, JAG; Escudero-Contreras, A; Moreno-Indias, I; Tinahones, FJ; Collantes-Estévez, E; Ruiz-Limón, P	Bone metabolism and inflammatory biomarkers in radiographic and non-radiographic axial spondyloarthritis patients: a comprehensive evaluation	FRONTIERS IN ENDOCRINOLOGY	3.9	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-04	Heredia-Torreon, M; Montañez, R; González-Meneses, A; Carcavilla, A; Medina, MA; Lechuga-Sancho, AM	VUS next in rare diseases? Deciphering genetic determinants of biomolecular condensation	ORPHANET JOURNAL OF RARE DISEASES	3.4	Q2	Article	2024
B-04	T, ADR; Virginia, CA; Angeles, AAM; Casimiro, CG; Claudia, PM; Eduardo, U; Félix, AG; Nathalie, K; Felix, LF; Sergey, D	Antitumor and antioxidant activities of polysaccharides from the seaweed Durvillaea antarctica	CHEMICAL BIOLOGY & DRUG DESIGN	3.2	Q2	Article	2024
B-04	Ramírez, CC; Alméciga-Díaz, CJ; Martín-Rufián, M; Cárdenas-García, C; Espejo-Mojica, AJ; Lobo, C; Benincore, EP	A close-up view of the Hunter syndrome	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS	2.5	Q3	Article	2024
B-04	Corpas, M; Soriano, V; Perucho, T; Rincón-Redondo, JS; Pérez-Alonso, M; Ranea, JAG; de Mendoza, C; Morán, F	Playing catching up: proceedings of the 1st Spanish conference on genomic medicine	AIDS REVIEWS	1.9	Q3	Article	2024
B-05	Desai, J; Alonso, G; Kim, SH; Cervantes, A; Karasic, T; Medina, L; Shacham-Shmueli, E; Cosman, R; Falcon, A; Gore, E; Guren, T; Massarelli, E; Jr, WHM; Paz-Ares, L; Prenen, H; Amatu, A; Cremolini, C; Kim, TW; Moreno, V; Ou, SH; Passardi, A; Sacher, A; Santoro, A; Stec, R; Ulahannan, S; Arbour, K; Lorusso, P; Luo, J; Patel, MR; Choi, Y; Shi, Z; Mandlekar, S; Lin, MT; Royer-Joo, S; Chang, J; Jun, T; Dharia, N; Schutzman, JL; Han, SW	Divarasib plus cetuximab in KRASG12C-positive colorectal cancer: a phase 1b trial	NATURE MEDICINE	59.0	D1	Article	2024
B-05	Velasco-Suelto, J; Gálvez-Carvajal, L; Comino-Méndez, I; Rueda-Domínguez, A	Hodgkin lymphoma and liquid biopsy: a story to be told	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	11.0	D1	Review	2024
B-05	Solero, TR; Aragón, MF; Raissouni, TA; Delgado-García, A; Cañada-Rodríguez, MJ; Viedma, SS	False Positive in [99mTc]Tc-DPD Scintigraphy for Cardiac Amyloidosis Due to Intravenous Iron Administration	CLINICAL NUCLEAR MEDICINE	10.0	D1	Editorial Material	2024
B-05	Vilches, JC; Santía, MC; Yates, EM; Pareja, R; Lozano, M; Ramirez, PT	Notable surgical trials in gynecologic oncology: a 10-year overview	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	4.5	D1	Review	2024
B-05	de la Cruz, MR; Martínez-Gregorio, H; Díaz-Velásquez, CE; Ambriz-Barrera, F; Resendiz-Flores, NG; Gitler-Weingarten, R; Rojo-Castillo, MP; Pradda, D; Oliver, J; Perdomo, S; Gómez-García, EM; de la Cruz-Montoya, AH; Terrazas, LI; Torres-Mejía, G; Hernández-Hernández, FD; Vaca-Paniagua, F	Methylation marks in blood DNA reveal breast cancer risk in patients fulfilling hereditary disease criteria	NPJ PRECISION ONCOLOGY	6.8	Q1	Article	2024
B-05	Omotesho, QA; Escamilla, A; Perez-Ruiz, E; Frecha, CA; Rueda-Dominguez, A; Barragan, I	Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Review	2024
B-05	Zafra, J; Onieva, JL; Oliver, J; Garrido-Barros, M; González-Hernández, A; Martínez-Gálvez, B; Román, A; Ordóñez-Marmolejo, R; Pérez-Ruiz, E; Benítez, JC; Mesas, A; Vera, A; Chicas-Sett, R; Rueda-Domínguez, A; Barragán, I	Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
B-05	Ocanto, A; Torres, L; Montijano, M; Rincon, D; Fernandez, C; Sevilla, B; Gonsalves, D; Teja, M; Guijarro, M; Glaria, L; Hernanz, R; Zafra-Martin, J; Sanmamed, N; Kishan, A; Alongi, F; Moghanaki, D; Nagar, H; Counago, F	MR-LINAC, a New Partner in Radiation Oncology: Current Landscape	CANCERS	4.5	Q1	Review	2024
B-05	Guardamagna, M; Meyer, ML; Berciano-Guerrero, MA; Mesas-Ruiz, A; Cobo-Dols, M; Perez-Ruiz, E; Gonzalez, AC; Lavado-Valenzuela, R; Barragán, I; Oliver, J; Garrido-Aranda, A; Alvarez, M; Rueda-Dominguez, A; Queipo-Ortuño, MI; Conejo, EA; Benitez, JC	Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review	TRANSLATIONAL LUNG CANCER RESEARCH	4.0	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-05	Villena-Salinas, J; Ortega-Lozano, SJ; Amrani-Raissouni, T; Agüera-Morales, E; Caballero-Villarraso, J	Comparative Study between the Diagnostic Effectiveness of Brain SPECT with [123I] Ioflupane and [123I]MIBG Scintigraphy in Multiple System Atrophy	BIOMEDICINES	3.9	Q1	Article	2024
B-05	Salas-Salas, BG; Ferrera-Alayón, L; Calleja-Fernández, A; Chicas-Sett, R; Nogués-Ramia, E; Zafra-Martín, J; Lloret, M	Impact of a glutamine-enriched peptide formula on gastrointestinal toxicity and on the interruption of oncologic treatment in patients with adenocarcinoma of the rectum	FRONTIERS IN NUTRITION	4.0	Q2	Article	2024
B-05	Lendínez-Sánchez, G; Díaz-Redondo, T; Iglesias-Campos, M; Garrido-Almazán, L; Alba-Conejo, E; Rueda-Domínguez, A; Sánchez-Muñoz, A	Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature	FRONTIERS IN ONCOLOGY	3.5	Q2	Article	2024
B-05	Ribelles, N; Pascual, J; Galvez-Carvajal, L; Ruiz-Medina, S; Garcia-Corbacho, J; Benítez, JC; Domínguez-Recio, ME; Torres, E; Oliva, L; Zalabardo, M; Rueda, A; Alba, E	Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study	JCO GLOBAL ONCOLOGY	3.2	Q2	Article	2024
B-05	Hernández, JJC; Arrula, VA; Alvarez, YE; Castaño, AG; de Castro, JJG; Docampo, LI; Sorrosal, JL; Segura, PP; Domínguez, AR; Campos-Lucas, FJ; Rodríguez, IS; Bessa, M; Gratal, P; Caballero-Martínez, F; Martín, DM; Antón-Rodríguez, C; López, R	Indicators to evaluate quality of care in head and neck cancer in Spain	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024
B-05	Martínez, AR; Pardal, CV; Arjona, JA; Ruiz, FR; Molinero, DD; Paulano, MR; Subert, A; Gutiérrez-Manzanedo, JV; Martín, JC; Aranda, MVD; López, LJ; Sánchez, NB; Martín, MD	Skin cancer prevention in extreme sports: Intervention in a 24-h race	PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE	2.5	Q2	Article	2024
B-05	García-Harana, C; Blázquez-Sánchez, N; Rodríguez-Martínez, A; Rivas-Ruiz, F; Aguilar-Ortega, D; Rodríguez-Martínez, AG; Cambil-Martín, J; de Gálvez, MV; de Troya-Martín, M	Positive impact of Distintivo Soludable on implementation of sun protection policies and practices in schools of Andalusia, Spain	JOURNAL OF PUBLIC HEALTH POLICY	2.3	Q2	Article	2024
B-05	Fernández, C; Zafra-Martín, J; Couñago, F	Current challenges in the treatment of gliomas: The molecular era	WORLD JOURNAL OF CLINICAL ONCOLOGY	2.6	Q3	Editorial Material	2024
B-05	Zoghbi, SER; Martín, MM; García, JC; Valero, M; Rincón, D; Huertas, MP; Fusco, JP; López, E; Zafra, J; Luengas, DF; Campos, FL; Couñago, F	Total neoadjuvant therapy approach for the treatment of locally advanced rectal cancer. Where do we stand?	ONCOLOGY	2.5	Q3	Article	2024
B-05	Lopez-Valcarcel, M; Lopez-Campos, F; Zafra, J; Cienfuegos, I; Ferri, M; Barrado, M; Hernando, S; Counago, F	Liquid biopsy to personalize treatment for metastatic prostate cancer	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH	1.7	Q3	Review	2024
B-05	Alors-Ruiz, J; Sanz-Viedma, S; Fernandez-Garcia, FJ; Sendra-Portero, F	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in cN0 Breast Cancer: Impact of HER2-Positive Status on Survival	EUROPEAN JOURNAL OF BREAST HEALTH	1.3	Q4	Article	2024
B-07	de los Santos-Jiménez, J; Campos-Sandoval, JA; Alonso, FJ; Márquez, J; Matés, JM	GLS and GLS2 Glutaminase Isoenzymes in the Antioxidant System of Cancer Cells	ANTIOXIDANTS	6.0	Q1	Review	2024
B-07	Guillén-Pérez, YM; Ortiz-Ruiz, MJ; Márquez, J; Pandiella, A; Esparís-Ogando, A	ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
B-07	Ramírez, CC; Alméjiga-Díaz, CJ; Martín-Rufián, M; Cárdenas-García, C; Espejo-Mojica, AJ; Lobo, C; Benincore, EP	A close-up view of the Hunter syndrome	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS	2.5	Q3	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-10	Navarro-Guillamón, PJ; Valencia-Serrano, M; Suarez-Perez, JA; Herrera-Acosta, E	Povidone iodine gel use as a conductive and antiseptic in ultrasound-guided invasive procedures	JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY	13.0	D1	Editorial Material	2024
B-10	Lluch-Galcerá, JJ; Carrascosa, JM; González-Quesada, A; Rivera-Díaz, R; Sahuquillo-Torralba, A; Llamas-Velasco, M; Gómez-García, F; Herrera-Acosta, E; de la Cueva, P; Baniandrés-Rodríguez, O; Lopez-Estebaranz, JL; Belinchón, I; Ferrán, M; Mateu, A; Rodríguez, L; Riera-Monroig, J; Abalde-Pintos, MT; Carretero, G; García-Donoso, C; Pujol-Marco, C; Del Alcázar, E; Santamaría-Domínguez, C; Suárez-Pérez, JA; Nieto-Benito, LM; Ruiz-Genao, D; Salgado-Boquete, L; Descalzo, MA; García-Doval, I	Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry	BRITISH JOURNAL OF DERMATOLOGY	11.0	D1	Article	2024
B-10	Munoz-Aceituno, E; Butrón-Bris, B; Ovejero-Benito, MC; Sahuquillo-Torralba, A; Rodríguez, OB; Herrera-Acosta, E; Rivera-Díaz, R; Ferran, M; Sanchez-Carazo, JL; Riera-Monroig, J; Pujol-Montcusí, J; Vidal, D; de la Cueva, P; García-Bustinduy, M; Ruiz-Villaverde, R; Ballescà, F; Llamas-Velasco, M; Navares, M; Palomar-Moreno, I; Sanchez-García, I; Garcia-Martínez, J; Novalbos, J; Zubiaur, P; Abad-Santos, F; Daudén-Tello, E; de la Fuente, H	Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	8.5	D1	Article	2024
B-10	Casas, CG; Ruiz-Villaverde, R; Prados-Carmona, A; Camporro, AF; Menéndez, AGA; Puente, MCAB; Pasquali, P; Vázquez, AA; Masferrer, E; González, LR; Ruiz-Sánchez, D; Caballero-Linares, CF; Tejera-Vaquerizo, A; Iglesias-Pena, N; de Piérola, SF; Maldonado-Seral, C; Armengot-Carbó, M; Alonso-Naranjo, L; Tornay, RB; Novo, TS; Tapia, VF; Martín-Gorgojo, A; Mas, JA; Amer, MEP; Feal, PP; Taberner, R; Utrera-Busquets, M; Sánchez, IV; Aller, LP; Sánchez-Gutiérrez, I; Usero-Bárcena, T; Manrique, BA; Velázquez, AS; García, EM; Grau-Pérez, M; García-Doval, I	Clinical and Epidemiological Characteristics of Patients Being Treated for Scabies in Spain: Opportunities for Improvement-- A Multicenter Cross-Sectional CLINI-AEDV Study	ACTAS DERMO-SIFILIOGRAFICAS	3.8	Q1	Article	2024
B-10	Salas-Marquez, C; García, RB; Jiménez, JBR; Escribano, PC; Ruiz, FR	Development of a Questionnaire on Knowledge, Habits, and Attitudes on Sexually Transmitted Infections in Teenagers and Young Adults	ACTAS DERMO-SIFILIOGRAFICAS	3.8	Q1	Article	2024
B-10	Aguilera, J; Bosch, RJ; de Galvez, MV	Discussion Abounds on the Potential Carcinogenic Risks Associated With the Use of UV Curing Lamps for Permanent Nail Polish	ACTAS DERMO-SIFILIOGRAFICAS	3.8	Q1	Article	2024
B-10	Couselo-Rodríguez, C; Batalla, A; Carrascosa, JM; Chicharro, P; González-Quesada, A; de la Cueva, P; Giménez-Arnau, AM; Gilaberte, Y; Rodríguez-Serna, M; Montero-Vilchez, T; Ruiz-Villaverde, R; Elosua-González, M; Silvestre-Salvador, JF; Munera-Campos, M; Sánchez-Pérez, J; Carretero, G; Mauleón-Fernández, C; Curto-Barredo, L; Ballano-Ruiz, A; Botella-Estrada, R; Arias-Santiago, S; Navarro-Triviño, FJ; Roustan-Gullón, G; Betlloch, I; del Alcázar, E; Abalde-Pintos, MT; Suárez-Perez, J; Garcia-Doval, I; Descalzo, MA; Flórez, A	Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)	ACTAS DERMO-SIFILIOGRAFICAS	3.8	Q1	Article	2024
B-10	Galván-Casas, C; Ortiz-Alvarez, J; Martínez-García, E; Corbacho-Monné, M	Spanish Academy of Dermatology and Venereology (AEDV) expert recommendations for the management of sexual transmitted parasitosis. Scabies, and pediculosis pubis	ACTAS DERMO-SIFILIOGRAFICAS	3.8	Q1	Article	2024
B-10	Aguilera, J; Navarrete-de Gálvez, END; El Houssaini, A; Soto-Lara, F; Herrera-Ceballos, E; de Galvez, MV	The topical application of different galenic formulations can alter the thermographic images of skin: Limitations for public thermal screening on infection control situations	AMERICAN JOURNAL OF INFECTION CONTROL	3.8	Q1	Article	2024
B-10	Daudén, E; Escario, E; Martos-Cabrera, L; Armesto, S; Herrera-Acosta, E; Vidal, D; Vilarrasa, E; Rivera, R; de la Cueva, P; Martorell, A; Ballesca, F; Belinchón, I; Carretero, G; Rodríguez, L; Romero-Maté, A; Pujol-Montcusí, J; Salgado, L; Sahuquillo-Torralba, A; Coto-Segura, P; Baniandrés, O; Feltes, R; Riera-Monroig, J; Garrido, J; Llamas-Velasco, M	Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting	INTERNATIONAL JOURNAL OF DERMATOLOGY	3.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-10	Grau-Echevarría, A; Labrandero-Hoyos, C; Peñuelas-Leal, R; Finello, M; Blaya-Imbernón, D; Magdaleno-Tapial, J; García, AG; Zafrilla, EP; García-García, JA; Cuenca, LG; Albiach, AN; Arjona, JA; Ocete-Mochón, MD; Díez-Recio, E; Hernández-Bel, P	Prospective observational study on scar sequelae after MPOX infection: an analysis of 40 patients	INTERNATIONAL JOURNAL OF DERMATOLOGY	3.5	Q1	Article	2024
B-10	Cerezo, PM; Aguilera, JA; Garcia-Gonzalez, A; Lopez-Crespo, P	Tomography of Laser Powder Bed Fusion Maraging Steel	MATERIALS	3.1	Q1	Article	2024
B-10	Martínez, AR; Pardal, CV; Arjona, JA; Ruiz, FR; Molinero, DD; Paulano, MR; Subert, A; Gutiérrez-Manzanedo, JV; Martín, JC; Aranda, MVD; López, LJ; Sánchez, NB; Martín, MD	Skin cancer prevention in extreme sports: Intervention in a 24-h race	PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE	2.5	Q2	Article	2024
B-10	Gracia-Cazaña, T; Aguilera, J; Navarro-Bielsa, A; González, S; Lim, HW; Gilaberte, Y	New trends on personalized sunscreens	PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE	2.5	Q2	Review	2024
B-10	García-Harana, C; Blázquez-Sánchez, N; Rodríguez-Martínez, A; Rivas-Ruiz, F; Aguilar-Ortega, D; Rodríguez-Martínez, AG; Cambil-Martín, J; de Gálvez, MV; de Troya-Martín, M	Positive impact of Distintivo Soludable on implementation of sun protection policies and practices in schools of Andalusia, Spain	JOURNAL OF PUBLIC HEALTH POLICY	2.3	Q2	Article	2024
B-11	Olmos, D; Lorente, D; Alameda, D; Cattrini, C; Romero-Laorden, N; Lozano, R; Lopez-Casas, PP; Jambrina, A; Capone, C; Vanden Broecke, AM; Trevisan, M; Van Sanden, S; Juergens, A; Herrera-Imbroda, B; Castro, E	Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes	ANNALS OF ONCOLOGY	57.0	D1	Article	2024
B-11	Garcia-Ruiz, A; Macarro, C; Zacchi, F; Morales-Barrera, R; Grussu, F; Casanova-Salas, I; Sanguedolce, F; Gonzalez, M; Cresta-Morgado, P; de Albert, M; Garcia-Bennett, J; Marmolejo, D; Planas, J; Roche, S; Mast, R; Zatse, C; Piulats, JM; Herrera-Imbroda, B; Regis, L; Agundez, L; Olmos, D; Calvo, N; Escobar, M; Carles, J; Mateo, J; Perez-Lopez, R	Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial	EUROPEAN UROLOGY	25.0	D1	Editorial Material	2024
B-11	Matas-Rico, E; Moolenaar, WH	Tumor immune escape by autotaxin: keeping eosinophils at bay	TRENDS IN CANCER	14.0	D1	Editorial Material	2024
B-11	Cespedes, JA; Fernandez-Santamaria, R; Bogas, G; Veguillas, AA; Dona, I; Salas, M; Labella, M; Duarte, TDF; Mayorga, C; Torres, MJ; Frecha, CA	LPS in combination with amoxicillin increases BAT sensitivity to amoxicillin IgE-mediated hypersensitivity	ALLERGY	13.0	D1	Article	2024
B-11	Tombal, BF; Gomez-Veiga, F; Gomez-Ferrer, A; López-Campos, F; Ost, P; Roumeguere, TA; Herrera-Imbroda, B; D'Hondt, LA; Quivrin, M; Gontero, P; Villà, S; Khaled, H; Fournier, B; Musoro, J; Krzystyniak, J; Pretzenbacher, Y; Lorient, Y	A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)	EUROPEAN UROLOGY ONCOLOGY	8.3	D1	Article	2024
B-11	Romero-Laorden, N; Lorente, D; de Velasco, G; Lozano, R; Herrera, B; Puente, J; López, PP; Medina, A; Almagro, E; Gonzalez-Billalabeitia, E; Villla-Guzman, JC; González-del-Alba, A; Borrega, P; Laínez, N; Fernández-Freire, A; Hernández, A; Rodriguez-Vida, A; Chirivella, I; Fernandez-Parra, E; López-Campos, F; Pacheco, MI; Morales-Barrera, R; Fernández, O; Villatoro, R; Luque, R; Hernando, S; Castellano, DC; Castro, E; Olmos, D	Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study	EUROPEAN UROLOGY ONCOLOGY	8.3	D1	Article	2024
B-11	Serrano, SC; Otón, RG; Veguillas, AA; Labella, M; Mayorga, C; Duarte, TDF; Torres, MJ; Frecha, C	Cytometer Harmonization as Part of IVD-R: A Key Component for Performance of Multicenter Studies	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	6.7	Q1	Editorial Material	2024
B-11	Garcia-Flores, LA; De Vera, MTD; Pilo, J; Rego, A; Gomez-Casado, G; Arranz-Salas, I; Martín, IH; Alcaide, J; Torres, E; Ortega-Gomez, A; Boughanem, H; Macias-Gonzalez, MM	Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-11	Alberca-del Arco, F; Santos-Perez De La Blanca, R; Amores Vergara, C; Herrera-Imbroda, B; Sáez-Barranquero, F	Bulbar urethroplasty techniques and stricture recurrence: differences between end-to-end urethroplasty versus the use of graft	MINERVA UROLOGY AND NEPHROLOGY	4.9	Q1	Review	2024
B-11	Alberca-del Arco, F; Prieto-Cuadra, D; Santos-Perez de la Blanca, R; Sáez-Barranquero, F; Matas-Rico, E; Herrera-Imbroda, B	New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine	CANCERS	4.5	Q1	Review	2024
B-11	Barbadilla, TC; Pérez, MA; Cuadra, JDP; de Vera, MTD; Alberca-del Arco, F; Muñoz, IG; de la Blanca, RSP; Herrera-Imbroda, B; Matas-Rico, E; Martín, MIH	The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer	DIAGNOSTICS	3.0	Q1	Review	2024
B-11	Correa, R; Vidal, N; Quesada-García, A; Marcos, R; del Toro, JM; Muñoz-Rodríguez, J	Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey	ACTAS UROLOGICAS ESPANOLAS	1.2	Q3	Article	2024
B-12	Gallego, F; Veredas, FJ	Recognition and normalization of multilingual symptom entities using in-domain-adapted BERT models and classification layers	DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION	3.4	Q1	Article	2024
B-12	Emmert-Streib, F; Bottini, S; Franco, L	Editorial: AI and multi-omics for rare diseases: challenges, advances and perspectives, Volume III	FRONTIERS IN MOLECULAR BIOSCIENCES	3.9	Q2	Editorial Material	2024
B-12	Cámara, J; Troya, J; Montes-Torres, J; Jaime, FJ	Generative AI in the Software Modeling Classroom: An Experience Report With ChatGPT and Unified Modeling Language	IEEE SOFTWARE	3.3	Q2	Article	2024
B-12	Pedrero-Martin, Y; Falla, D; Rodriguez-Brazzarola, P; Torrontegui-Duarte, M; Fernandez-Sanchez, M; Jerez-Aragones, JM; Liew, BXW; Luque-Suarez, A	Prognostic Factors of Perceived Disability and Perceived Recovery After Whiplash	CLINICAL JOURNAL OF PAIN	2.6	Q2	Article	2024
B-22	Cho, BC; Lu, S; Felip, E; Spira, AI; Girard, N; Lee, JS; Lee, SH; Ostapenko, Y; Danchaivijitr, P; Liu, BG; Alip, A; Korbenfeld, E; Dias, JM; Besse, B; Lee, KH; Xiong, HL; How, SH; Cheng, Y; Chang, GC; Yoshioka, H; Yang, JCH; Thomas, M; Nguyen, D; Ou, SHI; Mukhedkar, S; Prabhash, K; D'Arcangelo, M; Alatorre-Alexander, J; Limon, JCV; Alves, S; Stroyakovskiy, D; Peregudova, M; Sendur, MAN; Yazici, O; Califano, R; Calderon, VG; de Marinis, F; Passaro, A; Kim, SW; Gadgeel, SM; Xie, JH; Sun, T; Martinez, M; Ennis, M; Fennema, E; Daksh, M; Millington, D; Leconte, I; Iwasawa, R; Lorenzini, P; Baig, M; Shah, SJ; Bauml, JM; Shreeve, SM; Sethi, S; Knoblauch, RE; Hayashi, H	Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC	NEW ENGLAND JOURNAL OF MEDICINE	96.0	D1	Article	2024
B-22	Lu, S; Kato, T; Dong, XR; Ahn, MJ; Quang, L; Soparattanapaisarn, N; Inoue, T; Wang, CL; Huang, MJ; Yang, JCH; Cobo, M; Özgüroglu, M; Casarini, I; Khiem, DV; Sriuranpong, V; Cronemberger, E; Takahashi, T; Runglodvatana, Y; Chen, M; Huang, XN; Grainger, E; Ghiorghiu, D; van der Gronde, T; Ramalingam, SS	Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC	NEW ENGLAND JOURNAL OF MEDICINE	96.0	D1	Article	2024
B-22	Passaro, A; Wang, J; Wang, Y; Lee, SH; Melosky, B; Shih, JY; Wang, J; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, AB; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, JL; Salinas, J; Tomasini, P; Gentzler, RD; William, WN Jr; Reckamp, KL; Takahashi, T; Ganguly, S; Kowalski, DM; Bearz, A; MacKean, M; Barala, P; Bourla, AB; Girvin, A; Greger, J; Millington, D; Withelder, M; Xie, J; Sun, T; Shah, S; Diorio, B; Knoblauch, RE; Bauml, JM; Campelo, RG; Cho, BC	Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study	ANNALS OF ONCOLOGY	57.0	D1	Article	2024
B-22	Felip, E; Cho, BC; Gutiérrez, ; Alip, A; Besse, B; Lu, S; Spira, AI; Girard, N; Califano, R; Gadgeel, SM; Yang, JCH; Yamamoto, S; Azuma, K; Kim, YJ; Lee, KH; Danchaivijitr, P; Ferreira, CG; Cheng, Y; Sendur, MAN; Chang, GC; Wang, CC; Prabhash, K; Shinno, Y; Stroyakovskiy, D; Paz-Ares, L; Rodriguez-Cid, JR; Martin, C; Campelo, MRG; Hayashi, H; Nguyen, D; Tomasini, P; Gottfried, M; Dooms, C; Passaro, A; Schuler, M; Gelatti, ACZ; Owen, S; Perdrizet, K; Ou, SHI; Curtin, JC; Zhang, J; Gormley, M; Sun, T; Panchal, A; Ennis, M; Fennema, E; Bauml, JM; Daksh, M; Sethi, S; Lee, SH	Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA	ANNALS OF ONCOLOGY	57.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-22	Borghaei, H; de Marinis, F; Dumoulin, D; Reynolds, C; Theelen, WSME; Percent, I; Calderon, VG; Johnson, ML; Madroszyk-Flandin, A; Garon, EB; He, K; Planchard, D; Reck, M; Popat, S; Herbst, RS; Leal, TA; Shazer, RL; Yan, X; Harrigan, R; Peters, S	SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer	ANNALS OF ONCOLOGY	57.0	D1	Article	2024
B-22	Tan, DSW; Felip, E; de Castro, G; Solomon, BJ; Greystoke, A; Cho, BC; Cobo, M; Kim, TM; Ganguly, S; Carcereny, E; Paz-Ares, L; Bennouna, J; Garassino, MC; Schenker, M; Kim, SW; Brase, JC; Bury-Maynard, D; Passos, VQ; Deudon, S; Dharan, B; Song, YB; Caparica, R; Johnson, BE	Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial	JOURNAL OF CLINICAL ONCOLOGY	42.0	D1	Article	2024
B-22	Reck, M; Barlesi, F; Yang, JCH; Westeel, V; Felip, E; Özgüroglu, M; Dols, MC; Sullivan, R; Kowalski, DM; Andric, Z; Lee, DH; Sezer, A; Hu, P; Wang, XZ; von Heydebreck, A; Jacob, N; Mehr, KT; Park, K	Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial	JOURNAL OF THORACIC ONCOLOGY	21.0	D1	Article	2024
B-22	Carbone, DP; Ciuleanu, TE; Schenker, M; Cobo, M; Bordenave, S; Juan-Vidal, O; Menezes, J; Reinmuth, N; Richardet, E; Cheng, Y; Mizutani, H; Felip, E; Zurawski, B; Alexandru, A; Paz-Ares, L; Lu, S; John, T; Zhang, XQ; Mahmood, J; Hu, N; De, TL; Santi, I; Penrod, JR; Yuan, Y; Lee, A; Reck, M	Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial	JOURNAL FOR IMMUNOTHERAPY OF CANCER	10.0	D1	Article	2024
B-22	Molina-Alejandro, M; Perea, F; Calvo, V; Martinez-Toledo, C; Nadal, E; Sierra-Rodero, B; Casarrubios, M; Casal-Rubio, J; Martinez-Martí, A; Insa, A; Massuti, B; Viteri, S; Aranda, IB; Rodriguez-Abreu, D; de Castro, J; Martínez, JM; Cobo, M; Wistuba, II; Parra, ER; Martín-López, J; Megías, D; Muñoz-Viana, R; Garrido, F; Aptsiauri, N; Ruiz-Cabello, F; Provencio, M; Cruz-Bermúdez, A	Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer	JOURNAL FOR IMMUNOTHERAPY OF CANCER	10.0	D1	Article	2024
B-22	Peressini, M; Garcia-Campelo, R; Massuti, B; Marti, C; Cobo, M; Gutiérrez, V; Dómine, M; Fuentes, J; Majem, M; de Castro, J; Córdoba, JF; Diz, MP; Isla, D; Esteban, E; Carcereny, E; Vila, L; Moreno-Vega, A; Ros, S; Moreno, A; García, FJ; Huidobro, G; Aguado, C; Cebey-López, V; Valdivia, J; Palmero, R; Lianes, P; López-Brea, M; Vidal, OJ; Provencio, M; Arriola, E; Baena, J; Herrera, M; Bote, H; Molero, M; Adradas, V; Ponce-Aix, S; Nuñez-Buiza, A; Ucero, A; Hernandez, S; Lopez-Rios, F; Conde, E; Paz-Ares, L; Zugazagoitia, J	Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer	CLINICAL CANCER RESEARCH	10.0	D1	Article	2024
B-22	Candal-Pedreira, C; Ruano-Ravina, A; de Juan, VC; Cobo, M; Cantero, A; Rodríguez-Abreu, D; Estival, A; Carcereny, E; Hernandez, A; Castro, RL; Medina, A; Campelo, RG; Bruno, MF; Barnabé, R; Bosch-Barrera, J; Massuti, B; Dómine, M; Camps, C; Ortega, AL; Provencio, M	Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry	ARCHIVOS DE BRONCONEUMOLOGIA	8.7	D1	Article	2024
B-22	Candal-Pedreira, C; Ruano-Ravina, A; Juan, VCD; Cobo, M; Trigo, JM; Rodríguez-Abreu, D; Estival, A; Carcereny, E; Cucurull, M; Castro, RL; Medina, A; Campelo, RG; Gonzalez, PC; Sánchez-Gastaldo, A; Bosch-Barrera, J; Massuti, B; Dómine, M; Camps, C; Ortega, AL; Sánchez-Hernandez, A; Risueño, MG; Morillo, ED; Fernández, AG; Provencio, M	Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients	ARCHIVOS DE BRONCONEUMOLOGIA	8.7	D1	Article	2024
B-22	Alés-Martínez, JE; Balmaña, J; Sánchez-Rovira, P; Bofill, FJS; Sáenz, JAG; Pimentel, I; Morales, S; Fernández-Abad, M; Martínez, AL; Ferrer, N; Zamora, P; Bermejo, B; Díaz-Redondo, T; López-Ceballos, MH; Galán, M; Pérez-Escuredo, J; Calabuig, L; Sampayo, M; Pérez-Garcia, JM; Cortés, J; Llombart-Cussac, A	Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study	BREAST	5.7	D1	Article	2024
B-22	Reck, M; Ciuleanu, TE; Schenker, M; Bordenave, S; Cobo, M; Juan-Vidal, O; Reinmuth, N; Richardet, E; Felip, E; Menezes, J; Cheng, Y; Mizutani, H; Zurawski, B; Alexandru, A; Carbone, DP; Lu, S; John, T; Aoyama, T; Grootendorst, DJ; Hu, N; Eccles, LJ; Paz-Ares, LG	Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial	EUROPEAN JOURNAL OF CANCER	7.6	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-22	Alba-Bernal, A; Godoy-Ortiz, A; Domínguez-Recio, ME; López-López, E; Quirós-Ortega, ME; Sánchez-Martín, V; Roldán-Díaz, MD; Jiménez-Rodríguez, B; Peralta-Linero, J; Bellagarza-García, E; Troyano-Ramos, L; Garrido-Ruiz, G; Hierro-Martín, MI; Vicioso, L; González-Ortiz, A; Linares-Valencia, N; Velasco-Suelto, J; Carbajosa, G; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Comino-Méndez, I; Alba, E	Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	NPJ BREAST CANCER	6.6	Q1	Article	2024
B-22	Pernas, S; Sanfeliu, E; Villacampa, G; Salvador, J; Perello, A; Gonzalez, X; Jimenez, B; Merino, M; Palacios, P; Pascual, T; Alba, E; Villanueva, L; Chillara, S; Ferrero-Cafiero, JM; Galvan, P; Prat, A; Ciruelos, E	Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy	NPJ BREAST CANCER	6.6	Q1	Article	2024
B-22	Provencio, M; de Lope, LR; Serna-Blasco, R; Nadal, E; Tain, PD; Massuti, B; González-Larriba, JL; Insa, A; Sánchez-Hernández, A; Casal-Rubio, J; García-Campelo, R; López, SS; Rogado, J; Martínez-Martí, A; Bosch-Barrera, J; Bernabé, R; Estévez, SV; Ponce, S; de Castro, J; Sarto, JC; Reguart, N; Dómine, M; Aguilar, A; Majem, M; Estival, A; Cabia, SP; Martín, AL; González, MAS; Cobo, M; Camps, C; Barneto, I; Calvo, V; Collazo-Lorduy, A; Cruz-Bermúdez, A; Romero, A	BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC	LUNG CANCER	4.5	Q1	Article	2024
B-22	-Ares, LP; Goto, Y; Lim, DWT; Halmos, B; Cho, BC; Cobo, M; Larriba, JLG; Zhou, CC; Demedts, I; Atmaca, A; Baka, S; Mookerjee, B; Portella, S; Zhu, ZW; Wu, JC; Demanse, D; Dharan, B; Reck, M	Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial	LUNG CANCER	4.5	Q1	Article	2024
B-22	Felip, E; Metro, G; Tan, DSW; Wolf, J; Mark, M; Boyer, M; Hughes, BGM; Bearz, A; Moro-Sibilot, D; Le, XN; Puente, J; Massuti, B; Tiedt, R; Wang, YY; Xu, C; Mardjuadi, FI; Cobo, M	Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer	LUNG CANCER	4.5	Q1	Article	2024
B-22	Provencio, M; Cobo, M; Rodriguez-Abreu, D; Carcereny, E; Cantero, A; Calvo, V; Castro, RL; Bernabe, R; Bosch-Barrera, J; Massuti, B; Campeloi, RG; Sanchez-Hernandez, A; Ortega, AL; Guirado, M; del Barco, E; Camps, C; Casal-Rubio, J; Domine, M; Sala, MA; Padilla, A; Larriba, JLG; Aparisi, FD	Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry	LUNG CANCER	4.5	Q1	Article	2024
B-22	Calvo, V; Niazmand, E; Carcereny, E; Rodriguez-Abreu, D; Cobo, M; López-Castro, R; Guirado, M; Camps, C; Ortega, AL; Bernabé, R; Massutí, B; Garcia-Campelo, R; del Barco, E; González-Larriba, JL; Bosch-Barrera, J; Martínez, M; Torrente, M; Vidal, ME; Provencio, M	Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk	LUNG CANCER	4.5	Q1	Article	2024
B-22	Kato, T; Casarini, I; Cobo, M; Faivre-Finn, C; Hegi-Johnson, F; Lu, S; Özgüroglu, M; Ramalingam, SS	Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives	LUNG CANCER	4.5	Q1	Review	2024
B-22	Guardamagna, M; Meyer, ML; Berciano-Guerrero, MA; Mesas-Ruiz, A; Cobo-Dols, M; Perez-Ruiz, E; Gonzalez, AC; Lavado-Valenzuela, R; Barragán, I; Oliver, J; Garrido-Aranda, A; Alvarez, M; Rueda-Dominguez, A; Queipo-Ortuño, MI; Conejo, EA; Benitez, JC	Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review	TRANSLATIONAL LUNG CANCER RESEARCH	4.0	Q1	Review	2024
B-22	Piedra, A; Martínez-Recio, S; Hernández, A; Morán, T; Arriola, E; Recuero-Borau, J; Cobo, M; Cordeiro, P; Mosquera, J; Fernández, M; García-Campelo, R; Calles, A; Alvarez, R; Zapata-García, M; Isla, D; Callejo, A; Iranzo, P; Serra-López, J; Barba, A; Sullivan, I; Felip, E; Majem, M	First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study	FRONTIERS IN ONCOLOGY	3.5	Q2	Article	2024
B-22	Lendinez-Sanchez, G; Diaz-Redondo, T; Iglesias-Campos, M; Garrido-Almazán, L; Alba-Conejo, E; Rueda-Dominguez, A; Sanchez-Muñoz, A	Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature	FRONTIERS IN ONCOLOGY	3.5	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-22	Sánchez-Martín, V; López-López, E; Reguero-Paredes, D; Godoy-Ortiz, A; Domínguez-Recio, ME; Jiménez-Rodríguez, B; Alba-Bernal, A; Quirós-Ortega, ME; Roldán-Díaz, MD; Velasco-Suelto, J; Linares-Valencia, N; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Alba, E; Comino-Méndez, I	Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients	CLINICA CHIMICA ACTA	3.2	Q2	Article	2024
B-22	Ospina, AV; Nadal, SB; de la Cruz, JLCC; Larriba, JLG; Vidueira, IM; Sureda, BM; Nadal, E; Trancho, FH; Kindelan, AA; Morillo, E; Caro, RB; Barrera, JB; de Juan, VC; Rubio, JC; de Castro, J; Ramos, AC; Dols, MC; Gomez, M; Almanzar, S; Campelo, RG; Molla, AI; Sarceda, JRJ; Maestre, UJ; Castro, RL; Majem, M; Martínez-Marti, A; Tellez, EM; Lorente, DS; Provencio, M	Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Review	2024
B-22	Carcereny, E; Rodriguez-Abreu, D; Lopez, R; Franco, F; Guirado, M; Massuti, B; Cobo, M; Blasco, A; Suay, G; del Barco, E; Ortega, AL; Sala, MA; Cordeiro, P; Bernabé, R; Larriba, JLG; Bosch-Barrera, J; Calzas, J; Casal, J; Padilla, A; Sánchez-Hernandez, A; Provencio, M	Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024
B-22	Provencio-Pulla, M; Pérez-Parente, D; Olson, S; Hasan, H; Balea, BC; Rodríguez-Abreu, D; Piqueras, MLB; Pal, N; Wilkinson, S; Vilas, E; Ruiz-Gracia, P; Cobo-Dols, M	Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024
B-22	Viñolas, N; Mezquita, L; Corral, J; Cobo, M; Gil-Moncayo, F; Paz-Ares, L; Remon, J; Rodríguez, M; Ruano-Raviña, A; Conde, E; Majem, M; Garrido, P; Felip, E; Isla, D; de Castro, J	The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024
B-22	Calvo, V; Camps, C; Carcereny, E; Cobo, M; Dómine, M; Campelo, MRG; Larriba, JLG; Guirado, M; Hernando-Trancho, F; Massuti, B; Nadal, E; Rodriguez-Abreu, D; Sánchez, A; Sullivan, IG; Provencio, M	Difficulties on the access to innovative targeted therapies for lung cancer in Spain	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Review	2024
B-22	Lendinez-Sanchez, G; Diaz-Redondo, T; Campos, MI; Pelayo, JP; Pelayo, JMP; Muriel-López, C	ATM Variant as a Cause of Hereditary Cutaneous Melanoma in a Spanish Family: A case report.	CASE REPORTS IN ONCOLOGY	0.7	Q4	Article	2024
BA-16	Rodríguez-Muñoz, A; Martínez-Montoro, JI; Sojo-Rodríguez, B; Benitez-Porres, J; Carrillo-Albornoz-Gil, M; Carrasco-Fernandez, L; Subiri-Verdugo, A; Molina-Ramos, A; Cobos-Díaz, A; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Glycaemic Response to Acute Aerobic and Anaerobic Exercise Performed in the Morning or Afternoon in Healthy Subjects: A Crossover Trial	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1	Article	2024
BA-16	Peña-Montero, N; Linares-Pineda, TM; Fernández-Valero, A; Lima-Rubio, F; Fernández-Ramos, AM; Gutiérrez-Repiso, C; Suárez-Arana, M; Picón-César, MJ; Molina-Vega, M; Morcillo, S	Differences in DNA Methylation in Genes Involved in Vitamin D Metabolism Are Related to Insulin Requirement in Pregnant Women with Gestational Diabetes Mellitus	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
BA-16	Zamudio-Sánchez, A; Camarero-Gómez, P; Rodríguez-Manjón, E; Iglesias-Parra, MR; Gómez-Salgado, J; Romero, A	Needs and Expectations of Long-Term Cancer Survivors: Multi-Centre Study Protocol	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Article	2024
BA-16	Muñoz, M; Aragón, S; Ballesteros, M; Bisbe-Vives, E; Jericó, C; Llamas-Sillero, P; Meijide-Míguez, HM; Rayó-Martin, E; Rodríguez-Suárez, MJ	Executive summary of the consensus document on the management of perioperative anemia in Spain	REVISTA CLINICA ESPANOLA	2.3	Q2	Article	2024
BA-16	Romero-Arana, A; González-Rodríguez, MJ; Sánchez-Vega, P; Gómez-Salgado, J; Romero, A	Effectiveness of a self-management program for anticoagulated patients to improve their knowledge about treatment and time in therapeutic range	MEDICINE	1.4	Q2	Article	2024
BA-16	Escobar-Segovia, K; Domínguez-Salas, S; García-Iglesias, JJ; López-López, D; Allande-Cussó, R; Romero, A; Gómez-Salgado, J	Sense of coherence in Spanish-speaking countries during the COVID-19 pandemic: A systematic review	MEDICINE	1.4	Q2	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BA-20	Zamora, V; Garin, O; Suárez, JF; Gutiérrez, C; Guedea, F; Cabrera, P; Castells, M; Herruzo, I; Fumadó, L; Samper, P; Ferrer, C; Regis, L; Pont, A; Ferrer, M	Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures	CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY	2.7	Q2	Article	2024
BE-03	Piemontese, S; Labopin, M; Choi, G; Broers, AEC; Peccatori, J; Meijer, E; Van Gorkom, G; Rovira, M; Cascon, MJP; Sica, S; Vydra, J; Kulagin, A; Spyridonidis, A; Nagler, A; Bazarbachi, A; Savani, B; Brissot, E; Sanz, J; Mohty, M; Ciceri, F	Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide	LEUKEMIA	13.0	D1	Article	2024
BE-03	Moreno, DF; Jiménez, C; Escalante, F; Askari, E; Castellanos-Alonso, M; Arnao, M; Heredia, A; Canales, MA; Alcalá, M; Bermúdez, A; Carreres, AS; Casanova, M; Palomera, L; Motlló, C; García-Sánchez, R; Rull, PR; García-Sanz, R; de Larrea, CF	Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry	HEMASPHERE	12.0	D1	Article	2024
BE-03	Torio, A; Cabo-Zabala, L; Rodriguez-Nicolas, A; Caballero, A	Identification of the novel HLA-C05:279 allele in a Spanish renal transplant recipient	HLA	6.5	D1	Editorial Material	2024
BE-03	Torio, Alberto; Rodriguez-Nicolas, Antonio; Cabo-Zabala, Laura; Caballero, Abelardo	Characterization of the novel HLA-A*33:237 allele by sequencing-based typing.	HLA	6.5	D1	Editorial Material	2024
BE-03	Fonseca-Santos, M; Bailen, R; Lopez-Godino, O; Herruzo-Delgado, B; Bermudez, MA; García-Cadenas, I; Huguet-Mas, M; Ferra-Coll, C; Esquirol, A; Cortés-Rodríguez, M; Yañez-Sansegundo, L; Pascual-Cascon, MJ; Heras, I; Kwon, M; Lopez-Corral, L	Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC	TRANSPLANTATION	5.5	D1	Article	2024
BE-03	Garderet, L; Gras, L; Koster, L; de Wreede, L; Montserrat, R; Vincent, L; Fenk, R; Karunanithi, K; Deeren, D; Kaufmann, M; Kuball, J; Ozdogu, H; Cascon, MJP; Passweg, J; Rye, A; Salmenniemi, U; Snowden, J; Hansen, CT; Leleu, X; Gastaud, L; Drozd-Sokolowska, J; Raj, K; Beksac, M; Schönland, S; Hayden, P; Mclornan, D	Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation	HAEMATOLOGICA	8.2	Q1	Article	2024
BE-03	Salas, MQ; Cascos, E; López-García, A; Pérez, E; Baile-González, M; Rodríguez, CM; Cascón, MJP; Luque, M; Esquirol, A; Fernando, IH; Peña-Muñoz, F; Ormtegi, IO; Marín, AJS; Fernández-Luis, S; Domínguez-García, JJ; Fernández, SV; Girón, MFD; Pinedo, LG; Garcia, L; González-Rodríguez, AP; Torrado, T; Filaferro, S; Cedillo, A; Orti, G; Chacón, MJ	Cardiac events after allo-HCT in patients with acute myeloid leukemia	BLOOD ADVANCES	7.4	Q1	Article	2024
BE-03	Lentz, SR; Chowdary, P; Gil, L; Lopez-Jaime, FJ; Mahlangu, J; Matytsina, I; Nielsen, AL; Windyga, J	FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic	JOURNAL OF THROMBOSIS AND HAEMOSTASIS	5.5	Q1	Article	2024
BE-03	Piñana, JL; Tridello, G; Xhaard, A; Wendel, L; Montoro, J; Vazquez, L; Heras, I; Ljungman, P; Mikulska, M; Salmenniemi, U; Perez, A; Kröger, N; Cornelissen, J; Sala, E; Martino, R; Geurten, C; Byrne, J; Maertens, J; Kerre, T; Martin, M; Pascual, MJ; Yeshurun, M; Finke, J; Groll, AH; Shaw, PJ; Blijlevens, N; Arcese, W; Ganser, A; Suarez-Lledo, M; Alzahrani, M; Choi, G; Forcade, E; Paviglianiti, A; Solano, C; Wachowiak, J; Zuckerman, T; Bader, P; Clausen, J; Mayer, J; Schroyens, W; Metafuni, E; Knelange, N; Averbuch, D; de la Camara, R	Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation	JOURNAL OF INFECTIOUS DISEASES	5.0	Q1	Article	2024
BE-03	Salas, MQ; Cascos, E; López-García, A; Pérez-López, E; Baile-González, M; López-Corral, L; Cascón, MJP; Luque, M; Esquirol, A; Fernando, IH; Ormtegi, IO; Marin, AJS; Peña-Muñoz, F; Fernández-Luis, S; Domínguez-García, JJ; Fernández, SV; Girón, MFD; Pinedo, LG; González-Rodríguez, AP; Torrado, T; García, L; Filaferro, S; Cedillo, A; Basalobre, P; Ortí, G; Chacón, MJ	Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC	BONE MARROW TRANSPLANTATION	4.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BE-03	Salas, MQ; Eikema, DJ; Koster, L; Maertens, J; Passweg, J; Finke, J; Broers, AEC; Koc, Y; Kroeger, N; Ozkurt, ZN; Pascual-Cascon, MJ; Platzbecker, U; Van Gorkom, G; Schroeder, T; López-Lorenzo, JL; Martino, M; Chiusolo, P; Kaufmann, M; Onida, F; Gurnari, C; Scheid, C; Drozd-Sokolowska, J; Raj, K; Robin, M; McLornan, DP	Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT	BONE MARROW TRANSPLANTATION	4.5	Q1	Article	2024
BE-03	Potter, V; Gras, L; Koster, L; Kroger, N; Sockel, K; Ganser, A; Finke, J; Labussiere-Wallet, H; de Latour, RP; Koc, Y; Salmenniemi, U; Friis, LS; Jindra, P; Schroeder, T; Tischer, J; Arat, M; Cascon, MP; de Wreede, LC; Hayden, P; Raj, K; Drozd-Sokolowska, J; Scheid, C; McLornan, DP; Robin, M; Yakoub-Agha, I	Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT	BONE MARROW TRANSPLANTATION	4.5	Q1	Article	2024
BE-03	Navas-Acosta, J; Hernández-Sánchez, A; González, T; Ramiro, AV; Santos, S; Miguel, C; Ribera, J; Granada, I; Morgades, M; Sánchez, R; Such, E; Barrena, S; Ciudad, J; Dávila, J; de las Heras, N; García-de Coca, A; Labrador, J; Queizán, JA; Martín, S; Orfao, A; Ribera, JM; Benito, R; Hernández-Rivas, JM	Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia	CANCERS	4.5	Q1	Article	2024
BE-03	Esquirol, A; Pascual, MJ; Montoro, J; Piñana, JL; Ferrà, C; Herruzo, B; Garcia-Cadenas, I; Balaguer, A; Perez, A; Huguet, M; Redondo, S; Villalba, M; Hernandez-Boluda, JC; Choraó, P; Hernani, R; Sanz, J; Solano, C; Sierra, J; Martino, R	Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil	TRANSPLANTATION AND CELLULAR THERAPY	3.6	Q1	Article	2024
BE-03	Sisinni, L; Monserrate, GXA; Hurtado, JMP; Panesso, M; Molina, B; Fuentes, C; Fuster, JL; Verdu-Amoros, J; Regueiro, A; Palomo, P; Beléndez, C; Pascual, A; Badell, I; Mozo, Y; Bueno, D; Pérez-Martínez, A; Fernández, JM; Vicent, MG; de Heredia, CD	Haploidentical versus Cord Blood Transplantation in Pediatric AML. A Retrospective Outcome Analysis on Behalf of the Pediatric Subcommittee of GETH (Grupo Espanol de Trasplante Hematopoyetico)	TRANSPLANTATION AND CELLULAR THERAPY	3.6	Q1	Article	2024
BE-03	Kwon, M; Gómez-Centurión, I; Oarbeascoa, G; Torres, M; Martinez, AP; Suarez-Lledó, M; Chinae, A; Cascón, MJP; Vazquez, L; Espigado, I; Izquierdo, I; Parody, R; Cadenas, IG; Calbacho, M; Sierra, PG; Heras, I; Yañez, L; Torrent, A; Bautista, G; Gonzalez, S; Roldan, E; Vallejo, JC; Bailen, R; Borrero, A; Lopez-Jiménez, J; Casas, MAC; Solano, C	Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain	TRANSPLANTATION AND CELLULAR THERAPY	3.6	Q1	Article	2024
BE-03	Gómez-Centurión, I; Morillo, AIG; Martínez, AP; Calvo, MC; Chinae, A; González, L; Pedraza, A; Lorenzo, MJJ; Robles, MC; Bailén, R; Cascón, MJP; Cabero, A; Sánchez, JLP; Luna, A; Alvarez, MP; Rovira, M; Catarineu, AT; Sanchez-Pina, J; Kwon, M	Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular (GETH)	TRANSPLANTATION AND CELLULAR THERAPY	3.6	Q1	Article	2024
BE-03	Pinana, JL; Vazquez, L; Heras, I; Aiello, TF; López-Corral, L; Arroyo, I; Soler-Espejo, E; García-Cadenas, I; Garcia-Gutierrez, V; Aroca, C; Choraó, P; Olave, MT; Lopez-Jimenez, J; Gómez, MA; Arellano, E; Cuesta-Casas, M; Avendano-Pita, A; González-Santillana, C; Hernández-Rivas, JA; Roldán-Perez, A; Mico-Cerdá, M; Guerreiro, M; Morell, J; Rodriguez-Galvez, P; Labrador, J; Campos, D; Cedillo, A; Vidal, CG; Martino, R; Solano, C	Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy	FRONTIERS IN ONCOLOGY	3.5	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BE-03	Suárez, EU; Boluda, B; Lavilla, E; Tormo, M; Botella, C; Gil, C; Vives, S; Rodríguez, C; Serrano, J; Sayas, MJ; Martínez-Sánchez, P; Ramos, F; Bernal, T; Algarra, L; Bergua-Burgues, JM; Pérez-Simón, JA; Herrera, P; Barrios, M; Noriega-Concepción, V; Raposo-Puglia, JA; Ayala, R; Barragán, E; Martínez-Cuadrón, D; Amigo, ML; López-Lorenzo, JL; Lázaro-García, A; Guimaraes, JE; Colorado, M; García-Boyer, R; De Rueda-Ciller, B; Foncillas-García, M; Hong, A; Labrador, J; Alonso-Dominguez, JM; Montesinos, P	Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?	ANNALS OF HEMATOLOGY	3.0	Q2	Article	2024
BE-03	Alvarez-Román, MT; Vazquez, RJN; Hidalgo, OB; Paris, LQ; Urena, LE; Jaime, FJL; la De Corte-Rodríguez, H; Dasi, MG; Bosch, P; Castellano, MEM; Garaeta, IG; Soto-Ortega, I	Humanistic burden of haemophilia A without inhibitors: A cross-sectional analysis of the HemoLIFE study	HAEMOPHILIA	3.0	Q2	Article	2024
BE-03	Bravo, AP; Bonilla, RP; Rebollar, DB; López-Jaime, FJ; Fernández-Bello, I	Successful immunosuppressive drug-free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report	CLINICAL CASE REPORTS	0.6	Q3	Article	2024
BE-15	Castellano-Castillo, D; Ramos-Molina, B; Frutos, MD; Arranz-Salas, I; Reyes-Engel, A; Queipo-Ortuño, MI; Cardona, F	RNA expression changes driven by altered epigenetics status related to NASH etiology	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
BE-15	Carrillo-García, J; Hindi, N; Conceicao, M; Sala, MA; Ugalde, A; López-Pousa, A; Bagué, S; Sevilla, I; Vicioso, L; Ramos, R; Martínez-Trufero, J; Mateo, MCG; Cruz, J; Hernández-León, CN; Redondo, A; Mendiola, M; García, JM; Hernández, JE; Alvarez, R; Agra, C; de Juan-Ferré, A; Valverde, C; Cano, JM; de Sande, LM; Pérez-Fidalgo, JA; Lavernia, J; Marcilla, D; Gutiérrez, A; Moura, DS; Martín-Broto, J	Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor	EUROPEAN JOURNAL OF CANCER	7.6	Q1	Article	2024
BE-15	Cornejo-Pareja, I; Amiar, MR; Ocaña-Wilhelmi, L; Soler-Humanes, R; Arranz-Salas, I; Garrido-Sánchez, L; Gutiérrez-Repiso, C; Tinahones, FJ	Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism	JOURNAL OF GASTROENTEROLOGY	6.9	Q1	Article	2024
BE-15	Alba-Bernal, A; Godoy-Ortiz, A; Domínguez-Recio, ME; López-López, E; Quirós-Ortega, ME; Sánchez-Martín, V; Roldán-Díaz, MD; Jiménez-Rodríguez, B; Peralta-Linero, J; Bellagarza-García, E; Troyano-Ramos, L; Garrido-Ruiz, G; Hierro-Martín, MI; Vicioso, L; González-Ortiz, A; Linares-Valencia, N; Velasco-Suelto, J; Carbajosa, G; Garrido-Aranda, A; Lavado-Valenzuela, R; Alvarez, M; Pascual, J; Comino-Méndez, I; Alba, E	Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	NPJ BREAST CANCER	6.6	Q1	Article	2024
BE-15	García-Flores, LA; De Vera, MTD; Pilo, J; Rego, A; Gomez-Casado, G; Arranz-Salas, I; Martín, IH; Alcaide, J; Torres, E; Ortega-Gomez, A; Boughanem, H; Macias-Gonzalez, MM	Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
BE-15	Martínez-Montoro, JI; Arranz-Salas, I; Gutiérrez-Repiso, C; Sánchez-García, A; Ocana-Wilhelmi, L; Pinazo-Bandera, JM; Fernández-García, D; Munoz-Garach, A; Morales-García, D; Garcia-Cortes, M; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study	NUTRIENTS	4.8	Q1	Article	2024
BE-15	Barbadilla, TC; Pérez, MA; Cuadra, JDP; de Vera, MTD; Alberca-del Arco, F; Muñoz, IG; de la Blanca, RSP; Herrera-Imbroda, B; Matas-Rico, E; Martín, MIH	The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer	DIAGNOSTICS	3.0	Q1	Review	2024
BE-15	Alvarez-Mancha, AI; Mancha-Doblas, I; Molina-Vega, M; Fernández-García, D; Gómez-Pérez, AM; Gallego-Domínguez, E; Ortega-Jiménez, MV; Hierro-Martín, I; Tinahones, FJ	Evolutionary analysis of indeterminate cytology and risk of malignancy in a thyroid nodule unit	EUROPEAN THYROID JOURNAL	3.5	Q2	Article	2024
BE-15	de Vera, MTD; Crespo, FJD; Manso, R; Coello, AP; Morillo-Giles, D; Rodríguez-Pinilla, SM; de la Pinta, FJD	Intraparenchymal low-grade B-cell lymphomas of the central nervous system: Clinicopathologic and molecular analysis of three cases and a review of the literature	ANNALS OF DIAGNOSTIC PATHOLOGY	1.5	Q3	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BE-17	Zafra, J; Onieva, JL; Oliver, J; Garrido-Barros, M; González-Hernández, A; Martínez-Gálvez, B; Román, A; Ordóñez-Marmolejo, R; Pérez-Ruiz, E; Benítez, JC; Mesas, A; Vera, A; Chicas-Sett, R; Rueda-Domínguez, A; Barragán, I	Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
BE-17	Gómez-Aparicio, MA; López-Campos, F; Buchser, D; Lazo, A; Willisich, P; Ocanto, A; Sargos, P; Shelan, M; Couñago, F	Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?	CANCERS	4.5	Q1	Review	2024
BE-17	Calvo, A; Anaya, MJ; Guillot, SS; Romero, NM; Ocón, MJ; Carmona, J; Gómez-Millán, J; Ríos, IG	Ultrahypofractionation in postoperative radiotherapy for breast cancer: A single-institution retrospective cohort series	CANCER MEDICINE	2.9	Q2	Article	2024
BE-17	Rivas, D; de la Torre-luque, A; Moreno-Olmedo, E; Moreno, P; Suárez, V; Serradilla, A; Arregui, G; Alvarez, D; Sallabanda, M; Lazo, A; Núñez, MI; López, E	Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?	WORLD JOURNAL OF UROLOGY	2.8	Q2	Article	2024
BE-17	Rodríguez-Rodríguez, D; Sanz-Sánchez, CI; Cazorla-Ramos, OE	Cervical necrotizing fascitis of odontogenous origin. A case report	REVISTA ORL	0.1	Q4	Article	2024
BE-17	Rodríguez-Rodríguez, D; Sanz-Sánchez, CI; Cazorla-Ramos, OE	Necrotizing fascitis of the neck management with vacuum assisted therapy (VAC). Systematic review	REVISTA ORL	0.1	Q4	Review	2024
BE-18	Bettinetti-Luque, M; Trujillo-Estrada, L; Garcia-Fuentes, E; Andreo-Lopez, J; Sanchez-Varo, R; Garrido-Sánchez, L; Gómez-Mediavilla, A; López, MG; Garcia-Caballero, M; Gutierrez, A; Baglietto-Vargas, D	Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease	BRITISH JOURNAL OF PHARMACOLOGY	6.8	D1	Review	2024
BE-18	de Zeeuw, P; Treps, L; García-Caballero, M; Harjes, U; Kalucka, J; De Legher, C; Brepoels, K; Peeters, K; Vinckier, S; Souffreau, J; Bouché, A; Taverna, F; Dehairs, J; Talebi, A; Ghesquiere, B; Swinnen, J; Schoonjans, L; Eelen, G; Dewerchin, M; Carmeliet, P	The gluconeogenesis enzyme PCK2 has a non-enzymatic role in proteostasis in endothelial cells	COMMUNICATIONS BIOLOGY	5.2	Q1	Article	2024
BE-19	Sendra-Portero, F; Lorenzo-Alvarez, R; Rudolphi-Solero, T; Ruiz-Gómez, MJ	The Second Life Metaverse and Its Usefulness in Medical Education After a Quarter of a Century	JOURNAL OF MEDICAL INTERNET RESEARCH	5.8	D1	Article	2024
BE-19	Burgos-Molina, AM; Santana, TT; Redondo, M; Romero, MJB	The Crucial Role of Inflammation and the Immune System in Colorectal Cancer Carcinogenesis: A Comprehensive Perspective	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
BE-19	Martín-Sierra, C; Bravo, MJ; Sáez, ME; De Rojas, I; Santos, M; Martín-Carmona, J; Corma-Gómez, A; González-Serna, A; Royo, JL; Pineda, JA; Rivero, A; Rivero-Juárez, A; Macías, J; Real, LM	The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations (GEHEP-012 study)	ANTIVIRAL RESEARCH	4.5	Q1	Article	2024
BE-19	Rudolphi-Solero, T; Lorenzo-Alvarez, R; Domínguez-Pinos, D; Ruiz-Gómez, MJ; Sendra-Portero, F	An Interuniversity Competition for Medical Students to Learn Radiology in the Second Life Metaverse	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY	4.0	Q1	Article	2024
BE-19	Atencia-Jiménez, I; Balajee, AS; Ruiz-Gómez, MJ; Sendra-Portero, F; Montoro, A; Molina-Cabello, MA	Neural Network Ensemble to Detect Dicentric Chromosomes in Metaphase Images	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BE-19	García-Alberca, JM; de Rojas, I; Sanchez-Mejias, E; Garrido-Martín, D; Gonzalez-Palma, L; Jimenez, S; Pino-Angeles, A; Cruz-Gamero, JM; Mendoza, S; Alarcón-Martín, E; Muñoz-Castro, C; Real, LM; Tenao, JJ; Polvillo, R; Govantes, F; Lopez, A; Royo-Aguado, JL; Navarro, V; Gonzalez, I; Ruiz, M; Reyes-Engel, A; Gris, E; Bravo, MJ; Lopez-Gutierrez, L; Mejias-Ortega, M; De la Guía, P; de la Rica, ML; Ocejo, O; Torrecilla, J; Zafra, C; Nieto, MD; Urbano, C; Jiménez-Sánchez, R; Pareja, N; Luque, M; García-Peralta, M; Carrillejo, R; Furniet, MD; Rueda, L; Sánchez-Fernández, A; Mancilla, T; Peña, I; García-Casares, N; Moreno-Grau, S; Hernández, I; Montreal, L; Quintela, I; González-Pérez, A; Calero, M; Franco-Macías, E; Macías, J; Menéndez-González, M; Frank-García, A; Vilas, RH; Diez-Fairen, M; Lage, C; García-Madrona, S; García-González, P; Valero, S; Sotolongo-Grau, O; Pérez-Cordón, A; Rabano, A; Pastor, AA; Pastor, AB; Espinosa, A; Corma-Gómez, A; Montes, AM; Sanabria, A; Rodríguez, CM; Buiza-Rueda, D; Rodriguez-Rodriguez, E; Ortega, G; Alvarez, I; Allende, IR; Pineda, JA; Rosende-Roca, M; Sánchez-Arjona, MB; Fernández-Fuertes, M; Alegret, M; Roberto, N; del Ser, T; Garcia-Ribas, G; Sánchez-Juan, P; Pastor, P; Piñol-Ripoll, G; Bullido, MJ; Alvarez, V; Mir, P; Medina, M; Marquié, M; Sáez, ME; Carracedo, A; Laplana, M; Tomas-Gallardo, L; Orellana, A; Tarraga, L; Boada, M; Palazon, JF; Vitorica, J; Ruiz, A; Guigo, R; Gutierrez, A; Royo, JL	An Insertion Within SIRP α 1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
BE-19	Castro, AA; Pinos, DD; Utrilla, VS; del Campo, JAO; Portero, FS; Ruiz-Gómez, MJ	Update in imaging tests used for the localization of parathyroid pathology	RADIOLOGIA	1.1	Q3	Article	2024
BE-21	Moreno, DF; Jiménez, C; Escalante, F; Askari, E; Castellanos-Alonso, M; Arnao, M; Heredia, A; Canales, MA; Alcalá, M; Bermúdez, A; Carreres, AS; Casanova, M; Palomera, L; Motlló, C; García-Sánchez, R; Rull, PR; García-Sanz, R; de Larrea, CF	Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry	HEMASPHERE	12.0	D1	Article	2024
BE-21	Omotesho, QA; Escamilla, A; Perez-Ruiz, E; Frecha, CA; Rueda-Dominguez, A; Barragan, I	Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Review	2024
BE-21	Jiménez-Bárcenas, R; García-Donas-Gabaldón, G; Campos-Alvarez, RM; de Mora, MCFS; Luis-Navarro, J; Domínguez-Rodríguez, JF; Nieto-Hernández, MD; Sánchez-Bazán, I; Yera-Cobo, M; Cardesa-Cabrera, R; Jiménez-Gonzalo, FJ; Ruiz-Cobo, MA; Caparrós-Miranda, I; Entrena-Ureña, L; Jiménez, DF; Díaz-Canales, D; Moreno-Carrasco, G; Calderón-Cabrera, C; Núñez-Vazquez, RJ; Pedrote-Amador, B; Mingot-Castellano, ME	Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study	BRITISH JOURNAL OF HAEMATOLOGY	5.1	Q1	Article	2024
BE-21	Arrari, F; Ortiz-Flores, RM; Lhamyani, S; Garcia-Fuentes, E; Jabri, MA; Sebai, H; Bermudez-Silva, FJ	Protective Effects of Spirulina Against Lipid Micelles and Lipopolysaccharide-Induced Intestinal Epithelium Disruption in Caco-2 Cells: In Silico Molecular Docking Analysis of Phycocyanobilin	NUTRIENTS	4.8	Q1	Article	2024
BE-21	Mingot-Castellano, ME; García-Donas, G; Campos-Alvarez, RM; de Mora, MCFS; Luis-Navarro, J; Domínguez-Rodríguez, JF; Nieto-Hernández, MD; Sanchez-Bazán, I; Yera-Cobo, M; Cardesa-Cabrera, R; Jiménez-Gonzalo, FJ; Caparrós-Miranda, I; Entrena-Urena, L; Herrera, SJ; Jiménez, DF; Díaz-Canales, D; Moreno-Carrasco, G; Calderón-Cabrera, C; Núñez-Vázquez, RJ; Pedrote-Amador, B; Bárcenas, RJ	Platelet Responses After Tapering and Discontinuation of Fostamatinib in Patients with Immune Thrombocytopenia: A Continuation of the Fostasur Study	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
BE-21	Vallejo, C; Rosell, A; Xicoy, B; Garcia, C; Albo, C; Polo, M; Jarque, I; Esteban, B; Codesido, ML	A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)	ANNALS OF HEMATOLOGY	3.0	Q2	Article	2024
BE-21	Flores, RMO; Cáceres, CS; Cortiñas, TI; Mejiba, SEG; Sasso, CV; Ramirez, DC; Domínguez, MAM	Exotoxins secreted by Clostridium septicum induce macrophage death: Implications for bacterial immune evasion mechanisms at infection sites	TOXICON	2.6	Q2	Article	2024
BE-21	Theocharides, A; Gisslinger, H; De Stefano, V; Accurso, V; Iurlo, A; Devos, T; Egyed, M; Lippert, E; Delgado, RG; Cantoni, N; Dahm, AEA; Sotiropoulos, D; Houtsma, E; Smyth, A; Iqbal, A; Di Matteo, P; Zuurman, M; te Boekhorst, PAW	Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	EUROPEAN JOURNAL OF HAEMATOLOGY	2.3	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BE-23	Morris, MJ; Castellano, D; Herrmann, K; de Bono, JS; Shore, ND; Chi, KN; Crosby, M; Piulats, JM; Fléchon, A; Wei, XX; Mahammedi, H; Roubaud, G; Studentová, H; Nagarajah, J; Mellado, B; Montesa-Pino, A; Kpamegan, E; Ghebremariam, S; Kreisl, TN; Wilke, C; Lehnhoff, K; Sartor, O; Fizazi, K	177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial	LANCET	98.0	D1	Article	2024
BE-23	Márquez-Rodas, I; Alvarez, A; Arance, A; Valduvieto, I; Berciano-Guerrero, MA; Delgado, R; Soria, A; Campos, FL; Sánchez, P; Romero, JL; Martín-Liberal, J; Lucas, A; Díaz-Beveridge, R; Conde-Moreno, AJ; de la Gala, MDA; García-Castaño, A; Prada, PJ; Cao, MG; Puertas, E; Vidal, J; Foro, P; de la Rosa, CA; Corona, JA; Cerezuela-Fuentes, P; López, P; Luna, P; Aymar, N; Puértolas, T; Sanagustín, P; Berrocal, A	Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)	NEURO-ONCOLOGY	16.0	D1	Article	2024
BE-23	Weiss, SA; Sznol, M; Shaheen, M; Berciano-Guerrero, MA; Couselo, EM; Rodríguez-Abreu, D; Boni, V; Schuchter, LM; Gonzalez-Cao, M; Arance, A; Wei, W; Ganti, AK; Hauke, RJ; Berrocal, A; Iannotti, NO; Hsu, FJ; Kluger, HM	A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy	CLINICAL CANCER RESEARCH	10.0	D1	Article	2024
BE-23	Flechon, A; Morales-Barrera, R; Powles, T; Alva, A; Özgüroglu, M; Csösz, T; Loriot, Y; Rodriguez-Vida, A; Géczi, L; Cheng, SY; Fradet, Y; Oudard, S; Vulsteke, C; Gunduz, S; Mamtani, R; Yu, EY; Pino, AM; Anido, U; Sendur, MAN; Gravis, G; Révész, J; Kostorov, V; Huillard, O; Ma, JS; Rajasagi, M; Vajdi, A; Lunceford, J; Cristescu, R; Imai, K; Moreno, BH; Matsubara, N	Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma	CLINICAL CANCER RESEARCH	10.0	D1	Article	2024
BE-23	Torio, A; Cabo-Zabala, L; Rodriguez-Nicolas, A; Caballero, A	Identification of the novel HLA-C05:279 allele in a Spanish renal transplant recipient	HLA	6.5	D1	Editorial Material	2024
BE-23	Torio, Alberto; Rodriguez-Nicolas, Antonio; Cabo-Zabala, Laura; Caballero, Abelardo	Characterization of the novel HLA-A*33:237 allele by sequencing-based typing.	HLA	6.5	D1	Editorial Material	2024
BE-23	Contreras-Toledo, D; Jiménez-Fonseca, P; López, CL; Montes, AF; Muñoz, AML; Rivera, FV; Alonso, V; Alcaide, J; Salvà, F; Rúa, MC; Guillot, M; Carnicero, AM; Mate, RJ; García, SC; Martínez, EA; Astorga, BG; Fernandez-Diaz, AB; Villaroel, PG; Manrique, ACV; Sosa, MM; Alonso, B; Castiñeiras, AC; López, CC; Aparicio, J; Carmona-Bayonas, A	Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?	BRITISH JOURNAL OF CANCER	6.4	Q1	Article	2024
BE-23	Garcia-Flores, LA; De Vera, MTD; Pilo, J; Rego, A; Gomez-Casado, G; Arranz-Salas, I; Martín, IH; Alcaide, J; Torres, E; Ortega-Gomez, A; Boughanem, H; Macias-Gonzalez, MM	Increased neutrophil counts are associated with poor overall survival in patients with colorectal cancer: a five-year retrospective analysis	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
BE-23	Guardamagna, M; Meyer, ML; Berciano-Guerrero, MA; Mesas-Ruiz, A; Cobo-Dols, M; Perez-Ruiz, E; Gonzalez, AC; Lavado-Valenzuela, R; Barragán, I; Oliver, J; Garrido-Aranda, A; Alvarez, M; Rueda-Dominguez, A; Queipo-Ortuño, MI; Conejo, EA; Benitez, JC	Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review	TRANSLATIONAL LUNG CANCER RESEARCH	4.0	Q1	Review	2024
BE-23	Zamudio-Sánchez, A; Camarero-Gómez, P; Rodríguez-Manjón, E; Iglesias-Parra, MR; Gómez-Salgado, J; Romero, A	Needs and Expectations of Long-Term Cancer Survivors: Multi-Centre Study Protocol	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Article	2024
BE-23	Royo-Cebrecos, C; Laporte-Amargós, J; Peña, M; Ruiz-Camps, I; Garcia-Vidal, C; Abdala, E; Oltolini, C; Akova, M; Montejó, M; Mikulska, M; Martín-Dávila, P; Herrera, F; Gasch, O; Drgona, L; Morales, HMP; Brunel, AS; García, E; Isler, B; Kern, WV; Palacios-Baena, ZR; de la Calle, GM; Montero, MM; Kanj, SS; Sipahi, OR; Calik, S; Márquez-Gómez, I; Marin, JJ; Gomes, MZR; Hemmatii, P; Araos, R; Peghin, M; Del Pozo, JL; Yáñez, L; Tilley, R; Manzur, A; Novo, A; Carratalà, J; Gudiol, C	Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy	MICROORGANISMS	4.1	Q2	Article	2024
BE-23	Gonzalez-Cao, M; Puertolas, T; Manzano, JL; Maldonado, C; Yelamos, O; Berciano-Guerrero, MA; Cerezuela, P; Martín-Liberal, J; Muñoz-Couselo, E; Espinosa, E; Drozdowskyj, A; Berrocal, A; Soria, A; Marquez-Rodas, I; Martín-Algarra, S; Quindos, M; Puig, S	Access to melanoma drugs in Spain: a cross-sectional survey	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BE-23	Marquez-Rodas, I; Couselo, EM; Moreno, JFR; Fernández, AMA; Guerrero, MAB; Balea, BC; Merino, LD; Arranz, EE; Castaño, AG; Jaime, AB	SEOM-GEM clinical guidelines for cutaneous melanoma (2023)	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024
BE-23	Pericay, C; Montagut, C; Reina, JJ; Melian, M; Alcaide, J; Tarazona, N; Ruiz-Casado, A; González-Flores, E; Graña, B; Grávalos, C	SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)	CLINICAL & TRANSLATIONAL ONCOLOGY	2.8	Q2	Article	2024
BE-23	Gomez Moyano, Elisabeth; Llamas Carmona, Jose Antonio; Lopez Riquelme, Irene; Martinez Pilar, Leandro	Trichothiodystrophy, playing with optical microscope.	Anales de pediatria	1.5	Q2	Article	2024
BE-23	Herrera, MJV; Herrera, VV; Pérez, VM; Puche, FS; Vegas, IV	Pheochromocytoma as a simulator of cardiac pathology	HIPERTENSION Y RIESGO VASCULAR	1.2	Q4	Article	2024
BE-23	Vallejo Herrera, M J; Vallejo Herrera, V; Serrano Puche, F	Extraadrenal abdominal paraganglyoma: Review of the literature	MEDICINA DE FAMILIA-SEMERGEN	0.9	Q4	Review	2024
C-01	Baños, JE; Blanco-Reina, E; Bellido-Estévez, I; Bosch, F; Cabello, MR; Cambra-Badii, I; Cruz, JPD; D'Ocón, P; Ivorra, MD; Ferrándiz, M; Gonzalez-Correa, JA; Martin-Montanez, E; Martos, F; Pavia, J; Sanz, E	Beyond lectures and practical courses: Teaching pharmacology using imaginative pedagogical tools	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
C-01	Wreven, E; de Adana, MSR; Hardiville, S; Gmyr, V; Kerr-Conte, J; Chetboun, M; Pasquetti, G; Delalleau, N; Thévenet, J; Coddeville, A; Herrera, MJV; Hinden, L; Espínola, ICB; Duro, MG; Salido, LS; Linares, F; Bermúdez-Silva, FJ; Tam, J; Bonner, C; Egan, JM; Olveira, G; Colomo, N; Pattou, F; González-Mariscal, I	Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulinitis in humans	DIABETOLOGIA	8.4	D1	Article	2024
C-01	Vilaseca, A; Farina, A; Villagrán-Garcia, M; Pegat, A; Benaiteau, M; Ciano-Petersen, NL; Do, L; Rogemond, V; Gonçalves, D; Psimaras, D; Birzu, C; Honnorat, J; Joubert, B	Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors	JOURNAL OF NEUROLOGY	8.3	D1	Article	2024
C-01	Ciano-Petersen, NL; Muñoz-Castrillo, S; Villagrán-García, M; Farina, A; Vogrig, A; Wucher, V; Do, L; Birzu, C; Goncalves, D; Flabeau, O; Duwicquet, C; Benard, A; Nicole, F; Rogemond, V; Picard, G; Joubert, B; Honnorat, J	Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma	NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION	8.3	D1	Article	2024
C-01	Serrano-Castro, PJ; Ramírez-García, T; Cabezudo-García, P; Garcia-Martin, G; De La Parra, J	Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study	CNS DRUGS	7.4	D1	Article	2024
C-01	López-Villodres, JA; García-Díaz, B	Oligodendroctyes: the forgotten players of diabetes pathophysiology	NEURAL REGENERATION RESEARCH	5.9	Q1	Article	2024
C-01	Estivill-Torrús, G; Martínez-Padilla, A; Sánchez-Salido, L; Evercooren, ABV; García-Díaz, B	The dorsal root ganglion as a target for neurorestoration in neuropathic pain	NEURAL REGENERATION RESEARCH	5.9	Q1	Review	2024
C-01	Fernández, O; Sörensen, PS; Comi, G; Vermersch, P; Hartung, HP; Leocani, L; Berger, T; Van Wijmeersch, B; Oreja-Guevara, C	Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Review	2024
C-01	Mena-Vázquez, N; Ortiz-Márquez, F; Ramírez-García, T; Cabezudo-García, P; García-Studer, A; Mucientes-Ruiz, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Redondo-Rodríguez, R; Manrique-Arija, S; Cano-García, L; Serrano-Castro, PJ; Fernández-Nebro, A	Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis	RMD OPEN	5.1	Q1	Article	2024
C-01	Fernández-Arjona, MD; Navarro, JA; López-Gambero, AJ; de Ceglia, M; Rodríguez, M; Rubio, L; de Fonseca, FR; Barrios, V; Chowen, JA; Argente, J; Rivera, P; Suárez, J	Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments	BIOLOGY OF SEX DIFFERENCES	4.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-01	Aguilar-Castillo, MJ; Cabezudo-Garcia, P; Garcia-Martin, G; Lopez-Moreno, Y; Estivill-Torru, G; Ciano-Petersen, NL; Oliver-Martos, B; Narvaez-Pelaez, M; Serrano-Castro, PJ	A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
C-01	Rada, A; Hagemann, A; Poulsen, CA; Baumgartner, T; Berki, T; Blaabjerg, M; Brenner, J; Britton, JW; Christiana, A; Ciano-Petersen, NL; Crijnen, Y; Elisák, M; Farina, A; Friedman, AR; Hayden, Z; Hébert, J; Holtkamp, M; Hong, Z; Honnorat, J; Ilyas-Feldmann, M; Irani, SR; Kovac, S; Marusic, P; Muñoz-Castrillo, S; Ramanathan, S; Smith, KM; Steriade, C; Strippel, C; Surges, R; Titulaer, MJ; Uy, CE; de Vries, JM; Bien, CG; Specht, U	Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving	NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION	4.8	Q1	Article	2024
C-01	Peter, E; Ciano-Petersen, NL; Do, L; Perrot, J; Ngo, T; Pluvinage, J; Bartley, CM; Zorn, KC; Miske, R; Scharf, M; Villagrán-García, M; Farina, A; Rogemond, V; Antoine, JC; Tranchant, C; Dubois, V; Derisi, JL; Pleasure, SJ; Wilson, MR; Gelfand, JM; Traverse-Glehen, A; Honnorat, J; Desestret, V	Anti-RGS8 paraneoplastic cerebellar ataxia is preferentially associated with a particular subtype of Hodgkin's lymphoma	JOURNAL OF NEUROLOGY	4.8	Q1	Article	2024
C-01	Sánchez-Varo, R; López-Salas, A; Beltran-Casanueva, R; Díaz-Sánchez, E; Alvarez-Contino, JE; Barbancho-Fernández, MA; Serrano-Castro, P; Fuxe, K; Borroto-Escuela, DO; García-Casares, N; Narváez, M	Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions	BEHAVIORAL AND BRAIN FUNCTIONS	4.7	Q1	Article	2024
C-01	Oreja-Guevara, C; Martinez-Yélamos, S; Eichau, S; Llanea, MA; Martín-Martínez, J; Peña-Martínez, J; Meca-Lallana, V; Alonso-Torres, AM; Moral-Torres, E; Río, J; Calles, C; Ares-Luque, A; Ramió-Torrentà, L; Marzo-Sola, ME; Prieto, JM; Martínez-Ginés, ML; Arroyo, R; Otano-Martínez, MA; Brieva-Ruiz, L; Gómez-Gutiérrez, M; Rodríguez-Antigüedad, A; Sánchez-Seco, V; Costa-Frossard, L; Hernández-Pérez, MA; Landete-Pascual, L; González-Platas, M; Meca-Lallana, JE	Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management	THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS	4.7	Q1	Review	2024
C-01	Borroto-Escuela, D; Serrano-Castro, P; Sánchez-Pérez, JA; Barbancho-Fernández, MA; Fuxe, K; Narváez, M	Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder	EXPERT OPINION ON THERAPEUTIC TARGETS	4.6	Q1	Article	2024
C-01	Arrabal-Gómez, C; Serrano-Castro, P; Sánchez-Pérez, JA; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, D; Narvaéz, M	Potential of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus	EXPERT OPINION ON THERAPEUTIC TARGETS	4.6	Q1	Article	2024
C-01	Beltran-casanueva, R; Hernández-García, A; Serrano-Castro, PJ; Sánchez-Pérez, JA; Barbancho-Fernández, MA; García-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Long-term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co-administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus	FASEB JOURNAL	4.4	Q1	Article	2024
C-01	Figueroa, FL; Castro-Varela, P; Vega, J; Losantos, R; Peñín, B; López-Cóndor, L; Pacheco, MJ; Redoli, SL; Marí-Beffa, M; Abdala-Díaz, R; Sampedro, D	Novel synthetic UV screen compounds inspired in mycosporine-like amino acids (MAAs): Antioxidant capacity, photoprotective properties and toxicity	JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY	3.9	Q1	Article	2024
C-01	de Diego-Otero, Y; El Bekay, R; García-Guirado, F; Sánchez-Salido, L; Giráldez-Pérez, RM	Apocynin, a Selective NADPH Oxidase (Nox2) Inhibitor, Ameliorates Behavioural and Learning Deficits in the Fragile X Syndrome Mouse Model	BIOMEDICINES	3.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-01	de Fonseca, FR; Medina-Paz, F; Sapozhnikov, M; Hurtado-Guerrero, I; Rubio, L; Martín-de-las-Heras, S; Requena-Ocaña, N; Flores-Lopez, M; Fernández-Arjona, MD; Rivera, P; Serrano, A; Serrano, P; Zapico, SC; Suárez, J	Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study	TOXICS	3.9	Q1	Article	2024
C-01	Ocaña-Tienda, B; Pérez-Beteta, J; Romero-Rosales, JA; Asenjo, B; de Mendivil, AO; Romasanta, LAP; Labarra, JDA; Nagib, F; Denis, MV; Luque, B; Arana, E; Pérez-García, VM	Volumetric analysis: Rethinking brain metastases response assessment	NEURO-ONCOLOGY ADVANCES	3.7	Q1	Article	2024
C-01	Ocaña-Tienda, B; Pérez-Beteta, J; de Mendivil, AO; Asenjo, B; Albillo, D; Pérez-Romasanta, LA; LLorente, M; Carballo, N; Arana, E; Pérez-García, VM	Morphological MRI features as prognostic indicators in brain metastases	CANCER IMAGING	3.5	Q1	Article	2024
C-01	Ibáñez-Botella, G; Narváez, IF; Pugliese, B; Ros, B; Arráez, MA	Endoscopic resection of third ventricle colloid cysts using an ultrasonic aspirator	NEUROSURGICAL REVIEW	2.5	Q1	Review	2024
C-01	Arrabal-Gómez, C; Beltran-Casanueva, R; Hernández-García, A; Bayolo-Guanche, JV; Barbancho-Fernández, MA; Serrano-Castro, PJ; Narváez, M	Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats	CELLS	5.1	Q2	Article	2024
C-01	Beltran-Casanueva, R; Hernández-García, A; García, PD; Blanco-Reina, E; Serrano-Castro, P; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2	Article	2024
C-01	Ramos-Cazorla, P; Carazo-Barrios, L; Reyes-Bueno, JA; Sagües-Sesé, E; de Rojas-Leal, C; Barbancho, MA; Garzón-Maldonado, FJ; de la Cruz-cosme, C; García-Arnés, JA; García-Casares, N	Olfactory Dysfunction as a Biomarker for Early Diagnosis of Cognitive Impairment in Patients With Type 2 Diabetes: A Systematic Review	JOURNAL OF DIABETES RESEARCH	3.6	Q2	Review	2024
C-01	Matias-Guiu, JA; Alvarez-Sabín, J; Botía, E; Casado-Naranjo, I; Castellanos, M; Frank, A; Iñiguez, C; Jiménez-Hernández, MD; Jiménez-Jiménez, FJ; Láinez, JM; Moral, E; Pérez-Martínez, DA; Rodríguez-Antigüedad, A; Ruiz-Lavilla, N; Segura, T; Serrano-Castro, PJ; Matias-Guiu, J	Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
C-01	Gordillo-Resina, M; Aranda-Martinez, C; Arias-Verdú, MD; Guerrero-López, F; Castillo-Lorente, E; Rodríguez-Rubio, D; Rivera-López, R; Rosa-Garrido, C; Gómez-Jiménez, FJ; Lafuente-Baraza, J; Aguilar-Alonso, E; Arráez-Sanchez, MA; Rivera-Fernández, R	Mortality, Functional Status, and Quality of Life after 5 Years of Patients Admitted to Critical Care for Spontaneous Intracerebral Hemorrhage	NEUROCRITICAL CARE	3.1	Q2	Article	2024
C-01	Oreja-Guevara, C; Meca-Lallana, JE; Díaz-Díaz, J; Ara, JR; Pérez, MAH; Gil, JG; Torres, AMA; de la Fuente, BP; Ramió-Torrentà, L; Madueño, SE; Gascón-Giménez, F; Casanova, B; Martínez-Yélamos, S; Valcárcel, MA; Ginés, MLM; Montero, YE; Real, AML; González-Quintanilla, V; De Torres, L; Martínez-Rodríguez, JE; Costa-Frossard, L; Redondo, MG; Fontcuberta, AL; Castellanos-Pinedo, F; Merino, JAG; Fernández, CM; Castillo-Triviño, T; Meca-Lallana, V; Martinez, JP; Rodríguez-Antigüedad, A; González, JMP; Morales, EA; Molina, IP; Sánchez, DMS; Varo, NH; Sevilla, RR; Vicente, LG; Río, J	Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study	MULTIPLE SCLEROSIS AND RELATED DISORDERS	2.9	Q2	Article	2024
C-01	Meca-Lallana, JE; Yélamos, SM; Eichau, S; Llaneza, MA; Martínez, JM; Martínez, JP; Lallana, VM; Torres, AMA; Torres, EM; Río, J; Calles, C; Luque, AA; Ramió-Torrentà, L; Sola, MEM; Prieto, JM; Ginés, MLM; Arroyo, R; Martínez, MAO; Ruiz, LB; Gutiérrez, MG; Zarranz, ARA; Sánchez-Seco, VG; Costa-Frossard, L; Pérez, MAH; Pascual, LL; Platas, MG; Oreja-Guevara, C	Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023	NEUROLOGIA	2.9	Q2	Article	2024
C-01	Fuenmayor, SB; Castro, PJS; Subirana, PQ; Palmero, SL; Mullor, MMR; Carreño, TP	Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)	NEUROLOGIA	2.9	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-01	Sabin, J; Salas, E; Martín-Martínez, J; Candelieri-Merlicco, A; Barrero, FJ; Alonso, A; Sánchez-Menoyo, JL; Borrega, L; Rodríguez-Rodríguez, M; Gómez-Gutiérrez, M; Eichau, S; Hernández-Pérez, MA; Calles, C; Fernández-Díaz, E; Carmona, O; Orviz, A; López-Real, A; López-Muñoz, P; Mendonza, A; Agüera, E; Maurino, J	Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis	MULTIPLE SCLEROSIS AND RELATED DISORDERS	2.9	Q2	Article	2024
C-01	Cabezudo-García, P; Mena-Vázquez, N; Ciano-Petersen, NL; Oliver-Martos, B; Serrano-Castro, PJ	Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review	NEUROLOGIA	2.9	Q2	Review	2024
C-01	Campetella, L; Villagrán-García, M; Farina, A; Benaiteau, M; Iorio, R; Calabresi, P; Vogrig, A; Versace, S; Ciano-Petersen, NL; Brotelle, EB; Branger, P; Verlut, C; Langner-Lemercier, S; Leclancher, A; Duwicquet, C; Charif, M; Kerschen, P; Capet, N; Renard, D; Chanson, E; Rafiq, M; Tyvaert, L; Joubert, B; Cotton, F; Honnorat, J; Muñoz-Castrillo, S	Corticospinal tract hyperintensity in patients with LGI1-antibody encephalitis and other central nervous system disorders with neuroglial antibodies	JOURNAL OF NEUROIMMUNOLOGY	2.9	Q2	Article	2024
C-01	Aguirre, C; Alonso-Torres, A; Agüera, E; García-Domínguez, JM; Montero-Escribano, P; González-Quintanilla, V; Costa-Frossard, L; Oreja-Guevara, C; Reyes-Garrido, V; Caminero-Rodríguez, AB; Riancho, J; Sánchez, O; Forero, L; Pérez-Parra, F; Ares-Luque, A; Téllez, N; Arzalluz-Luque, J; Iglesias, F; Casado-Ruiz, V; Castellano-Vicente, AJ; Borrega, L; Galán, V; de Antonio, LAR; Romero, C; García-Rodríguez, R; Cano-Orgaz, AT; Sánchez-Menoyo, JL; Pérez-Ruiz, D; Gutiérrez-Martin, F; Hernández-Echevarría, L; Meca-Lallana, V	Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study	CLINICAL DRUG INVESTIGATION	2.9	Q2	Article	2024
C-01	Martínez-Marin, RJ; Reyes-Leiva, D; Nascimento, A; Muelas, N; Dominguez-González, C; Paradas, C; Olivé, M; García-Romero, M; Pascual-Pascual, SI; Grau, JM; Barba-Romero, MA; Gomez-Caravaca, MT; de las Heras, J; Casquero, P; Mendoza, MD; de León, JC; Gutierrez, A; Morís, G; Blanco-Lago, R; Ramos-Fransi, A; Pintós, G; García-Antelo, MJ; Rabasa, M; Morgado, Y; Usón, M; Miralles, FJ; Bárcena-Llona, JE; Gómez-Belda, AB; Pedraza-Hueso, MI; Hortelano, M; Colomé, A; Garcia-Martin, G; de Munain, AL; Jericó, I; Galán-Dávila, L; Pardo, J; Salgueiro-Origlia, G; Alonso-Pérez, J; Pla-Junca, F; Schiava, M; Segovia-Simón, S; Díaz-Manera, J	Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry	NEUROMUSCULAR DISORDERS	2.7	Q2	Article	2024
C-01	Fernández, OF; Costa-Frossard, L; Ginés, MLM; Escribano, PM; González, JMP; Ramió-Torrentà, L; Aladro, Y; Torres, AA; Rodríguez, EA; Labiano-Fontcuberta, A; Pascual, LL; Martínez, AM; Torres, EM; Oliva-Nacarino, P	Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis	FRONTIERS IN NEUROLOGY	2.7	Q2	Article	2024
C-01	Sabin, J; Salas, E; Martín-Martínez, J; Candelieri-Merlicco, A; Barrero, FJ; Alonso, A; Sánchez-Menoyo, JL; Borrega, L; Rodríguez-Rodríguez, M; Gómez-Gutiérrez, M; Eichau, S; Hernandez-Pérez, MA; Calles, C; Fernández-Díaz, E; Carmona, O; Orviz, A; López-Real, A; López-Muñoz, P; Mendoza, A; Agüera, E; Maurino, J; Ballesteros, J	Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale	MULTIPLE SCLEROSIS JOURNAL- EXPERIMENTAL TRANSLATIONAL AND CLINICAL	2.5	Q2	Article	2024
C-01	Sabin, J; Salas, E; Martín-Martínez, J; Candelieri-Merlicco, A; Hernández, FJB; Torres, AMA; Sánchez-Menoyo, JL; Borrega, L; Rodríguez-Rodríguez, M; Gómez-Gutiérrez, M; Eichau, S; Hernández-Pérez, MA; Calles, C; Fernandez-Diaz, E; Carmona, O; Orviz, A; López-Real, A; López-Muñoz, P; Rodríguez, AM; Aguera-Morales, E; Maurino, J	Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis	PATIENT PREFERENCE AND ADHERENCE	2.0	Q2	Article	2024
C-01	Santos-García, D; López-Manzanares, L; Muro, I; Lorenzo-Barreto, P; Peña, EC; García-Ramos, R; Valle, TF; Morata-Martínez, C; Baviera-Muñoz, R; Martínez-Torres, I; alvarez-Sauco, M; Alonso-Modino, D; Legarda, I; Valero-García, MF; Suárez-Muñoz, JA; Martínez-Castrillo, JC; Perona, AB; Salom, JM; Cubo, E; Valero-Merino, C; López-Ariztegui, N; Alonso, PS; Ponte, SN; Gónzález, EG; García, RM; Espinosa, R; Carmona, M; Feliz, CE; Ruiz, PG; Ruiz, TM; Rodríguez, BF; Alvarez-Santullano, MM	Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease	BRAIN SCIENCES	2.7	Q3	Article	2024
C-01	Casado-Ruiz, J; Ros, B; Iglesias, S; Ros, A; Arráez, M	Spinal cord lipomas: lessons learned in the era of total resection	CHILDS NERVOUS SYSTEM	1.3	Q3	Article	2024
C-01	Arenas-Cabrera, C; Cabezudo-García, P; Calvo-Medina, R; Galeano-Bilbao, B; Martínez-Agredano, P; Ruiz-Giménez, J; Rodríguez-Uranga, JJ; Quiroga-Subirana, P	Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol	REVISTA DE NEUROLOGIA	0.8	Q4	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-01	Fernández, O; Montalbán, X; Agüera, E; Aladro, Y; Alonso, A; Arroyo, R; Brieva, L; Calles, C; Costa-Frossard, L; Eichau, S; García-Domínguez, JM; Hernández, MA; Landete, L; Llaneza, M; Llufriu, S; Meca-Lallana, JE; Meca-Lallana, V; Moral, E; Prieto, JM; Ramió-Torrentà, L; Téllez, N; Romero-Pinel, L; Vilaseca, A; Rodríguez-Antigüedad, A	XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)	REVISTA DE NEUROLOGIA	0.8	Q4	Review	2024
C-01	Fernández, O; Montalbán, X; Agüera, E; Aladro, Y; Alonso, A; Arroyo, R; Brieva, L; Calles, C; Costa-Frossard, L; Eichau, S; García-Domínguez, JM; Hernández, MA; Landete, L; Llaneza, M; Llufriu, S; Meca-Lallana, JE; Meca-Lallana, V; Moral, E; Prieto, JM; Ramió-Torrentà, L; Téllez, N; Romero-Pinel, L; Vilaseca, A; Rodríguez-Antigüedad, A	XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)	REVISTA DE NEUROLOGIA	0.8	Q4	Review	2024
C-02	Bellón, JA	Exercise for the treatment of depression Even low intensity activities such as walking or yoga are beneficial	BMJ-BRITISH MEDICAL JOURNAL	94.0	D1	Editorial Material	2024
C-02	de la Torre, JA; Ronaldson, A; Vilagut, G; Martínez-Alés, G; Dregan, A; Bakolis, I; Valderas, JM; Molina, AJ; Martin, V; Bellón, JA; Alonso, J	Implementation of community screening strategies for depression	NATURE MEDICINE	59.0	D1	Editorial Material	2024
C-02	Taubner, S; Ioannou, Y; Saliba, A; Sales, CMD; Volkert, J; Protic, S; Adler, A; Barkauskiene, R; Conejo-Cerón, S; Di Giacomo, D; Mestre, JM; Moreno-Peral, P; Vieira, FM; Mota, CP; Henriques, MIRS; Rossberg, JI; Perdihi, TS; Schmidt, SJ; Zettl, M; Ulberg, R; Heinonen, E	Mediators of outcome in adolescent psychotherapy and their implications for theories and mechanisms of change: a systematic review	EUROPEAN CHILD & ADOLESCENT PSYCHIATRY	6.0	D1	Review	2024
C-02	Protic, S; Wittmann, L; Taubner, S; Conejo-Cerón, S; Ioannou, Y; Heinonen, E; Saliba, A; Moreno-Peral, P; Volkert, J; Barkauskiene, R; Schmidt, SJ; Henriques, MIRS; Mota, CP; Sales, CMD; Rossberg, JI; Adler, A; Di Giacomo, D; Vieira, FM; Drndarevic, N; Ulberg, R; Perdihi, TS; Mestre, JM	Mediators of Outcome in Trauma-Focused Psychotherapy with Youth: A Systematic Review	TRAUMA VIOLENCE & ABUSE	5.4	D1	Review	2024
C-02	Bellón, D; Rodriguez-Ayllon, M; Solis-Urra, P; Fernandez-Gamez, B; Olvera-Rojas, M; Coca-Pulido, A; Toval, A; Martín-Fuentes, I; Bakker, EA; Sclafani, A; Fernández-Ortega, J; Cabanas-Sánchez, V; Mora-Gonzalez, J; Gómez-Río, M; Lubans, DR; Ortega, FB; Esteban-Cornejo, I	Associations between muscular strength and mental health in cognitively normal older adults: a cross-sectional study from the AGUEDA trial	INTERNATIONAL JOURNAL OF CLINICAL AND HEALTH PSYCHOLOGY	5.3	D1	Article	2024
C-02	Gobbi, C; Sánchez-Marin, L; Flores-López, M; Medina-Vera, D; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-dependent effects of acute stress and alcohol exposure during adolescence on mRNA expression of brain signaling systems involved in reward and stress responses in young adult rats	BIOLOGY OF SEX DIFFERENCES	4.9	Q1	Article	2024
C-02	Rados, SN; Akik, BK; Zutic, M; Rodriguez-Muñoz, MF; Uriko, K; Motrico, E; Moreno-Peral, P; Apter, G; van den Berg, ML	Diagnosis of peripartum depression disorder: A state-of-the-art approach from the COST Action Riseup-PPD	COMPREHENSIVE PSYCHIATRY	4.3	Q1	Article	2024
C-02	Gómez-Gómez, I; Barquero-Jiménez, C; Johnson, E; Conejo-Cerón, S; Moreno-Peral, P; Bellón, JA; Motrico, E	Effectiveness of multiple health behavior change interventions in reducing symptoms of anxiety in the adult population: A systematic review and meta-analysis of randomized controlled trials	PREVENTIVE MEDICINE	4.3	Q1	Review	2024
C-02	de Fonseca, FR; Medina-Paz, F; Sapozhnikov, M; Hurtado-Guerrero, I; Rubio, L; Martín-de-las-Heras, S; Requena-Ocaña, N; Flores-Lopez, M; Fernández-Arjona, MD; Rivera, P; Serrano, A; Serrano, P; Zapico, SC; Suárez, J	Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study	TOXICS	3.9	Q1	Article	2024
C-02	Moreno-Peral, P; Conejo-Ceron, S; Wijnen, B; Lokkerbol, J; Fernandez, A; Smit, F; Bellon, JA	Health-Economic Evaluation of Psychological Interventions for Anxiety Prevention: A Systematic Review	PSYCHIATRIC SERVICES	3.3	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-02	Muñoz-Cobos, F; Aguiar-Leiva, VP; Argüello-Suárez, C; Colacicchi, P; Calleja-Cartón, LA; Leiva-Fernández, F	Validation of an Inhaled Therapy Beliefs Questionnaire in Patients with Chronic Obstructive Pulmonary Disease	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
C-02	Suárez, FJC; Cobos, FM; Ruiz, AG; Alcaraz, LFG	Alteration of the ankle brachial index, follow-up of patients at risk of peripheral arterial disease, a descriptive longitudinal study	CURRENT PROBLEMS IN CARDIOLOGY	3.0	Q2	Review	2024
C-02	Martínez-Vispo, C; García-Huércano, C; Conejo-Cerón, S; Rodríguez-Morejón, A; Moreno-Peral, P	Personalized online intervention based on a risk algorithm for the universal prevention of anxiety disorders: Design and development of the prevANS intervention	DIGITAL HEALTH	2.9	Q2	Article	2024
C-03	del Campo-avila, J; Ramos-Martín, J; Gómez-Sánchez-Lafuente, C; García-Pedrosa, J; García-Martín, S; Martínez-García, AI; Guzmán-Parra, J; Morales-Bueno, R; Moreno-Küstner, B	Data mining process to detect suicidal behaviour in out-of-hospital emergency departments	ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE	7.5	D1	Article	2024
C-03	Varela-Moreno, E; Anarte-Ortiz, MT; Jodar-Sanchez, F; Garcia-Palacios, A; Monreal-Bartolome, A; Gili, M; García-Campayo, J; Mayoral-Cleries, F	Economic Evaluation of a Web Application Implemented in Primary Care for the Treatment of Depression in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial	JMIR MHEALTH AND UHEALTH	5.4	D1	Article	2024
C-03	Ramos-Martín, J; Guzmán-Parra, J; Martínez-García, AI; Moreno-Küstner, B	Prevalence of suicidal behavior in patients seen by the prehospital emergency services of the Malaga Health District in Spain	EMERGENCIAS	5.4	D1	Editorial Material	2024
C-03	Ruiz-Sastre, P; Gómez-Sánchez-Lafuente, C; Martín-Martín, J; Herrera-Imbroda, J; Mayoral-Cleries, F; Santos-Amaya, I; de Fonseca, FR; Guzmán-Parra, J; Rivera, P; Suárez, J	Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	5.3	D1	Review	2024
C-03	García-Sastre, MM; Castro-Molina, FJ; Cabanillas, RC; Corrales, CS; Golmar, LJ; Román, JC; Serrano, CA	Psychotherapeutic nursing as Advanced Clinical Practice for the promotion of mental health in Spain	INTERNATIONAL NURSING REVIEW	3.8	D1	Article	2024
C-03	El-Abidi, K; Moreno-Poyato, AR; Cañabate-Ros, M; Garcia-Sanchez, JA; Lluch-Canut, MT; Muñoz-Ruoco, E; Pérez-Moreno, JJ; Pita-De-La-Vega, J; Puig-Llobet, M; Rubia-Ruiz, G; Santos-Pariente, C; López, AMR; Golmar, LJ; López, CE; Roldán-Merino, JF	The therapeutic relationship from the perspective of patients and nurses in the first days of admission: A cross-sectional study in acute mental health units	INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING	3.6	D1	Article	2024
C-03	Zanchetta, MS; Fredericks, S; Metersky, K; Martorella, G; Petrucka, P; Clune, L; Vedana, KGG; Baixinho, CRSL; Rocha, CMF; Campagna, S; He, SZ; Gouveia, MTD; Medeiros, M; Munari, DB; Albarracin, DGE; Aguilera-Serrano, C; Santos, WS	Scanning resources to build an international nursing knowledge network	INTERNATIONAL JOURNAL OF NURSING SCIENCES	2.9	D1	Article	2024
C-03	Barnestein-Fonseca, P; Guerrero-Pertiñez, G; Gúzman-Parra, J; Valera-Moreno, E; Mayoral-Cleries, F	Is it possible to diagnose therapeutic adherence in mild cognitive impairment and dementia patients in clinical practice?	FRONTIERS IN PHARMACOLOGY	4.4	Q1	Article	2024
C-03	Pousa, E; Brébion, G; López-Carrilero, R; Ruiz, AI; Grasa, E; Barajas, A; Cobo, J; Gutiérrez-Zotes, A; Lorente, E; Barrigón, ML; Ruiz-Delgado, I; González-Higueras, F; Frigola-Capell, E; Ochoa, S	Predictors of clinical insight in first-episode psychosis: Different patterns in men and women	PSYCHIATRY RESEARCH	4.2	Q1	Article	2024
C-03	Goodman-Casanova, JM; Guzman-Parra, J; Mayoral-Cleries, F; Cuesta-Lozano, D	Community-based art groups in mental health recovery: A systematic review and narrative synthesis	JOURNAL OF PSYCHIATRIC AND MENTAL HEALTH NURSING	2.6	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-03	Goodman-Casanova, JM; Coles, A; Cuesta-Lozano, D; Mayoral-Cleries, F	It's all about the journey! An online museum-based recovery-oriented art psychotherapy group	INTERNATIONAL JOURNAL OF ART THERAPY	2.3	Q1	Article	2024
C-03	Quemada-González, C; Becerra-Martos, EF; Blenkarn, M; Gutiérrez-Rodríguez, L; García-Mayor, S; Leán-Campos, A; Martí-García, C	Nursing students' experience of approaching risk for suicide behaviour through simulated environments: A content analysis study	ARCHIVES OF PSYCHIATRIC NURSING	2.2	Q1	Article	2024
C-03	Jimena, AV; Morales-Asencio, JM; Quemada, C; Hurtado, MM	Sustaining the burden. A qualitative study on the emotional impact and social functioning of family caregivers of patients with psychosis	ARCHIVES OF PSYCHIATRIC NURSING	2.2	Q1	Article	2024
C-03	Aleman-Navarro, M; Sánchez-Barbero, B; Reguera-Pozuelo, P; Altea-Manzano, L; Gómez-Garrido, A; Rocha-González, I; Garrido-Torres, N; Ruiz-Veguilla, M; García-Cerro, S; Rosso-Fernández, CM; Villagrán-Moreno, JM; Sarramea, F; Cervilla-Ballesteros, J; Martínez-Leal, R; Mayoral-Cleries, F; Crespo-Facorro, B	Efficacy of clozapine versus standard treatment in adult individuals with intellectual disability and treatment-resistant psychosis (CLOZAIID): study protocol of a multicenter randomized clinical trial	FRONTIERS IN PSYCHIATRY	3.2	Q2	Article	2024
C-03	Carbonell-Aranda, V; Herrera-Imbroda, J; Moreno-Kuestner, B; Guzman-Parra, J	Gender differences and risk of readmission in hospitalizations with a diagnosis of psychotic spectrum disorders	ARCHIVES OF WOMENS MENTAL HEALTH	3.2	Q2	Article	2024
C-03	Vila-Badia, R; Ochoa, S; Fábrega-Ruz, J; Gonzalez-Caballero, JL; Romero, C; Cid, J; Frigola-Capell, E; Salvador-Carulla, L; Moreno-Küstner, B	Sex differences in patient-reported outcome measure of psychotic symptoms in schizophrenia	ARCHIVES OF WOMENS MENTAL HEALTH	3.2	Q2	Article	2024
C-03	Espinosa, V; Naides, N; López-Carrilero, R; Vila-Badia, R; Colomer-Salvans, A; Barajas, A; Barrigón, ML; Birulés, I; Butjosa, A; Díaz-Cutraró, L; Del Cacho, N; Frigola-Capell, E; González-Higueras, F; Grasa, E; Gutiérrez-Zotes, A; Lorente-Rovira, E; Moreno-Kustner, B; Pélaez, T; Pousa, E; Ruiz-Delgado, I; Serra-Arumí, C; Verdaguer-Rodríguez, M; Usall, J; Ochoa, S	The influence of gender in cognitive insight and cognitive bias in people with first-episode psychosis: an uncontrolled exploratory analysis	ARCHIVES OF WOMENS MENTAL HEALTH	3.2	Q2	Article	2024
C-03	Ramírez-Martín, A; Sirignano, L; Streit, F; Foo, JC; Forstner, AJ; Frank, J; Nöthen, MM; Strohmaier, J; Witt, SH; Mayoral-Cleries, F; Moreno-Küstner, B; Rietschel, M; Guzmán-Parra, J	Impulsivity, decision-making, and risk behavior in bipolar disorder and major depression from bipolar multiplex families	BRAIN AND BEHAVIOR	2.6	Q2	Article	2024
C-03	Fernández-Martínez, S; Armas-Landaeta, C; Pérez-Aranda, A; Guzmán-Parra, J; Monreal-Bartolomé, A; Carbonell-Aranda, V; García-Campayo, J; López-del-Hoyo, Y	Post-COVID job Stressors and Their Predictive Role on Mental Health: A Cross-Sectional Analysis Between Physicians and Nurses	SAGE OPEN NURSING	2.0	Q2	Article	2024
C-03	Carbonel-Aranda, V; González, A; García-Illanes, Y; Traverso-Rodríguez, M; Bordallo-Aragón, A; Goodman-Casanova, JM; Guzman-Parra, J	Factors Associated with Hospital Readmission in a Population with a Diagnosis of Personality Disorder	ACTAS ESPANOLAS DE PSIQUIATRIA	1.0	Q4	Article	2024
C-05	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	Article	2024
C-05	Navarro-Lobato, I; Masmudi-Martín, M; López-Aranda, MF; López-Téllez, JF; Delgado, G; Granados-Durán, P; Gaona-Romero, C; Carretero-Rey, M; Posadas, S; Quiros-Ortega, ME; Khan, ZU	Promotion of structural plasticity in area V2 of visual cortex prevents against object recognition memory deficits in aging and Alzheimer's disease rodents	NEURAL REGENERATION RESEARCH	5.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-05	Masmudi-Martín, M; Navarro-Lobato, I; Lopez-Aranda, MF; Quiros-Ortega, ME; Carretero-Rey, M; Garcia-Garrido, MF; Téllez, JFL; Jiménez-Recuerda, I; López, CAMDL; Khan, ZU	Brain areas interconnected to ventral pathway circuits are independently able to induce enhancement in object recognition memory and cause reversal in object recognition memory deficit	CNS NEUROSCIENCE & THERAPEUTICS	4.8	Q1	Article	2024
C-05	López-Aranda, MF; Bach, K; Bui, R; Phan, M; Lu, ODL; Thadani, C; Luchetti, A; Mandanas, R; Herrera, I; López-avalos, MD; Silva, AJ	Early Post-Natal Immune Activation Leads to Object Memory Deficits in Female Tsc2+/- Mice: The Importance of Including Both Sexes in Neuroscience Research	BIOMEDICINES	3.9	Q1	Article	2024
C-05	Ibáñez-Botella, G; Narváez, IF; Pugliese, B; Ros, B; Arráez, MA	Endoscopic resection of third ventricle colloid cysts using an ultrasonic aspirator	NEUROSURGICAL REVIEW	2.5	Q1	Review	2024
C-05	Rodríguez-Pérez, LM; López-de-San-Sebastián, J; de Diego, I; Smith, A; Roales-Buján, R; Jiménez, AJ; Paez-Gonzalez, P	A selective defect in the glial wedge as part of the neuroepithelium disruption in hydrocephalus development in the mouse hyh model is associated with complete corpus callosum dysgenesis	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2	Article	2024
C-05	Hedrich, C; Patel, P; Haider, L; Taylor, T; Lau, E; Hook, R; Dorfer, C; Roessler, K; Stepien, N; Lippolis, MA; Schned, H; Koeller, C; Mayr, L; Azizi, AA; Peyrl, A; Lopez, BR; Lassaletta, A; Bennett, J; Gojo, J; Bartels, U	Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma	FRONTIERS IN ONCOLOGY	4.0	Q2	Article	2024
C-05	Masmudi-Martín, M; López-Aranda, MF; Navarro-Lobato, I; Khan, ZU	A role of frontal association cortex in long-term object recognition memory of objects with complex features in rats	EUROPEAN JOURNAL OF NEUROSCIENCE	2.7	Q3	Article	2024
C-05	López-Téllez, A; Torres, JMR; Vázquez, EP; Fernández, MAB; López-Martí, H; Martínez, IZ; Fernández, CT; Vargas, MF; Pinos, MDD; Morant, JFP; González-Fajardo, JA; Felices, PV	Ultrasound screening for abdominal aortic aneurysm in primary care	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
C-05	Massimi, L; Cinalli, G; Frassanito, P; Arcangeli, V; Auer, C; Baro, V; Bartoli, A; Bianchi, F; Dietvorst, S; Di Rocco, F; Gallo, P; Giordano, F; Hinojosa, J; Iglesias, S; Jecko, V; Kahilogullari, G; Knerlich-Lukoschus, F; Laera, R; Locatelli, D; Luglietto, D; Luzi, M; Messing-Juenger, M; Mura, R; Ragazzi, P; Riffaud, L; Roth, J; Sagarribay, A; Pinheiro, MS; Spazzapan, P; Spennato, P; Syrmos, N; Talamonti, G; Valentini, L; Van Veelen, ML; Zucchelli, M; Tamburrini, G	Intracranial complications of sinogenic and otogenic infections in children: an ESPN survey on their occurrence in the pre-COVID and post-COVID era	CHILDS NERVOUS SYSTEM	1.3	Q3	Article	2024
C-05	Casado-Ruiz, J; Ros, B; Iglesias, S; Ros, A; Arráez, M	Spinal cord lipomas: lessons learned in the era of total resection	CHILDS NERVOUS SYSTEM	1.3	Q3	Article	2024
C-05	Ramos-Fernández, JM; Cano-Martínez, M; Martínez-Leon, MI	Magnetic resonance images of onset and evolution of a child with a new genetic variant of evanescent leukodystrophy	REVISTA DE NEUROLOGIA	0.8	Q4	Editorial Material	2024
C-06	Cárdenas-Quesada, J; Mestre-Pintó, J; Maldonado, R; de Fonseca, FR; Torrens, M; Farré, M	Substance use disorders and cooperative research on addictions: Spanish approach as a model	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
C-06	del Campo-avila, J; Ramos-Martín, J; Gómez-Sánchez-Lafuente, C; García-Pedrosa, J; García-Martín, S; Martínez-García, AI; Guzmán-Parra, J; Morales-Bueno, R; Moreno-Küstner, B	Data mining process to detect suicidal behaviour in out-of-hospital emergency departments	ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE	7.5	D1	Article	2024
C-06	Aliaga-Gaspar, Pablo; Brichette-Mieg, Isabel; Fernandez-Arjona, MdM; Rodriguez-Bada, Jose Luis; Lopez-Moreno, Yolanda; Serrano-Castro, Pedro; Fernandez-Fernandez, Oscar; Ciano-Petersen, Nicolas Lundahl; Oliver-Martos, Begona	Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy.	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-06	Palma-Morales, M; Rangel-Huerta, OD; Díaz, C; Ortega, EC; Rodríguez-Pérez, C	Integration of network-based approaches for assessing variations in metabolic profiles of alkalized and non-alkalized commercial cocoa powders	FOOD CHEMISTRY-X	6.5	D1	Article	2024
C-06	Ruiz-Sastre, P; Gómez-Sánchez-Lafuente, C; Martín-Martín, J; Herrera-Imbroda, J; Mayoral-Cleries, F; Santos-Amaya, I; de Fonseca, FR; Guzmán-Parra, J; Rivera, P; Suárez, J	Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	5.3	D1	Review	2024
C-06	Comiskey, C; Bergeron, H; Clausen, T; Colman, C; Ferrer-Wreder, L; Fischer, G; de Matos, MG; Ivers, JH; Jauffret-Roustide, M; Liem, M; Lintonen, T; Moeller, K; Ojanperä, I; de Fonseca, FR; Mèlich, MT	The importance of co-produced, multi-method, independent scientific evidence in times of alternative truths and global policy debates	INTERNATIONAL JOURNAL OF DRUG POLICY	4.4	D1	Editorial Material	2024
C-06	Palma-Morales, M; Rune, CJB; Castilla-Ortega, E; Giacalone, D; Rodríguez-Pérez, C	Factors affecting consumer perception and acceptability of chocolate beverages	LWT-FOOD SCIENCE AND TECHNOLOGY	6.0	Q1	Article	2024
C-06	Medina-Vera, D; López-Gambero, A; Navarro, JA; Sanjuan, C; Baixeras, E; Decara, J; de Fonseca, FR	Novel insights into D-Pinitol based therapies: a link between tau hyperphosphorylation and insulin resistance	NEURAL REGENERATION RESEARCH	5.9	Q1	Review	2024
C-06	Melgar-Locatelli, S; Manas-Padilla, MC; Castro-Zavala, A; Rivera, P; Razola-Díaz, MD; Monje, FJ; Rodríguez-Pérez, C; Castilla-Ortega, E	Diet enriched with high-phenolic cocoa potentiates hippocampal brain-derived neurotrophic factor expression and neurogenesis in healthy adult micewith subtle effects on memory	FOOD & FUNCTION	5.1	Q1	Article	2024
C-06	Tovar, R; de Ceglia, M; Rodríguez-Pozo, M; Vargas, A; Gavito, A; Suárez, J; Boronat, A; de la Torre, R; de Fonseca, FR; Baixeras, E; Decara, J	Hydroxytyrosol Linoleoyl Ether Ameliorates Metabolic-Associated Fatty Liver Disease Symptoms in Obese Zucker Rats	ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE	5.1	Q1	Article	2024
C-06	Fernández-Arjona, MD; Navarro, JA; López-Gambero, AJ; de Ceglia, M; Rodríguez, M; Rubio, L; de Fonseca, FR; Barrios, V; Chowen, JA; Argente, J; Rivera, P; Suárez, J	Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments	BIOLOGY OF SEX DIFFERENCES	4.9	Q1	Article	2024
C-06	Gobbi, C; Sánchez-Marin, L; Flores-López, M; Medina-Vera, D; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-dependent effects of acute stress and alcohol exposure during adolescence on mRNA expression of brain signaling systems involved in reward and stress responses in young adult rats	BIOLOGY OF SEX DIFFERENCES	4.9	Q1	Article	2024
C-06	Suárez, J; de Ceglia, M; Rodríguez-Pozo, M; Vargas, A; Santos, I; Melgar-Locatelli, S; Castro-Zavala, A; Castilla-Ortega, E; de Fonseca, FR; Decara, J; Rivera, P	Inhibition of Adult Neurogenesis in Male Mice after Repeated Exposure to Paracetamol Overdose	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
C-06	González-Portilla, M; Montagud-Romero, S; Mellado, S; de Fonseca, FR; Pascual, M; Rodríguez-Arias, M	Region-Specific Gene Expression Changes Associated with Oleoylethanolamide-Induced Attenuation of Alcohol Self-Administration	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
C-06	Aguilar-Castillo, MJ; Cabezudo-Garcia, P; Garcia-Martin, G; Lopez-Moreno, Y; Estivill-Torrus, G; Ciano-Petersen, NL; Oliver-Martos, B; Narvaez-Pelaez, M; Serrano-Castro, PJ	A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
C-06	Serrano, M; Saumell-Esnaola, M; Ocerin, G; del Cano, GG; Puente, N; Sallés, J; de Fonseca, FR; Rodríguez-Arias, M; Gerrikagoitia, I; Grandes, P	Impact of Omega-3 on Endocannabinoid System Expression and Function, Enhancing Cognition and Behavior in Male Mice	NUTRIENTS	4.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-06	Medina-Vera, D; López-Gambero, AJ; Verheul-Campos, J; Navarro, JA; Morelli, L; Galeano, P; Suárez, J; Sanjuan, C; Pacheco-Sánchez, B; Rivera, P; Pavon-Morón, FJ; Rosell-Valle, C; Fonseca, FRD	Therapeutic Efficacy of the Inositol D-Pinitol as a Multi-Faceted Disease Modifier in the 5xFAD Humanized Mouse Model of Alzheimer’s Amyloidosis	NUTRIENTS	4.8	Q1	Article	2024
C-06	Gómez-Revuelta, M; Sánchez-Lafuente, C; Yáñez , J; Pindado, LM; Echevarria, LE; Meseguer, T; Ruiz, E; Bourgon, J; Simón, JA; Díaz, AI; Terán, JM	Long-term COVID-19 pandemic impact on suicide Thoughts and Behaviors (STB): An interrupted time series analysis in Spain 2-year after pandemic outbreak	PSYCHIATRY RESEARCH	4.2	Q1	Article	2024
C-06	de Fonseca, FR; Medina-Paz, F; Sapozhnikov, M; Hurtado-Guerrero, I; Rubio, L; Martín-de-las-Heras, S; Requena-Ocaña, N; Flores-Lopez, M; Fernández-Arjona, MD; Rivera, P; Serrano, A; Serrano, P; Zapico, SC; Suárez, J	Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study	TOXICS	3.9	Q1	Article	2024
C-06	Carbonell-Aranda, V; Herrera-Imbroda, J; Moreno-Kuestner, B; Guzman-Parra, J	Gender differences and risk of readmission in hospitalizations with a diagnosis of psychotic spectrum disorders	ARCHIVES OF WOMENS MENTAL HEALTH	3.2	Q2	Article	2024
C-06	Zuluaga, P; Fuster, D; Blanes, R; Hernandez-Rubio, A; Miquel, L; Torrens, M; Rubio, G; Bolao, F; Liangpunsakul, S; Abellí-Deulofeu, E; de Fonseca, FR; Muga, R	Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder	ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH	3.0	Q2	Article	2024
C-06	Melgar-Locatelli, S; Mañas-Padilla, MC; Gavito, AL; Rivera, P; Rodríguez-Pérez, C; Castilla-Ortega, E; Castro-Zavala, A	Sex-specific variations in spatial reference memory acquisition: Insights from a comprehensive behavioral test battery in C57BL/6JRj mice	BEHAVIOURAL BRAIN RESEARCH	2.6	Q2	Article	2024
C-06	Luque-Rojas, MJ; Palermo, S	Editorial: Reviews in neuropsychology	FRONTIERS IN PSYCHOLOGY	2.6	Q2	Editorial Material	2024
C-06	Torres-Galván, S; Flores-López, M; Ochoa, E; Requena-Ocana, N; Araos, P; Herrera-Imbroda, J; Muga, R; Serrano, A; de Fonseca, FR; Pavón-Morón, FJ; Haro, G; García-Marchena, N	Dysregulation of Plasma Growth Factors and Chemokines in Cocaine Use Disorder: Implications for Dual Diagnosis with Schizophrenia and Antisocial Personality Disorder in an Exploratory Study	NEUROPSYCHOBIOLOGY	2.3	Q2	Article	2024
C-06	de-la-Peña, C; Luque-Rojas, MJ; Chaves-Yuste, B	Perceptions on e-service-learning: active methodology to connect pre-service teachers and society	CULTURE AND EDUCATION	1.1	Q3	Article	2024
C-06	de-la-Peña, C; Chaves-Yuste, B; Luque-Rojas, MJ	Digital Reading Comprehension: Multimodal and Monomodal Inputs under Debate	READING PSYCHOLOGY	1.2	Q4	Article	2024
C-07	Baños, JE; Blanco-Reina, E; Bellido-Estévez, I; Bosch, F; Cabello, MR; Cambra-Badii, I; Cruz, JPD; D’Ocón, P; Ivorra, MD; Ferrándiz, M; Gonzalez-Correa, JA; Martin-Montanez, E; Martos, F; Pavia, J; Sanz, E	Beyond lectures and practical courses: Teaching pharmacology using imaginative pedagogical tools	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
C-07	Sendra-Portero, F; Lorenzo-Alvarez, R; Rudolphi-Solero, T; Ruiz-Gómez, MJ	The Second Life Metaverse and Its Usefulness in Medical Education After a Quarter of a Century	JOURNAL OF MEDICAL INTERNET RESEARCH	5.8	D1	Article	2024
C-07	Alcaraz, AB; Alegre, JC; Domínguez, SG; Castaño, PL; Rodríguez, PP; Hofheinz, SB; Roy, MAS; Pérez, EZ; Lorenzo, RF; Ferro, MM; Gómez, AM; Orea, MS; Oliva, MM; Rivas, SG; Montoto, NA; González, MJE; Osorio, EMPA; Muñoz, EC; Fernández, EL; Almendral, GL; Parra, MVU; Merino, AG; Martínez, AG; Cervera, DM; Pardo, LF; Piñero, JMG	Intention to use physical restraint in paediatric intensive care units and correlated variables: A multicentre and cross-sectional study	INTENSIVE AND CRITICAL CARE NURSING	4.9	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-07	Alcaraz, AB; Hofheinz, SB; Alegre, JC; Pinero, JMG; Dominguez, SG; Lorenzo, RF; Ferro, MM; Gómez, AM; Orea, MS; Castaño, PL; Roy, MAS; Pérez, EZ; Oliva, MM; Rivas, SG; Montoto, NA; González, MJE; Osorio, EMP; Muñoz, EC; Fernández, EL; Almendral, GL; Parra, MVU; Merino, AG; Martínez, AG; Cervera, DM; Pardo, LF; Lerma, AD; Rodríguez, PP	Prevalence of use of physical restraints in pediatric intensive care units and correlated variables: A Spanish multicenter study	INTENSIVE AND CRITICAL CARE NURSING	4.9	D1	Article	2024
C-07	Alcaraz, AB; Rodríguez, PP; Alegre, JC; Piñero, JMG; Hofheinz, SB; Domínguez, SG; Pérez, EZ; Castaño, PL; Roy, MAS; Oliva, MM; Rivas, SG; Montoto, NA; Gonzalez, MJE; Osorio, EMP; Munoz, EC; Fernández, EL; Almendral, GL; Merino, AG; Cervera, DM; Lorenzo, RF; Ferro, MM; Gómez, AM; Orea, MS; López, CE; Clavero, GV	Adaptation and validation of the Physical Restraint-Theory of Planned Behaviour Questionnaire to the paediatric context	NURSING IN CRITICAL CARE	3.0	D1	Article	2024
C-07	López-García, S; López-Merino, E; Fernández-Rodrigo, A; Zamorano-González, P; Gutiérrez-Eisman, S; Jiménez-Sánchez, R; Esteban, JA	PI3K couples long-term synaptic potentiation with cofilin recruitment and actin polymerization in dendritic spines via its regulatory subunit p85	CELLULAR AND MOLECULAR LIFE SCIENCES	6.2	Q1	Article	2024
C-07	Aguilar-Castillo, MJ; Cabezudo-Garcia, P; Garcia-Martin, G; Lopez-Moreno, Y; Estivill-Torru, G; Ciano-Petersen, NL; Oliver-Martos, B; Narvaez-Pelaez, M; Serrano-Castro, PJ	A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
C-07	Sánchez-Varo, R; López-Salas, A; Beltran-Casanueva, R; Díaz-Sánchez, E; Alvarez-Contino, JE; Barbancho-Fernández, MA; Serrano-Castro, P; Fuxe, K; Borroto-Escuela, DO; García-Casares, N; Narváez, M	Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions	BEHAVIORAL AND BRAIN FUNCTIONS	4.7	Q1	Article	2024
C-07	Borroto-Escuela, D; Serrano-Castro, P; Sánchez-Pérez, JA; Barbancho-Fernández, MA; Fuxe, K; Narváez, M	Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder	EXPERT OPINION ON THERAPEUTIC TARGETS	4.6	Q1	Article	2024
C-07	Arrabal-Gómez, C; Serrano-Castro, P; Sánchez-Pérez, JA; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, D; Narvaéz, M	Potential of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus	EXPERT OPINION ON THERAPEUTIC TARGETS	4.6	Q1	Article	2024
C-07	Beltran-casanueva, R; Hernández-García, A; Serrano-Castro, PJ; Sánchez-Pérez, JA; Barbancho-Fernández, MA; García-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Long-term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co-administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus	FASEB JOURNAL	4.4	Q1	Article	2024
C-07	Lopez-Diaz, A; Palermo-Zeballos, FJ; Gutierrez-Rojas, L; Alameda, L; Gotor-Sanchez-Luengo, F; Garrido-Torres, N; Metrailler, J; Alerci, L; Bonnarel, V; Cano-Dominguez, P; Avanesi-Molina, E; Soto-Ontoso, M; Torrecilla-Olavarrieta, R; Munoz-Manchado, LI; Torres-Hernandez, P; Gonzalez-Higuera, F; Prados-Ojeda, JL; Herrera-Cortes, M; Meca-Garcia, JM; Gordillo-Urbano, RM; Sanchez-Robles, C; Delgado-Duran, T; Soriano-Pena, MF; Golay, P; Conus, P; Crespo-Facorro, B; Ruiz-Veguilla, M	Proxy measures for the assessment of psychotic and affective symptoms in studies using electronic health records	BJPSYCH OPEN	3.9	Q1	Article	2024
C-07	Boraldi, F; Lofaro, FD; Bonacorsi, S; Mazzilli, A; Garcia-Fernandez, M; Quaglino, D	The Role of Fibroblasts in Skin Homeostasis and Repair	BIOMEDICINES	3.9	Q1	Review	2024
C-07	González-García, M; Carrillo-Franco, L; Morales-Luque, C; Dawid-Milner, MS; López-González, MV	Central Autonomic Mechanisms Involved in the Control of Laryngeal Activity and Vocalization	BIOLOGY-BASEL	3.6	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-07	Carrillo-Franco, L; González-García, M; Morales-Luque, C; Dawid-Milner, MS; López-González, MV	Hypothalamic Regulation of Cardiorespiratory Functions: Insights into the Dorsomedial and Perifornical Pathways	BIOLOGY-BASEL	3.6	Q1	Review	2024
C-07	Rocha, I; González-García, M; Carrillo-Franco, L; Dawid-Milner, MS; López-González, MV	Influence of Brainstem's Area A5 on Sympathetic Outflow and Cardiorespiratory Dynamics	BIOLOGY-BASEL	3.6	Q1	Review	2024
C-07	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-cosme, C; Lara, JP	Early Occupational Therapy Intervention Programme and Coping Strategies and Burden in Caregivers of People with Sub-Acute Stroke: A Randomised Controlled Trial	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Article	2024
C-07	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-Cosme, C; Lara, JP	Early Occupational Therapy Intervention post-stroke (EOTIPS): A randomized controlled trial	PLOS ONE	2.9	Q1	Article	2024
C-07	Arrabal-Gómez, C; Beltran-Casanueva, R; Hernández-García, A; Bayolo-Guanche, JV; Barbancho-Fernández, MA; Serrano-Castro, PJ; Narváez, M	Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats	CELLS	5.1	Q2	Article	2024
C-07	Beltran-Casanueva, R; Hernández-García, A; García, PD; Blanco-Reina, E; Serrano-Castro, P; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2	Article	2024
C-07	Ramos-Cazorla, P; Carazo-Barrios, L; Reyes-Bueno, JA; Sagües-Sesé, E; de Rojas-Leal, C; Barbancho, MA; Garzón-Maldonado, FJ; de la Cruz-cosme, C; García-Arnés, JA; García-Casares, N	Olfactory Dysfunction as a Biomarker for Early Diagnosis of Cognitive Impairment in Patients With Type 2 Diabetes: A Systematic Review	JOURNAL OF DIABETES RESEARCH	3.6	Q2	Review	2024
C-07	García-Alberca, JM; de la Guia, P; Gris, E; Mendoza, S; de la Rica, ML; López-Trigo, JA; López-Mongil, R; García-López, T; López-García, R; Del Rey, TR; Gay-Puente, J; García-Castro, J; Casales, F; Morato, X; Boada, M; González-Velasco, G; Marín-Carmona, JM; Páez, NI; León, M; Carrillejo, R; Rius, F; Barbancho, MA; Lara, JP; Blanco-Reina, E	Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
C-07	González-García, M; Carrillo-Franco, L; Morales-Luque, C; Ponce-Velasco, M; Gago, B; Dawid-Milner, MS; Lopez-González, MV	Uncovering the neural control of laryngeal activity and subglottic pressure in anaesthetized rats: insights from mesencephalic regions	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY	2.9	Q2	Article	2024
C-07	Julián-Jiménez, A; Alvarez, RL; Bueno, VG; Trujillo, MS; García, DE	Early source control of infection in patients seen in the emergency department: a systematic review	REVISTA ESPANOLA DE QUIMIOTERAPIA	1.9	Q3	Review	2024
C-08	Varela-Moreno, E; Anarte-Ortiz, MT; Jodar-Sanchez, F; Garcia-Palacios, A; Monreal-Bartolome, A; Gili, M; García-Campayo, J; Mayoral-Cleries, F	Economic Evaluation of a Web Application Implemented in Primary Care for the Treatment of Depression in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial	JMIR MHEALTH AND UHEALTH	5.4	D1	Article	2024
C-08	Biundo, E; Dronova, M; Chicoye, A; Cookson, R; Devlin, N; Doherty, TM; Garcia, S; Garcia-Ruiz, AJ; Garrison, LP; Nolan, T; Postma, M; Salisbury, D; Shah, HR; Sheikh, S; Smith, R; Toumi, M; Wasem, J; Beck, E	Capturing the Value of Vaccination within Health Technology Assessment and Health Economics-Practical Considerations for Expanding Valuation by Including Key Concepts	VACCINES	5.2	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-08	Antelo-Pais, P; Prieto-Díaz, MA; Micó-Pérez, RM; Pallarés-Carratalá, V; Velilla-Zancada, S; Polo-García, J; Barquilla-García, A; Ginel-Mendoza, L; Segura-Fragoso, A; Vitelli-Storelli, F; Martín-Sánchez, V; Hermida-Ameijerías, A; Cinza-Sanjurjo, S; Investigators IBERICAN Study; Spanish Soc Primary Care Phys SEMERGEN Fdn	Urate Levels as a Predictor of the Prevalence and Level of Cardiovascular Risk Factors: An Identificación de La PoBlación Espanola de Riesgo Cardiovascular y Renal Study	BIOMOLECULES	4.8	Q1	Article	2024
C-08	Moreno-Juste, A; Laguna-Berna, C; Poblador-Plou, B; Calderón-Larrañaga, A; Librero, J; Lozano-Hernández, C; Santos-Mejías, A; Castillo-Jimena, M; Gimeno-Miguel, A; Gimeno-Feliú, LA	Intersectional analysis of social determinants of health and their association with mortality in patients with multimorbidity	JOURNAL OF GLOBAL HEALTH	4.5	Q1	Article	2024
C-08	Hafez, G; Aarnio, E; Mucherino, S; Kamusheva, M; Qvarnström, M; Potocnjak, I; Treciokiene, I; Mihajlovic, J; Ekenberg, M; van Boven, JFM; Leiva-Fernández, F	Barriers and Unmet Educational Needs Regarding Implementation of Medication Adherence Management Across Europe: Insights from COST Action ENABLE	JOURNAL OF GENERAL INTERNAL MEDICINE	4.3	Q1	Article	2024
C-08	Muñoz-Cobos, F; Aguiar-Leiva, VP; Argüello-Suárez, C; Colacicchi, P; Calleja-Cartón, LA; Leiva-Fernández, F	Validation of an Inhaled Therapy Beliefs Questionnaire in Patients with Chronic Obstructive Pulmonary Disease	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
C-08	Ruiz-Baena, JM; Moreno-Juste, A; Poblador-Plou, B; Castillo-Jimena, M; Calderón-Larrañaga, A; Lozano-Hernández, C; Gimeno-Miguel, A; Gimeno-Feliú, LA	Influence of social determinants of health on quality of life in patients with multimorbidity and polypharmacy	PLOS ONE	2.9	Q1	Article	2024
C-08	García-Alberca, JM; de la Guía, P; Gris, E; Mendoza, S; de la Rica, ML; López-Trigo, JA; López-Mongil, R; García-López, T; López-García, R; Del Rey, TR; Gay-Puente, J; García-Castro, J; Casales, F; Morato, X; Boada, M; González-Velasco, G; Marín-Carmona, JM; Páez, NI; León, M; Carrillejo, R; Rius, F; Barbancho, MA; Lara, JP; Blanco-Reina, E	Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
C-08	Kamusheva, M; Aarnio, E; Qvarnström, M; Hafez, G; Mucherino, S; Potocnjak, I; Treciokiene, I; Mihajlovic, J; Ekenberg, M; van Boven, JFM; Leiva-Fernandez, F	Pan-European survey on medication adherence management by healthcare professionals	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY	3.1	Q2	Article	2024
C-08	Ruiz-Núñez, C; Rodríguez, JG; Ruiz, AJG; Moreno, SMG; Santos, MSC; Herrera-Peco, I	Can Generative AI Contribute to Health Literacy? A Study in the Field of Ophthalmology	MULTIMODAL TECHNOLOGIES AND INTERACTION	2.4	Q2	Article	2024
C-08	Corral-Perez, J; Casals, C; avila-Cabeza-de-Vaca, L; Gonzalez-Mariscal, A; Mier, A; Espinar-Toledo, M; Soler, NGA; Vazquez-Sanchez, MA	Associations Between Physical Activity and Inactivity Levels on Physical Function and Sleep Parameters of Older Adults With Frailty Phenotype	JOURNAL OF APPLIED GERONTOLOGY	2.2	Q2	Article	2024
C-08	Cinza-Sanjurjo, S; Prieto-Díaz, MA; Pallarés-Carratalá, V; Micó-Pérez, RM; Velilla-Zancada, S; Barquilla-García, A; Ginel-Mendoza, L; Segura-Fragoso, A; Martín-Sánchez, V; Polo-García, J	Characteristics of the phenotypes in prevalent and incident cases of heart failure in primary care: IBERICAN study	BMC PRIMARY CARE	2.0	Q2	Article	2024
C-08	Pozo, AH; Ortega, DT; Ruiz, AJG; Serrano, JE; Cobalea, ME; Soler, NGA	Approach to patients with diabetes and obesity in primary care	ATENCION PRIMARIA	1.8	Q2	Article	2024
C-08	Hosszú, D; Dima, AL; Fernández, FL; Schneider, MP; van Dijk, L; Tóth, K; Duman, M; Davis, W; Andriciu, C; Egan, R; Vrijens, B; Kardas, P; Bitterman, N; Mucalo, I; Ghiciu, CM; Agh, T	Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH	1.8	Q3	Article	2024
C-08	Romero-Secin, AA; Díez-Espino, J; Prieto-Díaz, MA; Pallares-Carratala, V; Barquilla-García, A; Micó-Pérez, RM; Polo-García, J; Velilla-Zancada, SM; Martín-Sanchez, V; Segura-Fragoso, A; Ginel-Mendoza, L; Arce-Vazquez, VM; Cinza-Sanjurjo, S	Prevalence, impact and management of hypertension-mediated organ damage in type 2 diabetes patients	MEDICINA DE FAMILIA-SEMERGEN	0.9	Q4	Article	2024
C-09	Mora-Romero, B; Capelo-Carrasco, N; Pérez-Moreno, JJ; Alvarez-Vergara, MI; Trujillo-Estrada, L; Romero-Molina, C; Martinez-Marquez, E; Morano-Catalan, N; Vizuite, M; Lopez-Barneo, J; Nieto-Gonzalez, JL; García-Junco-Clemente, P; Vitorica, J; Gutierrez, A; Macias, D; Rosales-Nieves, AE; Pascual, A	Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality	NATURE METABOLISM	19.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-09	Bettinetti-Luque, M; Trujillo-Estrada, L; Garcia-Fuentes, E; Andreo-Lopez, J; Sanchez-Varo, R; Garrido-Sánchez, L; Gómez-Mediavilla, A; López, MG; Garcia-Caballero, M; Gutierrez, A; Baglietto-Vargas, D	Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease	BRITISH JOURNAL OF PHARMACOLOGY	6.8	D1	Review	2024
C-09	Sánchez-Varo, R; López-Salas, A; Beltran-Casanueva, R; Díaz-Sánchez, E; Alvarez-Contino, JE; Barbancho-Fernández, MA; Serrano-Castro, P; Fuxe, K; Borroto-Escuela, DO; García-Casares, N; Narváez, M	Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions	BEHAVIORAL AND BRAIN FUNCTIONS	4.7	Q1	Article	2024
C-09	Baglietto-Vargas, D; Freude, KK; Garcia-Leon, JA	Animal and Cellular Models of Alzheimer's Disease	BIOMEDICINES	3.9	Q1	Article	2024
C-09	Noriega-Prieto, JA; Maglio, LE; Perez-Domper, P; Dávila, JC; Gutiérrez, A; Torres-Alemán, I; de Sevilla, DF	Bidirectional modulation of synaptic transmission by insulin-like growth factor-I	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2	Article	2024
C-09	García-Alberca, JM; de Rojas, I; Sanchez-Mejias, E; Garrido-Martín, D; Gonzalez-Palma, L; Jimenez, S; Pino-Angeles, A; Cruz-Gamero, JM; Mendoza, S; Alarcón-Martín, E; Muñoz-Castro, C; Real, LM; Tenao, JJ; Polvillo, R; Govantes, F; Lopez, A; Royo-Aguado, JL; Navarro, V; Gonzalez, I; Ruiz, M; Reyes-Engel, A; Gris, E; Bravo, MJ; Lopez-Gutierrez, L; Mejias-Ortega, M; De la Guía, P; de la Rica, ML; Ocejó, O; Torrecilla, J; Zafra, C; Nieto, MD; Urbano, C; Jiménez-Sánchez, R; Pareja, N; Luque, M; García-Peralta, M; Carrillejo, R; Furniet, MD; Rueda, L; Sánchez-Fernández, A; Mancilla, T; Peña, I; García-Casares, N; Moreno-Grau, S; Hernández, I; Montreal, L; Quintela, I; González-Pérez, A; Calero, M; Franco-Macías, E; Macías, J; Menéndez-González, M; Frank-García, A; Vilas, RH; Diez-Fairen, M; Lage, C; García-Madrona, S; García-González, P; Valero, S; Sotolongo-Grau, O; Pérez-Cordón, A; Rabano, A; Pastor, AA; Pastor, AB; Espinosa, A; Corma-Gómezn, A; Montes, AM; Sanabria, A; Rodríguez, CM; Buiza-Rueda, D; Rodríguez-Rodríguez, E; Ortega, G; Alvarez, I; Allende, IR; Pineda, JA; Rosende-Roca, M; Sánchez-Arjona, MB; Fernández-Fuertes, M; Alegret, M; Roberto, N; del Ser, T; García-Ribas, G; Sánchez-Juan, P; Pastor, P; Piñol-Ripoll, G; Bullido, MJ; Alvarez, V; Mir, P; Medina, M; Marquié, M; Sáez, ME; Carracedo, A; Laplana, M; Tomas-Gallardo, L; Orellana, A; Tarraga, L; Boada, M; Palazon, JF; Vitorica, J; Ruiz, A; Guigo, R; Gutierrez, A; Royo, JL	An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
C-11	Czub, M; Serrano-Ibáñez, ER; Piskorz, J; Esteve, R; Lydon, HK; López-Martínez, AE; Mullen, B; Ramírez-Maestre, C; Heary, C; O'Neill, C; Sainero, G; Escalera, JFR; Caes, L; Murcia, SM; McDarby, V; McGuire, BE	Virtual Reality Distraction for Needle-Related Pain and Distress in Children: A Multicenter Randomized Controlled Trial	CYBERPSYCHOLOGY BEHAVIOR AND SOCIAL NETWORKING	4.2	Q1	Article	2024
C-11	de la Vega, R; Sakulsriprasert, P; Miró, J; Jensen, MP	Optimizing Pain Intensity Assessment in Clinical Trials: How Many Ratings are Needed to Best Balance the Need for Validity and to Minimize Assessment Burden?	JOURNAL OF PAIN	4.0	Q1	Article	2024
C-11	Ramírez-Maestre, C; Barrado-Moreno, V; Esteve, R; Serrano-Ibáñez, ER; de la Vega, R; Ruiz-Párraga, GT; Fernández-Baena, M; Jensen, MP; López-Martínez, AE	Vulnerability Factors, Adjustment, and Opioid Misuse in Chronic Noncancer Pain Individuals	JOURNAL OF PAIN	4.0	Q1	Article	2024
C-11	Esteve, R; Barrado-Moreno, V; Ramírez-Maestre, C; Serrano-Ibáñez, ER; de la Vega, R; Ruiz-Parraga, GT; Sainero-Tirado, G; Baena, MF; Jensen, M; López-Martínez, AE	Psychological profiles and prescription opioid misuse, craving, and withdrawal in people with chronic pain	EUROPEAN JOURNAL OF PAIN	3.5	Q1	Article	2024
C-11	de la Vega, R; Bartels, SL; Wicksell, RW	Implementation frameworks guiding digital self-management intervention in chronic pain: A scoping review	EUROPEAN JOURNAL OF PAIN	3.5	Q1	Review	2024
C-11	Czub, M; Kowal, M; Zarazaga, RE; Serrano-Ibáñez, ER; Ruíz-Párraga, GT; Ramirez-Maestre, C; López-Martínez, AE; Paccione, C; Piskorz, J	A slow diaphragmatic breathing intervention for anxiety: How do respiration rate and inhalation/exhalation ratio influence self-reported anxiety?	STRESS AND HEALTH	3.1	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-11	Huerta, I; Cumsille, P; Vergés, A; Gómez-Pérez, L	Bidirectional Relationship Between Intraindividual Changes in Behavioral Activation and Intraindividual Changes in Postpartum Depressive Symptoms: A Random Intercept Cross-Lagged Panel Model	JOURNAL OF PSYCHOPATHOLOGY AND CLINICAL SCIENCE	3.1	Q1	Article	2024
C-11	Esteve, R; Serrano-Ibáñez, ER; Castillo-Real, S; Ramírez-Maestre, C; Lpóez-Martníez, AE	How do the activity patterns of people with chronic pain influence the empathic response of future health professionals: an experimental study	ADVANCES IN HEALTH SCIENCES EDUCATION	3.0	Q1	Article	2024
C-11	López-Martínez, AE; Esteve, R; Sainero-Tirado, G; Ramírez-Maestre, C; Serrano-Ibáñez, ER; de la Vega, R; Day, MA; Jensen, MP	Measuring Pain-related Behavioral Inhibition and Behavioral Activation System Responses	CLINICAL JOURNAL OF PAIN	2.6	Q2	Article	2024
C-11	Garrido-Bolton, J; Alcamí-Pertejo, M; de la Vega, R; Hernández-Oliveros, F; Pérez-Martínez, A; Bravo-Ortiz, MF; Fernández-Jiménez, E	Neuropsychological and biopsychosocial evolution, therapeutic adherence and unmet care needs during paediatric transplantation: study protocol of a mixed-methods design (observational cohort study and focus groups) -the TransplantKIDS mental health project	FRONTIERS IN PSYCHOLOGY	2.6	Q2	Article	2024
C-11	Serrano-Ibáñez, ER; Czub, M; Cordero, CO; López-Martínez, AE; Ramírez-Maestre, C; Piskorz, J; Zarazaga, RE	Effect of a controlled diaphragmatic breathing session on perceived pain and state anxiety in people with chronic pain	CURRENT PSYCHOLOGY	2.5	Q2	Article	2024
C-11	Flores-Torres, J; McRae, K; Campos-Arteaga, G; Gómez-Pérez, L	Enhancing cognitive control of our decisions: Making the most of humor during the IGT in females and males	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE	2.5	Q2	Article	2024
C-11	Hotz-Boendermaker, S; Tirez, J; Morf, R; Esteve, R	Translation, reliability, and validity of the German version of the Activity Patterns Scale (APS) in musculoskeletal pain: a methodological study	BMC MUSCULOSKELETAL DISORDERS	2.2	Q2	Article	2024
C-12	Dávila, G; Berthier, ML	Are pharmacotherapeutics effective for treating aphasia?	EXPERT REVIEW OF NEUROTHERAPEUTICS	3.4	Q2	Article	2024
C-12	Sala-Padro, J; de la Cruz-Puebla, M; Miró, J; Cucurell, D; López-Barroso, D; Vilà-Balló, A; Plans, G; Santurino, M; Falip, M; Rodríguez-Fornells, A; Camara, E	De novo depression following temporal lobe epilepsy surgery	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY	2.7	Q2	Article	2024
C-13	Cobo-Sánchez, JL; Blanco-Mavillard, I; Pelayo-Alonso, R; Mancebo-Salas, N; Fernández-Fernández, I; Larrañeta-Inda, I; Ulzurrun-García, A; Sánchez-Villar, I; González-García, F; Hernando-García, J; Sota, MJRD; Lopes, LMVB; Prieto-Rebollo, MD; Sesmero-Ramos, C; Jaume-Riutort, C; Casas-Cuesta, R; Alcántara-Crespo, M; de Pedro-Gómez, JE	Validation of a Clinical Scale for Early Detection of Infections at the Exit Site of Central Venous Catheters for Hemodialysis	KIDNEY INTERNATIONAL REPORTS	5.7	D1	Article	2024
C-13	Soria-Martínez, M; Navarro-Pérez, CF; Pérez-Ardanaz, B; Martí-García, C	Conceptual framework of mental health literacy: Results from a scoping review and a Delphi survey	INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING	3.6	D1	Review	2024
C-13	Morales-Puerto, M; Ruiz-Díaz, M; Garcia-Mayor, S; León-Campos, A; Morales-Asencio, JM; Canca-Sánchez, JC; Gavira-Guerra, S; Toledo-Fernandez, C; Aranda-Gallardo, M	Spanish transcultural adaptation of the 4AT score for the evaluation of delirium in the emergency department: a prospective diagnostic test accuracy study	BMC NURSING	3.1	D1	Article	2024
C-13	Zaforteza-Lallemand, C; Blanco-Mavillard, I; Pol-Castañeda, S; Villafáfila-Gomila, CJ; Ferrer-Cruz, F; Rodríguez-Calero, MA	Strategies for knowledge mobilization by advanced practice nurses in three hospitals in Spain: a qualitative study	BMC NURSING	3.1	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-13	Cervera-Garvi, P; Galan-Hurtado, MH; Ortega-Avila, AB; Marchena-Rodriguez, A; Lopezosa-Reca, E; Castillo-Dominguez, A; Diaz-Miguel, S	Measurement properties of the Foot Function Index (FFI) questionnaire: A systematic review	CLINICAL REHABILITATION	2.6	D1	Article	2024
C-13	Saucedo-Figueredo, MC; Morilla-Herrera, JC; Gálvez-González, M; Rivas-Ruiz, F; Nava-DelVal, A; San Alberto-GiralDOS, M; Hierrezuelo-Martín, MJ; Gómez-Borrego, AB; Kaknani-Uttumchandani, S; Morales-Asencio, JM	Anchor-Based and Distributional Responsiveness of the Spanish Version of the Edinburgh Feeding Evaluation in Dementia Scale in Older People with Dementia: A Longitudinal Study	NUTRIENTS	4.8	Q1	Article	2024
C-13	Chicharro-Luna, E; Gijón-Nogueron, G; Evans, AMF; Martínez-Nova, A	Evaluating sustainability awareness and practices in podiatry clinics in Spain: A path toward a healthy and sustainable future1,2,3	HEALTH POLICY AND TECHNOLOGY	3.4	Q1	Article	2024
C-13	Martinez-Sebastian, C; Gijon-Nogueron, G; Ramos-Petersen, L; Molina-Garcia, C; Sánchez-Gómez, R; Evans, AM	The resting calcaneal stance position (RCSP): an old dog, with new tricks	EUROPEAN JOURNAL OF PEDIATRICS	3.0	Q1	Article	2024
C-13	Cervera-Garvi, P; Galan-Hurtado, MH; Marchena-Rodriguez, A; Chicharro-Luna, E; Guerra-Marmolejo, C; Diaz-Miguel, S; Ortega-Avila, AB	Transcultural Adaptation and Validation of the Spanish Version of the Visual Analogue Scale for the Foot and Ankle (VASFA)	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
C-13	Alabau-Dasi, R; Dominguez-Maldonado, G; Ortega-Avila, AB; Gordillo-Fernandez, LM; Ortiz-Romero, M; Melchor-Rodriguez, JM; Gijon-Nogueron, G	Validation of Fixed Ultrasonography for Achilles Tendon Assessment: A Reliability Study	DIAGNOSTICS	3.0	Q1	Article	2024
C-13	Martinez-Rico, M; Gijon-Nogueron, G; Ortega-Avila, AB; Roche-Seruendo, LE; Climent-Pedrosa, A; Sanchis-Sales, E; Deschamps, K	The Direct Impact Effect of Different Foot Orthotic Designs on the Plantar Loading of Patients with Structural Hallux Limitus: A Quasi-Experimental Study	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
C-13	Banwell, G; Ramos-Petersen, L; Gatt, A; Gijon-Nogueron, G; Lopezosa-Reca, E	Assessments Associated with the Diagnostics and Non-Surgical Treatment of Posterior Tibialis Tendon Dysfunction: A Systematic Review	APPLIED SCIENCES-BASEL	2.5	Q1	Review	2024
C-13	Martínez-Sebastián, C; Gijon-Nogueron, G; Ramos-Petersen, L; Morales-Asencio, JM; Molina-García, C; Evans, AM	Development, validation, and psychometric analysis of Foot and Ankle Flexibility Index (FAFI)	JOURNAL OF TISSUE VIABILITY	2.4	Q1	Article	2024
C-13	-Luna, EC; Gracia-Vesga, MA; Ramos-Petersen, L; Gijón-Nogueron, G	Impact of foot functionality in patients with systemic sclerosis: Cross-sectional study	JOURNAL OF TISSUE VIABILITY	2.4	Q1	Article	2024
C-13	Gamez-Guijarro, M; Reinoso-Cobo, A; Gordillo-Fernandez, LM; Ortiz-Romero, M; Ortega-Avila, AB; Chicharro-Luna, E; Gijon-Nogueron, G; Lopezosa-Reca, E	Update of Modified Version of the Foot Function Index Tool Spanish Version (FFI-Sp), in Patients with Rheumatoid Arthritis: Cross Sectional Study	MEDICINA-LITHUANIA	2.4	Q1	Article	2024
C-13	Fernandez-Fernandez, I; Parra-García, G; Blanco-Mavillard, I; Carr, P; Santos-Costa, P; Rodríguez-Calero, MA	Vascular access specialist teams versus standard practice for catheter insertion and prevention of failure: a systematic review	BMJ OPEN	2.4	Q1	Article	2024
C-13	Matias-Soto, J; Pineda-Galan, C; Martin-Sanchez, AI; Gonzalez-Mesa, JM; Aguayo-Alves, A; Luque-Suarez, A	Unveiling relevant emotions, cognitions, and behaviours from the viewpoint of people with chronic low back pain: A qualitative study with patient involvement	MUSCULOSKELETAL SCIENCE AND PRACTICE	2.2	Q1	Article	2024
C-13	Quemada-González, C; Becerra-Martos, EF; Blenkarn, M; Gutiérrez-Rodríguez, L; García-Mayor, S; Leán-Campos, A; Martí-García, C	Nursing students’ experience of approaching risk for suicide behaviour through simulated environments: A content analysis study	ARCHIVES OF PSYCHIATRIC NURSING	2.2	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-13	Jimena, AV; Morales-Asencio, JM; Quemada, C; Hurtado, MM	Sustaining the burden. A qualitative study on the emotional impact and social functioning of family caregivers of patients with psychosis	ARCHIVES OF PSYCHIATRIC NURSING	2.2	Q1	Article	2024
C-13	Martinez-Rico, M; Gijon-Nogueron, G; Ortega-Avila, AB; Roche-Seruendo, LE; Climent-Pedrosa, A; Sanchis-Sales, E; Deschamps, K	Effect of Custom-Made Foot Orthotics on Multi-Segment Foot Kinematics and Kinetics in Individuals with Structural Hallux Limitus	SENSORS	3.4	Q2	Article	2024
C-13	Ramos-Petersen, L; Reinoso-Cobo, A; Ortega-Avila, AB; Garcia-Campos, J; Bernal, JA; Cantero-Tellez, R; Martin-Martin, JM; Caliz-Caliz, R; Tejero, S; Cano-Garcia, L; Gijon-Nogueron, G	A clinical practice guideline for the management of the foot and ankle in rheumatoid arthritis	RHEUMATOLOGY INTERNATIONAL	3.2	Q2	Review	2024
C-13	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Gijon-Noguerón, G; Navarro-Flores, E; González-Sánchez, M	Validity and reliability of the English version of the Diabetic Foot Self-Care Questionnaire: a cross-cultural adaptation	FRONTIERS IN PUBLIC HEALTH	3.0	Q2	Article	2024
C-13	Pedrero-Martin, Y; Falla, D; Rodriguez-Brazzarola, P; Torrontegui-Duarte, M; Fernandez-Sanchez, M; Jerez-Aragones, JM; Liew, BXW; Luque-Suarez, A	Prognostic Factors of Perceived Disability and Perceived Recovery After Whiplash	CLINICAL JOURNAL OF PAIN	2.6	Q2	Article	2024
C-13	Gamez-Guijarro, M; Reinoso-Cobo, A; Perez-Galan, MJ; Ortega-Avila, AB; Ramos-Petersen, L; Torrontegui-Duarte, M; Gijon-Nogueron, G; Lopezosa-Reca, E	Foot Anthropometry Measures in Relation to Treatment in Patients with Rheumatoid Arthritis: A Longitudinal Study	HEALTHCARE	2.4	Q2	Article	2024
C-13	Guerra-Marmolejo, C; Morante-García, W; Berthe-Kone, O; Chica-Pérez, A; Dobarrio-Sanz, I; Granero-Molina, J; Ortega-Avila, AB	Nursing Students’ Perceptions of Learning Through a Service Learning Programme with Older Adults Living in Poverty in a High-Income Country: A Descriptive Qualitative Study	HEALTHCARE	2.4	Q2	Article	2024
C-13	Canca-Sanchez, FJ; Morales-Asencio, JM; Ortega-Avila, AB; Gijon-Nogueron, G; Cervera-Garvi, P; Marchena-Rodriguez, A; Canca-Sanchez, JC	Predictive factors for foot pain in the adult population	BMC MUSCULOSKELETAL DISORDERS	2.2	Q2	Article	2024
C-13	Pérez-Ardanaz, B; Gutierrez-Rodríguez, L; Pelaez-Cantero, MJ; Morales-Asencio, JM; Gómez-González, A; García-Piñero, JM; Lupiáñez-Perez, I	Healthcare service use for children with chronic complex diseases: A longitudinal six-year follow-up study	JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES	2.1	Q2	Article	2024
C-13	Marchena-Rodriguez, A; Cabello-Manrique, D; Ortega-Avila, AB; Martinez-Rico, M; Cervera-Garvi, P; Gijon-Nogueron, G	Aetiology, epidemiology and treatment of musculoskeletal injuries in badminton players: a systematic review and meta-analysis	RESEARCH IN SPORTS MEDICINE	1.9	Q2	Review	2024
C-13	Cantero, MJP; Asencio, JMM; Plantagenet-Whyte, FP; Carmona, ML; Antonelli, MR; Bigatá, TG; Alba, RM	Sedation in pediatric palliative care: The role of pediatric palliative care teams	PALLIATIVE & SUPPORTIVE CARE	1.9	Q3	Article	2024
C-13	Cavaggion, C; Luque-Suarez, A; Voogt, L; Juul-Kristensen, B; Wollants, G; Beke, L; Fransen, E; Struyf, F	Exercise into Pain in Chronic Rotator Cuff-Related Shoulder Pain: A Randomized Controlled Trial with 6-Month Follow-Up	OPEN ACCESS JOURNAL OF SPORTS MEDICINE	1.3	Q3	Article	2024
C-16	Castellano-Castillo, D; Ramos-Molina, B; Frutos, MD; Arranz-Salas, I; Reyes-Engel, A; Queipo-Ortuño, MI; Cardona, F	RNA expression changes driven by altered epigenetics status related to NASH etiology	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
C-16	Ye, MJ; Palomares, AR; Iwarsson, E; Oberg, AS; Rodriguez-Wallberg, KA	Imprinting disorders in children conceived with assisted reproductive technology in Sweden	FERTILITY AND STERILITY	6.6	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-16	Peña-Montero, N; Linares-Pineda, TM; Fernández-Valero, A; Lima-Rubio, F; Fernández-Ramos, AM; Gutiérrez-Repiso, C; Suárez-Arana, M; Picón-César, MJ; Molina-Vega, M; Morcillo, S	Differences in DNA Methylation in Genes Involved in Vitamin D Metabolism Are Related to Insulin Requirement in Pregnant Women with Gestational Diabetes Mellitus	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
C-16	Díaz-Mohedo, E; Carrillo-León, AL; Calvache-Mateo, A; Ptak, M; Romero-Franco, N; Carlos-Fernández, J	App-Mohedo ® : A mobile app for the management of chronic pelvic pain. A design and development study	INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS	3.7	Q1	Article	2024
C-16	Agud, MF; González, MM; Rodríguez, SM; Arana, MS; Alonso, MB; Lopez, JJ; Arias, IN	Multidisciplinary Approach in the Diagnosis and Treatment of Twin Anemia Polycythemia Sequence in Monochorionic Twin Pregnancies: A case report.	LIFE-BASEL	3.2	Q1	Article	2024
C-16	Blanco-Díaz, M; Vielva-Gomez, A; Legasa-Susperregui, M; Perez-Dominguez, B; Medrano-Sánchez, EM; Díaz-Mohedo, E	Exploring Pelvic Symptom Dynamics in Relation to the Menstrual Cycle: Implications for Clinical Assessment and Management	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Article	2024
C-16	García-Morales, L; Contreras-Matos, FJ; Blanca-Pedregosa, A; Mellado-Castillero, A; Campos-Hernández, JP; Lara, MF; Puche-Sanz, I; Gómez-Gómez, E	Multi-Centre Study of Progression Factors and Intravesical Recurrence in Patients with Urothelial Carcinoma of the Upper Urinary Tract	DIAGNOSTICS	3.0	Q1	Article	2024
C-16	González-Cazorla, E; Brenes-Romero, AP; Sánchez-Gómez, MJ; Estévez-Ruiz, E; Díaz-Enjuto, A; Cantón-Cisneros, A; Lubián-López, D; Mozas-Moreno, J; González-Mesa, ES	Physical Activity in Work and Leisure Time during Pregnancy, and Its Influence on Maternal Health and Perinatal Outcomes	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
C-16	Medrano-Sanchez, EM; Pena-Cantonero, B; Candon-Ballester, P; Blanco-Díaz, M; Díaz-Mohedo, E	Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Review	2024
C-16	Méndez-Echevarria, A; Calle-Miguel, L; Miralbés, S; Barreiro-Pérez, S; Afonso-Rodriguez, O; Soler-Simón, JA; Espeleta-Fox, A; Jiménez-Jiménez, AB; Méndez-Sánchez, A; Rementeria-Radigales, JI; Guerrero-Del-Cueto, F; Laveglia, V; Ortiz-Valentin, I; Gomez-Mera, E; Fernández-Puentes, V; Rodriguez-Noriega-Bejar, L; Bustillo, M; Retuerta, A; Fernández-Cantalejo, J; Sanz-Rueda, L; Ibáñez, MM; Berzosa, A; Fernández-Ledesma, B; Alvaro, A; Santamaria-Barrena, T; Carazo-Gallego, B; Moraleda, C; Calvo, C	Increased Severity of Mycoplasma pneumoniae Infections in Spanish Children	PEDIATRIC INFECTIOUS DISEASE JOURNAL	2.9	Q1	Article	2024
C-16	Gómez-Castellano, M; Morente, LS; López-Zambrano, MA; de Miguel-Luken, V; Jiménez-López, JS	Temporary clamping of the uterine arteries versus coventional technique for the prevention of postpartum hemorrhage during cesarean section: a randomized controlled trial study	BMC PREGNANCY AND CHILDBIRTH	2.8	Q1	Article	2024
C-16	Matias-Soto, J; Pineda-Galan, C; Martin-Sanchez, AI; Gonzalez-Mesa, JM; Aguayo-Alves, A; Luque-Suarez, A	Unveiling relevant emotions, cognitions, and behaviours from the viewpoint of people with chronic low back pain: A qualitative study with patient involvement	MUSCULOSKELETAL SCIENCE AND PRACTICE	2.2	Q1	Article	2024
C-16	Frías, LC; Peralta, CTL; Oliva, NS; Arana, MS; Marín, CC; López, JSJ	Case Series of Listeria monocytogenes in Pregnancy: Maternal-Foetal Complications and Clinical Management in Six Cases	MICROORGANISMS	4.1	Q2	Article	2024
C-16	Hao, X; Palomares, AR; Anastácio, A; Liu, K; Rodriguez-Wallberg, KA	Evidence of apoptosis as an early event leading to cyclophosphamide-induced primordial follicle depletion in a prepubertal mouse model	FRONTIERS IN ENDOCRINOLOGY	3.9	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-16	García-Alberca, JM; de Rojas, I; Sanchez-Mejias, E; Garrido-Martín, D; Gonzalez-Palma, L; Jimenez, S; Pino-Angeles, A; Cruz-Gamero, JM; Mendoza, S; Alarcón-Martín, E; Muñoz-Castro, C; Real, LM; Tenao, JJ; Polvillo, R; Govantes, F; Lopez, A; Royo-Aguado, JL; Navarro, V; Gonzalez, I; Ruiz, M; Reyes-Engel, A; Gris, E; Bravo, MJ; Lopez-Gutierrez, L; Mejias-Ortega, M; De la Guía, P; de la Rica, ML; Ocejo, O; Torrecilla, J; Zafra, C; Nieto, MD; Urbano, C; Jiménez-Sánchez, R; Pareja, N; Luque, M; García-Peralta, M; Carrillejo, R; Furniet, MD; Rueda, L; Sánchez-Fernández, A; Mancilla, T; Peña, I; García-Casares, N; Moreno-Grau, S; Hernández, I; Montreal, L; Quintela, I; González-Pérez, A; Calero, M; Franco-Macías, E; Macías, J; Menéndez-González, M; Frank-García, A; Vilas, RH; Diez-Fairen, M; Lage, C; García-Madrona, S; García-González, P; Valero, S; Sotolongo-Grau, O; Pérez-Cordón, A; Rabano, A; Pastor, AA; Pastor, AB; Espinosa, A; Corma-Gómez, A; Montes, AM; Sanabria, A; Rodríguez, CM; Buiza-Rueda, D; Rodriguez-Rodriguez, E; Ortega, G; Alvarez, I; Allende, IR; Pineda, JA; Rosende-Roca, M; Sánchez-Arjona, MB; Fernández-Fuertes, M; Alegret, M; Roberto, N; del Ser, T; Garcia-Ribas, G; Sánchez-Juan, P; Pastor, P; Piñol-Ripoll, G; Bullido, MJ; Alvarez, V; Mir, P; Medina, M; Marquié, M; Sáez, ME; Carracedo, A; Laplana, M; Tomas-Gallardo, L; Orellana, A; Tarraga, L; Boada, M; Palazon, JF; Vitorica, J; Ruiz, A; Guigo, R; Gutierrez, A; Royo, JL	An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
C-16	Diaz-Mohedo, E; Hita-Contreras, F; Castro-Martin, E; Pilat, A; Perez-Dominguez, B; Valenza-Peña, G	Using Myofascial Therapy to Improve Psychological Outcomes, Quality of Life, and Sexual Function in Women with Chronic Pelvic Pain-A Case Series	HEALTHCARE	2.4	Q2	Article	2024
C-16	Valenza-Pena, G; Calvache-Mateo, A; Valenza, MC; Granados-Santiago, M; Raya-Benitez, J; Cabrera-Martos, I; Diaz-Mohedo, E	Effects of Telerehabilitation on Pain and Disability in Patients with Chronic Neck Pain: A Systematic Review and Meta-Analysis	HEALTHCARE	2.4	Q2	Review	2024
C-16	García-Mejido, JA; Martín-Martinez, A; García-Jimenez, R; González-Díaz, E; Núñez-Matas, MJ; Fernández-Palacín, F; Carballo-Rastrilla, S; Fernández-Fernández, C; Sainz-Bueno, JA	Is the Presence of Levator Ani Muscle Avulsion Relevant for the Diagnosis of Uterine Prolapse?	JOURNAL OF ULTRASOUND IN MEDICINE	2.1	Q2	Article	2024
C-16	González-Mesa, E; González-Cazorla, A; González-Cazorla, E; Mozas-Moreno, J; Isbir, GG; Abreu, W; Lubián-López, D	Contribution of the abbreviated CAVE-st questionnaire in Spanish: the attitudes toward childbirth experiences	JOURNAL OF PSYCHOSOMATIC OBSTETRICS & GYNECOLOGY	2.1	Q2	Article	2024
CA-10	Cobos, PL; Quintero, MJ; Lopez, FJ; Luque, D; Ciria, LF; Moris, J	Intolerance of uncertainty does not significantly predict decisions about delayed, probabilistic rewards: A failure to replicate Luhmann, C. C., Ishida, K., & Hajcak, G. (2011)	PLOS ONE	2.9	Q1	Article	2024
CA-10	Quintero, MJ; López, FJ; Vadillo, MA; Moris, J	Occasional Reinforced Extinction as a Method for Relapse Prevention: A Critical Systematic Review and Future Directions	COGNITIVE THERAPY AND RESEARCH	2.9	Q1	Article	2024
CA-10	Balea, P; Molinero, S; Vadillo, MA; Luque, D	The Role of Selection History in the Learned Predictiveness Effect	JOURNAL OF EXPERIMENTAL PSYCHOLOGY-HUMAN PERCEPTION AND PERFORMANCE	2.1	Q2	Article	2024
CA-10	Beesley, T; Earl, L; Butler, H; Sharp, I; Jaceviciute, I; Luque, D	Contextual cuing survives an interruption from an endogenous cue for attention	ATTENTION PERCEPTION & PSYCHOPHYSICS	1.7	Q3	Article	2024
CA-10	Quintero, MJ; Moris, J; López, FJ	Evaluating the effects of counterconditioning, novelty-facilitated, and standard extinction on the spontaneous recovery of threat expectancy and conditioned stimulus valence	QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY	1.5	Q3	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CE-17	Maroto-García, J; Mañez, M; Martínez-Escribano, A; Hachmaoui-Ridaoui, A; Ortiz, C; Abalos-García, C; Gónzález, I; de la Torre, AG; Ruiz-Galdón, M	A sex-dependent algorithm including kappa free light chain for multiple sclerosis diagnosis	SCANDINAVIAN JOURNAL OF IMMUNOLOGY	4.1	Q2	Article	2024
CE-18	Ruiz-Sastre, P; Gómez-Sánchez-Lafuente, C; Martín-Martín, J; Herrera-Imbroda, J; Mayoral-Cleries, F; Santos-Amaya, I; de Fonseca, FR; Guzmán-Parra, J; Rivera, P; Suárez, J	Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	5.3	D1	Review	2024
CE-18	Fernández-Arjona, MD; Navarro, JA; López-Gambero, AJ; de Ceglia, M; Rodríguez, M; Rubio, L; de Fonseca, FR; Barrios, V; Chowen, JA; Argente, J; Rivera, P; Suárez, J	Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments	BIOLOGY OF SEX DIFFERENCES	4.9	Q1	Article	2024
CE-18	Suárez, J; de Ceglia, M; Rodríguez-Pozo, M; Vargas, A; Santos, I; Melgar-Locatelli, S; Castro-Zavala, A; Castilla-Ortega, E; de Fonseca, FR; Decara, J; Rivera, P	Inhibition of Adult Neurogenesis in Male Mice after Repeated Exposure to Paracetamol Overdose	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
CE-18	de Fonseca, FR; Medina-Paz, F; Sapozhnikov, M; Hurtado-Guerrero, I; Rubio, L; Martín-de-las-Heras, S; Requena-Ocaña, N; Flores-Lopez, M; Fernández-Arjona, MD; Rivera, P; Serrano, A; Serrano, P; Zapico, SC; Suárez, J	Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study	TOXICS	3.9	Q1	Article	2024
CE-18	Gutiérrez-Sánchez, D; López-Leiva, I; Martin-de-las-Heras, S; Rubio, L; Martín-Martín, J	Validation of the Collett-Lester fear of death scale in occupational therapy students: psychometric testing and implications for palliative care education	BMC PALLIATIVE CARE	2.5	Q2	Article	2024
CE-18	Andreasen, K; Lopez, RF; Wu, CS; Linde, DS; Oviedo-Gutierrez, A; Martin-de-las-Heras, S; Zapata-Calvente, AL; Ankerstjerne, L; de-Leon-de-Leon, S; Dokkedahl, S; Schei, B; Rasch, V	The effect of a digital intervention on symptoms of depression in pregnant women exposed to Intimate partner violence in Denmark and Spain (STOP study)	EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY	2.1	Q2	Article	2024
CE-18	Ramos-Cozar, SN; Martín-Masot, R; Rodríguez-Gallego, B; Rubio, L; Cabanillas-Moruno, JL; Navas-López, VM	Assessment of the length of sick leave in patients with inflammatory bowel disease	GASTROENTEROLOGIA Y HEPATOLOGIA	2.2	Q3	Article	2024
CE-20	Schiano-Lomoriello, D; Abicca, I; Contento, L; Gabrielli, F; Alfonsi, C; Di Pietro, F; Papa, FT; Ballesteros-Sánchez, A; Sánchez-González, JM; Rocha-De-Lossada, C; Mazzotta, C; Giannaccare, G; Bonzano, C; Borroni, D	Infectious Keratitis: Characterization of Microbial Diversity through Species Richness and Shannon Diversity Index	BIOMOLECULES	4.8	Q1	Article	2024
CE-20	Francisco, ZM; Sara, MM; José-María, SG; Facundo, U; Carlos, RD; María, GL; Jessica, M; Carmen, AL; Santiago, OP; Carlos, SEJ	Standardized clinical evaluation of dry anophthalmic socket syndrome in a real-world approach	CONTACT LENS & ANTERIOR EYE	4.1	Q1	Article	2024
CE-20	Romano, V; Ferrara, M; Gatti, F; Airaldi, M; Borroni, D; Aragona, E; Rocha-de-lossada, C; Gabrielli, F; Papa, FT; Romano, MR; Calza, S; Semeraro, F	Topical Antiseptics in Minimizing Ocular Surface Bacterial Load Before Ophthalmic Surgery: A Randomized Controlled Trial	AMERICAN JOURNAL OF OPHTHALMOLOGY	4.1	Q1	Article	2024
CE-20	Ballesteros-Sánchez, A; Borroni, D; De-Hita-Cantalejo, C; Sánchez-González, MC; Sanchez-Gomez, S; Rocha-de-Lossada, C; Sánchez-González, JM	Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review	CONTACT LENS & ANTERIOR EYE	4.1	Q1	Review	2024
CE-20	Ballesteros-Sánchez, A; Sánchez-González, JM; Sánchez-González, MC; Rocha-de-Lossada, C; Gargallo-Martínez, B	Efficacy of meibomian gland expression combined with Home-Based therapy in the management of dry eye Disease: A systematic review and Meta-Analysis	CONTACT LENS & ANTERIOR EYE	4.1	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CE-20	Ballesteros-Sánchez, A; Sánchez-González, JM; Tedesco, GR; Rocha-de-Lossada, C; Murano, G; Spinelli, A; Mazzotta, C; Borroni, D	Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
CE-20	Romano, V; Passaro, ML; Bachmann, B; Baydoun, L; Dhubhghaill, SN; Dickman, M; Levis, HJ; Parekh, M; Rodriguez-Calvo-De-Mora, M; Costagliola, C; Virgili, G; Semeraro, F	Combined or sequential DMEK in cases of cataract and Fuchs endothelial corneal dystrophy-A systematic review and meta-analysis	ACTA OPHTHALMOLOGICA	3.0	Q1	Review	2024
CE-20	Fernández, J; Ribeiro, F; Rocha-de-Lossada, C; Rodríguez-Vallejo, M	Functional Classification of Intraocular Lenses Based on Defocus Curves: A Scoping Review and Cluster Analysis	JOURNAL OF REFRACTIVE SURGERY	2.9	Q1	Review	2024
CE-20	Zamorano-Martín, F; Chumaceiro, G; Navarro-Torres, P; Borroni, D; Urbinati, F; Molina, A; Paytuví-Gallart, A; Rocha-de-Lossada, C	A Comparative Analysis of the Ocular Microbiome: Insights into Healthy Eyes and Anophthalmic Sockets	MICROORGANISMS	4.1	Q2	Article	2024
CE-20	Ballesteros-Sánchez, A; Sánchez-González, JM; Tedesco, GR; Rocha-De-Lossada, C; Russo, F; Spinelli, A; Ingrande, I; Borroni, D	Efficacy and Safety of Quantum Molecular Resonance Electrotherapy in Patients with Aqueous-Deficient, Evaporative and Mixed-Type Dry Eye: A Randomized Interventional Study	OPHTHALMOLOGY AND THERAPY	2.6	Q2	Article	2024
CE-20	Pac, CP; Munteanu, M; Sánchez-González, JM; Rocha-de-Lossada, C; Mercea, N; Ferrari, F; Stanca, HT; Cosnita, DAR; Ionica, M; Boruga, O; Danieleescu, C; Blidisel, A	Long-Term Impacts of Intense Pulsed Light Therapy on Ocular Surface Health and Tear Film Dynamics in Patients with Dry Eye Disease: Detailed Analysis and Observations Over a 1-Year Follow-Up Period	OPHTHALMOLOGY AND THERAPY	2.6	Q2	Article	2024
CE-20	Ballesteros-Sánchez, A; Sánchez-González, JM; Borrone, MA; Borroni, D; Rocha-de-Lossada, C	The Influence of Lid-Parallel Conjunctival Folds and Conjunctivochalasis on Dry Eye Symptoms with and Without Contact Lens Wear: A Review of the Literature	OPHTHALMOLOGY AND THERAPY	2.6	Q2	Review	2024
CE-20	Pac, CP; Sánchez-González, JM; Rocha-de-Lossada, C; Mercea, N; Ferrari, F; Preda, MA; Rosca, C; Munteanu, M	Intense Pulsed Light Therapy for Dry Eye Disease: Analyzing Temporal Changes in Tear Film Stability and Ocular Surface between IPL Sessions	HEALTHCARE	2.4	Q2	Article	2024
CE-20	Fernández, J; Burguera, N; Rocha-de-Lossada, C; Zamorano-Martín, F; Rodríguez-Vallejo, M	Screening of positive dysphotopsia before multifocal intraocular lens implantation	INDIAN JOURNAL OF OPHTHALMOLOGY	2.1	Q2	Article	2024
CE-20	Albertazzi, R; Rocha-de-Lossada, C; Zaldivar, R	A new technique to implant intracorneal ring-segments from the perilimbal region: one-year prospective pilot study report	BMC OPHTHALMOLOGY	1.7	Q3	Article	2024
CE-20	Alba-Linero, C; Garcia-Lorente, M; Rachwani-Anil, R; Luque-Aranda, G; Pérez-Cabeza, MI; Escudero, J	Treatment of orbital lymphatic malformation with oral sirolimus: a case report Malformação linfática orbital tratada com sirolimo oral: relato de caso	ARQUIVOS BRASILEIROS DE OFTALMOLOGIA	1.1	Q3	Article	2024
CE-21	Corral-Pérez, J; Avila-Cabeza-de-Vaca, L; Valero-Cantero, I; González-Mariscal, A; Ponce-Gonzalez, JG; Vázquez-Sánchez, MA; Casals, C	Predictors of Urinary and Fecal Incontinence in Prefrail and Frail Older Adults: A Cross-Sectional Study of the FRAGSALUD Project	JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES	4.3	Q1	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CE-21	Corral-Pérez, J; Vázquez-Sánchez, MA; Casals-Sánchez, JL; Contreras-García, FJ; Costilla, M; Casals, C	A 6-month educational program improves sleep behaviour in community-dwelling frail older adults: A randomised controlled trial	SLEEP MEDICINE	3.8	Q1	Article	2024
CE-21	Casals, C; Corral-Pérez, J; Avila-Cabeza-de-Vaca, L; González-Mariscal, A; Carrión-Velasco, Y; Rodríguez-Martínez, MC; Jiménez-Cebrián, AM; Vázquez-Sánchez, MA	Exploring the interplay of frailty, physical function, physical activity, nutritional status, and their association with quality of life and depressive symptoms in older adults with the frailty phenotype	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	3.6	Q1	Article	2024
CE-21	Valero-Cantero, I; Vázquez-Sánchez, MA; Casals-Sánchez, JL; Espinar-Toledo, M; Corral-Pérez, J; Casals, C	Complementary Musical Intervention for Patients in Palliative Care in Spain: A Randomized Controlled Trial	HEALTHCARE	2.4	Q2	Article	2024
CE-21	Corral-Perez, J; Casals, C; avila-Cabeza-de-Vaca, L; Gonzalez-Mariscal, A; Mier, A; Espinar-Toledo, M; Soler, NGA; Vazquez-Sanchez, MA	Associations Between Physical Activity and Inactivity Levels on Physical Function and Sleep Parameters of Older Adults With Frailty Phenotype	JOURNAL OF APPLIED GERONTOLOGY	2.2	Q2	Article	2024
D-01	Gasca-Capote, C; Lian, XD; Gao, C; Roseto, IC; Jiménez-Léon, MR; Gladkov, G; Camacho-Sojo, MI; Perez-Gomez, A; Gallego, I; Lopez-Cortes, LE; Bachiller, S; Vitalle, J; Benhnia, MRE; Ostos, FJ; Collado-Romacho, AR; Santos, J; Palacios, R; Gomez-Ayerbe, C; Munoz-Medina, L; Ruiz-Sancho, A; Frias, M; Rivero-Juarez, A; Roca-Oporto, C; Hidalgo-Tenorio, C; Rull, A; Olalla, J; Lopez-Ruz, MA; Vidal, F; Vilades, C; Mastrangelo, A; Cavassini, M; Espinosa, N; Perreau, M; Peraire, J; Rivero, A; López-Cortes, LF; Lichterfeld, M; Yu, XG; Ruiz-Mateos, E	The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers	JOURNAL OF CLINICAL INVESTIGATION	13.0	D1	Article	2024
D-01	Corma-Gómez, A; Cabello, A; Orviz, E; Morante-Ruiz, M; Ayerdi, O; Al-Hayani, A; Muñoz-Gómez, A; De Los Santos, I; Gómez-Ayerbe, C; Rodrigo, D; Riestra, SDR; Reus-Bañuls, S; Silva-Klug, A; Galindo, MJ; Santos, M; Serrano-Fuentes, M; Faro-Míguez, N; Pérez-Camacho, I; Corona-Mata, D; Morano, L; López-Ruz, MA; Montero, M; Anaya-Baz, B; Merino, D; Castillo-Navarro, A; Pineda, JA; Macías, J	Long or complicated mpox in patients with uncontrolled HIV infection	JOURNAL OF MEDICAL VIROLOGY	6.8	D1	Article	2024
D-01	Caballero-Gómez, J; Pereira, S; Rivero-Calle, I; Perez, AB; Viciana, I; Casares-Jiménez, M; Rios-Muñoz, L; Rivero-Juarez, A; Aguilera, A; Rivero, A	Acute Hepatitis in Children Due to Rat Hepatitis E Virus	JOURNAL OF PEDIATRICS	3.9	D1	Article	2024
D-01	Gavilán, P; Gavilán, JC; Arnedo, R; Clavijo, E; Viciana, I; González-Correa, JA	Prediction model of hepatocellular carcinoma development in chronic hepatitis B virus infection in a Spanish cohort	CLINICAL MEDICINE	2.6	Q1	Article	2024
D-01	Calderon-Parra, Jorge; Dominguez, Fernando; Gonzalez-Rico, Claudia; Arnaiz de Las Revillas, Francisco; Goenaga, Miguel Angel; Alvarez, I; Munoz, Patricia; Alonso, David; Rodriguez-Garcia, Raquel; Miro, Jose Maria; De Alarcon, Aristides; Antorrena, Isabel; Goikoetxea-Agirre, Josune; Moral-Escudero, Encarnacion; Ojeda-Burgos, Guillermo; Ramos-Martinez, Antonio	Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort.	Open forum infectious diseases	3.8	Q2	Article	2024
D-01	Sequera-Arquelladas, S; Hidalgo-Tenorio, C; Lopez-Cortés, L; Gutiérrez, A; Santos, J; Téllez, F; Omar, M; Ferra-Murcia, S; Fernández, E; Javier, R; García-Vallecillos, C; Pasquau, J	DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain	VIRUSES-BASEL	3.8	Q2	Article	2024
D-01	Gomez Ayerbe, Cristina	Acute and recent hepatitis C virus (HCV) infections in men having sex with men (MSM): Is the test&treat strategy fundamental to reduce the incidence in this population?	Enfermedades infecciosas y microbiologia clinica	2.6	Q3	Editorial Material	2024
D-01	Balderas Fernandez, Lourdes; Garcia Collado, Yolanda; Prolo Acosta, Andrea	Elizabethkingia anophelis bacteraemia in a patient with pneumonia.	Enfermedades infecciosas y microbiologia clinica	2.6	Q3	Editorial Material	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-03	Hernández-Cruz, B; Otero-Varela, L; Freire-González, M; Busquets-Pérez, N; González, AJG; Moreno-Ramos, M; Blanco-Madrigal, JM; Manrique-Arija, S; Perez-Pampin, E; Ruiz-Montesino, D; Sánchez-Alonso, F; Sanchez-Piedra, C; Castrejón, I	Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry	ANNALS OF THE RHEUMATIC DISEASES	20.0	D1	Article	2024
D-03	Aterido, A; López-Lasanta, M; Blanco, F; Juan-Mas, A; García-Vivar, ML; Erra, A; Pérez-García, C; Sánchez-Fernández, SA; Sanmarti, R; Fernández-Nebro, A; Alperi-López, M; Tornero, J; Ortiz, AM; Fernández-Cid, CM; Palau, N; Pan, WJ; Byrne-Steele, M; Starenki, D; Weber, D; Rodriguez-Nunez, I; Han, J; Myers, RM; Marsal, S; Julia, A	Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes	GENOME BIOLOGY	10.0	D1	Article	2024
D-03	Muñoz-Barrera, L; Perez-Sanchez, C; Ortega-Castro, R; Corrales, S; Luque-Tevar, M; Cerdó, T; Sanchez-Pareja, I; Font, P; Lopez-Mejías, R; Calvo, J; Abalos-Aguilera, MC; Ruiz-Vilchez, D; Seguí, P; Merlo, C; Perez-Venegas, J; Montesino, MDR; Rodriguez-Escalera, C; Barco, CR; Fernandez-Nebro, A; Vazque, NM; Marenco, JL; Montañes, JU; Godoy-Navarrete, J; Cabezas-Lucena, AM; Estevez, EC; Aguirre, MA; González-Gay, MA; Barbarroja, N; Escudero-Contreras, A; Lopez-Pedra, C	Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
D-03	Martínez-Montoro, JI; Martín-Núñez, GM; González-Jiménez, A; Garrido-Sánchez, L; Moreno-Indias, I; Tinahones, FJ	Interactions between the gut microbiome and DNA methylation patterns in blood and visceral adipose tissue in subjects with different metabolic characteristics	JOURNAL OF TRANSLATIONAL MEDICINE	6.1	Q1	Article	2024
D-03	Mena-Vázquez, N; Redondo-Rodríguez, R; Rojas-Gimenez, M; Romero-Barco, CM; Fuego-Varela, C; Perez-Gómez, N; Añón-Oñate, I; Pérez, PC; García-Studer, A; Hidalgo-Conde, A; de los Ríos, RAD; Cabrera-César, E; Velloso-Feijoo, ML; Manrique-Arija, S; Calvo-Gutiérrez, J; Gandía-Martínez, M; Morales-Garrido, P; Godoy-Navarrete, FJ; Mouriño-Rodríguez, C; Espildora, F; Aguilar-Hurtado, MC; Fernández-Nebro, A	Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
D-03	López-Medina, C; Calvo-Gutiérrez, J; Abalos-Aguilera, MC; Cepas, F; Plasencia-Rodríguez, C; Martínez-Feito, A; Balsa, A; Faré-García, R; Juan-Mas, A; Ruiz-Esquide, V; Sainz, L; Díaz-Torné, C; Godoy-Navarrete, FJ; Añón-Oñate, I; Mena-Vázquez, N; Manrique-Arija, S; Moreno-García, MS; Ortega-Castro, R; Escudero-Contreras, A	Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study	RMD OPEN	5.1	Q1	Article	2024
D-03	Mena-Vázquez, N; Ortiz-Márquez, F; Ramírez-García, T; Cabezudo-García, P; García-Studer, A; Mucientes-Ruiz, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Redondo-Rodríguez, R; Manrique-Arija, S; Cano-García, L; Serrano-Castro, PJ; Fernández-Nebro, A	Impact of inflammation on cognitive function in patients with highly inflammatory rheumatoid arthritis	RMD OPEN	5.1	Q1	Article	2024
D-03	Mucientes, A; Lisbona-Montañez, JM; Mena-Vázquez, N; Ruiz-Limón, P; Manrique-Arija, S; García-Studer, A; Ortiz-Márquez, F; Fernández-Nebro, A	Intestinal Dysbiosis, Tight Junction Proteins, and Inflammation in Rheumatoid Arthritis Patients: A Cross-Sectional Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
D-03	Jiménez-Cortegana, C; López-Enríquez, S; Alba, G; Santa-María, C; Martín-Núñez, GM; Moreno-Ruiz, FJ; Valdés, S; García-Serrano, S; Rodríguez-Díaz, C; Ho-Plágaro, A; Fontalba-Romero, MI; García-Fuentes, E; Garrido-Sánchez, L; Sánchez-Margalet, V	The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver Function	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
D-03	López-Maraver, M; Serrano-Combarro, A; Atienza-Mateo, B; del Val, N; Casafont-Sole, I; Melero-Gonzalez, RB; Pérez-Linaza, A; Gutiérrez, JC; Mena-Vázquez, N; Vegas-Revenga, N; Domínguez-Casas, L; Martos, JL; Ginés, CAP; Morrondo, CD; Albaladejo, LP; Sánchez, RL; Canabal, MGM; Brandy-García, AM; Viejo, PL; Bonilla, G; Maiz-Alonso, O; Carrasco-Cubero, C; Bufort, MG; Moreno, M; Urruticoechea-Arana, A; Ordóñez-Palau, S; González-Montagut, C; Serret, EG; De Aberasturi, JRDJ; Morillo, FL; Rodríguez, TV; Carreira, PE; Madrigal, JMB; Ibáñez, BM; López, MR; Fernández-Díaz, C; Loricera, J; Ferraz-Amaro, I; Ferrer-Pargada, D; Castañeda, S; Blanco, R	Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients	SEMINARS IN ARTHRITIS AND RHEUMATISM	4.6	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-03	Altabás-González, I; Rua-Figueroa, I; Mouriño, C; Roberts, K; Jimenez, N; Martinez-Barrio, J; Galindo, M; Alen, JC; Perez, VD; Itzazelaia, EU; Tomero, E; Freire-Gonzalez, M; Taboada, VM; Salgado, E; Vela, P; Fernandez-Nebro, A; Olive, A; Narvaez, J; Menor-Almagro, R; Soler, GS; Hernandez-Beriain, JA; Manero, J; Aurrecochea, E; Ibarguengoitia-Barrena, O; Montilla, C; Bonilla, G; Torrente-Segarra, V; Cacheda, AP; Garcia-Villanueva, MJ; Moriano-Morales, C; Manteca, CF; Lozano-Rivas, N; Bohorquez, C; Pego-Reigosa, JM	Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis	LUPUS SCIENCE & MEDICINE	3.7	Q1	Article	2024
D-03	Rua-Figueroa, I; de Yébenes, MJG; Martinez-Barrio, J; Izquierdo, MG; Alén, J; Fernandez-Nebro, A; Menor-Almagro, R; Carmona, L; Segura, BT; Tomero, E; Freire-González, M; Sangüesa, C; Horcada, L; Blanco, R; Itzazelaia, EU; Narvaez, J; de Salazar, JCRG; Gómez-Sabater, S; Morales, CM; Andreu, JL; Segarra, VT; Aurrecochea, E; Perez, A; Medina, JN; Salgado, E; Lozano-Rivas, N; Montilla, C; Ruiz-Lucea, E; Arevalo, M; Iñiguez, C; García-Villanueva, MJ; Exposito, L; Ibáñez-Barcelo, M; Bonilla, G; Carrión-Barberà, I; Erausquin, C; Gil, JJF; Pecondón, A; Toyos, FJ; Cobo, T; Muñoz-Jiménez, A; Oller, J; Nolla, JM; Pego-Reigosa, JM	SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	LUPUS SCIENCE & MEDICINE	3.7	Q1	Article	2024
D-03	Cano-García, L; Redondo-Rodríguez, R; Mena-Vázquez, N; Manrique-Arija, S; García-Studer, A; Ortiz-Marquez, F; Borregón-Garrido, P; Fernández-Nebro, A	Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study	BMJ OPEN	2.4	Q1	Article	2024
D-03	Martínez-Vidal, MP; Fernández-Carballido, C; Otero-Varela, L; Ruiz, FJM; Pérez-Vera, Y; Arijao, SM; Fernández, CC; Jovaní, V; Expósito, L; Lario, BA; García-González, J; Sánchez-Alonso, F; Castrejón, I	Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry	JOURNAL OF RHEUMATOLOGY	3.6	Q2	Article	2024
D-03	Garcia-Villanueva, MJ; Garrote-Corral, S; Pego-Reigosa, JM; Otero, NJ; Isazelaia, EU; Marqué, AO; Gómez, CS; González, MF; Aguinaga, EA; Alvarez, ER; Muriel, ET; Morales, CM; Izquierdo, MG; Calvo-Alén, J; Menor-Almagro, R; Benavente, BS; Martinez-Barrio, J; Hernández-Beriain, JA; Barceló, MI; Hernan, GB; Rosas, J; Pérez, ES; Fernández-Nebro, A; Rua-Figueroa, I	Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumatology Lupus Register (RELESSER)	RHEUMATOLOGY INTERNATIONAL	3.2	Q2	Article	2024
D-03	Ramos-Petersen, L; Reinoso-Cobo, A; Ortega-Avila, AB; Garcia-Campos, J; Bernal, JA; Cantero-Tellez, R; Martin-Martin, JM; Caliz-Caliz, R; Tejero, S; Cano-Garcia, L; Gijon-Nogueron, G	A clinical practice guideline for the management of the foot and ankle in rheumatoid arthritis	RHEUMATOLOGY INTERNATIONAL	3.2	Q2	Review	2024
D-03	Cabezudo-García, P; Mena-Vázquez, N; Ciano-Petersen, NL; Oliver-Martos, B; Serrano-Castro, PJ	Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review	NEUROLOGIA	2.9	Q2	Review	2024
D-03	Castrejón, I; Cano, L; Cuadrado, MJ; Borrás, J; Galindo, M; Salman-Monte, TC; Amorós, C; Román, CS; Cabezas, I; Comellas, M; Muñoz, A	Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care	BMC RHEUMATOLOGY	2.1	Q3	Article	2024
D-03	Cano-García, L; Manrique-Arija, S; Redondo-Rodríguez, R; Vera-Ruiz, M; Lisbona-Montañez, JM; Mucientes-Ruiz, A; García-Studer, A; Ortiz-Marquez, F; Mena-Vázquez, N; Fernández-Nebro, A	Impact of the COVID-19 pandemic on psychosocial health in rheumatic patients: A longitudinal study	REUMATOLOGIA CLINICA	1.2	Q4	Article	2024
D-03	Rúa-Figueroa, I; Salman-Monte, T; Reigosa, JM; Izquierdo, M; Alvarez, E; Fernández-Nebro, A; Ivorra, JA; Penades, I; Beobide, J; Alén, J	Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus	REUMATOLOGIA CLINICA	1.2	Q4	Article	2024
D-03	Alvaro, JMAG; Fontecha, PDD; Sánchez, JLA; Criado, AB; Cáliz, RC; Fernández, IC; Corominas, H; Puerta, JAG; Arija, SM; Vázquez, NM; García, AO; Rodríguez, CP; Fernández, LS; Molina, JT	Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis	REUMATOLOGIA CLINICA	1.2	Q4	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Chacón, P; Vega-Rioja, A; Doukkali, B; Rodriguez, ADV; Fernández-Delgado, L; Domínguez-Cereijo, L; Segura, C; Perez-Machuca, BM; Perkins, JR; El Bekay, R; Cornejo-García, JA; Hajji, N; Monteseirín, J; Rivas-Pérez, D	Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE	19.0	D1	Article	2024
D-04	Cruz-Amaya, A; Martin-Astorga, MD; Lebron-Martín, C; Paris, JL; Céspedes, JA; Núñez, R; Torres, MJ; Aranda, CJ; Cañas, JA; Mayorga, C	Butyrate dietary supplementation promotes tolerant responses in a Pru p 3-anaphylactic mouse model	ALLERGY	13.0	D1	Article	2024
D-04	Jimenez-Rodriguez, TW; de las Vecillas, L; Labella, M; Lynch, DM; Besz, KM; Marquis, K; Burgos, A; Gomis, VS; Lozano, I; Antón, RAM; de la Calle, FM; Delgado, MPG; Gutiérrez, A; Montenegro, E; Rodríguez, F; Sánchez, FJF; Castells, M	Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization	ALLERGY	13.0	D1	Article	2024
D-04	Pfaar, O; Sousa-Pinto, B; Papadopoulos, NG; Larenas-Linnemann, DE; Ordak, M; Torres, MJ; Mösges, R; Klimek, L; Zuberbier, T; Matricardi, PM; Berger, UE; Berger, M; Dramburg, S; Mahler, V; Toppila-Salmi, SK; Bergmann, KC; Ollert, M; Tripodi, S; Jutel, M; Agache, I; Eguiluz-Gracia, I; Canonica, GW; Akdis, CA; Sokolowska, M; Sofiev, M; Shamji, MH; Czarlewski, W; Fonseca, JA; Bedbrook, A; Bousquet, J	Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: An ARIA-EAACI Position Paper	ALLERGY	13.0	D1	Article	2024
D-04	Pascal, M; Edelman, SM; Nopp, A; Möbs, C; Geilenkeuser, WJ; Knol, EF; Ebo, DG; Mertens, C; Shamji, MH; Santos, AF; Patil, S; Eberlein, B; Mayorga, C; Hoffmann, HJ	EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance	ALLERGY	13.0	D1	Article	2024
D-04	Barbaud, A; Garvey, LH; Torres, M; Laguna, JJ; Arcolaci, A; Bonadonna, P; Hofmeier, KS; Chiriac, AM; Cernadas, J; Caubet, JC; Brockow, K	EAACI/ENDA position paper on drug provocation testing	ALLERGY	13.0	D1	Article	2024
D-04	Mayorga, C; Çelik, GE; Pascal, M; Hoffmann, HJ; Eberlein, B; Torres, MJ; Brockow, K; Garvey, LH; Barbaud, A; Madrigal-Burgaleta, R; Caubet, JC; Ebo, DG	Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper	ALLERGY	13.0	D1	Article	2024
D-04	Pascal, M; Bax, HJ; Bergmann, C; Bianchini, R; Castells, M; Chauhan, J; de las Vecillas, L; Hartmann, K; Alvarez, EI; Jappe, U; Jimenez-Rodriguez, TW; Knol, E; Levi-Schaffer, F; Mayorga, C; Poli, A; Redegeld, F; Santos, AF; Jensen-Jarolim, E; Karagiannis, SN	Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper	ALLERGY	13.0	D1	Article	2024
D-04	Bavbek, S; Özdemir, SK; Bonadonna, P; Atanaskovic-Markovic, M; Barbaud, A; Brockow, K; Martinez, JL; Nakonechna, A; Pagani, M; Arcolaci, A; Lombardo, C; Torres, MJ	Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper	ALLERGY	13.0	D1	Article	2024
D-04	Céspedes, JA; Fernandez-Santamaria, R; Bogas, G; Veguillas, AA; Dona, I; Salas, M; Labella, M; Duarte, TDF; Mayorga, C; Torres, MJ; Frecha, CA	LPS in combination with amoxicillin increases BAT sensitivity to amoxicillin IgE-mediated hypersensitivity	ALLERGY	13.0	D1	Article	2024
D-04	Roth-Walter, F; Adcock, IM; Benito-Villalvilla, C; Bianchini, R; Bjermer, L; Caramori, G; Cari, L; Chung, KF; Diamant, Z; Eguiluz-Gracia, I; Knol, EF; Jesenak, M; Levi-Schaffer, F; Nocentini, G; O'Mahony, L; Palomares, O; Redegeld, F; Sokolowska, M; Van Esch, BCAM; Stellato, C	Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology	ALLERGY	13.0	D1	Article	2024
D-04	Eguiluz-Gracia, I; Parkin, RV; Layhadi, JA; Palmer, E; Meng, X; Zhu, RF; Sahiner, U; Durham, SR; Torres, MJ; Mayorga, C; Rondon, C; Shamji, MH	Nasal allergen-neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis	ALLERGY	13.0	D1	Article	2024
D-04	Smolinska, S; Popescu, FD; Izquierdo, E; Antolin-Amerigo, D; Price, OJ; Alvarez-Perea, A; Gracia, IE; Papadopoulos, NG; Pfaar, O; Fassio, F; Hoffmann-Sommergruber, K; Dramburg, S; Agache, I; Jutel, M; Brough, HA; Fonseca, JA; Angier, E; Boccabella, C; Bonini, M; Galvin, AD; Gibson, PG; Gawlik, R; Hannachi, F; Kalayci, O; Klimek, L; Knibb, R; Matricardi, P; Chivato, T	Telemedicine with special focus on allergic diseases and asthma-Status 2022: An EAACI position paper	ALLERGY	13.0	D1	Article	2024
D-04	Torres, MJ; Doña, I	Drug hypersensitivity: Past, present and future	ALLERGY	13.0	D1	Editorial Material	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Torres, MJ; Klimek, L; Agache, I; Jutel, M; Akdis, M; Shamji, MH; Akdis, CA	Four years into the COVID-19 pandemic: Timely published articles for patient care and EAACI's leadership role	ALLERGY	13.0	D1	Editorial Material	2024
D-04	Giovannini, M; Beken, B; Agache, I; Akdis, CA; Carvalho, D; Chivato, T; Comberiati, P; de las Vecillas, L; Eguiluz-Gracia, I; Heffler, E; Jutel, M; Karabacak, DE; Kolkhir, P; Moya, B; Ollert, M; O'Neil, S; Santos, AF; Schwarze, J; Skevaki, C; Sokolowska, M; Tsilochristou, O; van Wijk, RG; del Giacco, S; Riggioni, C	Mentoring as the cornerstone of continued education in Allergy and Clinical Immunology: 10th anniversary of the EAACI mentorship program	ALLERGY	13.0	D1	Editorial Material	2024
D-04	Mayorga, C; Ariza, A; Munoz-Cano, R; Sabato, V; Dona, I; Torres, MJ	Biomarkers of immediate drug hypersensitivity	ALLERGY	13.0	D1	Review	2024
D-04	Doña, I; Torres, MJ; Celik, G; Phillips, E; Tanno, LK; Castells, M	Changing patterns in the epidemiology of drug allergy	ALLERGY	13.0	D1	Review	2024
D-04	Cabanillas, B; Murdaca, G; Guemari, A; Torres, MJ; Azkur, AK; Aksoy, E; Vitte, J; Fernández-Santamaria, R; Karavelia, A; Castagnoli, R; Valdelvira, R; Orsi, A; Ogliastro, M; Massaro, E; Yücel, EÖ; Novak, N; Agache, I; Akdis, M; Akdis, CA	Monkeypox 2024 outbreak: Fifty essential questions and answers	ALLERGY	13.0	D1	Review	2024
D-04	Canani, RB; Caminati, M; Carucci, L; Eguiluz-Gracia, I	Skin, gut, and lung barrier: Physiological interface and target of intervention for preventing and treating allergic diseases	ALLERGY	13.0	D1	Review	2024
D-04	Sun, N; Ogulur, I; Mitamura, Y; Yazici, D; Pat, Y; Bu, XT; Li, MR; Zhu, XY; Babayev, H; Ardicli, S; Ardicli, O; D'Avino, P; Kiykim, A; Sokolowska, M; van de Veen, W; Weidmann, L; Akdis, D; Ozdemir, BG; Brügggen, MC; Biedermann, L; Straumann, A; Kreienbühl, A; Guttman-Yassky, E; Santos, AF; Del Giacco, S; Traidl-Hoffmann, C; Jackson, DJ; Wang, DY; Lauerma, A; Breiteneder, H; Zhang, L; O'Mahony, L; Pfaar, O; O'Hehir, R; Eiwegger, T; Fokkens, WJ; Cabanillas, B; Ozdemir, C; Kistler, W; Bayik, M; Nadeau, KC; Torres, MJ; Akdis, M; Jutel, M; Agache, I; Akdis, CA	The epithelial barrier theory and its associated diseases	ALLERGY	13.0	D1	Review	2024
D-04	Li, HH; Anjani, QK; Hutton, ARJ; Paris, JL; Moreno-Castellanos, N; Himawan, A; Larrañeta, E; Donnelly, RF	Design of a Novel Delivery Efficiency Feedback System for Biphasic Dissolving Microarray Patches Based on Poly(Lactic Acid) and Moisture-Indicating Silica	ADVANCED HEALTHCARE MATERIALS	10.0	D1	Article	2024
D-04	Caro, C; Guzzi, C; Moral-Sánchez, I; Urbano-Gámez, JD; Beltrán, AM; García-Martín, ML	Smart Design of ZnFe and ZnFe@Fe Nanoparticles for MRI-Tracked Magnetic Hyperthermia Therapy: Challenging Classical Theories of Nanoparticles Growth and Nanomagnetism	ADVANCED HEALTHCARE MATERIALS	10.0	D1	Article	2024
D-04	Al-Shaikhly, T; Cox, A; Nowak-Wegrzyn, A; Cianferoni, A; Katelaris, C; Ebo, DG; Konstantinou, GN; Brucker, H; Yang, HJ; Protudjer, JLP; Boechat, JL; Yu, JE; Wang, J; Blatman, KSH; Blazowski, L; Anand, MP; Ramesh, M; Torres, MJ; Holbreich, M; Goodman, R; Wasserman, RL; Hopp, R; Sato, S; Skypala, I	An International Delphi Consensus on the Management of Pollen-Food Allergy Syndrome: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	8.2	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Bousquet, J; Schünemann, HJ; Sousa-Pinto, B; Zuberbier, T; Togias, A; Samolinski, B; Bedbrook, A; Czarlewski, W; Hofmann-Apitius, M; Litynska, J; Vieira, RJ; Anto, JM; Fonseca, JA; Brozek, J; Bognanni, A; Brussino, L; Canonica, GW; Cherrez-Ojeda, I; Cruz, AA; de las Vecillas, L; Dykewicz, M; Gemicioglu, B; Giovannini, M; Haahtela, T; Jacobs, M; Jacomelli, C; Klimek, L; Kvedariene, V; Larenas-Linnemann, DE; Louis, G; Lourenço, O; Leemann, L; Morais-Almeida, M; Neves, AL; Nadeau, KC; Nowak, A; Palamarchuk, Y; Palkonen, S; Papadopoulos, NG; Parmelli, E; Pereira, AM; Pfaar, O; Regateiro, FS; Savouré, M; Taborda-Barata, L; Toppila-Salmi, SK; Torres, MJ; Valiulis, A; Ventura, MT; Williams, S; Yepes-Nunez, JJ; Yorgancioglu, A; Zhang, L; Zuberbier, J; Latiff, AHA; Abdullah, B; Agache, I; Al-Ahmad, M; Al-Nesf, MA; Al Shaikh, NA; Amaral, R; Ansotegui, IJ; Asllani, J; Balotro-Torres, MC; Bergman, KC; Bernstein, JA; Bindsløv-Jensen, C; Blaiss, MS; Bonaglia, C; Bonini, M; Bossé, I; Braidó, F; Caballero-Fonseca, F; Camargos, P; Carreiro-Martins, P; Casale, T; Castillo-Vizueté, JA; Cecchi, L; Teixeira, MD; Chang, YS; Loureiro, CC; Christoff, G; Ciprandi, G; Cirule, I; Correia-de-Sousa, J; Costa, EM; Cvetkovski, B; de Vries, G; Del Giacco, S; Devillier, P; Dokic, D; Douagui, H; Durham, SR; Enecilla, ML; Fiocchi, A; Fokkens, WJ; Fontaine, JF; Gawlik, R; Gereda, JE; Gil-Mata, S; Giuliano, AFM; Gotua, M; Gradauskiene, B; Guzman, MA; Hossny, E; Hrubisko, M; Iinuma, T; Irani, C; Ispayeva, Z; Ivancevich, JC; Jartti, T; Jesenák, MS; Julge, K; Jutel, M; Kaidashev, I; Bennoor, KS; Khaltaev, N; Kirenga, B; Kraxner, H; Kull, I; Kulus, M; Kuna, P; Kupczyk, M; Kurchenko, A; La Grutta, S; Lane, S; Miculinic, N; Lee, SM; Tuyet, LLT; Lkhagvaa, B; Louis, R; Mahboub, B; Makela, M; Makris, M; Maurer, M; Melén, E; Milenkovic, B; Mohammad, Y; Moniuszko, M; Montefort, S; Moreira, A; Moreno, P; Mullol, J; Nadif, R; Nakonechna, A; Navarro-Locsin, CG; Neffen, HE; Nekam, K; Niedożytko, M; Nunes, E; Nyembue, D; O’Hehir, R; Ollert, M; Ohta, K; Okamoto, Y; Okubo, K; Olze, H; Padukudru, MA; Palomares, O; Pali-Scholl, I; Panzner, P; Palosuo, K; Park, HS; Passalacqua, G; Patella, V; Pawankar, R; Pétré, B; Pitsios, C; Plavec, D; Popov, TA; Puggioni, F; Quirce, S; Raciborski, F; Ramonaité, A; Recto, M; Repka-Ramirez, S; Roberts, G; Robles-Velasco, K; Roche, N; Rodriguez-Gonzalez, M; Romualdez, JA; Rottem, M; Rouadi, PW; Salapatas, M; Sastre, J; Serpa, FS; Sayah, Z; Scichilone, N; Senna, G; Sisul, JC; Solé, D; Soto-Martinez, ME; Sova, M; Sozinova, O; Stevanovic, K; Ulrik, CS; Szylling, A; Tan, FM; Tantilipikorn, P; Todo-Bom, A; Tomic-Spiric, V; Tsaryk, V; Tsiligianni, I; Urrutia-Pereira, M; Rostan, MV; Sofiev, M; Valovirta, E; Van Eerd, M; Van Ganse, E; Vasankari, T; Vichyanond, P; Viegi, G; Wallace, D; Wang, DY; Wasserman, S; Wong, G; Worm, M; Yusuf, OM; Zaitoun, F; Zidarn, M	Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	8.2	D1	Article	2024
D-04	Torres, MJ; Gil-Mata, S; Bognanni, A; Ferreira-da-Silva, R; Yepes-Nuñez, JJ; Lourenco-Silva, N; Cardoso-Fernandes, A; Ferreira, A; Ferreira-Cardoso, H; Portela, D; Teles, J; Kvedariene, V; Torres, MJ; Klimek, L; Pfaar, O; Brussino, L; Zuberbier, T; Fonseca, JA; Schunemann, H; Bousquet, J; Sousa-Pinto, B; Vieira, RJ	Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review With Meta-Analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	8.2	D1	Review	2024
D-04	Pérez-Moreno, AM; Aranda, CJ; Torres, MJ; Mayorga, C; Paris, JL	Immunomodulatory potential of rapamycin-loaded mesoporous silica nanoparticles: pore size-dependent drug loading, release, and in vitro cellular responses	DRUG DELIVERY AND TRANSLATIONAL RESEARCH	5.7	D1	Article	2024
D-04	Arasi, S; Caubet, JC; Ceylan, O; Eguíluz-Gracia, I; Del Giacco, S; Gelincik, A; Jutel, M; Meyer, R; Ollert, M; Torres, MJ	Working with companies that manufacture breastmilk substitutes: An EAACI position paper	PEDIATRIC ALLERGY AND IMMUNOLOGY	4.3	D1	Article	2024
D-04	Freundt-Serpa, NP; Salas-Cassinello, M; Gonzalo-Fernández, A; Marchán-Pinedo, N; Doña, ; Serrano-García, ; Humanes-Navarro, AM; Bogas, G; Labella, M; Sánchez-Morillas, L; Torres, MJ; Fernández-Rivas, M	Deconstructing Adverse Reactions to AmoxicillinClavulanic Acid: The Importance of Time of Onset	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	6.7	Q1	Article	2024
D-04	Plaza, V; Eguiluz, I; Garin, N; Martinez Moragon, E; Palomares, O; Davila, I	EPI-SURVEY. Grade of awareness of Spanish allergist, hospital pharmacist, and pulmonologists on the relevance of bronchial epithelium and alarmins in the pathogenesis and management of severe asthma.	Journal of investigational allergology AND clinical immunology	6.7	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Sousa-Pinto, B; Palamarchuk, Y; Leemann, L; Jankin, S; Basagaña, X; Ballester, J; Bedbrook, A; Czarlewski, W; Almeida, R; Haahtela, T; Haveri, H; Prass, M; Henriques, T; Vieira, RJ; Klimek, L; Ollert, M; Shamji, MH; Jutel, M; Del Giacco, S; Torres, MJ; Zuberbier, T; Fonseca, JA; Sofiev, M; Anto, JM; Bousquet, J	From MASK-air and SILAM to CATALYSE (Climate Action To Advance HeaLthY Societies in Europe)	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	6.7	Q1	Article	2024
D-04	Serrano, SC; Otón, RG; Veguillas, AA; Labella, M; Mayorga, C; Duarte, TDF; Torres, MJ; Frecha, C	Cytometer Harmonization as Part of IVD-R: A Key Component for Performance of Multicenter Studies	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	6.7	Q1	Editorial Material	2024
D-04	Plaza, V; Eguíluz , ; Garin, N; Moragón , EM; Palomares, O; Dávila ,	EPI-SURVEY: Grade of Awareness Among Spanish Allergists, Hospital Pharmacists, and Pulmonologists of the Relevance of Bronchial Epithelium and Alarmins in the Pathogenesis and Management of Severe Asthma	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	6.7	Q1	Editorial Material	2024
D-04	Zubiaga-Fernandez, L; Testera-Montes, A; Rondon, C; Perez-Sanchez, N; Gomez-Perez, F; Vega-Chicote, JM; Bartra, J; Ferrer, M; Eguiluz-Gracia, I; Torres, MJ	Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria	CLINICAL AND EXPERIMENTAL ALLERGY	6.3	Q1	Article	2024
D-04	Camino-Mera, A; Pardo-Seco, J; Bello, X; Argiz, L; Boyle, RJ; Custovic, A; Herberg, J; Kaforou, M; Arasi, S; Fiocchi, A; Pecora, V; Barni, S; Mori, F; Bracamonte, T; Echeverria, L; O'Valle-Aisa, V; Hernandez-Martinez, NL; Carballeira, I; Garcia, E; Garcia-Magan, C; Moure-Gonzalez, JD; Gonzalez-Delgado, P; Garriga-Baraut, T; Infante, S; Zambrano-Ibarra, G; Tomas-Perez, M; Machinena, A; Pascal, M; Prieto, A; Vazquez-Cortes, S; Fernandez-Rivas, M; Vila, L; Alsina, L; Torres, MJ; Mangone, G; Quirce, S; Martinon-Torres, F; Vazquez-Ortiz, M; Gomez-Carballa, A; Salas, A	Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction-Related Biomarkers in Food Protein-Induced Enterocolitis Syndrome	CLINICAL AND EXPERIMENTAL ALLERGY	6.3	Q1	Article	2024
D-04	Palomares, F; Pérez-Sánchez, N; Nieto, N; Núñez, R; Cañas, JA; Martín-Astorga, MD; Cruz-Amaya, A; Torres, MJ; Eguiluz-Gracia, I; Mayorga, C; Gómez, F	Group 2 innate lymphoid cells are key in lipid transfer protein allergy pathogenesis	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Article	2024
D-04	Omotesho, QA; Escamilla, A; Perez-Ruiz, E; Frecha, CA; Rueda-Dominguez, A; Barragan, I	Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures	FRONTIERS IN IMMUNOLOGY	5.7	Q1	Review	2024
D-04	Calvo-Serrano, S; Matamoros, E; Céspedes, JA; Fernández-Santamaría, R; Gil-Ocaña, V; Perez-Inestrosa, E; Frecha, C; Montañez, MI; Vida, Y; Mayorga, C; Torres, MJ	New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen-Silica Nanoparticle Composites	PHARMACEUTICS	4.9	Q1	Article	2024
D-04	Urbano-Gámez, JD; Guzzi, C; Bernal, M; Solivera, J; Martínez-Zubiaurre, I; Caro, C; García-Martín, ML	Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
D-04	John, SM; Bonertz, A; Zimmer, J; Aerts, O; Bauer, A; Bova, M; Brans, R; Del Giacco, S; Dickel, H; Corazza, M; Crepy, MN; Gallo, R; Garcia-Abujeta, JL; Gimenez-Arnau, AM; Klimek, L; Lepoittevin, JP; Hadzavdic, SL; Matura, M; Mortz, CG; Özkaya, E; Pesonen, M; Raison-Peyron, N; Rustemeyer, T; Skudlik, C; Spiewak, R; Stingeni, L; Suomela, S; Symanzik, C; Taylor, J; Torres, M; Uter, W; White, I; Wilkinson, M; Mahler, V; Johansen, JD	Severely compromised supply of patch test allergens in Europe hampers adequate diagnosis of occupational and non-occupational contact allergy. A European Society of Contact Dermatitis (ESCD), European Academy of Allergy and Clinical Immunology (EAACI), European Academy of Dermatology and Venereology (EADV) task forces ‘Contact Dermatitis’ and ‘Occupational Skin Disease’ position paper	CONTACT DERMATITIS	4.8	Q1	Article	2024
D-04	Parron-Ballesteros, J; Martin-Pedraza, L; Gordo, RG; Mayorga, C; Pastor-Vargas, C; Titaux-Delgado, GA; Villalba, M; Batanero, E; Pantoja-Uceda, D; Turnay, J	Long-chain fatty acids block allergic reaction against lipid transfer protein Sola l 7 from tomato seeds	PROTEIN SCIENCE	4.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Fernandez-Santamaria, R; Ariza, A; Bogas, G; Salas, M; Calvo-Serrano, S; Frecha, C; Mayorga, C; Torres, MJ; Fernandez, TD	Involvement of autologous myeloid dendritic cells in the evaluation of immediate hypersensitivity reactions to betalactams	CLINICAL IMMUNOLOGY	4.5	Q2	Article	2024
D-04	Mori, F; Liccioli, G; Tomei, L; Barni, S; Giovannini, M; Sarti, L; Pessina, B; Torres, MJ	How to manage drug-virus interplay underlying skin eruptions in children	WORLD ALLERGY ORGANIZATION JOURNAL	3.9	Q2	Review	2024
D-04	Núñez, R; Doña, I; Cornejo-García, J	Predictive models and applicability of artificial intelligence-based approaches in drug allergy	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY	3.0	Q2	Review	2024
D-04	Martínez-Moragón, E; Ercoreca, IA; García, MM; Maldonado, FC; Lamas, MC; Vives, EC; Diz, CC; Díaz-Pérez, D; Gracia, IE; Gil, SG; González-Pérez, R; Mena, AH; Valverde, TH; Montaña, SJ; López-Carrasco, V; López, IM; Merino-Bohórquez, V; Moreno-Ancillo, A; Cabeza, ACM; Monte-Boquet, E; Revuelta-Herrero, JL; Sánchez-Cuellar, S	Patient-reported outcome measures in severe asthma: an expert consensus	JOURNAL OF ASTHMA	1.7	Q3	Article	2024
D-05	Segovia-Zafra, A; Villanueva-Paz, M; Serras, AS; Matilla-Cabello, G; Bodoque-García, A; Zeo-Sánche, DED; Niu, H; Alvarez-Alvarez, I; Sanz-Villanueva, L; Godec, S; Milisav, I; Bagnaninchi, P; Andrade, RJ; Lucena, MI; Fernández-Checa, JC; Cubero, FJ; Miranda, JP; Nelson, LJ	Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network	JOURNAL OF HEPATOLOGY	27.0	D1	Article	2024
D-05	Colapietro, F; Maisonneuve, P; Lytvyak, E; Beuers, U; Verdonk, RC; van der Meer, AJ; van Hoek, B; Kuiken, SD; Brouwer, JT; Muratori, P; Aghemo, A; Carella, F; van den Berg, AP; Zachou, K; Dalekos, GN; Di Zeo-Sanchez, DE; Robles, M; Andrade, RJ; Montano-Loza, AJ; van den Brand, FF; Slooter, CD; Macedo, G; Liberal, R; de Boer, YS; Lleo, A	Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis	JOURNAL OF HEPATOLOGY	27.0	D1	Article	2024
D-05	Montano-Loza, AJ; Lytvyak, E; Hirschfield, G; Hansen, BE; Ebadi, M; Berney, T; Toso, C; Magini, G; Villamil, A; Nevens, F; Van den Ende, N; Pares, A; Ruiz, P; Terrabuio, D; Trivedi, PJ; Abbas, N; Donato, MF; Yu, L; Landis, C; Dumortier, J; Dyson, JK; Van der Meer, AJ; De Veer, R; Pedersen, M; Mayo, M; Manns, MP; Taubert, R; Kirchner, T; Belli, LS; Mazzarelli, C; Stirnimann, G; Floreani, A; Cazzagon, N; Russo, FP; Burra, P; Zigmound, U; Houri, I; Carbone, M; Mulinacci, G; Fagioli, S; Pratt, DS; Bonder, A; Schiano, TD; Haydel, B; Lohse, A; Schramm, C; Rüther, D; Casu, S; Verhelst, X; Beretta-Piccoli, BT; Robles, M; Mason, AL; Corpechot, C	Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation	JOURNAL OF HEPATOLOGY	27.0	D1	Article	2024
D-05	Slooter, CD; van den Brand, FF; Lleo, A; Colapietro, F; Lenzi, M; Muratori, P; Kerkar, N; Dalekos, GN; Zachou, K; Lucena, MI; Robles-Díaz, M; Di Zeo-Sánchez, DE; Andrade, RJ; Montano-Loza, AJ; Lytvyak, E; Lissenberg-Witte, BI; Maisonneuve, P; Bouma, G; Macedo, G; Liberal, R; de Boer, YS	Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAHG retrospective registry	HEPATOLOGY	13.0	D1	Article	2024
D-05	Thomson, P; Fragkas, N; Kafu, LM; Aithal, GP; Lucena, MI; Terracciano, L; Meng, XL; Pirmohamed, M; Brees, D; Kullak-Ublick, GA; Odermatt, A; Hammond, T; Kammüller, M; Naisbitt, DJ	Patients with naproxen-induced liver injury display T-cell memory responses toward an oxidative (S)-O-Desmethyl Naproxen metabolite but not the acyl glucuronide	ALLERGY	13.0	D1	Article	2024
D-05	Gratacós-Ginès, J; Ruz-Zafra, P; Celada-Sendino, M; Martí-Carretero, A; Pujol, C; Martín-Mateos, R; Echavarria, V; Frisancho, LE; García, S; Barreales, M; Tejedor-Tejada, J; Vázquez-Rodríguez, S; Cañete, N; Fernández-Carrillo, C; Valenzuela, M; Martí-Aguado, D; Horta, D; Quiñones, M; Bernal-Monterde, V; Acosta, S; Artaza, T; Pinazo, J; Villar-Lucas, C; Clemente-Sánchez, A; Badia-Aranda, E; Giráldez-Gallego, A; Rodríguez, M; Sancho-Bru, P; Cabezas, J; Ventura-Cots, M; Fernández-Rodríguez, C; Aguilera, V; Tomé, S; Bataller, R; Caballeria, J; Pose, E	Recurrent alcohol-associated hepatitis is common and is associated with increased mortality	HEPATOLOGY	13.0	D1	Article	2024
D-05	Gil-Pitarch, C; Serrano-Maciá, M; Simon, J; Mosca, L; Conter, C; Rejano-Gordillo, CM; Zapata-Pavas, LE; Peña-Sanfélix, P; Azkargorta, M; Rodríguez-Agudo, R; Lachiondo-Ortega, S; Mercado-Gómez, M; Delgado, TC; Porcelli, M; Aurrekoetxea, I; Sutherland, JD; Barrio, R; Xirodimas, D; Aspichueta, P; Elortza, F; Martínez-Cruz, LA; Nogueiras, R; Iruzubiet, P; Crespo, J; Masson, S; McCain, MV; Reeves, HL; Andrade, RJ; Lucena, MI; Mayor, U; Goikoetxea-Usandizaga, N; González-Recio, I; Martínez-Chantar, ML	Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway	CELL REPORTS MEDICINE	12.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-05	Baños, JE; Blanco-Reina, E; Bellido-Estévez, I; Bosch, F; Cabello, MR; Cambra-Badii, I; Cruz, JPD; D’Ocón, P; Ivorra, MD; Ferrándiz, M; Gonzalez-Correa, JA; Martin-Montanez, E; Martos, F; Pavia, J; Sanz, E	Beyond lectures and practical courses: Teaching pharmacology using imaginative pedagogical tools	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
D-05	Niu, H; Solis-Muñoz, P; García-Cortés, M; Sanabria-Cabrera, J; Robles-Diaz, M; Romero-Flores, R; Bonilla-Toyos, E; Ortega-Alonso, A; Pinazo-Bandera, JM; Cabello, MR; Bessone, F; Hernandez, N; Lucena, MI; Andrade, RJ; Medina-Caliz, I; Alvarez-Alvarez, I	Prior drug allergies are associated with worse outcome in patients with idiosyncratic drug-induced liver injury: A machine learning approach for risk stratification	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
D-05	Pinazo-Bandera, JM; Niu, H; Alvarez-Alvarez, I; Medina-Cáliz, I; Campo-Herrera, ED; Ortega-Alonso, A; Robles-Díaz, M; Hernández, N; Paraná, R; Nunes, V; Giralda, M; Bessone, F; Lucena, MI; Andrade, RJ; Cortés, MG	Rechallenge in idiosyncratic drug-induced liver injury: An analysis of cases in two large prospective registries according to existing definitions	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
D-05	Lucena, MI; Villanueva-Paz, M; Alvarez-Alvarez, I; Aithal, GP; Björnsson, ES; Cakan-Akdogan, G; Cubero, FJ; Esteves, F; Falcon-Perez, JM; Fromenty, B; Garcia-Ruiz, C; Grove, JI; Konu, O; Kranendonk, M; Kullak-Ublick, GA; Miranda, JP; Remesal-Doblado, A; Sancho-Bru, P; Nelsons, L; Andrade, RJ; Daly, AK; Fernandez-Checa, JC	Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
D-05	Cárdenas-Quesada, J; Mestre-Pintó, J; Maldonado, R; de Fonseca, FR; Torrens, M; Farré, M	Substance use disorders and cooperative research on addictions: Spanish approach as a model	PHARMACOLOGICAL RESEARCH	9.1	D1	Article	2024
D-05	Ceña, V; Lucena, MI	Special Issue Spanish Basic and Clinical Pharmacology	PHARMACOLOGICAL RESEARCH	9.1	D1	Editorial Material	2024
D-05	Bettinetti-Luque, M; Trujillo-Estrada, L; Garcia-Fuentes, E; Andreo-Lopez, J; Sanchez-Varo, R; Garrido-Sánchez, L; Gómez-Mediavilla, A; López, MG; García-Caballero, M; Gutierrez, A; Baglietto-Vargas, D	Adipose tissue as a therapeutic target for vascular damage in Alzheimer’s disease	BRITISH JOURNAL OF PHARMACOLOGY	6.8	D1	Review	2024
D-05	Ruiz-Cobo, JC; Llaneras, J; Forns, X; Moya, AG; Amiel, IC; Arencibia, A; Diago, M; Garcia-Samaniego, J; Castellote, J; Llerena, S; Rodriguez-Seguel, E; Mateos, B; Rodriguez, M; Zabal, JMR; Fernandez, I; Calleja, JL; Morillas, RM; Montoliu, S; Andrade, RJ; Aranda, EB; Hernandez-Guerra, M; Mate, CJ; Gonzalez-Santiago, JM; de Cuenca, B; Bernal-Monterde, V; Delgado, M; Turnes, J; Lens, S; Buti, M	Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir	ALIMENTARY PHARMACOLOGY & THERAPEUTICS	6.6	D1	Article	2024
D-05	Ampuero, J; Aller, R; Gallego-Durán, R; Crespo, J; Calleja, JL; García-Monzón, C; Gómez-Camarero, J; Caballería, J; Lo Iacono, O; Ibañez, L; García-Samaniego, J; Albillos, A; Francés, R; Fernández-Rodríguez, C; Maya-Miles, D; Diago, M; Poca, M; Andrade, RJ; Latorre, R; Jorquera, F; Morillas, RM; Escudero, D; Hernández-Guerra, M; Pareja-Megía, MJ; Banales, JM; Aspichueta, P; Benlloch, S; Rosales, JM; Turnes, J; Romero-Gómez, M	The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis	JOURNAL OF GASTROENTEROLOGY	6.9	Q1	Article	2024
D-05	Pocurull, A; Moreta, MJ; Heitman, D; Olivas, I; Collazos, C; Canga, E; Sáez-Peñataro, J; Andrade, RJ; Lucena, MI; Mariño, Z; Díaz, A; Lens, S; Londoño, MC; Forns, X	Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital	LIVER INTERNATIONAL	6.0	Q1	Article	2024
D-05	Gallego-Durán, R; Ampuero, J; Maya-Miles, D; Pastor-Ramírez, H; Montero-Vallejo, R; Rivera-Esteban, J; Alvarez-Amor, L; Pareja, MJ; Rico, MC; Millán, R; Robles-Frías, MJ; Aller, R; Rojas, A; Muñoz-Hernández, R; Gil-Gómez, A; Gato, S; García-Lozano, M; Arias-Loste, MT; Abad, J; Calleja, JL; Andrade, RJ; Crespo, J; González-Rodríguez, A; García-Monzón, C; Andreola, F; Pericás, JM; Jalan, R; Martín-Bermudo, F; Romero-Gómez, M	Fibroblast growth factor 21 is a hepatokine involved in MASLD progression	UNITED EUROPEAN GASTROENTEROLOGY JOURNAL	5.8	Q1	Article	2024
D-05	Román-Sagüillo, S; Castro, RQ; Juárez-Fernández, M; Soluyanova, P; Stephens, C; Robles-Díaz, M; Plaza, FJ; González-Gallego, J; Martínez-Flórez, S; García-Mediavilla, MV; Nistal, E; Jover, R; Sánchez-Campos, S	Idiosyncratic Drug-Induced Liver Injury and Amoxicillin-Clavulanate: Spotlight on Gut Microbiota, Fecal Metabolome and Bile Acid Profile in Patients	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
D-05	Jiménez-Cortegana, C; López-Enríquez, S; Alba, G; Santa-María, C; Martín-Núñez, GM; Moreno-Ruiz, FJ; Valdés, S; García-Serrano, S; Rodríguez-Díaz, C; Ho-Plágaro, A; Fontalba-Romero, MI; García-Fuentes, E; Garrido-Sánchez, L; Sánchez-Margalet, V	The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver Function	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-05	Medina-Cáliz, I; Sanabria-Cabrera, J; Villanueva-Paz, M; Aukstikalne, L; Stephens, C; Robles-Díaz, M; Pinazo-Bandera, JM; García-Cortes, M; Conde, I; Soriano, G; Bessone, F; Hernandez, N; Nunes, V; Paraná, R; Lucena, MI; Andrade, RJ; Niu, H; Alvarez-Alvarez, I	Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries	ARCHIVES OF TOXICOLOGY	4.8	Q1	Article	2024
D-05	Arrari, F; Ortiz-Flores, RM; Lhamyani, S; Garcia-Fuentes, E; Jabri, MA; Sebai, H; Bermudez-Silva, FJ	Protective Effects of Spirulina Against Lipid Micelles and Lipopolysaccharide-Induced Intestinal Epithelium Disruption in Caco-2 Cells: In Silico Molecular Docking Analysis of Phycocyanobilin	NUTRIENTS	4.8	Q1	Article	2024
D-05	Martínez-Montoro, JI; Arranz-Salas, I; Gutiérrez-Repiso, C; Sánchez-García, A; Ocana-Wilhelmi, L; Pinazo-Bandera, JM; Fernández-García, D; Munoz-Garach, A; Morales-García, D; Garcia-Cortes, M; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study	NUTRIENTS	4.8	Q1	Article	2024
D-05	.Cohen, EB; Patwardhan, M; Raheja, R; Alpers, DH; Andrade, RJ; Avigan, MI; Lewis, JH; Rockey, DC; Chui, F; Iacob, AM; Linardi, CC; Regev, A; Shick, J; Lucena, MI	Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative	DRUG SAFETY	4.0	Q1	Article	2024
D-05	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-cosme, C; Lara, JP	Early Occupational Therapy Intervention Programme and Coping Strategies and Burden in Caregivers of People with Sub-Acute Stroke: A Randomised Controlled Trial	JOURNAL OF PERSONALIZED MEDICINE	3.0	Q1	Article	2024
D-05	Garcia-Alberca, Jose Maria; De La Guia, Paz; Gris, Esther; Mendoza, Silvia; Lopez De La Rica, Maria; Barbancho, Miguel Angel; Lara, Jose Pablo; Blanco-Reina, Encarnacion	Effectiveness of Vortioxetine Treatment on Depression and Cognitive Functions in Patients with Alzheimer’s Disease: A 12-Month, Retrospective, Observational Study.	Journal of personalized medicine	3.0	Q1	Article	2024
D-05	García-Pérez, P; Rodríguez-Martínez, MC; Gallardo-Tur, A; Blanco-Reina, E; de la Cruz-Cosme, C; Lara, JP	Early Occupational Therapy Intervention post-stroke (EOTIPS): A randomized controlled trial	PLOS ONE	2.9	Q1	Article	2024
D-05	Beltran-Casanueva, R; Hernández-García, A; García, PD; Blanco-Reina, E; Serrano-Castro, P; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narváez, M	Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition	FRONTIERS IN CELLULAR NEUROSCIENCE	4.2	Q2	Article	2024
D-05	Martinez, E; Berg, N; Rodriguez, C; Daube, G; Taminiau, B	Influence of microbiota on the growth and gene expression of Clostridioides difficile in an in vitro coculture model	MICROBIOLOGYOPEN	4.0	Q2	Article	2024
D-05	Pinazo-Bandera J.M.; Aranda J.; Garcia-Garcia A.M.; Alcantara R.; Ortega-Alonso A.; Campo-Herrera E.D.; Clavijo E.; Dolores Garcia-Escano M.; Ruiz J.J.R.; Morales-Herrera M.; Valle-Lopez V.; Martín-Alarcon R.; Viciano I.; Jimenez J.B.; Fernandez-Garcia F.; Toro-Ortiz J.P.; Sanchez-Yanez E.; Alvarez- Alvarez I.; Andrade R.J.; Robles-Diaz M.; Garcia-Cortes M.	Hepatitis C virus point-of-care microelimination approach in a vulnerable population in the South of Spain	Gastroenterology Report	3.8	Q2	Article	2024
D-05	Hernandez, N; Bessone, F; Andrade, R	Emerging role of immunotherapy for cancer as a major cause of drug-induced liver injury	ANNALS OF HEPATOLOGY	3.7	Q2	Editorial Material	2024
D-05	García-Alberca, JM; de la Guia, P; Gris, E; Mendoza, S; de la Rica, ML; López-Trigo, JA; López-Mongil, R; García-López, T; López-García, R; Del Rey, TR; Gay-Puente, J; García-Castro, J; Casales, F; Morato, X; Boada, M; González-Velasco, G; Marín-Carmona, JM; Páez, NI; León, M; Carrillejo, R; Rius, F; Barbancho, MA; Lara, JP; Blanco-Reina, E	Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer’s disease	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-05	Carrasco-Zafra, MI; Ocaña-Riola, R; Gómez-García, R; Martín-Roselló, ML; Blanco-Reina, E	Palliative sedation at the end of life: prevalence, characteristics and possible determinants	BMC PALLIATIVE CARE	2.5	Q2	Article	2024
D-05	Moya, MC; Gismero, FM; Ferrer, CS; Hernández-Camba, A; Carlón, DV; Benasach, FG; Peris, MA; Oliva, FJD; González-Lama, Y; Scheiding, MM; Sebastián, IA; Martel, LC; Arriero, VG; Piudo, AE; Castillo, PB; Sanz, NC; Mendoza, MIV; Labajos, RS; Martínez, AV; Restoy, LP; Abdo, YZ; Ciria, MM; Rodríguez-Moranta, F; Barreiro-de Acosta, M; Casbas, AG	Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease	GASTROENTEROLOGIA Y HEPATOLOGIA	2.2	Q3	Article	2024
D-05	Alvarado-Tapias, E; Maya-Miles, D; Albillos, A; Aller, R; Ampuero, J; Andrade, RJ; Arechederra, M; Aspichueta, P; Banales, JM; Blas-García, A; Caparros, E; Delgado, TC; Carrillo-Vico, A; Claria, J; Cubero, FJ; Díaz-Ruiz, A; Fernández-Barrena, MG; Fernández-Iglesias, A; Fernández-Veledo, S; Frances, R; Gallego-Duran, R; Gracia-Sancho, J; Irimia, M; Lens, S; Martínez-Chantar, ML; Minguez, B; Muñoz-Hernandez, R; Nogueiras, R; Ramos-Molina, B; Riveiro-Barciela, M; Rodríguez-Peralvarez, ML; Romero-Gomez, M; Sabio, G; Sancho-Bru, P; Ventura-Cots, M; Vidal, S; Gahete, MD	Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)	GASTROENTEROLOGIA Y HEPATOLOGIA	2.2	Q3	Article	2024
D-05	Ferrandis, R; Sierra, P; Gomez-Luque, A	COVID-19 thromboprophylaxis: New evidences	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION	0.9	Q3	Article	2024
DA-06	Muñoz-Barrera, L; Perez-Sanchez, C; Ortega-Castro, R; Corrales, S; Luque-Tevar, M; Cerdó, T; Sanchez-Pareja, I; Font, P; Lopez-Mejías, R; Calvo, J; Abalos-Aguilera, MC; Ruiz-Vilchez, D; Seguí, P; Merlo, C; Perez-Venegas, J; Montesino, MDR; Rodriguez-Escalera, C; Barco, CR; Fernandez-Nebro, A; Vazquez, NM; Marenco, JL; Montañes, JU; Godoy-Navarrete, J; Cabezas-Lucena, AM; Estevez, EC; Aguirre, MA; González-Gay, MA; Barbarroja, N; Escudero-Contreras, A; Lopez-Pedrerá, C	Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs	BIOMEDICINE & PHARMACOTHERAPY	6.9	D1	Article	2024
DA-06	Pinto-Bonilla, R; Baeza-Noci, J; Blanco, CC; Gumbau, GJV; Fernández, RJ; Pascual-Pastor, M; Magamón, BG; Lamothe, BP; Pastor, CM; Aviñó, RI; Aguilar, EG; Saz-Leal, P	Real-world effectiveness and safety of combined calcium 600 mg and cholecalciferol 2000 IU for treating vitamin d deficiency: Results from a nationwide study with focus in osteoporosis	BONE REPORTS	2.1	Q3	Article	2024
DA-06	Espíldora-Hernández, J; Díaz-Antonio, T; Olmedo-Llanes, J; León, JZ; Rioja, J; Valdivielso, P; Sánchez-Chaparro, MA; Ariza, MJ	Clinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
DA-06	Barbadillo-Villanueva, S; del Aguila, VA; Robustillo-Cortés, MD; Gimeno-Gracia, M; Yáñez, ES; Hermenegildo-Caudevilla, M; Aznárez, HN; López, AL; Vicente, E; Monte-Boquet, E	Telematic interview in telepharmacy: consensus document for pharmacotherapeutic monitoring and informed drug delivery	FARMACIA HOSPITALARIA	1.0	Q4	Article	2024
DE-02	López-Cortés, LE; Delgado-Valverde, M; Moreno-Mellado, E; Aguirre, JG; Carrión, LG; Vidal, MJB; Soria, LML; Pérez-Rodríguez, MT; Lamas, LM; de las Revillas, FA; Arminanzas, C; de Alegría-Puig, CR; Aguilar, PJ; Martínez-Rubio, MD; Sáez-Bejar, C; de las Cuevas, C; Martín-Aspas, A; Galán, F; Yuste, JR; Leiva-León, J; Bou, G; González, PC; Boix-Palop, L; Xercavins-Valls, M; Goenaga-Sánchez, MA; Anza, DV; Castón, JJ; Rufián, MR; Merino, E; Rodríguez, JC; Loeches, B; Cuervo, G; Laso, JMG; Plata, A; Cortés, SP; Mato, PL; Monzón, JLS; Rosso-Fernández, C; Bravo-Ferrer, J; Retamar-Gentil, P; Rodríguez-Baño, J	Efficacy and safety of a structured de-escalation from antipseudomonal β -lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial	LANCET INFECTIOUS DISEASES	36.0	D1	Article	2024
DE-02	Maldonado, N; López-Hernández, I; García-Montaner, A; López-Cortés, LE; Pérez-Crespo, PMM; Retamar-Gentil, P; Sousa-Domínguez, A; Goikoetxea, J; Pulido-Navazo, A; Labayru-Echeverría, C; Natera-Kindelán, C; Jover-Sáenz, A; del Arco-Jiménez, A; Armiñanzas-Castillo, C; Aller, AI; Fernández-Suárez, J; Marrodán-Ciordia, T; Boix-Palop, L; Smithson-Amat, A; Reguera-Iglesias, JM; Galán-Sánchez, F; Bahamonde, A; Calvo, JMS; Gea-Lázaro, I; Pérez-Camacho, I; Reyes-Bertos, A; Becerril-Carral, B; Rodríguez-Baño, J; Pascual, A	Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study	LANCET MICROBE	21.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-02	Maldonado, N; López-Hernández, I; López-Cortés, LE; Pérez-Crespo, PMM; Retamar-Gentil, P; García-Montaner, A; Riestra, SD; Sousa-Domínguez, A; Goikoetxea, J; Pulido-Navazo, A; Ortíz, MD; Natera-Kindelán, C; Jover-Sáenz, A; del Arco-Jiménez, A; Armiñanzas-Castillo, C; Aller-García, AI; Fernández-Suárez, J; Marrodán-Ciordia, T; Boix-Palop, L; Smithson-Amat, A; Reguera-Iglesias, JM; Galán-Sánchez, F; Bahamonde, A; Sánchez-Calvo, JM; Gea-Lázaro, I; Pérez-Camacho, I; Reyes-Bertos, A; Becerril-Carral, B; Pascual, A; Rodríguez-Baño, J	Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study	CLINICAL MICROBIOLOGY AND INFECTION	11.0	D1	Article	2024
DE-02	Paniagua-García, M; Bravo-Ferrer, JM; Pérez-Galera, S; Kostyanev, T; de Kraker, MEA; Feifel, J; Palacios-Baena, ZR; Schotsman, J; Cantón, R; Daikos, GL; Carevic, B; Dragovac, G; Tan, LK; Raka, L; Hristea, A; Viale, P; Akova, M; Cano, A; Reguera, JM; Bartoloni, A; Florescu, SA; Benea, S; Bukarica, L; Asensio, A; Kortén, V; Grundmann, H; Goossens, H; Bonten, MJ; Gutiérrez-Gutiérrez, B; Rodríguez-Baño, J	Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)	CLINICAL MICROBIOLOGY AND INFECTION	11.0	D1	Article	2024
DE-02	Fernandez-Garcia, MD; Garcia-Ibañez, N; Camacho, J; Gutierrez, A; García, LS; Calvo, C; Moreno-Docón, A; Menasalvas, AI; Medina, A; Perez-Ruiz, M; Toboso, MCN; Munoz-Almagro, C; Launes, C; Berengua, C; Cabrerizo, M	Enhanced echovirus 11 genomic surveillance in neonatal infections in Spain following a European alert reveals new recombinant forms linked to severe cases, 2019 to 2023	EUROSURVEILLANCE	10.0	D1	Article	2024
DE-02	Corma-Gómez, A; Cabello, A; Orviz, E; Morante-Ruiz, M; Ayerdi, O; Al-Hayani, A; Muñoz-Gómez, A; De Los Santos, I; Gómez-Ayerbe, C; Rodrigo, D; Riestra, SDR; Reus-Bañuls, S; Silva-Klug, A; Galindo, MJ; Santos, M; Serrano-Fuentes, M; Faro-Míguez, N; Pérez-Camacho, I; Corona-Mata, D; Morano, L; López-Ruz, MA; Montero, M; Anaya-Baz, B; Merino, D; Castillo-Navarro, A; Pineda, JA; Macías, J	Long or complicated mpox in patients with uncontrolled HIV infection	JOURNAL OF MEDICAL VIROLOGY	6.8	D1	Article	2024
DE-02	Alvarez-Zaballos, S; Vázquez-Alen, P; Muñoz, P; de Alarcón, A; Carretero, EG; Alvarez-Uría, A; Fariñas, MC; Rodríguez-García, R; Goenaga, MA; Cuervo, G; Plata-Ciezar, A; Hidalgo-Tenorio, C; Aldamiz-Echevarría, G; Martínez-Sellés, M	Prevalence and prognostic impact of stroke in a national cohort of infective endocarditis	INTERNATIONAL JOURNAL OF STROKE	6.3	D1	Article	2024
DE-02	Escrihuella-Vidal, F; Palacios-Baena, ZR; Agirre, JG; Pérez-Rodríguez, MT; Iglesias, JMR; Pedragosa, JC; Gómez, LS; Boix-Palop, L; Carrasco, AB; Natera-Kindelán, C; Fernández-Suárez, J; Jover-Sáenz, A; Amat, AS; Jiménez, AD; Calvo, JMS; Martín-Aspas, A; Perez-Crespo, PMM; López-Hernández, I; Rodríguez-Baño, J; López-Cortés, LE	Early Antibiotic De-escalation in Patients With Severe Infections Due to Bloodstream Infection by Enterobacterales: A Post Hoc Analysis of a Prospective Multicentre Cohort	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS	4.9	Q1	Article	2024
DE-02	de la Rosa-Riestra, S; Pérez-Crespo, PMM; Rodríguez, MTP; Sousa, A; Goikoetxea, J; Iglesias, JMR; Arminanzas, C; López-Hernández, I; López-Cortés, LE; Rodríguez-Baño, J	Mortality impact of further delays in active targeted antibiotic therapy in bacteraemic patients that did not receive initial active empiric treatment: Results from the prospective, multicentre cohort PROBAC	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	4.8	Q1	Article	2024
DE-02	Guedes, M; Gathara, D; López-Hernández, I; Pérez-Crespo, PMM; Pérez-Rodríguez, MT; Sousa, A; Plata, A; Reguera-Iglesias, JM; Boix-Palop, L; Dietl, B; Blanco, JS; Castillo, CA; Galán-Sánchez, F; Kindelán, CN; Jover-Saenz, A; Aguirre, JG; Alemán, AA; Ciordia, TM; Jiménez, AD; Fernandez-Suarez, J; Lopez-Cortes, LE; Rodríguez-Baño, J	Differences in clinical outcomes of bloodstream infections caused by Klebsiella aerogenes, Klebsiella pneumoniae and Enterobacter cloacae: a multicentre cohort study	ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS	4.6	Q1	Article	2024
DE-02	Tamimi, I; Gasca, M; Halbardier, A; Martin, S; Caballero, GM; Serrano, CL; Martin, E; Tamimi, F; González-Quevedo, D; de Quevedo, DG; Sobrino, B; Palop, B; Guerado, E; Lara, AP; Urdiales, C; de Gabriel, JMG	The treatment of bacterial biofilms cultivated on knee arthroplasty implants using the bioelectric effect	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY	4.3	Q1	Article	2024
DE-02	De la Rosa-Riestra, S; López-Hernández, I; Pérez-Rodríguez, MT; Sousa, A; Agirre, JG; Iglesias, JMR; León, E; Castillo, CA; Gómez, LS; Fernández-Natal, I; Fernández-Suárez, J; Boix-Palop, L; Pedragosa, JC; Jover-Sáenz, A; Calvo, JMS; Martín-Aspas, A; Natera-Kindelán, C; Jimenez, AD; Carrasco, AB; Amat, AS; García, DV; Pérez-Crespo, PMM; López-Cortés, LE; Rodríguez-Baño, J	A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study	JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY	3.9	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-02	Scharloo, F; Dezza, FC; López-Hernández, I; Pérez-Crespo, PMM; Aguirre, AJG; Pérez-Rodríguez, MT; Fernandez-Suarez, J; Jiménez, EL; Rodríguez, MAM; Fernández-Natal, I; Iglesias, JMR; Kindelán, CN; Alvares, MCF; Boix-Palop, L; Lopez-Cortes, LE; Rodríguez-Baño, J	Clinical characteristics, predisposing factors and outcomes for Enterococcus faecalis versus Enterococcus faecium bloodstream infections: a prospective multicentre cohort study	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES	3.7	Q2	Article	2024
DE-02	Benito, N; Martinez-Pastor, JC; Lora-Tamayo, J; Ariza, J; Baeza, J; Belzunegui-Otano, J; Cobo, J; del-Toro, MD; Fontecha, CG; Font-Vizcarra, L; Horcajada, JP; Morata, L; Murillo, O; Nolla, JM; Nunez-Cuadros, E; Pigrau, C; Portillo, ME; Rodriguez-Pardo, D; Sobrino-Diaz, B; Saavedra-Lozano, J	Executive summary: Guidelines for the diagnosis and treatment of septic arthritis in adults and children, developed by the GEIO (SEIMC), SEIP and SECOT	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.6	Q3	Article	2024
DE-07	Reta-Pérez, O; Colmenero-Ruiz, M; Hernández-Socorro, CR; Saavedra, P; Maichle, SF; Portugal, E; Cerezo-Arias, M; Alés, LS; Martínez-Carmona, JF; Mateu-Campos, L; Lorenzo-Cárdenas, C; García-Miguelé, A; Sosa-Durr, M; San Martín-Bragado, M; Ruiz-Santana, S	Trophic Nutrition in ICU Patients Undergoing High-Flow Oxygen Therapy and/or Noninvasive Mechanical Ventilation: The Nutri-Trophic Study	NUTRIENTS	4.8	Q1	Article	2024
DE-07	Herrera-Linares, ME; Rico-Pérez, B; Yaffy, D; Fernández-Parra, R; Llanos, C; Parra-Martínez, C; Herrera-Gutiérrez, ME; Sanchis-Mora, S	Cadaveric study of the ultrasound-guided erector spinae plane block over the transverse process of the twelfth thoracic vertebra in dogs: Transversal vs longitudinal approach	VETERINARY JOURNAL	2.3	Q1	Article	2024
DE-07	Gordillo-Resina, M; Aranda-Martinez, C; Arias-Verdú, MD; Guerrero-López, F; Castillo-Lorente, E; Rodríguez-Rubio, D; Rivera-López, R; Rosa-Garrido, C; Gómez-Jiménez, FJ; Lafuente-Baraza, J; Aguilar-Alonso, E; Arráez-Sanchez, MA; Rivera-Fernández, R	Mortality, Functional Status, and Quality of Life after 5 Years of Patients Admitted to Critical Care for Spontaneous Intracerebral Hemorrhage	NEUROCRITICAL CARE	3.1	Q2	Article	2024
DE-07	Trasobares, NQ; González-Fernández, M; Barea-Mendoza, JA; Arias-Verdú, MD; Barrueco-Francioni, JE; Seller-Pérez, G; Molina-Collado, Z; Gonzalez-de Aledo, AL; Herrera-Gutiérrez, M; Riera, JASI	The Role of Immunomodulatory Therapy with Oxiris in COVID-19 with Renal Failure and Immune Dysfunction	BLOOD PURIFICATION	2.2	Q2	Article	2024
DE-07	Subirà, C; Rognoni, G; Baquerizo, H; Garcia, C; Cabanes, S; de la Torre, M; Quevedo, B; Pedros, C; Tizon, AI; Murillo, N; Parro, L; Eiras, F; Rialp, G; Altaba, S; Gonzalez-Castro, A; Pacheco, AF; Bayoumi, P; Gomez-Medrano, N; Vallverdu, I; Higon, A; Navarro, MD; Falcon, A; Keough, E; Arizo, D; Martinez, JF; Duran, N; Rodriguez, R; Popoviciu-Koborzan, MR; Guerrero, I; Concha, P; Barral, P; Battle, M; Cano, S; Garcia-Castrillon, S; Andorra, X; Tua, Y; Arnau, A; Fernandez, R	Effect of lung volume preservation during spontaneous breathing trial on successful extubation in patients receiving mechanical ventilation: protocol for a multicenter clinical trial	TRIALS	2.0	Q3	Article	2024
DE-07	Barrueco-Francioni, JE; Martinez-González, MC; Martínez-Carmona, JF; Benítez-Moreno, MP; Aragón-Gonzalez, C; Herrera-Gutiérrez, ME	ECMO in severe hypoxemia post liver transplant for hepatopulmonary syndrome	INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS	1.4	Q3	Article	2024
DE-08	Rodríguez-Perálvarez, ML; de la Rosa, G; Gómez-Orellana, AM; Aguilera, MV; Vicente, TP; Pereira, S; Ortiz, ML; Pagano, G; Suarez, F; Grande, RG; Cachero, A; Tomé, S; Barreales, M; Mateos, RM; Pascual, S; Romero, M; Bilbao, I; Martín, CA; Otón, E; Diéguez, LG; Espinosa, MD; Milla, AA; Fernández, GB; Lorente, S; Lavín, AC; García, AR; Cano, CS; Cepeda-Franco, C; Pons, JA; Colmenero, J; Guijo-Rubio, D; Otero, A; Navarrete, AA; Moreno, SR; Soler, MR; Martínez, CH; Gastaca, M	GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study	ECLINICALMEDICINE	9.6	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-08	Perrone, G; Giuffrida, M; Abu-Zidan, F; Kruger, VF; Livrini, M; Petracca, GL; Rossi, G; Tarasconi, A; Tian, BWCA; Bonati, E; Mentz, R; Mazzini, FN; Campana, JP; Gasser, E; Kafka-Ritsch, R; Felsenreich, DM; Dawoud, C; Riss, S; Gomes, CA; Gomes, FC; Gonzaga, RAT; Canton, CAB; Pereira, BM; Fraga, GP; Zem, LG; Cordeiro-Fonseca, V; Tauil, RD; Atanasov, B; Belev, N; Kovachev, N; Meléndez, LJJ; Dimova, A; Dimov, S; Zelic, Z; Augustin, G; Bogdanic, B; Moric, T; Chouillard, E; Bajul, M; De Simone, B; Panis, Y; Esposito, F; Notarnicola, M; Lauka, L; Fabbri, A; Hentati, H; Fnaiech, I; Aurélien, V; Bougard, M; Roulet, M; Demetrashvili, Z; Pipia, I; Merabishvili, G; Bouliaris, K; Koukoulis, G; Doudakmanis, C; Xenaki, S; Chrysos, E; Kokkinakis, S; Vassiliu, P; Michalopoulos, N; Margaris, I; Kechagias, A; Avgerinos, K; Katunin, J; Lostoridis, E; Nagorni, EA; Pujante, A; Mulita, F; Maroulis, I; Vailas, M; Marinis, A; Siannis, I; Bourbouteli, E; Manatakis, DK; Tasis, N; Acheimastos, V; Maria, S; Stylianos, K; Kuzeridis, H; Korkolis, D; Fradelos, E; Kavalieratos, G; Petropoulou, T; Polydorou, A; Papacostantinou, I; Triantafyllou, T; Kimpizi, D; Theodorou, D; Toutouzas, K; Chamzin, A; Frountzas, M; Schizas, D; Karavokyros, I; Syllaïos, A; Charalabopoulos, A; Boura, M; Baili, E; Ioannidis, O; Loutzidou, L; Anestiadou, E; Tsouknidas, I; Petrakis, G; Polenta, E; Bains, L; Gupta, R; Singh, SK; Khanduri, A; Bala, M; Kedar, A; Pisano, M; Podda, M; Pisanu, A; Martines, G; Trigiante, G; Lantone, G; Agrusa, A; Di Buono, G; Buscemi, S; Veroux, M; Gioco, R; Veroux, G; Oragano, L; Zonta, S; Lovisetto, F; Feo, CV; Pesce, A; Fabbri, N; Lantone, G; Marino, F; Perrone, F; Vincenti, L; Papagni, V; Picciariello, A; Rossi, S; Picardi, B; Del Monte, SR; Visconti, D; Osella, G; Petruzzelli, L; Pignata, G; Andreuccetti, J; D'Alessio, R; Buonfantino, M; Guaitoli, E; Spinelli, S; Sampietro, GM; Corbellini, C; Lorusso, L; Frontali, A; Pezzoli, I; Bonomi, A; Chierici, A; Cotsoglou, C; Manca, G; Delvecchio, A; Musa, N; Casati, M; Letizia, L; Abate, E; Ercolani, G; D'Acapito, F; Solaini, L; Guercioni, G; Cicconi, S; Sasia, D; Borghi, F; Giraudo, G; Sena, G; Castaldo, P; Cardamone, E; Portale, G; Zuin, M; Spolverato, Y; Esposito, M; Isernia, RM; Di Salvo, M; Manunza, R; Esposito, G; Agus, M; Asti, ELG; Bernardi, DT; Tonucci, TP; Luppi, D; Casadei, M; Bonilauri, S; Pezzolla, A; Panebianco, A; Laforgia, R; De Luca, M; Zese, M; Parini, D; Jovine, E; De Sario, G; Lombardi, R; Aprea, G; Palomba, G; Capuano, M; Argenio, G; Orio, G; Armellino, MF; Troian, M; Guerra, M; Nagliati, C; Biloslavo, A; Germani, P; Aizza, G; Monsellato, I; Chahrour, AC; Anania, G; Bombardini, C; Bagolini, F; Sganga, G; Fransvea, P; Bianchi, V; Boati, P; Ferrara, F; Palmieri, F; Cianci, P; Gattulli, D; Restini, E; Cillara, N; Cannavera, A; Nita, GE; Sarnari, J; Roscio, F; Clerici, F; Scandroglio, I; Berti, S; Cadeo, A; Filippelli, A; Conti, L; Grassi, C; Cattaneo, GM; Pighin, M; Papis, D; Gambino, G; Bertino, V; Schifano, D; Prando, D; Fogato, L; Cavallo, F; Ansaloni, L; Picheo, R; Pontarolo, N; Depalma, N; Spampinato, M; D'Ugo, S; Lepre, L; Capponi, MG; Campa, RD; Sarro, G; Dinuzzi, VP; Olmi, S; Uccelli, M; Ferrari, D; Inama, M; Moretto, G; Fontana, M; Favi, F; Picariello, E; Rampini, A; Barberis, A; Azzinnaro, A; Oliva, A; Totaro, L; Benzoni, I; Ranieri, V; Capolupo, GT; Carannante, F; Caricato, M; Ronconi, M; Casiraghi, S; Casole, G; Pantalone, D; Alemanno, G; Scheiterle, M; Ceresoli, M; Cereda, M; Fumagalli, C; Zanzi, F; Bolzon, S; Guerra, E; Lecchi, F; Cellerino, P; Ardito, A; Scaramuzzo, R; Balla, A; Lepiane, P; Tartaglia, N; Ambrosi, A; Pavone, G; Palini, GM; Veneroni, S; Garulli, G; Ricci, C; Torre, B; Russo, IS; Rottoli, M; Tanzanu, M; Belvedere, A; Milone, M; Manigrasso, M; De Palma, GD; Piccoli, M; Pattacini, GC; Magnone, S; Bertoli, P; Pisano, M; Massucco, P; Palisi, M; Luzzi, AP; Fleres, F; Clarizia, G; Spolini, A; Kobe, Y; Toma, T; Shimamura, F; Parker, R; Ranketi, S; Mitei, M; Svagzdys, S; Pauzas, H; Zilinskas, J; Poskus, T; Kryzauskas, M; Jakubauskas, M; Zakaria, AD; Zakaria, Z; Wong, MPK; Jusoh, AC; Zakaria, MN; Cruz, DR; Elizalde, ABR; Reynaud, AB; Hernandez, EEL; Monroy, JMVP; Hinojosa-Ugarte, D; Quiodettis, M; Du Bois, ME; Latorraca, J; Major, P; Pedziwiatr, M; Pisarska-Adamczyk, M; Waledziak, M; Kwiatkowski, A; Czyzykowski, L; da Costa, SD; Pereira, B; Ferreira, ARO; Almeida, F; Rocha, R; Carneiro, C; Perez, DP; Carvas, J; Rocha, C; Ferreira, C; Marques, R; Fernandes, U; Leao, P; Goulart, A; Pereira, RG; Patrociinio, SDD; de Mendonça, NGG; Manso, MIC; Morais, HMC; Cardoso, PS; Calu, V; Miron, A; Toma, EA; Gachabayov, M; Abdullaev, A; Litvin, A; Nechay, T; Tyagunov, A; Yuldashev, A; Bradley, A; Wilson, M; Panyko, A; Látecková, Z; Lacko, V; Lesko, D; Soltes, M; Radonak, J; Turrado-Rodriguez, V; Termes-Serra, R; Morales-Sevillano, X; Lapolla, P; Mingoli, A; Brachini, G; Degiuli, M; Sofia, S; Reddavid, R; Garberini, AD; Buffone, A; del Pozo, EP; Aparicio-Sánchez, D; Dos Barbeito, S; Estaire-Gómez, M; Vitón-Herrero, R; Olarte-Marquez, MDG; Gil-Martínez, J; Alconchel, F; Nicolás-López, T; Rahy-Martin, AC; Pelloni, M; Bañolas-Suarez, R;	Goodbye Hartmann trial: a prospective, international, multicenter, observational study on the current use of a surgical procedure developed a century ago	WORLD JOURNAL OF EMERGENCY SURGERY	6.0	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-08	Mendoza-Moreno, F; Nisa, FGM; Díez-Alonso, M; Rodas, MEV; Agundez, MC; Andrés, MIP; Moreira, CCL; Perez, AL; Ponce, IA; González-Castillo, AM; Membrilla-Fernández, E; Salvans, S; Serradilla-Martín, M; Pardo, PS; Rivera-Alonso, D; Dziakova, J; Huguet, JM; Valle, NP; Ruiz, EC; Valcarcel, CR; Moreno, CR; Salazar, YTM; Garcia, JJR; Mico, SS; López, JR; Farré, SP; Gomez, MS; Petit, NM; Titos-García, A; Aranda-Narváez, JM; Romacho-López, L; Sánchez-Guillén, L; Aranaz-Ostariz, V; Bosch-Ramírez, M; Martínez-Pérez, A; Martínez-López, E; Sebastián-Tomás, JC; Jimenez-Riera, G; Jimenez-Vega, J; Cuellar, JAN; Campos-Serra, A; Muñoz-Campaña, A; Gràcia-Roman, R; Alegre, JM; Pinto, FL; O'Sullivan, SN; Antona, FB; Jiménez, BM; López-Sánchez, J; Carmona, ZG; Fernández, RT; Sierra, IB; de León, LRG; Moreno, VP; Iglesias, E; Cumplido, PL; Bravo, AA; Simó, IR; Domínguez, CL; Caamaño, AG; Lozano, RC; Martínez, MD; Torres, AN; de Quiros, JTMB; Pellino, G; Cloquell, MM; Moller, EG; Jalal-Eldin, S; Abdoun, AK; Hamid, HKS; Lohsiriwat, V; Mongkhonsupphawan, A; Baraket, O; Ayed, K; Abbassi, I; Ben Ali, A; Ammar, H; Kchaou, A; Tlili, A; Zribi, I; Colak, E; Polat, S; Koylu, ZA; Guner, A; Usta, MA; Reis, ME; Mantoglu, B; Gonullu, E; Akin, E; Altintoprak, F; Bayhan, Z; Firat, N; Isik, A; Memis, U; Bayrak, M; Altintas, Y; Kara, Y; Bozkurt, MA; Kocatas, A; Das, K; Seker, A; Ozer, N; Atici, SD; Tuncer, K; Kaya, T; Ozkan, Z; Ilhan, O; Agackiran, I; Uzunoglu, MY; Demirbas, E; Altinel, Y; Meric, S; Hacim, NA; Uymaz, DS; Omarov, N; Balik, E; Tebala, GD; Khalil, H; Rana, M; Khan, M; Florence, C; Swaminathan, C; Leo, CA; Liasis, L; Watfah, J; Trostchansky, I; Delgado, E; Pontillo, M; Latifi, R; Coimbra, R; Edwards, S; Lopez, A; Velmahos, G; Dorken, A; Gebran, A; Palmer, A; Oury, J; Bardes, JM; Seng, SS; Coffua, LS; Ratnasekera, A; Egodage, T; Echeverria-Rosario, K; Armento, I; Napolitano, LM; Sangji, NF; Hemmila, M; Quick, JA; Austin, TR; Hyman, TS; Curtiss, W; McClure, A; Cairl, N; Biffl, WL; Truong, HP; Schaffer, K; Reames, S; Banchini, F; Capelli, P; Cocolini, F; Sartelli, M; Bravi, F; Vallicelli, C; Agnoletti, V; Baiocchi, GL; Catena, F	Goodbye Hartmann trial: a prospective, international, multicenter, observational study on the current use of a surgical procedure developed a century ago	WORLD JOURNAL OF EMERGENCY SURGERY	6.0	D1	Article	2024
DE-08	Jiménez-Cortegana, C; López-Enríquez, S; Alba, G; Santa-María, C; Martín-Núñez, GM; Moreno-Ruiz, FJ; Valdés, S; García-Serrano, S; Rodríguez-Díaz, C; Ho-Plágaro, A; Fontalba-Romero, MI; García-Fuentes, E; Garrido-Sánchez, L; Sánchez-Margalet, V	The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver Function	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2024
DE-08	Bastón-Rey, I; Rodríguez-Lago, I; Luque, AM; Caballol, B; Soutullo-Castiñeiras, C; Bravo, A; Castaño, A; Gros, B; Bernal, L; Diz-Lois, MT; Alonso-Galan, H; Canete, F; Castro, B; Perez-Galindo, P; Gonzalez-Munoz, C; El Hajra, I; Martínez-Montiel, P; Alonso-Abreu, I; Mesonero, F; González-Vivo, M; Peries, L; Martín-Arranz, E; Abril, C; Marín-Jiménez, I; Baltar, R; Vicuña, M; Moreno, N; Brunet, E; de Célix, CR; Fajardo, I; Cruz, N; Calvino-Suárez, C; Rojas-Feria, M; Fernández-Clotet, A; Gimeno-Torres, M; Nieto-Garcia, L; de la Iglesia, D; Zabana, Y; Suarez-Ferrer, C; de Acosta, MB	The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU	INFLAMMATORY BOWEL DISEASES	4.5	Q1	Article	2024
DE-08	Serradilla-Martín, M; Villodre, C; Falgueras-Verdaguer, L; Zambudio-Carroll, N; Castell-Gómez, JT; Blas-Laina, JL; Borrego-Estella, V; Domingo-del-Pozo, C; García-Plaza, G; González-Rodríguez, FJ; Montalvá-Orón, EM; Moya-Herraiz, A; Paterna-López, S; Suárez-Muñoz, MA; Alkorta-Zuloaga, M; Blanco-Fernández, G; Dabàn-Collado, E; Gómez-Bravo, MA; Miota-de-Llamas, JI; Rotellar, F; Sánchez-Pérez, B; Sanchez-Cabus, S; Pacheco-Sanchez, D; Rodríguez-Sanjuan, JC; Varona-Bosque, MA; Carrión-Alvarez, L; de la Serna-esteban, S; Dopazo, C; Martín-Pérez, E; Martínez-Cecilia, D; Castro-Santiago, MJ; Dorcaratto, D; Gutiérrez-Díaz, ML; Asencio-Pascual, JM; Burdio-Pinilla, F; Carracedo-Iglesias, R; Escartín-Arias, A; Ielpo, B; Rodríguez-Laiz, G; Valdivieso-López, A; De-Vicente-López, E; Alonso-Orduña, V; Ramia, JM	Feasibility and Short-Term Outcomes in Liver-First Approach: A Spanish Snapshot Study (the RENACI Project)	CANCERS	4.5	Q1	Article	2024
DE-08	Burgos, MM; Grande, RG; Ortega, SL; Leiva, IS; Lombardo, JD; Santoyo, JS; Pérez, MJ	Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence	BIOMEDICINES	3.9	Q1	Article	2024
DE-08	Ramia, JM; Villodre-Tudela, C; Falgueras-Verdaguer, L; Zambudio-Carroll, N; Castell-Gómez, JT; Carbonell-Morote, S; Blas-Laina, JL; Borrego-Estella, V; Sánchez-Pérez, B; Serradilla-Martín, M	Textbook outcomes in the liver-first approach for colorectal liver metastases: prospective multicentre analysis	BJS OPEN	3.4	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-08	González, MB; Martín, RVO; Bermúdez, AIM; Pérez, MJ	Characterization of Inflammatory Bowel Disease in the Elderly According to Age of Onset	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
DE-08	Reyes, MP; Pérez, BS; González, CS; Daga, JAP; Villalba, JS; Santoyo, JS	Implementation of an ERAS protocol on cirrhotic patients in liver resection: a cohort study	UPDATES IN SURGERY	2.4	Q1	Article	2024
DE-08	Bilbao, I; Lladó, L; Cachero, A; Campos-Varela, I; Colmenero, J; del Hoyo, J; García, EF; Pajares, FG; Diéguez, LG; Grande, RG; Sánchez, AG; Oliveros, FH; Santos, JIH; Lorente, S; Mateos, RM; López, MJM; Alvarez, JLM; Codoceo, CM; Ferreiro, AO; Nieto, EO; Soler, MR; Cristóbal, MR; Oliver, LS; Labiano, MS; Martín, JMS; Trapero-Marugán, M; Varo, E; de la Rosa, G; Rodríguez-Perálvarez, ML	First consensus document of waiting list prioritization for liver transplantation by the Spanish Society of Liver Transplantation (SETH)	REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS	2.7	Q2	Article	2024
DE-08	Rojas-Holguín, A; Fondevila-Campo, C; Sanjuanbenito, A; Fabregat-Prous, J; Secanella-Medayo, L; Rotellar-Sastre, F; Pardo-Sánchez, F; Prieto-Calvo, M; Marín-Ortega, H; Sánchez-Cabús, S; Diez-Valladares, L; Alonso-Casado, O; González-Serrano, C; Rodríguez-Sanjuan, JC; García-Plaza, G; Jaén-Torrejimeno, I; Suárez-Muñoz, MA; Becerra-Massare, A; Rio, PSD; Pando, E; López-Andújar, R; Muñoz-Forner, E; Rodríguez-López, M; Pereira, F; Serrablo-Requejo, A; Turrión, VS; Garrido, MJ; Burdío, F; Martín-Pérez, E; Estevan-Estevan, R; López-Guerra, D; Castell-Gómez, J; Salinas-Gómez, J; López-Baena, JA; López-Ben, S; Solar-Garcia, L; Perez-Alonso, AJ; Martinez-Insfran, LA; Blas, JL; Cornejo, M; Gutierrez-Calvo, A; Pozo, CDD; Ochando-Cerdan, F; Muñoz-Bellvís, L; Rebollar-Saenz, J; Sánchez, B; Jover, JM; Gómez-Bravo, MA; Ramia, JM; Blanco-Fernández, G	Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)	SURGICAL ONCOLOGY- OXFORD	2.3	Q2	Article	2024
DE-08	Aranda-Nárvaez, JM; Fernández-Galeano, P; Romacho-López, L; Cabrera-Serna, I; Titos-García, A; Mirón-Fernández, I; Santoyo-Santoyo, J	Improving early cholecystectomy rate in acute cholecystitis with an evidence-based local multidisciplinary protocol and a surgical audit: single-center experience through an Acute Care Surgery Division	LANGENBECKS ARCHIVES OF SURGERY	2.1	Q2	Article	2024
DE-08	Sánchez-Pérez, B; Ramia, JM	Does enhanced recovery after surgery programs improve clinical outcomes in liver cancer surgery?	WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY	2.5	Q3	Editorial Material	2024
DE-08	Ramia, JM; Villodre, C; Pérez, BS; Verdaguer, LF; Martín, MS	Postoperative complications after liver-first surgery. RENACI Project	CIRUGIA ESPANOLA	1.3	Q3	Editorial Material	2024
DE-09	Borrego-Ruiz, A; Borrego, JJ	An updated overview on the relationship between human gut microbiome dysbiosis and psychiatric and psychological disorders	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	5.3	D1	Article	2024
DE-09	Souto, S; Oliveira, JG; López-Vázquez, C; Dopazo, CP; Labella, A; Bandín, I	Nervous necrosis virus (NNV) vaccination of carrier Senegalese sole (<i>Solea senegalensis</i>)	AQUACULTURE	3.9	D1	Article	2024
DE-09	Leiva-Rebollo, R; Labella, AM; Gémez-Mata, J; Castro, D; Borrego, JJ	Fish Iridoviridae: infection, vaccination and immune response	VETERINARY RESEARCH	3.7	D1	Review	2024
DE-09	Ortega-Prieto, A; Jimenez-Guardeño, JM	Interferon-stimulated genes and their antiviral activity against SARS-CoV-2	MBIO	5.1	Q1	Review	2024
DE-09	Borrego-Ruiz, A; Borrego, JJ	Nutritional and Microbial Strategies for Treating Acne, Alopecia, and Atopic Dermatitis	NUTRIENTS	4.8	Q1	Review	2024
DE-09	Rosales, R; McGovern, BL; Rodriguez, ML; Leiva-Rebollo, R; Diaz-Tapia, R; Benjamin, J; Rai, DK; Cardin, RD; Anderson, AS; Sordillo, EM; van Bakel, H; Simon, V; Garcia-Sastre, A; White, KM	Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants	ANTIVIRAL RESEARCH	4.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-09	Borrego-Ruiz, A; González-Domenech, CM; Borrego, JJ	The Role of Fermented Vegetables as a Sustainable and Health-Promoting Nutritional Resource	APPLIED SCIENCES-BASEL	2.5	Q1	Review	2024
DE-09	Borrego-Ruiz, A; Borrego, JJ	Microbial Dysbiosis in the Skin Microbiome and Its Psychological Consequences	MICROORGANISMS	4.1	Q2	Review	2024
DE-09	Jimenez-Guardeño, JM; Menéndez-Arias, L; Betancor, G	Editorial: Host factors involved in viral infection	FRONTIERS IN MICROBIOLOGY	4.0	Q2	Editorial Material	2024
DE-09	Ortega-Prieto, AM; Regla-Nava, JA; Jimenez-Guardeño, JM	Editorial: Interferon response against viral infections	FRONTIERS IN MICROBIOLOGY	4.0	Q2	Editorial Material	2024
DE-09	Borrego-Ruiz, A; Borrego, JJ	Influence of human gut microbiome on the healthy and the neurodegenerative aging	EXPERIMENTAL GERONTOLOGY	3.3	Q2	Review	2024
DE-09	Borrego-Ruiz, A; Borrego, JJ	Epigenetic Mechanisms in Aging: Extrinsic Factors and Gut Microbiome	GENES	2.8	Q2	Review	2024
DE-09	Borrego-Ruiz, A; Borrego, JJ	Neurodevelopmental Disorders Associated with Gut Microbiome Dysbiosis in Children	CHILDREN-BASEL	2.0	Q2	Review	2024
DE-09	de Andrade, JR; Scourfield, E; Peswani-Sajnani, SL; Poulton, K; ap Rees, T; Khooshemehri, P; Doherty, G; Ong, S; Ivan, IF; Goudarzi, N; Gardiner, I; Caine, E; Maguire, TJA; Leightley, D; Torrico, L; Gasulla, A; Menendez-Vazquez, A; Ortega-Prieto, AM; Pickering, S; Jimenez-Guardeño, JM; Batra, R; Rubinchik, S; Tan, AVF; Griffin, A; Sherrin, D; Papaioannou, S; Trouillet, C; Mischo, HE; Giralt, V; Wilson, S; Kirk, M; Neil, SJD; Galao, RP; Martindale, J; Curtis, C; Zuckerman, M; Razavi, R; Malim, MH; Martinez-Nunez, RT	KCL TEST: an open-source inspired asymptomatic SARS-CoV-2 surveillance programme in an academic institution	BIOLOGY METHODS & PROTOCOLS	2.5	Q3	Article	2024
DE-09	Borrego Ruiz, A; Borrego, JJ	Influence of the vegetarian diet on the human intestinal microbiome	NUTRICION CLINICA Y DIETETICA HOSPITALARIA	0.4	Q4	Article	2024
DE-10	Francisco, ZM; Sara, MM; José-María, SG; Facundo, U; Carlos, RD; María, GL; Jessica, M; Carmen, AL; Santiago, OP; Carlos, SEJ	Standardized clinical evaluation of dry anophthalmic socket syndrome in a real-world approach	CONTACT LENS & ANTERIOR EYE	4.1	Q1	Article	2024
DE-10	Bueno, JAR; Sánchez-Guijo, G; Ráez, PD; García-Arnes, JA; Garzón-Maldonado, FJ; Castro, VS; de la Cruz-Cosme, C; Alba-Linero, C; Gutiérrez-Bedmar, M; García-Casares, N	Effects of Type 2 Diabetes on the Neuropsychological Profile in Mild Cognitive Impairment	JOURNAL OF ALZHEIMERS DISEASE	3.4	Q2	Article	2024
DE-10	Mesa-del-Castillo, P; Ugarte, IY; Bolarín, JM; Martínez, D; Montesinos, BL; González, HB; Penadés, IC; Pérez, LL; Clemente, D; Robledillo, JC; Ferrán, IV; Mancheño, BB; Plats, MR; Pedraz, LM; Linero, CA; Sevilla-Pérez, B; García-Serrano, JL; Mir-Perelló, MC; Druetta, N; Souto, A; Lopez-Lopez, F; Zarallo-Reales, C; Fidalgo, MJ; Fajardo, JS; Fontana, NP; Pablo, RD; Pinedo, MC; Fonollosa, A; Casano, VJ; García, JJM; Brandy, A; López, AG; Esteban-Ortega, M; Reinoso, T; Calzada-Hernández, J; Cardeñosa, AL; Martín, CG; Verdú, EM; Vidal, MPM; Martí, NQ; Alvarado, MC; De Inocencio, J; Alonso-Martín, B; Recuero-Díaz, S; Carreño, E; González, JCN; Ibares, L; de Salazar, JRG; Sevilla, JL	Childhood-Onset Non-Infectious Uveitis in the Biologic Era. Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings	OCULAR IMMUNOLOGY AND INFLAMMATION	2.6	Q2	Article	2024
DE-10	Urbinati, F; Rachwani-Anil, R; Martín, FZ; Aranda, GL; Gómez, JE	Total recovery of visual acuity in a pediatric patient with compressive optic neuropathy secondary to sphenoid sinus mucocoele	ARQUIVOS BRASILEIROS DE OFTALMOLOGIA	1.1	Q3	Article	2024
DE-10	Alba-Linero, C; Garcia-Lorente, M; Rachwani-Anil, R; Luque-Aranda, G; Pérez-Cabeza, MI; Escudero, J	Treatment of orbital lymphatic malformation with oral sirolimus: a case report Malformação linfática orbital tratada com sirolimo oral: relato de caso	ARQUIVOS BRASILEIROS DE OFTALMOLOGIA	1.1	Q3	Article	2024
F-02	Nazzal, W; Thurnhofer-Hemsi, K; López-Rubio, E	Improving Medical Image Segmentation Using Test-Time Augmentation with MedSAM	MATHEMATICS	2.3	D1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-02	Díaz-Francés, JA; Fernández-Rodríguez, JD; Thurnhofer-Hemsi, K; López-Rubio, E	Semi-Supervised Semantic Image Segmentation by Deep Diffusion Models and Generative Adversarial Networks	INTERNATIONAL JOURNAL OF NEURAL SYSTEMS	6.6	Q1	Article	2024
F-02	García-Aguilar, I; García-González, J; Medina, D; Luque-Baena, RM; Domínguez, E; López-Rubio, E	Detection of dangerously approaching vehicles over onboard cameras by speed estimation from apparent size	NEUROCOMPUTING	5.5	Q1	Article	2024
F-02	Torres-Salomón, P; Rodriguez-Capitán, J; Molina-Cabello, MA; Thurnhofer-Hemsi, K; Costa, F; Sanchez-Fernández, PL; Muñoz-Muñoz, MA; Carmona-Segovia, AD; Romero-Cuevas, M; Pavón-Morón, FJ; Jiménez-Navarro, M	Exploring the Prognostic Impact of Non-Obstructive Coronary Artery Lesions through Machine Learning	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
F-02	Molina-Cabello, MA; Serrano-Angulo, J; Benito-Picazo, J; Thurnhofer-Hemsi, K	Grades and Learning Styles: New Software for Analyzing Correlations in a Longitudinal Study Across Different Branches of Knowledge and Years	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
F-02	Khan, N; Elizondo, D; Deka, L; Molina-Cabello, MA	Natural Language Processing Tools and Workflows for Improving Research Processes	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
F-02	Atencia-Jiménez, I; Balajee, AS; Ruiz-Gómez, MJ; Sendra-Portero, F; Montoro, A; Molina-Cabello, MA	Neural Network Ensemble to Detect Dicentric Chromosomes in Metaphase Images	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
F-02	Jiménez-Partinen, A; Thurnhofer-Hemsi, K; Rodríguez-Capitán, J; Molina-Ramos, AI; Palomo, EJ	Coronary Artery Disease Classification With Different Lesion Degree Ranges Based on Deep Learning	IEEE ACCESS	3.4	Q2	Article	2024
F-02	Ruiz-Casado, JL; Molina-Cabello, MA; Luque-Baena, RM	Enhancing Histopathological Image Classification Performance through Synthetic Data Generation with Generative Adversarial Networks	SENSORS	3.4	Q2	Article	2024
F-02	Rodríguez-Rodríguez, JA; López-Rubio, E; Angel-Ruiz, JA; Molina-Cabello, MA	The Impact of Noise and Brightness on Object Detection Methods	SENSORS	3.4	Q2	Article	2024
F-02	Jiménez-Partinen, A; Molina-Cabello, MA; Thurnhofer-Hemsi, K; Palomo, EJ; Rodríguez-Capitán, J; Molina-Ramos, AI; Jiménez-Navarro, M	CADICA: A new dataset for coronary artery disease detection by using invasive coronary angiography	EXPERT SYSTEMS	3.0	Q2	Article	2024
F-02	Moyano, MAM; García-Aguilar, I; López-Rubio, E; Luque-Baena, RM	Improving Art Style Classification Through Data Augmentation Using Diffusion Models	ELECTRONICS	2.6	Q2	Article	2024
F-02	García-Aguilar, I; García-Gonzalez, J; Domínguez, E; López-Rubio, E; Luque-Baena, RM	Real-Time Deep Learning Framework for Accurate Speed Estimation of Surrounding Vehicles in Autonomous Driving	ELECTRONICS	2.6	Q2	Article	2024
F-02	Alfonso-Arsuaga, M; García-González, J; Castiella-Aguirrezabala, A; Alonso, MA; Garcés, E	DyNeRFactor: Temporally consistent intrinsic scene decomposition for dynamic NeRFs	COMPUTERS & GRAPHICS-UK	2.5	Q2	Article	2024
F-03	Vitali, V; Bucio, TD; Liu, H; González, JML; Jurado-Romero, F; Ortega-Moñux, A; Churchill, G; Gates, JC; Hillier, J; Kalfagiannis, N; Melati, D; Schmid, JH; Cristiani, I; Cheben, P; Wangüemert-Pérez, JG; Molina-Fernández, I; Gardes, F; Lacava, C; Petropoulos, P	Fully integrated and broadband Si-rich silicon nitride wavelength converter based on Bragg scattering intermodal four-wave mixing	PHOTONICS RESEARCH	6.6	Q1	Article	2024
F-03	Sánchez-Ramírez, A; Luque-González, JM; Wangüemert-Pérez, JG; Ortega-Moñux, A; Molina-Fernández, I	Comparing dielectric and plasmonic waveguides in a Mach-Zehnder architecture with coherent readout for sensing applications	OPTICS AND LASER TECHNOLOGY	4.6	Q1	Article	2024
F-03	Torres-Cubillo, A; Sanchez-Postigo, A; Jagerska, J; Wangueemert-Perez, JG; Halir, R	Simultaneous measurement of refraction and absorption with an integrated near-infrared Mach-Zehnder interferometer	OPTICS AND LASER TECHNOLOGY	4.6	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-03	Torres-Cubillo, A; Luque-González, JM; Sánchez-Postigo, A; Fernández-Gavela, A; Wangüemert-Pérez, JG; Molina-Fernández, I; Halir, R	High-Performance Bimodal Evanescent-Field Sensor With Coherent Phase Readout	JOURNAL OF LIGHTWAVE TECHNOLOGY	4.1	Q1	Article	2024
F-03	Torres-Cubillo, A; Teuber, A; Halir, R; Mizaikoff, B	Optimized waveguides for mid-infrared lab-on-chip systems: A rigorous design approach	SENSORS AND ACTUATORS A-PHYSICAL	4.1	Q1	Article	2024
F-03	Fernández-Hinestrosa, A; Luque-González, JM; Cheben, P; Schmid, JH; Wang, SR; Wangüemert-Pérez, JG; Molina-Fernandez, I; Ortega-Moñux, A	Nanophotonic Bragg grating assisted Mach-Zehnder interferometers for O-band add-drop filters	SCIENTIFIC REPORTS	3.8	Q1	Article	2024
F-03	Sánchez-postigo, A; Ginel-moreno, P; Schmid, JH; Hadij-ElHouati, A; Ortega-moñux, A; Wanguemert-perez, JG; Halir, R; Cheben, P; Molina-fernández, I	Ultra-efficient surface grating couplers for chip-to-fiber and chip-to-free-space coupling based on single-beam radiation	OPTICS EXPRESS	3.2	Q2	Article	2024
F-03	Reyes-Iglesias, PJ; Ortega-Moñux, A; Izquierdo, D; Garcés, I; Molina-Fernández, I	Simplified colorless characterization scheme for coherent receivers in DWDM scenarios using a single interferer	OPTICAL FIBER TECHNOLOGY	2.6	Q2	Article	2024
F-03	Vitali, V; Bottrill, KRH; Bucio, TD; Liu, H; González, JML; Ortega-Moñux, A; Churchill, G; Gates, JC; Hillier, JA; Kalfagiannis, N; Melati, D; Schmid, JH; Cristiani, I; Cheben, P; Wangüemert-Pérez, JG; Molina-Fernández, I; Gardes, F; Lacava, C; Petropoulos, P	L- to U-Band Wavelength Conversion of QPSK Signals Using Intermodal Four-Wave Mixing	IEEE PHOTONICS TECHNOLOGY LETTERS	2.3	Q2	Article	2024
F-04	Ojeda, P; Monroy, J; Gonzalez-Jimenez, J	Robotic Gas Source Localization With Probabilistic Mapping and Online Dispersion Simulation	IEEE TRANSACTIONS ON ROBOTICS	9.4	D1	Article	2024
F-04	Jaenal, A; Ruiz-Sarmiento, JR; Gonzalez-Jimenez, J	MachNet, a general Deep Learning architecture for Predictive Maintenance within the industry 4.0 paradigm	ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE	7.5	D1	Article	2024
F-04	Fernández-Madrigal, JA; Gómez-de-Gabriel, JM; Rey-Merchán, MD; López-Arquillos, A	Inferring Helmet Compliance on E-Scooters Using Bluetooth and Angle-of-Arrival (AoA) Technology	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.6	Q1	Article	2024
F-04	Garcia-Salguero, M; Gonzalez-Jimenez, J	Certifiable planar relative pose estimation with gravity prior	COMPUTER VISION AND IMAGE UNDERSTANDING	4.3	Q1	Article	2024
F-04	Garcia-Salguero, M; Dima, E; Mateus, A; Gonzalez-Jimenez, J	Fast Certifiable Algorithm for the Absolute Pose Estimation of a Camera\ast	SIAM JOURNAL ON IMAGING SCIENCES	2.1	Q1	Article	2024
F-05	Castilla-Arquillo, R; Mandow, A; Pérez-del-Pulgar, CJ; Alvarez-Llamas, C; Vadillo, JM; Laserna, J	Thermal Imagery for Rover Soil Assessment Using a Multipurpose Environmental Chamber Under Simulated Mars Conditions	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.6	Q1	Article	2024
F-05	Rivas-Blanco, I; López-Casado, C; Herrera-López, JM; Cabrera-Villa, J; Pérez-del-Pulgar, CJ	Instrument Detection and Descriptive Gesture Segmentation on a Robotic Surgical Maneuvers Dataset	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024
F-05	Herrera-López, JM; Galán-Cuenca, A; Reina, AJ; García-Morales, I; Muñoz, VF	Laparoscopic Suture Gestures Recognition via Machine Learning: A Method for Validation of Kinematic Features Selection	IEEE ACCESS	3.4	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-05	Galán-Cuenca, A; De Luis-Moura, D; Herrera-López, JM; Rollón, M; García-Morales, I; Muñoz, VF	Automated suture for a robotic platform to assist laparoscopic surgery	REVISTA IBEROAMERICANA DE AUTOMATICA E INFORMATICA INDUSTRIAL	1.1	Q4	Article	2024
F-05	Herrera-López, JM; Galán-Cuenca, A; García-Morales, I; Rollón, M; Rivas-Blanco, I; Muñoz, VF	Cyber-physical framework for laparoscopic surgery	REVISTA IBEROAMERICANA DE AUTOMATICA E INFORMATICA INDUSTRIAL	1.1	Q4	Article	2024
F-09	Fernández-Madrigal, JA; Gómez-de-Gabriel, JM; Rey-Merchán, MD; López-Arquillos, A	Inferring Helmet Compliance on E-Scooters Using Bluetooth and Angle-of-Arrival (AoA) Technology	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.6	Q1	Article	2024
F-09	Tamimi, I; Gasca, M; Halbardier, A; Martin, S; Caballero, GM; Serrano, CL; Martin, E; Tamimi, F; González-Quevedo, D; de Quevedo, DG; Sobrino, B; Palop, B; Guerado, E; Lara, AP; Urdiales, C; de Gabriel, JMG	The treatment of bacterial biofilms cultivated on knee arthroplasty implants using the bioelectric effect	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY	4.3	Q1	Article	2024
F-09	Remache-Vinueza, B; Trujillo-León, A; Vidal-Verdú, F	Phantom sensation: Threshold and quality indicators of a tactile illusion of motion	DISPLAYS	3.7	Q1	Article	2024
F-09	Lora-Rivera, R; Oballe-Peinado, O; Trujillo-León, A; Vidal-Verdú, F	The Goertzel Algorithm for the Extraction of Texture Features	IEEE ROBOTICS AND AUTOMATION LETTERS	4.6	Q2	Article	2024
F-09	Remache-Vinueza, B; Trujillo-León, A; Vidal-Verdú, F	A Comparative Investigation of Cutaneous Rabbit and Funneling Tactile Illusions for Implementation in Vibrotactile Displays	IEEE ACCESS	3.4	Q2	Article	2024
F-09	Tobar-Subía-Contento, LM; Mandow, A; Gómez-de-Gabriel, JM	Open On-Limb Robot Locomotion Mechanism with Spherical Rollers and Diameter Adaptation	MACHINES	2.1	Q2	Article	2024
F-10	Wu, YF; Lloveras, V; Morgado, A; Perez-Inestrosa, E; Babaliari, E; Psilodimitrakopoulos, S; Vida, Y; Vidal-Gancedo, J	Water-Soluble Bimodal Magnetic-Fluorescent Radical Dendrimers as Potential MRI-FI Imaging Probes	ACS APPLIED MATERIALS & INTERFACES	8.5	Q1	Article	2024
F-10	Calvo-Serrano, S; Matamoros, E; Céspedes, JA; Fernández-Santamaría, R; Gil-Ocaña, V; Perez-Inestrosa, E; Frecha, C; Montañez, MI; Vida, Y; Mayorga, C; Torres, MJ	New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen-Silica Nanoparticle Composites	PHARMACEUTICS	4.9	Q1	Article	2024
F-10	Matamoros, E; Pérez, EMS; Light, ME; Cintas, P; Martínez, RF; Palacios, JC	A True Reverse Anomeric Effect Does Exist After All: A Hydrogen Bonding Stereocontrolling Effect in 2-Iminoaldoses	JOURNAL OF ORGANIC CHEMISTRY	3.4	Q1	Article	2024
F-10	Sosa-Gil, C; Matamoros, E; Cintas, P; Palacios, JC	Bifunctional Azido(thio)ureas from an O-Protected 2-Amino-2-deoxy-d-glucopyranose: Synthesis and Structural Analyses	MOLECULES	4.2	Q2	Article	2024
F-10	Pérez, EMS; Matamoros, E; Cintas, P; Palacios, JC	Exploring and Re-Assessing Reverse Anomeric Effect in 2-Iminoaldoses Derived from Mono- and Polynuclear Aromatic Aldehydes	MOLECULES	4.2	Q2	Article	2024
F-10	Matamoros, E; Light, ME; Cintas, P; Palacios, JC	From Potential Prebiotic Synthons to Useful Chiral Scaffolds: A Synthetic and Structural Reinvestigation of 2-Amino-Aldononitriles	MOLECULES	4.2	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-10	Ghasemi, S; Shamsabadi, M; Olesund, A; Najera, F; Hillers-Bendtsen, AE; Edhborg, F; Aslam, AS; Larsson, W; Wang, ZH; Noa, FMA; Salthouse, RJ; Öhrström, L; Hölzel, H; Perez-Inestrosa, E; Mikkelsen, KV; Hanrieder, J; Albinsson, B; Dreos, A; Moth-Poulsen, K	Pyrene Functionalized Norbornadiene-Quadricyclane Fluorescent Photoswitches: Characterization of their Spectral Properties and Application in Imaging of Amyloid Beta Plaques	CHEMISTRY-A EUROPEAN JOURNAL	3.9	Q2	Article	2024
F-14	Ruiz-Sastre, P; Gómez-Sánchez-Lafuente, C; Martín-Martín, J; Herrera-Imbroda, J; Mayoral-Cleries, F; Santos-Amaya, I; de Fonseca, FR; Guzmán-Parra, J; Rivera, P; Suárez, J	Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	5.3	D1	Review	2024
F-14	Vargas-Molina, S; Garcia-Sillero, M; Bonilla, DA; Petro, JL; Garcia-Romero, J; Benitez-Porres, J	The effect of the ketogenic diet on resistance training load management: a repeated-measures clinical trial in trained participants	JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION	4.5	D1	Article	2024
F-14	Manuel, RS; Paula, ST; Isabel, AF; Rafael, GM; Pablo, SM; Antonio, RS; Daniel, GS; Inmaculada, LL	Development and validation of a new satisfaction scale for objective structured clinical assessments (S-OSCA): A multicenter cross-sectional study	NURSE EDUCATION TODAY	3.6	D1	Article	2024
F-14	Fuentes-Abolafio, IJ; Trinidad-Fernández, M; Ricci, M; Roldán-Jiménez, C; Gómez-Huelgas, R; Arjona-Caballero, JM; Escriche-Escuder, A; Bernal-López, MR; Pérez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic parameters related to functional capacity, fatigue, and breathlessness during the 6-min walk test in older adults with heart failure with preserved ejection fraction	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	2.9	D1	Article	2024
F-14	del-Rosal-Jurado, A; González-Sánchez, M; Cuesta-Vargas, AI	Effect of therapeutic exercise on peak oxygen consumption in oncological population: a systematic review with meta-analysis	SUPPORTIVE CARE IN CANCER	2.8	D1	Review	2024
F-14	Díaz-Balboa, E; Peña-Gil, C; Rodríguez-Romero, B; Cuesta-Vargas, AI; Lado-Baleato, O; Martínez-Monzonís, A; Pedreira-Pérez, M; Palacios-Ozores, P; López-López, R; González-Juanatey, JR; González-Salvado, V	Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial	PROGRESS IN CARDIOVASCULAR DISEASES	5.6	Q1	Review	2024
F-14	Mostaqim, K; Lahousse, A; Ubaghs, S; Timmermans, A; Deliens, T; Vanhoeij, M; Fontaine, C; de Jonge, E; Van Hoecke, J; Polastro, L; Lamotte, M; Cuesta-Vargas, AI; Huysmans, E; Nijs, J	A Multimodal Patient-Centered Teleprehabilitation Approach for Patients Undergoing Surgery for Breast Cancer: A Clinical Perspective	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
F-14	Trinidad-Fernández, M; González-Molina, F; Roldán-Jiménez, C; Vaes, P; González-Sánchez, M; Cuesta-Vargas, AI	New learning technique based on real-time kinematic feedback from an inertial sensor for manual therapy in shoulder joint: a randomised trial	BMC MEDICAL EDUCATION	2.7	Q1	Article	2024
F-14	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Pérez-Panero, AJ; Pérez-Belloso, AJ; Martínez-Barrios, FJ; González-Sánchez, M	Development and validation of a new questionnaire for the assessment of patients with diabetic foot disease: The Diabetic Foot Questionnaire (DiaFootQ)	PRIMARY CARE DIABETES	2.6	Q1	Article	2024
F-14	Ruiz-Muñoz, M; Martinez-Barrios, FJ; Cervera-Garvi, P; Lopezosa-Reca, E; Marchena-Rodriguez, AJ	Fish skin grafts versus standard of care on wound healing of chronic diabetic foot ulcers: A systematic review and meta-analysis	PRIMARY CARE DIABETES	2.6	Q1	Article	2024
F-14	Biró, A; Cuesta-Vargas, AI; Szilágyi, L	AI-Assisted Fatigue and Stamina Control for Performance Sports on IMU-Generated Multivariate Times Series Datasets	SENSORS	3.4	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-14	Pareja-Cano, A; Arjona, JM; Caulfield, B; Cuesta-Vargas, A	Parameterization of Biomechanical Variables through Inertial Measurement Units (IMUs) in Occasional Healthy Runners	SENSORS	3.4	Q2	Article	2024
F-14	Fuentes-Abolafio, IJ; Ricci, M; Bernal-López, MR; Gómez-Huelgas, R; Cuesta-Vargas, AI; Pérez-Belmonte, LM	Relationship between quadriceps femoris echotexture biomarkers and muscle strength and physical function in older adults with heart failure with preserved ejection fraction	EXPERIMENTAL GERONTOLOGY	3.3	Q2	Article	2024
F-14	Ruiz-Muñoz, M; Fernández-Torres, R; Formosa, C; Gatt, A; Gijon-Noguerón, G; Navarro-Flores, E; González-Sánchez, M	Validity and reliability of the English version of the Diabetic Foot Self-Care Questionnaire: a cross-cultural adaptation	FRONTIERS IN PUBLIC HEALTH	3.0	Q2	Article	2024
F-14	Pimentel-Ponce, M; Romero-Galisteo, RP; Palomo-Carrión, R; Pinero-Pinto, E; Merchán-Baeza, JA; Ruiz-Muñoz, M; Oliver-Pece, J; González-Sánchez, M	Gamification and neurological motor rehabilitation in children and adolescents: A systematic review	NEUROLOGIA	2.9	Q2	Review	2024
F-14	Gutiérrez-Sánchez, D; López-Leiva, I; Martin-de-las-Heras, S; Rubio, L; Martín-Martín, J	Validation of the Collett-Lester fear of death scale in occupational therapy students: psychometric testing and implications for palliative care education	BMC PALLIATIVE CARE	2.5	Q2	Article	2024
F-14	Sánchez-Guarnido, AJ; Ruiz-Granados, MI; Garrido-Cervera, JA; Herruzo, J; Herruzo, C	Implementation of the Recovery Model and Its Outcomes in Patients with Severe Mental Disorder	HEALTHCARE	2.4	Q2	Article	2024
F-14	Gabel, CP; Cuesta-Vargas, A; Dibai, AV; Mokhtarinia, HR; Melloh, M; Bejer, A	Developing a shortened spine functional index (SFI-10) for patients with sub-acute/ chronic spinal disorders: a cross-sectional study	BMC MUSCULOSKELETAL DISORDERS	2.2	Q2	Article	2024
F-14	Ramírez-Pérez, L; Cuesta-Vargas, AI	Effect of a multicomponent exercise program focused on multivariable fatigue improvement versus standard care for glenohumeral instability: MoveUS study protocol	BMC MUSCULOSKELETAL DISORDERS	2.2	Q2	Article	2024
F-14	Bravo, C; Hernández-García, D; Trinidad-Fernández, M; Badia, G; Solé, S; Serrano, J	Movement Awareness Therapies in Eating Disorders: A Systematic Review and Meta-Analysis	NURSING & HEALTH SCIENCES	2.1	Q2	Review	2024
F-14	García-Conejo, C; Roldán-Jiménez, C; Ramírez-Pérez, L; Díaz-Balboa, E; Cuesta-Vargas, A	Self-care education during Cardiac Rehabilitation programs for patients with Heart Failure with preserved Ejection Fraction: a Delphi Study	ATENCION PRIMARIA	1.8	Q2	Article	2024
F-14	Garrido-Cervera, JA; Ruiz-Granados, MI; Cuesta-Vargas, AI; Sánchez-Guarnido, AJ	Critical Analysis of Tools for Measuring Recovery-Oriented Practice in Mental Health Facilities: A Scoping Review	CLINICS AND PRACTICE	1.7	Q2	Review	2024
F-14	Ruiz-Muñoz, M; Martinez-Barrios, FJ; Fernandez-Torres, R; Lopezosa-Reca, E; Marchena-Rodriguez, A	Autologous platelet-rich plasma (APRP) in diabetes foot disease: a meta-analysis	JOURNAL OF DIABETES AND ITS COMPLICATIONS	2.9	Q3	Article	2024
F-14	Sandgren, A; García-Fernández, FP; Sánchez, DG; Strang, P; López-Medina, IM	Hospitalised patients with palliative care needs: Spain and Sweden compared	BMJ SUPPORTIVE & PALLIATIVE CARE	2.0	Q3	Article	2024
F-14	Alberton, CL; Andrade, LS; Xavier, BEB; Pinheiro, VH; Cuesta-Vargas, AI; Pinto, SS	Land-and water-based aerobic exercise program on health-related outcomes in breast cancer survivors (WaterMama): study protocol for a randomized clinical trial	TRIALS	2.0	Q3	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-14	Linero-Bocanegra, M; García-Conejo, C; Ramírez-Pérez, L; Cuesta-Vargas, AI; Trinidad-Fernández, M	Effectiveness of Therapeutic Exercise for Children Undergoing Treatment for Cancer: A Systematic Review	PEDIATRIC PHYSICAL THERAPY	1.3	Q3	Review	2024
F-14	Ortega-Castillo, M; Cuesta-Vargas, A; Melloh, M; Trinidad-Fernández, M	Cross-Cultural Adaptation and Validation of the German Version of the Upper Limb Functional Index	JOURNAL OF SPORT REHABILITATION	1.3	Q3	Article	2024
F-15	Nematzadeh, H; García-Nieto, J; Aldana-Montes, JF; Navas-Delgado, I	Pattern recognition frequency-based feature selection with multi-objective discrete evolution strategy for high-dimensional medical datasets	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1	Article	2024
F-15	Picornell, A; Hurtado, S; Antequera-Gómez, ML; Barba-González, C; Ruiz-Mata, R; de Gálvez-Montañez, E; Recio, M; Trigo, MD; Aldana-Montes, JF; Navas-Delgado, I	A deep learning LSTM-based approach for forecasting annual pollen curves: Olea and Urticaceae pollen types as a case study	COMPUTERS IN BIOLOGY AND MEDICINE	7.0	D1	Article	2024
F-15	Segura-Ortiz, Adrian; Garcia-Nieto, Jose; Aldana-Montes, Jose F; Navas-Delgado, Ismael	Multi-objective context-guided consensus of a massive array of techniques for the inference of Gene Regulatory Networks.	Computers in biology and medicine	7.0	D1	Article	2024
F-15	Hurtado, S; Antequera-Gómez, ML; Barba-González, C; Picornell, A; Navas-Delgado, I	e-Science workflow: A semantic approach for airborne pollen prediction	KNOWLEDGE-BASED SYSTEMS	7.2	Q1	Article	2024
F-15	Nematzadeh, H; García-Nieto, J; Navas-Delgado, I; Aldana-Montes, JF	Feature selection using a classification error impurity algorithm and an adaptive genetic algorithm improved with an external repository	KNOWLEDGE-BASED SYSTEMS	7.2	Q1	Article	2024
F-15	Barba-González, C; Caballero, I; Varela-Vaca, AJ; Cruz-Lemus, JA; Gómez-López, MT; Navas-Delgado, I	BIGOWL4DQ: Ontology-driven approach for Big Data quality meta-modelling, selection and reasoning	INFORMATION AND SOFTWARE TECHNOLOGY	3.8	Q1	Article	2024
F-15	Nebro, AJ; López-Ibáñez, M; García-Nieto, J; Coello, CAC	On the automatic design of multi-objective particle swarm optimizers: experimentation and analysis	SWARM INTELLIGENCE	2.1	Q3	Article	2024
F-19	Falgueras-Cano, J; Falgueras-Cano, JA; Moya, A	The influence of stochastic fluctuations on population dynamics: An in-silico approach	ECOLOGICAL MODELLING	2.6	Q2	Article	2024
F-19	Falgueras-Cano, J; Falgueras-Cano, JA; Moya, A	ECA, a Python tool to study the evolution of life	SOFTWARE IMPACTS	1.3	Q3	Article	2024
FA-07	Savarirayan, R; Irving, M; Wilcox, WR; Bacino, CA; Hoover-Fong, JE; Harmatz, P; Polgreen, LE; Mohnike, K; Prada, CE; Kubota, T; Arundel, P; Leiva-Gea, A; Rowell, R; Low, A; Sabir, I; Huntsman-Labed, A; Day, J	Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life	GENETICS IN MEDICINE	6.7	D1	Article	2024
FA-07	Boero, S; Vodopiutz, J; Maghnie, M; de Bergua, JM; Ginebreda, I; Kitoh, H; Langendoerfer, M; Leiva-Gea, A; Malone, J; McClure, P; Mindler, GT; Popkov, D; Rodl, R; Rosselli, P; Verdoni, F; Vilenskii, V; Huser, AJ	International expert opinion on the considerations for combining vosoritide and limb surgery: a modified delphi study	ORPHANET JOURNAL OF RARE DISEASES	3.4	Q2	Article	2024
FA-07	Lombardo-Torre, M; Espejo-Reina, A; Sevillano-Pérez, E; Verdejo-Parrilla, M; Espejo-Reina, MJ; Espejo-Baena, A	Graft Reorientation and Lateral Extra-articular Tenodesis in Revision Surgery for Persistent Rotational Instability of a Verticalized Anterior Cruciate Ligament Graft	ARTHROSCOPY TECHNIQUES	1.2	Q3	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
FA-07	Gómez-Palomo, JM; Rodríguez-Delourme, I; García-Vera, JJ; Irizar-Jiménez, SS; Huertas-Segador, PJ; Montañez-Heredia, E	Medial patellofemoral ligament reconstruction with an extensor hallucis longus allograft: a retrospective study of 45 cases	ACTA ORTHOPAEDICA BELGICA	0.5	Q4	Article	2024
FE-17	Cervera-Garvi, P; Galan-Hurtado, MH; Ortega-Avila, AB; Marchena-Rodriguez, A; Lopezosa-Reca, E; Castillo-Dominguez, A; Diaz-Miguel, S	Measurement properties of the Foot Function Index (FFI) questionnaire: A systematic review	CLINICAL REHABILITATION	2.6	D1	Article	2024
FE-17	Medina-Porqueres, I; Martin-Garcia, P; Sanz-De-Diego, S; Reyes-Eldblom, M; Moya-Torrecilla, F; Mondragon-Cortes, R; Rosado-Velazquez, D; Gomez-Caceres, A	Platelet-Rich Plasma Injections in Chronic Lateral Ankle Instability: A Case Series	BIOMEDICINES	3.9	Q1	Article	2024
FE-17	Castro, C; Salazar-Frías, D; Szot, A; Laffarga, L; Rodríguez-Bailón, M	Hazard prediction and risky decision-making by drivers affected by non-hemineglect strokes	TRANSPORTATION RESEARCH PART F-TRAFFIC PSYCHOLOGY AND BEHAVIOUR	3.5	Q1	Article	2024
FE-17	Villalobos-García, A; Cruz-Gambero, L; Uceró-Lozano, R; Valdes, K; Cantero-Téllez, R	Kinesiophobia and Its Correlation with Upper Limb and Hand Functionality Among Individuals with Wrist/Hand Injury: A Cross-Sectional Study	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
FE-17	Gomez-Caceres, A; Tamimi-Mariño, I; Martinez-Malo, FJ; Idiart-Charrier, RP; Vieitez-Riestra, I; Medina-Porqueres, I	Outcomes of Over the Top Anterior Cruciate Ligament Reconstruction Associated with a Lateral Extra-Articular Tenodesis in Children	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
FE-17	Cervera-Garvi, P; Galan-Hurtado, MH; Marchena-Rodriguez, A; Chicharro-Luna, E; Guerra-Marmolejo, C; Diaz-Miguel, S; Ortega-Avila, AB	Transcultural Adaptation and Validation of the Spanish Version of the Visual Analogue Scale for the Foot and Ankle (VASFA)	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024
FE-17	Salazar-Frías, D; Rodríguez-Bailón, M; Ricchetti, G; Navarro-Egido, A; Funes, MJ	The Cognitive Awareness Scale for Basic and Instrumental activities of daily living to measure self-awareness after acquired brain injury: preliminary evidence of its validity	CLINICAL NEUROPSYCHOLOGIST	3.0	Q1	Article	2024
FE-17	Moreno-Marin, AC; Rios, MP; Lopezosa-Reca, E; García, CM; Díaz-Miguel, S; Gómez-Martín, B; Cobos-Moreno, P	Resources for innovative learning of anatomy and foot ossification: Graphic design and virtual reality	JOURNAL OF FOOT AND ANKLE RESEARCH	2.5	Q1	Review	2024
FE-17	Ortega-Castillo, M; Gomez-Caceres, A; Medina-Porqueres, I	The Role of Platelet-Rich Plasma in the Management of Ankle Osteoarthritis: A Systematic Review	APPLIED SCIENCES-BASEL	2.5	Q1	Review	2024
FE-17	Cantero-Tellez, R	A global proprioception concept after hand injury-Patient report	JOURNAL OF HAND THERAPY	2.1	Q1	Article	2024
FE-17	Cantero-Téllez, R; Algar, LA; Gambero, LC; Villafañe, JH; Naughton, N	Joint position sense testing at the wrist and its correlations with kinesiophobia and pain intensity in individuals who have sustained a distal radius fracture: A cross-sectional study	JOURNAL OF HAND THERAPY	2.1	Q1	Article	2024
FE-17	Ricchetti, G; Navarro-Egido, A; Rodríguez-Bailón, M; Salazar-Frías, D; Merchán-Baeza, JA; Ariza-Vega, MP; Funes, MJ	The Breakfast and Dressing Conflict Task: Preliminary Evidence of Its Validity to Measure Online Self-Awareness After Acquired Brain Injury	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY	2.1	Q1	Article	2024
FE-17	Ramos-Petersen, L; Reinoso-Cobo, A; Ortega-Avila, AB; Garcia-Campos, J; Bernal, JA; Cantero-Tellez, R; Martin-Martin, JM; Caliz-Caliz, R; Tejero, S; Cano-Garcia, L; Gijon-Nogueron, G	A clinical practice guideline for the management of the foot and ankle in rheumatoid arthritis	RHEUMATOLOGY INTERNATIONAL	3.2	Q2	Review	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
FE-17	Medina-Porqueres, I; Sancho-Garcia, S; Gomez-Caceres, A; Mondragon-Cortes, R; Madrid-Rodríguez, A; Rosado-Velazquez, D	Injury surveillance in Spanish professional female soccer players: A three-season retrospective study	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2	Article	2024
FE-17	González-Quevedo, D; Fernández-Arroyabe, N; Moriel-Garceso, DJ; Martínez-Malo, FJ; Martín-García, F; Arenas-Ros, J; Zambrana-Vico, S; Puerta-Migueles, L; Sáez-Casado, M; Sánchez-García, A; Tamimi, I	Reverse total shoulder arthroplasty for proximal humerus fractures: Primary or delayed after failed treatment?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2	Article	2024
FE-17	Rodríguez-Bailon, M; Vidaña-Moya, L; Fernández-Solano, AJ; Grau-Carrion, S; Merchán-Baeza, JA	Effectiveness of an occupational self-analysis intervention through a mobile application (OcupApp) in people with anxiety or depression: a randomised controlled trial protocol	DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY	1.9	Q2	Article	2024
FE-17	Capdevila, E; Portell, M; Penelo, E; Rodríguez-Bailón, M	Measurement properties of the Spanish COPM in older adult rehabilitation inpatients	SCANDINAVIAN JOURNAL OF OCCUPATIONAL THERAPY	1.9	Q2	Article	2024
FE-17	Ricchetti, G; Navarro-Egido, A; Rodriguez-Bailon, M; Salazar-Frias, D; Narganes-Pineda, C; Funes, MJ	Identifying conflict monitoring as a specific executive component that contributes to impaired self-awareness in patients with acquired brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY	1.8	Q3	Article	2024
FE-17	García-Orza, J; Gutiérrez-Cordero, I; Rodríguez-Montenegro, I; Alvarez-Montesinos, JA	Children's comparison of different-length numbers: Managing different attributes in multidigit number processing	JOURNAL OF EXPERIMENTAL CHILD PSYCHOLOGY	1.8	Q3	Article	2024
FE-18	González-Quevedo, D; Fernández-Arroyabe, N; Moriel-Garceso, DJ; Martínez-Malo, FJ; Martín-García, F; Arenas-Ros, J; Zambrana-Vico, S; Puerta-Migueles, L; Sáez-Casado, M; Sánchez-García, A; Tamimi, I	Reverse total shoulder arthroplasty for proximal humerus fractures: Primary or delayed after failed treatment?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2	Article	2024
FE-20	Solero, TR; Aragón, MF; Raissouni, TA; Delgado-García, A; Cañada-Rodríguez, MJ; Viedma, SS	False Positive in [99mTc]Tc-DPD Scintigraphy for Cardiac Amyloidosis Due to Intravenous Iron Administration	CLINICAL NUCLEAR MEDICINE	10.0	D1	Editorial Material	2024
FE-20	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	Article	2024
FE-20	Sendra-Portero, F; Lorenzo-Alvarez, R; Rudolphi-Solero, T; Ruiz-Gómez, MJ	The Second Life Metaverse and Its Usefulness in Medical Education After a Quarter of a Century	JOURNAL OF MEDICAL INTERNET RESEARCH	5.8	D1	Article	2024
FE-20	Tamimi, I; Gasca, M; Halbardier, A; Martin, S; Caballero, GM; Serrano, CL; Martin, E; Tamimi, F; González-Quevedo, D; de Quevedo, DG; Sobrino, B; Palop, B; Guerado, E; Lara, AP; Urdiales, C; de Gabriel, JMG	The treatment of bacterial biofilms cultivated on knee arthroplasty implants using the bioelectric effect	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY	4.3	Q1	Article	2024
FE-20	Rudolphi-Solero, T; Lorenzo-Alvarez, R; Domínguez-Pinos, D; Ruiz-Gómez, MJ; Sendra-Portero, F	An Interuniversity Competition for Medical Students to Learn Radiology in the Second Life Metaverse	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY	4.0	Q1	Article	2024
FE-20	Lozano, A; Nava, E; Méndez, MDG; Moreno-Torres, I	Computing nasalance with MFCCs and Convolutional Neural Networks	PLOS ONE	2.9	Q1	Article	2024
FE-20	Atencia-Jiménez, I; Balajee, AS; Ruiz-Gómez, MJ; Sendra-Portero, F; Montoro, A; Molina-Cabello, MA	Neural Network Ensemble to Detect Dicentric Chromosomes in Metaphase Images	APPLIED SCIENCES-BASEL	2.5	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
FE-20	Berbís, MA; Godino, FP; Rodríguez-Comas, J; Nava, E; García-Figueiras, R; Baleato-González, S; Luna, A	Radiomics in CT and MR imaging of the liver and pancreas: tools with potential for clinical application	ABDOMINAL RADIOLOGY	2.3	Q2	Review	2024
FE-20	Khan, AY; Luque-Nieto, MA; Saleem, MI; Nava-Baro, E	X-Ray Image-Based Real-Time COVID-19 Diagnosis Using Deep Neural Networks (CXR-DNNs)	JOURNAL OF IMAGING	2.7	Q3	Article	2024
FE-20	Rivas-Navas, D; Rudolphi-Solero, T; Fernández-Fernández, J; Villa-Palacios, J; Ramos-Font, C	Prostatic rhabdomyosarcoma in a 6 years old patient evaluated by [18F]FDG PET/CT	REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR	1.6	Q3	Editorial Material	2024
FE-20	Terrón, CL; Alvarez, RL; Portero, FS	A problem-based learning experience in a radiology rotation for sixth-year medical students	RADIOLOGIA	1.1	Q3	Article	2024
FE-20	Aung, NWA; Bayarri, MS; Portero, FS	End-of-degree projects in radiology in Spanish universities	RADIOLOGIA	1.1	Q3	Article	2024
FE-20	Castro, AA; Pinos, DD; Utrilla, VS; del Campo, JAO; Portero, FS; Ruiz-Gómez, MJ	Update in imaging tests used for the localization of parathyroid pathology	RADIOLOGIA	1.1	Q3	Article	2024
FE-20	Alors-Ruiz, J; Sanz-Viedma, S; Fernandez-Garcia, FJ; Sendra-Portero, F	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in cN0 Breast Cancer: Impact of HER2-Positive Status on Survival	EUROPEAN JOURNAL OF BREAST HEALTH	1.3	Q4	Article	2024
G-01	Caro, C; Guzzi, C; Moral-Sánchez, I; Urbano-Gámez, JD; Beltrán, AM; García-Martín, ML	Smart Design of ZnFe and ZnFe@Fe Nanoparticles for MRI-Tracked Magnetic Hyperthermia Therapy: Challenging Classical Theories of Nanoparticles Growth and Nanomagnetism	ADVANCED HEALTHCARE MATERIALS	10.0	D1	Article	2024
G-01	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	Article	2024
G-01	Gómez-González, E; Núñez, NO; Caro, C; García-Martín, ML; Becerro, AI; Ocaña, M	Lanthanide vanadate-based nanoparticles as multimodal T1 T2 MRI contrast agent and NIR luminescent imaging probe	JOURNAL OF ALLOYS AND COMPOUNDS	5.8	D1	Article	2024
G-01	Gómez-González, E; Caro, C; Núñez, NO; González-Mancebo, D; Urbano-Gámez, JD; Garcia-Martin, ML; Ocaña, M	Sodium lanthanide tungstate-based nanoparticles as bimodal contrast agents for in vivo high-field MRI and CT imaging	JOURNAL OF MATERIALS CHEMISTRY B	6.1	Q1	Article	2024
G-01	Urbano-Gámez, JD; Guzzi, C; Bernal, M; Solivera, J; Martínez-Zubiaurre, I; Caro, C; García-Martín, ML	Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
G-01	González-Mancebo, D; Becerro, AI; Caro, C; Gómez-González, E; Luisa, GMM; Ocaña, M	Nanoparticulated Bimodal Contrast Agent for Ultra-High-Field Magnetic Resonance Imaging and Spectral X-ray Computed Tomography	INORGANIC CHEMISTRY	4.3	Q1	Article	2024
G-01	Gimeno-Ferrero, R; Valdivia, V; Fernández, I; García-Martín, ML; Leal, MP	Engineering amphiphilic alkenyl lipids for self-assembly in functional hybrid nanostructures	SCIENTIFIC REPORTS	3.8	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
G-01	Brokate-Llanos, AM; Sanchez-Ibanez, M; Perez-Jimenez, MM; Monje-Moreno, JM; Gomez-Marin, C; Caro, C; Vivar-Rios, C; Moreno-Mateos, MA; Garcia-Martin, ML; Munoz, MJ; Royo, JL	Ribonucleotide reductase inhibition improves the symptoms of a Caenorhabditis elegans model of Alzheimer's disease	G3-GENES GENOMES GENETICS	2.1	Q3	Article	2024
H-02	Duran, I	ANGPTL4-mediated inflammation: A new mechanism of disease and therapeutic approach for rheumatoid arthritis	MOLECULAR THERAPY	12.0	D1	Editorial Material	2024
H-02	Fernandez-Bastit, L; Cano-Terriza, D; Caballero-Gomez, J; Beato-Benitez, A; Fernandez, A; Garcia-Parraga, D; Domingo, M; Sierra, C; Canales, R; Borragan, S; de la Riva-fraga, M; Molina-Lopez, R; Cabezon, O; Puig-Ribas, M; Espunyes, J; Vazquez-Calero, DB; Vergara-Alert, J; Garcia-Bocanegra, I; Segales, J	Survey of severe acute respiratory syndrome coronavirus 2 in captive and free-ranging wildlife from Spain	VETERINARY RESEARCH	3.7	D1	Article	2024
H-02	Kot, A; Chun, C; Martin, JH; Wachtell, D; Hudson, D; Weis, M; Marks, H; Srivastava, S; Eyre, DR; Duran, I; Zieba, J; Krakow, D	Loss of the long form of Plod2 phenocopies contractures of Bruck syndrome-osteogenesis imperfecta	JOURNAL OF BONE AND MINERAL RESEARCH	5.1	Q1	Article	2024
H-02	Figueroa, FL; Castro-Varela, P; Vega, J; Losantos, R; Peñín, B; López-Cóndor, L; Pacheco, MJ; Redoli, SL; Marí-Beffa, M; Abdala-Díaz, R; Sampedro, D	Novel synthetic UV screen compounds inspired in mycosporine-like amino acids (MAAs): Antioxidant capacity, photoprotective properties and toxicity	JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY	3.9	Q1	Article	2024
H-02	Vega-Granados, K; Escobar-Ibarra, P; Palomino-Vizcaino, K; Cruz-Reyes, J; Valverde-Guillén, P; Latorre-Redoli, S; Caneda-Santiago, CT; Marí-Beffa, M; Romero-Sánchez, LB	Hexyltrimethylammonium ion enhances potential copper-chelating properties of ammonium thiomolybdate in an in vivo zebrafish model	ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS	3.8	Q1	Article	2024
H-02	Moncayo-Donoso, MA; Garzón-Alvarado, DA; Visser, RR; Ratia, JB; Vaca-González, JJ; Duque, MRF	Effects Of Biophysical Stimuli On Osteogenic Differentiation Of Mesenchymal Stem Cells	BIOMEDICAL ENGINEERING-APPLICATIONS BASIS COMMUNICATIONS	0.6	Q4	Review	2024
H-03	Cano, E; Schwarzkopf, J; Kanda, M; Lindberg, EL; Hollfinger, I; Pogontke, C; Braeuning, C; Fischer, C; Huebner, N; Gerhardt, H	Intramyocardial Sprouting Tip Cells Specify Coronary Arterialization	CIRCULATION RESEARCH	17.0	D1	Article	2024
H-03	Yu, DQ; Ren, YD; Uesaka, M; Beavan, AJS; Muffato, M; Shen, JY; Li, YX; Sato, I; Wan, WT; Clark, JW; Keating, JN; Carlisle, EM; Dearden, RP; Giles, S; Randle, E; Sansom, RS; Feuda, R; Fleming, JF; Sugahara, F; Cummins, C; Patricio, M; Akanni, W; D'Aniello, S; Bertolucci, C; Irie, N; Alev, C; Sheng, GJ; de Mendoza, A; Maeso, I; Irimia, M; Fromm, B; Peterson, KJ; Das, S; Hirano, M; Rast, JP; Cooper, MD; Paps, J; Pisani, D; Kuratani, S; Martin, FJ; Wang, W; Donoghue, PCJ; Zhang, YE; Pascual-Anaya, J	Hagfish genome elucidates vertebrate whole-genome duplication events and their evolutionary consequences	NATURE ECOLOGY & EVOLUTION	14.0	D1	Article	2024
H-03	Pascual-Anaya, J; Donoghue, PCJ	Hagfish genome sequence sheds light on early vertebrate genome evolution	NATURE ECOLOGY & EVOLUTION	14.0	D1	Article	2024
HE-01	Rodriguez-Perez, LM; Ojeda-Pérez, B; López-de-San-Sebastián, J; García-Bonilla, M; González-García, M; Fernández-Muñoz, B; Sánchez-Pernaute, R; García-Martín, ML; Domínguez-Pinos, D; Cárdenas-García, C; Jiménez, AJ; Paez-Gonzalez, P	Design of a Stem Cell-Based Therapy for Ependymal Repair in Hydrocephalus Associated With Germinal Matrix Hemorrhages	STROKE	7.9	D1	Article	2024
HE-01	Rodriguez, MDB; Muñoz, EG; Moore, T	Oligodendrocyte-specific expression of PSG8-AS1 suggests a role in myelination with prognostic value in oligodendroglioma	NON-CODING RNA RESEARCH	5.9	Q1	Article	2024
HE-01	Algarra, M; Gonzalez-Muñoz, E	Efficient and scalable gene delivery method with easily generated cationic carbon dots	BIOLOGICAL PROCEDURES ONLINE	3.7	Q2	Article	2024
HE-01	Algarra, M; Soto, J; Pino-González, MS; Gonzalez-Munoz, E; Ducic, T	Multifunctionalized Carbon Dots as an Active Nanocarrier for Drug Delivery to the Glioblastoma Cell Line	ACS OMEGA	3.7	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AA-24	Trullàs, JC; Peláez, AI; Blázquez, J; Sánchez-Biosca, A; López-Reborio, ML; Salamanca-Bautista, P; Fernández-Rodríguez, JM; Vázquez-Ronda, MA; Dávila-Ramos, MF; Mendoza-Ruiz-De-Zuazu, H; Morales-Rull, JL; Olmedo-Llanes, J; Llacer, P; Conde-Martel, A	The significance of metabolic alkalosis on acute decompensated heart failure: the ALCALOTIC study	CLINICAL RESEARCH IN CARDIOLOGY	3.8	Q1	Article	2024
AA-24	Espíldora-Hernández, J; Díaz-Antonio, T; Olmedo-Llanes, J; León, JZ; Rioja, J; Valdivielso, P; Sánchez-Chaparro, MA; Ariza, MJ	Clinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.9	Q3	Article	2024
AA-25	Martin-Gómez, MA; Torres, AR; Hernández, ME; Mendoza, ML; Sánchez, JMS; Armada, MM; Suarez, IM; Rubio, JLC; Castellano, MMC; Pintado, JCA; Marín, ACB; Esteban, MDM; Guerra, LC; Garrido, ED	Mortality and cardiovascular risk in vasculitis ANCA. Importance of hypertension and renal function. Experience from southern Spain	HIPERTENSION Y RIESGO VASCULAR	1.2	Q4	Article	2024
BA-14	Abbad-Gomez, D; Domingo, L; Comas, M; Santia, P; Jansana, A; Poblador, B; Sanz, T; del Cura, I; Ibañez, B; Padilla, M; Redondo, M; Castells, X; Sala, M	Effect of comorbidity and multimorbidity on adherence to follow-up recommendations among long-term breast cancer survivors	MATURITAS	3.9	Q1	Article	2024
BA-14	Barnestein-Fonseca, P; Guerrero-Pertiñez, G; Gúzman-Parra, J; Valera-Moreno, E; Mayoral-Cleries, F	Is it possible to diagnose therapeutic adherence in mild cognitive impairment and dementia patients in clinical practice?	FRONTIERS IN PHARMACOLOGY	4.4	Q1	Article	2024
BA-14	Burgos-Molina, AM; Santana, TT; Redondo, M; Romero, MJB	The Crucial Role of Inflammation and the Immune System in Colorectal Cancer Carcinogenesis: A Comprehensive Perspective	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
BA-14	Martín-García, D; García-Aranda, M; Redondo, M	Biomarker Identification through Proteomics in Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2024
BA-14	Martín-García, D; Téllez, T; Redondo, M; García-Aranda, M	The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer	CURRENT MEDICINAL CHEMISTRY	3.5	Q2	Review	2024
BA-14	Hernández-Herrador, M; Marilina, GA; Hortas, ML; Carrillo-Lucena, S; Caracuel, Z; Castilla-Alcalá, JA; Martín-García, D; Redondo, M	Clusterin expression and distribution in spermatozoa as predictor of male fertility	MOLECULAR REPRODUCTION AND DEVELOPMENT	2.7	Q2	Article	2024
BA-14	Martín-García, D; García-Aranda, M; Redondo, M	Therapeutic Potential of Clusterin Inhibition in Human Cancer	CELLS	5.1	Q2	Review	2024
BA-14	Fernández-Sánchez, F; Martín-Bautista, E; Rivas-Ruiz, F; Wu, WN; García-Aranda, M	Evaluation of the EasyNAT SARS-CoV-2 assay PCR test for the diagnosis of SARS-CoV-2 infection	JOURNAL OF VIROLOGICAL METHODS	2.2	Q3	Article	2024
BA-14	Rivas Ruiz, Francisco; Padilla Ruiz, Maria; Perez Aisa, Angeles; Pelaez Cherino, Joaquin; Lara Blanquer, Antonio; Jimenez Puente, Alberto	Hospital emergencies due to alcohol consumption in times of COVID-19 on the Costa del Sol (Spain)	Revista espanola de salud publica	0.9	Q4	Article	2024
BA-14	Varela-Moreno, E; Anarte-Ortiz, MT; Jodar-Sanchez, F; Garcia-Palacios, A; Monreal-Bartolome, A; Gili, M; García-Campayo, J; Mayoral-Cleries, F	Economic Evaluation of a Web Application Implemented in Primary Care for the Treatment of Depression in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial	JMIR MHEALTH AND UHEALTH	5.4	D1	Article	2024
CA-14	Mellado-García, E; Díaz-Rodríguez, L; Cortés-Martín, J; Sánchez-García, JC; Piqueras-Sola, B; Macías, JCH; Ruiz, FR; Rodríguez-Blanke, R	Comparative Analysis of Therapeutic Showers and Bathtubs for Pain Management and Labor Outcomes-A Retrospective Cohort Study	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CA-14	Salas-Marquez, C; García, RB; Jiménez, JBR; Escribano, PC; Ruiz, FR	Development of a Questionnaire on Knowledge, Habits, and Attitudes on Sexually Transmitted Infections in Teenagers and Young Adults	ACTAS DERMOSIFILIOGRAFICAS	3.8	Q1	Article	2024
CA-14	Saucedo-Figueredo, MC; Morilla-Herrera, JC; Gálvez-González, M; Rivas-Ruiz, F; Nava-DelVal, A; San Alberto-Giraldos, M; Hierrezuelo-Martín, MJ; Gómez-Borrego, AB; Kaknani-Uttumchandani, S; Morales-Asencio, JM	Anchor-Based and Distributional Responsiveness of the Spanish Version of the Edinburgh Feeding Evaluation in Dementia Scale in Older People with Dementia: A Longitudinal Study	NUTRIENTS	4.8	Q1	Article	2024
CA-14	Calderon-Parra, J; Dominguez, F; Gonzalez-Rico, C; de las Revillas, FA; Goenaga, MA; Alvarez, ; Munoz, P; Alonso, D; Rodriguez-Garcia, R; Miro, JM; De Alarcon, A; Antorrena, I; Goikoetxea-Agirre, J; Moral-Escudero, E; Ojeda-Burgos, G; Ramos-Martinez, A; Spanish Collaboration on Endocarditis (GAMES)	Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort	OPEN FORUM INFECTIOUS DISEASES	3.8	Q2	Article	2024
CA-14	Espiga, FR; Delia, MA; Martínez, FC; Martín, DM; Serrano, FN; López, RQ	Delayed diagnosis and missed opportunities in the early detection of atrial fibrillation: a cross-sectional study	REVISTA CLINICA ESPANOLA	2.3	Q2	Article	2024
CA-14	Martínez, AR; Pardal, CV; Arjona, JA; Ruiz, FR; Molinero, DD; Paulano, MR; Subert, A; Gutiérrez-Manzanedo, JV; Martín, JC; Aranda, MVD; López, LJ; Sánchez, NB; Martín, MD	Skin cancer prevention in extreme sports: Intervention in a 24-h race	PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE	2.5	Q2	Article	2024
CA-14	García-Harana, C; Blázquez-Sánchez, N; Rodríguez-Martínez, A; Rivas-Ruiz, F; Aguilar-Ortega, D; Rodríguez-Martínez, AG; Cambil-Martín, J; de Gálvez, MV; de Troya-Martín, M	Positive impact of Distintivo Soludable on implementation of sun protection policies and practices in schools of Andalusia, Spain	JOURNAL OF PUBLIC HEALTH POLICY	2.3	Q2	Article	2024
CA-14	Lorenzo-Hernández, E; Rivas-Ruiz, F; Del Arco-Jiménez, A	Consequences of the COVID-19 Pandemic on the Incidence, Management and Outcomes of Staphylococcus aureus Bacteraemia: Experience in a Spanish Hospital	PATHOGENS	3.3	Q2	Article	2024
CA-14	de Lomas-Guerrero, JG; Jiménez-García, N; Fernández-Sánchezb, F; del Arco-Jiménez, A; Prada-Pardal, JL; de la Torre-lima, J	Missed opportunities in the early detection of HIV infection in patients with sexually transmitted infections: A real-life study	ENFERMEADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.6	Q3	Article	2024
CA-14	Fernandez-Pereza, FJ; Fernandez-Morenoa, N; Soria-Lopez, E; Rodriguez-Gonzalez, FJ; Fernandez-Galeoteb, FJ; Lifante-Olivac, A; Ruiz-Hernandezc, C; Escalante-Quijaitec, E; Rivas-Ruizd, F	Granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: A useful therapeutic tool not just in ulcerative colitis but also in Crohn's disease	GASTROENTEROLOGIA Y HEPATOLOGIA	2.2	Q3	Article	2024
CA-14	Fernández-Sánchez, F; Martín-Bautista, E; Rivas-Ruiz, F; Wu, WN; García-Aranda, M	Evaluation of the EasyNAT SARS-CoV-2 assay PCR test for the diagnosis of SARS-CoV-2 infection	JOURNAL OF VIROLOGICAL METHODS	2.2	Q3	Article	2024
CA-14	Rivas Ruiz, Francisco; Padilla Ruiz, Maria; Perez Aisa, Angeles; Pelaez Cherino, Joaquin; Lara Blanquer, Antonio; Jimenez Puente, Alberto	Hospital emergencies due to alcohol consumption in times of COVID-19 on the Costa del Sol (Spain)	REVISTA ESPAÑOLA DE SALUD PÚBLICA	0.9	Q4	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CA-14	Gasca-Capote C, Lian X, Gao C, Roseto IC, Jiménez-León MR, Gladkov G, Camacho-Sojo MI, Pérez-Gómez A, Gallego I, Lopez-Cortes LE, Bachiller S, Vitalle J, Rafii-El-Idrissi Benhnia M, Ostos FJ, Collado-Romacho AR, Santos J, Palacios R, Gomez-Ayerbe C, Muñoz-Medina L, Ruiz-Sancho A, Frias M, Rivero-Juarez A, Roca-Oporto C, Hidalgo-Tenorio C, Rull A, Olalla J, Lopez-Ruz MA, Vidal F, Viladés C, Mastrangelo A, Cavassini M, Espinosa N, Perreau M, Peraire J, Rivero A, López-Cortes LF, Lichterfeld M, Yu XG, Ruiz-Mateos E.	The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers	J Clin Invest	13.3	D1	Article	2024
CA-14	Maldonado N, López-Hernández I, García-Montaner A, López-Cortés LE, Pérez-Crespo PMM, Retamar-Gentil P, Sousa-Domínguez A, Goikoetxea J, Pulido-Navazo Á, Labayru-Echeverría C, Natera-Kindelán C, Jover-Sáenz A, Del Arco-Jiménez A, Armiñanzas-Castillo C, Aller AI, Fernández-Suárez J, Marrodán-Ciordia T, Boix-Palop L, Smithson-Amat A, Reguera-Iglesias JM, Galán-Sánchez F, Bahamonde A, Sánchez Calvo JM, Gea-Lázaro I, Pérez-Camacho I, Reyes-Bertos A, Becerril-Carral B, Rodríguez-Baño J, Pascual Á; Grupo PROBAC REIPI/GEIH-SEIMC/SAEI.	Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study	Lancet Microbe	20.9	D1	Article	2024
CA-14	Maldonado N, López-Hernández I, López-Cortés LE, Martínez Pérez-Crespo PM, Retamar-Gentil P, García-Montaner A, De la Rosa Riestra S, Sousa-Domínguez A, Goikoetxea J, Pulido-Navazo Á, Del Valle Ortíz M, Natera-Kindelán C, Jover-Sáenz A, Arco-Jiménez AD, Armiñanzas-Castillo C, Aller-García AI, Fernández-Suárez J, Marrodán-Ciordia T, Boix-Palop L, Smithson-Amat A, Reguera-Iglesias JM, Galán-Sánchez F, Bahamonde A, Sánchez-Calvo JM, Gea-Lázaro I, Pérez-Camacho I, Reyes-Bertos A, Becerril-Carral B, Pascual Á, Rodríguez-Baño J; PROBAC REIPI/GEIRAS-SEIMC/SAMICEI Group	Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study	CLINICAL MICROBIOLOGY AND INFECTION	10.9	D1	Article	2024
CA-14	De la Rosa-Riestra S, López-Hernández I, Pérez-Rodríguez MT, Sousa A, Goikoetxea Agirre J, Reguera Iglesias JM, León E, Armiñanzas Castillo C, Sánchez Gómez L, Fernández-Natal I, Fernández-Suárez J, Boix-Palop L, Cuquet Pedragosa J, Jover-Sáenz A, Sánchez Calvo JM, Martín-Aspas A, Natera-Kindelán C, Del Arco Jiménez A, Bahamonde Carrasco A, Amat AS, Vinuesa García D, Martínez Pérez-Crespo PM, López-Cortés LE, Rodríguez-Baño J; PROBAC/GEIRAS-SEIMC/SAMICEI	A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study	JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY	3.9	Q1	Article	2024
CA-14	Guedes M, Gathara D, López-Hernández I, Pérez-Crespo PMM, Pérez-Rodríguez MT, Sousa A, Plata A, Reguera-Iglesias JM, Boix-Palop L, Dietl B, Blanco JS, Castillo CA, Galán-Sánchez F, Kindelán CN, Jover-Saenz A, Aguirre JG, Alemán AA, Ciordia TM, Del Arco Jiménez A, Fernandez-Suarez J, Lopez-Cortes LE, Rodríguez-Baño J; PROBAC/GEIRAS-SEIMC/SAMICEI group.	Differences in clinical outcomes of bloodstream infections caused by Klebsiella aerogenes, Klebsiella pneumoniae and Enterobacter cloacae: a multicentre cohort study	ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS	4.6	Q1	Article	2024
CA-14	Gutner CA, Hocqueloux L, Jonsson-Oldenbüttel C, Vandekerckhove L, van Welzen BJ, Slama L, Crusells-Canales M, Sierra JO, DeMoor R, Scherzer J, Ait-Khaled M, Bontempo G, Gill M, Patel N, D'Amico R, Hove K, Baugh B, Barnes N, Hadi M, Low EL, Anand SB, Hamilton A, Garges HP, Czarnogorski M.	Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations	JOURNAL OF THE INTERNATIONAL AIDS SOCIETY	4.6	Q1	Article	2024
CA-14	Escrihuahela-Vidal F, Palacios-Baena ZR, Agirre JG, Pérez-Rodríguez MT, Reguera Iglesias JM, Cuquet Pedragosa J, Sánchez Gómez L, Boix-Palop L, Bahamonde Carrasco A, Natera-Kindelán C, Fernández-Suárez J, Jover-Sáenz A, Smithson Amat A, Del Arco Jiménez A, Sánchez Calvo JM, Martín-Aspas A, Martínez Pérez-Crespo PM, López-Hernández I, Rodríguez-Baño J, López-Cortés LE; PROBAC/GEIRAS-SEIMC/SAMICEI group.	Early antibiotic de-escalation in patients with severe infections due to bloodstream infection by enterobacterales: A post hoc analysis of a prospective multicentre cohort	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS	2.2	Q2	Article	2024
CA-14	Yun S, Casado J, Pérez-Silvestre J, Salamanca P, Llàcer P, Quirós R, Ruiz-Hueso R, Méndez M, Manzano L, Formiga F.	Clinical suspicion, diagnosis and management of cardiac amyloidosis: update document and executive summary	REVISTA CLINICA ESPANOLA	2.3	Q2	Review	2024
CA-15	Barnestein-Fonseca, P; Guerrero-Pertiñez, G; Gúzman-Parra, J; Valera-Moreno, E; Mayoral-Cleries, F	Is it possible to diagnose therapeutic adherence in mild cognitive impairment and dementia patients in clinical practice?	FRONTIERS IN PHARMACOLOGY	4.4	Q1	Article	2024
CA-15	Muñoz-Cobos, F; Aguiar-Leiva, VP; Argüello-Suárez, C; Colacicchi, P; Calleja-Cartón, LA; Leiva-Fernández, F	Validation of an Inhaled Therapy Beliefs Questionnaire in Patients with Chronic Obstructive Pulmonary Disease	JOURNAL OF CLINICAL MEDICINE	3.0	Q1	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CA-15	Barnestein-Fonseca, P; Nebro-Gil, A; Aguiar-Leiva, VP; Víbora-Martín, E; Ruiz-Torreras, I; Martín-Rosello, ML; van der Heide, A; Tripodoro, V; Veloso, VI; Montilla, S; De Simone, GG; Goldraij, G; Boughey, M; Berger, M; Fischer, C; Simon, J; Voltz, R; Joshi, M; Strupp, J; Halfdanardottir, SI; Sigurdardottir, V; Yildiz, B; Korfage, IJ; Goossensen, A; van Zuylen, C; Geijteman, ECT; Allan, S; Haugen, DF; Iversen, GS; Lunder, U; Bakan, M; Kodba-Ceh, H; Fürst, CJ; Schelin, MEC; Eychmüller, S; Zambrano, SC; Ellershaw, J; Mason, S; McGlinchey, T; Smeding, R	Barriers and drivers of public engagement in palliative care, Scoping review	BMC PALLIATIVE CARE	2.5	Q2	Article	2024
CA-15	Carrasco-Zafra, MI; Ocaña-Riola, R; Gómez-Garcia, R; Martín-Roselló, ML; Blanco-Reina, E	Palliative sedation at the end of life: prevalence, characteristics and possible determinants	BMC PALLIATIVE CARE	2.5	Q2	Article	2024
CA-15	Tripodoro, VA; Veloso, VI; Martín, EV; Kodba-Ceh, H; Bakan, M; Rasmussen, BH; Zambrano, SC; Joshi, M; Hálfðánardóttir, SI; Asgeirsdóttir, GH; Romarheim, E; Haugen, DF; McGlinchey, T; Yildiz, B; Barnestein-Fonseca, P; Goossensen, A; Lunder, U; van der Heide, A	‘Someone must do it’: multiple views on family’s role in end-of-life care -an international qualitative study	PALLIATIVE CARE & SOCIAL PRACTICE	2.7	Q2	Article	2024
CA-15	Yildiz, B; van der Heide, A; Bakan, M; Iversen, GS; Haugen, DF; McGlinchey, T; Smeding, R; Ellershaw, J; Fischer, C; Simon, J; Vibora-Martin, E; Ruiz-Torreras, I; Goossensen, A	Facilitators and barriers of implementing end-of-life care volunteering in a hospital in five European countries: the iLIVE study	BMC PALLIATIVE CARE	2.5	Q2	Article	2024
CA-19	Gutiérrez-Guisado, J; Calvo-Sotelo, AE; Hernández-Blasco, L; Fidalgo, A; Gómez-Cuervo, C; López-Ruiz, A; Aibar, J; Verhamme, P; Meireles, J; Monreal, M	Venous thromboembolism (VTE) developing after ankle sprain. Comparison with VTE after knee arthroplasty	THROMBOSIS RESEARCH	3.7	Q1	Review	2024
CA-19	Caballero, T; Alonso, C; Baeza, ML; Baynova, K; Cabeza, J; Cortés, I; Oblitas, DE; Guilarte, M; Joral, A; Palomo, JJ; Jiménez, MAL; Virto, AM; Medrano, L; Boquet, EM; Navarro, M; Pérez, D; Martí, MJP; Foltz, SLS; Suero, C; Zamora, C	Hereditary angioedema in Spain: medical care and patient journey	ORPHANET JOURNAL OF RARE DISEASES	3.4	Q2	Article	2024
CA-19	Caballero, T; Alonso, C; Baeza, ML; Baynova, K; Cabeza, J; Cortés, I; Oblitas, DE; Guilarte, M; Joral, A; Palomo, JJ; Jiménez, MAL; Virto, AM; Medrano, L; Boquet, EM; Navarro, M; Pérez, D; Martí, MJP; Foltz, SLS; Suero, C; Zamora, C	Hereditary angioedema in Spain: medical care and patient journey	ORPHANET JOURNAL OF RARE DISEASES	3.4	Q2	Article	2024
CA-19	Ramírez-Morros, A; Berenguera, A; Millaruelo, L; Buil-Cosiales, P; Garcia, CG; Cos, X; Lachica, LA; Artola, S; Millaruelo, JM; Mauricio, D; Franch-Nadal, J	Impact of Gender on Patient Experiences of Self-Management in Type 2 Diabetes: A Qualitative Study	PATIENT PREFERENCE AND ADHERENCE	2.0	Q2	Article	2024
CA-19	Echevarria-Lucas, L; Senciales-Gonzalez, JM; Rodrigo-Comino, J	Analysing the Evidence of the Effects of Climate Change, Air Pollutants, and Occupational Factors in the Appearance of Cataracts	ENVIRONMENTS	3.5	Q2	Article	2024
CA-19	Fernández-Luque,AM; Ramírez-Montoya, MS	Health Professionals’ Competencies in the Framework of Complexity: Digital Training Model for Education 4.0	REVISTA ESPAÑOLA DE DOCUMENTACION CIENTIFICA	1.0	Q3	Article	2024
FA-16	PIPPAS Study Group	Optimizing periprosthetic fracture management and in-hospital outcome: insights from the PIPPAS multicentric study of 1387 cases in Spain	JOURNAL OF ORTHOPAEDICS AND TRAUMATOLOGY	3.0	Q1	Article	2024
FA-16	Tamimi, I; Gasca, M; Halbardier, A; Martin, S; Caballero, GM; Serrano, CL; Martin, E; Tamimi, F; González-Quevedo, D; de Quevedo, DG; Sobrino, B; Palop, B; Guerado, E; Lara, AP; Urdiales, C; de Gabriel, JMG	The treatment of bacterial biofilms cultivated on knee arthroplasty implants using the bioelectric effect	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY	4.3	Q1	Article	2024
FA-16	González-Quevedo, D; Fernández-Arroyabe, N; Moriel-Garceso, DJ; Martínez-Malo, FJ; Martín-García, F; Arenas-Ros, J; Zambrana-Vico, S; Puerta-Miguel, L; Sáez-Casado, M; Sánchez-García, A; Tamimi, I	Reverse total shoulder arthroplasty for proximal humerus fractures: Primary or delayed after failed treatment?	INJURY- INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2	Article	2024

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
FA-16	Guerra-Farfan, E; Borges, FK; Bhandari, M; Garcia-Sanchez, Y; Nuoez, JH; Mestre-Torres, J; Tomas-Hernandez, J; Teixidor-Serra, J; Balaguer-Castro, M; Castillon, P; Dealbert, A; Rodriguez, JD; Aguado, HJ; Guerado, E; Popova, E; Tonelli, AC; Balasubramanian, K; Vincent, J; Harvey, V; Kocaqi, E; Slobogean, G; Devereaux, PJ	Mortality, perioperative complications and surgical timelines in hip fracture patients: Comparison of the Spanish with the non-Spanish Cohort of the HIP ATTACK-1 trial	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2	Article	2024
FA-16	Sevillano-Perez, E; Prado-Novoa, M; Postigo-Pozo, S; Peña-Trabalón, A; Guerado, E	L4 fixation is not necessary in L5-Iliac spinopelvic fixation after trauma, but coadjuvant transilio-transsacral fixation is	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	2.2	Q2	Article	2024
FA-16	Maldonado N, López-Hernández I, García-Montaner A, López-Cortés LE, Pérez-Crespo PMM, Retamar-Gentil P, Sousa-Domínguez A, Goikoetxea J, Pulido-Navazo Á, Labayru-Echeverría C, Natera-Kindelán C, Jover-Sáenz A, Del Arco-Jiménez A, Armiñanzas-Castillo C, Aller AI, Fernández-Suárez J, Marrodán-Ciordia T, Boix-Palop L, Smithson-Amat A, Reguera-Iglesias JM, Galán-Sánchez F, Bahamonde A, Sánchez Calvo JM, Gea-Lázaro I, Pérez-Camacho I, Reyes-Bertos A, Becerril-Carral B, Rodríguez-Baño J, Pascual Á; Grupo PROBAC REIPI/GEIH-SEIMC/SAEI.	The transformation of Jordan's healthcare system in an area of conflict	BMC HEALTH SERVICES RESEARCH	2.7	Q2	Article	2024
FA-16	González-Quevedo, D; Rubia-Ortega, C; Sánchez-Delgado, A; Moriel-Garcesó, D; Sánchez-Siles, JM; Bravo-Bardaji, M; Garcia-de-Quevedo, D; Tamimi, I	Secondary osteoporosis prevention: three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients	AGING CLINICAL AND EXPERIMENTAL RESEARCH	3.4	Q2	Article	2024
FA-16	Cáceres, AG; Mariño, IT; Malo, FJM; Riestra, IV; Idiart, RP	Meniscal Ramp Lesion Repair Without the Need for a Posteromedial Portal	ARTHROSCOPY TECHNIQUES	1.2	Q3	Article	2024
FA-16	Cano, JR; Bogallo, JM; Ramirez, A; Guerado, E	Immediate management of a stable patient with unstable pelvis	EFORT OPEN REVIEWS	4.3	D1	Article	2024

COMPETITIVE RESEARCH GRANTS ACTIVE IN 2024

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-01	PI20/01322 Valor predictivo de los miRNA séricos en el desarrollo de enfermedades metabólicas y su relación con el grado de exposición a partículas y otros contaminantes del aire	GEMMA ROJO MARTINEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
A-01	The Effectiveness of MyDiaMate, a Self-guided Web-based App for Mental Health in Type 1 Diabetes: a Multinational Randomized Controlled Trial	MARÍA TERESA ANARTE ORTÍZ	INTERNATION-AL NON-EU	PI	JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL	2022
A-01	PMP21-00006. ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2	GEMMA ROJO MARTINEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-01	PI23-00347 Estado de nutrición de selenio en la población española. Relación con la prevalencia e Incidencia de enfermedad tiroidea y diabetes tipo 2. Estudio di@bet.es.IP: SERGIO VALDES HERNANDEZ. COI: GEMMA ROJO MARTINEZ	SERGIO VALDÉS HERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-01	CPP2022-010108 MetabPlus: a flexible and efficient multi-IEM Newborn Screening Program.	RAQUEL YAHYAOUI MACÍAS	NATIONAL	PI	STATE RESEARCH AGENCY	2023
A-01	AP177082021 DETECCION PRECOZ Y TRATAMIENTO DE PACIENTES AFECTADOS DE ADRENOLEUCODISTROFIA LIGADA AL CROMOSOMA X: UN ESTUDIO POBLACIONAL PROSPECTIVO.	RAQUEL YAHYAOUI MACÍAS	NATIONAL	PI	MUTUA MADRILEÑA FOUNDATION	2021
A-01	4050-22_miR21-AuNPs dirigido específicamente al tejido adiposo como terapia pionera contra la obesidad, la resistencia a la insulina y la diabetes tipo 2	RAJAA EL BEKAY RIZKY	NATIONAL	PI	FOUNDATION FOR INNOVATION AND FORESIGHT IN HEALTH IN SPAIN	2022
A-01	PI21-01924 Papel de los miARNs exosomales inflamatorios en la comunicación entre tejido adiposo-cerebro. Nuevos mecanismos subyacentes de las comorbilidades neuropsiquiátricas relacionadas con la obesidad	RAJAA EL BEKAY RIZKY	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-01	PID2021-128926OA-I00_REgulación del receptor de cannabinoide tipo 1 en la fisiología del islote humano y en el contexto de la Diabetes de tipo 1	NATALIA COLOMO RODRIGUEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2021
A-01	FSEEN22_OBESIDAD_01 Impacto del aceite de oliva virgen extra (AOVE) sobre algunos microRNAs (miRNAs) y su efecto sobre la meta-inflamación y estrés oxidativo en personas con obesidad y prediabetes.	IGNACIO RUIZ GARCÍA	NATIONAL	PI	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION FOUNDATION	2022
A-01	INN24_03 Secuenciación de sujetos con DM2 para validación de un algoritmo de diagnóstico diferencial entre sujetos con DM2 vs sujetos con MODY-HFN1a. En el camino hacia la aplicación clínica	SARA GARCÍA SERRANO	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
A-01	INV-CLIN-01-2023 Evaluación del perfil clínico y analítico de los pacientes con diabetes mellitus tipo 2 en Endocrinología: Un estudio multicéntrico nacional (estudio REDIEN).	JOSÉ CARLOS FERNÁNDEZ GARCÍA	NATIONAL	PI	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION FOUNDATION	2023
A-01	NUTRICION PARENTERAL_23-01 Evaluación del uso de la fórmula de nutrición parenteral tricameral Finomel ® en plantas de hospitalización no críticas	ROSARIO VALLEJO MORA	REGIONAL	PI	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2023
A-01	PI-01-2021_SANCYD-BAXTER_GOLveira. Hiperglucemia en nutrición parenteral: efecto sobre biomarcadores de inflamación, oxidación y permeabilidad intestinal. Estudio INSUPAR	GABRIEL OLVEIRA FUSTER	REGIONAL	PI	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-01	PI-0141-2024 Cronobiología y cronodisrupción en personas que reciben terapia médica nutricional y su repercusión sobre la calidad de vida de pacientes y cuidadores. Estudio descriptivo y de intervención	GABRIEL OLVEIRA FUSTER	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
A-01	PI23-00984 Medicina de precisión en diabetes monogénicas: estrategias genómicas, caracterización clínico-genética y costes asociados. LR: CRISTINA MALDONADO ARAQUE CO-IP: MARIA SOLEDAD RUIZ DE ADANA NAVAS	CRISTINA MALDONADO ARAQUE	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-01	PI23-01785 Control glucémico y metabólico tras intervención nutricional con AOV de alto contenido en oleocantal y oleaceína en personas con diabetes tipo 2. Un ensayo aleatorizado, doble ciego y controlado. LR: FRANCISCO JAVIER BERMUDEZ SILVA_ COI: MARIA JOSE TAPIA GUERRERO	FRANCISCO JAVIER BERMÚDEZ SILVA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-01	PMP22-00033 “El primer Estudio de asociación de genoma completo (GWAS) con enfermedad coronaria poblacional a 10 años en más de 100.000 participantes para personalizar la prevención cardiovascular en España”	SERGIO VALDÉS HERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
A-01	SED-2022-01 Estudio del papel regulador del receptor de cannabinoide 1 de la célula beta en el inicio y desarrollo de la insulitis en humanos mediante ablación génica por CRISPR/saCas9	ISABEL GONZALEZ MARISCAL	NATIONAL	PI	SPANISH DIABETES SOCIETY	2022
A-01	SED-2022-03 DISEÑO Y EVALUACIÓN DEL IMPACTO DE UN PROGRAMA DE INTERVENCIÓN GRUPAL ONLINE PARA LA REDUCCIÓN DEL IMPACTO BIOPSICOLÓGICO CAUSADO POR EL COVID-19 EN PERSONAS CON DIABETES MELLITUS TIPO 1. ESTUDIO PSICOVIDI@BETES.	MÓNICA CARREIRA SOLER	NATIONAL	PI	SPANISH DIABETES SOCIETY	2022
A-01	SENPE PISENIOR 24_01 Cambios en la microbiota, toxinas urémicas y biomarcadores de inflamación tras tratamiento nutricional personalizado en la enfermedad renal crónica avanzada (Ensayo clínico ERCANUT)	GABRIEL OLVEIRA FUSTER	NATIONAL	PI	SPANISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM	2024
A-01	Efecto neuroprotector del IGF-II en un modelo celular de enfermedad de Parkinson con acumulación de agregados tóxicos de α-sinucleína	SILVANA YANINA ROMERO ZERBO	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
A-01	ESTUDIO MOLECULAR DE LA DISBACTERIOSIS ORAL EN PERSONAS CON PREDIABETES Y DIABETES. ESTUDIO SMILE	RODOLFO MATÍAS ORTIZ FLORES	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
A-01	CARACTERIZACIÓN DE LAS ALTERACIONES OFTALMOLÓGICAS EN PACIENTES CON FIBROSIS QUÍSTICA Y BRONQUIECTASIAS NO DEBIDAS A FIBROSIS QUÍSTICA	CASILDA OLVEIRA FUSTER	NATIONAL	PI	Spanish Society of Pulmonology and Thoracic Surgery (Separ)	2023
A-01	Análisis de marcadores de inflamación, oxidación y adipoquinas en pacientes con linfedema secundario a cáncer de mama y con sobrepeso u obesidad, en respuesta a un programa estructurado de ejercicio y pérdida de peso.	CORINA VERONICA SASSO	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
A-01	RC-0003-2021 Renovación II del Programa Nicolás Monardes 2013. Gemma Rojo Martínez	GEMMA ROJO MARTINEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
A-01	RC-0001-2021 Renovación II del Programa Nicolás Monardo 2013. Francisco Javier Bermúdez Silva	FRANCISCO JAVIER BERMÚDEZ SILVA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
A-01	MV23/00073 APLICACIÓN DE LA METABOLÓMICA Y LA EPIGENÉTICA AL ESTUDIO DE LAS REACCIONES DE HIPERSENSIBILIDAD A ANTI-INFLAMATORIOS NO ESTEROIDEOS	ISABEL MARIA JIMENEZ SANCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-01	IFI20/00034 Contratos I-PFIS: Doctorados IIS-Empresa en ciencias y tecnologías de la salud. Candidate: Marina Padial Barranco, Group Leader: Gabriel Olveira Fuster	MARINA PADIAL BARRANCO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-01	RC-0006-2020 Renovación de la Acción C (Programa Nicolás Monardes) de la Convocatoria 2016.	RAJAA EL BEKAY RIZKY	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2020
A-01	DOC_01138 Incorporación de ayudas posdoctorales. Candidate: Said Lhamyani, Group Leader: Rajaa El Bekay Rizky	SAID LHAMYANI	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2019

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-01	A1-0044-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: SERGIO VALDES HERNANDEZ AND JOSE CARLOS FERNANDEZ GARCIA.	SERGIO VALDÉS HERNÁNDEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-01	C1-0005-2023 PROGRAMA NICOLAS MONARDE_CONVOCATORIA 2023_CANDIDATA FRANCISCA RODRIGUEZ PACHECO.	FRANCISCA RODRIGUEZ PACHECO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-01	CD23-00110 Contrato Sara Borrel 2023_Alicia Gonzalez Gonzalez_Jefe de Grupo: Jose Carlos Fernandez Garcia	ALICIA GONZÁLEZ GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-01	CM21-00214 Contratos Rio Hortega 2021 Viyey Kishore Doulatram Gamgaram Jefe de grupo José Carlos Fernández García	VIYEY KISHORE DOULATRAM GAMGARAM	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-01	FI21-00040 Contratos predoctorales de formación en investigación de salud. Wasima Oualla Bachiri jefe de grupo Gemma Rojo Martínez.	WASIMA OUALLA BACHIRI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-01	MA-INV-0031-2022-03 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Gabriel Oliveira Fuster	ROSA MARIA ORTIZ BRAVO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
A-01	RBL-0004-1905 Generacion de nuevos ingredientes y alimentos beneficiosos dirigidos a condiciones de riesgo y al bienestar global de personas con cáncer colorrectal-acrónimo Tératrofo. Efecto coadyuvante en pacientes con tratamiento quimioterápico.	FRANCISCO JOSE SÁNCHEZ TORRALVO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
A-01	COM_24-04 Evaluación de la masa muscular en pacientes con neoplasia colorrectal: correlación entre el análisis de tc de abdomen a la altura de l3 y otras medidas antropométricas y funcionales	VIRGINIA SORIA UTRILLA	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2024
A-01	COM_24-01 ¿En Seguridad Alimentaria se considera la fibra de bambú como ingrediente de los preparados de carne picada?	VERÓNICA GONZÁLEZ ABREU	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2024
A-01	COM_24-02 Necesidades, barreras y facilitadores de la dieta en personas con enfermedad renal crónica y sus cuidadores. Proyecto goodrenal	MARINA PADIAL BARRANCO	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2024
A-01	COM_24-03 Biomarcadores de oxidación e infl amación y permeabilidad intestinal en personas con diabetes mellitus que reciben nutrición parenteral total: efecto del tipo de fórmula lipídica.	GABRIEL OLVEIRA FUSTER	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2024
A-01	EDUCACION_23-01 “Establecimiento de un programa de educación nutricional para mejorar la adherencia dietética y la calidad de vida de las personas con enfermedad renal crónica avanzada (ERCA)”	MARINA PADIAL BARRANCO	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2023
A-01	MejorTrabajo_23-01 PREMIO AL MEJOR TRABAJO ORIGINAL PUBLICADO POR LICENCIADOS 2023-2024.	FRANCISCO JOSE SÁNCHEZ TORRALVO	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2023
A-01	PI-06-2021-SANCYD-NUTRICIA. Evaluación del control glucémico mediante monitorización flash de glucosa (MFG) en pacientes desnutridos con diabetes tipo 2 y suplementos orales: fórmula estándar vs fórmula específica para diabetes	VIYEY KISHORE DOULATRAM GAMGARAM	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2021
A-01	PR-02030507-SANCYD. VARIOS PREMIOS SANCYD 2021-2022. 2.-Premio Triana Congresos. Investigador Principal: Dr. Gabriel Oliveira Fuster. 3.-Premio SANCYD-LACTALIS. Investigadora Principal: Victoria Contreras Bolívar. 5.-Premio a la mejor comunicación sobre nutrición clínica y dietética. Investigador Principal: F. Sánchez Torralvo. 7.-Premio SANCYD-GRIFOLS. Investigadora Principal: Montserrat Gonzalo.	GABRIEL OLVEIRA FUSTER	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2021
A-01	SENPE-01-2022_FSanchezTorralvo CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients	FRANCISCO JOSE SÁNCHEZ TORRALVO	NATIONAL	AWARDS	SPANISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-01	PR 24 01 PREMIO FUNDACIÓN SEEN A LA TRAYECTORIA DE UN GRUPO EN ENDOCRINOLOGÍA Y NUTRICIÓN	GABRIEL OLVEIRA FUSTER	NATIONAL	AWARDS	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION TEACHING FOUNDATION	2024
A-01	PR TESIS DOC 24 01 Eficacia de la inyección intragástrica de toxina botulínica A mediante endoscopia en pacientes con obesidad. (Estudio IntraTox)	FRANCISCO JOSE SÁNCHEZ TORRALVO	NATIONAL	AWARDS	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION TEACHING FOUNDATION	2024
A-01	SENPE CORAL 24_01 Grado de desnutrición en el estudio DRECO Asociación con variables morfofuncionales	GABRIEL OLVEIRA FUSTER	NATIONAL	AWARDS	SPANISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM	2024
A-01	SENPE NCLINICA 24 01 Ultrasound Muscle Evaluation for Predicting the Prognosis of Patients with Head and Neck Cancer: A large-Scale and Multicenter Prospective Study	MARIA GARCIA OLIVARES	NATIONAL	AWARDS	SPANISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM	2024
A-01	SENPE PIJOVEN 24_01 Aplicación clínica de la composición corporal por TC a nivel de D12 en pacientes con fibrosis quística.	VIRGINIA SORIA UTRILLA	NATIONAL	AWARDS	SPANISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM	2024
A-01	Trayectoria_23-01 PREMIO SANCYD 2023-2024 A LA TRAYECTORIA PROFESIONAL EN NUTRICIÓN CLÍNICA.	GABRIEL OLVEIRA FUSTER	REGIONAL	AWARDS	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2023
A-01	CIBER-D1 Metabolic fatty liver disease in people with Type 1 Diabetes in Spain. Prevalence, physiological determinants, and clinical relevance	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
A-01/A-02	PI20/01559 Glomerulopatía asociada a Obesidad: Evaluación de la eficacia de una dieta de muy bajo contenido calórico o de la inhibición de SGLT2 sobre albuminuria y función renal	JOSÉ CARLOS FERNÁNDEZ GARCÍA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
A-01/A-19	PI21-01042 Detección precoz y tratamiento de niños afectados de adrenoleucodistrofia ligada al X: un estudio poblacional prospectivo	RAQUEL YAHYAOUÏ MACÍAS	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-01/DE-08	PI23-01818 Enfermedad por hígado graso asociada a disfunción metabólica y diabetes tipo 1. Análisis de factores predictivos y evaluación de potenciales estrategias terapéuticas. LR: JOSE CARLOS FERNANDEZ GARCIA_COI: MIGUEL JIMENEZ PEREZ	JOSÉ CARLOS FERNÁNDEZ GARCÍA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-02	Susceptibilidad genética para predecir la pérdida de peso tras cirugía bariátrica.	LOURDES GARRIDO SÁNCHEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
A-02	Lifestyle Interventions, metabolites, microbiome, and diabetes risk	FRANCISCO JOSÉ TINAHONES MADUEÑO	INTERNATIONAL NON-EU	PI	NATIONAL INSTITUTES OF HEALTH	2020
A-02	Project COMFORT -Patient-Centric BLOod SaMpling FOr ImpRoved HealThcar	MANUEL MACIAS GONZÁLEZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
A-02	The Microbiome-Gut-Brain Axis and Personalized Mediterranean Diet Interventions for Alzheimer's Dementia Prevention	FRANCISCO JOSÉ TINAHONES MADUEÑO	INTERNATIONAL NON-EU	PI	NATIONAL INSTITUTES OF HEALTH	2023
A-02	PI21-01864 Definiendo la heterogeneidad en la Diabetes Gestacional: hacia una medicina de precisión. Una ventana crítica para parar el ciclo vicioso de diabetes-obesidad.	Mª SONSOLES MORCILLO ESPINA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-02	CP22-00033 Ayuda adicional contrato Miguel Servet 2022_Virginia Mela Rivas	VIRGINIA MELA RIVAS	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
A-02	PI21-01677 Medicina personalizada o de precisión en el abordaje dietético de la obesidad	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-02	ICI23-00019 Efecto de la levotiroxina como terapia adyuvante a la dieta hipocalórica en el tratamiento de la obesidad: ensayo clínico aleatorizado controlado por placebo.	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-02	PI19/00507 Fitness mitocondrial diana para la terapia contra la prediabetes IP MORA MURRI PIERRI	MORA MURRI PIERRI	NATIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
A-02	PI-0235-2021. miRNoma circulante asociado a diferentes estrategias nutricionales para el abordaje personalizado de la obesidad. NutrimiRs: caracterización y potencial terapéutico.	MARIA MERCEDES CLEMENTE POSTIGO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-02	PI-0108-2022 BÚSQUEDA DE POTENCIALES BIOMARCADORES DE DIAGNÓSTICO / EVOLUCION DE LA ESTEATOHEPATITIS NO ALCOHÓLICA EN PACIENTES CON OBESIDAD MÓRBIDA SOMETIDOS A CIRUGÍA BARIÁTRICA	LOURDES GARRIDO SÁNCHEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
A-02	SECO_PI23_01 FACTORES PREDICTORES DE LA RESPUESTA A LA CIRUGÍA BARIÁTRICA: PAPEL DE LA COMPOSICIÓN CORPORAL Y LA PÉRDIDA DE PESO PREVIA A LA CIRUGÍA"	LUIS TOMAS OCAÑA WILHELMI	NATIONAL	PI	SPANISH SOCIETY OF OBESITY SURGERY	2023
A-02	CP20-00066: Impact of glucose-lowering strategies on gut microbiota. Proyecto Miguel Servet 2020 Carolina Gutierrez Repiso	CAROLINA GUTIÉRREZ REPISO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
A-02	CP22-00096 Ayuda adicional Contrato Miguel Servet 2022. IP Patricia Ruiz Limon.	PATRICIA RUIZ LIMON	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
A-02	PI23-01449 Hacia la diagnosis de la disfunción del tejido adiposo para el manejo personalizado de la obesidad y las enfermedades metabólicas_ICornejo_McClemente	ISABEL MARÍA CORNEJO PAREJA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-02	SED-2018-02 DIFERENCIAS EN MICROBIOTA ENTRE PACIENTES CON DIABETES MELLITUS GESTACIONAL TRATADAS CON INSULINA FRENTE A AQUELLAS TRATADAS CON METFORMINA Y SU POSIBLE PAPEL EN EL CONTROL METABÓLICO, LA INFLAMACIÓN Y LOS RESULTADOS OBSTÉTRICOS Y PERINATALES. LR: María Molina Vega	MARIA MOLINA VEGA	NATIONAL	PI	SPANISH DIABETES SOCIETY	2018
A-02	CP20-00060: Footprint of an early nutritional intervention on breastfeeding mothers in the quality of the breast milk and health of the infant. Proyecto Miguel Servet 2020 Almudena Ortega Gomez	ALMUDENA ORTEGA GOMEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
A-02	ANPQ23_01 PROYECTO DE VALORACIÓN NUTRICIONAL EN EL PACIENTE PENDIENTE DE CIRUGÍA DE COLON ENFOCADO A LA COMPOSICIÓN CORPORAL (TAC, Ecografía nutricional y Bioimpedancia vectorial) (PROGRAMA DE PREHABILITACIÓN)	MIGUEL DAMAS FUENTES	NATIONAL	PI	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION FOUNDATION	2023
A-02	INN24_05 APP para la orientación nutricional (L1)	DANIEL JOSE HINOJOSA NOGUERIA	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
A-02	OBESIDAD-METABOLISMO_23_01 Papel de la enfermedad por hígado graso asociada a disfunción metabólica (MASLD) como marcador predictivo de remisión de diabetes tras cirugía bariátrica	JOSE IGNACIO MARTINEZ MONTORO	REGIONAL	PI	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2023
A-02	PI-0071-2024 Intervención Nutricional	LIBIA ALEJANDRA GARCIA FLORES	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
A-02	PI-0288-2024 Hacia la diagnosis de la disfunción del tejido adiposo para el manejo personalizado de la obesidad y las enfermedades metabólicas.	MARIA MERCEDES CLEMENTE POSTIGO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
A-02	PI23-01724 Una visión holística para el desarrollo de biomarcadores para NAFLD relacionado con la obesidad. LR: LOURDES GARRIDO SANCHEZ_ COI: JOSE MANUEL GARCIA ALMEIDA	LOURDES GARRIDO SÁNCHEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-02	CD23-00111 Contrato Sara Borrel 2023_Daniel Hinojosa-Nogueira_Jefe de Grupo: Isabel Moreno Indias	DANIEL JOSE HINOJOSA NOGUERIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-02	FI23-00104 Contratos predoctorales de formación en investigación de salud. BN: GEMA GOMEZ CASADO.IP: ALMUDENA ORTEGA GOMEZ.	GEMA GOMEZ CASADO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-02	RC-0008-2021 Renovación I Acción C (Programa Nicolás Monardes) Convocatoria 2017. LR: Sonsoles Morecillo	Mª SONSOLES MORCILLO ESPINA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
A-02	MS22-00033 Contrato Miguel Servet 2022_Virginia Mela Rivas	VIRGINIA MELA RIVAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	CD22/00144 Contrato Sara Borrell_Violeta Heras Dominguez_Jefe de Grupo Francisco Jose Tinahones Madueño.	VIOLETA HERAS DOMINGUEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	RB-0001-2019 RENOVACIÓN ACCION B CONVOCATORIA 2014 EN LAS UNIDADES DE GESTIÓN CLÍNICA (UGC) DEL SERVICIO ANDALUZ DE SALUD (SAS)	ANA MARIA GOMEZ PEREZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
A-02	RC1-0002-2023 Renovación II del Programa Nicolás Monardes 2023	MANUEL MACIAS GONZÁLEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-02	CPII22-00013 Contratos Miguel Servet Tipo II 2022 Mora Murri	MORA MURRI PIERRI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	CPII21-00013 Contratos Miguel Servet Tipo II 2021 Isabel Moreno Indias	ISABEL MORENO INDIAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-02	FI22-00193 Contratos predoctorales de formación en investigación de salud. BN: Alba Subiri Verdugo IP Isabel Morneo Indias	ALBA SUBIRI VERDUGO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	C-0028-2018 Acciones para el refuerzo con recursos humanos de la actividad investigadora en las Unidades de Gestión Clínica del Servicio Andaluz de Salud 2018. Acción C. Vinculación de investigadores a las UGC del SAS. Programa Nicola Monardes. Lourdes Garrido	LOURDES GARRIDO SÁNCHEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2018
A-02	CP20-00066 Contratos Miguel Servet 2020 Carolina Gutierrez Repiso	CAROLINA GUTIÉRREZ REPISO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-02	MS22-00096 Contrato Miguel Servet 2022. IP Patricia Ruiz Limon.	PATRICIA RUIZ LIMON	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	JR19-00054 Contratos Juan Rodes 2019 Isabel María Cornejo Pareja	ISABEL MARÍA CORNEJO PAREJA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
A-02	CP20-00060 Contratos Miguel Servet 2020 Almudena Ortega Gomez	ALMUDENA ORTEGA GOMEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-02	DOC_01095 Incorporación de ayudas posdoctorales. Candidate: Wilfredo Oliva Olivera, Group Leader: Lourdes Garrido Sánchez	WILFREDO OLIVA OLIVERA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2019
A-02	CD21-00131 Contratos Sara Borrell 2021 Libia Alejandra Garcia Flores jefe de grupo Manuel Macías González	LIBIA ALEJANDRA GARCIA FLORES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-02	CM22-00217 Contrato Rio Hortega 2022 Jose Ignacio Martinez Montoro_Jefe de Grupo Francisco Jose Tinahones Madueño.	JOSE IGNACIO MARTINEZ MONTORO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	MA-INV-0031-2022-02 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigto. LR: Francisco Tinahones Madueño	ANGEL MARTIN CALVO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
A-02	MOV24-15 Papel de los Cuerpos Cetónicos y Funcionalidad Mitocondrial en el abordaje dietético de la obesidad. Ayuno intermitente, Cetosis y Cronobiología	ALBA RODRÍGUEZ MUÑOZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-02	MOV24-17 Exploring the potential of brown adipose tissue-derived circulating small non-coding RNAs as biomarkers of tissue dysfunction.	MARIA MERCEDES CLEMENTE POSTIGO	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
A-02	MV24-00084 Estancia predoctoral APC Microbiome Institute (University College Cork)	ALBA SUBIRI VERDUGO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2024
A-02	RBL-0001-2024 Renovación 2024 Acción B-Refuerzos de larga duración. UC Endocrinología	FRANCISCO JOSÉ TINAHONES MADUEÑO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2024
A-02	A1-0064-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: FRANCISCO JOSE TINAHONES.	FRANCISCO JOSÉ TINAHONES MADUEÑO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-02	CM23-00128 Contrato Rio Hortega 2023_Cristina Maria Diaz Perdigones_Jefe de Grupo:Isabel Moreno Indias.	ISABEL MORENO INDIAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-02	PR24_DOCTOR_03 Premio IBIMA - Doctor al mejor expediente de último año	JOSE IGNACIO MARTINEZ MONTORO	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	ISABEL MORENO INDIAS	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2021
A-02	CA23151 (Medi-CaSE) - Mediterranean Cancer Screening and Early Diagnosis Network	MANUEL MACIAS GONZÁLEZ	EUROPEAN UNION	OTHER	COST ASSOCIATION	2023
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	PATRICIA RUIZ LIMON	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	CAROLINA GUTIÉRREZ REPISO	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
A-02/A-03	PI23-00293 Medicina Personalizada en el Abordaje Dietético de la Insuficiencia Cardiaca. Ayuno intermitente, cetosis y cronobiología. LR: MORA MURRI PIERRI_ COI: JOSE MANUEL GARCIA PINILLA	MORA MURRI PIERRI	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-02/A-09	PI23-01825 Alteraciones del olfato y gusto en la obesidad como potenciales predictores de la pérdida de peso y su relación con redes cerebrales. LR: CAROLINA GUTIERREZ REPISO_ COI: NATALIA GARCIA CASARES	CAROLINA GUTIÉRREZ REPISO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-02/A-10	PMP21/00106 AVANCES EN MEDICINA DE PRECISIÓN DE LA OBESIDAD: ANÁLISIS MULTIÓMICO Y DINÁMICO PARA EL DESCUBRIMIENTO Y VALIDACIÓN DE BIOMARCADORES PREDICTORES DE PÉRDIDA DE PESO TRAS INTERVENCIÓN EN PERSONAS DE ALTO RIESGO”	DOLORES CORELLA PIQUER/ FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-02/BE-18/C-06/D-04/D-05/DE-09	FORT23/00013 IBIMA FORTALECE 2023	MARÍA JOSÉ TORRES JAÉN	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-02/BE-23	PI21-00633 El estado de inflamación como principal impulsor de la metilación aberrante del ADN-ARN en el cáncer colorrectal.	MANUEL MACIAS GONZÁLEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-02/C-16	PI22-01813 El papel de los neutrófilos de leche materna de madres con enfermedades metabólicas tras una intervención nutricional. Impacto en el desarrollo del niño y respuesta a infecciones pulmonares	ALMUDENA ORTEGA GOMEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
A-03	Proy_Excel_01009 Identificación de marcadores moleculares de aortopatía bicúspide (MaMolAo)	GEMMA SÁNCHEZ ESPÍN	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-03	PI22/00570 Relación de la microbiota fecal y oral, y sus metabolitos, con la presencia de arterias coronarias lisas, irregulares y con lesión IP Fco Manuel Jimenez obstructiva significativa	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
A-03	SECFEC-INV-BAS 2318 Evaluación del Riesgo de Cardiopatía Isquémica en Pacientes con Trastorno por Uso de Alcohol en Abstinencia: Determinación de Marcadores de Estrés Cardíaco e Inflamación en Plasma	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	PI	SPANISH SOCIETY OF CARDIOLOGY	2023
A-03	PI-0245-2021. Caracterización de Pacientes con Hipertensión Pulmonar Basada en la Función Mitocondrial para el Desarrollo de una Prueba Diagnóstica	JUAN JOSÉ GÓMEZ DOBLAS	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-03	PI22-01833 Caracterización de Marcadores de Estrés Cardíaco y Quimioquinas en Pacientes con Trastorno por Uso de Alcohol para Evaluar el Riesgo de Cardiopatía Isquémica: Biomarcadores Específicos.	FRANCISCO JAVIER PAVÓN MORÓN	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
A-03	AFFIRMO - ATRIAL FIBRILLATION INTEGRATED APPROACH IN FRAIL, MULTIMORBID, AND POLYMEDICATED OLDER PEOPLE	JORGE RODRIGUEZ CAPITAN	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2020
A-03	PI23-01192 Eficacia, seguridad y efecto sobre el estado inflamatorio de un programa de telerehabilitación en pacientes con hipertensión arterial pulmonar. LR: VICTOR MANUEL BECERRA MUÑOZ	VICTOR MANUEL BECERRA MUÑOZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
A-03	SAC PI 24_01 Evaluación de marcadores de riesgo cardiovascular en el seguimiento en mujeres con Diabetes Gestacional y su relación con biomarcadores epigenéticos	LUIS GARCÍA RODRÍGUEZ	REGIONAL	PI	ANDALUSIAN SOCIETY OF CARDIOLOGY	2024
A-03	ORACLE - Optimize risk prediction after myocardial infarction through artificial intelligence and multidimensional evaluation	FRANCESCO COSTA	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2022
A-03	FI23-00016 Contratos predoctorales de formación en investigación de salud.BN: ADA DEL MAR CARMONA SEGOVIA. LR: MANUEL FRANCISCO JIMENEZ NAVARRO.	ADA DEL MAR CARMONA SEGOVIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-03	FI20/00227 Contratos predoctorales de formación en investigación en salud. Candidate: Dina Medina Vera: Group Leader: Francisco Javier Pavón Morón	DINA MEDINA VERA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-03	C1-0049-2019 SOLICITUD PARA EL PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2019	FRANCISCO JAVIER PAVÓN MORÓN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
A-03	CM21-00027 Contratos Rio Hortega 2021 Ana Isabel Molina Ramos. Group Leader Francisco Javier Pavón Morón	ANA ISABEL MOLINA RAMOS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-03	JR22-00067 Contratos Juan Rodes 2022 Victor Manuel Becerra Muñoz	VICTOR MANUEL BECERRA MUÑOZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-03	MA-INV-0031-2022-07 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Francisco Javier Pavón	MARIA DIAZ OTTAVIANO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
A-03	RHE-0039-2024 BIOMARCADORES EN SANGRE Y PARÁMETROS DE IMAGEN CARDÍACA PARA EL DIAGNÓSTICO PRECOZ DE CARDIOPATÍA ISQUÉMICA EN PACIENTES DE EDAD AVANZADA	MANUEL FRANCISCO JIMÉNEZ NAVARRO	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
A-03	A1-0063-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: JUAN JOSE GOMEZ DOBLAS AND MANUEL FRANCISCO JIMENEZ NAVARRO.	JUAN JOSÉ GÓMEZ DOBLAS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-03	CM23-00125 Contrato Rio Hortega 2023 Ainhoa Robles Mezcuea_Jefe de grupo: Manuel Francisco Jimenez Navarro.	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-03	INT23-00033 Contrato intensificación Manuel Jiimenez	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-03	JR23-00033 Contratos Juan Rodes 2023 Francesco Costa	FRANCESCO COSTA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	JORGE RODRIGUEZ CAPITAN	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
A-03	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	MARIA JOSE SANCHEZ QUINTERO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
A-03	CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure	MARIA JOSE SANCHEZ QUINTERO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-03	CA20137 (VOICES) -Making Young Researchers’ Voices Heard for Gender Equality	MARIA JOSE SANCHEZ QUINTERO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
A-03	CA20121 (BenBedPhar) -Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	MARIA JOSE SANCHEZ QUINTERO	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
A-03/F-02	Inteligencia Artificial para el modelado de un Sistema de Apoyo a la Decisión Clínica aplicado a las enfermedades cardiovasculares	PARAG CHATTERJEE	INTERNATION-AL NON-EU	HR	NATIONAL RESEARCH AND INNOVATION AGENCY OF URUGUAY	2023
A-06	e2-ducass -e2-ducass digital tool intervention: bringing the health literacy to vulnerable populations for promoting physical activity, healthy diet patterns and mental and cardiovascular health	RICARDO GÓMEZ HUELGAS	EUROPEAN UNION	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2023
A-06	3TR -Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory and Allergic Conditions	CARLOS ROMERO GOMEZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2018
A-06	PI21/00465 Envejecimiento saludable: enfoque multidisciplinario del impacto del estilo de vida en la salud humana. Estudio HEAG	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-06	PI-0040-2024 Obesidad Sarcopénica en la Infancia: Un problema emergente con graves consecuencias. Estudio OSIN	MARÍA ROSA BERNAL LÓPEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
A-06	Secoiridoides del olivo en la terapia nutricional del lupus eritematoso sistémico: implicaciones epigenéticas. SerLES Study	RICARDO GÓMEZ HUELGAS	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
A-06	CPII20/00014 Contratos Miguel Servet Tipo II 2020 María Rosa Bernal López	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-06	FI22/00294 Contratos predoctorales de formación en investigación de salud. BN: María de los Ángeles Silva Soto IP Rosa Bernal Lopez	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	C1-0005-2020_Solicitud para el programa Nicolás Monarde. Convocatoria 2020	MARÍA ROSA BERNAL LÓPEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2020
A-06	IHMC22/00011 Impact of lipid stress on sperm cytoskeleton: -omic study and damage reversal strategy through diet	ESTEFANÍA SAEZ LANCELLOTTI LANCELLOTTI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	A1-0047-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: RICARDO GOMEZ HUELGAS	MARÍA ISABEL PÉREZ MEDINA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-06	CM22/00155 Contrato Rio Hortega 2022 Michele Ricci Jefe de Grupo Ricardo Gomez Huelgas.	MICHELE RICCI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	CM22/00225 Contrato Rio Hortega 2022 Miguel Angel Perez Velasco_Jefe de Grupo Luis Miguel Perez Belmonte.	MIGUEL ÁNGEL PÉREZ VELASCO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	CA18216 (VascAgeNet) -Network for Research in Vascular Ageing	MARÍA ROSA BERNAL LÓPEZ	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
A-06	CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases	MARIA DEL MAR AYALA GUTIÉRREZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-07	Eficacia de los polifenoles del aceite de oliva y el ejercicio programado sobre la microangiopatía diabética	JOSÉ ANTONIO GONZÁLEZ CORREA	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
A-07	PI-0120-2020 Efectividad de la asociación aceite de oliva virgen extra-ácido acetilsalicílico vs. ácido acetilsalicílico cada 12 h sobre la resistencia al tratamiento antiagregante en pacientes con diabetes mellitus tipo 2.	JOSÉ ANTONIO GONZÁLEZ CORREA	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
A-07	PS17174 NUTRADAF, ITC-20161265 Caracterización de las fracciones funcionales de la aceituna, formulación de nuevos productos y análisis de sus defectos	JOSÉ ANTONIO GONZÁLEZ CORREA	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2016
A-07	PS17173 NUTRADAF, ITC-20161265 Caracterización de las fracciones funcionales de la aceituna, formulación de nuevos productos y análisis de sus defectos	JOSÉ ANTONIO GONZÁLEZ CORREA	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2016
A-07	PI-0137-2024 Estudio traslacional del efecto cardiosaludable de la asociación polifenoles-pectina obtenida del alperujo	JOSÉ ANTONIO GONZÁLEZ CORREA	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
A-07	PRINV_24_01 Effects of some olive fruits derived products on oxidative stress and cardiovascular biomarkers on experimental diabetes mellitus	JOSÉ PEDRO DE LA CRUZ CORTÉS	REGIONAL	AWARDS	ANDALUSIAN COUNCIL OF COLLEGES OF PHYSICIANS	2024
A-09	Caracterización clínica de sujetos con hiperalfalipoproteinemia extrema e identificación de variantes de secuencia en genes candidatos	PEDRO VALDIVIELSO FELICES	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
A-09	HOR-2024-01 MDR in AIS -Minimizing Door to Reperfusion Times in Drip and Ship Model for Patients with Acute Ischemic Stroke	CARLOS DE LA CRUZ COSME	EUROPEAN UNION	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2023
A-09	PI19/01375 Biomarcadores de deterioro cognitivo mediante neuroimagen estructural (tractografía) y funcional (conectividad cerebral) en pacientes con diabetes tipo 2.	NATALIA GARCÍA CASARES	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
A-09	BICE 05-20 Caracterización clínica de sujetos con hiperalfalipoproteinemia extrema e identificación de variantes de secuencia en genes candidatos	MARÍA JOSÉ ARIZA CORBO	NATIONAL	PI	SPANISH SOCIETY OF ARTERIOSCLEROSIS	2020
A-09	MA-INV-0031-2022-17 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Pedro Valdivielso -María José Ariza	ROSA MARIA ORDOÑEZ SIMON	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
A-10	PI-0067-2022. Influencia de los Entornos Obesogénicos Durante una Intervención para la Pérdida de Peso en el contexto andaluz del ensayo PREDIMED-PLUS. (PRE-ENVIRONS ANDALUCÍA)	JULIA WARNBERG	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
A-17	Desarrollo embrionario del origen anatómico de las arterias coronarias en modelos animales	FRANCISCO DE BORJA FERNÁNDEZ CORUJO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
A-17	MA-INV-0031-2022-26 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Borja Fernández Corujo	ANA HERNANDEZ MARTINEZ	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
A-19	BECA_SPAO_2021_Entrenamiento de la fuerza labial y lingual en sujetos pediátricos y su repercusión en la mejora de la disfagia orofaríngea.	VÍCTOR MANUEL NAVAS LÓPEZ	REGIONAL	PI	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	2021
A-19	PI-0070-2024 ESTUDIO A NIVEL DE CÉLULA ÚNICA DE LA RESPUESTA INMUNOLÓGICA SISTÉMICA A LA INGESTA CONTROLADA DE GLUTEN EN LA ENFERMEDAD CELIACA PEDIÁTRICA (CELLiomicS)	RAFAEL MARTIN MASOT	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-19	SEGHNP-2022-01. ANÁLISIS DE LA RESPUESTA FISIOLÓGICA AL AYUNO DE NIÑOS Y ADOLESCENTES CON OBESIDAD, EN COMPARACIÓN CON ADULTOS, Y TRAS UNA INTERVENCIÓN DE RESTRICCIÓN TEMPORAL DE LA INGESTA DE ALIMENTOS	RAFAEL MARTIN MASOT	NATIONAL	PI	SPANISH SOCIETY OF GASTROENTEROLOGY, HEPATOLOGY, AND PEDIATRIC NUTRITION	2022
A-19	CONECT4CHILDREN - European Paediatric Clinical Trials Network	ESMERALDA NUÑEZ CUADROS	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2017
A-19	AI-01-2023. ESTUDIO A NIVEL DE CÉLULA ÚNICA DEL EFECTO DE UNA DIETA SIN GLUTEN EN EL PERFIL INMUNOLÓGICO SISTÉMICO DE PACIENTES PEDIÁTRICOS CON ENFERMEDAD CELÍACA	RAFAEL MARTIN MASOT	REGIONAL	PI	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	2023
A-19	AI-01-2024 Desarrollo de una herramienta predictora de respuesta a terapia biológica en niños con enfermedad inflamatoria intestinal	VÍCTOR MANUEL NAVAS LÓPEZ	REGIONAL	PI	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	2024
A-19	BECA_SPAO_2022 ANÁLISIS DE LA RESPUESTA FISIOLÓGICA AL AYUNO DE NIÑOS Y ADOLESCENTES CON OBESIDAD, EN COMPARACIÓN CON ADULTOS, Y TRAS UNA INTERVENCIÓN DE RESTRICCIÓN TEMPORAL DE LA INGESTA DE ALIMENTOS	RAFAEL MARTIN MASOT	REGIONAL	PI	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	2022
A-19	SEFQ_24_01 ESTIMACIÓN DEL GASTO ENERGÉTICO EN REPOSO EN PACIENTES PEDIÁTRICOS CON FIBROSIS QUÍSTICA EN DIFERENTES FASES LA ENFERMEDAD Y SU TRATAMIENTO: EVALUACIÓN DE LA VALIDEZ DE LAS ECUACIONES PREDICTIVAS.	RAFAEL MARTIN MASOT	NATIONAL	PI	SPANISH CYSTIC FIBROSIS SOCIETY	2023
A-19	SEGHNP-2021-01. RESTRICCIÓN HORARIA DE LA INGESTA DE ALIMENTOS EN NIÑOS Y ADOLESCENTES CON OBESIDAD Y COMORBILIDADES METABÓLICAS: ESTUDIO PILOTO	VÍCTOR MANUEL NAVAS LÓPEZ	NATIONAL	PI	SPANISH SOCIETY OF GASTROENTEROLOGY, HEPATOLOGY, AND PEDIATRIC NUTRITION	2021
A-19	Estudio de factores predictivos para la alteración del crecimiento intrauterino mediante la identificación de biomarcadores clínicos, metabólicos y metagenómicos	FERNANDO CARDONA DÍAZ	NATIONAL	PI	STATE RESEARCH AGENCY	2021
A-19	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	ISABEL LEIVA GEA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
A-19	CA19115 (HyperChildNET) - Network for blood pressure research in children and adolescents	VERONICA MARTINEZ RIVERA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
A-19	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	PILAR SÁNCHEZ YAÑEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-19	CA21168 (JIR-CLiPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	ROCIO GALINDO ZAVALA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-21	AAEAR23_01 “Variación de la recidiva oncológica en el perioperatorio de cirugía tumoral de mama: comparación de anestesia libre de opiáceos e hipnóticos intravenosos vs opiáceos e hipnóticos inhalatorios. Papel de los circRNA como biomarcadores en este grupo de pacientes”.	AIDA RAIGÓN PONFERRADA	REGIONAL	PI	ANDALUSIA-EXTREMADURA ASSOCIATION OF ANESTHESIOLOGY, RESUSCITATION, AND PAIN THERAPEUTICS	2023
A-21	A1-0065-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: JOSE LUIS GUERRERO ORRIACH	JOSE CRUZ MAÑAS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-21	CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care	AIDA RAIGÓN PONFERRADA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-23	La vacunación de los adultos como factor protector para el desarrollo de demencias. Revisión sistemática y metaanálisis	ALBERTO MARISCAL LARRUBIA	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
AA-20	CA19133 (FOSTREN) -Fostering and strengthening approaches to reducing coercion in European mental health services	DANIEL MORENO SANJUÁN	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
AA-20	CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims	DANIEL MORENO SANJUÁN	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
AA-22	MOV24-10 Evaluación de las habilidades motoras en pacientes con Síndrome de Rett tratados con leriglitazona. IP:Rita Pilar Romero Galisteo	RITA PILAR ROMERO GALISTEO	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
AA-22	CA18205 (WORCK) -Worlds of Related Coercions in Work	FRANCISCO JAVIER ALCALDE DE HOYOS	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
AE-11	PMP22-00119 Red Nacional de Laboratorios de Función Renal	ELENA GUTIÉRREZ VILCHEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
AE-11	SEN22_01 Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico: estudio prospectivo, controlado y aleatorizado de grupos paralelos	ARMANDO TORRES RAMÍREZ	NATIONAL	PI	SPANISH NEPHROLOGY SOCIETY	2022
AE-11	RD21-0005-0012 Red de Enfermedades Inflamatorias RICORS2040	VERONICA LÓPEZ JIMÉNEZ	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
B-01	CARACTERIZACIÓN GENÓMICA PROFUNDA DEL CÁNCER DE MAMA LOCALIZADO TRATADO CON TERAPIA NEOADYUVANTE USANDO BIOPSIA LÍQUIDA	EMILIO ALBA CONEJO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
B-01	Análisis multifactorial y unicelular del control epigenético modulado por lamicrobiota en cáncer de mama triple negativo resistente a quimioterapia neoadyuvante	Mª ISABEL QUEIPO ORTUÑO	NATIONAL	PI	STATE RESEARCH AGENCY	2022
B-01	Modulación epigenética de distintos subtipos hormonales de cáncer de mama por el microbioma intratumoral: An approach at the single cell level	Mª ISABEL QUEIPO ORTUÑO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
B-01	B-0045-2023 Refuerzo con RRHH de la actividad investigadora en las UC del SAS -Acción B IP:Laura Gálvez	LAURA GALVEZ CARVAJAL	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
B-01	Ayudas para la Formación de Personal Universitario (FPU)	Lucía Aránega Martín	NATIONAL	HR	Ministry of Universities	2022
B-01	Ayudas para Personal Técnico de Apoyo	Isaac Jesús Plaza Andrades	NATIONAL	HR	Ministry of Science and Innovation	2022
B-01	SEOM23 PI_01 Hematopoyesis clonal y envejecimiento precoz en largos supervivientes de tumores de células germinales testiculares	LAURA GALVEZ CARVAJAL	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2023
B-01	PI21-00321Impacto del microbioma intestinal e intratumoral en la respuesta a la quimioterapia neoadyuvante en pacientes con cáncer de mama triple negativo (TNBC).	MARÍA ISABEL QUEIPO ORTUÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
B-01	SEOM23-PI-GE-01 CARACTERIZACIÓN DE LOS PACIENTES LARGOS SUPERVIVIENTES TRATADOS CON INMUNOTERAPIA.	LAURA MEDINA RODRÍGUEZ	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2023
B-01	CPC21211-SEOM. 68-GAPSMA como utilidad diagnóstica en pacientes con cáncer de mama subtipo triple negativo en estadios precoces y avanzados	MARIA EMILIA DOMINGUEZ RECIO	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2021
B-01	INN24_01 Avances en la Detección Temprana del Cáncer de Mama mediante Firmas de RNAs no Codificantes en Sangre	IÑAKI COMINO MÉNDEZ	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
B-01	SAOM22-01-MR Circulating tumor DNA as a predictive biomarker of response in patients with de novo classical Hodgkin’s lymphoma: a personalized medicine strategy	LAURA GALVEZ CARVAJAL	REGIONAL	PI	ANDALUSIAN SOCIETY OF MEDICAL ONCOLOGY	2022
B-01	SAOM22-01-RB “MULTIOMIC ANALYSIS IN HER2-POSITIVE BREAST CANCER: DIFERENCIAS MOLECULARES ENTRE SUBTIPO INTRÍNSECO MOLECULAR HER2- ENRICHED Y NO-ENRIQUECIDO, RELACIÓN CON HETEROGENEIDAD BIOLÓGICA Y RESPUESTA AL TRATAMIENTO”	ANA GODOY ORTIZ	REGIONAL	PI	ANDALUSIAN SOCIETY OF MEDICAL ONCOLOGY	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
B-01	FI19/00112 Contratos predoctorales de formación en investigación en salud Aurora Laborda Illanes Jefe de grupo: Maria Isabel Queipo Ortuño	AURORA LABORDA ILLANES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
B-01	PREDOC-001-2023 Caracterización de subtipos moleculares definidos por PAM50 y estudio del comportamiento clínico del fenotipo basal en distintas localizaciones tumorales.	CELIA GAONA ROMERO	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2022
B-01	CD21-00164 Contratos Sara Borrell 2021 Daniel Castellano Castillo jefe de grupo Emilio Alba Conejo	DANIEL CASTELLANO CASTILLO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
B-01	SEOM23-RT-01 MAPS-LUNG: Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial sequencing to reveal Lung Cancer Metastatic Landscape.	JOSE CARLOS BENÍTEZ MONTAÑÉS	NATIONAL	HR	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2023
B-01	EspacioSPERantia_01_24 Beca SAOM para la humanización de las Salas de Espera de los servicios de Oncología Médica de Andalucía	JAVIER GARCÍA CORBACHO	REGIONAL	COMPLEMENTARY ACTIONS	ANDALUSIAN SOCIETY OF MEDICAL ONCOLOGY	2023
B-04	PID2019-108096RB-C21 Aproximaciones sistémicas basadas en asociaciones fenotipo-genotipo para mejorar el diagnóstico de pacientes con enfermedades raras. Funding Entity	JUAN ANTONIO GARCÍA RANEA	NATIONAL	PI	MINISTRY OF ECONOMIC AFFAIRS AND DIGITAL TRANSFORMATION	2019
B-04	Comprehensive Platform for the Sustainable Development of Therapies Based On Oligonucleotides	JUAN ANTONIO GARCÍA RANEA	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2021
B-04	Integración de fenotipo, genotipo y transcriptómica en una plataforma bioinformática para ayudar en el diagnóstico de enfermedades raras	JUAN ANTONIO GARCÍA RANEA	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
B-04	Papel de los Condensados Biomoleculares en la Patofisiología de las Enfermedades Raras	MIGUEL ÁNGEL MEDINA TORRES	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
B-04	Destino celular, inflamación, metabolismo y angiogénesis en microambientes patológicos como dianas para enfoques farmacológicos biotecnológicos	MIGUEL ÁNGEL MEDINA TORRES	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
B-04	Cell Fate, Inflammation, Metabolism and Angioogenesis in Pathological Microenvironments as Targets for Biotechnological Pharmacologic Approaches	MIGUEL ÁNGEL MEDINA TORRES	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
B-04	MA-INV-0031-2022-20 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Miguel Angel Medina	MARIA DEL CARMEN BANQUERI PEGALAJAR	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
B-04/B-12/ F-09	Altas de expresión del olivo (OXA) para interrogación prospectiva del olivo en estrés salino	MANUEL GONZALO CLAROS DÍAZ/ FRANCISCO VEREDAS NAVARRO/ JESÚS MANUEL GÓMEZ DE GABRIEL	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
B-05	EUnetCCC JA - The European Comprehensive Cancer Centre Network	ANTONIO RUEDA DOMÍNGUEZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2024
B-05	Proy_Excel_01002 Farmacogenómica de precisión aplicada al tratamiento de inmunoterapia en Cáncer de pulmón y Cabeza y Cuello.	FRANCISCO JAVIER OLIVER MARTOS	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
B-05	DTS23-00114 EPIPREDICT: Desarrollo de un panel de marcadores epigenéticos en biopsia líquida para la predicción de respuesta y pronóstico en nuevas estrategias inmunoterápicas	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
B-05	CPC21201_SEOM Detección temprana de metástasis hepáticas en cáncer de mama basado en el estudio de patrones de metilación e hidroximetilación en el adn libre circulante en sangre	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2021
B-05	CPC21210-SEOM Micro-RNAs como huellas en la caracterización y detección precoz del efecto de cancerización de campo en el carcinoma escamoso de cavidad oral.	ELISABETH PEREZ RUIZ	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
B-05	GLD23-00137 “MAPS-LUNG: Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial sequencing to reveal Lung Cancer Metastatic Landscape”	ANTONIO RUEDA DOMÍNGUEZ	NATIONAL	PI	GILEAD SCIENCES, S.L.U.	2023
B-05	PRYES247250BARR Descifrando las firmas epigenéticas de la respuesta abscopal para guiar la inmunoterapia de precisión (EPI-SABR)	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	PI	SPANISH ASSOCIATION AGAINST CANCER	2023
B-05	C1-0003-2023 PROGRAMA NICOLAS MONARDE CONVOCATORIA 2023_CANDIDATO FRANCISCO OLIVER MARTOS_ Farmacogenómica y toxocogenomica de precisión en Oncología	FRANCISCO JAVIER OLIVER MARTOS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
B-05	RC-0009-2021 Renovación I Acción C (Programa Nicolás Monardes) Convocatoria 2017. LR: Isabel Barragán	MARIA ISABEL BARRAGÁN MALLOFRET	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
B-05	PREDOC_01691 Integración de ómicas para la identificación de marcadores predictivos de respuesta a inmunoterapia del cáncer.	MARIA ISABEL BARRAGÁN MALLOFRET	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
B-05	MA-INV-0031-2022-14 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Isabel Barragan	MARINA RIVERO AGUILAR	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
B-05	MOV24-09 Estudio de la inmunoterapia del cáncer desde una perspectiva integradora de ómicas, con un enfoque particular en la epigenética como marcador pronóstico. IP:Juan Luis Onieva Zafra	JUAN LUIS ONIEVA ZAFRA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
B-05	JDC2023-050934-I Ayuda Juan de la Cierva 2023_ Candidato: Alba Rodríguez Martínez Jefe de Grupo: María Isabel Barragán Mallofret	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	HR	STATE RESEARCH AGENCY	2024
B-05	CNS2023-145629-RRHH Contrato. Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial Transcriptomics to reveal Lung Cancer Distant Relapse predictors (MAPS-LUNG)	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	HR	STATE RESEARCH AGENCY	2023
B-05	A1-0046-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: MANUEL COBOS DOLS	EMILIO ALBA CONEJO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
B-05	ISMB/ECCB 2023 Award for the Best Poster at TransMed	JUAN LUIS ONIEVA ZAFRA	INTERNATION-AL NON-EU	AWARDS	INTERNATIONAL SOCIETY FOR COMPUTATIONAL BIOLOGY	2023
B-05	CNS2023-145629-PI Ayuda Adiccional Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial Transcriptomics to reveal Lung Cancer Distant Relapse predictors (MAPS-LUNG)	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	PI	STATE RESEARCH AGENCY	2023
B-05/B-22	PI22-01816 Biomarcadores de resistencia a la inmunoterapia: integrando Efecto Abscopal y epigenética en una estrategia de medicina de precisión no invasiva.	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
B-05/BE-23	GEM23_01 “Ex vivo characterization of the mechanisms associated with Abscopal Response”.	MARIA ISABEL BARRAGÁN MALLOFRET	LOCAL	PI	SPANISH MULTIDISCIPLINARY MELANOMA GROUP (GEM)	2023
B-07	EL DIALOGO ENTRE GLS Y GLS2 COMO DIANA TERAPEUTICA EN CANCER	José Manuel Matés Sánchez	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
B-07	MA-INV-0031-2022-06 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Javier Marquez	VIRGINIA JIMENEZ FERRER	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
B-10	EFICACIA DE LOS FOTOPROTECTORES TÓPICOS EN PACIENTES CON FOTODERMATOSIS. NUEVOS MÉTODOS ENFOTODIAGNÓSTICO	MARÍA VICTORIA DE GÁLVEZ ARANDA / ENRIQUE HERRERA CEBALLOS	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
B-11	PID2021-125385OB-I00 Abordando el papel del ATX como una nueva diana terapéutica en el cáncer de vejiga urotelial	ELISA MATAS RICO	NATIONAL	PI	STATE RESEARCH AGENCY	2021
B-11	CPP2022-010045 Desarrollo y validación de nuevo sistema automático de predicción, diagnóstico y análisis temprano de patologías del tracto urinario inferior, a través de nuevas técnicas de procesamiento de señal e investigación de IA usando martwatch (SWALU23)	BERNARDO HERRERA IMBRODA	NATIONAL	PI	STATE RESEARCH AGENCY	2023
B-11	AEU21-001 EVALUACIÓN CLÍNICO-RADIOLÓGICA Y GENÉTICA EN PACIENTES CON CÁNCER DE PRÓSTATA METASTÁSICO HORMONOSENSIBLE TRATADOS CON ANTIANDRÓGENOS DE NUEVA GENERACIÓN. CPC21065	BERNARDO HERRERA IMBRODA	NATIONAL	PI	SPANISH ASSOCIATION OF UROLOGY	2020
B-11	LABAE223471MATA: LAB AECC_01 LA SEÑALIZACIÓN POR AUTOTAXINA-ÁCIDO LISOFOSFATIDICO COMO DIANA TERAPEUTICA PARA MEJORAR LA EFICACIA DE LA INMUNOTERAPIA EN EL CÁNCER UROTELIAL DE VEJIGA. LABAE223471MATA	ELISA MATAS RICO	NATIONAL	PI	SPANISH ASSOCIATION AGAINST CANCER	2022
B-11	Evaluación del papel de Autotaxina como factor pronóstico en Cáncer de Vejiga	ELISA MATAS RICO	NATIONAL	PI	STATE RESEARCH AGENCY	2022
B-11	AECC_JUNIOR_01_ Validación de marcadores y nuevas dianas de tratamiento en cáncer urotelia. Candidate. Fernando Alberca	FERNANDO ALBERCA DEL ARCO	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2023
B-11	MA-INV-0031-2022-16 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Elisa Matas	LAURA CORREA ARNEDO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
B-11	MOV24-08 Establecimiento de organoides derivados de tejido urotelial humano. LR: Alejandro Rego Calvo	ALEJANDRO REGO CALVO	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
B-11	Abordando el papel de ATX como una nueva diana terapéutica en el Cáncer Urotelial de Vejiga	ISMAEL ARANDA BRAVO	NATIONAL	HR	STATE RESEARCH AGENCY	2022
B-12	PID2020-116898RB-I00 INTELIGENCIA ARTIFICIAL PARA PROCESAMIENTO DE LENGUAJE NATURAL DE TEXTO CLÍNICO EN ESPAÑOL PARA ANÁLISIS DE REAL-WORLD-DATA (Text2RWD)	JOSÉ MANUEL JEREZ ARAGONÉS	NATIONAL	PI	STATE RESEARCH AGENCY	2020
B-12	Primer kit del mercado para el diagnóstico temprano de la esclerosis múltiple en sangre	JOSÉ MANUEL JEREZ ARAGONÉS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
B-22	RETOS245794PAZA SOSCLC – AECC: Cáncer de pulmón de célula pequeña. De las redes biológicas a la terapia personalizada	MANUEL COBO DOLS	NATIONAL	PI	SPANISH ASSOCIATION AGAINST CANCER	2024
BA-16	CGEE-PI-2021. Influencia en la calidad de vida, adherencia al tratamiento y mejora de conocimientos en pacientes anticoagulados con anti-vitamina K (AVK)	ADOLFO ROMERO RUIZ	NATIONAL	AWARDS	GENERAL NURSING COUNCIL OF SPAIN	2021
BE-18	PI21/00653 Discovery of new therapeutic targets to battle cancer and prevent lymphatic metastasis / Descubrimiento de Nuevas Dianas Terapéuticas en la Lucha Contra el Cáncer y la Prevención de las Metástasis Linfáticas	MELISSA GARCÍA CABALLERO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
BE-18	Targeting the non tumor players of the tumor microenvironment to improve the efficacy of the current therapies	MELISSA GARCIA CABALLERO	NATIONAL	PI	SPANISH ASSOCIATION AGAINST CANCER	2021
BE-18	Descifrando la interacción entre la vasculatura linfática y las células inmunes en microambientes tumorales para el desarrollo de inmunoterapias mejoradas	MELISSA GARCIA CABALLERO	NATIONAL	PI	STATE RESEARCH AGENCY	2023
BE-18	PREDOC-003-2023 Caracterización de la vasculatura tumoral linfática y descubrimiento de prometedoras dianas terapéuticas.	CRISTINA VIUDEZ PAREJA	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2022
BE-18	MA-INV-0031-2022-12 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Melissa García	MARIA GUERRERO SANCHEZ	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
BE-18	INT-F2-2401 PLAN PROPIO F2. Ayudas para la asistencia a eventos internacionales de posicionamientoIP: Melissa García Caballero	MELISSA GARCÍA CABALLERO	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
BE-18	CA21154 (TRANSLACORE) -Translational control in Cancer European Network	MELISSA GARCÍA CABALLERO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
BE-18	CA21135 (IMMUNO-model) -Modelling immunotherapy response and toxicity in cancer	MELISSA GARCÍA CABALLERO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
BE-19	Elaboración de un protocolo nacional en dosimetría biológica	Miguel José Ruiz Gómez (colaborador)	NATIONAL	PI	Nuclear Safety Council	2022
BE-19	INN24_04 Nuevos marcadores moleculares de resistencia a 5-Fluorouracilo	MIGUEL JOSÉ RUIZ GÓMEZ	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
BE-19	MOV24-11 Biomarcadores clínicos y biodosimétricos aplicados en medicina con equipos automatizados. IP:Antonio Manuel Burgos Molina	ANTONIO MANUEL BURGOS MOLINA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
BE-21	Estudio del infiltrado de linfocitos B en pacientes con melanoma metastásico mediante la validación interna	ALEJANDRO ESCAMILLA SANCHEZ	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
C-01	PID2020-117464RB-I00 EL RECEPTOR LPA1 COMO POSIBLE BIOMARCADOR VULNERABILIDAD A LA DEPRESION. PAPEL EN LA SENSIBILIZACION MICROGLIAL Y EN LOS CAMBIOS NEUROGENICOS INDUCIDOS POR ESTRES JUVENIL	CARMEN PEDRAZA BENÍTEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2020
C-01	ICI19/00027 Ensayo clínico fase IIb para confirmar la seguridad y eficacia de la administración intralesional de dos dosis de células mesenquimales de tejido adiposo alogénicas en pacientes con incontinencia fecal. IP. Laura Leyva Fernández	LAURA LEYVA FERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
C-01	PI21-01668 Biomarcadores pronósticos de evolución clínica en pacientes con esclerosis múltiple remitente recurrente de diagnóstico reciente: volumetría de la médula espinal	LAURA LEYVA FERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-01	CPP2021-008512 PRIMER KIT DEL MERCADO PARA EL DIAGNÓSTICO TEMPRANO DE LA ESCLEROSIS MÚLTIPLE EN SANGRE	BEGOÑA OLIVER MARTOS	NATIONAL	PI	STATE RESEARCH AGENCY	2022
C-01	PI22-00596 Caracterización genética y evaluación funcional de la respuesta de interferón tipo I en pacientes con encefalitis anti-receptor NMDA (IFN-NMDAR).	BEGOÑA OLIVER MARTOS	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-01	PI22-01141 Papel de los vasos sanguíneos en las alteraciones en el patrón de mielina asociado al abuso de alcohol durante la adolescencia: una nueva vía terapéutica para el tratamiento de las adicciones.	BEATRIZ GARCIA DIAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-01	CPP2021-008689 SISTEMA PORTABLE INTELIGENTE DE MONITORIZACIÓN Y TERAPIA PARA TRASTORNOS DEL SUEÑO REM (SMOTTS).	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2022
C-01	ProyExcel_00996 Evaluation of the Lysophosphatidic acid signalling pathway as a high potential target for the Pelizaeus-Merzbacher disease treatment.	BEATRIZ GARCIA DIAZ	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
C-01	Evaluación de las propiedades antivirales e inmunomoduladoras del receptor de IFN beta soluble en encefalitis herpética y encefalitis NMDAR postherpética	BEGOÑA OLIVER MARTOS	NATIONAL	PI	STATE RESEARCH AGENCY	2023
C-01	Prevención de la sensibilización cruzada a alcohol y cocaína en la adolescencia: efectos neuroprotectores de la oleoiletanolamida	EDUARDO BLANCO CALVO	NATIONAL	PI	MINISTRY OF HEALTH	2021
C-01	Facilitación de la conectividad hicampo-corteza prefrontal ventromedial como herramienta para favorecer la extinción de asociaciones cocaína-contexto	DAVID LADRÓN DE GUEVARA MIRANDA	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-01	RC-0002-2021 Renovación II del Proyecto Nicolás Monardes 2013. Guillermo Estivill Torrús	GUILLERMO ESTIVILL TORRÚS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-01	FI19-00139 Contratos predoctorales de formación e investigación en salud Isabel Brichette Mieg Jefe de grupo: Laura Leyva Fernández	ISABEL BRICHETTE MIEG	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-01	A1-0003-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS). LR: PEDRO J SERRANO CASTRO.	PEDRO JESÚS SERRANO CASTRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-01	MA-INV-0031-2022-05 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. LR: Guillermo Estivill - Eduardo Blanco Calvo	GEMA GARRIDO MORAL	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
C-01	MOV24-16 IMPLICATION OF TREM2 MICROGLIAL RECEPTOR IN POSTNATAL SYNAPTIC PRUNING, CONNECTIVITY AND BEHAVIOR OF MICE UNDERGOING EARLY LIFE STRESS.	JOSÉ MUÑOZ MARTÍN	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
C-01	RBL-0001-2023_Renovación 2023 Acción B-Refuerzos de larga duración	PATRICIA URBANEJA ROMERO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-01	IFEQ22_00032 Equipamiento para dotación de equipamiento para ECAI Genómica	PEDRO JESÚS SERRANO CASTRO	NATIONAL	INFRASTRUCTURE	CARLOS III INSTITUTE OF HEALTH	2022
C-01	IFEQ22_00098 Síntetizador de péptidos para dotación de la Unidad de Química de IBIMA-Plataforma Bionand	PEDRO JESÚS SERRANO CASTRO	NATIONAL	INFRASTRUCTURE	CARLOS III INSTITUTE OF HEALTH	2022
C-01	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	BEATRIZ GARCIA DIAZ	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
C-02	PI21-01695 Prevención de la ansiedad y depresión por evaluación de riesgos: ensayo controlado aleatorio (El Estudio PANDORA)	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-02	AP-0210-2021-C2-F2 Prevención de la depresión en población trabajadora, mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayuda a las decisiones: ensayo controlado aleatorio	JUAN ÁNGEL BELLÓN SAAMEÑO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
C-02	AP-0212-2019 Estudio Cualitativo Sobre el Espacio Colaborativo Atención primaria-Salud Mental	FRANCISCA MUÑOZ COBOS	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2019
C-02	PID2020-119652RA-I00 Efectividad de una intervención personalizada a través de internet basada en un algoritmo de riesgo para la prevención universal de la ansiedad. El estudio prevANS.	PATRICIA MORENO PERAL	NATIONAL	PI	STATE RESEARCH AGENCY	2020
C-02	AP-0608-2024-C5-F2 Participación ciudadana en la adaptación de una intervención online personalizada para la prevención de los trastornos de ansiedad a población joven adulta: prevent-YA PPI.	SANTIAGO GALAN ORTEGA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2024
C-02	AP-0614-2024-C5-F2 PAMDA: una aPlicAción móvil para increMentar los niveles de activiDad física y proteger la salud mental en Adolescentes.	MARIA RODRIGUEZ GARCIA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2024
C-02	POSTDOC-21-00620 Incorporación de ayudas posdoctorales. Candidato:Sonia Conejo Cerón Jefe de equipo: Juan Angel Bellon Saameño	SONIA CONEJO CERÓN	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-02	FI22-00221 Contratos predoctorales de formación en investigación de salud. BN: Carmen María Garrido González IP: Juan Ángel Bellón Saameño	CARMEN MARÍA GARRIDO GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
C-02	CD23-00096 Contrato Sara Borrell 2023_Maria Rodriguez Garcia_Jefe de grupo: Juan Angel Bellon.	MARIA RODRIGUEZ GARCIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-02	FPU22-04269 CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE PROFESORADO UNIVERSITARIO-FPU 2022. CANDIDATE: MARIA CRISTINA GONZALEZ MONROY	CRISTINA GONZÁLEZ MONROY	NATIONAL	HR	MINISTRY OF UNIVERSITIES	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-02	PRE2021-098359 AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE DOCTORES 2021.	CRISTINA GARCÍA HUÉRCANO	NATIONAL	HR	STATE RESEARCH AGENCY	2021
C-02	PREDOC_02151. Impacto de las medidas de aislamiento por COVID-19 en personas mayores con deterioro cognitivo y sus cuidadores.	SARA REYES MARTIN	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-02	INT22-00103 Prevención de la ansiedad y depresión por evaluación de riesgos: ensayo controlado aleatorio (El Estudio PANDORA).	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
C-02	MA-INV-0031-2022-10 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Juan Ángel Bellón	ABEL GOMEZ DIAZ	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
C-02	RD21/0016/0012 Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud RICAPPS	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
C-03	HOR-2024-02 DADAP -Digitizing and Automating the Diagnostic psychiatric Assessment Process	MARINA ROMERO GONZÁLEZ	EUROPEAN UNION	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2023
C-03	MENTOR -Mental Health Together	JOSÉ GUZMAN PARRA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
C-03	PI19/01131 Evaluación de la implementación de un programa de terapia psicológica online para el tratamiento de la depresión en atención primaria: Estudio multicéntrico con diseño híbrido. IP FERMIN MAYORAL CLERIES	FERMÍN MAYORAL CLERIES	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
C-03	PI21-01328 Eficacia e implementación de un programa online de psicoterapia para la prevención de los efectos de la pandemia de la COVID-19 en la salud mental de los profesionales sociosanitarios	JOSÉ GUZMAN PARRA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-03	Gilead20-001 Eficacia de un programa de acompañamiento de enfermería para la microeliminación de la hepatitis C en pacientes con diagnóstico psiquiátrico grave PSIQUIÁTRICO GRAVE	CASTA QUEMADA GONZÁLEZ	NATIONAL	PI	GILEAD SCIENCES EUROPE LTD.	2020
C-03	iGAME - Multi-dimensional Intervention Support Architecture for Gamified eHealth and mHealth Products	FERMÍN MAYORAL CLERIES	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2018
C-03	A1-0024-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: JOSE GUZMAN PARRAS.	JOSÉ GUZMAN PARRA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-03	CM22/00232 Contrato Rio Hortega 2022 Vera Carbonell Aranda_Jefe de Grupo Jose Guzman Parra.	VERA CARBONELL ARANDA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
C-03	JR23/00008 Contratos Juan Rodes 2023 Jessica Marian Goodman Casanova	JESSICA MARIAN GOODMAN CASANOVA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-03	MA-INV-0031-2022-09 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Fermin Mayoral	ISABEL PRIETO TORRERO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
C-03	RB-0005-2019 RENOVACIÓN ACCION B CONVOCATORIA 2014 EN LAS UNIDADES DE GESTIÓN CLÍNICA (UGC) DEL SERVICIO ANDALUZ DE SALUD (SAS)	ANTONIO BORDALLO ARAGÓN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
C-03	RHJ-0043-2024 Investigadora Postdoctoral	GLORIA MARGARITA GUERRERO PERTÍÑEZ	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
C-03	B-0023-2023 Refuerzo con RRHH de la actividad investigadora en las UC del SAS - Acción B IPJessica Marian Goodman	JESSICA MARIAN GOODMAN CASANOVA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-03	RBL-0005-2024 Renovación 2024 Acción B-Refuerzos de larga duración. UC Salud Mental.	ANTONIO BORDALLO ARAGÓN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2024

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	ANA BELEN PABA DOTES	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
C-03	CA19133 (FOSTREN) - Fostering and strengthening approaches to reducing coercion in European mental health services	JOSÉ GUZMAN PARRA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2020
C-03	CA22114 (TREARURE) - Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants’ development	GLORIA MARGARITA GUERRERO PERTÍÑEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-03	CA23153 (YouthDMH) - Digital Mental Health for Young People	JESSICA MARIAN GOODMAN CASANOVA	EUROPEAN UNION	OTHER	COST ASSOCIATION	2023
C-03	CA23153 (YouthDMH) - Digital Mental Health for Young People	JOSÉ GUZMAN PARRA	EUROPEAN UNION	OTHER	COST ASSOCIATION	2023
C-05	PI19/00778 Testing non-embryonic based stem cells as regenerative cell sources for treating neonates with intraventricular hemorrhages that develop posthemorrhagic hydrocephalus. IP ANTONIO JESUS JIMENEZ LARA	ANTONIO JESÚS JIMÉNEZ LARA	NATIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
C-05	PID2022-141741NB-I00 Efectos de la microglía condicionada sobre el eje hipotálamo-hipofisario-adrenal y la respuesta al estrés. Modulación farmacológica con un inhibidor de CSF1R y cannabidiol	María Dolores López Ávalos	NATIONAL	PI	Ministry of Science, Innovation, and Universities	2022
C-05	Testing a synergistic combination of non-embryonic stem cells as a novel therapeutic strategy to regenerate the ventricular walls after neonatal intracerebral hemorrhage.	ANTONIO JESÚS JIMÉNEZ LARA	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
C-05	MA-INV-0031-2022-25 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Antonio Jesús Jiménez Lara	DIEGO JESUS MATEOS AGUILAR	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
C-05	MOV24-05 Consequences of a Traumatic Brain Injury on the priming of hypothalamic microglia and its effect on the Hypothalamic-Pituitary-Adrenal axis regulation.Modulation with the CSF1R inhibitor PLX5622 (Consecuencias de un traumatismo Craneoencefálico en el condicionamiento de la microglía hipotalámica y su efecto en la regulación del eje Hipotalámico-Hipofisario-Adrenal. Modulación con el inhibidor del CSF1R PLX5622). LR: Ana León Rodríguez	ANA LEÓN RODRÍGUEZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
C-06	PID2020-114374RB-I00 Estrategias nutricionales para potenciar la neurogénesis y la función hipocampal: uso de cacao como nuevo tratamiento para las alteraciones cognitivas inducidas por la cocaína (CHOCovsCOCA)	ESTELA CASTILLA ORTEGA	NATIONAL	PI	STATE RESEARCH AGENCY	2020
C-06	PI22/00427 PAPEL DEL BDNF Y LAS ACILETANOLAMIDAS EN EL DETERIORO COGNITIVO ASOCIADO A LOS TRASTORNOS POR USO DE ALCOHOL: UN ESTUDIO TRASLACIONAL.	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-06	DTS22/00021 DESARROLLO DE LOS INOSITOLES D-PINITOL Y D-CHIROINOSITOL COMO TRATAMIENTO DE ENFERMEDADES QUE CURSAN CON ACUMULACIÓN DE PROTEÍNA TAU FOSFORILADA (TAUOPATHIES)	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-06	2022I020 BIOMARCADORES DE DETERIORO COGNITIVO EN EL TRASTONO POR USO DE ALCOHOL: UN ESTUDIO TRASLACIONAL	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	MINISTRY OF HEALTH	2022
C-06	SUBV23/00030: ESTUDIO DE LA ASOCIACIÓN JUEGO PATOLÓGICO-USO ANÓMALO DEL MÓVIL EN LA POBLACIÓN GENERAL ESPAÑOLA: DETERMINANTES SOCIALES E INDIVIDUALES	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	MINISTRY OF CONSUMER AFFAIRS	2023
C-06	202212-32_Towards understanding and predicting treatment resistance in major depression.	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	FUNDACIÓ LA MARATO DE TV3	2022
C-06	PI20/01399 Papel de la señalización lipídica mediada por monoacilglicerolos y ácido lisofosfatídico en la Asociación entre trastornos por uso de alcohol y Depresión: Identificación de Biomarcadores	ANTONIA SERRANO CRIADO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
C-06	CONECTA 02 Bienestar Social mediante la Neuropsicología, aumento en la tasa de rehabilitación y detec-ción de abandono en adicciones a sustancias.	ESTELA CASTILLA ORTEGA	NATIONAL	PI	LA CAIXA FOUNDATION	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-06	CP21/00021 Proyecto Miguel Servet 2021 Juan Manuel Decara del Olmo	JUAN MANUEL DECARA DEL OLMO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-06	Análisis del papel neuroprotector del fitocannabinoide no-psicoactivo cannabidiol en defectos del neurodesarrollo por intoxicación etílica: evaluación de las alteraciones morfológicas, neurogénicas y cognitivo-emocionales	JUAN SUÁREZ PÉREZ	REGIONAL	PI	REGIONAL MINISTRY OF TRANSFORMATION, ECONOMY, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2022
C-06	Biomarcadores de respuesta de Interferón tipo I en pacientes con enfermedades neurológicas y su posible efecto agravante en modelo animal de Alzheimer con intoxicación etílica.	Isaac Hurtado Guerrero	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
C-06	MS19/00068 Contrato Miguel Servet Patricia Rivera González	PATRICIA RIVERA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-06	RC1-0001-2023 Renovación II del Programa Nicolás Monardes 2023.	FERNANDO RODRÍGUEZ DE FONSECA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-06	C1-0005-2022 PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2022. CANDIDATE ANTONIA MARIA SERRANO CRIADO. CARACTERIZACIÓN DE SISTEMAS DE SEÑALIZACIÓN LIPÍDICOS ASOCIADOS A LA COMORBILIDAD PSIQUIÁTRICA EN LOS TRASTORNOS POR USO DE SUSTANCIAS: IDENTIFICACIÓN DE BIOMARCADORES Y DIANAS TERAPÉUTICAS.	ANTONIA SERRANO CRIADO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
C-06	CD20/00192 Contratos Sara Borrell 2020 Sara Peñasco Iglesias. Group Leader: Fernando Rodriguez de Fonseca	SARA PEÑASCO IGLESIAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
C-06	DOC_01153 Incorporación de ayudas posdoctorales. Candidate: Mª Mar Fernández Arjona. Team leader: Juan Suárez Pérez	MARÍA DEL MAR FERNÁNDEZ ARJONA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2019
C-06	MS21/00021 Contrato Miguel Servet 2021 Juan Manuel Decara del Olmo	JUAN MANUEL DECARA DEL OLMO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
C-06	IFI21/00024: Contratos I-PFIS 2021 Beatriz Pacheco Sánchez. Group leader: Fernando Rodríguez de Fonseca	BEATRIZ PACHECO SANCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
C-06	MV23/00058 Estancia formativa en el Karolinska Institute para investigar el papel de los receptores CB2 y GPR55 en modelos de Alzheimer	BEATRIZ PACHECO SANCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-06	CM21/00255 Contratos Rio Hortega 2021 Jesús Herrera Imbroda Jefe de grupo fernando Antonio Rodríguez de Fonseca	JESÚS HERRERA IMBRODA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
C-06	CM23/00150 Contrato Rio Hortega 2023_ Yolanda Lopez Moreno_ Jefe de Grupo: Fernando Rodriguez de Fonseca	YOLANDA LÓPEZ MORENO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-06	MA-INV-0031-2022-08 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Antonia Serrano	ESPERANZA PEREZ GARRIDO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
C-06	DGP_POST_2024_00372 Incorporación de ayudas posdoctorales. Candidata:María Luisa Ceglia. Jefe de Grupo:Fernando Rodríguez de Fonseca.	María Luisa Ceglia	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2024
C-06	PR24_DOCTOR_02 Premio IBIMA - Doctor al mejor expediente de último año.	MARÍA FLORES LÓPEZ	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
C-06	RD21/0009/0003 Red de Investigación en Atención Primaria de Adicciones RIAPAd	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-06	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	ADRIANA CASTRO ZAVALA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-06	CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development	ANTONIA SERRANO CRIADO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-07	Aislamiento social en la pandemia de COVID-19 y consumo de alcohol: Combinación Galanina (1-15)-Naltrexona como estrategia terapéutica.	Carmelo Millón Peñuela	NATIONAL	PI	National Drug Plan, Ministry of Health	2022
C-07	Papel de la Galanina 1-15 en el consumo del opioide sintético fentanilo-8221	Carmelo Millón Peñuela	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
C-07	Nuevos heterocomplejos como posibles biomarcadores en el deterioro cognitivo: Un enfoque multidisciplinar integrando mod	Manuel Alejandro Narváez Peláez	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
C-07	Primer kit del mercado para el diagnóstico temprano de la esclerosis múltiple en sangre	ELISA MARTÍN MONTAÑÉS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2021
C-07	USO DE IGF-II PARA EL TRATAMIENTO DE LAS ALTERACIONES HIPOCAMPALES Y CONDUCTUALES INDUCIDAS POR EL CONSUMO CRONICO DE COCAINA DURANTE LA ADOLESCENCIA	LJ Santin	NATIONAL	PI	Ministry of Science and Innovation	2020
C-07	DEPRESION RESISTENTE AL TRATAMIENTO: UNA NUEVA ESTRATEGIA FARMACOLOGICA UTILIZANDO GALANINA (1-15)	ZAIDA DIAZ CABIALE	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2020
C-07	Efecto neuroprotector de IGF-II en modelos experimentales de Enfermedad de Parkinson con acumulación de agregados tóxicos de á-sinucleína	ELISA MARTÍN MONTAÑÉS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-07	Estudio de la vulnerabilidad de los complejos heteroreceptores de serotoninas en la depresión. Efecto moduladorio potencial de los antidepresivos de espectro rápido	DANIEL OSCAR BORROTO ESCUELA	NATIONAL	PI	STATE RESEARCH AGENCY	2022
C-07	Nueva estrategia contra la depresión resistente en ratas hembra.	ANTONIO FLORES BURGUESS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-07	Estudio de la combinación GAL(1-15)-FLX en ratas hembra. Nueva terapia antidepresiva	ANTONIO FLORES BURGUESS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2021
C-07	Tratamiento del dolor nociceptivo: D4R como potencial adjuvante para la utilización segura de la morfina.	ALICIA RIVERA RAMÍREZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
C-07	Potenciación de la antinocicepción inducida por opioides: estrategia basada en el sistema dopaminérgico	ALICIA RIVERA RAMÍREZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-07	Síndrome de Covid Persistente y Disfunción Autonómica. Estudio Pots Ochos Post Covid	MARC STEFAN DAWID MILNER	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-07	Efecto neuroprotector del IGF-II en enfermedades neurodegenerativas y neuropsiquiátricas con deterioro cognitivo. Papel de receptor IGF-II/M6P	JOSÉ ÁNGEL NARVÁEZ BUENO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-07	ProyExcel_00613 Depression: From classical neurotransmitters to Neuropeptides.	MANUEL ALEJANDRO NARVÁEZ PELÁEZ	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-07	MA-INV-0031-2022-24 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Zaida Diaz	ANA MARIA RUIZ CONDE	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
C-08	STOP IATRO -Start Therapeutic OPTimisazion and IATRogenesis prevention on Older People	FRANCISCA LEIVA FERNÁNDEZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
C-08	PI22-01651 Multimorbilidad en el Sistema Nacional de Salud: Caracterización poblacional e impacto de sus patrones y trayectorias en personas mayores (Proyecto MM-SNS)	FRANCISCA LEIVA FERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-08	PI-0129-2024 Validación de una versión corta de la herramienta IDC-PAL para su uso en población adulta en Atención Primaria (IDC-Pal-AP). Diseño y estudio de Aceptabilidad de una APP para su uso	FRANCISCA LEIVA FERNÁNDEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
C-08	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	FRANCISCA LEIVA FERNÁNDEZ	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-09	Descifrando el papel de los astrocitos en la patología de la enfermedad de Alzheimer: abordar las consecuencias funcionales de portar el factor de riesgo APOE4 empleando células derivadas de pacientes	Juan Antonio García León	NATIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-09	Diabetes y Alzheimer. Mecanismos moleculares de coagregación proteica	Inés Moreno González	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2019
C-09	AGREGADOS TAU EN SANGRE. UNA VENTANA A LA PATOGENESIS PERIFERICA Y LA INTERVENCION TERAPEUTICA	INÉS MORENO GONZÁLEZ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
C-09	Propagación de la patología amiloidea en un modelo esporádico de la enfermedad de Alzheimer: descifrando nuevos meanismos patogénicos y dianas terapéuticas	David Baglietto Vargas	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2019
C-09	Impact of white adipose tissue on tau pathology in transgenic mice	DAVID BAGLIETTO VARGAS	INTERNATION-AL NON-EU	PI	ALZHEIMER'S ASSOCIATION	2022
C-09	PI21/00915 Descifrando la transición de fase presintomática a clínica en la enfermedad de Alzheimer: el eje microglía-astroglía como diana terapéutica clave para prevenir el desarrollo de la enfermedad	ANTONIA GUTIÉRREZ PÉREZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-09	INN24_02 OPTIMIZACIÓN PLATAFORMA PARA IDENTIFICACIÓN FÁRMACOS Y MECANISMOS INVOLUCRADOS EN ENFERMEDADES NEURODEGENERATIVAS	JUAN ANTONIO GARCÍA LEÓN	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
C-09	Disfunción glial y enfermedad de Alzheimer	ANTONIA GUTIÉRREZ PÉREZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-09	MA-INV-0031-2022-18 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Antonia Gutierrez	TATYANA MARIA CABALLERO CONDE	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
C-09	MOV24-02 Propagación de la patología amiloidea en un modelo esporádico de alzheimer: descifrando nuevos mecanismos patogénicos y dianas terapéuticas. IP:Juana Andreo López	JUANA ANDREO LÓPEZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
C-09	MOV24-04 Estudio de la influencia de los agregados amiloides periféricos en la progresión de la enfermedad de Alzheimer. IP:Miriam Bettinetti Luque	MÍRIAM BETTINETTI LUQUE	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
C-09	CNS2022-135424 AGREGADOS TAU EN SANGRE. UNA VENTANA A LA PATOGENESIS PERIFERICA Y LA INTERVENCION TERAPEUTICA	INÉS MORENO GONZÁLEZ	NATIONAL	HR	STATE RESEARCH AGENCY	2022
C-09	NED22PI01G-PI2022/01 Connecting microglial metabolic dysfunction with tau pathology:clinical relevance for Alzheimer's disease	ANTONIA GUTIÉRREZ PÉREZ	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2022
C-09	CIBERNED CB06/05/1116. Programa Enfermedad de Alzheimer y otras demencias. Subvención anual (2024) para nuestro grupo CIBERNED	ANTONIA GUTIÉRREZ PÉREZ	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2024
C-11	Efectividad e implementación de una intervención digital para el dolor crónico infantil co-diseñada con pacientes (Digital SPA)	Rocío de la Vega de Carranza	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
C-11	Variables predictoras del abuso de opioides prescritos en los pacientes con dolor crónico no oncológico: desarrollo de una escala de detección de riesgo	MARÍA DEL CARMEN RAMÍREZ MAESTRE	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2019
C-11	Desarrollo de una e-intervención motivacional para potenciar factores resilientes en pacientes ...	GEMA TERESA RUIZ PÁRRAGA	LOCAL	PI	UNIVERSITY OF MÁLAGA	2021
C-11	Perfil psicológico asociado a la complejidad de los síndromes de sensibilización central, comórbido al trauma y al trastorno de estrés postraumático en mujeres.	ELENA ROCÍO SERRANO IBÁÑEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-12	MOV24-03 Inteligencia Artificial para el Procesamiento de Lenguaje Natural de Naturaleza Biomédica y la Normalización de Entidades Biomédicas Nombradas. LR: Fernando Gallego Donoso.	FERNANDO GALLEGO DONOSO	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
C-12	Análisis transdiagnóstico de la ecolalia: de la normalidad a las fases iniciales del deterioro cognitivo	GUADALUPE DÁVILA ARIAS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-12	Comprendiendo las diferencias interindividuales en el aprendizaje de palabras a través de la neuroimagen y la neuromodulación	DIANA LÓPEZ BARROSO	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
C-12	Automatic assessment of Hypernasality in Spanish language using running Speech	IGNACIO MORENO TORRES SANCHEZ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
C-12	Correlatos cognitivos, acústicos y cerebrales de la imitación verbal	Mª JOSÉ TORRES PRIORIS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2021
C-13	PRYES235081MORA Validation and evaluation of the Cui-DAR Cudeca Plan in people in the last days of life versus conventional care. Asociación Española contra el Cáncer	JOSE MIGUEL MORALES ASENSIO	NATIONAL	PI	SPANISH ASSOCIATION AGAINST CANCER	2023
C-13	IMP/00021 Impact Programa de Medicina Predictiva.	JORGE CARO BAUTISTA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
C-13	AP-0245-2020 Componentes de la Gestión de Casos en Demencias: Estudio de Métodos Mixtos (Gecade)	JUAN CARLOS MORILLA HERRERA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2019
C-13	AP-0244-2020 Calidad de Vida, Salud Física y Mental, y Evaluación Económica de Cuidadores Familiares de Población Infantil Dependiente y Con Enfermedad Crónica: (Seguimiento Cohorte Infaprint)	MAGDALENA CUEVAS FERNÁNDEZ-GALLEGO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2019
C-13	PI21-01197 Perfusión y Oxigenación Tisular Periférica en zonas de riesgo de deterioro de la integridad cutánea sometidas a tratamiento con Ácidos Grasos Hiperoxigenados vs Aceite de Oliva Virgen	INMACULADA LUPIÁÑEZ PÉREZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-13	AP-0174-2021-C2-F2 Efectividad de los ácidos grasos hiperoxigenados y aceite de oliva virgen extra en la prevención de las úlceras por presión relacionada con la perfusión y oxigenación tisular periférica.	INMACULADA LUPIÁÑEZ PÉREZ	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
C-13	AP-0228-2021-C2-F2 Barreras de Autocuidado y Complicaciones micro/macrovaskulares asociadas en Diabetes Mellitus tipo 2 (Estudio BACA-DM2).	JORGE CARO BAUTISTA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
C-13	PI-0107-2020 Desarrollo de una regla de predicción clínica para eventos adversos en pacientes con multimorbilidad que ingresan en hospitalización aguda y Urgencias. Estudio PREDI-CUIDD-HU	MARTA ARANDA GALLARDO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
C-13	AP-0065-2020-C1-F2. Valoración del patrón de alimentación de personas con demencia en la comunidad a través de la escala Edinburgh Feeding Evaluation in Dementia Scale (EdFED). Seguimiento Longitudinal	MARIA CARMEN SAUCEDO FIGUEREDO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2020
C-13	PMP22-00003 Salud pública y Medicina preventiva de precisión combinando exploración física, hábitos de vida e información genómica: monitorización de la pandemia de obesidad a través de extensión de la Cohorte IMPaCT (Obes-IMPaCT)	JORGE CARO BAUTISTA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-13	SEM23-01 Valoración del patrón de alimentación de personas con demencia en la comunidad a través de la escala edinburgh feeding evaluation in dementia scale (edfed). Seguimiento longitudinal.	MARIA CARMEN SAUCEDO FIGUEREDO	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-13	Interacción de variables de composición corporal en la perfusión y oxigenación tisular periférica de tejidos sometidos a presión	JOSE MIGUEL MORALES ASENSIO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
C-13	Barreras en la atención sexual y reproductiva integral de la población LGBTQ+ en los servicios de atención primaria del distrito sanitario Málaga-Valle del Guadalhorce	SHAKIRA KAKNANI UTTUMCHANDANI	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-13	A2-0068-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: MARIA DEL CARMEN SAUCEDO	MARIA CARMEN SAUCEDO FIGUEREDO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-13	A2-0049-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: JORGE CARO BAUTISTA	CELIA GARCÍA GARCÍA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-13	A2-0055-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: INMACULADA LUPIAÑEZ PEREZ.	JOSÉ CARLOS PÉREZ SÁNCHEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-13	CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims	JOSÉ CARLOS CANCA SÁNCHEZ	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
C-13	Adquisición de infraestructuras científicas y equipamientos de I+D+i,	JOSE MIGUEL MORALES ASENSIO	LOCAL	IF	UNIVERSITY OF MÁLAGA	2023
C-13	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	EVA TIMONET ANDREU	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-13	CA21168 (JIR-CLiPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	EVA TIMONET ANDREU	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-13	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	GABRIEL ANTONIO GIJON NOGUERON	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-13	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	ANA BELEN ORTEGA AVILA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-13	CA19137 (PARQ): Sudden cardiac arrest prediction and resuscitation network: Improving the quality of care	EVA TIMONET ANDREU	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2020
C-16	EMG22-005 Propiedades de la leche materna tras diabetes gestacional: sistema inmune innato y la respuesta del lactante ante infecciones respiratorias	MARTA BLASCO ALONSO	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2022
C-16	ProyExcel_00962 El sistema inmune innato de la leche materna; efecto de la dieta y obesidad de la madre.	ERNESTO GONZÁLEZ MESA	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-16	INCORPORACIÓN DE FACULTATIVOS ESPECIALISTAS AL PROGRAMA MARIA CASTELLANO ARROYO. SAS-UMA	FUENSANTA GUERRERO DEL CUETO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2024
C-16	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	MARÍA FERNANDA LARA CABANÁS	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-16	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	ERNESTO GONZÁLEZ MESA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-16	CA21108 (NETSKINMODELS) - European Network for Skin Engineering and Modeling	MARÍA FERNANDA LARA CABANÁS	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
CA-10	Estrategias de reducción de recaídas de miedos tras un tratamiento experimental de extinción	FRANCISCO JOSE LOPEZ GUTIERREZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
CA-10	Investigando experimentalmente la formación de nuevos hábitos en humanos	FRANCISCO JOSE LOPEZ GUTIERREZ/ DAVID LUQUE RUIZ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
CA-10	Aprendizaje de nuevos hábitos en humanos: una perspectiva multiproceso	DAVID LUQUE RUIZ	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
CA-10	MOV24-06 Validación de instrumentos para la evaluación de conductas de hábitos.IP:Pablo Martínez López	PABLO MARTINEZ LOPEZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
CE-18	CA22106 (MDVI) - Migrant Disaster Victim Identification	STELLA MARTIN HERAS, DE LAS	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2023
CE-18	STOP, STop intimate partner viOlence in Pregnancy	Stella Martín de las Heras	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2019
CE-18	VIOLENCIA DE GÉNERO EN EMBARAZADAS: TIPIFICACIÓN Y CRIBADO EN EL CONTEXTO SANITARIO (VIOLEMB)	Stella Martín de las Heras	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
CE-21	Capacitación para evitar la vulnerabilidad personal e incrementar la resistencia personal a la presión de grupo en relación con la discriminación en la atención socio-sanitaria.	MARI ANGELES VAZQUEZ SANCHEZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2022
CE-21	AP-0615-2024-C5-F2 Impacto de una intervención basada en un programa ejercicios multicomponente en población mayor adulta prefrágil en Atención Primaria: Un Estudio Cuasiexperimental	ALBERTO GÓMEZ MORENO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2024
D-01	CA21164 (ADVANCE-TB) - Towards an improvement in diagnostics and treatment strategies for TB control	ISABEL ASCENSION PEREZ HERNANDEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
D-03	FAR-01-23 Identificación de biomarcadores metagenómicos y transcriptómicos para el diagnóstico y pronóstico de Enfermedad Pulmonar Intersticial (EPI) asociada a Artritis Reumatoide (AR)	NATALIA MENA VAZQUEZ	REGIONAL	PI	ANDALUSIAN FOUNDATION OF RHEUMATOLOGY	2023
D-03	FAR2021-001. Identificación de biomarcadores de Enfermedad Pulmonar Intersticial (EPI) asociada a Artritis Reumatoide (AR)	NATALIA MENA VAZQUEZ	REGIONAL	PI	ANDALUSIAN FOUNDATION OF RHEUMATOLOGY	2021
D-03	PI22-01207 Análisis integral de datos clínicos, metagenómicos y transcriptómicos para identificar biomarcadores de respuesta a tratamiento Anti- TNF en pacientes con artritis reumatoide	NATALIA MENA VAZQUEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-03	PMP22-00101 “Validación clínica del algoritmo OPTIBIO para predecir permanencia en remisión en pacientes con artritis reumatoide a tratamiento con terapia biológica (REMRABIT-plus)”,	ANTONIO FERNÁNDEZ NEBRO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-03	Criterios de cribado de enfermedad pulmonar intersticial difusa en pacientes con artritis reumatoide. Estudio de Validez. VAR-EPIDSER	NATALIA MENA VAZQUEZ	NATIONAL	PI	SPANISH SOCIETY OF RHEUMATOLOGY	2022
D-03	A1-0009-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: ANTONIO FERNANDEZ NEBRO.	ANTONIO FERNÁNDEZ NEBRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-03	CD23-00082 Contrato Sara Borrell 2023_Arkaitz Mucientes Ruiz_Jefe de grupo: Antonio Fernandez Nebro	ARKAITZ MUCIENTES RUIZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-03	FI23-00084 Contratos predoctorales de formación en investigación de salud. BN: JOSE MANUEL LISBONA MONTAÑEZ_IP: ANTONIO FERNANDEZ NEBRO.	JOSÉ MANUEL LISBONA MONTAÑEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-03	INT-SER-01-2022 INTENSIFICACIÓN DE LA ACTIVIDAD INVESTIGADORA PARA FACULTATIVOS ESPECIALISTAS. NATALIA MENA VAZQUEZ.	NATALIA MENA VAZQUEZ	NATIONAL	HR	SPANISH SOCIETY OF RHEUMATOLOGY	2023
D-03	INT23-00030 Contrato de intensificación Natalia Mena	NATALIA MENA VAZQUEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-03	RD21-0002-0037 Red de Enfermedades Inflamatorias RICORS-REI	ANTONIO FERNÁNDEZ NEBRO	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
D-04	Diseño de Nanoestructuras basadas en Dendrímeros y Fármacos para Aplicaciones Biomédicas	Mª ISABEL MONTAÑEZ VEGA	NATIONAL	PI	STATE RESEARCH AGENCY	2022
D-04	Optimización diagnóstica en alergia a betalactámicos: desarrollo de test in vitro innovadores basados en biotecnología	Mª JOSÉ TORRES JAÉN	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	De rol van autoreactieve T cellen en autoreactive IgE antilichamen in atopisch eczeem; van het labo naar de patient en terug	IBON EGUILUZ GRACIA	INTERNATION-AL NON-EU	PI	RESEARCH FOUNDATION FLANDERS	2021
D-04	JARED - Joint Action on REspiratory Diseases	IBON EGUILUZ GRACIA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2024
D-04	AC19/00082 DrNanoDAll - Nanodiagnosis for Betalactam Hypersensitivity	MARÍA JOSÉ TORRES JAÉN	EUROPEAN UNION	PI	CARLOS III INSTITUTE OF HEALTH	2019
D-04	PI21/00329 Optimización diagnóstica en alergia a betalactámicos: de la estandarización y racionalización de las pruebas in vivo, al desarrollo de test in vitro innovadores basados en nanotecnología y metabólica. test in vitro innovadores basados en nanotecnología y metabólica.	MARÍA JOSÉ TORRES JAÉN	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
D-04	CPP2022-009994 Development of a photonic point of care device for multiplexed detection of biomarkers, tryptase, IL-6, and PAF in the events of hypersensitivity during oncological or biological agent administration, and anaesthesia”	MARÍA JOSÉ TORRES JAÉN	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-04	PI21/00346 Microagujas y nanopartículas como estrategia innovadora para la administración de inmunoterapia epicutánea en enfermedades alérgicas. Identificación de biomarcadores para una tolerancia duradera.	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
D-04	CNS2023-145123-PI Ayuda adicional.Papel del sistema inmune innato en alergia a alimentos y en la inducción de tolerancia específica. (INNA-TOOLS)	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-04	PI-0047-2022. Biomarcadores diagnósticos y de gravedad clínica para la optimización del fenotipado de pacientes con alergia a LTP	NATALIA ISABEL PÉREZ SÁNCHEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
D-04	PI23/00875 Caracterización de endofenotipos en Rinosinusitis Crónica con Pólipos Nasales y Asma T2 comórbida. Análisis ómicos en el tratamiento con biológicos. LR: ALMUDENA TESTERA MONTES_ COI: CARMEN RONDON SEGOVIA	ALMUDENA TESTERA MONTES	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
D-04	RYC2021-034536-I Proyecto Ramon y Cajal. IP.Juan Luis Paris.	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	PI	STATE RESEARCH AGENCY	2022
D-04	PID2022-142781OA-I00 Nanoingeniería de tolerancia inmunitaria para alergia: interacción de nanomateriales y vía de administración (NANO-TOLERANCE)	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-04	CNS2023-145619-PI Ayuda adicional. Nanopartículas de ARNm para inmunoterapia inductora de tolerancia en alergia (mRNA-TOLERANCE)	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-04	ProyExcel_00971 Diseño de Nanoestructuras Multivalentes Conjugadas a Antibióticos para el Estudio de la Activación de Células Efectoras. Aplicación Diagnóstica en Reacciones Alérgicas a Antibióticos Betalactámicos	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
D-04	PI20/01734 Nanoarquitecturas altamente eficientes para un entrecruzamiento eficaz de la IgE en mastocitos y basófilos. Aplicación al diagnóstico de reacciones alérgicas a amoxicilina y ácido clavulánico	MARÍA ISABEL MONTAÑEZ VEGA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
D-04	PI23/00620 Nuevas aproximaciones aplicadas al diagnóstico de alergia a fármacos: Desarrollo de nanoestructuras que incorporan ligando TLR y determinantes antigénicos de antibióticos betalactámicos.IP: MARIA ISABEL MONTAÑEZ VEGA_ COI: CECILIA FRECHA	MARÍA ISABEL MONTAÑEZ VEGA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
D-04	PI-0127-2020 Aproximación diagnóstica al paciente alérgico a antibióticos betalactámicos mediante la optimización del test de activación de basófilos profundizando en los mecanismos de degranulación del basófilo y la sensibilización pasiva.	ADRIANA ARIZA VEGUILLAS	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
D-04	PI20/01540 Hipersensibilidad a anti-inflamatorios no esteroides: Fenotipado preciso e historia natural. Papel de la atopía y de una respuesta inmune innata	INMACULADA DOÑA DÍAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	PI23/01655 Reacciones de hipersensibilidad a anti-inflamatorios no esteroideos: desarrollo de un algoritmo diagnóstico basado en métodos de aprendizaje automático y caracterización de biomarcadores. LR: INMACULADA DOÑA DIAZ_ COI: JOSE ANTONIO CORNEJO GARCIA	INMACULADA DOÑA DÍAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
D-04	PI21/01391 Fenotipado clínico e inmunologico de pacientes con alergia a LTP	FRANCISCA GÓMEZ PÉREZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
D-04	PI-0129-2021 Aplicabilidad del aprendizaje automático y la inteligencia artificial en el diagnóstico de la hipersensibilidad a anti-inflamatorios no esteroideos. Papel del test de activación de basófilo en las reacciones selectivas.	MARÍA SALAS CASSINELLO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
D-04	PI20/01715 Estudio de la prevalencia, clarificación de la inmunopatología e identificaicón de biomarcadores diagnósticos de alergia respiratoria local en fenotipos graves y de difícil control de rinitis y asma	IBON EGUILUZ GRACIA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
D-04	PI23/01516 Identificación de biomarcadores inmunológicos de linfocitos B para diferenciar fenotipos, diagnosticar la presencia de asma y predecir la respuesta a la inmunoterapia con alérgenos en pacientes con rinitis de causa alérgica. LR: IBON EGUILUZ GRACIA_COI: CARLOS JOSE ARANDA CLEMENTE.	IBON EGUILUZ GRACIA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
D-04	PI22/01119 Biomarcadores endofenotípicos y pronósticos en las reacciones de hipersensibilidad por quimioterápicos. Gestión del riesgo de la administración controlada y desensibilización	GADOR BOGAS HERRERA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-04	PI-0099-2020 Papel de las células linfoides innatas tipo 2 (ILC2) en las reacciones alérgicas a alimentos y su implicación en la respuesta inmunológica durante la inmunoterapia específica.	MARIA FRANCISCA PALOMARES JEREZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
D-04	PI23/00820 Análisis de la eficacia clínica y del efecto inmunomodulador de pectinas administradas en pacientes alérgicos a LTP mediante un estudio de intervención controlado con placebo y seguimiento a largo plazo. LR: NATALIA ISABEL PEREZ SANCHEZ	NATALIA ISABEL PÉREZ SÁNCHEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
D-04	RYC2023-044231-I-PI Proyecto Ramon y Cajal.	ADRIANA ARIZA VEGUILLAS	NATIONAL	PI	STATE RESEARCH AGENCY	2024
D-04	PRE-BIT - Understanding the role of B cell phenotypes as a predictor of the efficacy and prognosis of allergen immunotherapy using allergic rhinitis to house dust mite as a model	CARLOS ARANDA CLEMENTE	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2022
D-04	CD22/00112 Contrato Sara Borrell_Patricia Diez Echave_Jefe de Grupo Maria Jose Torres Jaen.	PATRICIA DIEZ ECHAVE	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	FI22/00199 Contratos predoctorales de formación en investigación de salud. BN Jose Antonio Céspedes Lago IP: Maria Jose Torres Jaen	JOSE ANTONIO CESPEDES LAGO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	C1-0006-2022 PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2022. CANDIDATO JOSE ANTONIO CORNEJO. Mecanismos moleculares y base genética de las reacciones de hipersensibilidad a anti-inflamatorios no esteroideos.	JOSÉ ANTONIO CORNEJO GARCÍA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
D-04	FI22/00106 Contratos predoctorales de formación en investigación de salud. BN: María Del Carmen Martín Astorga IP: Cristobalina Mayorga	Mª DEL CARMEN MARTÍN ASTORGA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	RC-0004-2021 Renovación II del Programa Nicolás Monardes 2013. Cristobalina Mayorga	CRISTOBALINA MAYORGA MAYORGA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
D-04	RYC2021-034536-I Contrato Ramon y Cajal. Juan Luis Paris	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	HR	STATE RESEARCH AGENCY	2022
D-04	PID2022-142781OA-I00 AYUDAS CONCEDIDAS PARA LA FORMACIÓN DE PERSONAL INVESTIGADOR PREDOCTORAL	ANA MARIA PEREZ MORENO	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-04	C1-0007-2023 Programa Nicolas Monarde_Convocatoria 2023_Candidata: Adriana Ariza Veguillas. Optimización del diagnóstico de las enfermedades alérgicas a fármacos: antibióticos betalactámicos y agentes quimioterapéuticos.	ADRIANA ARIZA VEGUILLAS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	FI21/00274 Contratos predoctorales de formación en investigación en salud. Isabel María Jiménez Sánchez jefe de grupo Inmaculada Doña Díaz	ISABEL MARIA JIMENEZ SANCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	CD20/00085 Contratos Sara Borrell 2020 José Antonio Cañas Mañas. Jefe de Grupo: Cristobalina Mayorga Mayorga	JOSE ANTONIO CAÑAS MAÑAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
D-04	FI23/00027 Contratos predoctorales de formación en investigación de salud,BN: CLARA ENCARNACION LEBRON MARTIN. LR: GADOR BOGAS HERRERA	CLARA ENCARNACIÓN LEBRON MARTIN	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	FI21/00116: Contrato PFIS 2021 Pablo Torres Fernández. Group leader: Maria Isabel Montañez Vega.	PABLO TORRES FERNANDEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	A1-0008-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: CARMEN RONDON SEGOVIA AND INMACULADA DOÑA DIAZ.	CARMEN RONDÓN SEGOVIA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-04	B-0007-2022 SAS 2022-REFUERZO CON RRHH DE LA ACTIVIDAD INVESTIGADORA EN LAS UC DEL SAS -ACCIONES B-GBOGAS	GADOR BOGAS HERRERA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
D-04	B-0007-2023 Refuerzo con RRHH de la actividad investigadora en las UC del SAS -Acción B Ibon Eguiluz	IBON EGUILUZ GRACIA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-04	CM21/00262 Contratos Rio Hortega 2021 Carmen Alba Linero. Group leader: Ibon Eguíluz Gracia	CARMEN ALBA LINERO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	CM23/00092 Contrato Rio Hortega 2023_ Guillermo Bentabol Ramos_Jefe de Grupo: Carmen Rondon Segovia	GUILLERMO BENTABOL RAMOS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	CM23/00130 Contrato Rio Hortega 2023_ Marta Libertad Andugar Moreno.Jefe de Grupo: Cristobalina Mayorga Mayorga	MARTA LIBERTAD ANDUGAR MORENO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	CM23/00151_Contrato Rio Hortega 2023_IP: Rocio Saenz de Santa Maria Garcia_Jefe de grupo: Maria Jose Torres Jaen	ROCÍO SÁENZ DE SANTA MARÍA GARCÍA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	CNS2023-145123-RHH Contrato.Papel del sistema inmune innato en alergia a alimentos y en la inducción de tolerancia específica. (INNA-TOOLS)	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-04	JR19/00029 Contratos Juan Rodés 2019 Ibon Eguiluz Gracia	IBON EGUILUZ GRACIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
D-04	JR21/00024 Contratos Juan Rodes 2021 Natalia Isabel Pérez Sánchez	NATALIA ISABEL PÉREZ SÁNCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	JR22/00048 Contratos Juan Rodes 2022 Almudena Testera Montes	ALMUDENA TESTERA MONTES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	JR23/00039 Contratos Juan Rodes 2023 Marina Labella Alvarez	MARINA LABELLA ALVAREZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	MA-INV-0031-2022-01 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestiggo. IP:María José Torres	LUCIA VALECILLOS AZOR	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
D-04	MOV24-07 Caracterización genotípica de células efectoras en el contexto de la alergia a antibióticos betalactámicos. LR: Silvia Calvo Serrano	SILVIA CALVO SERRANO	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
D-04	ASSERT -Development of a nanotechnology-based innovative assay for the diagnosis of allergy to Betalactams	CECILIA ARIANA FRECHA	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	MV23-00104 Procesamiento y análisis de datos poblacionales del estudio estadounidense BLSA enfocado en diabetes y estudio de los mecanismos moleculares implicados en la patogenia de la diabetes en relación a la proteína SPD	WASIMA OUALLA BACHIRI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	RBL-0002-2023_Renovación 2023 Acción B-Refuerzos de larga duración	PAOLA ELVIRA PALAO OCHARAN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-04	RYC2023-044231-I Contrato Ramon y Cajal.	ADRIANA ARIZA VEGUILLAS	NATIONAL	HR	STATE RESEARCH AGENCY	2024
D-04	CNS2023-145619-RRHH Contrato Nanopartículas de ARNm para inmunoterapia inductora de tolerancia en alergia (mRNA-TOLERANCE)	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-04	PR-EIR-01-2024 Premio IBIMA-EIR al mejor expediente investigador del último año	LAURA ZUBIAGA FERNANDEZ	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
D-04	INT-F1-2401 PLAN PROPIO F.1.Ayuda para asistir en la revisión y escritura de propuestas de investigación coordinadas en el Horizonte Europa o programas similares en complejidad y prestigio. Modalidad 4: Propuestas ERC. LR: Juran Luis París	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
D-04	RD21/0002/0008 Red de Enfermedades Inflamatorias RICORS-REI	MARÍA JOSÉ TORRES JAÉN	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
D-04	CA18227 (COMFA) -The Core Outcome Measures for Food Allergy	CRISTOBALINA MAYORGA MAYORGA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
D-04	CA18226 (ADOPT)-New approaches for the detection of pathogens and aeroallergens	IBON EGUILUZ GRACIA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
D-04/A-02/BE-18	INT-F2-2402 PLAN PROPIO F2. Ayudas para la asistencia a eventos internacionales de posicionamiento IP: Ibon Eguiluz, Isabel Moreno Indias, Melissa García Caballero	ISABEL MORENO INDIAS	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
D-05	Ayudas para la constitución de redes temáticas-Convocatoria 2022 para el proyecto: Creación de un registro multicéntrico internacional de pacientes con hepatitis autoimmunelike por fármacos o suplementos dietéticos, incluidas vacunas	MARÍA ISABEL LUCENA GONZÁLEZ	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
D-05	Papel del sistema inmune y la permeabilidad intestinal en el daño hepático inducido por fármacos (DILI) y la esteatosis inducida por fármacos (DIS).	MARÍA ISABEL LUCENA GONZÁLEZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
D-05	Phase II proof-of-concept and mechanistic analysis study to evaluate the efficacy and safety of corticosteroids in the treatment of idiosyncratic hepatotoxicity (DILI-CORT)	RAÚL J. ANDRADE BELLIDO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
D-05	Análisis mecanístico del daño y la recuperación en un estudio de fase II de prueba de concepto para evaluar la eficacia y la seguridad de los corticosteroides en el tratamiento de la hepatotoxicidad idiosincrásica (DILI-CORT)	HAO NIU	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
D-05	Generación de un modelo Multi-organ on a Chip (MIVO) para el estudio del eje hígado-intestino en enfermedades del sistema digestivo.	CARLOS LOPEZ GOMEZ	REGIONAL	PI	REGIONAL GOVERNMENT OF ANDALUSIA	2024
D-05	Análisis integrado del perfil epigenético y del exposoma en pacientes con daño hepático inducido por fármacos. IBIMA-UMA-13	JUDITH ADRIANA SANABRIA CABRERA	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
D-05	halt-RONIN -Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies	RAÚL J. ANDRADE BELLIDO	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2022
D-05	PID2021-127764OB-I00_Uso de biomarcadores como medicina personalizada en la predicción de la respuesta terapéutica a fármacos biológicos en la enfermedad de Crohn (BIORESCROHN)	EDUARDO GARCÍA FUENTES	NATIONAL	PI	STATE RESEARCH AGENCY	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-05	PI-0117-2022 Multiómicas para la identificación de biomarcadores microbianos predictivos de la respuesta a Ustekinumab en pacientes con enfermedad de Crohn	CRISTINA RODRIGUEZ DIAZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
D-05	PI20/00455 Papel de la regulación circadiana y epigenética de los corticoides y sus receptores en la resistencia a estos fármacos en la enfermedad de Crohn	FRANCISCA RODRIGUEZ PACHECO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
D-05	TRANSBIOLINE -Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease	RAÚL J. ANDRADE BELLIDO	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2018
D-05	PI21-01248 Fenotipado y caracterización mecanística de la lesión hepática inducida por fármacos, la esteatosis inducida por fármacos y la enfermedad del hígado graso asociado al metabolismo	RAÚL J. ANDRADE BELLIDO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
D-05	PI19/00883 Análisis de las poblaciones linfocitarias inmunoreguladoras en hepatotoxicidad mediante citometría de masas (CyTOF): detectando la huella dactilar inmunológica de la hepatotoxicidad inducida por fármacos. LR MARIA ISABEL LUCENA GONZALEZ	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
D-05	PID2022-140169OB-C21 Funcionalidad mitocondrial y estrés oxidativo en un estudio fase II para evaluar la eficacia y seguridad del tratamiento con corticoides en hepatotoxicidad	MERCEDES ROBLES DÍAZ	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-05	DIAGNÓSTICO Y ELIMINACIÓN DE HEPATITIS CRÓNICA C EN CENTROS DE SALUD MENTAL DE LA PROVINCIA DE MÁLAGA.	MIREN GARCÍA CORTÉS	NATIONAL	PI	GILEAD SCIENCES EUROPE LTD.	2021
D-05	CP22-00050 Ayuda Adicional Contrato Miguel Servet 2022. Carlos Lopez Gomez	CARLOS LOPEZ GOMEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-05	PI-0244-2021. Búsqueda de biomarcadores de respuesta terapéutica a fármacos biológicos en enfermedad de Crohn. Un enfoque desde la medicina personalizada de precisión.	GUILLERMO JOSÉ ALCAIN MARTÍNEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
D-05	CP23/00088 Ayuda Adicional Contrato Miguel Servet 2023 Cristina Rodriguez Diaz	CRISTINA RODRIGUEZ DIAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2023
D-05	PMP22-00055 Proyecto iPHARMGx: Estudio colaborativo nacional para evaluar la efectividad y eficiencia de la implementación de biomarcadores farmacogenéticos mediante una estrategia de genotipado anticipado en el SNS.	JUDITH ADRIANA SANABRIA CABRERA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-05	CD23/00117 Contrato Sara Borrell 2023_Antonio Jesus Ruiz Malagon_Group Leader: Eduardo Garcia Fuentes	ANTONIO JESUS RUIZ MALAGON	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	RC-0005-2020 Renovación de la Acción C (Programa Nicolás Monardes) de la Convocatoria 2016.	EDUARDO GARCÍA FUENTES	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2020
D-05	MS18-00042 Miguel Servet Tipo I 2018 FRANCISCA RODRIGUEZ PACHECO	FRANCISCA RODRIGUEZ PACHECO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2018
D-05	PID2022-140169OB-C21 AYUDAS CONCEDIDAS PARA LA FORMACIÓN DE PERSONAL INVESTIGADOR PREDOCTORAL-PREP2022-000511	ANGELA REMESAL DOBLADO	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-05	MS22-00050 Contrato Miguel Servet 2022. LR Carlos Lopez	CARLOS LOPEZ GOMEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-05	MS23/00088 Contrato Miguel Servet 2023 Cristina Rodriguez Diaz	CRISTINA RODRIGUEZ DIAZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	IFI21-00034 Contratos I-PFIS: Doctorados IIS -Empresas de ciencias y tecnología en salud.Daniel Enrique Di Zeo Sánchez jefe de grupo Raúl J. Andrade Bellido	DANIEL ENRIQUE DI ZEO SÁNCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-05	CD21-00198 Contratos Sara Borrell 2021 Marina Villanueva jefe de grupo Maria Isabel Lucena Gonzalez	MARINA VILLANUEVA PAZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-05	CM23-00103 Contrato Rio Hortega 2023_ Irene Diaz Alberola_Group leader: Maria Isabel Lucena Gonzalez.	IRENE DIAZ ALBEROLA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	CM23-00126 Contrato Rio Hortega 2023_ Juan Pedro Toro Ortiz_Jefe de Grupo:Raul Jesús Andrade Bellido	JUAN PEDRO TORO ORTIZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	INT-AEEH-01-2023. Beca de intensificación para investigadores	MIREN GARCÍA CORTÉS	NATIONAL	HR	SPANISH FOUNDATION FOR THE STUDY OF THE LIVER	2023
D-05	JR21-00066 Contratos Juan Rodes 2021 Judith Adriana Sanabria Cabrera	JUDITH ADRIANA SANABRIA CABRERA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-05	MA-INV-0031-2022-04 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Eduardo García Fuentes	MARINA HERRAIZ VIRELA	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
D-05	A1-0027-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS): RAUL JESUS ANDRADES.	Gonzalo Matilla Cabello	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-05	FPU22/03868. Ayudas para Formación de Profesorado Universitario (FPU). Gonzalo Matilla Cabello. Group leader: Raúl J. Andrade Bellido	RAÚL J. ANDRADE BELLIDO	NATIONAL	HR	Ministry of Science, Innovation, and Universities	2022
D-05	PR_DIVULGA_01_2024 IBIMA Award. Plataforma BIONAND-Divulga a las mejores publicaciones del último año.	FLORES MARTIN REYES	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
D-05	SAPD_PREMIO_21_01 Estudio piloto de microeliminación en la hepatitis C: derivación directa entre los centros de drogodependencia y la unidad de hepatología en un hospital universitario.	MIREN GARCÍA CORTÉS	REGIONAL	AWARDS	ANDALUSIAN SOCIETY OF GASTROINTESTINAL DISORDERS	2021
D-05	SAPD_PREMIO_22_01 Influence of hepatocarcinoma surveillance programs on cirrhotic patient’s survival: A real life study.	MIREN GARCÍA CORTÉS	REGIONAL	AWARDS	ANDALUSIAN SOCIETY OF GASTROINTESTINAL DISORDERS	2022
D-05	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	CARLOS LOPEZ GOMEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
DE-07	ECRAID-Base -European Clinical Research Alliance on Infectious Diseases	MANUEL ENRIQUE HERRERA GUTIERREZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2020
DE-08	MICRO GILD24_25620 MICROELIMINACIÓN DE HEPATITIS C Y DE DIAGNÓSTICO Y VINCULACIÓN DE HEPATITIS B Y D AL SISTEMA SANITARIO EN EL SERVICIO DE APARATO DIGESTIVO DEL HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA.	ROCÍO GONZÁLEZ GRANDE	NATIONAL	PI	GILEAD SCIENCES, S.L.U.	2024
DE-08	INCORPORACIÓN DE FACULTATIVOS ESPECIALISTAS AL PROGRAMA MARIA CASTELLANO ARROYO. SAS-UMA	ROSA PÉREZ RODRÍGUEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2024
DE-09	Innate immune response to SARS-CoV-2 infection and mechanisms of viral immunopathology	José Manuel Jiménez Guardeno	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2023
DE-09	Immune response and immunopathology mechanisms against viruses of biomedical relevance	José Manuel Jiménez Guardeno	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
DE-09	Estudio de la interacción entre HIV-1 y la respuesta de interferón: investigando los factores del hospedador y las estrategias de evasión.	José Manuel Jiménez Guardeno	NATIONAL	PI	STATE RESEARCH AGENCY	2023
DE-09	PPRO-RNM112-G-2023	Juan José Borrego García	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
DE-09	MEDIDAS PARA LA PREVENCION DE LA INFECCION POR BETANODAVIRUS EN LENGUADO	Mª DOLORES CASTRO LÓPEZ	REGIONAL	PI	Regional Ministry of Universities, Research, and Innovation	2023
DE-09	identificación de factores del hospedador implicados en el bloqueo inducido por interferón a la infección por SARS-CoV-2	ANA MARÍA ORTEGA PRIETO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
DE-09	Investigating innate immune sensing in SARS-CoV-2 infection	ANA MARÍA ORTEGA PRIETO	LOCAL	HR	UNIVERSITY OF MÁLAGA	2024
DE-09	PI-0128-2024 Investigación de los determinantes inmunogenéticos humanos asociados con la resistencia y vulnerabilidad frente a la COVID-19: hacia el diseño de nuevas estrategias de prevención y tratamiento basadas en medicina de precisión	ANA MARIA ORTEGA PRIETO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
DE-09	Respuesta inmune frente a infecciones virales	José Manuel Jiménez Guardeno	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
DE-09	Virus-host interactions in human infectious diseases	JOSE MANUEL JIMENEZ GUARDEÑO	NATIONAL	HR	STATE RESEARCH AGENCY	2021
DE-09	PR_INV_EMERG24_01 Premio Investigadora emergente del año	ANA MARIA ORTEGA PRIETO	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
DE-09	CA21145 (EURESTOP) -European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	CARMEN MARÍA GONZÁLEZ DOMENECH	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
DE-09	CA20128 (PIMENTO) -Promoting Innovation of fermented foods	CARMEN MARÍA GONZÁLEZ DOMENECH	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
DE-10	Estudio de biomarcadores en humor acuoso y sangre en LHON	IGNACIO GARCIA BASTERRA	NATIONAL	PI	CHESI	2022
F-02	Sistema Inteligente de ayuda al diagnóstico clínico de la enfermedad coronaria no obstructiva en coronariografías“.	ESTEBAN JOSÉ PALOMO FERRER	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
F-02	Detección Automática de Epilepsia Focal No Lesional mediante Modelos Neuronales Profundos de Difusión Probabilística	ESTEBAN JOSÉ PALOMO FERRER	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
F-02	Detección de trayectorias anómalas de vehículos en cámaras de tráfico	JOSE DAVID FERNANDEZ RODRIGUEZ	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
F-02	Detección de estenosis coronaria mediante aprendizaje profundo aplicado a coronariografías	MIGUEL ÁNGEL MOLINA CABELLO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2021
F-02	Sistema de videovigilancia basado en cámaras itinerantes robotizadas	JOSÉ JESÚS DE BENITO PICAZO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
F-02	Detección automática de Enfermedad Coronaria No Obstructiva en Coronariografías	EZEQUIEL LÓPEZ RUBIO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
F-02	IFI19/00009 Contratos I-PFIS: Doctorados IIS-Empresa en ciencias y tecnologías de la salud Rosa Maria Maza Quiroga. Group leader: Ezequiel Lopez Rubio	ROSA MARIA MAZA QUIROGA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
F-02	MA-INV-0031-2022-22 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Ezequiel López Rubio.	JAVIER BERRAL ANDRADE	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
F-02 / A-03	PUNI-003_2023 Sistema Inteligente de Ayuda al Diagnóstico Clínico de la Enfermedad Coronaria No Obstructiva en Coronariografías	ESTEBAN JOSÉ PALOMO FERRER	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
F-03	Sensores de campo lejano en fotónica del silicio	ALEJANDRO ORTEGA MOÑUX/ ROBERT HALIR	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
F-03	Diseño Inverso Inteligente para Fotónica Integrada Avanzada usando Metamateriales Sublongitud de Onda	ROBERT HALIR/ IÑIGO MOLINA FERNANDEZ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2023
F-04	Percepción robotica avanzada para construccion de mapas y localizacion	JAVIER GONZÁLEZ JIMÉNEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2020
F-04	Creación de mapas topológicos de lugares para la localización de una cámara	JAVIER GONZÁLEZ JIMÉNEZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
F-04	VOXELAND: HACIA UNA REPRESENTACIÓN EFECTIVA DEL ENTORNO DE TRABAJO DE ROBOTS MÓVILES	JOSÉ RAÚL RUIZ SARMIENTO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
F-04	MINDMAPS: Semantic Topometric Maps as Models of the Environment for Intelligent Robots /Mapas semánticos topométricos como modelos del entorno para robots inteligentes.	M	NATIONAL	PI	Ministry of Science and Innovation	2023
F-04	MA-INV-0031-2022-23 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Francisco Ángel Moreno Dueñas	ENRIQUE SERGIO RODRIGUEZ NAVARRO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
F-05	Planificador de tareas con aprendizaje para la colaboración humano-robot en un sistema industrial ciber-físico.	VICTOR FERNANDO MUÑOZ MARTÍNEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2021
F-05	Asistente robótico colaborativo para mejorar la cirugía laparoscópica del hígado	VICTOR FERNANDO MUÑOZ MARTINEZ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2023
F-05	Digital Twin for VET schools (DiTwin)	VICTOR FERNANDO MUÑOZ MARTÍNEZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
F-05	Robot quirúrgico para el aspirado autónomo de sangrado durante una intervención laparoscópica	RIVAS BLANCO, IRENE	NATIONAL	PI	STATE RESEARCH AGENCY	2022
F-05	Intelligent GNC for Space Robotics (Proyecto Horizonte Europa)	CARLOS JESÚS PÉREZ DEL PULGAR MANCEBO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
F-05	MOV24-01 Aprendizaje por Reforzamiento desde la Demostración en Cirugía Robótica: Sutura Laparoscópicas Autónoma con la plataforma Da Vinci. IP:Álvaro Galán Cuenca	ALVARO GALAN CUENCA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
F-09	INSTRUMENTACION INTELIGENTE Y APLICACION EN SALUD	FERNANDO VIDAL VERDÚ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
F-09	Estímulos Táctiles para Transmitir Música a Personas con Discapacidad Auditiva	FERNANDO VIDAL VERDÚ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
F-10	SISTEMAS MULTIVALENTES Y MARCADORES LUMINISCENTES PARA APLICACIONES BIOMEDICAS	EZEQUIEL PÉREZ-INESTROSA VILLATORO	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2023
F-10	Poliaminales para el encapsulamiento y liberación de fármacos antineoplásicos.	ANTONIO JESÚS RUIZ SÁNCHEZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2024
F-10	CPP2022-009994 Development of a photonic point of care device for multiplexed detection of biomarkers, tryptase, IL-6, and PAF in the events of hypersensitivity during oncological or biological agent administration, and anaesthesia	EZEQUIEL PÉREZ-INESTROSA VILLATORO	NATIONAL	PI	STATE RESEARCH AGENCY	2023
F-10	MIG-20231023 Investigación para la integración de nuevas arquitecturas sensoras de fotónica integrada multiplexada y terahercios hiperespectrales para un sistema microfluídico in vitro para monitorizar tratamientos farmacológicos contra el cáncer	EZEQUIEL PÉREZ-INESTROSA VILLATORO	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2023
F-10	Síntesis de sistemas Dendrimericos multivalentes tipo Janus	EZEQUIEL PÉREZ-INESTROSA VILLATORO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
F-10	CNS2022-135409 ioglicósidos: epítomos de glicano no hydrolizables para el desarrollo de vacunas sintéticas basadas en carbohidratos contra el VIH. (HIVTHIOVAC)	EZEQUIEL PÉREZ-INESTROSA VILLATORO/ JOSÉ JUAN REINA MARTÍN	NATIONAL	HR	STATE RESEARCH AGENCY	2022
F-10	MA-INV-0031-2022-19 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Ezequiel Perez-Inestrosa	CRISTINA MORA CORDERO	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
F-14	Competencias y actitudes frente a los cuidados paliativos en estudiantes y profesionales en Ciencias de la Salud	JAIME MARTIN MARTIN	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
F-14	Mejora de la fatiga en hombro inestable a través de un programa de ejercicio terapéutico en fisioterapia (MoveUS).	ANTONIO CUESTA VARGAS	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
F-14	Identificación de personas frágiles en atención primaria a través de parámetros funcionales, metabólicos, cognitivos y de composición corporal	JERÓNIMO GARCÍA ROMERO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
F-14	MA-INV-0031-2022-21 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. IP:Antonio Cuesta	TIFFANY MARIA CARDERO JODAR	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
F-14	CA21152 (INE-CSC) -Implementation Network Europe for Cancer Survivorship Care	CRISTINA ROLDÁN JIMÉNEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
F-14/A-06	PI22-00315 Efectividad de un programa de rehabilitación cardíaca en biomarcadores cinemáticos, estructurales y fisiológicos en pacientes de edad avanzada con insuficiencia cardíaca. FUNNEL+	ANTONIO CUESTA VARGAS	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
F-15	5G+TACTILE_3. Gestión “zero touch” de los servicios con IA aplicada a datos masivos en redes B5G/6G	JOSÉ FRANCISCO ALDANA MONTES/ PEDRO MERINO GÓMEZ	NATIONAL	PI	Ministry of Economic Affairs and Digital Transformation	2021
F-15	PID2020-112540RB-C41 Una aproximación holística de smart data para el análisis de datos guiado por el contexto: explotación de semántica y contexto.	JOSÉ FRANCISCO ALDANA MONTES	NATIONAL	PI	STATE RESEARCH AGENCY	2020
F-15	CA19134 (DKG) -Distributed Knowledge Graphs	MARÍA DEL MAR ROLDÁN GARCÍA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2020
F-19	La emoción racional a través de las redes de sociabilidad presenciales y los ecosistemas digitales	JOSÉ IGNACIO PELÁEZ SÁNCHEZ	NATIONAL	PI	Ministry of Science and Innovation	2021
FA-07	SECOT-001 ESTABILIDAD EN LA CARGA AXIAL DEL FIJADOR EXTERNO Francisco Javier Duran Garrido.	FRANCISCO JAVIER DURAN GARRIDO	NATIONAL	PI	SPANISH SOCIETY OF ORTHOPEDIC SURGERY AND TRAUMATOLOGY	2019
FE-17	Mecanismos cerebrales y cognitivos de los errores del habla en la afasia	JAVIER GARCÍA ORZA	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
FE-17	CA21110 (NetwoArk) -Building an open European Network on OsteoArthritis research	RAQUEL CANTERO TELLEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
FE-18	Efectividad de la adición del entrenamiento de la musculatura inspiratoria a un programa de rehabilitación cardíaca de personas con cardiopatía isquémica revascularizadas mediante angioplastia coronaria transluminal percutánea	Adela María Gómez González	NATIONAL	PI	Spanish Society of Cardiorespiratory Rehabilitation SORECAR	2024
FE-18	PR_INN24-01 Premio IBIMA. Plataforma BIONAND a las innovaciones trasladadas a la práctica clínica	LORENA AGUILAR CANO	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
FE-20	Diseño de un entorno de multimodal de evaluación del habla: aplicación al caso de pacientes con disfunción velofaríngea	ENRIQUE NAVA BARO	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
FE-20	Grupo Permanente de Innovación Educativa en Mundos virtuales (GPIEMUVI)	Francisco Sendra Portero	LOCAL	PI	UNIVERSITY OF MÁLAGA	2022
G-01	Targeting strategies of multifunctional magnetic nanosystems for therapy and in vivo imaging of high-grade gliomas: validation in PDOX models	Mª LUISA GARCÍA MARTÍN	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
H-02	ESTUDIO DE INTERACCIONES VASCULO-ESQUELETICAS COMO MECANISMO DIANA DE PATOLOGÍA ÓSEA Y DESARROLLA DE UN NUEVO BIOMATERIAL BIOMIMETICO PARA EL TRATAMIENTO DE CONDICIONES ÓSEAS	IVAN DURAN JIMENEZ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
H-02	Cellular Stress and Senescence as a Crosstalk Mechanism of Disease in Bone Fragility	IVAN DURAN JIMENEZ	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
H-02	Desarrollo de terapias avanzadas para enfermedades musculoesqueléticas	IVAN DURAN JIMENEZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
H-02	Evaluación in vitro e in vivo del uso de postbióticos y polisacáridos de algas frente a patógenos de importancia en acuicultura	MANUEL MARI BEFFA	REGIONAL	PI	Regional Ministry of Universities, Research, and Innovation	2023
H-02	Mechanisms of bone pathologies caused by alteration of skeletal differentiation towards adipogenesis and its link with metabolism	Fabiana Csukasi	REGIONAL	PI	REGIONAL GOVERNMENT OF ANDALUSIA	2022
H-02	Mechanisms of skeletal stem cells differentiation in skeletal diseases	FABIANA CSUKASI CABRERA	EUROPEAN UNION	PI	STATE RESEARCH AGENCY	2021
H-02	MA-INV-0031-2022-11 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestig. LR: Iván Durán	IVÁN DELGADO SÁNCHEZ	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
H-02	CA22170 (TENET) - TEndon Regeneration NETwork	IVAN DURAN JIMENEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
H-03	Estratificación de fibroblastos cardíacos: origen y segregación espacial de fibroblastos activados en la fisiopatología cardiovascular	JOSE MARIA PEREZ POMARES	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
H-03	Análisis histopatológico y transcriptómico de constructos de bioingeniería cardíaca para el estudio de la fibrosis	JOSE MARIA PEREZ POMARES	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
H-03	Estudio evolutivo del sistema sanguíneo en peces cartilaginosos: implicaciones sobre el origen de la hematopoyesis en vertebrados	Juan Pascual Anaya	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
H-03	Estudio evolutivo del sistema sanguíneo de la lamprea: implicaciones sobre el origen de la hematopoyesis en vertebrados	Juan Pascual Anaya	NATIONAL	PI	STATE RESEARCH AGENCY	2021
H-03	Estudio evolutivo del sistema cardiovascular y sanguíneo de anélidos: implicaciones sobre el origen de la sangre en metazoos	Juan Pascual Anaya	NATIONAL	PI	STATE RESEARCH AGENCY	2023
H-03	PID2020-119430RJ-I00 DESENMARAÑANDO EL INTERACTOMA CELULAR CARDIACO POST-INFARTO: HACIA LAREGULACION DE LA CICATRIZACION FIBROTICA	ADRIÁN RUIZ VILLALBA	NATIONAL	PI	STATE RESEARCH AGENCY	2020
H-03	SECFEC-INV-BAS 22016 Nueva perspectiva en los mecanismos fisiopatológicos de la Enfermedad de Kawasaki	ADRIÁN RUIZ VILLALBA	NATIONAL	PI	SPANISH SOCIETY OF CARDIOLOGY	2022
H-03	PI-0185-2024 RUTAS DE SEÑALIZACIÓN CLAVE EN LA PATOGÉNESIS DE LA ENFERMEDAD DE KAWASAKI: HACIA LA VALIDACIÓN DE CTHRC1 COMO MARCADOR DIAGNÓSTICO Y PRONÓSTICO	ADRIÁN RUIZ VILLALBA	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2024
H-03	Engineering a living human Mini-heart and a swimming Bio-robot	JOSE MARIA PEREZ POMARES AND JUAN ANTONIO GUADIX DOMÍNGUEZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2021
H-03	Desenmarañando el interactoma celular en el infarto de miocardio	ADRIÁN RUIZ VILLALBA	NATIONAL	PI	STATE RESEARCH AGENCY	2022
H-03	PR_DIVULGA_02_2024 IBIMA Award. Plataforma BIONAND-Divulga a las mejores publicaciones del último año	JOSÉ MARÍA PÉREZ POMARES	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
HE-01	Pluripotencia adquirida: Análisis de la reprogramación celular usando factores del ovocito para estudiar los estados de pluripotencia humana para aplicaciones biomédicas	MARIA ELENA GONZALEZ MUÑOZ	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
HE-01	EIDI-2021-15410 Reprogramación Celular y modelos de enfermedad	MARIA ELENA GONZALEZ MUÑOZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
HE-01	MA-INV-0031-2022-13 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigato. LR: Elena González Muñoz	FRANCISCO JOSE RODRIGUEZ YAÑEZ	REGIONAL	HR	REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	2022
HE-01	CA21151 (HAPLO-iPS) - GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS FROM HAPLO-SELECTED CORD BLOOD SAMPLES	MARIA ELENA GONZALEZ MUÑOZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
HE-01	CA20140 (CorEuStem) - The European Network for Stem Cell Core Facilities	MARIA ELENA GONZALEZ MUÑOZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
ECAI BIOBANK	MOV24-13 Bancos de cerebros: pieza angular en la investigación de enfermedades neurológicas actuales. IP:Carmen Cañadas Jiménez	CARMEN CAÑADAS JIMENEZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
ECAI BIOBANK	MOV24-14 Creación de una unidad de cultivos celulares 3D y organoidoteca: piedra angular de la medicina de precisión	ALVARO JIMENEZ VISTA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2024
ECAI BIOBANK	PT23/00049 Plataforma Biobanco y Biomodelos piedra angular de la Medicina de Precisión: ampliación, virtualización e internacionalización del servicio. Generation of organoids	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
ECAI BIOBANK	RF2-0003-2023 SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS)Tatiana Diaz Cordoba	TATIANA DÍAZ CORDOBA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
ECAI BIOBANK	PT20/00101 Plataforma Biobanco y Biomodelos	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2020
ECAI BIOINFORMATICS	F2-0026-2022 MEMORIA DESCRIPTIVA DE LA ECAI: ORGANIZACIÓN, RECURSOS Y ACTIVIDAD DE LA ECAI.	ANDRES GONZÁLEZ JIMENEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
GENOMICS ECAI	RF2-0005-2024 RENOVACIÓN TÉCNICOS VINCULADOS A ECAIS 2024. LR: DANIEL ALAMEDA	DANIEL ALAMEDA SERRANO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2024
GENOMICS ECAI	PR-SAEDYN-2021. Validación de un algoritmo desarrollado con PCR-hs y miRNAs circulantes como biomarcadores de HNF1A-MODY en pacientes previamente diagnosticados por Sangre	ANA MARIA LAGO SAMPEDRO	NATIONAL	AWARDS	ANDALUSIAN SOCIETY OF ENDOCRINOLOGY, DIABETES AND NUTRITION	2021
ECAI CLINICAL RESEARCH	ORTHOALLOUNION -ORTHOPaedic treatment with Allogeneic combined ATMP in long bone fracture delayed UNION and non-union	MIRIAM ROL GARCIA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
ECAI CLINICAL RESEARCH	LIVERaTION -Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence?	MIRIAM ROL GARCIA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2022
ECAI CLINICAL RESEARCH	ERA4Health -Fostering a European Research Area for Health Research	MIRIAM ROL GARCIA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2022
ECAI CLINICAL RESEARCH	RF2-0002-2023 SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS), Gloria Luque	GLORIA LUQUE FERNÁNDEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
ECAI CLINICAL RESEARCH	PT20/00127 Plataforma Soporte para la investigación clínica independiente y Ensayos Clínicos	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2020
ECAI CLINICAL RESEARCH	PT23/00137 Unidad de Investigación Clínica y Ensayos Clínicos, UICEC IBIMA_Plataforma BIONAND. ISCiii Clinical Research Platform: Consolidation of its international projection, comprehensive management, collaboration, and transfer.	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
ECAI NANOIMAGEN	PTA2020-019744 AYUDAS PERSONAL TÉCNICO DE APOYO. ECAI NANOIMAGING. IBIMA PLATAFORMA BIONAND. CANDIDATE: MÓNICA FEIJÓO CUARESMA	MONICA FEIJOO CUARESMA	NATIONAL	HR	STATE RESEARCH AGENCY	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
ECAI PRODUCCIÓN CELULAR Y SALAS GMP	PI22-01627 Evaluación preclínica de implantes personalizados, fabricados por bioimpresión, para la corrección quirúrgica de defectos críticos cráneo-maxilofaciales en pacientes pediátricos	LEONOR SANTOS RUIZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
ECAI PRODUCCIÓN CELULAR Y SALAS GMP	RF2-0004-2022 Vinculación de Técnicos a las Estructuras Comunes de Apoyo a la Investigación. Renovación de los refuerzos de la actividad investigadora cuyas ayudas vencen en 2022 Tecnio Superior: Rafael Maldonado	RAFAEL MALDONADO SÁNCHEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
CELL PRODUCTION AND GMP ROOMS ECAI	RF2-0004-2020 Vinculación de técnicos a estructuras comunes de apoyo a la investigación. Segunda renovación de los refuerzos aprobados en la convocatoria 2012	ANTONIO RODRÍGUEZ ACOSTA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2020
CELL PRODUCTION AND GMP ROOMS ECAI	RF2-0004-2024 RENOVACIÓN TÉCNICOS VINCULADOS A ECAIS 2024. LR: ANTONIO RODRIGUEZ ACOSTA	ANTONIO RODRÍGUEZ ACOSTA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2024
IBIMA STRUCTURE /A-02/D-05	CERT22/00034. Networked State Consortium for the Development of Medicines for Advanced Therapies (CERTERA)	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
IBIMA GESTION	PT23/00082 Unidad de Innovación de IBIMA Plataforma BIONAND. Promotion of technological valorization, knowledge transfer, and consolidation of the industrial network.	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
IBIMA GESTION	GIS22-00015 Contratos de Gestión en Investigación en Salud en IIS acreditados 2022	ROSA MARIA GOMEZ GALVEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022

ASSOCIATED GROUPS. COMPETITIVE RESEARCH GRANTS ACTIVE IN 2024

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
AA-24	AP-0333-2022-C3-F2 Valoración del estrés psicosocial como un factor determinante en las enfermedades cardiovasculares agudas y análisis de implantación de un programa de intervención estructurado grupal psicoeducativo.	ISABEL PEREZ AMORES	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2022
AA-24	AP-0553-2024-C5-F2 Efecto de la monitorización intersticial de glucosa en pacientes con diabetes mellitus tipo 2 en tratamiento con una dosis de insulina basal.	MARIA JOSE PERAL PRADOS	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2024
AA-24	A3-0071-2023 OLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: MIGUEL ANGEL GARCIA ORDÓÑEZ.	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
AA-24	CA20104 (PhysAgeNet) -Network on evidence-based physical activity in old age	JESUS OLMEDO LLANES	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
AA-24	CA22169 (EU-METAHEART) -EUropean network to tackle METAbolic alterations in HEART failure	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
AA-24	CA20104 (PhysAgeNet) -Network on evidence-based physical activity in old age	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
BA-14	INTERACT-EUROPE 100	MARILINA GARCÍA ARANDA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
BA-14	PI21-00252 Estudio del estado de salud y calidad de vida en pacientes supervivientes de cáncer de colon y recto a 12 años de seguimiento postcirugía	MAXIMINO REDONDO BAUTISTA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
BA-14	INT22-00055 Contrato de intensificación Maximino Redondo	MAXIMINO REDONDO BAUTISTA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
BA-14	RD21-0016-0015 Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS). LR: Maximino Redondo Bautista	MAXIMINO REDONDO BAUTISTA	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
BA-14	CA21152 (INE-CSC) -Implementation Network Europe for Cancer Survivorship Care	MARÍA PADILLA RUIZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
BA-14	CA21139 (IMPROVE) -3Rs concepts to improve the quality of biomedical science	MARILINA GARCÍA ARANDA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
BA-14	CA21135 (IMMUNO-model) -Modelling immunotherapy response and toxicity in cancer	MARILINA GARCÍA ARANDA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
BA-14	CA18240 (Adher N Rise) -ADHEsion GPCR Network: Research and Implementation Set the path for future Exploration	MARILINA GARCÍA ARANDA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2019
BA-14	CA23119 (SENESCENCE2030) -Targeting Cell Senescence to Prevent Age-Related Diseases	MARILINA GARCÍA ARANDA	EUROPEAN UNION	OTHER	COST ASSOCIATION	2023
CA-14	PROVIDE -Prediction and prevention of cardiovascular diseases in pre-diabetes and diabetes	MARÍA DOLORES MARTÍN ESCALANTE	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
CA-14	PI20/00783 Efectividad de la asistencia sanitaria a los pacientes con Insuficiencia Cardiaca utilizando datos del mundo real	RAUL QUIROS LÓPEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
CA-14	A1-0069-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: MARTA ARANDA GALLARDO, RAUL QUIROS LOPEZ	JOSÉ JAVIER GARCÍA ALEGRÍA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
CA-15	CA19132 (ENABLE) -European Network to Advance best practices & technology on medication adherence	PILAR BARNESTEIN FONSECA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
FA-16	SECOT_02Estudio del transcriptoma con identificación de nuevos biomarcadores no invasivos para el diagnóstico de la escoliosis idiopática del adolescente.	ENRIQUE GUERADO PARRA	NATIONAL	PI	SPANISH SOCIETY OF ORTHOPEDIC SURGERY AND TRAUMATOLOGY	2022

CLINICAL STUDIES ACTIVE IN 2024

Group	Title	Subtype	LR Name	Phase
A-01	Registro español informatizado de pacientes con Bronquiectasias.	NON-POST-AUTHORIZATION STUDY	CASILDA OLVEIRA FUSTER	Not applicable
A-01	Estudio fase III, multicéntrico, aleatorizado, doble ciego, de 48 semanas, con un periodo inicial de 12 semanas controlado con placebo, para evaluar la seguridad y la eficacia de osilodrostat en pacientes con enfermedad de Cushing	COMMERCIAL CLINICAL TRIAL	INMACULADA GONZÁLEZ MOLERO	III
A-01	Eficacia del tratamiento con metformina en diabetes gestacional no controlada con dieta frente al uso de insulinoterapia. Estudio MeDiGes	INDEPENDENT CLINICAL TRIAL	STELLA GONZÁLEZ ROMERO	IV
A-01	Impacto sobre el estrés oxidativo de los distintos análogos de insulina en personas con diabetes tipo 1. Ensayo clínico de bajo nivel de intervención. Estudio Ineox	INDEPENDENT CLINICAL TRIAL	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	IV
A-01	Pemafibrato para reducir los episodios cardiovasculares mediante la reducción de los triglicéridos en pacientes con diabetes (PROMINENT)	COMMERCIAL CLINICAL TRIAL	INMACULADA GONZÁLEZ MOLERO	III
A-01	Estudio europeo, observacional, de pasireotida LAR en acromegalia. Estudio ACRONIS. CSOM230CIC05	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZÁLEZ MOLERO	Not applicable
A-01	Estudio Fase IIb, 2-brazos, aleatorizado, Doble-cego, Placebo-Controlado, Multicéntrico para Optimizar la terapia de Diamyd® Administrada dentro de los ganglios linfáticos combinados con la vitamina D oral para investigar el impacto en la progresión de la diabetes tipo 1.	COMMERCIAL CLINICAL TRIAL	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	II
A-01	Estudio observacional retrospectivo del uso de evolucumab en unidades españolas de endocrinología (Retrospective Observational Study of Evalocumab Use in Spain Endocrinology Units [RETOSS-Endo]). Sponsor Code: 20160140	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZÁLEZ MOLERO	Not applicable
A-01	Estudio observacional, trasversal y multicéntrico, para valorar el grado de actividad de la enfermedad de los pacientes acromegálicos en España según la escala ACRODAT (ACROmegaly Disease Activity Tool). ACROVAL Study	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZÁLEZ MOLERO	Not applicable
A-01	Cumplimiento de un Suplemento Nutricional Oral (SNO) de alto contenido energético y bajo volumen	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Suplementos nutricionales específicos con probióticos para el tratamiento dietético de enfermedades crónicas	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Ensayo en fase III, aleatorizado, con enmascaramiento doble, comparativo con placebo y multicéntrico para evaluar la eficacia y la seguridad de Diamyd® en la conservación del funcionamiento de las células β endógenas en adolescentes y adultos con un diagnóstico reciente de diabetes de tipo 1 que presentan el haplotipo genético HLA DR3-DQ2. DIAGNODE-3	COMMERCIAL CLINICAL TRIAL	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	III
A-01	Accu-Chek Solo Country Implementation Observational Network SCION	CLINICAL RESEARCH WITH MEDICAL DEVICES	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	Not applicable
A-01	Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, multicéntrico y en 2 partes para evaluar la eficacia, la seguridad y la tolerabilidad de RGH-706 en el síndrome de Prader-Willi	CLINICAL TRIALS WITH DRUGS	JOSÉ CARLOS FERNÁNDEZ GARCÍA	II
A-01	Real-world patient experience with weekly injectable dulaglutide versusdaily oral semaglutide in SpainTRU-Experience Study	OBSERVATIONAL STUDIES WITH DRUGS	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly	CLINICAL TRIALS WITH DRUGS	INMACULADA GONZÁLEZ MOLERO	III
A-01	Estudio multicéntrico, prospectivo, no intervencionista y de un solo grupo, para investigar los parámetros clínicos asociados al uso de semaglutida por vía oral una vez al día en una población adulta no restringida con diabetes detipo 2 en España.	OBSERVATIONAL STUDIES WITH DRUGS	GABRIEL OLVEIRA FUSTER	Not applicable

Group	Title	Subtype	LR Name	Phase
A-01	Efecto de un suplemento dietético con propiedades antioxidantes y antiinflamatorias sobre la microbiota intestinal en pacientes con cáncer de colon. Ensayo clínico aleatorizado y controlado con placebo. Estudio TERATROFO.	CLINICAL RESEARCH WITH MEDICAL DEVICES	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Valoración de la calidad de vida, el estado nutricional y la capacidad funcional en personas con enfermedad renal crónica avanzada (ERCA) tras la implantación de un plan de educación nutricional e intervención dietética individualizada.	CLINICAL RESEARCH WITH MEDICAL DEVICES	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Protocolo maestro para investigar la eficacia y la seguridad de LY3437943 administrado una vez a la semana en participantes con diabetes mellitus de tipo 2 y obesidad o sobrepeso: un estudio aleatorizado, doble ciego y controlado con placebo (TRIUMPH-2).	CLINICAL TRIALS WITH DRUGS	GABRIEL OLVEIRA FUSTER	III
A-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de olezarsen (ISIS 678354) administrado por vía subcutánea a pacientes con hipertrigliceridemia grave	CLINICAL TRIALS WITH DRUGS	INMACULADA GONZÁLEZ MOLERO	III
A-01	Estudio observacional, prospectivo y multicéntrico de práctica clínica real (RWE) para evaluar el grado de adherencia a un programa de soporte nutricional y su relación con el estado nutricional evaluado mediante valoración morfofuncional en pacientes oncológicos desnutridos	OBSERVATIONAL STUDIES WITH DRUGS	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Estudio de fase 2b, aleatorizado, doble ciego, controlado con placebo y multicéntrico de 52 semanas de duración con una extensión ciega de 52 semanas que evalúa la seguridad y la eficacia de frexalimab, un anticuerpo monoclonal antagonista de CD40L, para la preservación de la función de las células β pancreáticas en adultos y adolescentes con diagnóstico reciente de diabetes tipo 1 en tratamiento con insulina	CLINICAL TRIALS WITH DRUGS	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	II
A-01	Estudio de extensión abierto de Olezarsen (ISIS 678354) administrado por vía subcutánea a pacientes con hipertrigliceridemia grave	CLINICAL TRIALS WITH DRUGS	INMACULADA GONZÁLEZ MOLERO	III
A-01	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome	CLINICAL TRIALS WITH DRUGS	GABRIEL OLVEIRA FUSTER	III
A-01	Ensayo sobre el efecto del apoyo nutricional coninuado tras el alta hospitalaria sobre la mortalidad, la debilidad, los resultados funcionales y la recuperación	CLINICAL RESEARCH WITH MEDICAL DEVICES	GABRIEL OLVEIRA FUSTER	Not applicable
A-02	Eficacia del tratamiento con metformina en diabetes gestacional no controlada con dieta frente al uso de insulinoterapia. Estudio MeDiGes.	INDEPENDENT CLINICAL TRIAL	MARÍA JOSÉ PICÓN CESAR	IV
A-02	Estudio observacional retrospectivo del uso de evolucumab en unidades españolas de endocrinología (Retrospective Observational Study of Evalocumab Use in Spain Endocrinology Units [RETOSS-Endo]). Sponsor Code: 20160140	COMMERCIAL POST-AUTHORIZATION STUDY	JOSE ANTONIO LÓPEZ MEDINA	Not applicable
A-02	Registro Nacional de pacientes con Diabetes tipo 1	INDEPENDENT POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	Estudio observacional multinacional para evaluar la seguridad de Repatha en el embarazo. (20150162, 200150162)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	Antagonismo del receptor de glucocorticoides en el tratamiento del síndrome de Cushing estudio (GRACE): ensayo en fase III, con dobleenmascaramiento, controlado con placebo y con retirada aleatorizada sobre la eficacia y la seguridad del relacorilant.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Eficacia de dos fórmulas de suplementación nutricional oral sobre parámetros metabólicos y de monitorización glucémica en pacientes en riesgo nutricional con diabetes mellitus tipo 2. PS19089 Estudio JGA-DIACARE-2018-01 Bi1	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MANUEL GARCÍA ALMEIDA	Not applicable
A-02	Estudio de resultados cardiovasculares con semaglutida en pacientes con diabetes tipo 2 Estudio ALMA	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar el impacto de evolocumab sobre los acontecimientos cardiovasculares mayores en pacientes con riesgo cardiovascular elevado sin infarto de miocardio o ictus previo	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III

Group	Title	Subtype	LR Name	Phase
A-02	Estudio Metabolómico de Potenciales Factores Involucrados en la Cardioprotección. Inhibición de SGLT-2 y Enfermedad Cardiovascular	INDEPENDENT CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	IV
A-02	Estudio de extensión sin enmascaramiento de la seguridad de relacorilant (CORT125134) en el tratamiento de los signos y síntomas del síndrome de Cushing endógeno	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (SURPASS-CVOT)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2, aleatorizado, sin enmascaramiento, con un tratamiento comparativo y grupos paralelos, para evaluar la seguridad y la eficacia de LY3209590 en pacientes con diabetes mellitus de tipo 1 que anteriormente han recibido tratamiento con varias inyecciones diarias.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Antagonismo del receptor de glucocorticoides en el tratamiento del hipercortisolismo en pacientes con adenomas suprarrenales que secretan cortisol o hiperplasia (GRADIENT): Estudio de fase III, aleatorizado, doble ciego y comparado con placebo sobre la eficacia y la seguridad de relacorilant	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo clínico para valorar el Impacto de un suplemento nutricional en la Recuperación del Estado Nutricional de pacientes ancianos con fractura Espontánea de cadera	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MANUEL GARCÍA ALMEIDA	Not applicable
A-02	Estudio aleatorizado, doble ciego (investigador y sujeto) y controlado con placebo para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia de CFZ533 en niños y adultos jóvenes con diabetes mellitus de tipo 1 (DMT1) de nueva aparición	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Cambios en la capacidad de digestión y secreción pancreática exocrina en pacientes tras una cirugía gástrica	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA ALMEIDA	Not applicable
A-02	Eficacia y seguridad de insulina icodec una vez a la semana en comparación con 100 unidades/ml una vez al día de insulina degludec, ambas en combinación con insulina aspart, en adultos con diabetes de tipo 1. Ensayo de tratamiento hasta conseguir el objetivo, de 26 semanas de duración, aleatorizado, multicéntrico, abierto, con control activo, de grupos paralelos y con dos brazos para investigar el efecto sobre el control de la glucemia y la seguridad del tratamiento con insulina icodec una vez a la semana en comparación con insulina degludec una vez al día, ambas en combinación con insulina aspart en adultos con diabetes de tipo 1, con una extensión de 26 semanas para investigar la seguridad a largo plazo. (ONWARDS 6)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2a, abierto, aleatorizado y controlado con un producto comparativo activo, para evaluar la eficacia y la seguridad de efinopegdutida (MK-6024) en participantes con esteatosis hepática no alcohólica	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio aleatorizado, doble ciego, controlado con placebo sobre la relación dosis-respuesta para evaluar la eficacia y la seguridad de MEDI7352 en pacientes con neuropatía diabética dolorosa	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Red global de ensayos de pacientes renales.	NON-POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	A Phase 2b Multicentre, Randomised, Double-Blind, PlaceboControlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2 (Zenith-CKD)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Correlación en el mundo real del tiempo dentro del rango con los resultados notificados por los pacientes y el uso de recursos sanitarios en pacientes con diabetes en España: estudio CorrelaTIR	REST OF OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	Estrategias de control y estudio farmacogenético para el tratamiento personalizado del hígado graso asociado a disfunción metabólica en pacientes con prediabetes.	INDEPENDENT CLINICAL TRIAL	LOURDES GARRIDO SÁNCHEZ	III
A-02	Estudio de fase 3, multicéntrico, aleatorizado, sin enmascaramiento, con grupos paralelos, para evaluar la eficacia y la seguridad de LY3209590 en comparación con la insulina degludec en participantes con diabetes de tipo 2 actualmente tratados con insulina basal (QWINT-3)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la seguridad y eficacia a largo plazo de lanifibranor en pacientes adultos con esteatohepatitis no alcohólica (EHNA) sin cirrosis y estadio de fibrosis hepática grado 2 (F2)/grado 3 (F3)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III

Group	Title	Subtype	LR Name	Phase
A-02	Estudio en fase II, doble ciego y controlado con placebo de setmelanotide en pacientes con defectos genéticos específicos en la vía del receptor de la melanocortina 4, en dos etapas (preinclusión abierta seguida de retirada aleatorizada)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase 3, aleatorizado, comparativo, sin enmascaramiento, con grupos paralelos, para comparar la eficacia y la seguridad de LY3209590 como insulina basal semanal con la de la insulina glargina en adultos con diabetes de tipo 2 que reciben múltiples inyecciones diarias	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo fase IIb/III, aleatorizado, doble ciego, comparado con placebo para evaluar la seguridad y eficacia de la cotadutida en pacientes con esteatohepatitis no alcohólica no cirrótica con fibrosis. (Estudio PROXYMO-ADVANCE)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio fase IIa, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y farmacodinámica de AZD4831 en pacientes con esteatohepatitis no alcohólica (EHNA) no cirrótica con fibrosis (COSMOS)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, multicéntrico y en 2 partes para evaluar la eficacia, la seguridad y la tolerabilidad de RGH-706 en el síndrome de Prader-Willi	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase 3, aleatorizado, doble ciego, comparativo con un placebo, para investigar el efecto de tirzepatida sobre la reducción de la morbilidad en adultos con obesidad	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2, aleatorizado, controlado con placebo, doble ciego y de búsqueda de dosis para evaluar la eficacia, seguridad y tolerabilidad de AMG 133 en sujetos adultos con sobrepeso u obesidad, con o sin diabetes mellitus tipo 2	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio multicéntrico y transversal para caracterizar la distribución de los niveles de lipoproteína(a) entre pacientes con antecedentes documentados de enfermedad cardiovascular aterosclerótica (ECVA).	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	Ensayo fase IIb, aleatorizado, doble ciego, multicéntrico, comparado con placebo para evaluar eficacia, seguridad y tolerabilidad de AZD2693 en pacientes con esteatohepatitis no alcohólica no cirrótica con fibrosis portadores del alelo de riesgo PNPLA3 rs738409 148M (FORTUNA)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio en fase III, aleatorizado a doble ciego y controlado con placebo: 5 subestudios independientes de setmelanotide en pacientes con defectos en los genes POMC, PCSK1, LEPR, SRC1, SH2B1 o PCSK1 N221D en la vía del receptor 4 de melanocortina	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	I
A-02	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisiran en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1 Prevent).	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de la efinopegdutida (MK-6024) en adultos con esteatohepatitis no alcohólica precirrótica.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 3, aleatorizado, doble ciego, para investigar la eficacia y seguridad de LY3502970 administrado una vez al día por vía oral en comparación con placebo en participantes adultos con obesidad o sobrepeso con comorbilidades relacionadas con el peso (ATTAIN-1).	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 3, aleatorizado, doble ciego para investigar la eficacia y la seguridad de LY3437943 administrado una vez a la semana en comparación con placebo en participantes con obesidad severa y con enfermedad cardiovascular establecida (TRIUMPH-3).	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III

Group	Title	Subtype	LR Name	Phase
A-02	Estudio observacional, prospectivo y multicéntrico de práctica clínica real (RWE) para evaluar el grado de adherencia a un programa de soporte nutricional y su relación con el estado nutricional evaluado mediante valoración morfofuncional en pacientes oncológicos desnutridos	OBSERVATIONAL STUDIES WITH DRUGS	JOSÉ MANUEL GARCÍA ALMEIDA	Not applicable
A-02	Protocolo maestro para investigar la eficacia y la seguridad del LY3437943 administrado una vez a la semana en participantes con diabetes mellitus de tipo 2 y obesidad o sobrepeso: un estudio aleatorizado, doble ciego y controlado con placebo (TRIUMPH-2)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de MK-0616 para reducir las complicaciones cardiovasculares graves en participantes con riesgo cardiovascular elevado	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo global de fase 3, de grupos paralelos, aleatorizado, prospectivo, intervencionista, doble ciego y multicéntrico para investigar la eficacia y seguridad de finerenona frente a placebo, en adición al tratamiento estándar, en participantes con enfermedad renal crónica asociada a diabetes tipo 1	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio fase IIa, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad, tolerabilidad, farmacocinética e interacción con la diana de GSK3858279 en participantes adultos con dolor neuropático diabético periférico crónico (DNPC).	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de seguridad cardiovascular de fase 3, aleatorizado, doble ciego, de grupos paralelos, basado en eventos con BI 456906 administrado por vía subcutánea en comparación con placebo en participantes con sobrepeso u obesidad con enfermedad cardiovascular (ECV) establecida o enfermedad renal crónica, y/o al menos dos complicaciones relacionadas con el peso o factores de riesgo de ECV	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio en fase II, de grupos paralelos, doble ciego y con tres grupos de tratamiento, para evaluar la eficacia y la seguridad de finerenona más empagliflozina en comparación con finerenona o empagliflozina en participantes con enfermedad renal crónica y diabetes tipo 2 CONFIDENCE	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio para evaluar la eficacia y seguridad de la insulina Icodec de administración semanal al cambiar de insulinas basales diarias en comparación con 100 UI de insulina glargina una vez al día en adultos con diabetes tipo 2	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo Fase III, aleatorizado, doble-cego, de grupos paralelos y controlado con principio activo para evaluar la eficacia, seguridad y tolerabilidad de Baxdrostat combinado con Dapagliflozina, comparado con Dapagliflozina sola en la progresión de Enfermedad Renal Crónica (ERC) en pacientes con ERC e hipertensión arterial. BaxDUO ARCTIC	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de extensión de fase 3 abierto para evaluar la seguridad y la eficacia de MK-0616 en adultos con hipercolesterolemia.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 3, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de MK-0616 en comparación con ezetimiba o ácido bempedoico o ezetimiba más ácido bempedoico en adultos con hipercolesterolemia	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de búsqueda de dosis de fase 2, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de maridebart cafraglutida en sujetos adultos con diabetes mellitus tipo 2.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II

Group	Title	Subtype	LR Name	Phase
A-02	Estudio fase IIB, aleatorizado, doble ciego, controlado con placebo y con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad de AZD5004 en adultos con diabetes mellitus tipo 2.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase II, aleatorizado, doble ciego y comparativo con placebo para investigar la eficacia y la seguridad de la volenrelaxina en adultos con insuficiencia renal crónica.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Effect of levothyroxine as adjuvant therapy to a hypocaloric diet in the treatment of obesity: a randomized placebo-controlled trial	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-03	Sustitución quirúrgica e implantación percutánea de válvula aórtica	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Registro prospectivo, multicéntrico e internacional de pacientes de ambos sexos con diagnóstico recientes de fibrilación auricular (GARFIELD)	INDEPENDENT POST-AUTHORIZATION STUDY	MANUEL FRANCISCO JIMÉNEZ NAVARRO	Not applicable
A-03	Mayor respuesta a la terapia de resincronización cardíaca (TRC) con Estimulación Multisitio. MORE-CRT MPP	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Efectividad de la titulación de fármacos por la enfermera especializada en pacientes de Insuficiencia Cardíaca (IC). Proyecto ETIFIC (Enfermera Titular Fármacos en IC).	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Evaluación de la eficacia de la Atorvastatina en la progresión de la dilatación aórtica y la degeneración valvular en pacientes con válvula aórtica bicúspide (BICATOR)	INDEPENDENT CLINICAL TRIAL	JUAN MANUEL ROBLEDO CARMONA	III
A-03	Ensayo prospectivo de INRA frente a inhibidor de la ECA para determinar la superioridad en reducir los acontecimientos de insuficiencia cardíaca tras infarto de miocardio. Estudio multicéntrico, aleatorizado, doble ciego, controlado con tratamiento activo, de grupos paralelos, de fase 3 para evaluar la eficacia y seguridad de LCZ696 comparado con ramipril en la morbilidad y mortalidad en pacientes de alto riesgo tras un infarto agudo de miocardio. PARADISE-MI:	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Non-vitamin K antagonist Oral anticoagulants in patients with Atrial high rate episodes	INDEPENDENT CLINICAL TRIAL	JUAN JOSÉ GÓMEZ DOBLAS	III
A-03	Registro Español de pacientes portadores de dispositivos cardíacos implantables que requieran una prueba de imagen diagnóstica con Resonancia Magnética Nuclear	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Estudio no intervencionista sobre el tratamiento con edoxabán en la práctica clínica habitual para pacientes con fibrilación auricular no valvular (ETNA-AF-Europe)	COMMERCIAL POST-AUTHORIZATION STUDY	JUAN JOSÉ GÓMEZ DOBLAS	Not applicable
A-03	Eficacia de la transposición de un pedículo adiposo pericárdico sobre el infarto de miocardio en pacientes (AGTP II trial.)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MANUEL FRANCISCO JIMÉNEZ NAVARRO	Not applicable
A-03	LCZ696 en pacientes con insuficiencia cardíaca con fracción de eyección deprimida y elevada comorbilidad: efecto en el remodelado y fibrosis de ventrículo izquierdo valorado por nuevos biomarcadores de insuficiencia cardíaca y resonancia magnética cardíaca.	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Tratamiento de la fibrilación auricular en pacientes con hipertensión arterial que son tratados por ablación venosa pulmonar en combinación y con la denervación arterial renal o solo ablación venosa pulmonar. Estudio ASAF	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Estudio observacional retrospectivo del uso de evolocumab en unidades españolas de cardiología - RETrospective Observational Study of Evolocumab Use in Spanish Cardiology Units RETOSS-Cardio. 20160139	COMMERCIAL POST-AUTHORIZATION STUDY	ELOY CARLOS RUEDA CALLE	Not applicable
A-03	Crioablación de venas pulmonares vs fármacos antiarrítmicos en fibrilación auricular persistente (CRAFT)	INDEPENDENT CLINICAL TRIAL	ALBERTO BARRERA CORDERO	IV
A-03	Registro prospectivo, de brazo único, multicéntrico, observacional, de utilización de stent liberador de zotarolimus RESOLUTE-ONYX™ en el intervencionismo coronario percutáneo en vasos pequeños	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Estudio de seguridad post autorización PASS: estudio observacional de cohorte con pacientes HAP tratados por primera vez con Upravi selexipag u otra terapia específica contra la hipertensión arterial pulmonar HAP en la práctica clínica. EXPOSURE, AC-065A401	COMMERCIAL POST-AUTHORIZATION STUDY	VICTOR MANUEL BECERRA MUÑOZ	Not applicable

Group	Title	Subtype	LR Name	Phase
A-03	Eficacia de choque de cardioversión/desfibrilación, un estudio aleatorizado que compara la Pendiente Fija y la Anchura de Impulso Fija en una población general con desfibrilador automático implantable, EFICAZ.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Registro Observacional prospectivo de pacientes con implante de stent bioabsorbible de magnesio MAGMARIS ES en la práctica clínica habitual	NON-POST-AUTHORIZATION STUDY	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Estudio intervencionista posterior a la comercialización del sistema CoreValve Evolut PRO	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Xience 28 Global Study	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Observación de la Asistencia Clínica Habitual en los pacientes con insuficiencia cardiaca y dispositivos de TRC BIOTRONIK implantados	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Beneficio del bloqueo del sistema renina-angiotensina sobre la evolución clínica y el remodelado ventricular tras la colocación de una prótesis percutánea aórtica	INDEPENDENT CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	IV
A-03	Estudio prospectivo y contemporáneo que evalúa la experiencia en el mundo real del rendimiento y la seguridad de los dispositivos MitraClip de última generación. Estudio MitraClip EXPAND	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Prevención de terapias inapropiadas y eventos adversos cardíacos y cerebrovasculares graves con un Desfibrilador Automático Implantable monocameral con detección auricular con dipolo flotante DX. Estudio PREVENT DX	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Evaluación de seguridad y comportamiento eléctrico de las sondas INVICTA equipadas con conector DF4. FRIENDS	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ALBERTO BARRERA CORDERO	Not applicable
A-03	Precisión en la Monitorización de Pacientes con Insuficiencia Cardíaca mediante HeartLogic. PREEMPT-HF	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Insuficiencia cardíaca Reducción de eventos con Monitorización Remota y Soporte de Salud Iniciada por el investigador. (Heart failure Events reduction with Remote Monitoring and eHealth Support Investigator Initiated Trial)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Concordancia entre FFR e iFR para la valoración de lesiones intermedias en el tronco común izquierdo. Aplicación prospectiva de un valor de iFR predefinido para la valoración de lesiones intermedias en el tronco común izquierdo. Estudio iLITRO.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Estudio sobre la PRevalencia de Amiloidosis Cardíaca por Transtiretina en pacientes con Insuficiencia CArdíaca con fracción de eyección preservada. Estudio PRACTICA	NON-POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Modulación de la Contractilidad Cardíaca (CCM©) en Pacientes con Insuficiencia Cardíaca en Andalucía. Registro DOLMENART-VIII-2018	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Registo Prospectivo observacional de pacientes con enfermedad de Fabry. Sponsor Code: AT1001-030 Estudio Amicus FollowMe	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Estudio multicntrico, aleatorizado, doble ciego (paciente e investigador) y controlado con placebo para estudiar la eficacia de sacubitrilo/valsartán por vía oral en pacientes adultos con miocardiopatía hipertrófica no obstructiva (MCH no obstructiva).	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de vutrisirán en pacientes con amiloidosis cardiaca por transtiretina (amiloidosis por ATTR con miocardiopatía). HELIOS-B.	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Estudio observacional de terapias inapropiadas tras recambio de DAI. Estudio OSIRIS	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	AMALIO RUIZ SALAS	Not applicable
A-03	COVID-19 en pacientes con insuficicnecia cardiaca y cardiopatías familiares. CDC	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	Not applicable

Group	Title	Subtype	LR Name	Phase
A-03	Sync Av estudio post-comercializacion	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable
A-03	Un registro multicéntrico para evaluar la calidad del tratamiento antitrombótico en pacientes con fibrilación auricular y cáncer activo. Registro CANAC-FA (CÁNCer ACTivo y Fibrilación Auricular):	INDEPENDENT POST-AUTHORIZATION STUDY	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Seguridad y rendimiento de las Sondas DF4 ventriculares invicta con fijación activa. Estudio APOLLO	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ALBERTO BARRERA CORDERO	Not applicable
A-03	Ensayo clínico multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para evaluar la eficacia y la seguridad de finerenona sobre la morbilidad y la mortalidad en participantes con insuficiencia cardíaca (NYHA II-IV) y fracción de eyección del ventrículo izquierdo =40 % (FEVI =40 %).	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Estudio observacional para evaluar el beneficio clínico neto del edoxabán en pacientes con fibrilación auricular no valvular, según la práctica clínica habitual en España Registro BENEFIT.Observational study to evaluate the Net Clinical Benefit of edoxaban in non-valvular Atrial Fibrillation patients, according to the routine clinical practice in Spain BENEFIT Registry	COMMERCIAL POST-AUTHORIZATION STUDY	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Registro Observacional Prospectivo de Pacientes con Insuficiencia Cardíaca	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Dapagliflozina después del implante de prótesis valvular aórtica percutánea. DAPATAVI	INDEPENDENT CLINICAL TRIAL	ANTONIO JESÚS MUÑOZ GARCÍA	III
A-03	Eficacia y Seguridad de la Furosemida Intravenosa administrada con Suero Salino Hipertónico en el Hospital de día de Insuficiencia Cardíaca. Estudio SSH-IC	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Impacto de DAPAGLIFOZINA en el remodelado auricular de pacientes con insuficiencia cardiaca: MODA study.	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Registo prospectivo, de brazo único, multicéntrico, observacional para la evaluación de la seguridad y eficacia del Stent Ultimaster Tnasei en pacientes con lesiones coronarias complejas. Estudio TANSEI	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Estudio de resultados clínicos del NVT ALLEGRA TAVI System TF en pacientes tratados con válvulas aórticas calcificadas en la vida real en una población de pacientes con riesgo quirúrgico elevado (FOLLOW)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	OpSens dPR para la evaluación fisiológica de lesiones coronarias iintermedias en estenosis aórtica.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Estudio de fase 2b, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento por vía oral con AZD9977 y dapagliflozina en pacientes con insuficiencia cardíaca (con fracción de eyección del ventrículo izquierdo por debajo del 55%) y nefropatía crónica (MIRACLE)	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de la eficacia y seguridad del spray nasal de etripamil para la resolución de episodios espontáneos de taquicardia supraventricular paroxística. El estudio RAPID (NODE-301 Parte 2)	COMMERCIAL CLINICAL TRIAL	MARÍA DEL CARMEN MEDINA PALOMO	III
A-03	Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria	INDEPENDENT CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	IV
A-03	Estrategia de cruzar dos técnicas de ablación (Criobalón y Radiofrecuencia) tras la recurrencia de FA paroxística y la necesidad de un nuevo procedimiento. X-TRA (Cross therapy for Re-Do Ablation)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ALBERTO BARRERA CORDERO	Not applicable
A-03	Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo queevalúa el impacto de inclisirán en los acontecimientos cardiovascularesadversos mayores (MACE) en participantes con enfermedad cardiovascularestablecida (ECV) (VICTORION-2 PREVENT)	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Registro Nacional de Pacientes con Insuficiencia Cardíaca tratados con Modulación de la Contractilidad Cardíaca en España	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	Not applicable

Group	Title	Subtype	LR Name	Phase
A-03	Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo de FDY-5301 intravenoso en pacientes con infarto de miocardio con elevación del segmento ST anterior. IOCYTE AMI-3	COMMERCIAL CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	III
A-03	Tratamiento cardiovascular y renal en pacientes con insuficiencia cardíaca con hiperpotasemia o con alto riesgo de hiperpotasemia (CARE-HK en el registro de IC)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Estudio en fase III, prospectivo, aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos y flexible con ampliación abierta para evaluar la eficacia y la seguridad de macitentán 75 mg en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente.Macitentán en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente (MACiTEPH)	COMMERCIAL CLINICAL TRIAL	VICTOR MANUEL BECERRA MUÑOZ	III
A-03	Retirada de tratamiento farmacologico en pacientes respondedores a terapia de resincronización cardíaca: Estudio abierto y aleatorizado	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Registro prospectivo del stent ihtDEStiny en práctica clínica habitual(Estudio VELAZQUEZ)	CLINICAL RESEARCH WITH MEDICAL DEVICES	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Inicio temprano de tratamiento con Candesartan vs Placebo en portadores genéticos de mutaciones causales de MCD sin evidencia de enfermedad (EARLY-GENE trial).	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	SEC-FA-2022-1 Registro SEC -EXCELENTE FA: una herramienta para la mejora de la calidad de la atención médica a pacientes con fibrilación auricular en España.	OBSERVATIONAL STUDIES WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Estudio de fase 2, doble ciego, aleatorizado, controlado con placebo, de 4 grupos para estudiar los síntomas, la funcionalidad, la calidad de vida relacionada con la salud y la seguridad de la administración subcutánea repetida de ponegromab comparado con placebo en participantes adultos con insuficiencia cardíaca.	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Estudio de fase 2, aleatorizado, con enmascaramiento doble, comparativo con un placebo, para investigar la eficacia y la seguridad de LY3540378 en adultos con empeoramiento de la insuficiencia cardíaca crónica con fracción de eyección preservada (ICFEp)	CLINICAL TRIALS WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	II
A-03	Plan de investigación de seguimiento clínico de poscomercialización (PMCF) para evaluar la seguridad y efectividad clínica de los dispositivos iVascular para el tratamiento de las enfermedades coronarias	CLINICAL RESEARCH WITH MEDICAL DEVICES	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	SAvvyWire™ Eficacia y seguridad en los procedimientos de implantación transcatéter de válvulas aórticas.	CLINICAL RESEARCH WITH MEDICAL DEVICES	ANTONIO JESÚS MUÑOZ GARCÍA	Not applicable
A-03	Ensayo fase III multicéntrico, internacional, aleatorizado, controlado con un comparador activo, doble ciego, con doble simulación y 2 grupos paralelos, para comparar la eficacia y la seguridad del inhibidor oral de FXIa asundexian (BAY 2433334) con apixaban para la prevención del ictus o embolia sistémica en participantes masculinos y femeninos de 18 años o más con fibrilación auricular y riesgo de ictus.	CLINICAL TRIALS WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	III
A-03	Estudio preliminar en fase IIa, abierto para evaluar la eficacia, la farmacocinética, la farmacodinámica, la seguridad y la tolerabilidad de MYK-224 en participantes con miocardiopatía hipertrófica sintomática y obstrucción del conducto de salida del ventriculo izquierdo	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Tratamiento antiplaquetario único con ticagrelor frente a aspirina después del implante percutáneo de válvula aórtica: ensayo clínico aleatorizado multicéntrico. REAC TAVI 2	CLINICAL TRIALS WITH DRUGS	ANTONIO JESÚS MUÑOZ GARCÍA	IV
A-03	Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies.	CLINICAL TRIALS WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	III
A-03	Seguimiento clínico retrospectivo, prospectivo y multicéntrico de pacientes con regurgitación tricúspidea severa tras tratamiento con el sistema de válvulas bicavales transcatéter TricValveTRICUS REGISTRY	OBSERVATIONAL STUDIES WITH DRUGS	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable

Group	Title	Subtype	LR Name	Phase
A-03	Estudio clínico aleatorizado, doble ciego y controlado con placebo para evaluar mavacamten en adultos con cardiomiopatía hipertrófica sintomática no obstructiva	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	New pathophysiological pathways involved in iron metabolism disorder in hear failure: The IRON PATH II investigator initiated Study.	OBSERVATIONAL STUDIES WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Estudio aleatorizado, doble ciego (participante e investigador) y controlado con placebo en el que se investigan la eficacia, la seguridad y la tolerabilidad de LTP001 en participantes con hipertensión arterial pulmonar.	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Diferencias de género en el manejo temprano y posterior al alta después de un infarto agudo de miocardio -genami prevention.	OBSERVATIONAL STUDIES WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	Not applicable
A-03	nvEstigation of the safety and perforMance of the NVT ALLEGRAHV System with a new delivery system in Patients with severecalciified aortlc stenosis or failed suRgical aortic bioprosthEsis	CLINICAL RESEARCH WITH MEDICAL DEVICES	JOSÉ MARÍA HERNÁNDEZ GARCÍA	Not applicable
A-03	Estudio en fase IV, de doble ciego, controlado con placebo, de retirada aleatorizada, para evaluar el uso de ciclosilicato de sodio y zirconio (CSZ) para el tratamiento de la hiperpotasemia en pacioentes con insuficiencia cardíaca sintomática con fracción de eyección reducida y que reciben espirolactona (REALIZE-K).	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Prevalencia en España de mal control de la anticoagulación en pacientes con fibrilación auricular ‘no valvular’ tratados con antagonistas de la Vitamina K. (20230228)	OBSERVATIONAL STUDIES WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y motivado por los acontecimientos para demostrar la eficacia y seguridad de milvexian, un inhibidor oral del factor XIa, después de padecer un síndrome coronario agudo reciente	CLINICAL TRIALS WITH DRUGS	MANUEL FRANCISCO JIMÉNEZ NAVARRO	III
A-03	Estudio prospectivo, aleatorizado, multicéntrico, abierto, guiado por eventos, para evaluar la no inferioridad de una estrategia personalizada de precisión para la prevención de la muerte súbita en pacientes con miocardiopatía dilatada no isquémica. ESTUDIO CIBER-SPANISH I.	CLINICAL RESEARCH WITH MEDICAL DEVICES	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Estudio de extensión abierto en el que se investigan la eficacia, la seguridad y la tolerabilidad de LTP001 en participantes con hipertensión arterial pulmonar	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Estudio aleatorizado, simple ciego, para demostrar la seguridad y la eficacia de la terapia corticosteroidea a altas dosis para tratar pacientes con miocarditis aguda complicada/fulminante. (Single blind randomized controlled trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant acute myocarditis)	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Post-Authorization Safety Study (PASS): Revisión retrospectiva de las historias clínicas de los pacientes con HAP tratados recientemente con Uptravi® (selexipag) o cualquier otro tratamiento específico para la HAP	OBSERVATIONAL STUDIES WITH DRUGS	VICTOR MANUEL BECERRA MUÑOZ	Not applicable
A-03	VIVA Estudio pivotal/de viabilidad de primera aplicación en seres humanos (PASH) en dos fases del sistema autoexpandible de válvula aórtica Vienna	CLINICAL RESEARCH WITH MEDICAL DEVICES	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation	CLINICAL TRIALS WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	III
A-03	Registro PERSEO: Prevención de eventos Embólicos tras una hemoRragia SEvera en pacientes anticoagulados con fibrilaciOn auricular.	OBSERVATIONAL STUDIES WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaLuar la efcacia y la seguridad de abeLacimab en pacientes de alto riesgo con fibrilación Auricular que no se consideren adecuados para la antiCoagulación oral (LILAC)	CLINICAL TRIALS WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	III
A-03	Estudio en fase 2ª, multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de JTT-861 administrado durante 12 semanas en pacientes con insuficiencia cardíaca con fracción de eyección reducida (POWER-HF)	CLINICAL TRIALS WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	II

Group	Title	Subtype	LR Name	Phase
A-03	Estudio de prueba de concepto y búsqueda de dosis, multicéntrico, aleatorizado, con control activo y placebo, de grupos paralelos y de 24 semanas de duración en el que se evalúan la eficacia, la seguridad y la tolerabilidad de XXB750 en pacientes con insuficiencia cardíaca	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Estudio de fase 2, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la seguridad y la eficacia de tovinontrina en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Study Title: Predicción de riesgo de cardiotoxicidad en las unidades de cardiooncología. Valor de la genética y diferentes biomarcadores. El registro CARDIOTOX	OBSERVATIONAL STUDIES WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	Not applicable
A-03	Estudio de fase 3, multinacional, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de NTLA-2001 en participantes con amiloidosis por transtiretina con miocardiopatía (ATTR-CM)	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Plan de investigación de seguimiento poscomercialización (PMCF) para evaluar la seguridad y efectividad del dispositivo liberador de paclitaxel SEQUENT PLEASE NEO en pacientes con enfermedad arterial coronaria	CLINICAL RESEARCH WITH MEDICAL DEVICES	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Uso clínico y seguridad de Vericiguat (agonista oral de la guanilato ciclasa) en la práctica clínica real. Prospective observational study with drugs.	OBSERVATIONAL STUDIES WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Resultados isquémicos y hemorrágicos tras la implantación del stent angiolute y una terapia antiplaquetaria dual abreviada. Un ensayo controlado aleatorizado, multicéntrico, factorial 2x2, de todos los participantes elegibles (allcomers) Angiodapt.”	CLINICAL TRIALS WITH DRUGS	JUAN HORACIO ALONSO BRIALES	III
A-03	A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)”	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Encuesta Europea sobre prevención de enfermedades cardiovasculares, diabetes y enfermedad renal crónica	OBSERVATIONAL STUDIES WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	Not applicable
A-03	Seguimiento clínico post-comercialización de los sistemas con dispositivo cardíaco electrónico implantable de MicroPort CRM	CLINICAL RESEARCH WITH MEDICAL DEVICES	MARÍA DEL CARMEN MEDINA PALOMO	Not applicable
A-03	Estudio RIESCAR. Riesgo cardiovascular de la población atendida por cardiólogos en España.	OBSERVATIONAL STUDIES WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	Not applicable
A-03	Estudio clínico de fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ovinontrina en pacientes con insuficiencia cardíaca crónica con fracción de eyección conservada.	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	EASi-HF: Ensayo de fase III de superioridad, doble ciego, aleatorizado y con grupos paralelos para evaluar la eficacia y la seguridad del uso combinado de BI 690517 por vía oral y empagliflozina en comparación con placebo y empagliflozina en participantes con insuficiencia cardíaca sintomática (IC: clases II-IV de la NYHA) y fracción de eyección ventricular izquierda (FEVI) =40 %	CLINICAL TRIALS WITH DRUGS	MANUEL FRANCISCO JIMÉNEZ NAVARRO	III
A-03	Estudio no intervencionista sobre el tratamiento con ácido bempedoico y/o su combinación de dosis fija con ezetimiba en la práctica clínica habitual en pacientes con hipercolesterolemia primaria o dislipidemia mixta (MILOS)	OBSERVATIONAL STUDIES WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	Not applicable
A-03	A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (ACACIA)	CLINICAL TRIALS WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Reparación temprana de la válvula mitral transcátéter después de un infarto de miocardio	CLINICAL RESEARCH WITH MEDICAL DEVICES	JUAN HORACIO ALONSO BRIALES	Not applicable

Group	Title	Subtype	LR Name	Phase
A-03	Estudio multicéntrico prospectivo no aleatorizado, de una cohorte no seleccionada de pacientes con diagnóstico de amiloidosis cardiaca por transtiretina que inicien tratamiento diario con tafamidis 61 mg.	OBSERVATIONAL STUDIES WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-03	Estudio de correlación del grado de congestión en insuficiencia cardiaca con el dispositivo SENSOCOR.	CLINICAL RESEARCH WITH MEDICAL DEVICES	JOSÉ MANUEL GARCÍA PINILLA	Not applicable
A-06	Prevención temprana de complicaciones por diabetes en personas con hiperglucemia en Europa (e-PREDICE)	INDEPENDENT CLINICAL TRIAL	RICARDO GÓMEZ HUELGAS	III
A-06	Registro de pacientes con enfermedad del Hígado graso no alcohólico	NON-POST-AUTHORIZATION STUDY	SERGIO JANSEN CHAPARRO	Not applicable
A-06	Cribado de la enfermedad de Pompe de inicio tardío mediante muestra de sangre seca de pacientes provenientes de Unidades de Medicina Interna. Estudio POMPE	NON-POST-AUTHORIZATION STUDY	IVÁN PÉREZ DE PEDRO	Not applicable
A-06	Estudio de seguridad post autorización PASS: estudio observacional de cohorte con pacientes HAP tratados por primera vez con Uptravi selexipag u otra terapia específica contra la hipertensión arterial pulmonar HAP en la práctica clínica. EXPOSURE, AC-065A401	COMMERCIAL POST-AUTHORIZATION STUDY	MARIA DEL MAR AYALA GUTIÉRREZ	Not applicable
A-06	Registro de la Sociedad española de Medicina Interna (SEMI) de pacientes hospitalizados por COVID-19	NON-POST-AUTHORIZATION STUDY	RICARDO GÓMEZ HUELGAS	Not applicable
A-06	Prevención de infección por COVID19 mediante administración de hidroxiclороquina en mayores institucionalizados y personal asistencial de residencias. Ensayo clínico controlado, abierto y aleatorizado escalonado (stepped-wedge) por clusters. CDC	INDEPENDENT CLINICAL TRIAL	RICARDO GÓMEZ HUELGAS	III
A-06	Efectos de semaglutida sobre la capacidad funcional en pacientes con diabetes tipo 2 y arteriopatía periférica	COMMERCIAL CLINICAL TRIAL	MARIA DOLORES LÓPEZ CARMONA	III
A-06	Seguridad de edoxabán en pacientes con fibrilación auricular no valvular (FANV) y diabetes mellitus tipo 2 (DM2). SEMI-FADIA-2020	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA GUIL GARCIA	Not applicable
A-06	Valoración del manejo y adecuación del tratamiento antitrombótico de los pacientes con Fibrilación Auricular No Valvular que ingresan en los Servicios de Medicina Interna de España.	COMMERCIAL POST-AUTHORIZATION STUDY	MARIA GUIL GARCIA	Not applicable
A-06	Estudio de fase IV, multicéntrico, aleatorizado, doble ciego y controlado con placebo de la eficacia, seguridad, tolerabilidad y calidad de vida de un tratamiento en curso hipolipemiente, optimizado individualmente, con o sin inclisiran (KJX839), en participantes con hipercolesterolemia.	COMMERCIAL CLINICAL TRIAL	SERGIO JANSEN CHAPARRO	IV
A-06	Estrategias de control y estudio farmacogenético para el tratamiento personalizado del hígado graso asociado a disfunción metabólica en pacientes con prediabetes.	INDEPENDENT CLINICAL TRIAL	RICARDO GÓMEZ HUELGAS	III
A-06	Estudio de fase II, prospectivo, en doble ciego, aleatorizado, de grupos paralelos, controlado con placebo y multicéntrico, para investigar la eficacia, el efecto neutralizador de los autoanticuerpos frente a los receptores acoplados a la proteína G (GPCR), la seguridad y la tolerabilidad del BC 007 en participantes con COVID-19 persistente	CLINICAL TRIALS WITH DRUGS	RICARDO GÓMEZ HUELGAS	II
A-06	Evaluación de la seguridad de Edoxabán en pacientes ancianos con criterios de fragilidad	OBSERVATIONAL STUDIES WITH DRUGS	RICARDO GÓMEZ HUELGAS	Not applicable
A-06	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisiran en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-PREVENT)	CLINICAL TRIALS WITH DRUGS	SERGIO JANSEN CHAPARRO	III
A-06	Estudio observacional retrospectivo para describir las características y resultados clínicos de pacientes con Lupus Eritematoso Sistémico que iniciaron Saphnelo (anifrolumab) en un entorno en vida real. D3461R00080 AZAHAR	OBSERVATIONAL STUDIES WITH DRUGS	CARLOS ROMERO GOMEZ	Not applicable
A-09	Registro de pacientes con enfermedad del Hígado graso no alcohólico	NON-POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	Not applicable
A-09	Revisión observacional en serie de historias clínicas del uso de Repath® en sujetos europeos con hiperlipidemia (20130296)	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	Not applicable
A-09	Manejo del paciente dislipémico pre-diabético en las unidades de lípidos. Estudio PRELIPID	INDEPENDENT POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	Not applicable

Group	Title	Subtype	LR Name	Phase
A-09	Estudio epidemiológico, multicéntrico y transversal para caracterizar la prevalencia y distribución de los niveles de lipoproteína (a) en pacientes con enfermedad cardiovascular establecida.	NON-POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	Not applicable
A-09	Registro informatizado de la enfermedad tromboembólica (RIETE)	NON-POST-AUTHORIZATION STUDY	RADKA IVANOVA GIORGIEVA	Not applicable
A-09	Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos cardiovasculares en Europa -Estudio Multinacional Observacional. Estudio SANTORINI (DSE-HCL-01-19)	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	Not applicable
A-09	Estudio multicéntrico sobre comorbilidad no infecciosa e inmunodeficiencia común variable	INDEPENDENT POST-AUTHORIZATION STUDY	JUAN LUIS CARRILLO LINARES	Not applicable
A-09	Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar el efecto de la disminución de la lipoproteína (a) con TQJ230 sobre los acontecimientos cardiovasculares mayores en pacientes con enfermedad cardiovascular (ECV) establecida.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	III
A-09	Estudio multicéntrico, aleatorizado y de dos partes (inclirán doble ciego frente a placebo [año 1] y a continuación inclirán abierto [año 2]) para evaluar la seguridad, tolerabilidad y eficacia de inclirán en adolescentes (de 12 a menos de 18 años de edad) con hipercolesterolemia familiar heterocigótica y colesterol LDL elevado (ORION-16).	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	III
A-09	Estudio de seguridad posterior a la autorización y registro de producto de WAYLIVRA. (WAY4001)	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	Not applicable
A-09	Seguridad de edoxabán en pacientes con fibrilación auricular no valvular (FANV) y diabetes mellitus tipo 2 (DM2). SEMI-FADIA-2020	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA JOSE BENITEZ TOLEDO	Not applicable
A-09	Valoración del manejo y adecuación del tratamiento antitrombótico de los pacientes con Fibrilación Auricular No Valvular que ingresan en los Servicios de Medicina Interna de España.	COMMERCIAL POST-AUTHORIZATION STUDY	MARIA JOSE BENITEZ TOLEDO	Not applicable
A-09	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CARLOS DE LA CRUZ COSME	Not applicable
A-09	Obicetrapib añadido a tratamientos modificadores de los lípidos máximos tolerados (BROOKLYN): Estudio de fase 3, aleatorizado, con doble enmascaramiento y comparativo con placebo para evaluar el efecto de 10?mg de obicetrapib en participantes con antecedentes de HFHe y C-LDL =70?mg/dl no controlados adecuadamente con sus tratamientos modificadores de los lípidos	CLINICAL TRIALS WITH DRUGS	PEDRO VALDIVIELSO FELICES	III
A-09	Estudio de fase 3, aaleatorizado, doble ciego, controlado con placebo, de olezarsen (ISIS678354) asministrado por vía subcutánea a pacientes con hipertrigliceridemia grave.	CLINICAL TRIALS WITH DRUGS	PEDRO VALDIVIELSO FELICES	III
A-09	Estudio de fase III, aleatorizado, doble ciego, comparativo con placebo, de olezarsén (ISIS 679354) en pacientes con hipertrigliceridemia y enfermedad cardiovascular aterosclerótica (establecida o con mayor riesgo de ella), o con hipertrigliceridemia grave	CLINICAL TRIALS WITH DRUGS	PEDRO VALDIVIELSO FELICES	III
A-09	Estudio de fase 2b, multinacional, aleatorizado y doble ciego para investigar la eficacia y la seguridad de redasemtide (S-005151) comparado con placebo en pacientes mayores de edad con ictus isquémico agudo que no son candidatos a tratamiento con activador tisular del plasminógeno o trombectomía.	CLINICAL TRIALS WITH DRUGS	ALEJANDRO GALLARDO TUR	II
A-09	Estudio de extensión abierto de Olezarsen (ISIS 678354) administrado por vía subcutánea a pacientes con hipertrigliceridemia grave	CLINICAL TRIALS WITH DRUGS	INMACULADA COCA PRIETO	III
A-09	Estudio aleatorizado, doble ciego con doble enmascaramiento y grupos paralelos en el que secompara la eficacia y seguridad de remibrutinib frente a teriflunomida en participantes con esclerosismúltiple recurrente, seguido de una extensión abierta del tratamiento con remibrutinib.	CLINICAL TRIALS WITH DRUGS	CARLOS DE LA CRUZ COSME	III
A-09	Un ensayo clínico fase IV adaptativo, multicéntrico, controlado, aleatorizado y simple ciego para evaluar la efecacia, seguridad y coste eficacia de una estrategia de fenotipado anticipado en una población en riesgo de enfermedad cardiovascular y susceptible de recibir de estatinas de alta o moderada intensidad.	CLINICAL TRIALS WITH DRUGS	INMACULADA COCA PRIETO	IV

Group	Title	Subtype	LR Name	Phase
A-09	Estudio no intervencionista sobre el tratamiento con ácido bempedoico y/o su combinación de dosis fija con ezetimiba en la práctica clínica habitual en pacientes con hipercolesterolemia primaria o dislipidemia mixta (MILOS)	OBSERVATIONAL STUDIES WITH DRUGS	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	Not applicable
A-19	ESTUDIO OBSERVACIONAL, PROSPECTIVO Y MULTICÉNTRICO A LARGO PLAZO EN UNA COHORTE DE NIÑOS CON TALLA BAJA NACIDOS PEQUEÑOS PARA SU EDAD GESTACIONAL (PEG) QUE HAN SIDO TRATADOS CON SAIZEN. Estudio SALTO	COMMERCIAL POST-AUTHORIZATION STUDY	JUAN PEDRO LÓPEZ SIGUERO	Not applicable
A-19	Kuvan Adult Maternal Pediatric European Registry (KAMPER)	NON-POST-AUTHORIZATION STUDY	JAVIER BLASCO ALONSO	Not applicable
A-19	Seguimiento hasta la talla adulta de una cohorte de sujetos nacidos pequeños para la edad gestacional y tratados con hormonas del crecimiento	COMMERCIAL POST-AUTHORIZATION STUDY	JUAN PEDRO LÓPEZ SIGUERO	Not applicable
A-19	VIGILANCIA POSTCOMERCIALIZACIÓN PARA CONTROLAR LA SEGURIDAD Y EFICACIA A LARGO PLAZO DE OMNITROPE EN NIÑOS Y ADOLESCENTES (PATRO CHILDREN)	COMMERCIAL POST-AUTHORIZATION STUDY	JUAN PEDRO LÓPEZ SIGUERO	Not applicable
A-19	Estudio postautorización de seguridad (EPAS) no intervencional para evaluar la seguridad a largo plazo del tratamiento con Orfadin en la Tirosinemia hereditaria tipo 1 (TH-1) en la práctica clínica estándar	COMMERCIAL POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Estudio clínico multicéntrico, aleatorizado, doble ciego, controlado para evaluar los efectos en el crecimiento, la seguridad y la tolerancia de una leche infantil a base de proteína hidrolizada de arroz comparada con una leche infantil de proteína de leche de vaca extensamente hidrolizada en el manejo de la alergia a la proteína de la leche de vaca (APLV) en lactantes	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Estudio de seguimiento para evaluar la seguridad y los resultados a largo plazo en lactantes nacidos de madres que participaron en los estudios de tratamiento con retosibán	COMMERCIAL CLINICAL TRIAL	TOMÁS SÁNCHEZ TAMAYO	III
A-19	Ensayo internacional, aleatorizado y controlado para el tratamiento del sarcoma de Ewing de diagnóstico reciente (EE2012)	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	III
A-19	Registro español informatizado de pacientes con Bronquiectasias	NON-POST-AUTHORIZATION STUDY	ESTELA PÉREZ RUIZ	Not applicable
A-19	Ensayo internacional, aleatorizado y controlado de quimioterapia para el tratamiento del sarcoma de Ewing recurrente o refractario	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II
A-19	Validación de la dosis única diaria de isoniazida a 10 mg/kg de peso en el lactante menor de 3 meses de vida.	INDEPENDENT POST-AUTHORIZATION STUDY	DAVID MORENO PÉREZ	Not applicable
A-19	Un registro no intervencionista a largo plazo para evaluar la seguridad y efectividad de HUMIRA (adalimumab) en pacientes pediátricos con enfermedad de Crohn (EdC) activa entre moderada y grave (CAPE). P11-292	COMMERCIAL POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Efectos de la suplementación con probióticos durante el periodo neonatal sobre el recién nacido prematuro.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	TOMÁS SÁNCHEZ TAMAYO	Not applicable
A-19	European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II
A-19	LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	II
A-19	Factores farmacogenómicos y monitorización terapéutica como predictores de respuesta a anti-TNFs en enfermedad inflamatoria intestinal en niños	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Ensayo aleatorizado y doble ciego de fase IIIb para evaluar la seguridad y la eficacia de 2 regímenes de tratamiento con Aztreonam 75 mg polvo y disolvente para solución para inhalación por nebulizador / Aztreonam solución para inhalación (AZLI) en pacientes pediátricos con fibrosis quística (FQ) e infección/colonización de las vías respiratorias por Pseudomonas aeruginosa (PA) de nueva aparición	COMMERCIAL CLINICAL TRIAL	ESTELA PÉREZ RUIZ	III
A-19	Estudio prospectivo internacional de Meduloblastoma riesgo estándar clínico en niños de 3 a 5 años con perfil bajo de riesgo biológico (PNET 5 MB-LR) o perfil-medio de riesgo biológico (PNET 5 MB-SR)	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II

Group	Title	Subtype	LR Name	Phase
A-19	Estudio abierto, aleatorizado, controlado en grupos paralelos para evaluar la seguridad, la farmacocinética y el control de amonio de RAVICTI® (fenilbutirato de glicerol [GPB]) líquido oral y del fenilbutirato de sodio (NaPBA) en pacientes que padecen trastornos del ciclo de la urea (TCU) y que no han recibido previamente tratamiento con fenilbutirato	COMMERCIAL CLINICAL TRIAL	JAVIER BLASCO ALONSO	III
A-19	Estudio Fase IIb, 2-brazos, aleatorizado, Doble-ciego, Placebo-Controlado, Multicéntrico para Optimizar la terapia de Diamyd® Administrada dentro de los ganglios linfáticos combinados con la vitamina D oral para investigar el impacto en la progresión de la diabetes tipo 1.	COMMERCIAL CLINICAL TRIAL	ISABEL LEIVA GEA	II
A-19	Registro Nacional de pacientes con Diabetes tipo 1	INDEPENDENT POST-AUTHORIZATION STUDY	JUAN PEDRO LÓPEZ SIGUERO	Not applicable
A-19	Estudio de Fase I, abierto y aleatorizado para evaluar la farmacocinética, la farmacodinamia y la seguridad de ETROLIZUMAB seguido de una extensión abierta y una vigilancia de la seguridad en pacientes pediátricos de entre 4 y menos de 18 años de edad con colitis ulcerosa o enfermedad de CROHN moderada o grave.	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	I
A-19	Ensayo internacional pediátrico en tumor hepático	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	III
A-19	Ensayo de fase III, para evaluación de la eficacia y la seguridad de los comprimidos sublinguales de inmunoterapia frente a ácaros del polvo doméstico, en niños y adolescentes (de 5 a 17 años) con asma alérgica inducida por ácaros del polvo doméstico	COMMERCIAL CLINICAL TRIAL	CANDELARIA MUÑOZ ROMAN	III
A-19	Estudio Nacional de vigilancia de infección nosocomial en UCI. (ENVIN-HELICS)	INDEPENDENT POST-AUTHORIZATION STUDY	PATRICIA GARCÍA SOLER	Not applicable
A-19	Estudio fase 3 aleatorizado, abierto, para evaluar la Eficacia, Seguridad y Farmacocinética del tratamiento de Golimumab, un anticuerpo humano monoclonal anti-TNFα, administrado por vía subcutánea en pacientes pediátricos con Colitis Ulcerosa activa de moderada a severa.	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated with Distributive Shock	COMMERCIAL CLINICAL TRIAL	ANTONIO MORALES MARTINEZ	II
A-19	Investigación integrada y guías para diagnóstico y terapia estandarizados de tumores de riñón en niños, adolescentes y adultos jóvenes. UMBRELLA SIOP-RTSG 2016	NON-POST-AUTHORIZATION STUDY	GUIOMAR GUTIERREZ SCHIAFFINO	Not applicable
A-19	Estudio observacional multicéntrico de pacientes con parálisis cerebral: aspectos neurológicos y nutricionales	NON-POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Estudio en fase II/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en niños de alto riesgo (MEDLEY)	COMMERCIAL CLINICAL TRIAL	PILAR CARO AGUILERA	III
A-19	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. GIS-DUMBO-2018	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Estudio en fase 3, aleatorizado, enmascarado para el evaluador y multicéntrico para evaluar la eficacia y seguridad de ALXN1840 administrado durante 48 semanas en comparación con el tratamiento de referencia en pacientes con enfermedad de Wilson de 12 años de edad o más con un período de extensión de hasta 60 meses	COMMERCIAL CLINICAL TRIAL	MARÍA JULIANA SERRANO NIETO	III
A-19	Marcadores genéticos,transcriptómicos y celulares de respuesta a terapia biológica en enfermedad inflamatoria intestinal pediátrica	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Ensayo Clínico Fase I para establecer la seguridad del uso de células mesenquimales troncales fetales alogénicas de cordón umbilical expandidas en pacientes prematuros con displasia broncopulmonar..	INDEPENDENT CLINICAL TRIAL	TOMÁS SÁNCHEZ TAMAYO	I
A-19	Diseño y validación psicométrica de un conjunto de cuestionarios “Toolbox” para evaluar los resultados de salud en atrofia muscular espinal desde el punto de vista del paciente. Estudio SMA TOOL. Spnosor protocol code: ML41962	NON-POST-AUTHORIZATION STUDY	ROCIO CALVO MEDINA	Not applicable

Group	Title	Subtype	LR Name	Phase
A-19	Estudio aleatorizado con control activo para comparar la eficacia y la seguridad de isoflurano inhalado administrado mediante el dispositivo AnaConDa-S (dispositivo de conservación de anestésico) con midazolam intravenoso para la sedación en pacientes pediátricos con ventilación mecánica de entre 3 y 17 años (menos de 18 años). IsoCOMFORT Study	COMMERCIAL CLINICAL TRIAL	PILAR SÁNCHEZ YAÑEZ	III
A-19	Estudio de Fase III, Abierto y Multicéntrico para Evaluar la Eficacia y Seguridad de Darvadstrocel en el Tratamiento de la Fístula Perianal Compleja en Población Pediátrica con Enfermedad de Crohn Durante 24 Semanas y un período de seguimiento extendido de hasta 52 semanas	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	Estudio multicéntrico, sin enmascaramiento, con un grupo de referencia con adalimumab, para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de ixekizumab por vía subcutánea en niños con los subtipos de artritis idiopática juvenil: artritis relacionada con entesitis (incluida la espondilitis anquilosante de aparición durante la infancia) y artritis psoriásica juvenil	COMMERCIAL CLINICAL TRIAL	ESMERALDA NUÑEZ CUADROS	III
A-19	Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al Virus Respiratorio Sincitial (VRS), administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la Enfermedad vías respiratorias Bajas (EVRB) asociada al VRS en sus hijos hasta los 6 meses de edad. RSV-MAT-009	COMMERCIAL CLINICAL TRIAL	BEGOÑA CARAZO GALLEGO	III
A-19	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de 2 partes, para evaluar pautas de tratamiento de EDP-938 en pacientes de 28 días a 24 meses de edad con infección por el virus respiratorio sincitial (VRS) RSVPEDs	COMMERCIAL CLINICAL TRIAL	PILAR CARO AGUILERA	II
A-19	Un estudio global para niños y adultos con Rabdomiosarcoma recién diagnosticado y recidivante. FaR-RMS	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	I
A-19	Registro ALERGODATA	INDEPENDENT POST-AUTHORIZATION STUDY	CANDELARIA MUÑOZ ROMAN	Not applicable
A-19	Ensayo clínico para evaluar la eficacia y seguridad de la adición de la granulocitoféresis al tratamiento con Infliximab en pacientes pediátricos con colitis ulcerosa corticorresistente	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Registro observacional sobre la enfermedad y los resultados clínicos de pacientes con deficiencia de lipasa ácida lisosomal (LAL)	NON-POST-AUTHORIZATION STUDY	JAVIER BLASCO ALONSO	Not applicable
A-19	Estudio de inducción abierto y de mantenimiento de CP-690,550 (Tofacitinib) oral en niños con colitis ulcerosa de moderada a gravemente activa	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	Registro Español de Artritis Idiopática Juvenil Sistémica (AIJS) y Enfermedad de Still del Adulto	NON-POST-AUTHORIZATION STUDY	ESMERALDA NUÑEZ CUADROS	Not applicable
A-19	Estudio observacional y abierto en niños y adolescentes con asma grave con fenotipo eosinofílico tratados con mepolizumab. Estudio CASAM	REST OF OBSERVATIONAL STUDIES WITH DRUGS	PILAR CARO AGUILERA	Not applicable
A-19	Beneficio de los programas de transición de pediatría a gastroenterólogos de adultos en pacientes con enfermedad inflamatoria intestinal. Estudio BUTTERFLY	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Ensayo clínico aleatorizado doble ciego comparando noradrenalina más placebo versus noradrenalina más terlipresina en shock séptico	INDEPENDENT CLINICAL TRIAL	PILAR CARO AGUILERA	III
A-19	Ensayo de 6 meses multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad, farmacocinética y farmacodinámica de un régimen de finerenona oral, ajustado por edad y peso corporal, añadido a un IECA o ARA II para el tratamiento de pacientes pediátricos de 6 meses a <18 años con enfermedad renal crónica y proteinuria	COMMERCIAL CLINICAL TRIAL	VERONICA MARTINEZ RIVERA	III
A-19	Estudio con enmascaramiento doble, controlado con placebo, de aumento progresivo de la dosis ara evaluar la eficacia, la seguridad y la farmacocinética de la voclosporina en adolescentes con nefritis lúpica	COMMERCIAL CLINICAL TRIAL	FRANCISCO ANTONIO NIETO VEGA	III
A-19	Estudio multicéntrico, abierto, de búsqueda de dosis, de dosis única y múltiples, con una extensión abierta opcional para evaluar la seguridad, tolerabilidad y farmacocinética del ácido obeticólico en sujetos pediátricos con atresia biliar	COMMERCIAL CLINICAL TRIAL	JAVIER BLASCO ALONSO	II

Group	Title	Subtype	LR Name	Phase
A-19	Estudio en fase III para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario	CLINICAL TRIALS WITH DRUGS	CANDELARIA MUÑOZ ROMAN	III
A-19	Estudio integral, en canasta, abierto, sobre la seguridad y la farmacocinética de Daprodustat para tratar la anemia asociada a la enfermedad renal crónica en niños y adolescentes de ambos sexos de entre 3 meses y menos de 18 años, necesiten o no diálisis.	CLINICAL TRIALS WITH DRUGS	FRANCISCO ANTONIO NIETO VEGA	III
A-19	Estudio aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de taldefgrobep alfa en participantes ambulatorios y no ambulatorios con atrofia muscular espinal con extensión abierta (RESILIENT)	CLINICAL TRIALS WITH DRUGS	ROCIO CALVO MEDINA	III
A-19	Estudio de cohortes prospectivo, observacional, de canasta e integral de niños y adolescentes menores de 18 años con anemia asociada a la enfermedad renal crónica que requieren o no diálisis.	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO ANTONIO NIETO VEGA	Not applicable
A-19	Registro de Pfizer de los resultados en la investigación sobre la hormona del crecimiento (PROGRES) Estudio de cohortes prospectivo, no intervencionista e internacional entre pacientes con tratamientos con hormona del crecimiento humana (hGH) bajo atención clínica habitual	OBSERVATIONAL STUDIES WITH DRUGS	JUAN PEDRO LÓPEZ SIGUERO	Not applicable
A-19	Estudio aleatorizado. doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y seguridad de la terapia adyuvante de Cenobamato en pacientes con crisis tónico-clónicas generalizadas primarias.	CLINICAL TRIALS WITH DRUGS	ROCIO CALVO MEDINA	III
A-19	Un estudio de extensión abierto para evaluar la seguridad y eficacia a largo plazo de devoclosporina en sujetos adolescentes con nefritis lúpica	CLINICAL TRIALS WITH DRUGS	FRANCISCO ANTONIO NIETO VEGA	III
A-19	Estudio del Neuroblastoma de alto riesgo 2.0 de SIOPEuropa-Neuroblastoma/SIOPEN Estudio internacional, multicéntrico y aleatorizado de fase III, que evalúa y compara dos estrategias de tratamiento en tres fases terapéuticas (inducción, quimioterapia de altas dosis y radioterapia) para pacientes con neuroblastoma de alto riesgo.	CLINICAL TRIALS WITH DRUGS	LAURA GARCIA HIDALGO	III
A-19	Estudio aleatorizado de fase III, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de la inmunoterapia epicutánea con DBV712 250 µg en niños de entre 4 y 7 años con alergia al cacahuete.	CLINICAL TRIALS WITH DRUGS	CANDELARIA MUÑOZ ROMAN	III
A-19	Estudio observacional retrospectivo para evaluar el manejo diagnóstico y terapéutico del Síndrome de Noonan en España/ retrospective observational study to assess the diagnostic and therapeutic management of noonan syndrome in Spain.	OBSERVATIONAL STUDIES WITH DRUGS	JUAN PEDRO LÓPEZ SIGUERO	Not applicable
A-19	Ensayo de extensión de seguridad de 18 meses, abierto y de un solo brazo, de un régimen de finerenona oral, ajustado por edad y peso corporal, añadido a un IECA o ARA II para el tratamiento de pacientes pediátricos y adultos jóvenes de 1 a 18 años con enfermedad renal crónica y proteinuria.	CLINICAL TRIALS WITH DRUGS	VERONICA MARTINEZ RIVERA	III
A-19	Manejo terapéutico y situación actual de uso de recursos y costes de la Atrofia Muscular Espinal (AME) en España: análisis retrospectivo, multicéntrico de revisión de historias clínicas. Estudio TREaSURE	OBSERVATIONAL STUDIES WITH DRUGS	ROCIO CALVO MEDINA	Not applicable
A-19	Estudio de fase 3 multicéntrico para evaluar la eficacia, seguridad y farmacocinética de la inducción de upadacitinib en régimen abierto, aleatorizado, mantenimiento doble ciego y extensión abierta a largo plazo en sujetos pediátricos con colitis ulcerosa activa de moderada a severa y con respuesta insuficiente, intolerancia o contraindicaciones médicas al tratamiento con corticosteroides, inmunosupresores o terapias biológicas.	CLINICAL TRIALS WITH DRUGS	RAFAEL MARTIN MASOT	III
A-19	Estudio de fase III, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para evaluar la farmacocinética, farmacodinamia, eficacia y seguridad de anifrolumab intravenoso en participantes pediátricos de entre 5 y <18 años de edad con lupus eritematoso sistémico activo de moderado a severo que reciben tratamiento estándar de base	CLINICAL TRIALS WITH DRUGS	ROCIO GALINDO ZAVALA	III
A-19	Ensayo Clínico Fase II para establecer la seguridad del uso de células mesenquimales troncales fetales alogénicas de cordón umbilical expandidas en pacientes prematuros con displasia broncopulmonar	CLINICAL TRIALS WITH DRUGS	NATALIA SALDAÑA GARCÍA	II

Group	Title	Subtype	LR Name	Phase
A-19	A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension	CLINICAL TRIALS WITH DRUGS	JAVIER BLASCO ALONSO	II
A-19	Estudio multicéntrico de fase 3 para evaluar la farmacocinética, la eficacia y la seguridad de risankizumab en periodo inducción abierto, mantenimiento aleatorizado dobleciego y periodos de extensión a largo plazo en pacientes pediátricos (de 2 a < 18 años de edad) con enfermedad de Crohn activa de moderada a grave	CLINICAL TRIALS WITH DRUGS	PILAR ORTIZ PEREZ	III
A-19	Observational multicentre RWE study to characterize neurofibromatosis type1 (NF1) diagnosed patients with plexiform neurofibromas (PN) in Spain. “MULtyMATin Study	OBSERVATIONAL STUDIES WITH DRUGS	LAURA GARCIA HIDALGO	Not applicable
A-19	Alergopediátrica. Estudio epidemiológico de las enfermedades alérgicas pediátricas en España	OBSERVATIONAL STUDIES WITH DRUGS	CANDELARIA MUÑOZ ROMAN	Not applicable
A-19	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños (registro DUMBO)	CLINICAL TRIALS WITH DRUGS	VÍCTOR MANUEL NAVAS LÓPEZ	II
A-19	Estudio multicéntrico de fase III para evaluar la eficacia, seguridad y farmacocinética de upadacitinib en una inducción abierta, un mantenimiento aleatorizado doble ciego y una extensión abierta a largo plazo en pacientes pediátricos con enfermedad de Crohn activa de moderada a grave y respuesta inadecuada, intolerancia o contraindicaciones médicas a los corticosteroides, inmunodepresores y/o tratamientos biológicos.	CLINICAL TRIALS WITH DRUGS	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	Understanding the long-term Management of Organic Acidemia Patients with CARBAGLU®: A Mixed Methods Approach	OBSERVATIONAL STUDIES WITH DRUGS	JAVIER BLASCO ALONSO	Not applicable
A-19	Uso del Isavuconazole en pediatría. Una alternativa atractiva para las infecciones fúngicas invasivas.	OBSERVATIONAL STUDIES WITH DRUGS	BEGOÑA CARAZO GALLEG0	Not applicable
A-19	Eficacia y seguridad de la tirzepatida administrada una vez a la semana en comparación con un placebo en el tratamiento de la obesidad y enfermedades asociadas con el peso en adolescentes: estudio aleatorizado, con enmascaramiento doble y comparativo con un placebo (SURMOUNT-ADOLESCENTS-2).	CLINICAL TRIALS WITH DRUGS	ISABEL LEIVA GEA	III
A-19	Un estudio abierto, multicéntrico, de un solo grupo para evaluar la seguridad, tolerabilidad y farmacocinética de Vaborem (meropenem-vaborbactam) en población pediátrica con infecciones urinarias complicadas incluida pielonefritis aguda	CLINICAL TRIALS WITH DRUGS	FRANCISCO ANTONIO NIETO VEGA	II
A-19	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. Registro DUMBO 2	OBSERVATIONAL STUDIES WITH DRUGS	VÍCTOR MANUEL NAVAS LÓPEZ	Not applicable
A-19	Estudio multicéntrico, aleatorizado y de dos partes (inclirán doble ciego frente a placebo [año 1] y, a continuación, inclirán abierto [año 2]) para evaluar la seguridad, tolerabilidad y eficacia de inclirán en niños (de 6 a menos de 12 años de edad) con hipercolesterolemia familiar heterocigótica y colesterol LDL elevado (ORION-20).	CLINICAL TRIALS WITH DRUGS	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-21	Evaluación de la nefroprotección en cirugía cardíaca de sustitución valvular aórtica del desflurano en comparación con el propofol	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE LUIS GUERRERO ORRIACH	Not applicable
A-21	Análisis de la expresión de microRNAs en pacientes sometidos a cirugía cardíaca tratados con anestésicos halogenados. Identificación de microRNAs relacionados con el efecto cardioprotector	INDEPENDENT CLINICAL TRIAL	JOSE LUIS GUERRERO ORRIACH	IV
A-21	Mecanismos de cardio y nefroprotección en pacientes que van a ser intervenidos de cirugía cardíaca con disfunción ventricular derecha, con tratamiento preoperatorio de levosimendán en comparación con placebo. (PRELEV-D-Estudio piloto)	INDEPENDENT CLINICAL TRIAL	JOSE LUIS GUERRERO ORRIACH	III
A-23	Un estudio de no inferioridad de fase IIb, doble ciego, aleatorizado, con control activo, multicéntrico, seguido de un estudio de fase III, de un solo brazo y abierto, para evaluar la inmunogenicidad y la seguridad de una vacuna de refuerzo con un candidato de proteína recombinante dimerica de fusión RBD (PHH-1V) contra el SARS-CoV-2, en adultos completamente vacunados contra COVID-19	COMMERCIAL CLINICAL TRIAL	MARIA DEL MAR VAZQUEZ JIMENEZ	II

Group	Title	Subtype	LR Name	Phase
A-23	A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19	CLINICAL TRIALS WITH DRUGS	MARIA JESUS LOPEZ FERNANDEZ	II
A-23	A prospective study to evaluate the immune status in the elderly after receiving a booster dose under the Covid-19 vaccination program in Spain. N Covid Senior II, a substudy of Covidvac@spain.	OBSERVATIONAL STUDIES WITH DRUGS	BLANCA O'DONNELL CORTÉS	Not applicable
A-23	A Phase IIb/III, open label, single arm, multi-centre, clinical trial to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.	CLINICAL TRIALS WITH DRUGS	MARIA JESUS LOPEZ FERNANDEZ	III
AA-04	Tratamiento antiagregante en el síndrome coronario agudo. Seguridad y eficacia del cruce entre antiagregantes.	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA NIETO GONZÁLEZ	Not applicable
AA-04	STrategic Reperfusion in elderly patients Early After Myocardial Infarction. STREAM-2	INDEPENDENT CLINICAL TRIAL	MARÍA NIETO GONZÁLEZ	IV
AA-04	Tratamiento antiplaquetario en síndromes coronarios agudos. Seguridad y eficacia del cambio de antiplaquetario. Seguridad y eficacia de Tricagrelor VS Clopidogrel en pacientes con síndrome coronario agudo.Antiplatelet treatment in acute coronary syndromes. safety and efficacy of antiplatelet switching. Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients with Acute Coronary Syndrome.	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ANTONIA ESTECHA FONCEA	Not applicable
AA-15	Un estudio prospectivo, aleatorizado, multicéntrico para evaluar la seguridad y la eficacia del sistema de stent coronario liberador de sirolimus en el tratamiento de pacientes con hasta tres lesiones arteriales coronarias de novo o reestenóticas”. Estudio BIOFLOW-V	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Factores de riesgo asociados con la progresión de la Insuficiencia Cardíaca (IC) en pacientes con fibrilación auricular tratados con un anticoagulante oral directo (rivaroxaban). Estudio FARAONIC	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MARÍA PÉREZ RUIZ	Not applicable
AA-15	Registro Observacional Prospectivo de Pacientes con Insuficiencia Cardíaca	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MARÍA PÉREZ RUIZ	Not applicable
AA-15	Estudio observacional para evaluar el beneficio clínico neto del edoxabán en pacientes con fibrilación auricular no valvular, según la práctica clínica habitual en España Registro BENEFIT.Observational study to evaluate the Net Clinical Benefit of edoxaban in non-valvular Atrial Fibrillation patients, according to the routine clinical practice in Spain BENEFIT Registry	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA GARCÍA BELLÓN	Not applicable
AA-15	AF en la práctica real sobre el manejo de la anticoagulación oral - AFIRMA 4.0 (B0661131)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS DELGADO PRIETO	Not applicable
AA-15	Estudio observacional para evaluar la evolución clínica de pacientes de alto riesgo sometidos a intervención coronaria percutánea (ICP), con implante de stents liberadores de everolimus, utilizando técnicas intracoronarias para guiar y optimizar la ICP	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Estudio aleatorizado paralelo para evaluar la utilidad de la revisión angiográfica rutinaria 6 meses después del intervencionismo percutáneo en el tronco coronario izquierdo. Estudio ANGELINE	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Establecimiento de una referencia para la utilización de recursos y la calidad de asistencia en pacientes sometidos a la implantación transcatóter de una válvula aórtica en Europa	REST OF OBSERVATIONAL STUDIES WITH DRUGS	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Registro prospectivo del stent ihtDESTiny en práctica clínica habitual(Estudio VELAZQUEZ)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria	INDEPENDENT CLINICAL TRIAL	CRISTOBAL ANTONIO URBANO CARRILLO	IV
AA-15	Ensayo VERifyNow para Optimizar la iNhibición plaquetarla en el síndrome Coronario Agudo (VERONICA)	CLINICAL TRIALS WITH DRUGS	CRISTOBAL ANTONIO URBANO CARRILLO	IV
AA-15	EARLY treatment with Candesartan vs Placebo in asymptomatic GENetic carriersof Dilated Cardiomyopathy (EARLY-GENE trial).	CLINICAL TRIALS WITH DRUGS	ANA MARÍA GONZALEZ GONZALEZ	III
AA-15	Registro de seguimiento clínico postcomercialización en cirugía cardiaca de Medtronic -Cardiac Surgery Post Market (CSPM) Clinical Follow up Registry	CLINICAL RESEARCH WITH MEDICAL DEVICES	ENRIQUE RUIZ ALONSO	Not applicable

Group	Title	Subtype	LR Name	Phase
AA-15	Registro PERSEO: Prevención de eventos Embólicos tras una hemoRragia SEvera en pacientes anticoagulados con fibrilaciOn auricular.	OBSERVATIONAL STUDIES WITH DRUGS	JOSÉ LUIS DELGADO PRIETO	Not applicable
AA-15	Plan de investigación de seguimiento poscomercialización (PMCF) para evaluar la seguridad y efectividad del dispositivo liberador de paclitaxel SEQUENT PLEASE NEO en pacientes con enfermedad arterial coronaria	CLINICAL RESEARCH WITH MEDICAL DEVICES	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Estudio multicéntrico prospectivo no aleatorizado, de una cohorte no seleccionada de pacientes con diagnóstico de amiloidosis cardiaca por transtiretina que inicien tratamiento diario con tafamidis 61 mg.	OBSERVATIONAL STUDIES WITH DRUGS	ANA MARÍA GONZALEZ GONZALEZ	Not applicable
AA-15	Crioablación de Fibrilación Auricular guiada por Ondas de Presión: Registro POLAR-WAVE	CLINICAL RESEARCH WITH MEDICAL DEVICES	GABRIEL BALLESTEROS DERBENTI	Not applicable
AA-15	Estudio RIESCAR. Riesgo cardiovascular de la población atendida por Cardiólogos en España.	OBSERVATIONAL STUDIES WITH DRUGS	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with ST-segment elevation myocardial infarction. COPERNICAN TRIAL	CLINICAL RESEARCH WITH MEDICAL DEVICES	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Resultados isquémicos y hemorrágicos tras la implantación del stent angiolite y una terapia antiplaquetaria dual abreviada. Un ensayo controlado aleatorizado, multicéntrico, factorial 2x2, de todos los participantes elegibles (allcomers) Angiodapt.”	CLINICAL TRIALS WITH DRUGS	CRISTOBAL ANTONIO URBANO CARRILLO	III
AA-15	Evaluación de la viabilidad y seguridad de un protocolo de alta muy precoz tras implante de TAVI.	CLINICAL RESEARCH WITH MEDICAL DEVICES	CRISTOBAL ANTONIO URBANO CARRILLO	Not applicable
AE-11	Estudio posautorización de seguridad multicéntrico y no intervencionista de 6 años de duración realizado en pacientes a los que se ha recetado JINARC debido a poliquistosis renal autosómica dominante. Estudio 156-12-299	COMMERCIAL POST-AUTHORIZATION STUDY	Mª DOLORES MARTÍNEZ ESTEBAN	Not applicable
AE-11	Impacto de los niveles de tacrólimus en la prevención del rechazo en pacientes de edad avanzada receptores de trasplante renal de novo: estudio observacional prospectivo en las condiciones de la práctica clínica habitual. Estudio BITÁCORA	COMMERCIAL POST-AUTHORIZATION STUDY	VERONICA LÓPEZ JIMÉNEZ	Not applicable
AE-11	Estudio de fase II, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de ravulizumab en participantes adultos con nefritis lúpica (NL) proliferativa o nefropatía por inmunoglobulina A (NIgA)	COMMERCIAL CLINICAL TRIAL	REMEDIOS TOLEDO ROJAS	II
AE-11	Desarrollo y validación de la escala Neuro-Score for Transplanted Patients para la detección del deterioro cognitivo en pacientes con trasplante renal o hepático tratados con inmunosupresores	NON-POST-AUTHORIZATION STUDY	VERONICA LÓPEZ JIMÉNEZ	Not applicable
AE-11	Prevalencia de fragilidad en pacientes con enfermedad renal crónica en lista de espera de trasplante renal en España: un estudio multicéntrico	COMMERCIAL POST-AUTHORIZATION STUDY	VERONICA LÓPEZ JIMÉNEZ	Not applicable
AE-11	Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico: estudio prospectivo, controlado y aleatorizado de grupos paralelos (TRAINING)	INDEPENDENT CLINICAL TRIAL	VERONICA LÓPEZ JIMÉNEZ	IV
AE-11	Estudio prospectivo observacional para evaluar el cambio en la calidad de vida relacionada con la salud y la productividad laboral en pacientes con síndrome hemolítico urémico atípico primario tratados con eculizumab y cambian a ravulizumab en España. Estudio PROMET-SHUa.	OBSERVATIONAL STUDIES WITH DRUGS	VERONICA LÓPEZ JIMÉNEZ	Not applicable
AE-11	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de LNP023 en pacientes con nefropatía por IgA primaria. APPLAUSE	CLINICAL TRIALS WITH DRUGS	REMEDIOS TOLEDO ROJAS	III
AE-11	Estudio de fase II, aleatorizado, doble ciego y controlado con placebo de búsqueda de dosis para evaluar la eficacia y la seguridad de ALXN2050 en participantes adultos con nefritis lúpica (NL) proliferativa o nefropatía por inmunoglobulina A (NIgA).	CLINICAL TRIALS WITH DRUGS	REMEDIOS TOLEDO ROJAS	II

Group	Title	Subtype	LR Name	Phase
AE-11	Estudio aleatorizado, doble ciego, controlado con placebo de ALE.F02 administrado por vía intravenosa para evaluar la seguridad, la tolerabilidad, la farmacocinética y la preservación renal en la vasculitis asociada con anticuerpos citoplasmáticos antineutrófilos con glomerulonefritis rápidamente progresiva	CLINICAL TRIALS WITH DRUGS	CANDELA MOLIZ CORDÓN	II
AE-11	Ensayo Fase III, aleatorizado, doble-cego, de grupos paralelos y controlado con principio activo para evaluar la eficacia, seguridad y tolerabilidad de Baxdrostat combinado con Dapagliflozina, comparado con Dapagliflozina sola en la progresión de Enfermedad Renal Crónica (ERC) en pacientes con ERC e hipertensión arterial. BaxDUO ARCTIC	CLINICAL TRIALS WITH DRUGS	BEATRIZ AVILES BUENO	III
AE-11	Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de Ravulizumab en participantes adultos con nefropatía por()	CLINICAL TRIALS WITH DRUGS	REMEDIOS TOLEDO ROJAS	III
AE-11	Estudio observacional posterior a la autorización de seguridad (PASS) en Europa para caracterizar y cuantificar mejor el perfil de seguridad a largo plazo en relación con la neurotoxicidad, la nefrotoxicidad crónica y las neoplasias malignas con el uso de voclosporina	OBSERVATIONAL STUDIES WITH DRUGS	PILAR HIDALGO GUZMAN	Not applicable
B-01	Estudio multicéntrico, doble ciego, randomizado, controlado con placebo, para comparar quimioterapia más trastuzumab y placebo con quimioterapia más trastuzumab y pertuzumab, como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo operable	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye quimioterapia estándar vs histotipo-dirigida neoadyuvante	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
B-01	Ensayo aleatorizado, fase III, de terapia endocrina adyuvante estándar +/-quimioterapia en pacientes con cáncer de mama positivo para receptores hormonales y negativo para HER2 con afectación de 1 a 3 ganglios y con un recurrence score (RS) de 25 o inferior	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo clínico multicéntrico fase III, randomizado para la comparación de la combinación de Epirubicina y Ciclofosfamida (EC) seguido de Docetaxel (T) con Epirubicina y Docetaxel (ET) seguido de Capecitabina (X) en el tratamiento adyuvante de pacientes con cáncer de mama operable y ganglios linfáticos axilares positivos	INDEPENDENT CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
B-01	Registro de sarcomas raros: Herramienta de ayuda para evaluar el número de casos de cada subtipo y su orientación terapéutica por el Grupo Español de Investigación en Sarcomas (GEIS)	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	Not applicable
B-01	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, de ARN-509 controlado con placebo en hombres con cáncer de próstata no metastásico (M0) y resistente a la castración.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio de fase III, aleatorizado, para evaluar cabazitaxel y radioterapia pelviana en pacientes con cáncer de próstata localizado con alto riesgo de recaída, según un diseño factorial. PEACE 2	INDEPENDENT CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	“Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante”. Estudio OLYMPIA.	COMMERCIAL CLINICAL TRIAL	ANTONIA MÁRQUEZ ARAGONÉS	III
B-01	Estudio de fase IIIb, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de continuar el tratamiento con enzalutamida en pacientes con cáncer de próstata resistente a la castración metastásico, que no han recibido quimioterapia previa, que han experimentado progresión al tratamiento con enzalutamida sola, tratados con docetaxel más prednisolona. Estudio PRESIDE	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de Próstata resistente a la castración tratados con doceTAxel o Cabazitaxel. Estudio PROSTAC	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	Not applicable
B-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de Próstata resistente a la castración tratados con doceTAxel o Cabazitaxel. Estudio PROSABI	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	Not applicable
B-01	Estudio observacional para evaluar la estrategia de uso de las terapias dirigidas, en cáncer de colon metastásico. Estudio GEMCAD 1401	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	Not applicable

Group	Title	Subtype	LR Name	Phase
B-01	Ensayo internacional, aleatorizado y controlado para el tratamiento del sarcoma de Ewing de diagnóstico reciente (EE2012)	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
B-01	Ensayo internacional, aleatorizado y controlado de quimioterapia para el tratamiento del sarcoma de Ewing recurrente o refractario	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	II
B-01	Estudio observacional, retrospectivo y multicéntrico para identificar los perfiles de pacientes que más se benefician del tratamiento con Trabectedina en segunda línea en pacientes con sarcoma de tejidos blandos, localmente avanzados o metastáticos, que han progresado a un tratamiento de primera línea. GEIS 38	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	Not applicable
B-01	Phase II, multicenter, randomized, double-blind, parallel-group, double-blind study to compare the efficacy and tolerability of Fulvestrant (Faslodex™) 500mg with placebo and Fulvestrant (Faslodex™) 500mg in combination with PD-0332991 (Palbociclib) as first-line treatment for postmenopausal patients with hormone receptor positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and who remain disease-free for more than 12 months after completion of adjuvant therapy or who have de novo metastatic disease “FLIPPER Study”	INDEPENDENT CLINICAL TRIAL	ALFONSO SÁNCHEZ MUÑOZ	II
B-01	Estudio retrospectivo de casos y controles para la caracterización clínica y molecular del cáncer de próstata en pacientes con y sin defecto germinal en la reparación del DNA (BRCA1, BRCA2, Síndrome de Lynch)	NON-POST-AUTHORIZATION STUDY	ANTONIA MÁRQUEZ ARAGONÉS	Not applicable
B-01	Ensayo de fase III de quimioterapia postoperatoria frente a ningún tratamiento posterior en pacientes con cáncer de endometrio de riesgo intermedio o alto, en estadios I o II, con ganglios negativos	INDEPENDENT CLINICAL TRIAL	ALFONSO SÁNCHEZ MUÑOZ	III
B-01	Cáncer de vejiga invasivo hacia una medicina de precisión. SOG-CVI-2014-05	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	Not applicable
B-01	Estudio fase III randomizado en el que se compara el tratamiento con imatinib adyuvante durante 3 años frente a 5 años para pacientes con GIST operable con alto riesgo de recurrencia	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
B-01	Estudio de primera administración en humanos, abierto, Fase 1/2 para evaluar la seguridad, farmacocinética, farmacodinámica y la actividad clínica de JNJ-63723283, un anticuerpo monoclonal Anti-PD1 en sujetos con cáncer avanzado	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Estudio prospectivo de registro de pacientes con cáncer de mama localmente avanzado, no resecable o metastásico (CMM). RegistEM	NON-POST-AUTHORIZATION STUDY	ANA GODOY ORTIZ	Not applicable
B-01	Estudio piloto para la evaluación de la utilidad clínica del SWITCH (o cambio) de predniona por dexametasona tras progresión bioquímica inicial en pacientes con cáncer de próstata resistentes a la castración (CPRC) tratados con abiraterona. Estudio SWITCH	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	Not applicable
B-01	Estudio observacional, retrospectivo y multicéntrico para identificar el papel pronóstico y posibles implicaciones terapéuticas del receptor de la somatostatina (SSTR) en el tumor de estroma gastrointestinal (GIST) localizado (SOMAGIST). SOMAGIST	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	Not applicable
B-01	Multicenter, open-label, phase II trial to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2 negative breast cancer.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobreexpresión CDK4.	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	II
B-01	Trastuzumab y pertuzumab sin quimioterapia en cáncer de mama HER2 positivo: estrategia adaptada en función de la respuesta evaluada por FDG-PET. Estudio PHERGain	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	II
B-01	Estudio para evaluar los desenlaces del embarazo y la seguridad de la interrupción del tratamiento endocrino de mujeres jóvenes con cáncer de mama y respuesta el tratamiento endocrino que deseen quedarse embarazadas. Estudio POSITIVE	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA JOSE BERMEJO PEREZ	Not applicable

Group	Title	Subtype	LR Name	Phase
B-01	Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar en cáncer de mama precoz con receptores hormonales positivos (RH+) y HER2-negativo	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Estudio en fase III, multicéntrico, aleatorizado y abierto de rucaparib frente al tratamiento elegido por el médico para pacientes con cáncer de próstata metastásico resistente a la castración asociado a una deficiencia en la recombinación homóloga. TRITON3	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio prospectivo de la utilidad de la biopsia líquida como factor predictor y pronóstico en pacientes con carcinoma urotelial metastásico en progresión tras quimioterapia basada en platino	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	Not applicable
B-01	Estudio de largo seguimiento de pacientes con cáncer de mama incluidos en estudios en estadios precoces del Grupo GEICAM.	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	IV
B-01	Estudio de Fase III multicéntrico, doble ciego, randomizado, controlado con placebo para evaluar la eficacia y la seguridad de Atezolizumab más quimioterapia en pacientes con cáncer de mama triple negativo recurrente (localmente avanzado o metastásico inoperable) con recidiva precoz.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de palbociclib + tratamiento anti-HER2 + tratamiento endocrino frente a tratamiento anti-HER2 + tratamiento endocrino tras el tratamiento de inducción para el cáncer de mama metastásico positivo para receptores hormonales (HR+)/positivo para HER2	COMMERCIAL CLINICAL TRIAL	ALFONSO SÁNCHEZ MUÑOZ	III
B-01	Estudio fase I/2a, de escalada de dosis y de expansión de cohortes de la seguridad, tolerabilidad, y eficacia del anticuerpo monoclonal anti-LAG-3(BMS-986016) administrado solo y en combinación con el anticuerpo monoclonal anti-PD-1 (Nivolumab, BMS-936558) en tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Estudio Observacional multicéntrico prospectivo en pacientes con Cáncer de Origen Desconocido a los que se les realiza el test diagnóstico CODEPICUP	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ESPERANZA TORRES SÁNCHEZ	Not applicable
B-01	Estudio de Fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo para comparar la eficacia y seguridad de POLATUZUMAB VEDOTIN en combinación con RITUXIMAB Y CHP (R-CHP) en comparación con RITUXIMAB Y CHOP (R-CHOP) en pacientes con linfoma difuso de células grandes tipo b no tratado anteriormente. POLARIX	COMMERCIAL CLINICAL TRIAL	LAURA GALVEZ CARVAJAL	III
B-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de PROstata resistente a la castración tratados con RADUIM-223. PRORADIUM	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	Not applicable
B-01	Carolina conoce a HANNA -Análisis holístico de la supervivencia a largo plazo con cáncer de ovario. Código Promotor: Expression VI	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA JOSE BERMEJO PEREZ	Not applicable
B-01	Registro español de tumores neuroendocrinos	NON-POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	Not applicable
B-01	Estudio en fase 3 aleatorizado, abierto, de abemaciclib en combinación con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar, en pacientes con cáncer de mama en estadios iniciales, de alto riesgo, con afectación ganglionar, receptores hormonales positivos, HER2 negativo.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo fase III, aleatorizado y doble ciego de quimioterapia basada en platino con o sin atezolizumab, seguida de mantenimiento con niraparib con o sin atezolizumab, en pacientes con cáncer de ovario, de trompa de Falopio o peritoneal recidivante e intervalo libre de tratamiento con platino (ILP) >6 meses.	INDEPENDENT CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio Observacional Retrospectivo de Evolución de Casos de Cáncer de Mama en el Varón y Evaluación del Riesgo de Recidiva Mediante Secuenciación Genética. GEICAM/2016-04	INDEPENDENT POST-AUTHORIZATION STUDY	ALFONSO SÁNCHEZ MUÑOZ	Not applicable
B-01	Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar la eficacia de FOLFOX + panitumumab seguido por FOLFIRI + bevacizumab (Secuencia 1) frente a FOLFOX + bevacizumab seguido por FOLFIRI + panitumumab (Secuencia 2) en pacientes con cáncer colorrectal metastásico no resecable, RAS nativo, tumor primario en lado izquierdo, no tratado previamente: CR-SEQUENCE	INDEPENDENT CLINICAL TRIAL	ESPERANZA TORRES SÁNCHEZ	III

Group	Title	Subtype	LR Name	Phase
B-01	Ensayo en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo de olaparib y abiraterona en comparación con placebo y abiraterona como tratamiento de primera línea en varones con cáncer de próstata metastásico resistente a la castración.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio de fase I, con aumento escalonado de la dosis y ampliación de cohortes, de TSR-022, un anticuerpo monoclonal anti-TIM-3, en pacientes con tumores sólidos avanzados (AMBER)	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
B-01	Ensayo abierto, multicéntrico, de un solo brazo, de fase II con avelumab en combinación con doxorubicina liposomal pegilada en pacientes con cáncer endometrial recurrente o metastásico	INDEPENDENT CLINICAL TRIAL	ANTONIA MÁRQUEZ ARAGONÉS	II
B-01	Estudio de fase II de durvalumab (MEDI4736) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTHY)	INDEPENDENT CLINICAL TRIAL	SOFIA RUIZ MEDINA	II
B-01	Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo, de cabozantinib (XL184) en pacientes con cáncer diferenciado de tiroides resistente a radioyodo que han progresado después de tratamiento dirigido previo con VEGFR	COMMERCIAL CLINICAL TRIAL	SOFÍA RUIZ MEDINA	III
B-01	Estudio fase III, doble ciego, aleatorizado y controlado con placebo de niraparib en combinación con acetato de abiraterona y prednisona en comparación con acetato de abiraterona y prednisona para el tratamiento de sujetos con Cáncer de Próstata Metastásico	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio en fase III, intervencionista, aleatorizado, multicéntrico y abierto de DCC-2618 frente a Sunitinib en Pacientes con Tumores del Estroma Gastrointestinal Avanzados tras el tratamiento con Imatinib	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
B-01	Atezolizumab, pertuzumab y trastuzumab con quimioterapia como tratamiento neoadyuvante en pacientes con cáncer de mama precoz y localmente avanzado HER2 positivo de alto riesgo. GEICAM/2017-05 (APTneo)	INDEPENDENT CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Estudio en fase III, multicéntrico, aleatorizado, abierto y controlado con principio activo de DS-8201a, un conjugado de fármaco y anticuerpo anti-HER2, frente al tratamiento de elección del investigador para sujetos con cáncer de mama irresecable y/o metastásico que expresa HER-2 tratados previamente con tratamientos estándares para HER2, incluido T-DM1	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio de Fase 1b-2 para evaluar la seguridad, eficacia, farmacocinética y farmacodinamia de erdafitinib más JNJ-63723283, un anticuerpo monoclonal anti-PD-1, en sujetos con cáncer urotelial metastásico o no resecable con determinadas alteraciones del gen del FGFR	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	II
B-01	Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nuevo ensayo clínico en adyuvancia con ribociclib -[LEE011]: NATALEE)	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo aleatorizado, fase II, abierto, con el anti-PD1 TSR-042 como terapia de mantenimiento en pacientes con cáncer de cérvix localmente avanzado de alto riesgo después de quimioradioterapia	INDEPENDENT CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	II
B-01	Ensayo Clínico de fase III, doble ciego y aleatorizado, para evaluar la eficacia y seguridad de capivasertib + paclitaxel en comparación con un placebo + paclitaxel como tratamiento de primera línea en pacientes con cáncer de mama triple negativo (CMTN) localmente avanzado (inoperable) o metastásico, confirmado histológicamente	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Estudio en fase III, multicéntrico, aleatorizado, abierto y controlado con principio activo de DS-8201a, un conjugado de fármaco y anticuerpo (CAF) anti-HER2, en comparación con el tratamiento elegido por el médico en sujetos con cáncer de mama irresecable o metastásico (o ambos) con expresión baja de HER-2	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio fase 3, aleatorizado, de quimioterapia neoadyuvante sola frente a quimioterapia neoadyuvante más Nivolumab o Nivolumab y BMS-986205, seguido por tratamiento continuado post-cirugía con Nivolumab o Nivolumab y BMS-986205 en pacientes con cáncer de vejiga músculo-invasivo.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III

Group	Title	Subtype	LR Name	Phase
B-01	Incidencia de mutaciones BRCA somáticas y germinales en una cohorte amplia de pacientes procedentes de hospitales españoles con cáncer de ovario epitelial no mucinoso con validación de técnica somática entre laboratorios (BoRNEO).	NON-POST-AUTHORIZATION STUDY	ANTONIA MÁRQUEZ ARAGONÉS	Not applicable
B-01	A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Ensayo clínico en fase III abierto y aleatorizado de REGN2810 en comparación con el tratamiento de quimioterapia a elección del investigador para el carcinoma cervicouterino resistente a platino recurrente o metastásico	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio de fase III, abierto, multicéntrico y aleatorizado de palbociclib como tratamiento adyuvante combinado con hormonoterapia en comparación con hormonoterapia sola en pacientes con recidiva locorregional aislada de cáncer de mama extirpado con receptor hormonal positivo y HER2 negativo. POLAR	INDEPENDENT CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
B-01	Estudio de fase I-II para evaluar la seguridad, tolerabilidad y eficacia de PM01183 y atezolizumab en pacientes con cáncer de pulmón de células pequeñas avanzado que hayan progresado tras una quimioterapia previa de platino	INDEPENDENT CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
B-01	Estudio en fase IIa, sin enmascaramiento y multicéntrico para analizar la seguridady eficacia de la combinación de BL-8040 y pembrolizumab en pacientes con cáncer pancreático metastásico, el estudio COMBAT.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
B-01	Proyecto de colaboración global en CIC-DUX4, BCOR-CCN3, células redondas no diferenciadas de alto grado (URCS)GEIS-2I	NON-POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	Not applicable
B-01	Estudio en fase I, sin enmascaramiento, de aumento gradual y ampliación de la dosis para evaluar la seguridad, la tolerabilidad, la farmacocinética, la inmunogenia y la actividad antineoplásica de MEDI5752 en pacientes con tumores sólidos avanzados.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Estudio de fase II multicéntrico, controlado con activo, aleatorizado para comparar la eficacia y seguridad de la terapia dirigida o inmunoterapia para el cáncer guiada por el perfil genómico frente a la quimioterapia basada en platino en pacientes con cáncer de origen primario desconocido que han recibido tres ciclos de quimioterapia con doblete de platino	COMMERCIAL CLINICAL TRIAL	ESPERANZA TORRES SÁNCHEZ	II
B-01	Estudio Fase IIIB multicéntrico, abierto, de un solo brazo, para evaluar la seguridad de ATEZOLIZUMAB (TECENTRIQ) en combinación con NAB-PACLITAXEL O PACLITAXEL para el tratamiento del cáncer de mama triple negativo inoperable, localmente avanzado o metastásico.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Estudio Fase 1, multicentrico, abierto, de búsqueda de dosis para evaluar la seguridad, tolerabilidady eficacia preliminar de CC-90011 administrado en combinacioncon con Cisplatino y Etoposido, de primera linea para sujetos con cancer de pulmon de celulas pequeñas en estadio extenso	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Ensayo clínico de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de niraparib más inhibidores de aromatasas en el cáncer de mama metastásico con receptor hormonal (RH) positivo/ receptor del factor de crecimiento epidérmico humano 2 (HER2) negativo con o sin mutación de BRCA en línea germinal y con deficiencia en la recombinación homóloga (HRD)-La estrategia LUZERN.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302. HER2-PREDICT	INDEPENDENT CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	II
B-01	Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nuevo ensayo clínico en adyuvancia con ribociclib -[LEE011]: NATALEE)	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III

Group	Title	Subtype	LR Name	Phase
B-01	Estudio en fase III aleatorizado y doble ciego para evaluar la eficacia y la seguridad de capivasertib + fulvestrant frente a placebo + fulvestrant como tratamiento para el cáncer de mama localmente avanzado (inoperable) o metastásico con receptor hormonal positivo, receptor del factor de crecimiento epidérmico humano 2 negativo (HR+/HER2?) después de la recurrencia o la progresión durante o después del tratamiento con un inhibidor de la aromatasa (CAPItello-291)	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
B-01	Un ensayo multicéntrico, aleatorizado y abierto de fase 3 que compara selpercatinib con los medicamentos cabozantinib o vandetanib, preferidos por los médicos, en pacientes con cáncer medular de tiroides progresivo y avanzado con RET mutante y sin tratamiento anterior con inhibidores de quinasa (LIBRETTO-531)	COMMERCIAL CLINICAL TRIAL	SOFÍA RUIZ MEDINA	III
B-01	Estudio fase 3, aleatorizado, multicéntrico, doble ciego, controlado con placebo, de nivolumab frente a placebo en combinación con quimioterapia neoadyuvante y tratamiento hormonal adyuvante en pacientes con cáncer de mama primario de alto riesgo, receptores estrogénicos positivos (RE+) y receptor del factor de crecimiento epidérmico humano 2 negativo (HER2-). (CheckMate 7FL: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 7FL)	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo de Fase IIa, multicéntrico, abierto, no comparativo y de tres brazos de IPATASERTIB (GDC-0068) en combinación con quimioterapia sin TAXANOS para pacientes con cáncer de mama triple-negativo localmente avanzado irresecable o metastásico previamente tratadas con TAXANOS (PATHFINDER)	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	II
B-01	Primer estudio en seres humanos, fase 1/2 de BMS-986249 en monoterapia y en combinación con nivolumab en tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
B-01	Ensayo de fase II randomizado para evaluar la actividad antitumoral del tratamiento con Enzalutamida y Talazoparib (PF-06944076) en pacientes con cáncer de próstata metastásico sin terapia hormonal previa. (ZZFIRST)	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	II
B-01	Estudio observacional en pacientes con cáncer de mama metastásico HR+ y Her2- tratados con abemaciclib en el programa NPU (Programa de Uso Compasivo) en España- Estudio AbemusS	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIA MÁRQUEZ ARAGONÉS	Not applicable
B-01	Estudio de fase 2a de ZW25 en combinación con palbociclib más fulvestrant	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Estudio abierto, de un solo brazo, de continuación de tratamiento con darolutamida a pacientes incluidos previamente en estudios promovidos por Bayer.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio de fase III, multicéntrico, aleatorizado (1:1), doble ciego, controlado con placebo, de dos partes para evaluar la eficacia y seguridad de alpelisib (BYL719) en combinación con trastuzumab y pertuzumab como terapia de mantenimiento en pacientes con cáncer de mama avanzado HER2 positivo con una mutación de PIK3CA. EPIK-B2	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
B-01	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/ or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
B-01	Ensayo clínico exploratorio “basket” de cabozantinib más atezolizumab en neoplasias avanzadas y en progresión del sistema endocrino.	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	II
B-01	Primer ensayo en humanos, abierto, de aumento escalonado de la dosis con cohortes de ampliación para evaluar la seguridad de GEN1046 en sujetos con tumores sólidos malignos	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
B-01	Estudio de fase II, aleatorizado, abierto, internacional y multicéntrico, para comparar la eficacia de la quimioterapia estándar frente a letrozol más abemaciclib como terapia neoadyuvante en pacientes con cáncer de mama con RH-positivo/HER2-negativo de riesgo alto/intermedio. “Estudio CARABELA”	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Primer Estudio en seres humanos fase 1/2a, del anticuerpo monoclonal BMS-986218 en monoterapia y en combinación con nivolumab en tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Estudio de fase 2, aleatorizado y doble ciego para evaluar la eficacia de Dostarlimab más quimioterapia en comparación con Pembrolizumab más quimioterapia en el cáncer de pulmón no microcítico metastásico	COMMERCIAL CLINICAL TRIAL	ANDRES MESAS RUIZ	II

Group	Title	Subtype	LR Name	Phase
B-01	Ensayo Clínico de Fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento adyuvante con Atezolizumab o placebo y Trastuzumab Emtansina en el cáncer de mama con HER2+ y alta riesgo de recidiva después del tratamiento preoperatorio.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Estudio farmacocinético, multicéntrico y abierto sobre lurbinededina en pacientes con tumores sólidos avanzados y diversos grados de insuficiencia hepática.	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de fase I/II, multicéntrico, en dos partes, abierto, orientado a evaluar la seguridad y tolerabilidad de la administración de dosis crecientes de AGI-134 en los tumores sólidos no operables/ metastásicos.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
B-01	Estudio clínico de determinación de tiempos y desplazamientos de la combinación de una dosis fija subcutánea de PERTUZUMAB y TRASTUZUMAB para el tratamiento de pacientes con cáncer de mama precoz HER2 POSITIVO.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	IV
B-01	Estudio de Fase III, multicéntrico, aleatorizado, abierto y controlado de Trastuzumab Deruxtecán (T-DXd) frente a Trastuzumab Emtansina (T-DM1) en pacientes con cáncer de mama primario HER2 positivo de alto riesgo que presentan enfermedad invasiva residual en mama o en ganglios linfáticos axilares tras el tratamiento neoadyuvante. Estudio DESTINY	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
B-01	Estudio fase Ib/Ia para Evaluar la Seguridad y Eficacia del Tratamiento con el Inhibidor de la Ruta de Hedhegog NLM-001 Antes de Quimioterapia (Gemcitabina y Nab-Paclitaxel) más Zalifrelimab como Tratamiento de Primera Línea en Pacientes con Cáncer de Páncreas Avanzado.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Ensayo aleatorizado de fase III de trastuzumab + ALpelisib +/-fulvestrant frente a trastuzumab + quimioterapia en pacientes con cáncer de mama avanzado HER2+ con mutación de PIK3CA previamente tratadas. “Estudio ALPHABET”	INDEPENDENT CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Estudio plataforma, de fase II, abierto y multicéntrico para evaluar la eficacia y la seguridad de tratamientos basados en biomarcadores en pacientes con tumores epiteliales de ovario raros persistentes o recurrente	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	II
B-01	Estudio en fase III, aleatorizado, doble ciego y multicéntrico de dostarlimab (TSR-042) más carboplatino-paclitaxel frente a placebo más carboplatino-paclitaxel en pacientes con cáncer de endometrio avanzado recidivante o primario (RUBY)	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio de Fase IA/IB de aumento y ampliación de la dosis para evaluar la seguridad, la farmacocinética y la actividad de GDC-6036 en monoterapia y en combinación con otros tratamientos antineoplásicos en pacientes con tumores sólidos avanzados o metastásicos con la mutación KRAS G12C	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Ensayo de fase III aleatorizado, multicéntrico, doble ciego, de AZD9833 (un SERD, Degradador selectivo del RE, oral) más palbociclib en comparación con anastrozol más palbociclib para el tratamiento de pacientes con cáncer de mama avanzado con receptores estrogénicos positivos y HER2 negativo que no han recibido ningún tratamiento sistémico para la enfermedad avanzada. (SERENA-4)	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Ensayo en Fase 1B, abierto, con escalado de dosis, para determinar la seguridad y las respuestas inmunitarias dirigidas contra antígenos específicos provocadas por VB.01 NEO en combinación con ATEZOLIZUMAB en sujetos con tumores localmente avanzados y metastásicos	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Estudio de fase I/II de NM21-1480 (anticuerpo triespecífico anti-PDL-1/anti-4-1BB/anti-HSA) en pacientes adultos con tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Estudio de fase 1 de JNJ-78278343, un agente de redireccionamiento de células T dirigido a la Calicreína Humana 2 (KLK2), para cáncer de próstata avanzado	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Registro clínico de pacientes diagnosticadas con cáncer ginecológico del Grupo Español de Investigación en Cáncer de Ovario (GEICO)	NON-POST-AUTHORIZATION STUDY	MARIA JOSE BERMEJO PEREZ	Not applicable

Group	Title	Subtype	LR Name	Phase
B-01	Estudio clínico de fase 1 para evaluar la biodisponibilidad de pembrolizumab administrado en inyección subcutánea de MK-3475A, una formulación de pembrolizumab con MK-5180, en participantes con tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
B-01	Ensayo en fase III, doble ciego, aleatorizado para evaluar el cambio a AZD9833 (SERD oral de nueva generación) + inhibidor de CDK4/6 (palbociclib o abemaciclib) frente a continuar con un inhibidor de la aromatasa (letrozol o anastrozol) + inhibidor de CDK4/6 en pacientes con cáncer de mama metastásico HR+/HER2- con mutación detectable del ESR1 sin progresión de la enfermedad durante el tratamiento de 1L con inhibidor de la aromatasa + inhibidor de CDK4/6: estudio de cambio temprano guiado por ADNtc. SERENA-6	COMMERCIAL CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Ensayo en fase 3 aleatorizado, multicéntrico, abierto, comparativo con tratamiento activo para evaluar la eficacia y seguridad de octreotida (CAM2029) subcutánea de liberación prolongada frente a octreotida LP o lanreotida ATG en pacientes con tumores neuroendocrinos gastroenteropancreáticos	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
B-01	Ensayo clínico, fase III, abierto, aleatorizado de Dato-DXd en comparación con la quimioterapia a elección del investigador en pacientes con cáncer de mama inoperable o metastásico con receptores hormonales positivos, HER2 negativo, que han recibido una o dos líneas previas de quimioterapia sistémica (TROPION-Breast01)	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
B-01	Estudio de fase III, multicéntrico y abierto de ribociclib en comparación con palbociclib en pacientes con cáncer de mama avanzado con receptores hormonales positivos/HER2-negativo/HER2-Enriquecido-ensayo HARMONIA	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
B-01	Estudio fase 1b/2, abierto, aleatorizado, no comparativo de nadunolimab en combinación con gemcitabina y carboplatino en pacientes con cáncer de mama avanzado triple negativo. “Estudio TRIFOUR”.	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
B-01	Un estudio de fase III, aleatorizado, doble ciego y controlado con placebo de alpelisib en combinación con fulvestrant para hombres y mujeres posmenopáusicas con cáncer de mama avanzado HR positivo, HER2 negativo con mutación en PIK3CA, que ha progresado durante o después del tratamiento con un inhibidor de la aromatasa y un inhibidor de CDK4/6. EPIK-B5	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Ensayo en fase II con varios grupos (en canasta) para investigar la seguridad y eficacia de IO102-IO103 en combinación con pembrolizumab, como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico (CPNM) metastásico, carcinoma de células escamosas de cabeza y cuello (CCECC) o carcinoma urotelial de vejiga metastásico (CUVm)	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
B-01	Estudio de Fase I, abierto, de búsqueda de dosis de CC-95251, un anticuerpo monoclonal dirigido contra SIRPa, solo y en combinación con cetuximab o rituximab en sujetos con tumores sólidos y hematológicos avanzados	CLINICAL TRIALS WITH DRUGS	LAURA MEDINA RODRÍGUEZ	I
B-01	Estudio de fase 3, multicéntrico y abierto para evaluar la seguridad y la eficacia a largo plazo en participantes que actualmente están en tratamiento o en seguimiento en estudios que incluyen Pembrolizumab.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de Giredestrant adyuvante en comparación con la monoterapia endocrina adyuvante elegida por el médico en pacientes con cáncer de mama incipiente con receptores estrogénicos positivos y HER2 negativo. LIDERA	COMMERCIAL CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Estudio tipo cesta de fase 1b/2, multicéntrico y abierto que evalúa la seguridad y eficacia de bemarituzumab en monoterapia en tumores sólidos con sobreexpresión de FGFR2b (FORTITUDE-301)	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
B-01	Estudio fase III de post-neoadyuvancia que evalúa Sacituzumab Govitecan, un anticuerpo conjugado, en pacientes con cáncer primario de mama HER2 negativo con alto riesgo de recaída tras el tratamiento neoadyuvante estándar -SASCIA	INDEPENDENT CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Primer ensayo clínico en el ser humano, en fase I, de BMS-986406 como tratamiento en monoterapia y en combinación en participantes con tumores malignos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I

Group	Title	Subtype	LR Name	Phase
B-01	Brightline-1: Ensayo de fase II/III, aleatorizado, abierto, multicéntrico de BI 907828 comparado con doxorrubicina como tratamiento de primera línea de pacientes con liposarcoma desdiferenciado avanzado	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
B-01	Estudio en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo de fuzuloparib combinado con acetato de abiraterona y prednisona (AA-P) frente a placebo combinado con AA-P como tratamiento de primera línea en pacientes con cáncer de próstata resistente a la castración metastásico	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
B-01	Estudio de fase I/IIa, abierto y multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética y, de manera preliminar, la eficacia de ART0380, un inhibidor de la quinasa ATR, administrado por vía oral en monoterapia y en combinación a pacientes con tumores sólidos avanzados o metastásicos	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	II
B-01	Estudio de fase III, aleatorizado, abierto de sacituzumab govitecán frente al tratamiento elegido por el médico en pacientes con cáncer de mama triple negativo localmente avanzado, inoperable o metastásico, no tratado anteriormente cuyos tumores no presenten expresión de PD-L1 o en pacientes tratados previamente con agentes anti PD(L)1 en fase inicial cuyos tumores presenten expresión de PD-L1	INDEPENDENT CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Estudio observacional retrospectivo de los linfomas hodgkin (hdk) y no hodgkin (no-hdk) diagnosticados por el grupo cooperativo gotel para evaluar la supervivencia global y sus características.	INDEPENDENT POST-AUTHORIZATION STUDY	LAURA GALVEZ CARVAJAL	Not applicable
B-01	Estudio aleatorizado de paclitaxel –carboplatino seguido de mantenimiento con niraparib en comparación con paclitaxel –carboplatino –bevacizumab seguido de mantenimiento con niraparib + bevacizumab en pacientes con cáncer de ovario avanzado después de una cirugía citorreductora completa de primera línea	CLINICAL TRIALS WITH DRUGS	MARIA JOSE BERMEJO PEREZ	II
B-01	Estudio multicéntrico en fase I, abierto, de INCA00186 en monoterapia o en combinación con inmunoterapia en participantes con tumores sólidos avanzados	INDEPENDENT CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de fase 3, aleatorizado, abierto, controlado, de cabozantinib (XL184) en combinación con atezolizumab frente a una segunda terapia hormonal novedosa (THN) en pacientes con cáncer de próstata metastásico y resistente a la castración	CLINICAL TRIALS WITH DRUGS	MARIA ISABEL SÁEZ MEDINA	III
B-01	Primer ensayo en humanos, abierto, de aumento escalonado de la dosis con cohortes de ampliación para evaluar la seguridad y actividad antitumoral de GEN1042 en sujetos con tumores sólidos malignos	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
B-01	Protocolo maestro de fase II, multicéntrico, abierto, para evaluar la eficacia y seguridad de datopotamab deruxtecán (Dato-DXd) en monoterapia y en combinación con antineoplásicos, en pacientes con tumores sólidos en estadio avanzado o metastásico (TROPION-PanTumor03)	CLINICAL TRIALS WITH DRUGS	LAURA MEDINA RODRÍGUEZ	II
B-01	Un estudio de Fase Ia/Ib, etiqueta abierta, multicéntrico, de escalado de dosis para evaluar la seguridad, farmacocinética y actividad de RO7502175 como agente único y en combinación con ATEZOLIZUMAB en pacientes con tumores sólidos localmente avanzados o metastásicos.	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio en fase II, multicéntrico y sin enmascaramiento para evaluar la eficacia y la seguridad de la monoterapia con Olaparib y la combinación de Olaparib junto con Durvalumab como tratamiento neoadyuvante en pacientes con mutaciones BRCA y cáncer de mama HER2 negativo en fase temprana (OlympiaN)	CLINICAL TRIALS WITH DRUGS	ANTONIA MÁRQUEZ ARAGONÉS	II
B-01	Estudio con aumento escalonado y ampliación de la dosis para evaluar la seguridad y la farmacocinética del XB002 en monoterapia y politerapia en pacientes con tumores sólidos localmente avanzados o metastásicos inoperables	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Ensayo fase 3, abierto, aleatorizado, de Datopotamab Deruxtecan (Dato-DXd) en comparación con la quimioterapia de elección del investigador en pacientes con cáncer de mama triple negativo, localmente recurrente inoperable o metastásico, que no son candidatos a terapia con inhibidores de PD-1/PD-L1 en primera línea (TROPION-Breast02)	CLINICAL TRIALS WITH DRUGS	EMILIO ALBA CONEJO	III

Group	Title	Subtype	LR Name	Phase
B-01	Estudio de fase III, aleatorizado, abierto de sacituzumab govitecán y pembrolizumab frente al tratamiento elegido por el médico y pembrolizumab en pacientes con cáncer de mama triple negativo localmente avanzado inoperable o metastásico, no tratado anteriormente cuyos tumores presenten expresión de PD-L1	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Estudio abierto, de fase I de escalado de dosis, con confirmación y expansión de la dosis, de BI 1810631 en monoterapia en pacientes con tumores sólidos avanzados o metastásicos con aberraciones en HER2	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	ORACLE: Observación de cáncer residual mediante evaluación por biopsia líquida (Observation of ResiduAl Cancer with Liquid biopsy Evaluation)	OBSERVATIONAL STUDIES WITH DRUGS	EMILIO ALBA CONEJO	Not applicable
B-01	Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158)	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	II
B-01	Ensayo clínico aleatorizado, abierto, fase 3 de datopotamab deruxtecán (Dato-DXd) con o sin durvalumab frente al tratamiento de elección del investigador en pacientes con cáncer de mama triple negativo en estadio I-III que tienen enfermedad residual invasiva en la mama y/o en los ganglios linfáticos axilares en la resección quirúrgica después de tratamiento sistémico neoadyuvante (TROPION-Breast03)	CLINICAL TRIALS WITH DRUGS	EMILIO ALBA CONEJO	III
B-01	Evaluación de la Mitigación de las Reacciones Relacionadas con la Infusión de Amivantamab.	CLINICAL TRIALS WITH DRUGS	ANDRES MESAS RUIZ	II
B-01	Estudio de fase II, aleatorizado, abierto, de optimización de la dosis/pauta de NUC-3373/leucovorina/irinotecán más bevacizumab (NUFIRI-bev) frente a 5-FU/leucovorina/irinotecán más bevacizumab (FOLFIRI-bev) para el tratamiento de pacientes con cáncer colorrectal metastásico irresecable previamente tratado	CLINICAL TRIALS WITH DRUGS	ESPERANZA TORRES SÁNCHEZ	II
B-01	Estudio abierto de fase 1, primera vez en humanos, con GSK4381562 administrado en monoterapia y en combinación con agentes antineoplásicos en participantes con tumores sólidos avanzados seleccionados.	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Primer estudio en Humanos de IMGC936 (Conjugado de un fármaco y un anticuerpo anti ADAM9), fase 1/2, abierto, con escalada de dosis y posterior expansión en pacientes con tumores sólidos en estadio avanzados	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	II
B-01	Estudio de fase III aleatorizado, abierto para evaluar la eficacia y seguridad de GIREDESTRANT en combinación con PHESGO comparado con PHESGO tras tratamiento de inducción con PHESGO + TAXANO en pacientes con cáncer de mama localmente avanzado o metastásico HER2 Positivo y receptor de estrógenos positivo, no tratados previamente.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Estudio en fase I del inhibidor de SHP2 BBP-398 (anteriormente conocido como IACS-15509) en combinación con el inhibidor de KRAS-G12C sotorasib en pacientes con tumores sólidos avanzados y una mutación de KRAS-G12C	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de fase 3, aleatorizado, abierto, multicéntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con cáncer de mama avanzado con receptores estrogénicos, sin mutación del gen HER2 cuya enfermedad haya progresado después de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Estudio de fase 1/1b para evaluar la seguridad y la tolerabilidad de AB308 en combinación con AB122 en participantes con neoplasias malignas avanzadas	CLINICAL TRIALS WITH DRUGS	LAURA MEDINA RODRÍGUEZ	I
B-01	Ensayo fase 1, abierto, primer ensayo en humanos, de escalada de dosis y expansión, que evalúa la seguridad, tolerabilidad, máxima dosis tolerada o administrada, farmacocinética y farmacodinamia y perfil de respuesta tumoral del inhibidor de receptor de Aril Hidrocarburos BAY2416964 en participantes con tumores sólidos en estadio avanzado.	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio fase 1/2 de BMS-986340 en monoterapia y en combinación con Nivolumab o Docetaxel en pacientes con tumores sólidos avanzados.	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I

Group	Title	Subtype	LR Name	Phase
B-01	Estudio fase 1/2 de BMS-986408 en monoterapia y en combinación con nivolumab o con nivolumab e ipilimumab en participantes con tumores sólidos avanzados	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Ensayo en fase I/IIa, primero en el ser humano, de aumento de la dosis, multicéntrico y sin enmascaramiento, con cohortes de prolongación, para evaluar la seguridad y la eficacia preliminar de BNT142 en pacientes con tumores sólidos avanzados con presencia de CLDN6	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio en Fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de Inavolisib más Fulvestrant frente a alpelisib más Fulvestrant en pacientes con cáncer de mama con receptor hormonal positivo, HER2 NEGATIVO y PIK3CA Mutado, localmente avanzado o metastásico que experimentaron progresión durante o después del tratamiento combinado con inhibidor de CDK4/6 y tratamiento endocrino.	CLINICAL TRIALS WITH DRUGS	ANA GODOY ORTIZ	III
B-01	Estudio observacional de cohortes retrospectivo que utiliza datos secundarios obtenidos de la práctica clínica para evaluar los patrones de tratamiento y el índice de abandono entre líneas de tratamiento en pacientes con cáncer de mama metastásico HER2+	OBSERVATIONAL STUDIES WITH DRUGS	NURIA RIBELLES ENTRENA	Not applicable
B-01	Estudio fase 1, primero en humanos, multicéntrico y abierto con ABBV-CLS579 solo y en combinación, en pacientes con tumores localmente avanzados o metastásicos	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de Fase II multicéntrico, aleatorizado, doble ciego de R07247669 en combinación con NAB-PACLITAXEL comparado con Pembrolizumab en combinación con NAB-PACLITAXEL en participantes con cáncer de mama TRIPLE NEGATIVO PD-L1 POSITIVO localmente avanzado no resecable o metastásico, no tratados previamente.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	II
B-01	Ensayo en Fase I/IIa Multicéntrico, Abierto, para evaluar la Seguridad, Tolerabilidad, Farmacocinética, Farmacodinámica y actividad antitumoral preliminar del AZD8205 en pacientes con tumores sólidos avanzados o metastásicos.	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	III
B-01	Estudio de Fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de INAVOLISIB en combinación con PHESGO® comparado con placebo en combinación con PHESGO® como tratamiento de mantenimiento tras tratamiento de inducción de primera línea en participantes con cáncer de mama localmente avanzado o metastásico HER2 POSITIVO con mutación PIK3CA.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Estudio aleatorizado, doble ciego y en fase III de tucatinib o placebo en combinación con trastuzumab y pertuzumab como tratamiento de mantenimiento para el cáncer de mama HER2+metastásico (HER2CLIMB-05)	CLINICAL TRIALS WITH DRUGS	EMILIO ALBA CONEJO	III
B-01	Estudio de Fase 3, aleatorizado, abierto, multicéntrico de ARV-471 (PF07850327) más PALBOCICLIB en comparación con LETROZOL más PALBOCICLIB para el tratamiento de participantes con cáncer de mama con receptor estrogénico positivo y HER2 Negativo que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada (VERITAC-3).	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Estudio aleatorizado para investigar la eficacia y seguridad de la proteína de fusión humana L19TNF anticuerpo-citoquina dirigida a tumores en pacientes con sarcoma de tejidos blandos en estado avanzado o metastásico previamente tratados	CLINICAL TRIALS WITH DRUGS	MARÍA ISABEL SEVILLA GARCÍA	II
B-01	Un estudio por módulos, abierto, de fase I/II para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia de EP0031 en pacientes con neoplasias malignas avanzadas con alteraciones en el gen RET	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio fase 1/2 de BMS-986449 en monoterapia y en combinación con Nivolumab en pacientes con tumores sólidos avanzados.	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento estándar en pacientes con cáncer de colon resecable con pérdida del mecanismo de reparación de apareamiento de bases (dMMR)/inestabilidad de microsatélites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2	CLINICAL TRIALS WITH DRUGS	ESPERANZA TORRES SÁNCHEZ	III

Group	Title	Subtype	LR Name	Phase
B-01	Estudio ambispectivo de pacientes con cáncer de mama triple negativo tratados con sacituzumab govitecan en el sur de España.	OBSERVATIONAL STUDIES WITH DRUGS	ANA GODOY ORTIZ	Not applicable
B-01	Estudio marco abierto de fase Ib/II para evaluar la seguridad y eficacia de elacestrant en varias combinaciones en pacientes con cáncer de mama metastásico (ELEVATE)	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	II
B-01	2023-12144 Estudio observacional, internacional, retrospectivo de revisión de historiasclínicas, para describir las características, patrones de tratamiento y resultados clínicos en los pacientestratados con selpercatinib dentro de un Programa de Acceso Temprano en España y Portugal (EstudioSELPIBER).	OBSERVATIONAL STUDIES WITH DRUGS	ANDRES MESAS RUIZ	Not applicable
B-01	A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de fase Ib/II, multicéntrico, abierto y de escalada de dosis de JDQ443 en pacientes con tumores sólidos avanzados con mutación KRAS G12C	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de fase III, aleatorizado, multicéntrico y en abierto para evaluar DB-1303 frente a la quimioterapia elegida por el investigador en pacientes con cáncer de mama metastásico con receptor 2 del factor de crecimiento epidérmico humano (HER2) bajo y positivo para el receptor hormonal (HR+) cuyo cáncer ha progresado con el tratamiento endocrino (DYNASTY-Breast02)	CLINICAL TRIALS WITH DRUGS	MARIA EMILIA DOMINGUEZ RECIO	III
B-01	Ensayo de fase III, multicéntrico, aleatorizado, controlado con placebo y con doble enmascaramiento sobre el tratamiento de mantenimiento con selinexor tras un tratamiento sistémico en pacientes con carcinoma endometrial avanzado o recurrente sin mutaciones en la proteína p53	CLINICAL TRIALS WITH DRUGS	MARIA JOSE BERMEJO PEREZ	III
B-01	An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre-and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation	CLINICAL TRIALS WITH DRUGS	ANA GODOY ORTIZ	III
B-01	A retrospective, observational, multicenter study of treatment with sacituzumab govitecan in patients with locally advanced and/or metastatic triple-negative breast cancer within routine clinical practice in Spain (TROPSPAIN)	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	Not applicable
B-01	Un estudio observacional prospectivo multicéntrico y en varios países de pacientes que inician T-DXd en la primera o segunda línea de tratamiento para el cáncer de mama irresecable y/o metastásico HER2+ y HER2-bajo. DESTINY BREAST – RESPOND	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	Not applicable
B-01	Primer ensayo clínico en humanos, abierto de BAY 2927088 en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutación EGFR y/o HER2	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Ensayo modular fase I/IIa, abierto, multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia preliminar del escalado de dosis de AZD5335 en monoterapia y en combinación con otros agentes antineoplásicos en pacientes con tumores sólidos (FONTANA)	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	II
B-01	Estudio en fase III aleatorizado, abierto y multicéntrico de mirvetuximab soravtansina en combinación con bevacizumab frente a bevacizumab en monoterapia como tratamiento de mantenimiento para pacientes con cáncer de trompas de falopio, peritoneal primario o epitelial de ovario con expresión FRa alta recurrente y sensible al platino que no han progresado después de la quimioterapia de segunda línea con platino más bevacizumab (GLORIOSA).	CLINICAL TRIALS WITH DRUGS	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio en fase III, abierto y aleatorizado para evaluar la eficacia y la seguridad de camizestrant (AZD9833, un degradador selectivo del receptor de estrógenos por vía oral de última generación) frente a la hormonoterapia estándar (inhibidor de la aromatasa o tamoxifeno), como tratamiento adyuvante en pacientes con cáncer de mama en fase temprana RE+/HER2-y un riesgo intermedio-alto o alto de recidiva que han completado tratamiento locorregional definitivo y no presentan indicios de enfermedad.	CLINICAL TRIALS WITH DRUGS	ANA GODOY ORTIZ	III

Group	Title	Subtype	LR Name	Phase
B-01	Estudio de fase 1/2, multicéntrico, abierto, para evaluar la seguridad, tolerabilidad y actividad antitumoral preliminar del TNG462 en pacientes con tumores sólidos avanzados ometastásicos con delección del gen MTAP	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	CT Trial: “Ensayo de fase 1, primero en humanos, abierto, de escalada y expansión de dosis para evaluar la seguridad, la tolerabilidad, la dosis máxima tolerada o administrada, la farmacocinética, la farmacodinamia y la respuesta tumoral del inhibidor del diacilglicerol quinasa alfa (DGKai) BAY 2862789 en pacientes con tumores sólidos avanzados”	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
B-01	Estudio de fase I/IIa, abierto y multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia preliminar del inhibidor de la ADN-polimerasa Theta, ART6043, administrado por vía oral en monoterapia y en combinación a pacientes con tumores sólidos avanzados o metastásicos	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	I
B-01	Estudio en fase I, doble ciego, aleatorizado, con tres grupos paralelos y controlado con principio activo para evaluar la similitud farmacocinética de tres formulaciones de pembrolizumab (CT-P51, Keytruda aprobado por la UE y Keytruda autorizado por EE. UU.) como tratamiento adyuvante en pacientes con melanoma en estadio IIB, IIC y III completamente resecado.	CLINICAL TRIALS WITH DRUGS	MANUEL ZALABARDO AGUILAR	I
B-01	Estudio de intervención, abierto, aleatorizado, multicéntrico, de Fase 2 de PF-07220060 más Letrozol comparado con Letrozol solo en mujeres posmenopáusicas de 18 años o más con cáncer de mama con receptores hormonales Positivos y HER2 Negativo en el contexto neoadyuvante.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	II
B-01	Estudio en fase III aleatorizado y abierto de saruparib (AZD5305) más camizestrant en comparación con el inhibidor de CDK4/6 seleccionado por el médico más hormonoterapia o más camizestrant para el tratamiento de primera línea de pacientes con cáncer de mama avanzado positivo para receptores hormonales y HER2 negativo (0, 1+, 2+ según IHQ/sin amplificación por ISH) con mutaciones en BRCA1, BRCA2 o PALB2.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
B-01	Exploración de los reordenamientos del GEN NTRK 1/2/3 en sarcomas GIST Y ÓSEOS. GIBOTREK.	OBSERVATIONAL STUDIES WITH DRUGS	MARÍA ISABEL SEVILLA GARCÍA	Not applicable
B-01	A Phase IIIB study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by urvalumab with olaparib as first-line treatment in Patients with Newly Diagnosed pMMR Advanced or Recurrent Endometrial Cancer in Spain.	CLINICAL TRIALS WITH DRUGS	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio de fase III, abierto, multicéntrico y aleatorizado de una combinación de CBP501, cisplatino y nivolumab o la terapia elegida por el médico para pacientes con adenocarcinoma pancreático avanzado, en =3ª línea de tratamiento [FUJI-PanC01] /// A Phase 3, Open-Label, Multicenter, Randomized Study of a Combination of CBP501, Cisplatin and Nivolumab or Physician’s Choice of Therapy for =3rd Line Treatment of Patients with Advanced Pancreatic Adenocarcinoma [FUJI-PanC01]	CLINICAL TRIALS WITH DRUGS	LAURA MEDINA RODRÍGUEZ	III
B-01	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy	CLINICAL TRIALS WITH DRUGS	MARIA JOSE BERMEJO PEREZ	III
B-01	Estudio de fase Ib/II para evaluar la seguridad y eficacia preliminar del inhibidor de wee1 debio 0123 en combinación con sacituzumab govitecan en cáncer de mama triple negativo o hr+/her2-avanza-do/ metastásico (<win-b>)	CLINICAL TRIALS WITH DRUGS	NURIA RIBELLES ENTRENA	II
B-01	Elacestrant frente a la hormonoterapia de referencia en personas de ambos sexos con cáncer de mama incipiente con afectación ganglionar, con receptores estrogénicos y sin sobreexpresión del receptor HER2 con alto riesgo de recurrencia: estudio en fase III, aleatorizado, sin enmascaramiento, global y multicéntrico (ELEGANT) // Elacestrant versus Standard ndocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence — A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT).	CLINICAL TRIALS WITH DRUGS	EMILIO ALBA CONEJO	III

Group	Title	Subtype	LR Name	Phase
B-01	A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPitello-292-D361DC00001)	CLINICAL TRIALS WITH DRUGS	MARIA EMILIA DOMINGUEZ RECIO	III
B-01	Estudio fase III. aleatorizado, multicéntrico y controlado con placebo para evaluar la eficacia y la seguridad del péptico HER2/neu GLSI-100 (GP2+GM-CSF) en sujetos con enfermedad residual o RCp de alto riesgo HER2/neu positivo tras tratamiento neoadyuvate bbasada en trastuzumab (FLAMINGO-01)	CLINICAL TRIALS WITH DRUGS	ANA GODOY ORTIZ	III
B-03	Multicéntrico, abierto, brazo único, fase II, Estudio exploratorio para evaluar el efecto de un año de consolidación de tratamiento con ponatinib 15 mg en la tasa de paciente con leucemia mieloide crónica filadelfia positivo en remisión libre de tratamiento que previamente habían alcanzado respuesta molecular profunda con imatinib	INDEPENDENT CLINICAL TRIAL	ANTONIO JIMÉNEZ VELASCO	II
B-05	Ensayo fase III, internacional, multicéntrico, doble ciego, aleatorizado y controlado con placebo de Durvalumab tras el tratamiento con radioterapia estereotáctica corporal (SBRT), para el tratamiento de pacientes con cáncer de pulmón no microcítico, estadio I/II no reseado, con ganglios linfáticos negativos (PACIFIC-4/RTOG-3515)	COMMERCIAL CLINICAL TRIAL	JOSE CARLOS BENÍTEZ MONTAÑÉS	III
B-05	Estudio de Fase IB multicéntrico, abierto de R07082859 y Atezolizumab o Polatuzumab Vedoitna (más una dosis única de Obinutuzumab como pretratamiento) en pacientes adultos con linfoma no Hodgkin de células B recurrente/Refractario.	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
B-05	Estudio de Fase II/III, aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 o placebo en combinación con pembrolizumab para el tratamiento en primera línea del carcinoma de células escamosas de cabeza y cuello recurrente o metastático con expresiónde PD-L1	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
B-05	Estudio clínico de fase 2 aleatorizado abierto y de tres grupos, para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en participantes con carcinoma epidermoide de cabeza y cuello recurrente/metastásico (CECC R/M) que han progresado después del tratamiento con platino e inmunoterapia (inhibidores de PD-1/PD-L1) (LEAP-009)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
B-05	Ensayo aleatorizado fase III de nivolumab en adyuvancia y quimioterapia concomitante en pacientes de alto riesgo con carcinoma de células escamosas de cabeza y cuello reseado (NIVO POST-OP)	INDEPENDENT CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
B-05	Estudio de fase IB, sin enmascaramiento, multicéntrico, no aleatorizado, para evaluar la seguridad, la farmacocinética y la eficacia de mosunetuzumab en combinación con lenalidomida, o R07082859 en combinación con lenalidomida, o R07082859 en combinación con obinutuzumab más lenalidomida en pacientes con linfoma folicular resistente o recidivante	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
B-05	Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de Debio 1143 en combinación con quimioterapia con un derivado del platino y radioterapia de intensidad modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimiorradioterapia definitiva (TrilynX).	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
B-05	Ensayo de fase II abierto, aleatorizado, de BNT113 en combinación con pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) irreseable, recurrente o metastásico, que es positivo para el genotipo 16 del virus del papiloma humano (VPH16+) y expresa PD-L1	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
B-05	Estudio observacional, cuyo objetivo es evaluar la proporción de cáncer de cabeza y cuello (head and neck cancers, HNC) asociado al virus del papiloma humano (VPH), Estudio BROADEN.	NON-POST-AUTHORIZATION STUDY	ANTONIO RUEDA DOMÍNGUEZ	Not applicable
B-05	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y seguridad de tafasitamab más lenalidomida además de rituximab frente a lenalidomida además de rituximab en pacientes con linfoma folicular recidivante/resistente (R/R) de grado 1 a 3a o linfoma de la zona marginal R/R	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III

Group	Title	Subtype	LR Name	Phase
B-05	Estudio de fase Ib, abierto, global, multicéntrico, aleatorizado, de determinación y ampliación de la dosis, para determinar la dosis máxima tolerada y evaluar la seguridad, tolerabilidad, la farmacocinética y la eficacia preliminar de iberdomida (CC-220) en combinación con R-CHOP-21 y de CC-99282 en combinación con R-CHOP-21 en sujetos con linfoma de células B agresivo de bajo riesgo (IPI de 3 a 5) sin tratamiento previo.	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
B-05	Ensayo clínico de fase II de un solo brazo para evaluar la eficacia y seguridad de Bintrafusp alfa (M7824) en el mesotelioma pleural maligno avanzado previamente tratado (BIMES).	INDEPENDENT CLINICAL TRIAL	JOSE CARLOS BENÍTEZ MONTAÑÉS	II
B-05	Estudio en Fase II de ALX148 en combinación con PEMBROLIZUMAB en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (ASPEN-03).	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
B-05	Estudio Fase 1, multicéntrico, abierto para determinar la seguridad, farmacocinética y eficacia preliminar de una molécula pequeña, CC-99282, disponible para administración oral en monoterapia y en combinación con rituximab en sujetos con linfoma no Hodgkin en recaída o refractario (LNH R/R)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
B-05	Nivolumab e Ipilimumab más dos ciclos de quimioterapia basada en platino como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico (CPNM) estadio IV o recurrente con metástasis cerebrales sincrónicas. (NIVUPI-Brain)	INDEPENDENT CLINICAL TRIAL	ALEJANDRA CANTERO GONZÁLEZ	II
B-05	Estudio Fase I, multicéntrico, abierto, de búsqueda de dosis de CC-96673 en sujetos con linfoma no Hodgkin en recaída o refractario	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
B-05	A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor	COMMERCIAL CLINICAL TRIAL	JOSE CARLOS BENÍTEZ MONTAÑÉS	II
B-05	Estudio en fase II de ALX148 en combinación con pembrolizumab y quimioterapia en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (ASPEN-04)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
B-05	Estudio en Fase III, aleatorizado, doble ciego sobre los efectos de Encorafenib y Binimetinib más Pembrolizumab frente a placebo más Pembrolizumab en pacientes con diagnóstico de melanoma metastásico o melanoma localmente avanzado irresecable con mutación V600E/K en Braf positiva.	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
B-05	Ensayo de Fase 3, Abierto, Aleatorizado y Multicéntrico para Evaluar la Eficacia y Seguridad de Trastuzumab Deruxtecan como Tratamiento de Primera Línea en Cáncer de Pulmón No Microcítico, no Resecable y localmente Avanzado o Metastásico que presenta mutación del Exon 19 o 20 de HER2 (Destiny-Lung04)	COMMERCIAL CLINICAL TRIAL	ALEJANDRA CANTERO GONZÁLEZ	III
B-05	Estudio en fase III, abierto y aleatorizado, de LOXO-305 en comparación con un inhibidor de tirosina cinasa de Bruton (BTK, por sus siglas en inglés) a elegir por el investigador, en pacientes con linfoma de células del manto tratados previamente y sin tratamiento previo con inhibidoresde BTK (BRUIN MCL-321).	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
B-05	Estudio de fase 2 de tratamiento combinado con magrolimab en pacientes con carcinoma de células escamosas de cabeza y cuello	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	II
B-05	Estudio de fase III multicéntrico, aleatorizado y doble ciego de HBI-8000 combinado con nivolumab frente a placebo con nivolumab en pacientes con melanoma irresecable o metastásico no tratados previamente con inhibidores de PD-1 o PD-L1	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
B-05	Estudio en fase II, aleatorizado, doble ciego y multicéntrico de retifanimab en combinación con INCAGN02385 (anti-LAG-3) e INCAGN02390 (anti-TIM-3) como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante positivo para PD-L1 (CPS =1).	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	II
B-05	Estudio de fase 2 de multiples brazos de Magrolimab en pacientes con tumores solidos	INDEPENDENT CLINICAL TRIAL	ALEJANDRA CANTERO GONZÁLEZ	II
B-05	Estudio multicéntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirugía y una terapia adyuvante frente a cirugía y una terapia adyuvante en pacientes con melanoma en estadio IIIB/C	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	III

Group	Title	Subtype	LR Name	Phase
B-05	Estudio aleatorizado, prospectivo y multicéntrico para evaluar el impacto de la detección temprana de metástasis cerebrales asintomáticas (metástasis cerebrales) frente al seguimiento estándar en la supervivencia libre de metástasis cerebrales sintomáticas (SBMFS) en pacientes con melanoma no tratado previamente, no resecable o metastásico.	OBSERVATIONAL STUDIES WITH DRUGS	ELISABETH PEREZ RUIZ	Not applicable
B-05	Estudio en fase II abierto y aleatorizado de MORAb-202 (farletuzumab ecteribulina), un conjugado de anticuerpo y fármaco dirigido al receptor a de folato, en participantes con adenocarcinoma (AC) de pulmón no microcítico (ACPNM) metastásico después de haber progresado con tratamientos anteriores	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	II
B-05	Estudio de fase 1b que evalúa la seguridad, tolerabilidad, farmacocinética y eficacia de bemarituzumab en monoterapia y en combinación con otra terapia contra el cancer en sujetos con cáncer de pulmón no microcítico escamoso (FORTITUDE-201)	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	I
B-05	Estudio de fase III de fianlimab (REGN3767, anti-LAG-3) + cemiplimab en comparación con pembrolizumab en pacientes con melanoma metastásico o localmente avanzado inoperable no tratado previamente	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	III
B-05	Estudio de Fase II, aleatorizado, abierto, de encorafenib y binimetinib más pembrolizumab frente a nivolumab e ipilimumab en articipantes con melanoma positivo para la mutación V600E/K EN BRAF que progresó durante o después de un tratamiento previo con erapia anti-pd-1	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	II
B-05	Estudio fase 1b/2 de BMS-986442 en combinación con nivolumab o nivolumab y quimioterapias en participantes con tumores sólidos avanzados y cáncer de pulmón no microcítico.	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	II
B-05	Estudio de Fase III, aleatorizado, abierto y multicéntrico de lurbinectedina en combinación con atezolizumab, en comparación con atezolizumab, como tratamiento de mantenimiento en pacientes con cáncer de pulmón microcítico en enfermedad extensa (CPM-EE) después de tratamiento de inducción de primera línea con carboplatino, etopósido y atezolizumab.	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	III
B-05	Estudio multicéntrico, abierto, de fase I/II de EOS884448 en combinación con el tratamiento estándar y/o terapias experimentales en participantes con tumores sólidos avanzados	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	II
B-05	DAREON™-5: Estudio abierto, multicéntrica fase II de selección de dosis intravenosa de BI 764532, un T cell engager dirigido a DLL3, en pacientes con cáncer extensivo de pulmón microcítico refractario o en recaída y en pacientes con otras carcinomas neuroendocrinos refractarios o en recaída.	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	II
B-05	Estudio en Fase III, abierto y aleatorizado para comparar la eficacia y la seguridad de Odronextamab (REGN1979), un anticuerpo biespecífico ANTI-CD20 y ANTI-CD3, frente al tratamiento elegido por el investigador en participantes con Linfoma Folicular sin tratamiento previo (OLYMPIA-1).	CLINICAL TRIALS WITH DRUGS	ANTONIO RUEDA DOMÍNGUEZ	III
B-05	Estudio fase 1, multicéntrico, abierto, de búsqueda de dosis, para evaluar la seguridad, tolerabilidad, farmacocinética, farmacodinamia y eficacia preliminar de BMS-986458, en monoterapia y en combinación con agentes antilinfoma, en participantes con linfomas no Hodgkin en recaída/ refractarios (LNH R/R).	CLINICAL TRIALS WITH DRUGS	ANTONIO RUEDA DOMÍNGUEZ	I
B-05	Ensayo fase 3, aleatorizado, abierto, multicéntrico de repotrectinib frente a crizotinib en participantes con cáncer de pulmón no microcítico (CPNM), localmente avanzado o metastásico, ROS1-positivo, que no han sido previamente tratados con inhibidores de la tirosina quinasa (TKI) (TRIDENT-3)	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	III
B-05	A Randomized Study of Two Dosing Regimens of Adagrasib in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	II
B-05	BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/?, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)	CLINICAL TRIALS WITH DRUGS	ANTONIO RUEDA DOMÍNGUEZ	II
B-05	Estudio de fase I/II, primero en seres humanos, abierto y de aumento escalonado de la dosis de TAK-280 en pacientes con cáncer no resecable localmente avanzado o metastásico	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	I

Group	Title	Subtype	LR Name	Phase
B-05	Estudio clínico aleatorizado, de fase III, de MK 4280A (coformulación de favezelimab [MK 4280] y pembrolizumab [MK 3475]) en comparación con la quimioterapia de elección del médico en el Linfoma de Hodgkin clásico en recaída o refractario, con resistencia a PD-(L)1 (KEYFORM-008)	CLINICAL TRIALS WITH DRUGS	ANTONIO RUEDA DOMÍNGUEZ	III
B-05	A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	I
B-05	Estudio en fase II, multicéntrico, de varios grupos, abierto y de prueba de concepto de patritumab deruxtecán (HER3-DXd; U3-1402) en sujetos con tumores sólidos localmente avanzados o metastásicos (HERTHENA-PanTumor01).	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	II
B-05	A randomised, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after secondary resistance to anti-PD(L)1 inhibitors.	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	III
B-05	The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Afficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	II
B-05	ESTUDIO FASE I/II ABIERTO PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y ACTIVIDAD ANTITUMORAL PRELIMINAR DE RO7227166 (LIGANDO 4-1BB DIRIGIDO CONTRA CD19) EN COMBINACIÓN CON OBINUTUZUMAB Y CON GLOFITAMAB DESPUÉS DE UNA DOSIS DE PRETRATAMIENTO CON OBINUTUZUMAB, EN PACIENTES CON LINFOMA NO HODGKIN DE LINFOCITOS B RECIDIVANTE/REFRACTARIO	CLINICAL TRIALS WITH DRUGS	ANTONIO RUEDA DOMÍNGUEZ	I
B-05	A phase 3 randomized, controlled study of IMC-F106C plus Nivolumab versus Nivolumab regimens in HLA-A202:01-positive participants with previously untreated advanced melanoma (PRISM-MEL-301)	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	III
B-05	An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice settings in Europe (CEMI-LUNG).	OBSERVATIONAL STUDIES WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	Not applicable
B-05	Registro para recoger datos de las características y resultados de pacientes con Tumores Sólidos a los que se realizó una prueba de secuenciación de nueva generación (WAYFIND-R).	OBSERVATIONAL STUDIES WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	Not applicable
B-05	Estudio ambispectivo, no intervencionista, de cohortes múltiples para evaluar el manejo del tratamiento con osimertinib en pacientes con cáncer de pulmón no microcítico con mutaciones EGFR en condiciones reales en España	OBSERVATIONAL STUDIES WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	Not applicable
B-05	Estudio en fase Ib/II, abierto y de múltiples cohortes para evaluar la seguridad, la eficacia y la dosis óptima de ABBV-400 en combinación con budigalimab en el CPNM no epidermoide avanzado o metastásico sin tratamiento previo en caso de enfermedad avanzada y sin variaciones genómicas accionables (AndroMETa-Lung-536).	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	II
B-10	Estudio observacional para evaluar la eficacia descriptiva en la práctica clínica real en pacientes con psoriasis en placas moderada a grave tratados con brodalumab. Estudio BROACTIVE	COMMERCIAL POST-AUTHORIZATION STUDY	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Ensayo Clínico fase II para evaluar la seguridad y eficacia de dos modelos de piel autóloga creada mediante ingeniería de tejidos en la cirugía reconstructiva del carcinoma basocelular.	INDEPENDENT CLINICAL TRIAL	RICARDO BOSCH GARCÍA	II
B-10	Estudio observacional transversal para la caracterización del Paciente Adulto con Dermatitis Atópica (DA) moderada a grave y la estimación de la prevalencia de la DA en Unidades de Dermatología del ámbito hospitalario en España. (NIS-AD-2193). Estudio DACAR	NON-POST-AUTHORIZATION STUDY	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio observacional prospectivo con pacientes adultos en tratamiento con Dupixent para la dermatitis atópica	COMMERCIAL POST-AUTHORIZATION STUDY	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	P20-441 Uso en vida real de upadacitinib en pacientes adultos y adolescentes que padecen dermatitis atópica de moderada a grave (AD-VICE)	OBSERVATIONAL STUDIES WITH DRUGS	ENRIQUE HERRERA ACOSTA	Not applicable

Group	Title	Subtype	LR Name	Phase
B-10	Estudio observacional retrospectivo en pacientes con Dermatitis Atópica tratados con baricitinib en España (Estudio DAMA-S)	OBSERVATIONAL STUDIES WITH DRUGS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	A multicenter, Prospective, observational study measuring tildrakizumab benefit in Achieving Therapeutic goals in patients with moderate-to-severe plaque psoriasis and inadequate response to previous biologic treatments in clinical practice in Spain.	OBSERVATIONAL STUDIES WITH DRUGS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	BIOBADATOP Registro Español de Dermatitis atópica	OBSERVATIONAL STUDIES WITH DRUGS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	An international, prospective, observational cohort study to assess patient treatment satisfaction, patient-reported outcomes, effectiveness, and safety of a fixed-dose combination of Calcipotriene/ Betamethasone Dipropionate PAD cream in the treatment of mild-to-moderate plaque psoriasis of the scalp in adults (PRO-SCALP)	OBSERVATIONAL STUDIES WITH DRUGS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio en fase IIIb sin enmascaramiento para evaluar la eficacia y la seguridad del tratamiento con lebrikizumab en adultos y adolescentes con dermatitis atópica de moderada a grave.	CLINICAL TRIALS WITH DRUGS	ENRIQUE HERRERA ACOSTA	III
B-10	Registro Español de Hidradenitis Supurativa	OBSERVATIONAL STUDIES WITH DRUGS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio observacional retrospectivo del mundo real para describir el uso de recursos sanitarios y los costes asociados a las vías de tratamiento de la psoriasis en fuentes de datos hospitalarios	OBSERVATIONAL STUDIES WITH DRUGS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio en fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la seguridad y eficacia de lutikizumab en pacientes adolescentes y adultos con hidradenitis supurativa de moderada a grave.	CLINICAL TRIALS WITH DRUGS	ENRIQUE HERRERA ACOSTA	III
B-10	A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT)	CLINICAL TRIALS WITH DRUGS	ENRIQUE HERRERA ACOSTA	III
B-10	Ensayo multicéntrico, aleatorizado, comparativo con placebo, doble ciego, con grupos paralelos para evaluar la seguridad y la eficacia del espesolimab (BI7655130) en pacientes adultos con piodermia gangrenosa (PG) ulcerativa que necesitan tratamiento sistémico	CLINICAL TRIALS WITH DRUGS	ENRIQUE HERRERA ACOSTA	II
B-10	Estudio en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de sonelokimab subcutáneo en participantes adultos con hidradenitis supurativa de moderada a grave	CLINICAL TRIALS WITH DRUGS	ENRIQUE HERRERA ACOSTA	III
B-10	Ensayo de fase III para evaluar la eficacia y seguridad de N-acetil-GED-0507-34-LEVO gel al 5%, aplicado una vez al día durante 12 semanas en pacientes con acné vulgar (GEDACNE-I).	CLINICAL TRIALS WITH DRUGS	ENRIQUE HERRERA ACOSTA	III
B-11	Estudio fase 3 aleatorizado, doble ciego y controlado con placebo de JNJ-56021927 en sujetos con cáncer de próstata localizado o localmente avanzado y de alto riesgo que estén recibiendo tratamiento con radioterapia primaria.	COMMERCIAL CLINICAL TRIAL	RAQUEL CORREA GENEROSO	III
B-11	Un Estudio prospectivo aleatorizado de Fase III de terapia de privación de andrógenos con o sin Radioterapia local con o sin Acetato de Abiraterona y Prednisona en pacientes con cáncer de próstata metastásico sin genera de hormonas.	INDEPENDENT CLINICAL TRIAL	RAQUEL CORREA GENEROSO	III
B-11	Estudio en fase II, aleatorizado y abierto de ODM-201 oral frente al tratamiento de deprivación androgénica (TDA) con agonistas oantagonistas de LHRH en varones con cáncer de próstata sin tratamiento hormonal previo	INDEPENDENT CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	II
B-11	Ensayo mundial fase III, aleatorizado, abierto, multicéntrico de Durvalumab y el Bacilo de Calmette-Guerin (BCG) administrados como terapia combinada en comparación con BCG en monoterapia, en pacientes con cáncer de vejiga no músculo invasivo de alto riesgo sin tratamiento previo con BCG (POTOMAC)	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	RECAP (Registro Español de Cáncer de Próstata). Tratamiento radioterápico en pacientes con cáncer de próstata conforme a la práctica clínica habitual en los servicios de oncología radioterápica españoles	INDEPENDENT POST-AUTHORIZATION STUDY	ANA MARÍA OTERO ROMERO	Not applicable

Group	Title	Subtype	LR Name	Phase
B-11	Estudio fase III, aleatorizado, doble ciego y controlado con placebo sobre el uso de apalutamida en pacientes con cáncer de próstata de alto riesgo, localizado o localmente avanzado candidatos a una prostatectomía radical.PROTEUS	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Ensayo aleatorizado en fase IIIb para comparar la irradiación más la supresión adyuvante de andrógenos a largo plazo con antagonista de la GnRH frente al agonista de la GnRH más prevención de los brotes en pacientes con riesgo muy alto de cáncer de próstata localizado o localmente avanzado. Estudio conjunto ROG y GUCG de la EORTC. Pegasus	INDEPENDENT CLINICAL TRIAL	ANA MARÍA OTERO ROMERO	III
B-11	Estudio piloto de los efectos biológicos de la vitamina D en pacientes con carcinoma urotelial del tracto urinario resecable	INDEPENDENT CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	IV
B-11	Estudio multicéntrico de radioterapia postoperatoria hipofraccionada en pacientes diagnosticados de cáncer de próstata	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ANA MARÍA OTERO ROMERO	Not applicable
B-11	Estudio en fase III, aleatorizado, controlado con placebo y doble ciego de darolutamida además de tratamiento de privación de andrógenos (TPA) frente a placebo más TPA en hombres con cáncer de próstata metastásico sensible a las hormonas (CPMSH) (ARANOTE)	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Estudio clínico de fase 2b para evaluar la eficacia y seguridad de TAR-200 en combinación con cetrelimab, TAR-200 solo o cetrelimab solo en participantes con cáncer de vejiga no músculo-invasivo (CVNMI) de alto riesgo que no responde a la terapia del bacilo de Calmette-Guerin (BCG) intravesical y que no son candidatos o han elegido no someterse a cistectomía radical (SunRISe-1)	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio de fase 3, multinacional, aleatorizado, doble ciego, de no inferioridad, para evaluar la eficacia y la seguridad de HC-1119 oral frente a enzalutamida en el cáncer de próstata resistente a la castración metastásico (CPRCm). PROCADE	COMMERCIAL CLINICAL TRIAL	DAVID HERNANDEZ ALCARAZ	III
B-11	Estudio observacional de darolutamida en pacientes con cáncer de próstata resistente a la castración no metastásico. DAROL	COMMERCIAL POST-AUTHORIZATION STUDY	BERNARDO HERRERA IMBRODA	Not applicable
B-11	Ensayo de fase 3, multicéntrico, abierto y aleatorizado para comparar la seguridad y la eficacia de 177Lu-PSMA-I&T frente al tratamiento hormonal en pacientes con cáncer de próstata resistente a la castración metastásico.	CLINICAL TRIALS WITH DRUGS	DAVID HERNANDEZ ALCARAZ	III
B-11	Estudio de fase III con un solo grupo para evaluar la eficacia y la seguridad de ONCOFID-P-B (conjugado paclitaxel-ácido hialurónico) administrado por vía intravesical a pacientes con carcinoma in situ de vejiga sin respuesta a BCG, con o sin enfermedad papilar Ta-T1	CLINICAL TRIALS WITH DRUGS	FELIPE SÁEZ BARRANQUERO	III
B-11	Estudio de fase 2, multicéntrico, aleatorizado y abierto, de TAR-200 en combinación con cetrelimab y monoterapia con cetrelimab en participantes con carcinoma urotelial de vejiga músculo-invasivo que se vayan a tratar con cistectomía radical y no sean elegibles o rechacen recibir tratamiento con quimioterapia neoadyuvante basada en platino Sunrise 4	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio en fase III abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de TAR200 en combinación con cetrelimab frente al bacilo de Calmette-Guérin (BCG) intravesical en pacientes con cáncer de vejiga no músculo-invasivo de alto riesgo (HR-NMIBC) sin tratamiento previo con el BCG. Sunrise 3	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	III
B-11	Estudio observacional, multinacional y prospectivo de resultados clínicos en pacientes con cáncer de próstata hormonosensible metastásico (CPHSm) tratados con ADT más apalutamida o enzalutamida en la práctica clínica habitual. (Estudio ArtemisPRO).	OBSERVATIONAL STUDIES WITH DRUGS	DAVID HERNANDEZ ALCARAZ	Not applicable
B-11	Estudio en fase III, aleatorizado, controlado con placebo y doble ciego de darolutamida más tratamiento de privación de andrógenos (TPA) en comparación con placebo más TPA en pacientes con cáncer de próstata con recurrencia bioquímica (RB) de alto riesgo	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	III
B-11	Patrones de tratamiento y seguimiento prolongado de los pacientes con cáncer de próstata que recibieron darolutamida en el ensayo ARAMIS – PARASEC.	OBSERVATIONAL STUDIES WITH DRUGS	JUAN ANDRES CANTERO MELLADO	Not applicable

Group	Title	Subtype	LR Name	Phase
B-11	Estudio en fase 3, abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de TAR-200 frente a la quimioterapia intravesical elegida por el investigador en pacientes que recibieron el bacilo de Calmette-Guérin (BCG) y presentan recurrencia con cáncer de vejiga no músculo-invasivo de alto riesgo (HR-NMIBC) y no son elegibles o eligen no someterse a una cistectomía radical	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	III
B-11	Estudio aleatorizado en fase III para evaluar la eficacia y la seguridad del sistema de administración intravesical de erdafitinib TAR-210 en comparación con quimioterapia intravesical en monoterapia en pacientes con cáncer de vejiga no musculo-invasivo de riesgo intermedio (CVSIM-RI) y alteraciones sensibles del FGFR	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	III
B-11	Estudio de fase 3, multicéntrico, con un único grupo, para evaluar la eficacia y la seguridad de UGN-103, una nueva formulación de UGN-102, en el tratamiento de pacientes con cáncer de vejiga sin invasión muscular (CVSIM) de evolución lenta (EL) y riesgo intermedio (RI) de recurrencia (UTOPIA	CLINICAL TRIALS WITH DRUGS	FELIPE SÁEZ BARRANQUERO	III
B-11	Ensayo de fase II, multicéntrico, abiertoy y aleatorizado para evaluar la eficacia de Talazoparib junto con Enzalutamida como tratamiento de primera línea para pacientes con Cáncer de Próstata Metastásico resistente a la castración tras progresión con Abiraterona.	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio de fase I/II de EPI-7386 en combinación con enzalutamida en comparación con enzalutamida sola en sujetos con cáncer de próstata metastásico resistente a la castración	CLINICAL TRIALS WITH DRUGS	ROCIO SANTOS PEREZ DE LA BLANCA	II
B-11	Estudio clínico abierto de fase 1/2 para evaluar la seguridad y la eficacia de sacituzumab tirumotecán (sac-TMT, MK-2870) intravesical en participantes con cáncer de vejiga sin invasión muscular (CVSIM) de riesgo intermedio.	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio de Fase I/II abierto, de escalada de dosis y extensión, de eciskafusp alfa intravesical en combinación con bacilo de CALMETTE-GUÉRIN (BCG) en participantes con cáncer de vejiga no músculo invasivo (CVNMI) de alto riesgo que no responde a BCG	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	II
B-22	Estudio fase III aleatorizado, multicéntrico, abierto de lapatinib, tratuzumab, la administración secuencial de ambos y la administración combinada de ambos como tratamiento adyuvante en pacientes on cáncer de mama HER/ErbB2 positivo	COMMERCIAL CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	III
B-22	LUX–Head & Neck 2. Un estudio aleatorizado, doble ciego, controlado con placebo, en fase III para evaluar la eficacia y la seguridad de afatinib (BIBW 2992) como terapia adyuvante tras quimio-radioterapia en pacientes no sometidos a resección primaria con carcinoma de células escamosas de cabeza y cuello estadio III, IVa o IVb locorreionalmente avanzado	COMMERCIAL CLINICAL TRIAL	ESTHER VILLAR CHAMORRO	III
B-22	Estudio de Fase III, abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de trastuzumab emtansine versus trastuzumab como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo con presencia patológica de tumor residual en la mama o nódulo linfático axilar tras tratamiento preoperatorio. KATHERINE	COMMERCIAL CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	III
B-22	“Estudio de Fase III, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de AZD9291 frente a placebo en pacientes con carcinoma de pulmón no microcítico con mutación del receptor del factor de crecimiento epidérmico, en Estadio IB-IIIa, tras la resección completa del tumor, con o sin quimioterapia adyuvante (ADAURA)”	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Ensayo clínico fase II, exploratorio y multicéntrico, de quimioinmunoterapia neo-adyuvante para el tratamiento del cáncer de pulmón no microcítico estadio III operable	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio fundamental, randomizado y abierto de campos eléctricos para el tratamiento de tumores (TTFields) de forma simultánea con tratamientos de referencia para el tratamiento del cáncer de pulmón no microcítico (NSCLC) en estadio 4 después del fracaso con tratamiento que contenga platino. LUNAR	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MANUEL COBO DOLS	Not applicable
B-22	Ensayo de nivolumab más ipilimumab en combinación con quimioterapia frente a quimioterapia sola como tratamiento de primera línea en el cáncer de pulmón no microcítico (CPNM) en estadio IV	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio observacional, retrospectivo, para analizar el manejo de pacientes con adenocarcinoma ductal de páncreas en la práctica clínica habitual. Estudio PDAC2017	INDEPENDENT POST-AUTHORIZATION STUDY	INMACULADA ALÉS DÍAZ	Not applicable

Group	Title	Subtype	LR Name	Phase
B-22	Estudio de Fase II/III, multicéntrico, para evaluar la eficacia y la seguridad de múltiples terapias dirigidas como tratamiento para pacientes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico portadores de mutaciones somáticas accionables detectadas en sangre (B-FAST: PRIMER ANÁLISIS DE SCREENING EN SANGRE).	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio fundamental, randomizado y en abierto del tratamiento simultáneo con TTFields (campos eléctricos para el tratamiento de tumores, 150 kHz) y gemcitabina y nab-paclitaxel (paclitaxel unido a albúmina en formulación de nanopartículas), como tratamiento de primera línea del adenocarcinoma pancreático en estadio localmente avanzado. PANOVA-3	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	INMACULADA ALÉS DÍAZ	Not applicable
B-22	Estudio de Fase III, doble ciego, aleatorizado y multicéntrico para evaluar la eficacia y la seguridad del tratamiento neoadyuvante con ATEZOLIZUMAB o placebo en combinación con quimioterapia con derivados del platino, en pacientes con Cáncer de Pulmón no Microcítico Resecable en Estadio II, IIIA O IIIB de determinado tipo.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio abierto, multicéntrico, de fase Ib, de escalado de dosis, de MEN1611, un inhibidor de PI3K combinado con trastuzumab ± fulvestrant, en sujetos con cáncer de mama irresecable y localmente recurrente (avanzado) o metastásico (a/m) HER2 positivo con mutación PIK3CA que ha progresado con un tratamiento basado en anti-HER2.	COMMERCIAL CLINICAL TRIAL	BEGOÑA JIMENEZ RODRÍGUEZ	I
B-22	Estudio de Fase III, abierto y aleatorizado para evaluar la eficacia y seguridad de ALECTINIB adyuvante frente a la quimioterapia adyuvante con un derivado del platino en pacientes con carcinoma de pulmón no microcítico positivo para la cinasa del linfoma anaplásico en Estadio IB (tumores = 4 cm) a IIIA completamente extirpado.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio Fase II, aleatorizado, ciego y controlado con placebo de MTIG7192A, un anticuerpo ANTI-TIGIT, en combinación con ATEZOLIZUMAB en pacientes con Cáncer de Pulmón no Microcítico localmente avanzado o metastásico que no han recibido quimioterapia previa.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de extensión y observacional a largo plazo multicéntrico, abierto en pacientes incluidos previamente en un estudio clínico de atezolizumab promocionado por GENENTECH y/o f. HOFFMANN-la roche ltd.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase 3, aleatorizado y doble ciego de quimioterapia con pemetrexed + platino con o sin pembrolizumab (MK-3475) en pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide, metastásico, con mutación de EGFR y resistente a inhibidores de la tirosina cinasa (KEYNOTE-789).	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de largo seguimiento de pacientes con cáncer de mama incluidos en estudios en estadios precoces del grupo GEICAM.	INDEPENDENT CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	IV
B-22	Ensayo Fase III, randomizado, doble ciego, controlado con placebo, multicéntrico, internacional con Osimertinib como tratamiento de mantenimiento en pacientes con cáncer de pulmón no microcítico (estadio III) localmente avanzado e irresecable, con mutación de EGFR positiva, cuya enfermedad no ha progresado después de tratamiento definitivo con quimioradioterapia basada en platino (LAURA)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Ensayo clínico fase Ib, abierto, multicéntrico, de escalada de dosis intrapaciente para evaluar el perfil de seguridad de la combinación de Tilray FS Solución oral T10: C10 (THC + CBD) con temozolomida y radioterapia en pacientes con glioblastoma recién diagnosticado	INDEPENDENT CLINICAL TRIAL	CRISTINA GARCÍA GONZÁLEZ	I
B-22	Ensayo en fase III adaptativo, abierto, controlado, aleatorizado para evaluar la seguridad y eficacia del EndoTAG-1 más Gemcitabina frente a Gemcitabina como monoterapia en pacientes con adenocarcinoma mensurable de páncreas metastásico y /o localmente avanzado que no respondieron al tratamiento con FOLFIRINOX	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	XENERA-1: Ensayo de Fase II multicéntrico, doble-ciego, controlado con placebo y aleatorizado para comparar la eficacia de xentuzumab en combinación con everolimus y exemestano frente a everolimus y exemestano en mujeres posmenopáusicas con cáncer de mama mestastásico HR+/ HER2-y enfermedad no visceral. (XENERA)	COMMERCIAL CLINICAL TRIAL	TAMARA DÍAZ REDONDO	II

Group	Title	Subtype	LR Name	Phase
B-22	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de pemetrexed + quimioterapia a base de platino + pembrolizumab (MK-3475) con o sin lenvatinib (E7080/MK-7902) como intervención de primera línea en participantes con cáncer de pulmón no microcítico, no epidermoide, metastásico (LEAP-006)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio fase III, aleatorizado, doble ciego, controlado con placebo que evalúa la eficacia y seguridad de pembrolizumab más quimioterapia basada en doblete de platino con o sin canakinumab, como terapia de primera línea para pacientes con cáncer de pulmón de células no pequeñas escamoso o no escamoso, localmente avanzado o metastásico (CANOPY-1)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Ensayo clínico Fase II abierto de Atezolizumab en combinación con bevacizumab como primera línea de tratamiento para pacientes con carcinoma de pulmón no microcítico no escamoso localmente avanzado o metastásico seleccionados según carga mutacional tumoral (TMB) alta-intermedia. TELMA	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Ensayo clínico Fase II randomizado de quimioinmunoterapia neo-adyuvante versus quimioterapia sola para el tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) localmente avanzado y potencialmente resecable. NADIM II	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio en fase III, abierto, aleatorizado, multicéntrico y controlado con tratamiento activo para evaluar la eficacia y la seguridad de pemigatinib comparado con quimioterapia con gemcitabina y cisplatino en el tratamiento de primera línea de participantes con colangiocarcinoma no resecable o metastásico con reordenación del FGFR2 (FIGHT-302)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio clínico en fase III aleatorizado, doble ciego, controlado con placebo, para comparar la eficacia y la seguridad de tislelizumab (BGB-A317) más platino y fluoropirimidina frente a placebo más platino y fluoropirimidina como tratamiento de primera línea en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio fase 3 internacional, multicéntrico, doble ciego y aleatorizado, de la eficacia de zolbetuximab (IMAB362) más CAPOX, en comparación con placebo más CAPOX, como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico, claudin (CLDN)18.2 positivo y HER2 negativo	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio de fase 2, abierto, de encorafenib + binimetinib en pacientes con cáncer de pulmón no microcítico con mutación BRAFV600E (C4221008)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Registro de Tumores Torácicos.	NON-POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase 3 de pembrolizumab en combinación con carboplatino/taxano (paclitaxel o nab-paclitaxel), seguido de pembrolizumab con o sin mantenimiento con olaparib, en el tratamiento de primera línea del cáncer de pulmón no microcítico (CPNM) epidermoide metastásico	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase 3, aleatorizado, controlado con placebo y en doble ciego, para evaluar la eficacia y la seguridad de tislelizumab (BGB-A317) en combinación con quimioterapia como tratamiento de primera línea en pacientes con carcinoma de esófago, recurrente, localmente avanzado o metastásico, no resecable.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio de fase 3, aleatorizado y abierto de pembrolizumab (MK-3475) más lenvatinib (E7080/ MK-7902) frente a quimioterapia para el tratamiento de primera línea del carcinoma endometrial avanzado o recurrente (LEAP-001)	COMMERCIAL CLINICAL TRIAL	TAMARA DÍAZ REDONDO	III
B-22	Estudio multicéntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparación con quimiorradioterapia concurrente más placebo seguida de durvalumab en participantes con cáncer de pulmón no microcítico irresecable en estadio III	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab más gemcitabina/cisplatino en comparación con placebo más gemcitabina/cisplatino como tratamiento de primera línea en participantes con carcinoma de vías biliares avanzado o irresecable	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III

Group	Title	Subtype	LR Name	Phase
B-22	Atezolizumab en combinación con Bevacizumab y Quimioterapia versus Bevacizumab y Quimioterapia en el cáncer de ovario recurrente: un ensayo aleatorizado de Fase III	COMMERCIAL CLINICAL TRIAL	ESTHER VILLAR CHAMORRO	III
B-22	Ensayo clínico fase II multicéntrico aleatorizado para evaluar la eficacia y seguridad de la combinación de nivolumab y paclitaxel en primera línea de tratamiento en pacientes con carcinoma escamoso de cabeza y cuello recurrente o metastásico no candidatos a recibir quimioterapia basada en platino (NIVOTAX).	INDEPENDENT CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Ensayo de fase 3 abierto, aleatorizado de SAR408701 versus Docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso metastásico previamente tratados, con tumores positivos a CEACAM5 (CARMEN-LC03)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase III, abierto, aleatorizado y multicéntrico de irinotecán liposómico inyectable, oxaliplatino, 5-fluorouracilo/leucovorina frente a nab-paclitaxel más gemcitabina en pacientes que no han recibido previamente quimioterapia para el adenocarcinoma de páncreas metastásico	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Ensayo fase III, doble ciego, controlado con placebo, Internacional y multicéntrico de tratamiento neoadyuvante/adyuvante de Durvalumab para el tratamiento de pacientes con cáncer de pulmón no microcítico resecable en estadios II y III (AEGEAN)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio fase III, aleatorizado, doble ciego y controlado con placebo de Tiragolumab, un anticuerpo anti-Tigit, en combinación con Atezolizumab en pacientes con cáncer de pulmón no microcítico localmente avanzado irresecable o metastásico no tratado previamente seleccionados por PD-L1.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio pantumoral para el seguimiento a largo plazo de supervivientes de cáncer que han participado en ensayos de investigación de nivolumab	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio en fase III, aleatorizado y abierto de brigatinib (ALUNBRIG®) en comparación con alectinib (ALECENSA®) en pacientes con cáncer de pulmón no microcítico avanzado positivo para cinasa de linfoma anaplásico que han progresado con crizotinib (XALKORI®)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase II, multicéntrico, aleatorizado y abierto que evalúa la eficacia y seguridad de capmatinib (INC280) más pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para cáncer de pulmón de células no pequeñas localmente avanzado o metastásico con PD-L1 >=50 %	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Utilidad clínica de la biopsia líquida como herramienta para evaluar la evolución de pacientes tratados con brigatinib con cáncer de pulmón de células no pequeñas con translocación EML4-ALK: un estudio exploratorio	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de un solo grupo de lorlatinib en participantes con cáncer de pulmón no microcítico (CPNM) positivo para cinasa del linfoma anaplásico (ALK) cuya enfermedad ha progresado después de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generación	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
B-22	Estudio Fase 3 aleatorizado de la combinación de Amivantamab y Lazertinib frente a Osimertinib como tratamiento de Primera Línea en Pacientes con Cáncer de Pulmón No Microcítico Localmente Avanzado o Metastásico con mutación del EGFR. MARIPOSA	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de Fase III, aleatorizado, doble ciego y controlado con placebo de Atezolizumab con o sin Tiragolumab (Anticuerpo Anti-TIGIT) en pacinetes con cardinoma epidermoide de esófago localmente avanzado irresecable.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparación con durvalumab en pacientes con cáncer de pulmón no microcítico localmente avanzado en estadio III irresecable que no han presentado progresión después de quimiorradioterapia con platino concomitante (skyscraper-03)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo de pembrolizumab (MK-3475) en combinación con quimiorradioterapia concomitante seguido de pembrolizumab con o sin olaparib (MK-7339) en comparación con la quimiorradioterapia concomitante sola en participantes con cáncer de pulmón microcítico en estadio limitado (CPM-EL) de diagnóstico reciente y sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III

Group	Title	Subtype	LR Name	Phase
B-22	An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
B-22	Estudio epidemiológico observacional multicéntrico descriptivo sobre tumores digestivos. RETUD (Registro Español Tumores Digestivos)	NON-POST-AUTHORIZATION STUDY	INMACULADA ALÉS DÍAZ	Not applicable
B-22	Ensayo clínico Fase II de tratamiento neoadyuvante con Carboplatino-Pemetrexed-Bevacizumab más Atezolizumab para el tratamiento de pacientes con cáncer de pulmón localmente avanzado y potencialmente resecable y mutaciones de EGFR	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Ensayo fase III, aleatorizado, controlado, multicéntrico de 3 brazos para evaluar osimertinib neoadyuvante en monoterapia o en combinación con quimioterapia, frente a la quimioterapia de referencia, para el tratamiento de pacientes con CPNM resecable con mutación del EGFR positiva (NeoADAURA)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Ensayo Fase III, Randomizado, Doble ciego y controlado con Placebo de Durvalumab y Quimioterapia FLOT Neoadyuvante-Adyuvante seguido de Durvalumab Adyuvante en pacientes con cáncer gástrico y de la unión gastroesofágica resecable (GC/GEJC) (MATTERHORN)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio de paraguas de fase Ib/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamiento basados en múltiples inmunoterapias en pacientes con carcinoma de pulmón no microcítico metastásico (Morpheus Pulmonar)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de fase III aleatorizado de DS-1062a frente a docetaxel en cáncer de pulmón no microcítico avanzado o metastásico sin alteraciones genómicas accionales que ha recibido tratamiento previo. Estudio TROPION-LUNG01	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase 2 de MRTX849 en monoterapia y en combinación con pembrolizumab en pacientes con cáncer de pulmón no microcítico avanzado con mutación KRAS G12C	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio observacional para identificar pacientes con CPNM avanzado/metastásico y translocación de ALK y ROS1 y conocer su manejo terapéutico (IDEALK&ROS).	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	Not applicable
B-22	Estudio BURAN sobre buparlisib (AN2025) en combinación con paclitaxel frente a paclitaxel en monoterapia, para pacientes con carcinoma de células escamosas de cabeza y cuello recurrente o metastásico Estudio BURAN	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio fase 1/2 de relatlimab (anticuerpo monoclonal anti-LAG-3) administrado en combinación con nivolumab (anticuerpo monoclonal anti-PD-1) y BMS-986205 (inhibidor de IDO1) o en combinación con nivolumab e ipilimumab (anticuerpo monoclonal anti-CTLA-4) en tumores malignos avanzados	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio en fase II, aleatorizado, doble ciego de relatlimab más nivolumab en combinación con quimioterapia frente a nivolumab en combinación con quimioterapia como tratamiento de primera línea para los participantes con cáncer de pulmón de células no pequeñas (CPCNP) en estadio IV o recurrente.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio Fase III multicéntrico, abierto, aleatorizado de Entrectinib comparado con Crizotinib en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico on reordenamientos del Gen ROS1, con o sin metástasis en el sistema nervioso central.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Ensayo clínico de fase I para evaluar la seguridad y eficacia de repotrectinib combinado con osimertinib en pacientes con Cáncer de pulmón no microcítico (CPCNP) avanzado o metastásico con mutación del EGFR (TOTEM).	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	I
B-22	Estudio en fase II multicéntrico, abierto en pacientes con cáncer de pulmón no microcítico (CPNM) irresecable o metastásico no tratado anteriormente, CPNM resistente a PD-X recurrente o cáncer epidermoide de cabeza y cuello (CECC) recurrente o metastásico que reciben la proteína de fusión LAG-3 soluble eftilagimod alfa (IMP321) en combinación con pembrolizumab (antagonista de PD-1). TACTI-002 (Dos inmunoterapias activas):	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II

Group	Title	Subtype	LR Name	Phase
B-22	Estudio de Fase 3, aleatorizado, doble ciego, para comparar la eficacia y seguridad de niraparib frente a placebo en participantes con cáncer de mama HER2 negativo con mutación en BRCA o cáncer de mama triple negativo, con enfermedad molecular basada en la presencia de ADN tumoral circulante después de una terapia definitiva (ZEST).	COMMERCIAL CLINICAL TRIAL	BEGOÑA JIMENEZ RODRÍGUEZ	III
B-22	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se evalúa la administración adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusión en el gen RET (LIBRETTO-432)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio en fase III aleatorizado de MRTX849 en comparación con docetaxel en pacientes con y mutación G12C de KRAS previamente tratado	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3 de pembrolizumab (MK-3475) en combinación con quimiorradioterapia concurrente, seguidos de pembrolizumab con o sin olaparib, frente a quimiorradioterapia concurrente seguida de durvalumab en participantes con cáncer de pulmón no microcítico (CPNM) en estadio III, localmente avanzado e irresecable.	COMMERCIAL CLINICAL TRIAL	JOSÉ MIGUEL JURADO GARCÍA	III
B-22	Estudio en fase III abierto y aleatorizado del tratamiento combinado de amivantamab y lazertinib con quimioterapia basada en platino en comparación con quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico con mutación del EGFR localmente avanzado o metastásico tras el fracaso de osimertinib. MARIPOSA 2	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Proyecto basado en encuestas para evaluar la facilidad de uso y el nivel de satisfacción de los pacientes y sus profesionales sanitarios después de utilizar una herramienta de monitorización médica digital para pacientes con cáncer de pulmón	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase III, aleatorizado y abierto para comparar ociperlimab (BGB-A1217) más tislelizumab (BGB-A317) combinados con quimiorradioterapia simultánea (QRTs) seguida de ociperlimab más tislelizumab o tislelizumab más QRTs seguida de tislelizumab frente a QRTs seguida de durvalumab en pacientes con cáncer de pulmón no microcítico irresecable, localmente avanzado y sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	JOSÉ MIGUEL JURADO GARCÍA	III
B-22	Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera línea del cáncer de pulmón metastásico no microcítico metastásico positivo para el gen de fusión RET (BO42864)	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, aleatorizado y doble ciego de MK-7684A en combinación con etopósido y platino seguido de MK-7684A en comparación con atezolizumab en combinación con etopósido y platino seguido de atezolizumab para el tratamiento de primera línea de participantes con cáncer de pulmón microcítico en estadio extenso	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio fase III, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia y seguridad del osimertinib en adyuvancia frente al placebo en pacientes con cáncer de pulmón de células macrocíticas en estadio IA2-IA3 con mutación EGFR positiva, después de una resección tumoral completa. (ADAURA2)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Evaluación fase 1/2a/3 de la seguridad y eficacia de añadir AL3828 (Anlotinib, INN: Catequentinib), un inhibidor del receptor dual tirosina quinasa, a la quimioterapia estándar basada en platino en sujetos con carcinoma endometrial, ovárico, de trompas de Falopio, peritoneal primario o cervical recurrente o metastásico.	COMMERCIAL CLINICAL TRIAL	ESTHER VILLAR CHAMORRO	III
B-22	Estudio de Fase 1b/2, multicéntrico, de un solo grupo de RBN 2397 en combinación con pembrolizumab en pacientes con carcinoma epidermoide pulmonar (CEP)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
B-22	Estudio observacional para describir las características genotípicas y las mutaciones de resistencia en el NSCLC ALK	INDEPENDENT POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase II abierto para evaluar la eficacia y la seguridad de tusamitamab ravtansina en participantes con carcinoma pulmonar no microcítico no escamoso (CPNM NE), con tumores con expresión negativa o moderada de CEACAM5 y niveles de ACE circulante elevados (CARMEN-LC06)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II

Group	Title	Subtype	LR Name	Phase
B-22	Estudio de fase III, abierto, aleatorizado, global y multicéntrico de sacituzumab govitecán frente a docetaxel en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico con progresión durante o después de la quimioterapia a base de platino e inmunoterapia anti-PD-1/PD-L1	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	OPAL Protocolo Maestro:Estudio en paraguas de múltiples cohortes en fase IB/II para evaluar la seguridad y la eficacia de nuevos tratamientos y/o combinaciones de tratamientos en participantes con cáncer de ovario (OPAL).Cohorte C: Estudio de fase II, abierto, aleatorizado, controlado y multicéntrico para comparar niraparib frente a quimioterapia doble con platino-taxano como tratamiento neoadyuvante en participantes con cáncer de ovario en estadio III/IV con deficiencia de recombinación homóloga.	COMMERCIAL CLINICAL TRIAL	ESTHER VILLAR CHAMORRO	II
B-22	Estudio de fase III, multicéntrico y aleatorizado de zanidatamab en combinación con quimioterapia, con o sin tislelizumab, en sujetos con adenocarcinoma gastroesofágico (AGE) irresecable, localmente avanzado o metastásico, con HER-2 positivo (HERIZON-GEA-01)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio de fase 3 aleatorizado, multicéntrico, doble ciego y controlado con placebo de bemarituzumab más quimioterapia frente a placebo más quimioterapia en sujetos con cáncer gástrico o de la unión gastroesofágica avanzado no tratado previamente con sobreexpresión de FGFR2b (FORTITUDE-101)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio en fase II, multicéntrico, abierto, de combinaciones de sacituzumab govitecán como primera línea de tratamiento en pacientes con cáncer de pulmón no microcítico (CPNM) metastásico o avanzado sin alteraciones genómicas de utilidad clínica	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de fase 2 para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de AMG 757 en sujetos con cáncer de pulmón microcítico en recaída/refractario después de dos o más líneas de tratamiento previas	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio de Fase III multicéntrico para evaluar la eficacia y seguridad de múltiples tratamientos en cohortes de pacientes seleccionados basándose en el estado de los biomarcadores, con cáncer de pulmón no microcítico en estadio III localmente avanzado, no resecable.	CLINICAL TRIALS WITH DRUGS	JOSÉ MIGUEL JURADO GARCÍA	III
B-22	Estudio de fase Ib de búsqueda de dosis que evalúa la seguridad y la actividad de [177Lu]Lu-DOTATATE en el cáncer de pulmón avanzado de células pequeñas de nuevo diagnóstico, en combinación con carboplatino, etopósido y tislelizumab en la fase de inducción y en combinación con tislelizumab en la fase de mantenimiento del tratamiento.	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	I
B-22	Ensayo en fase III, aleatorizado, abierto de Dato-DXd más pembrolizumab frente a pembrolizumab en monoterapia en pacientes sin tratamiento previo con cáncer de pulmón no microcítico avanzado o metastásico con PD-L1 alto (PPT =50 %) sin alteraciones genómicas susceptibles de ser dianas terapéuticas (Tropion-Lung08)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio aleatorizado, doble ciego, y controlado con placebo de nab-paclitaxel y gemcitabina con o sin SBP-101 en pacientes con adenocarcinoma ductal de páncreas metastásico no tratados previamente.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
B-22	Estudio en fase II abierto, de un solo grupo y multicéntrico para evaluar la eficacia y la seguridad de taletrectinib en pacientes con CPNM ROS1 positivo avanzado o metastásico y otros tumores sólidos	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio en fase I/II, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia antitumoral de DZD9008 en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutación de EGFR o HER2	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio fase III, randomizado, abierto con savolitinib en combinación con osimertinib versus quimioterapia basada en doblete de platino en participantes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo y que la enfermedad ha progresado tras haber recibido tratamiento con osimertinib (SAFFRON)	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	HERTHENA–Lung02: Estudio en fase III, aleatorizado, abierto de patritumab deruxtecán frente a quimioterapia basada en platino en el cáncer de pulmón no microcítico (CPNM) metastásico o localmente avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFRm) tras el fracaso del tratamiento con inhibidores de la tirosina cinasa (ITC) del factor de crecimiento epidérmico (EGFR)	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	III

Group	Title	Subtype	LR Name	Phase
B-22	Estudio de fase II abierto, multicéntrico y aleatorizado de DS-7300a, un conjugado de anticuerpo y fármaco (CAF) B7-H3, en participantes con cáncer de pulmón microcítico en estadio avanzado (CPM-EA) pretratado	INDEPENDENT CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Ensayo clínico Fase II de combinación de pembrolizumab, lenvatinib y quimioterapia en primera línea para pacientes con cáncer de pulmón de células pequeñas con enfermedad avanzada (EA-CPNM)	INDEPENDENT CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Olaparib y durvalumab (MEDI4736) en pacientes con cáncer de páncreas metastásico y alteraciones en los genes de reparación de daño en el ADN	CLINICAL TRIALS WITH DRUGS	INMACULADA ALÉS DÍAZ	II
B-22	Estudio de fase III aleatorizado, multicéntrico y abierto de Lurbinectedina como agente único o Lurbinectedina en combinación con Irinotecán frente a la elección del investigador (Topotecán o Irinotecán) en Pacientes con cáncer de pulmón de células pequeñas en recaída (CPCP) (Ensayo LAGOON)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase III, abierto, aleatorizado y multicéntrico, de ceralasertib más durvalumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico avanzado o metastásico sin alteraciones genómicas aprovechables terapéuticamente y cuya enfermedad haya progresado durante o después del tratamiento previo con anti-PD-(L)1 y quimioterapia basada en el platino: LATIFY	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio de plataforma de fase 2, aleatorizado, abierto que utiliza el protocolo maestro para evaluar nuevas combinaciones con inmunoterapia en participantes con cáncer de pulmón no microcítico localmente avanzado/metastásico, seleccionados según la expresión del ligando de muerte programada 1, que no han recibido tratamiento previo	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
B-22	Estudio Fase 3, Abierto, Aleatorizado de Lazertinib con Amivantamab Subcutáneo Administrado por Inyección Manual, en Comparación con Amivantamab Intravenoso o Amivantamab Subcutáneo en un Sistema de Administración Corporal, en Pacientes con Cáncer de Pulmón No Microcítico Avanzado o Metastásico con mutación del EGFR tras la Progresión a Osimertinib y Quimioterapia. PALOMA-3.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio en fase II abierto y de cohortes paralelas de amivantamab subcutáneo con diversas pautas posológicas en pacientes con tumores sólidos avanzados o metastásicos, incluido el cáncer de pulmón no microcítico con mutaciones en el gen EGFR. PALOMA-2	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio aleatorizado, abierto, de fase 2/3 para comparar cobolimab + dostarlimab + docetaxel, dostarlimab + docetaxel y docetaxel en monoterapia en participantes con cáncer de pulmón no microcítico avanzado que hayan progresado al tratamiento previo con anti-PD (L)1 y quimioterapia (COSTAR Lung).	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Ensayo multicéntrico, de fase II, abierto y aleatorizado para evaluar la eficacia de Tedopi y docetaxel o Tedopi y nivolumab como tratamiento de segunda línea en el cáncer de pulmón de células no pequeñas metastásico y en progresión tras el tratamiento de primera línea con quimioinmunoterapia (Combi-TED)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
B-22	Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de dos grupos, para evaluar la eficacia y la seguridad de xevinapant y radioterapia en comparación con placebo y radioterapia para demostrar la mejora de la supervivencia sin enfermedad en participantes con carcinoma de células escamosas de cabeza y cuello resecao, que presentan un riesgo alto de recidiva y no son aptos para la administración de dosis altas de cisplatino.	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio en fase III, aleatorizado y abierto para evaluar Zimberelimab y Domvanalimab en combinación con quimioterapia frente a pembrolizumab con quimioterapia, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico sin aberraciones tumorales genómicas del receptor del factor de crecimiento epidérmico ni de la quinasa del linfoma anaplásico	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Registro de enfermedades en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con alteraciones por omisión de METex14 MOMENT (Met nOn sMall cEll caNcer registry)	OBSERVATIONAL STUDIES WITH DRUGS	MANUEL COBO DOLS	Not applicable
B-22	Estudio de Fase II, de un único brazo y abierto para evaluar la seguridad y la farmacocinética de una combinación a dosis fija por vía intravenosa (CDF IV) de Tiragolumab y Atezolizumab en pacientes con tumores sólidos localmente avanzados, recurrentes o metastásicos.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II

Group	Title	Subtype	LR Name	Phase
B-22	A Randomized Phase 3 Study of Datopotamab Deruxtecán (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) / Estudio en fase III aleatorizado de datopotamab deruxtecán (Dato-DXd) y pembrolizumab, con o sin quimioterapia con platino, en sujetos sin tratamiento previo para cáncer de pulmón avanzado o metastásico con TPS PD-L1 <50 % no microcítico no epidermoide sin alteraciones genómicas susceptibles de ser dianas terapéuticas (TROPION-Lung07).	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio de fase III, aleatorizado, en doble ciego y controlado con placebo, de platino y pemetrexed como quimioterapia más osimertinib frente a platino y pemetrexed como quimioterapia más placebo en pacientes con cáncer de pulmón no microcítico con mutación del EGFR, localmente avanzado o metastásico, que ha progresado extracranalmente tras el tratamiento de primera línea con osimertinib (COMPEL)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio de fase III, abierto, aleatorizado, multicéntrico y global para investigar la eficacia y la seguridad de furmonertinib en comparación con quimioterapia basada en platino como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio en fase I/II, abierto, de escalada de dosis y ampliación de la dosis del agonista de TLR7/8 TransCon, en monoterapia o en combinación con pembrolizumab, en participantes con tumores sólidos malignos localmente avanzados o metastásicos	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio de fase II, abierto, multicéntrico y aleatorizado, del tratamiento neoadyuvante y adyuvante de pacientes con cáncer de pulmón no microcítico resecable, en estadio inicial (II a IIIA) (NeoCOAST-2)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
B-22	Estudio observacional ambispectivo que describe los patrones de diagnóstico y de tratamiento en adultos con carcinomas pulmonares no microcíticos metastásicos con mutación del gen BRAF V600E en la práctica clínica, para evaluar la efectividad del tratamiento y la calidad de vida OCTOPUS	OBSERVATIONAL STUDIES WITH DRUGS	MANUEL COBO DOLS	Not applicable
B-22	Ensayo clínico fase II de quimio-inmunoterapia neoadyuvante seguida de tratamiento adyuvante según el estado de resección para el tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) con diagnóstico de tumor de pancoast. Un estudio exploratorio multicéntrico. DUMAS	CLINICAL TRIALS WITH DRUGS	JOSÉ MIGUEL JURADO GARCÍA	III
B-22	Estudio multicéntrico, sin enmascaramiento, con un grupo de referencia aleatorizado para evaluar la eficacia, la seguridad y la farmacocinética de berubicina mediante infusión intravenosa en pacientes adultos con glioblastoma multiforme (grado IV de la OMS) recidivante tras el fracaso del tratamiento de referencia de primera línea	CLINICAL TRIALS WITH DRUGS	CRISTINA GARCÍA GONZÁLEZ	II
B-22	Profilaxis de la enfermedad tromboembólica venosa con HBPM (TINzaparina) en pacientes con cáncer colorrectal metastásico que inician la primera línea de tratamiento.	CLINICAL TRIALS WITH DRUGS	DAVID FERNANDEZ GARAY	II
B-22	Estudio de fase 1, primero en el ser humano, de búsqueda de dosis/Estudio de fase 2, aleatorizado, de IMM60 y pembrolizumab en el melanoma avanzado y en el cáncer de pulmón no microcítico metastásico	CLINICAL TRIALS WITH DRUGS	JOSÉ MIGUEL JURADO GARCÍA	I
B-22	Estudio de fase Ib/II, multicéntrico, abierto, para evaluar la seguridad/tolerabilidad, la farmacocinética y la eficacia de GFH925 en combinación con cetuximab en pacientes con CPNM con mutación KRAS G12C en estadio avanzado no tratado previamente	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio en fase II, aleatorizado y abierto para evaluar la eficacia y la seguridad de zolbetuximab (IMAB362) en combinación con nab paclitaxel y gemcitabina (Nab-P + GEM) como tratamiento de primera línea en pacientes con adenocarcinoma de páncreas metastásico con presencia de claudina-18.2 (CLDN18.2)	OBSERVATIONAL STUDIES WITH DRUGS	INMACULADA ALÉS DÍAZ	Not applicable
B-22	ESTUDIO EN FASE I/II DE CEMIPLIMAB (ANTICUERPO ANTI-PD-1) EN COMBINACIÓN CON BNT116 (FIXVAC DE PULMÓN) COMPARADO CON CEMIPLIMAB EN MONOTERAPIA COMO TRATAMIENTO DE PRIMERA LÍNEA EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) AVANZADO CON TUMORES CON EXPRESIÓN DE PD-L1 =50 %	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II

Group	Title	Subtype	LR Name	Phase
B-22	Estudio aleatorizado y abierto de fase 3 en el que se compara tarlatamab con el tratamiento estándar en sujetos con cáncer de pulmón microcítico en recaída después de recibir quimioterapia de primera línea basada en platino (DeLLphi-304)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio en fase I/II, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica y la eficacia de CLN-081 en pacientes con carcinoma pulmonar no microcítico localmente avanzado o metastásico con mutaciones por inserción en el exón 20 del EGFR que han recibido anteriormente quimioterapia sistémica con un derivado del platino	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
B-22	Estudio preliminar, de un solo grupo, del uso concomitante de campos eléctricos para el tratamiento de tumores (TTFields, 150 kHz) y atezolizumab, gemcitabina y nab-paclitaxel como tratamiento de primera línea del adenocarcinoma ductal pancreático etastásico (ADPm)	CLINICAL TRIALS WITH DRUGS	INMACULADA ALÉS DÍAZ	I
B-22	An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies (DDRiver NSCLC 322)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONI)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio intervencional tipo plataforma para investigar el impacto de las soluciones de salud digital en los resultados en la salud y la utilización de recursos sanitarios en participantes que reciben tratamiento sistémico en la práctica clínica (ORIGAMA).	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	IV
B-22	Estudio de Fase II multicéntrico, aleatorizado, doble ciego, controlado, de R07247669 más quimioterapia basada en platino frente a Pembrolizumab más quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico no tratados previamente	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Ensayo abierto, de fase 2b, global multicéntrico de cohortes para evaluar la seguridad y la eficacia de Zipalertinib en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico coninserciones del Exón 20 y mutaciones poco frecuentes/simples o compuestas del receptor del factor de crecimiento epidérmico.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
B-22	A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer (HARMONI-3)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Ensayo Fase III, randomizado, en dos brazos paralelos, abierto, multicéntrico, internacional para comparar la eficacia de volrustomig (MEDI5752) en combinación con quimioterapia en primera línea de tratamiento vs pembrolizumab en combinación con quimioterapia en pacientes con cáncer de pulmón no microcítico avanzado (eVOLVE-Lung02).	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio en fase II abierto y aleatorizado que evalúa el impacto del tratamiento dermatológico mejorando frente al de referencia en acontecimientos adversos dermatológicos seleccionados en pacientes con CPNM localmente avanzado o metastásico con mutación del EGFR tratados en primera línea con amivantamab + lazertinib (COCOON)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio pivotal internacional en participantes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación en KRAS G12C para comparar el tratamiento de primera línea con LY3537982 y pembrolizumab frente a placebo y pembrolizumab en pacientes con expresión de PD-L1 =50% o con LY3537982 y pembrolizumab, pemetrexed, platino frente a placebo y pembrolizumab, pemetrexed, platino con independencia de la expresión de PD-L1 (SUNRAY-01)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase III, abierto, aleatorizado, multicéntrico, de DZD9008 frente a quimioterapia basada en doblete con platino como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación de inserción del exón 20 del receptor del factor de crecimiento epidérmico	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III

Group	Title	Subtype	LR Name	Phase
B-22	Retrospective, observational, multicentric and non-interventional study in Spain. Real-world trends in clinical management of metastatic non-small cell lung cancer patients (REVEAL Study)	OBSERVATIONAL STUDIES WITH DRUGS	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase 3 multicéntrico, aleatorizado y abierto que evalúa la eficacia de la combinación de doblete de platino con sotorasib frente a la combinación de doblete de platino con pembrolizumab como tratamiento de primera línea en sujetos con cáncer de pulmón no microcítico y no escamoso en estadio IV o en estadio IIIB/C avanzado, negativo para PD-L1 y positivo para p.G12C en el KRAS (CodeBreak 202)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, aleatorizado, doble ciego y multicéntrico de MK-1084 en combinación con pembrolizumab en comparación con pembrolizumab más un placebo como tratamiento de primera línea de participantes con CPNM metastásico con mutación KRAS G12C y TPS de PD-L1 =50%	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, abierto y aleatorizado de MK-2870 en comparación con quimioterapia (docetaxel o pemetrexed) en pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide, avanzado o metastásico, tratado previamente, con mutaciones de EGFR u otras alteraciones genómicas.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	An open-label randomized trial of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (BTC)	CLINICAL TRIALS WITH DRUGS	INMACULADA ALÉS DÍAZ	
B-22	Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Randomized, Controlled, Open-label, Phase 3, Global MultiCenter Trial to Assess the Efficacy and Safety of Ziplertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Ensayo internacional Fase III, Randomizado, Doble ciego, controlado con Placebo, multicéntrico, de Rilvegostomig en combinación con quimioterapia como tratamiento adyuvante tras Resección del cáncer de las vías biliares con intención curativa (ARTEMIDE-Biliary01)	CLINICAL TRIALS WITH DRUGS	INMACULADA ALÉS DÍAZ	III
B-22	Un estudio de fase 3, abierto, multicéntrico, aleatorizado de tarlatamab en combinación con durvalumab versus solo durvalumab en sujetos con cáncer de pulmón de células pequeñas en estadio extenso después de platino, etopósido y durvalumab (DeLLphi-305)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	1479-0008BEAMION Lung-2: estudio de fase III, abierto, aleatorizado, con control activo y multicéntrico para evaluar BI 1810631 por vía oral en comparación con el tratamiento de referencia como tratamiento de primera línea en pacientes con carcinoma pulmonar no microcítico no escamoso irresecable, localmente avanzado o metastásico con mutaciones del dominio tirosina-quinasa de HER2	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours.	CLINICAL TRIALS WITH DRUGS	INMACULADA ALÉS DÍAZ	I
B-22	Estudio en fase II/III, aleatorizado y doble ciego de fianlimab (anticuerpo anti-LAG-3) en combinación con cemiplimabanticuerpo anti-PD-1) en comparación con cemiplimab en monoterapia como tratamiento de primera línea en cientes con cáncer de pulmón no microcítico (CPNM) avanzado con tumores que expresen PD-L1 =50 %	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
B-22	LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer .	CLINICAL RESEARCH WITH MEDICAL DEVICES	AIRAM AYOZE PADILLA ALVAREZ	Not applicable
B-22	Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy.	CLINICAL RESEARCH WITH MEDICAL DEVICES	MANUEL COBO DOLS	Not applicable

Group	Title	Subtype	LR Name	Phase
B-22	Estudio en fase III, multicéntrico, aleatorizado y sin enmascaramiento de ifinatamab deruxtecán (I-DXd), un conjugado anticuerpo-fármaco (CAF) B7-H3 frente al tratamiento elegido por el médico (TPC) en participantes con carcinoma pulmonar de células pequeñas (CPCP) recidivante (IDeate-Lung02).	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de plataforma sobre combinaciones de inhibidores de RAS(ON) en pacientes con cáncer de pulmón no microcítico (CPNM) con mutación de RAS"/ "Estudio de fase 1b/2, abierto y multicéntrico de RMC-6291 en combinación con pembrolizumab, con o sin quimioterapia, en pacientes con tumores sólidos con mutación KRASG12C: subprotocolo A.	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	I
B-22	Ensayo aleatorizado de fase I/II en pacientes con carcinoma de células escamosas de la cabeza y el cuello (SCCHN) locorregionalmente avanzado, negativo para el VPH, de diagnóstico reciente, en el que se evalúa una inmunoterapia dirigida al mutanoma iniciada al finalizar el tratamiento primario o en el momento de la recidiva.	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	I
B-22	A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker – Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/ HER2-early breast cancer (ADAPTlate)	CLINICAL TRIALS WITH DRUGS	TAMARA DÍAZ REDONDO	III
B-22	Primer estudio en seres humanos de STX-721 en participantes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del gen EGFR.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
B-22	Estudio de fase 3, abierto y aleatorizado de MK-2870 combinado con pembrolizumab en comparación con pembrolizumab en monoterapia en el tratamiento de primera línea de participantes con cáncer de pulmón no microcítico metastásico con una TPS de PD-L1 superior o igual al 50%	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio de plataforma sobre combinaciones de inhibidores de RAS(ON) en pacientes con cáncer de pulmón no microcítico (CPNM) con mutación de RAS"/ "Estudio de fase 1b/2, abierto y multicéntrico de RMC-6236 en combinación con pembrolizumab, con o sin quimioterapia, en pacientes con cáncer de pulmón no microcítico (CPNM) con mutación de RAS: subprotocolo B	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
B-22	Estudio en Fase III multicéntrico, abierto, randomizado para evaluar la eficacia y la seguridad de divarasib comparado con sotorasib o adbrasib en pacientes con cáncer de pulmón no cicrcítico KRAS G12C ppositivo avanzado o metastásico, tratados previamente.	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico sobre el tratamiento con tarlatamab en sujetos con cáncer de pulmón microcítico en estadio limitado (CPM-EL) que no han progresado tras la quimiorradioterapia concurrente (DeLLphi-306).	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 1b para evaluar la seguridad, tolerabilidad, farmacocinética y actividad antitumoral preliminar de tarlatamab subcutáneo en sujetos con cáncer de pulmón microcítico en estadio extenso (DeLLphi-308)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	I
B-22	Estudio de fase 3, aleatorizado, abierto, de nivolumab + relatlimab en combinación a dosis fijas con quimioterapia frente a Pembrolizumab con quimioterapia como tratamiento de primera línea en participantes con cáncer de pulmón no microcítico no escamoso (NESC), en estadio IV o recurrente y con expresión de PD-L1 en las células tumorales del 1% al 49%.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
B-22	Estudio de fase I-III multicéntrico para evaluar la eficacia y seguridad de múltiples tratamientos en cohortes de pacientes con cáncer de pulmón no microcítico en estadio I-III resecable, seleccionados de acuerdo con el estado de los Biomarcadores.	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	I
B-22	A Post-Hoc Exploratory Outcomes Analysis of the Phase II PANOVA (EF-20) Trial	CLINICAL TRIALS WITH DRUGS	INMACULADA ALÉS DÍAZ	II
BA-20	Efectividad de los nuevos tratamientos para el cáncer de próstata localizado de bajo riesgo	NON-POST-AUTHORIZATION STUDY	ISMAEL HERRUZO CABRERA	Not applicable
BA-20	Estudio postautorización, multicéntrico, observacional, retrospectivo, de evaluación de seguridad, tolerabilidad y efectividad en el tratamiento con fármacos antiepilépticos en pacientes con crisis epilépticas secundarias a tumor cerebral tratados con radioterapia. NERAD	INDEPENDENT POST-AUTHORIZATION STUDY	ASUNCION VILLANUEVA ALVAREZ	Not applicable

Group	Title	Subtype	LR Name	Phase
BA-20	RECAP (Registro Español de Cáncer de Próstata). Tratamiento radioterápico en pacientes con cáncer de próstata conforme a la práctica clínica habitual en los servicios de oncología radioterápica españoles	INDEPENDENT POST-AUTHORIZATION STUDY	ASUNCION VILLANUEVA ALVAREZ	Not applicable
BA-20	Estudio pivotal, multinacional, aleatorizado, doble ciego y controlado con placebo, de SGX942 (Dusquetide) para el tratamiento de la mucositis oral en pacientes con carcinoma de células escamosas de cabeza y cuello tratado con quimiorradiación concomitante	COMMERCIAL CLINICAL TRIAL	JORGE CONTRERAS MARTÍNEZ	III
BA-20	Estudio de fase I de aumento escalonado de la dosis de NBTXR activado mediante radioterapia de intensidad modulada en pacientes con carcinoma de células escamosas localmente avanzado en la cavidad bucal o la orofaringe	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JORGE CONTRERAS MARTÍNEZ	Not applicable
BA-20	Estudio multicéntrico de radioterapia postoperatoria hipofraccionada en pacientes diagnosticados de cáncer de próstata	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ISMAEL HERRUZO CABRERA	Not applicable
BA-20	Estudio de fase III (etapa pivotal) de NBTXR3 activado por radioterapia, en monoterapia o en combinación con cetuximab a elección del investigador, en pacientes ancianos con carcinoma de células escamosas de cabeza y cuello localmente avanzado, que no cumplen los requisitos para recibir quimioterapia basada en platino	OBSERVATIONAL STUDIES WITH DRUGS	JORGE CONTRERAS MARTÍNEZ	Not applicable
BA-20	Linfadenectomía axilar versus Radioterapia axilar en pacientes con cáncer de mama y ganglio centinela positivo tras terapia neoadyuvante. Estudio multicéntrico aleatorizado. (ADARNAT)	CLINICAL RESEARCH WITH MEDICAL DEVICES	ISMAEL HERRUZO CABRERA	Not applicable
BE-03	Ensayo adaptativo de fase 3 aleatorizado, abierto y controlado para investigar la eficacia, seguridad y tolerabilidad del anticuerpo BiTE® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en sujetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo	COMMERCIAL CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	III
BE-03	Infusión de células Natural Killer como tratamiento de consolidación en niños y adolescentes con leucemia mieloblástica aguda.	INDEPENDENT CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	II
BE-03	Estudio observacional prospectivo para evaluar la precocidad, estabilidad y profundidad de la respuesta molecular en pacientes recién diagnosticados de leucemia mieloide crónica en fase crónica (LMC-FC) tratados con inhibidores de la actividad tirosina-quinasa (ITK) como tratamiento de primera línea en la práctica clínica	INDEPENDENT POST-AUTHORIZATION STUDY	CONCEPCIÓN RUÍZ NUÑO	Not applicable
BE-03	Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico del inhibidor PI3K intravenoso Copanlisib en combinación con inmunquimioterapia estándar versus inmunquimioterapia estándar en pacientes con linfoma no Hodgkin indolente tras recaída	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	III
BE-03	Estudio de fase IV multinacional para evaluar el patrón de tratamiento en la vida real en pacientes con hemofilia A tratados previamente que reciben KOVALTRY (octocog alfa) para la profilaxis habitual. TAURUS	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Estudio prospectivo de 24 meses, multicéntrico, no intervencional para evaluar la efectividad de Elocta en comparación con productos del factor convencional en el tratamiento profiláctico de pacientes con hemofilia A. (Sobi.Elocta-002)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Estudio de fase I/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de BAX 888, un vector de virus adenoasociado de serotipo 8 (VAA8) que expresa un factor VIII con el dominio B eliminado (B-Domain Deleted Factor VIII, BDD-FVIII) en sujetos con hemofilia A grave administrado como infusión única por vía intravenosa.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	I
BE-03	Trasplante alogénico de células madre en niños y adolescentes con leucemia linfoblástica aguda - FORUM (Para omitir radioterapia por debajo de la mayoría de edad)	INDEPENDENT CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	III
BE-03	Estudio observacional prospectivo sobre la supervivencia global y la calidad de vida en pacientes mayores de 60 años diagnosticados de leucemia mieloide aguda en España, tratados según la práctica clínica habitual. (Estudio SvLMA).	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL BARRIOS GARCÍA	Not applicable
BE-03	Estudio internacional para el tratamiento de la LLA infantil de alto riesgo 2010. IntReALL HR 2010	INDEPENDENT CLINICAL TRIAL	ANA ISABEL RODRÍGUEZ JIMÉNEZ	II

Group	Title	Subtype	LR Name	Phase
BE-03	Estudio prospectivo, multinacional y observacional en pacientes con hemofilia A y B, con o sin inhibidores, tratados según la práctica clínica habitual (explorer™6)Código Promotor: NN7415-4322	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de la profilaxis con letermovir (LET) cuando se prolonga de 100 a 200 días después del trasplante en receptores seropositivos para el citomegalovirus (CMV) (R+) de un trasplante alogénico de células madre hematopoyéticas (TCMH)	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCÓN	III
BE-03	Estudio posautorización de seguridad, no intervencionista, en pacientes con linfoma recurrente o resistente de células del manto, para seguir investigando y caracterizando la asociación de lenalidomida con la reacción de exacerbación tumoral y carga tumoral elevada. Code Sponsor's Protocol: CC-5013-MCL-005	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL ESPESO DE HARO	Not applicable
BE-03	Estudio fase II con aleatorización 2:1 para comparar la eficacia y seguridad del tratamiento con quimioterapia estándar más quizartinib frente a quimioterapia estándar más placebo en pacientes adultos con LMA de nuevo diagnóstico con el gen FLT3 no mutado	INDEPENDENT CLINICAL TRIAL	MANUEL BARRIOS GARCÍA	II
BE-03	Estudio prospectivo español de pacientes hematológicos pre y postrasplante hematopoyético que ingresan en unidades de cuidados intensivos: análisis de la práctica clínica, resultados en salud, factores pronósticos y utilización de recursos sanitarios.	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ÁNGELES CUESTA CASAS	Not applicable
BE-03	Guía de recomendaciones de la SEHOP para el tratamiento de la Leucemia Linfobástica Aguda o Bifenotípica del lactante menor de 1 año	NON-POST-AUTHORIZATION STUDY	ANA ISABEL RODRÍGUEZ JIMÉNEZ	Not applicable
BE-03	Estudio fase III aleatorizado abierto para comparar el tratamiento con azacitidina más pevonedistat frente a azacitidina en adultos con LMA de nuevo diagnóstico ancianos y/o no candidatos a quimioterapia estándar de inducción	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
BE-03	Estudio internacional del tratamiento y resultados de la leucemia mieloide crónica (LMC) en niños y adolescentes Sponsor Code: I-CML-Ped Study	INDEPENDENT POST-AUTHORIZATION STUDY	ANTONIA PASCUAL MARTÍNEZ	Not applicable
BE-03	Estudio de fase II, multicéntrico, abierto, de un solo brazo , de ruxolitinib añadido a corticosteroides en sujetos pediátricos con enfermedad de injerto contra huésped crónica moderada y grave tras trasplante alogénico de células madre.	COMMERCIAL CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	II
BE-03	Estudio fase II, exploratorio, multicéntrico, abierto, no controlado, para evaluar la reinducción y la segunda parada a un TKI como ponatinib en pacientes con LMC en respuesta molecular (ResToP).	INDEPENDENT CLINICAL TRIAL	CONCEPCIÓN RUÍZ NUÑO	II
BE-03	Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B sin inhibidores.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
BE-03	Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
BE-03	Estudio de fase III, aleatorizado, abierto y multicéntrico, para comparar zanubrutinib (BGB-3111) más rituximab frente a bendamustina más rituximab en pacientes con linfoma de células del manto no tratados previamente que no son aptos para recibir un trasplante de células madre.	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	III
BE-03	Estudio de fase Ib, abierto, aleatorizado, para evaluar la seguridad y la eficacia preliminar de Tafasitamab en combinación con R-CHOP o Tafasitamab más Lenalidomida en combinación con R-CHOP en pacientes con linfoma difuso de células B grandes (LDCBG) de nuevo diagnóstico -First-MIND	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	I
BE-03	Estudio observacional, multicéntrico de 48 meses de seguimiento para evaluar la eficacia a largo plazo de Elocta en la salud articular. Estudio A-MORE-ES	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Seguridad, tolerabilidad, farmacocinética y farmacodinámica de dosis subcutáneas únicas y múltiples de NNC0365-3769 (Mim8) en pacientes sanos y en pacientes con hemofilia A con o sin inhibidores del factor VIII. (FRONTIER I)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	II

Group	Title	Subtype	LR Name	Phase
BE-03	Estudio de fase 2b, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de EDP-938 en adultos receptores de un trasplante de células hematopoyéticas con infección aguda de las vías respiratorias altas por el virus respiratorio sincitial	COMMERCIAL CLINICAL TRIAL	MARÍA ÁNGELES CUESTA CASAS	II
BE-03	Estudio de fase III, abierto, aleatorizado y multicéntrico de ravulizumab en pacientes adultos y adolescentes que presentan microangiopatía trombótica (MAT) después de un trasplante de células madre hematopoyéticas (TCMH)	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCÓN	III
BE-03	Evaluación de la seguridad a largo plazo de ADYNOVI/ADYNOVATE (factor antihemofílico [recombinante] pegilado, ruriotocog alfa pegol) en pacientes con hemofilia A: un estudio de seguridad posterior a la autorización (PASS) de ADYNOVI/ADYNOVATE. (TAK-660-403)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Estudio observacional prospectivo para investigar la relación entre la duración del tratamiento (DoT) y la respuesta en pacientes con mieloma múltiple (MM) o amiloidosis sistémica (AL) tratados en condiciones de práctica clínica real. DOranT Study Sponsor Code: C16054	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALÁ PEÑA	Not applicable
BE-03	ENHANCE: Estudio multicéntrico, doble ciego y aleatorizado para comparar magrolimab en combinación con azacitidina frente a azacitidina más placebo en pacientes con síndrome mielodisplásico de alto riesgo sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
BE-03	Ensayo multinacional, abierto, aleatorizado y controlado para investigar la eficacia y la seguridad de NNC0365-3769 (Mim8) en adultos y adolescentes con hemofilia A con o sin inhibidores	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
BE-03	Impacto del desbalance del metaboloma y microbioma intestinales de receptores de trasplante hematopoyético en el desarrollo de enfermedad injerto contra huésped	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA JESÚS PASCUAL CASCÓN	Not applicable
BE-03	Estudio en fase II, de dosis múltiples ascendentes, aleatorizado, doble ciego y controlado con placebo de ALXN1830 administrado por vía subcutánea en pacientes con anemia hemolítica autoinmunitaria por anticuerpos calientes (WAIHA)	COMMERCIAL CLINICAL TRIAL	MAGDALENA ALCALÁ PEÑA	II
BE-03	Ensayo de fase 3, multicéntrico, doble ciego y controlado con placebo de Viralym-M (ALVR105) en el tratamiento de pacientes con cistitis hemorrágica asociada a virus tras un alotrasplante de células hematopoyéticas	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCÓN	III
BE-03	Estudio de fase IV, multicéntrico y abierto para evaluar la Salud general, la actividad física y los resultados articulares en participantes de 13 años o más y menos de 70 años con Hemofilia a grave o moderada sin inhibidores del FVIII que reciben profilaxis con emicizumab	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	IV
BE-03	Un ensayo aleatorizado multicéntrico de fosfomicina frente a ciprofloxacino para la neutropenia febril en pacientes hematológicos: eficacia y seguridad microbiológica.	INDEPENDENT CLINICAL TRIAL	MARÍA ÁNGELES CUESTA CASAS	III
BE-03	Estudio postautorización internacional, prospectivo, abierto, no controlado y no intervencionista de turoctocog alfa pegol (N8-GP) durante la profilaxis habitual y tratamiento a largo plazo de los episodios de sangrados en pacientes con hemofilia A	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Estudio en fase III, aleatorizado, abierto, con control activo, multicéntrico, para evaluar la eficacia y la seguridad de Crovalimab frente a Eculizumab en pacientes adultos y adolescentes con hemoglobinuria paroxística nocturna (HPN) actualmente tratada con inhibidores del complemento. Estudio COMMODORE	COMMERCIAL CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
BE-03	Estudio abierto para investigar la eficacia, la seguridad y la farmacocinética de la profilaxis con concizumab en niños menores de 12 años con hemofilia A o B con o sin inhibidores NN7415-4616	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
BE-03	Estudio de fase 1/2, abierto, de aumento escalonado de la dosis para evaluar la seguridad, la tolerabilidad, la eficacia preliminar y la farmacocinética de TAK-981 en pacientes adultos con tumores sólidos avanzados o metastásicos o con neoplasias malignas hematológicas recidivantes/resistentes	INDEPENDENT CLINICAL TRIAL	MANUEL ESPESO DE HARO	II
BE-03	Estudio en fase III, aleatorizado, abierto, para evaluar la seguridad y la eficacia de magrolimab en combinación con azacitidina frente a la elección del médico de venetoclax más azacitidina o quimioterapia intensiva, en pacientes con leucemia mieloide aguda y TP53 mutado no tratados previamente	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III

Group	Title	Subtype	LR Name	Phase
BE-03	PRAME Protocolo de registro y análisis de macroglobulinemia de waldenström en España	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALÁ PEÑA	Not applicable
BE-03	Estudio de los parámetros clínicos y biológicos determinantes de respuesta en pacientes con LLC tratados en primera línea con Ibrutinib (IBROMICS)	OBSERVATIONAL STUDIES WITH DRUGS	MACARENA ORTIZ PAREJA	Not applicable
BE-03	Estudio en fase III, aleatorizado, con doble enmascaramiento y controlado con placebo para evaluar la seguridad y la eficacia de magrolimab frente a placebo en combinación con venetoclax y azacitidina en pacientes con leucemia mieloide aguda recién diagnosticados, no tratados previamente y que no son aptos para la quimioterapia intensiva	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
BE-03	A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydouridine (NDec) in patients with sickle cell disease ESTUDIO MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DECITABINA-TETRAHIDROURIDINA ORAL (NDec) EN PACIENTES CON ANEMIA FALCIFORME	CLINICAL TRIALS WITH DRUGS	ALEJANDRO CONTENTO GONZALO	II
BE-03	Estudio de fase 3, de dos etapas, aleatorizado, multicéntrico, abierto, para comparar CC 92480 (BMS-986348), carfilzomib y dexametasona (480Kd) frente a carfilzomib y dexametasona (Kd) en participantes con mieloma múltiple en recidiva o refractario (MMRR).	CLINICAL TRIALS WITH DRUGS	MAGDALENA ALCALÁ PEÑA	III
BE-03	Ensayo de fase III en pacientes con MMND candidatos a TASPE para comparar VRD extendido hasta 18 ciclos más intervención temprana de rescate vs. Isatuximab-VRD vs. Isatuximab-V-iberdomida-D	CLINICAL TRIALS WITH DRUGS	MAGDALENA ALCALÁ PEÑA	III
BE-03	HA-SAFE: Estudio observacional para evaluar la seguridad a largo plazo del tratamiento con damoctocog alfa pegol en práctica habitual en pacientes con hemofilia A tratados previamente	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Estudio de investigación observacional sobre la salud de las articulaciones en personas con hemofilia que toman el medicamento Esperoct®	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Real-World Evidence, Non-interventional Study on Clinical Characteristics, Epidemiology, Treatment Patterns and Patient Journey of Chronic Lymphocytic Leukemia Patients in Spain (SPARCLL)	OBSERVATIONAL STUDIES WITH DRUGS	MACARENA ORTIZ PAREJA	Not applicable
BE-03	Estudio abierto de la seguridad y la eficacia a largo plazo de Mim8 en participantes con hemofilia A con o sin inhibidores	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	III
BE-03	Ambispective Non-Interventional Study to Assess the Effectiveness of Recombinant Fusion Protein linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) in Hemophilia B in a Real-World Setting	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Ensayo de fase III, aleatorizado, sin enmascaramiento y multicéntrico del tratamiento de primera línea con células mesenquimales estromales MC0518 en comparación con el mejor tratamiento disponible en sujetos adultos y adolescentes con enfermedad de injerto contra huésped aguda refractaria a esteroides después del trasplante alogénico de células madre hematopoyéticas (ensayo IDUNN)	CLINICAL TRIALS WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	III
BE-03	A Global, Non-interventional Study to Prospectively Evaluate Bleeding Episodes and Treatment Use in Patients with Hemophilia. 7037209	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Epidemiology of idiopathic multicentric Castleman disease in Spain.	OBSERVATIONAL STUDIES WITH DRUGS	MANUEL ESPESO DE HARO	Not applicable
BE-03	Estudio observacional, multinacional y no intervencionista con isatuximab en pacientes con mieloma múltiple recidivante o resistente al tratamiento (MMRR)	OBSERVATIONAL STUDIES WITH DRUGS	MAGDALENA ALCALÁ PEÑA	Not applicable
BE-03	Estudio abierto de seguridad en adultos y adolescentes con hemofilia A con y sin inhibidores del FVIII que cambian directamente de la profilaxis con emicizumab a la profilaxis con NNC0365 3769 (Mim8)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	III
BE-03	Estudio en Fase III, abierto, de 2 grupos, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de Elranatamab (PF-06863135) + DARATUMUMAB + LENALIDOMIDA en comparación con DARATUMUMAB + LENALIDOMIDA + DEXAMETASONA en participantes con mieloma múltiple de diagnóstico reciente no aptos para trasplante.	CLINICAL TRIALS WITH DRUGS	MAGDALENA ALCALÁ PEÑA	III
BE-03	Estudio de bajo nivel de intervención, prospectivo, multicéntrico, de 18 meses de duración para evaluar los resultados en salud articular de pacientes con Hemofilia A o B en tratamiento profiláctico con Efmoroctocog alfa o Eftrenonacog alfa.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	IV

Group	Title	Subtype	LR Name	Phase
BE-03	Estudio de la prevalencia de la Enfermedad déficit de esfingomielinasa ácida (ASMD) y Enfermedad de Gaucher en pacientes con Gammapatías Monoclonales y/o Mieloma	OBSERVATIONAL STUDIES WITH DRUGS	ALEJANDRO CONTENTO GONZALO	Not applicable
BE-03	Estudio observacional, multicéntrico, de un solo brazo, para evaluar la efectividad de pegcetacoplán en condiciones reales en pacientes con hemoglobinuria paroxística nocturna (HPN).	OBSERVATIONAL STUDIES WITH DRUGS	ALEJANDRO CONTENTO GONZALO	Not applicable
BE-03	Estudio observacional para describir el impacto clínico de los patrones de tratamiento en personas con hemofilia a leve-moderada en España (ESTUDIO LEMON).	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Estudio global, abierto y de diseño adaptativo para investigar la eficacia y la seguridad de SerpinPC en pacientes con hemofilia A grave o con hemofilia B de moderadamente grave a grave	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	III
BE-03	Ensayo de fase II, aleatorizado, sin enmascaramiento, controlado y multicéntrico del tratamiento de primera línea con células mesenquimales estromales MC0518 en comparación con el mejor tratamiento disponible en participantes pediátricos con enfermedad de injerto contra huésped aguda refractaria a esteroides después del trasplante alogénico de células madre (ensayo BALDER)	CLINICAL TRIALS WITH DRUGS	ANTONIA PASCUAL MARTÍNEZ	II
BE-03	Efectividad comparada en la vida real del belumosudil frente al mejor tratamiento disponible elegido por el médico para la enfermedad crónica de injerto contra huésped: Estudio retrospectivo basado en las historias clínicas de los pacientes	OBSERVATIONAL STUDIES WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	Not applicable
BE-03	Estudio de Fase I/II para evaluar la seguridad, Tolerabilidad, farmacocinética, farmacodinámica y eficacia de NXT007 en pacientes con hemofilia a grave o moderada.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	II
BE-03	Fundación de la Sociedad Española de Hematología y Oncología Pediátricas, actuando en nombre y representación del Promotor International BFM Study Group	OBSERVATIONAL STUDIES WITH DRUGS	ANA ISABEL RODRÍGUEZ JIMÉNEZ	Not applicable
BE-03	Estudio aleatorizado, doble ciego, multicéntrico, fase 3, para evaluar la eficacia y la seguridad de belumosudil en combinación con corticoesteroides frente a placebo en combinación con corticoesteroides en participantes de al menos 12 años con diagnóstico reciente de enfermedad de injerto contra huésped crónica (EICHc).	CLINICAL TRIALS WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	III
BE-03	Estudio europeo, multicéntrico, retrospectivo y no intervencionista para describir los resultados clínicos, los patrones de tratamiento y el uso de recursos sanitarios en la práctica real en pacientes tratados con avatrombopag para la trombocitopenia inmunitaria primaria (TPI) (AVA-EU)	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Ensayo clínico abierto, multicéntrico y de búsqueda de dosis para evaluar la seguridad, farmacocinética, farmacodinámica y eficacia clínica de RVU120 en combinación con venetoclax en participantes con leucemia mieloide aguda en los que fracasó el tratamiento previo con venetoclax y un agente hipometilante	CLINICAL TRIALS WITH DRUGS	ALEJANDRO CONTENTO GONZALO	II
BE-03	Estudio multicéntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinación con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitrión	CLINICAL TRIALS WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	III
BE-03	A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)	CLINICAL TRIALS WITH DRUGS	ALEJANDRO CONTENTO GONZALO	II
BE-03	Estudio transversal para evaluar la percepción de la actividad física en pacientes con Hemofilia a tratados con Emicizumab. Estudio HEMO-ACT.	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	Estudio multicéntrico, de fase 2, randomizado y abierto para evaluar la eficacia y seguridad de zanubrutinib en combinación con obinutuzumab en pacientes con Leucemia Linfocítica Crónica (LLC) o Linfoma Linfoblástico de Células Pequeñas (LLP) no tratados previamente.	CLINICAL TRIALS WITH DRUGS	MACARENA ORTIZ PAREJA	II
BE-03	A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	I
BE-03	Estudio en fase II, abierto, aleatorizado y multicéntrico para evaluar la seguridad y la eficacia de axatilimab en combinación con ruxolitinib en participantes con enfermedad de injerto contra huésped crónica recién diagnosticada	CLINICAL TRIALS WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	II

Group	Title	Subtype	LR Name	Phase
BE-03	Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors: an exploratory study from Spanish GETH/TC Centers	CLINICAL TRIALS WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	II
BE-03	Análisis de los pacientes con Leucemia Linfática Crónica (LLC) que discontinúan la monoterapia con un inhibidor de BTK sin progresión de la enfermedad.	OBSERVATIONAL STUDIES WITH DRUGS	MACARENA ORTIZ PAREJA	Not applicable
BE-03	Registro RESTI: Registro Español de la Trombocitopenia Inmune Primaria y otras trombocitopenias inmunes	OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Not applicable
BE-03	MAGNETISMM-16: Estudio de seguridad posterior a la autorización (PASS), internacional, multicéntrico y no intervencionista, para evaluar la efectividad y la seguridad de elranatamab en pacientes con mieloma múltiple recidivante/resistente (MMRR) tratados en situaciones de la vida real (VR).	OBSERVATIONAL STUDIES WITH DRUGS	MAGDALENA ALCALÁ PEÑA	Not applicable
BE-03	Estudio abierto, en Fase III, que evalúa ELRANATAMAB en monoterapia frente a Elotuzumabm, Pomalidomida y Dexametasona (EPd) o Pomalidomida, Bortezomib y Dexametasona (PVd) o Arfilzomib y Dexametasona (Kd) en participantes con Mieloma Múltiple Recidivante/Resistente al tratamiento que han recibido, tratamiento dirigido contra CD38.	CLINICAL TRIALS WITH DRUGS	MAGDALENA ALCALÁ PEÑA	III
BE-03	Impacto de la reconstitución inmune de CMV-específica al final de la profilaxis con Letermovir en el desarrollo de infección tardía por citomegalovirus en pacientes con trasplante de progenitores hematopoyéticos (Estudio INMUNOEND)	OBSERVATIONAL STUDIES WITH DRUGS	MARÍA ÁNGELES CUESTA CASAS	Not applicable
BE-17	Optimización de la radiación a través de la Evaluación Molecular de ganglios linfáticos después del tratamiento sistémico primario (OPTIMAL IIa).	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ISABEL GARCIA RIOS	Not applicable
BE-17	Linfadenectomía axilar versus Radioterapia axilar en pacientes con cáncer de mama y ganglio centinela positivo tras terapia neoadyuvante. Estudio multicéntrico aleatorizado. (ADARNAT)	CLINICAL RESEARCH WITH MEDICAL DEVICES	ANGEL CALVO TUDELA	Not applicable
BE-21	Estudio observacional prospectivo para identificar los aspectos clínicos que conducen a la toma de decisiones terapéuticas en pacientes con mielofibrosis. Estudio TRATABILIDAD	INDEPENDENT POST-AUTHORIZATION STUDY	REGINA GARCÍA DELGADO	Not applicable
BE-21	Estudio de Fase 2, multicéntrico, aleatorizado y abierto, que evalúa la seguridad y eficacia de tres regímenes diferentes de panobinostat en combinación con bortezomib subcutáneo y dexametasona oral en pacientes con mieloma múltiple recidivante o recidivante/refractario que hayan sido previamente expuestos a agentes inmunomoduladores.	COMMERCIAL CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	II
BE-21	Lenalidomida y dexametasona (Ld) versus Claritomicina/Lenalidomida (Revlimid) /Dexametasona (BiRd) como tratamiento del miloma multiple	INDEPENDENT CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio aleatorizado, doble ciego fase 3 de vadastuximab talirine (SGN-CD33A) frente a placebo en combinación con azacitidina o decitabina en el tratamiento de pacientes mayores con leucemia mieloide aguda de nuevo diagnóstico.	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	III
BE-21	Estudio aleatorizado, multicéntrico, abierto, de fase II para evaluar la eficacia y la seguridad de azacitidina subcutánea en combinación con durvalumab (MEDI4736) en pacientes con síndromes mielodisplásicos (SMD) de alto riesgo no tratados previamente o en pacientes de edad avanzada (= 65 años) con leucemia mieloide aguda (LMA) que no son aptos para un trasplante de células madre hematopoyéticas (TCMH). Estudio de fusión SMD de alto riesgo/LMA de edad avanzada 001.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio clínico de fase II, aleatorizado, controlado y abierto para comparar la eficacia y la seguridad de pevonedistat más azacitidina frente a azacitidina en monoterapia en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica y leucemia mielogena aguda pobre en blastos	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio aleatorizado, doble ciego, controlado con placebo, Fase 3, de Venetoclax en combinación con Azacitidina en comparación con Azacitidina, en pacientes con leucemia mieloide aguda no tratados anteriormente y no elegibles para terapias de inducción estándar.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
BE-21	Estudio multicéntrico, de extensión abierto y de seguridad, para describir la experiencia clínica a largo plazo con mepolizumab en pacientes con síndrome hipereosinofílico (HES) procedentes del estudio 200622	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III

Group	Title	Subtype	LR Name	Phase
BE-21	Estudio de discontinuación de inhibidores de la tirosina quinasa en LMC-FC	INDEPENDENT POST-AUTHORIZATION STUDY	ANA ISABEL ROSELL MAS	Not applicable
BE-21	Estudio observacional para valorar la carga de la enfermedad, en términos de Calidad de Vida Relacionada con la Salud y costes sanitarios directos, en pacientes con Mieloma Múltiple de nuevo diagnóstico no candidatos a trasplante autólogo de progenitores hematopoyéticos en España. QoLMMBuS	COMMERCIAL POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio observacional ambispectivo para evaluar la incidencia y el manejo de la aplasia medular en el Estado Español (IMAS)	INDEPENDENT POST-AUTHORIZATION STUDY	ANA ISABEL ROSELL MAS	Not applicable
BE-21	Estudio observacional, internacional, multicéntrico, sobre el uso de ruxolitinib en el tratamiento de pacientes con policitemia vera que presentan resistencia o intolerancia a la hidroxiurea. Sponsor Code: CINC424BIC04	COMMERCIAL POST-AUTHORIZATION STUDY	REGINA GARCÍA DELGADO	Not applicable
BE-21	Tratamiento de inducción con bortezomib, melfalán y prednisona (VMP) seguido de lenalidomida y dexametasona (Rd) frente a carfilzomib, lenalidomida y dexametasona (KRd) más/menos daratumumab, 18 ciclos, seguido de tratamiento de consolidación y mantenimiento con lenalidomida y daratumumab: un ensayo clínico de fase III, multicéntrico, aleatorizado para pacientes adultos mayores, de entre 65 y 80 años, con buen estado general y mieloma múltiple de nuevo diagnóstico	CLINICAL TRIALS WITH DRUGS	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio de fase II, multicéntrico, aleatorizado, controlado con placebo y doble ciego de MBG453 intravenoso en combinación con fármacos hipometilantes en pacientes adultos con síndrome mielodisplásico (SMD) de riesgo intermedio, alto o muy alto según los criterios del IPSS-R.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio retrospectivo de viabilidad de la guía clínica de PETHEMA-POMCIDEX para el tratamiento de pacientes con mieloma múltiple en recaída y refractario (RRMM)	INDEPENDENT POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio fase III aleatorizado abierto para comparar el tratamiento con azacitidina más pevonedistat frente a azacitidina en adultos con LMA de nuevo diagnóstico ancianos y/o no candidatos a quimioterapia estándar de inducción	INDEPENDENT CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	III
BE-21	Estudio en fase III, multicéntrico, abierto y aleatorizado para evaluar la eficacia y la seguridad del fedratinib comparado con la mejor terapia disponible en pacientes con mielofibrosis primaria de riesgo intermedio o alto riesgo según el Sistema dinámico internacional de puntuación pronóstica (DIPSS), mielofibrosis post-policitemia vera o mielofibrosis post-trombocitemia esencial tratados previamente con ruxolitinib	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
BE-21	Estudio fase II con aleatorización 2:1 para comparar la eficacia y seguridad del tratamiento con quimioterapia estándar más quizartinib frente a quimioterapia estándar más placebo en pacientes adultos con LMA de nuevo diagnóstico con el gen FLT3 no mutado	INDEPENDENT CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	II
BE-21	Ensayo multicéntrico en fase III, no enmascarado, aleatorizado, para evaluar la eficacia y la seguridad de CPI-613 en combinación con dosis altas de citarabina y mitoxantrona (CHAM) comparado con dosis altas de citarabina y mitoxantrona (HAM) en pacientes de edad avanzada (≥60 años) con leucemia mieloide aguda (LMA) en recaída o refractaria	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
BE-21	Eficacia y seguridad de M281 en adultos con anemia hemolítica autoinmunitaria por anticuerpos calientes: estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo. Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled, Study with a Long-term Open label Extension	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	III
BE-21	Impacto de la monitorización de enfermedad mínima residual mediante citometría de flujo en el manejo del mieloma múltiple. Estudio EMR CLINICAL	INDEPENDENT POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio de fase 3, abierto y aleatorizado para comparar la eficacia y la seguridad de luspatercept (ACE-536) frente a epoetina alfa para el tratamiento de la anemia debida a síndromes mielodisplásicos (SMD) de riesgo muy bajo, bajo o intermedio según la clasificación IPSS-R en pacientes sin tratamiento previo con estimulantes de la eritropoyesis que necesitan transfusiones de glóbulos rojos.	COMMERCIAL CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	III

Group	Title	Subtype	LR Name	Phase
BE-21	Estudio fase II, exploratorio, multicéntrico, abierto, no controlado, para evaluar la reinducción y la segunda parada a un TKI como ponatinib en pacientes con LMC en respuesta molecular (ResToP).	INDEPENDENT CLINICAL TRIAL	ANA ISABEL ROSELL MAS	II
BE-21	Estudio abierto, multicéntrico, de fase Ib/II de la seguridad y eficacia de KRT-232 en combinación con citarabina en dosis bajas (CDB) o decitabina en pacientes con leucemia mieloide aguda (LMA).	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio retrospectivo, observacional y no intervencionista, para registrar el uso, seguridad y efectividad de la utilización de inotuzumab en pacientes con leucemia linfoblástica aguda refractaria o resistente a tratamientos previos	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA GARCIA FORTES	Not applicable
BE-21	Estudio multicéntrico, prospectivo, no aleatorizado, fase I-II para evaluar la eficacia y la seguridad de la combinación de quizartinib oral con el esquema de quimioterapia FLAG-IDA en pacientes con leucemia mieloide aguda en primera recidiva o refractarios (LMA R/R)	INDEPENDENT CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	II
BE-21	Ensayo doble ciego, aleatorizado y de fase III, para evaluar la eficacia de Uproleselan administrado con quimioterapia en comparación con quimioterapia sola en pacientes con leucemia mieloide aguda recidivante/refractaria	COMMERCIAL CLINICAL TRIAL	MARIA GARCIA FORTES	III
BE-21	Estudio abierto en fase 2 para evaluar la tolerabilidad y la eficacia de navitoclax solo o en combinación con ruxolitinib en pacientes con mielofibrosis	COMMERCIAL CLINICAL TRIAL	MARIA GARCIA FORTES	II
BE-21	Estudio de fase 3, multicéntrico, abierto, aleatorizado de dos grupos de tratamiento, venetoclax y azacitidina en comparación con el mejor tratamiento de soporte, como tratamiento de mantenimiento en pacientes con leucemia mieloide aguda en primera remisión después de recibir quimioterapia convencional (VIALE M)	COMMERCIAL CLINICAL TRIAL	MARIA GARCIA FORTES	III
BE-21	Estudio de fase I/II, aleatorizado, abierto y de plataforma abierta en el que se evalúa la seguridad y eficacia de nuevas combinaciones de ruxolitinib en pacientes con mielofibrosis. (ADORE)	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio de fase 1/2 de dos partes para determinar la seguridad, tolerabilidad, farmacocinética y actividad de K0706, un nuevo inhibidor de la tirosina cinasa (ITC), en pacientes sanos y pacientes con leucemia mieloide crónica (LMC) o leucemia linfoblástica aguda (LLA) positiva para el cromosoma Filadelfia	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	II
BE-21	Estudio observacional para describir la repercusión de los anticuerpos monoclonales como tratamiento de primera línea frente a otros regímenes estándar en pacientes con mieloma múltiple de nuevo diagnóstico que no sean candidatos a trasplante. Datos de práctica clínica habitual en España. Estudio CARINAE (54767414MMY4024)	COMMERCIAL POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio de fase 3, controlado con placebo, aleatorizado y doble ciego de Navitoclax en combinación con Ruxolitinib comparado con Ruxolitinib en pacientes con Mielofibrosis	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
BE-21	Transformando la mielofibrosis y la policitemia vera incontrolada en enfermedades cuantificables y de diagnóstico precoz. Estudio de casos y controles	NON-POST-AUTHORIZATION STUDY	REGINA GARCÍA DELGADO	Not applicable
BE-21	Estudio de fase Ib/II abierto y multicéntrico de la seguridad y eficacia de KRT-232 combinado con ruxolitinib en pacientes con mielofibrosis primaria (MFP), mielofibrosis post-policitemia vera (MF-post-PV) o mielofibrosis post-trombocitemia esencial (MF-post-TE) que tienen una respuesta subóptima a ruxolitinib	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia analgésica y la seguridad de una combinación en dosis fijas por vía oral de dexketoprofeno trometamol y tramadol hidrocloreuro en el dolor agudo de moderado a intenso en pacientes con lumbalgia aguda: estudio DANTE	COMMERCIAL CLINICAL TRIAL	ANDRES FONTALBA NAVAS	IV
BE-21	Estudio de fase I, aleatorizado, de evaluación de dosis y esquema de tratamiento, para investigar la seguridad, farmacocinética, farmacodinámica y actividad clínica de Belantamab Mafodotín administrado en combinación con tratamiento estándar en pacientes con mieloma múltiple recién diagnosticado. DREAMM	COMMERCIAL CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	III

Group	Title	Subtype	LR Name	Phase
BE-21	Estudio de fase 3, aleatorizado y abierto, para evaluar imetelstat (GRN163L) frente al mejor tratamiento disponible en pacientes con mielofibrosis de riesgo intermedio 2 o alto resistente a inhibidores de las cinasas Jano	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	III
BE-21	Estudio de fase 2, abierto y multicéntrico de TL-895 en pacientes con mielofibrosis recidivante/ resistente, mielofibrosis intolerante para el inhibidor de la cinasa de Janus y mielofibrosis no apta para el tratamiento con inhibidor de la cinasa de Janus	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio Fase 1b de escalado de dosis de Lemzoparlimab (TJ011133) en combinación con Azacitidina y/o Venetoclax en pacientes con Leucemia Mieloide Aguda (LMA) o Síndrome Mielodisplásico (SMD)	COMMERCIAL CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	I
BE-21	Estudio de fase 3 abierto, aleatorizado y multicéntrico para comparar Iberdomida, Daratumumab y Dexametasona (IberDd) con Daratumumab, Bortezomib y Dexametasona (DVd) en pacientes con mieloma múltiple recidivante o resistente (MMRR)	CLINICAL TRIALS WITH DRUGS	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio de fase III aleatorizado, doble ciego y controlado con principio activo de CPI-0610 y ruxolitinib frente a placebo y ruxolitinib en pacientes con MF sin tratamiento previo con iJAK (NZA68438)	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
BE-21	Estudio de fase I/II, abierto y multicéntrico para determinar la dosis y la pauta recomendadas y evaluar la seguridad y la eficacia preliminar del CC-92480 en combinación con tratamientos estándar en sujetos con mieloma múltiple en recaída o refractario (MMRR) y mieloma múltiple de nuevo diagnóstico (MMND)".	COMMERCIAL CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	II
BE-21	Protocolo de registro y análisis de macroglobulinemia de waldenström en España PRAME HVV	COMMERCIAL POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio de fase 1b/2, abierto y multicéntrico para evaluar la seguridad y la eficacia de TL-895 combinado con ruxolitinib en sujetos con mielofibrosis (MF) sin tratamiento previo con inhibidores de la cinasa Janus (iJAK) y sujetos con mielofibrosis y respuesta subóptima a ruxolitinib.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
BE-21	Estudio aleatorizado de fase III para comparar Talquetamab SC combinado con Daratumumab SC y Pomalidomida (Tal-DP) o Talquetamab SC combinado con Daratumumab SC (Tal-D) frente a Daratumumab SC combinado con Pomalidomida y Dexametasona (DPd) en pacientes con mieloma múltiple refractario o recidivante que han recibido al menos 1 línea de tratamiento	CLINICAL TRIALS WITH DRUGS	RICARDA GARCIA SANCHEZ	III
BE-21	Ensayo de fase III en pacientes con MMND candidatos a TASPE para comparar VRD extendido hasta 18 ciclos más intervención temprana de rescate vs. Isatuximab-VRD vs. Isatuximab-V-iberdomida-D	CLINICAL TRIALS WITH DRUGS	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio en fase Ib abierto para evaluar la seguridad y la tolerabilidad de modakafusp alfa intravenoso como parte de un tratamiento combinado en pacientes adultos con mieloma múltiple	CLINICAL TRIALS WITH DRUGS	RICARDA GARCIA SANCHEZ	II
BE-21	Estudio observacional, naturalístico, transversal para describir el uso de Esketamina en pulverizador nasal en la depresión resistente al tratamiento en práctica clínica real. Estudio INtegrate.	OBSERVATIONAL STUDIES WITH DRUGS	ANDRES FONTALBA NAVAS	Not applicable
BE-21	A First-In-Human Phase 1/2 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Hematological Tumors	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	II
BE-21	Estudio de cohortes no intervencionista en pacientes con leucemia linfocítica crónica no tratados previamente o intolerantes a inhibidores BTK de primera generación para describir el uso de acalabrutinib en primera línea y sus resultados en vida real en España: estudio PICAROS.	OBSERVATIONAL STUDIES WITH DRUGS	BORJA CIDONCHA MORCILLO	Not applicable
BE-21	Estudio en fase II/III, aleatorizado, doble ciego, con grupos paralelos, comparativo con placebo, con dosis flexible y multicéntrico para evaluar la eficacia y la seguridad de SEP-363856 en el tratamiento de adultos con trastorno de ansiedad generalizada.	CLINICAL TRIALS WITH DRUGS	ANDRES FONTALBA NAVAS	III
BE-21	A Phase 1b/2 Dose Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB 11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/ Refractory Multiple Myeloma and t(11;14)	CLINICAL TRIALS WITH DRUGS	RICARDA GARCIA SANCHEZ	I

Group	Title	Subtype	LR Name	Phase
BE-21	Un estudio de Fase 3, aleatorizado, de etiqueta abierta de Linvoseltamab (REGN5458; Anticuerpo Bispecífico ANTI-BCMA X ANTI-CD3) versus la combinación de Elotuzumab, Pomalidomida y Dexametasona (EPd), en pacientes con Mieloma Múltiple en recidiva/refractario (LINKER-MM3).	CLINICAL TRIALS WITH DRUGS	RICARDA GARCIA SANCHEZ	III
BE-21	“Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	III
BE-21	Estudio en fase I/III para evaluar la eficacia y la seguridad del selinexor, un inhibidor selectivo de la exportación nuclear, en combinación con ruxolitinib en pacientes con mielofibrosis que no han recibido tratamiento previo”	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	III
BE-21	A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	III
BE-21	Estudio clínico de fase 3, abierto, aleatorizado y controlado con comparador activo para evaluar la seguridad y la eficacia de bomedemstat (MK 3543/IMG-7289) en comparación con el mejor tratamiento disponible (MTD) en participantes con trombocitemia esencial que presentan respuesta insuficiente o intolerancia a hidroxiurea.	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	III
BE-21	Estudio observacional retrospectivo para describir las características clínicas, el manejo y los resultados del anticuerpo Blespecífico antiGPRC5D (TALquetamab) en pacientes con mieloma múltiple en recaída refractario tratados fuera de ensayo clínico (SPR	OBSERVATIONAL STUDIES WITH DRUGS	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Study of Vysis IntelliFISH CCND1/IGH XT FISH Probe Kit in a Phase 1b/2 Dose Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB 11417 as Monotherapy, in Combination With Dexamethasone, methasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/ Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)	CLINICAL RESEARCH WITH MEDICAL DEVICES	RICARDA GARCIA SANCHEZ	Not applicable
BE-23	Estudio en Fase III, multicéntrico, Randomizado, doble ciego, controlado con placebo para investigar ipatasertib en combinación con abiraterona más Prednisona/Prednisolona, comparado con placebo en combinación con Abiraterona más Prednisona/Prednisolona, en pacientes adultos con cáncer de próstata resistente a castración metastásico, asintomáticos o levemente sintomáticos que no han sido tratados previamente.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
BE-23	Describe III Revisión retrospectiva de las historias clínicas de la monoterapia con dabrafenib y/o la terapia de combinación con dabrafenib y trametinib en pacientes con melanoma metastásico con el objeto de caracterizar a los pacientes que han obtenido un beneficio a largo plazo en el programa individualizado de pacientes (PIP)	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	Ensayo fase III, aleatorizado, abierto, controlado, multicéntrico, internacional de durvalumab en combinación con el tratamiento estándar con quimioterapia y durvalumab en combinación con tremelimumab y el tratamiento estándar con quimioterapia frente al tratamiento estándar con quimioterapia solo, en primera línea en pacientes con cáncer urotelial localmente avanzado irresecable o metastásico.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
BE-23	Estudio de fase 2, aleatorizado, doble ciego y controlado con placebo de acetato de abiraterona más prednisona con o sin abemaciclib en pacientes con cáncer de próstata metastásico resistente a la castración	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	II
BE-23	Estudio Observacional descriptivo sobre las características del melanoma avanzado y metastásico en España. GEM-1801	INDEPENDENT POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	Ensayo de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de pembrolizumab (MK-3475) y lenvatinib (E7080/MK-7902) en comparación con pembrolizumab en monoterapia como intervención de primera línea en participantes con melanoma avanzado (LEAP-003).	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar pembrolizumab frente a un placebo como tratamiento adyuvante después de cirugía y radioterapia del carcinoma epidermoide cutáneo localmente avanzado (CEC LA) de alto riesgo, MK3475-630.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III

Group	Title	Subtype	LR Name	Phase
BE-23	Estudio de fase 3, aleatorizado y abierto de pembrolizumab (MK-3475) más olaparib frente a acetato de abiraterona o enzalutamida en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) que no son seleccionados por defectos en la reparación por recombinación homóloga y que han mostrado fracaso con el tratamiento previo con un fármaco hormonal de última generación (FHUG) y quimioterapia (KEYLYNK-010)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
BE-23	Estudio fase 1, aleatorizado, doble ciego, paralelo, para comparar la farmacocinética de BMSCHO1-nivolumab de proceso D con la de nivolumab de proceso C después de la resección completa de melanoma en estadio IIIa/b/c/d o en estadio IV	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	I
BE-23	Ensayo de fase 3, aleatorizado y doble ciego de pembrolizumab (MK-3475) más enzalutamida frente a un placebo más enzalutamida en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) (KEYNOTE-641)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
BE-23	Un estudio en fase IV de seguimiento a largo plazo para definir el perfil de seguridad del dicloruro de radio 223	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	IV
BE-23	Ensayo fase 2 de nivolumab más ipilimumab, ipilimumab en monoterapia o cabazitaxel en varones con cáncer de próstata metastásico resistente a la castración	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	II
BE-23	Ensayo clínico fase 3b, aleatorizado, de nivolumab en monoterapia, nivolumab en combinación con ipilimumab o quimioterapia a elección del investigador en pacientes con cáncer colorrectal metastásico (CRCm) con alta inestabilidad de microsatélites (MSI-H) o déficit de reparación de discordancias (dMMR)	COMMERCIAL CLINICAL TRIAL	SILVIA GIL CALLE	III
BE-23	Estudio fase 3, aleatorizado, a doble ciego, de inmunoterapia adyuvante con nivolumab frente a placebo después de resección completa de melanoma en estadio IIB/C (CheckMate 76K: Evaluación en ensayo clínico de la vía de punto de control y nivolumab 76K)	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos cardiovasculares en Europa - Estudio Multinacional Observacional. Estudio SANTORINI (DSE-HCL-01-19)	COMMERCIAL POST-AUTHORIZATION STUDY	BEATRIZ PEREZ VILLARDON	Not applicable
BE-23	Estudio de fase III multicéntrico, aleatorizado, abierto para evaluar la eficacia y seguridad de Atezolizumab administrado en combinación con Cabozantinib frente a Cabozantinib en monoterapia en pacientes con carcinoma de células renales localmente avanzado o metastásico inoperable que han presentado progresión tumoral radiológica durante o después del tratamiento con un inhibidor de puntos de control inmunitario.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
BE-23	Estudio de fase IV, aleatorizado, abierto, multicéntrico de la eficacia y la seguridad de la dosis habitual de dicloruro de radio-223 en comparación con las dosis habituales de un tratamiento antihormonal nuevo (AHN) en pacientes con cáncer de próstata resistente a la castración metastásico predominante en huesos y en progresión durante/después de una línea de AHN.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	IV
BE-23	Estudio de fase III, multicéntrico, aleatorizado y abierto en el que se compara 177Lu-PSMA-617 frente a un cambio de terapia dirigida al receptor de andrógenos en el tratamiento de hombres con cáncer de próstata metastásico progresivo resistente a la castración que no hayan recibido taxanos. (PSMAfore) PSMAAddition	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
BE-23	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy-ARTISTRY-6	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio de fase 2, aleatorizado y abierto, de ceralasertib en monoterapia y ceralasertib más durvalumab en pacientes con melanoma irresecable o avanzado y con resistencia primaria o secundaria a la inhibición de PD (L)1. MONETTE	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio AGAMENON. Registro Español de Cáncer Esofagogástrico	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA DEL CARMEN REYNA FORTES	Not applicable

Group	Title	Subtype	LR Name	Phase
BE-23	Estudio aleatorizado, abierto de Fase III, para comparar PRALSETINIB con el tratamiento estándar del cáncer medular de tiroides con mutación en RET.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio abierto, multicéntrico, de fase Ib/2 con E7386 en combinación con Pembrolizumab en pacientes previamente tratados con tumores sólidos específicos	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio farmacocinético en fase III, abierto, aleatorizado y de no inferioridad de nivolumab administrado por vía subcutánea (Nivo s.c.) en comparación con la administración intravenosa de nivolumab en participantes con melanoma en estadio IIIA/B/C/D o estadio IV tras la resección completa en un entorno adyuvante	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de capivasertib + docetaxel frente a placebo + docetaxel como tratamiento para pacientes con cáncer de próstata resistente a la castración metastásico (CPRCm)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
BE-23	Estudio de fase III, aleatorizado y triple ciego en colaboración con el Grupo de Melanoma de la Organización Europea para la Investigación y el Tratamiento del Cáncer (EORTC) de encorafenib y binimetinib como tratamiento complementario comparado con placebo en el melanoma en estadio IIB/C completamente reseado con mutación V600E/K de BRAF	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio fase II, abierto de la eficacia preliminar de Sitravatinib en combinación con Tislelizumab en pacientes con melanoma metastásico uveal con hepáticas metastásis.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio de fase 2, multicéntrico y de varios grupos para evaluar MK-1308A (coformulación de quavonlimab (MK-1308)/ pembrolizumab) frente a otros tratamientos en participantes con cáncer colorrectal en estadio IV con inestabilidad de microsatélites alta (MSI-H) o con defectos en la reparación de los errores de emparejamiento (dMMR): (MK-1308A-008)	INDEPENDENT CLINICAL TRIAL	JULIA ALCAIDE GARCÍA	II
BE-23	Ensayo clínico de fase III, abierto y aleatorizado de IO102-IO103 en combinación con pembrolizumab en comparación con pembrolizumab en monoterapia en pacientes con melanoma irresecable o metastásico (avanzado) no tratados anteriormente	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio en fase II, multicéntrico, sin enmascaramiento, aleatorizado y controlado para comparar la eficacia de RO7198457 con la estrategia de actitud expectante en pacientes con cáncer colorrectal reseado en estadio II (riesgo elevado) y estadio III que presenten positividad de ADN tumoral circulante (ADNct) tras la resección tumoral.	CLINICAL TRIALS WITH DRUGS	JULIA ALCAIDE GARCÍA	II
BE-23	Estudio en fase III, abierto y aleatorizado de tucatinib en combinación con trastuzumab y mFOLFOX6 frente a mFOLFOX6 administrado con o sin cetuximab o bevacizumab como tratamiento de primera línea para pacientes con cáncer colorrectal metastásico HER2+.	CLINICAL TRIALS WITH DRUGS	JULIA ALCAIDE GARCÍA	III
BE-23	Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con un comparador activo de MK-7684A (vibostolimab con pembrolizumab) adyuvante frente a pembrolizumab adyuvante en participantes con melanoma en estadio II-IV de alto riesgo (KEYVIBE-010)	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Protocolo maestro de encorafenib/binimetinib: Estudio abierto de continuación para participantes que continúen desde ensayos clínicos de encorafenib/binimetinib.	CLINICAL TRIALS WITH DRUGS	ALVARO MONTESA PINO	IV
BE-23	Ensayo de extensión de fase III, abierto y multicéntrico para estudiar la seguridad y la eficacia a largo plazo en participantes con tumores avanzados que actualmente están en tratamiento o en seguimiento en un ensayo de pembrolizumab	CLINICAL TRIALS WITH DRUGS	JULIA ALCAIDE GARCÍA	III
BE-23	Comparison of different techniques for testing BRAF V600 mutation in blood in melanoma patients. BRAFI	OBSERVATIONAL STUDIES WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	Estudio abierto en fase I/II de la seguridad, la farmacocinética y la actividad preliminar de ASTX295 en pacientes con tumores sólidos avanzados con TP53 de tipo natural	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio fase II, multicéntrico, aleatorizado, abierto, de 2 brazos, para evaluar la eficacia y seguridad del retratamiento con cetuximab e irinotecán en tercera línea frente a la terapia de elección del investigador en pacientes con cáncer colorrectal metastásico seleccionados mediante análisis genómico de ADN tumoral circulante (ADNtc) (Estudio CITRIC)	CLINICAL TRIALS WITH DRUGS	JULIA ALCAIDE GARCÍA	II

Group	Title	Subtype	LR Name	Phase
BE-23	Estudio de fase II para evaluar INCB099280 en participantes con carcinoma epidermoide avanzado	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio aleatorizado y doble ciego para evaluar la eficacia, seguridad e inmunogenicidad de ABP 206 en comparación con OPDIVO® (nivolumab) en pacientes con melanoma irresecable o metastásico no tratado anteriormente	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase III, aleatorizado, doble ciego, comparativo con placebo y con tratamiento activo de V940 (ARNm-4157) adyuvante más pembrolizumab frente a un placebo adyuvante más pembrolizumab en participantes con melanoma en estadio II-IV de alto riesgo.	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase III aleatorizado y abierto de XL092 + nivolumab en comparación con sunitinib en participantes con carcinoma de células renales no claras metastásico o avanzado	CLINICAL TRIALS WITH DRUGS	ALVARO MONTESA PINO	III
BE-23	Estudio de fase 2 multicéntrico para evaluar la eficacia y la seguridad de Cetuximab en combinación con Encorafenib y Binimetinib como tratamiento de inducción en el cáncer colorrectal avanzado inicialmente resecable o potencialmente resecable con mutación BRAF V600E y MSS.	CLINICAL TRIALS WITH DRUGS	MARIA DEL CARMEN REYNA FORTES	II
BE-23	A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio clínico de fase 2/3, adaptativo, aleatorizado y abierto para evaluar V940 (ARNm-4157) neoadyuvante y adyuvante en combinación con pembrolizumab (MK-3475) frente al tratamiento habitual y pembrolizumab en monoterapia en participantes con carcinoma epidermoide cutáneo localmente avanzado (CEC LA) resecable (INTerpath-007).	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio aleatorizado, con doble enmascaramiento y de grupos paralelos para comparar la farmacocinética, la eficacia, la seguridad y la inmunogenia de JPB898 (biosimilar de nivolumab propuesto) y Opdivo® con licencia de EE. UU. y autorizado por la UE en combinación con Yervoy® en participantes con melanoma avanzado (irresecable/metastásico) sin tratar	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	IL Believe: Estudio de fase I/II, abierto, de escalada de dosis y expansión de dosis para investigar la seguridad y tolerabilidad de TransCon IL-2 β/? solo o en combinación con pembrolizumab, quimioterapia estándar o agonista de TransCon TLR7/8, o en combinación con pembrolizumab y quimioterapia estándar, en participantes adultos con tumores sólidos malignos localmente avanzados o metastásicos	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase 3 aleatorizado, abierto, con control activo y multicéntrico de sotorasib, panitumumab y FOLFIRI frente a FOLFIRI con o sin bevacizumab-awwb en sujetos con cáncer colorrectal metastásico con la mutación p.G12C en el KRAS no tratados previamente (CodeBreak 301)	CLINICAL TRIALS WITH DRUGS	JULIA ALCAIDE GARCÍA	III
BE-23	Un ensayo perioperatorio de Fase 2 y Fase 3 de Fianlimab y Cemiplimab comparados con Pembrolizumab en pacientes con Melanoma Resecable en Estadios III y IV.	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Outcome research of a European registry platform on real-world treatment data of patients with advanced non-melanoma skin cancer (NMSC)	OBSERVATIONAL STUDIES WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
C-01	Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex como fármaco control, para evaluar la eficacia, determinadas por las lesiones cerebrales que aparecen en la RMN y la seguridad de dos pautas terapéuticas de ocrelizumab en pacientes con EMRR	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	II
C-01	Estudio de extensión del estudio AC 058B201, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, para evaluar la seguridad, tolerabilidad, y eficacia a largo plazo de 10, 20, y 40 mg/día de ACT-128800, un agonista oral de los receptores S1P1, en pacientes con esclerosis múltiple recurrente-remitente.	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	II
C-01	Estudio multicéntrico, aleatorizado, doble ciego, con control activo, de dos años de duración para evaluar la seguridad y la eficacia de fingolimod administrado por vía oral una vez al día frente a interferon ?-1a i.m. administrado una vez a la semana en pacientes pediátricos con esclerosis múltiple	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	III

Group	Title	Subtype	LR Name	Phase
C-01	Ensayo Clínico Fase II, Multicéntrico, Abierto, Controlado y Aleatorizado, para valorar la eficacia de la Infusión Intra arterial de células Mononucleadas de Médula Ósea Autóloga en Pacientes Con Ictus Isquémico	INDEPENDENT CLINICAL TRIAL	JOSE ANTONIO TAMAYO TOLEDO	II
C-01	Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con LEMTRADA® (Alemtuzumab) en pacientes con formas recidivantes de esclerosis múltiple. (Estudio OBS13434)	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA ALONSO TORRES	Not applicable
C-01	Estudio de extensión del ensayo AC-058B301, multicéntrico, no comparativo, para valorar la seguridad, tolerabilidad y control de la enfermedad a largo plazo de ponesimod 20 mg en sujetos con esclerosis múltiple recidivante	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	III
C-01	Estudio de extensión abierto, de brazo único y multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de ofatumumab, en pacientes con esclerosis múltiple que cursa con brotes	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico, para evaluar la seguridad, la tolerabilidad y la eficacia del XEN1101 como tratamiento adyuvante en la epilepsia de inicio focal	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio multicéntrico no intervencional para evaluar la efectividad de ocrelizumab en pacientes con esclerosis múltiple recurrente o primaria progresiva en práctica clínica habitual. ESTUDIO MuSicalE (MN39889)	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA ALONSO TORRES	Not applicable
C-01	Estudio de evidencia en práctica clínica real: Estudio de cohorte prospectivo no intervencional post-autorización para evaluar la efectividad, la seguridad y los resultados de salud a largo plazo del tratamiento de la esclerosis múltiple recurrente en la práctica clínica de rutina en España con cladribina comprimidos. Sponsor Code: MS700568_0073. MAVEN 4 -	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA ALONSO TORRES	Not applicable
C-01	Monitorización de la Movilidad de enfermos de Parkinson con fines terapéuticos -Ensayo Clínico. Estudio (oMoPa-EC.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	TERESA MUÑOZ RUIZ	Not applicable
C-01	Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultoscon trastorno del espectro de neuromielitis óptica (NMOSD)	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	III
C-01	Estudio de Fase IIIb, multicéntrico, aleatorizado, doble ciego y controlado para evaluar la eficacia, la seguridad y la farmacocinética de una dosis más alta de Ocrelizumab en adultos con formas recurrentes de esclerosis múltiple.	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio de eficacia y seguridad de fase 3, aleatorizado y doble ciego que compara SAR442168 con placebo en participantes con esclerosis múltiple secundaria progresiva no recidivante (HERCULES)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio multicéntrico aleatorizado, doble ciego, controlado con placebo y de grupos paralelos acerca de CVL-865 como tratamiento complementario en adultos con crisis convulsivas de inicio focal resistentes a los fármacos (estudio REALIZE)	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio de eficacia y seguridad de fase 3, aleatorizado y doble ciego que compara SAR442168 con teriflunomida (Aubagio®) en participantes con formas recidivantes de esclerosis múltiple (GEMINI 1)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio en fase 3, aleatorizado, doble ciego para evaluar la eficacia y seguridad del tratamiento con SAR442168 frente a placebo en pacientes con esclerosis múltiple primaria progresiva (PERSEUS)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio prospectivo, no intervencionista, observacional y multicéntrico para investigar la dosis, la eficacia y la seguridad de perampanel cuando se utiliza como primer tratamiento complementario en la asistencia clínica habitual de pacientes mayores de 12 años con crisis de inicio parcial con o sin generalización secundaria o con crisis tonicoclónicas generalizadas primarias asociadas a epilepsia generalizada idiopática (sponsor's code E2007-M044-512)	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio fase III multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento y grupos paralelos para evaluar la eficacia y seguridad de Fenebrutinib comparado con Ocrelizumab en pacientes adultos con Esclerosis Múltiple Primaria Progresiva	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III

Group	Title	Subtype	LR Name	Phase
C-01	Estudio de extensión abierto, multicéntrico y con tratamiento activo de 57 semanas de CVL-865 como tratamiento complementario en adultos con crisis convulsivas de inicio focal resistentes a los fármacos	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio de fase 2, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar la eficacia, seguridad y farmacocinética de rozanolixizumab en adultos con encefalitis autoinmune asociada a anticuerpos dirigidos frente a la proteína 1 inactivada del glioma rica en leucina	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio en fase IIb, aleatorizado, con doble enmascaramiento, comparativo con placebo y multicéntrico, para evaluar la eficacia y la seguridad de prasinezumab intravenoso en participantes con enfermedad de parkinson incipiente	COMMERCIAL CLINICAL TRIAL	LUCIA GARCIA TRUJILLO	II
C-01	Estudio multinacional, observacional y no intervencionista de 12 meses para evaluar la efectividad, tolerabilidad y calidad de vida de la terapia añadida con brivaracetam en líneas de tratamiento precoz en pacientes adultos con antecedentes de crisis de inicio focales en la práctica clínica diaria. EP0103 UCB BRITOPA	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio de Fase III, multicéntrico, aleatorizado, doble ciego y con doble simulación para evaluar la seguridad y la eficacia de OCRELIZUMAB en comparación con FINGOLIMOD en niños y adolescentes con esclerosis múltiple esclerosis múltiple remitente-recurrente.	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio controlado aleatorizado y multicéntrico para evaluar la seguridad y eficacia de HEMOPATCH en comparación con la práctica habitual para el sellado de duramadre como refuerzo de la sutura dural para la prevención de fugas de líquido cefalorraquídeo (LCR) postoperatorias en pacientes sometidos a cirugía de fosa posterior.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MIGUEL ANGEL ARRÁEZ SÁNCHEZ	Not applicable
C-01	Estudio abierto, aleatorizado, con evaluador ciego, multicéntrico, de brazos paralelos, con comparador activo para evaluar la eficacia y tolerabilidad de Ofatumumab 20 mg s.c. administrado mensualmente vs. TME de primera línea a elección del médico en el tratamiento de pacientes con Esclerosis Múltiple Recurrente (EMR) de reciente diagnóstico (STHENOS)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio aleatorizado, doble ciego con doble enmascaramiento y grupos paralelos en el que se compara la eficacia y seguridad de remibrutinib 100 mg b.i.d. frente a teriflunomida 14 mg q.d. en participantes con esclerosis múltiple recurrente, seguido de una extensión abierta del tratamiento con remibrutinib.	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio de fase 2, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ALXN2050 en participantes adultos con miastenia grave generalizada	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	II
C-01	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSE ANTONIO TAMAYO TOLEDO	Not applicable
C-01	Estudio de fase 3, aleatorizado, doble ciego para evaluar la eficacia y seguridad del tratamiento con SAR442168 frente a teriflunomida (Aubagio®) en pacientes con esclerosis múltiple recidivante (GEMINI 2)	INDEPENDENT CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio de prolongación multicéntrico, de un solo grupo, abierto y de extensión para evaluar la seguridad y la eficacia a largo plazo de ocrelizumab en pacientes con esclerosis múltiple	INDEPENDENT CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y seguridad de FAB122 en pacientes con esclerosis lateral amiotrófica	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	III
C-01	Ensayo en fase III, doble ciego, aleatorizado y controlado con placebo del tratamiento adyuvante con ganaxolona (GNX) en niños y adultos con epilepsia relacionada con el complejo de esclerosis tuberosa (CET) (TrustTSC)	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	III
C-01	Registro en España del uso de los inhibidores de la COMT en el manejo de pacientes con enfermedad de Parkinson que presentan fluctuaciones motoras tempranas. Estudio REONPARK	OBSERVATIONAL STUDIES WITH DRUGS	LUCIA GARCIA TRUJILLO	Not applicable
C-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, paralelo y multicéntrico para evaluar la seguridad y eficacia de ALXN1720 en adultos con miastenia gravis generalizada.	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	III

Group	Title	Subtype	LR Name	Phase
C-01	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de soticlestat como tratamiento adyuvante en sujetos pediátricos y en adultos jóvenes con síndrome de Dravet (SD)	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de soticlestat como tratamiento adyuvante en sujetos pediátricos y en adultos con síndrome de Lennox-Gastaut (SLG)	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de Fase III, multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento y de grupos paralelos para evaluar la eficacia y la seguridad Fenebrutinib en comparación con Teriflunomida en pacientes adultos esclerosis múltiple recurrente.	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	III
C-01	Estudio de fase 2B, de 30 semanas, prospectivo, multicéntrico, cruzado, doble ciego, aleatorizado y controlado con placebo, seguido de un estudio de extensión abierto de 52 semanas, para evaluar la eficacia y seguridad de basimglurant como adyuvante de la terapia anticonvulsiva en curso en niños, adolescentes y adultos jóvenes con epilepsia asociada al complejo de esclerosis tuberosa	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio observacional retrospectivo para evaluar el uso de siponimod (MAYzent) en pacientes con Esclerosis Múltiple Secundaria Progresiva en la práctica clínica habitual en España. Estudio RESYZE	OBSERVATIONAL STUDIES WITH DRUGS	ANA MARÍA ALONSO TORRES	Not applicable
C-01	Estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo y de fase 2 en el que se evalúan la seguridad y la eficacia de CORT113176 (Dazucorilant) en pacientes con esclerosis lateral amiotrófica (DAZALS)	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	II
C-01	Estudio fase 3 prospectivo, abierto, multicéntrico y de extensión de los estudios Fase 3, para evaluar la seguridad y tolerabilidad a largo plazo de Soticlestat como tratamiento adyuvante en pacientes con Síndrome Dravet o Síndrome de Lennox-Gastaut (ENDYMION 2).	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad y la eficacia de XEN1101 como tratamiento complementario de las crisis convulsivas de inicio focal_	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase III, sin enmascaramiento, de un único grupo, multicéntrico para evaluar la farmacocinética, la farmacodinámica, la eficacia, la seguridad y la inmunogenicidad del ravulizumab administrado por vía intravenosa en participantes pediátricos (de 6 a <18 años de edad) con miastenia grave generalizada (MGg)	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	III
C-01	Estudio abierto de fase III del tratamiento adyuvante con ganaxolona (GNX) en niños y adultos con epilepsia relacionada con el complejo de esclerosis tuberosa (CET) (TrustTSC OLE)	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	A 12-month, prospective, observational study in adult patients with focal onset seizures who are treated with adjunctive ASM in real world setting	OBSERVATIONAL STUDIES WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio de fase 3, de carácter pivotal, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, con un período de extensión abierta, para evaluar la eficacia y la seguridad de rozanolixizumab en participantes adultos con enfermedad asociada a anticuerpos contra la glucoproteína de la mielina del oligodendrocito (MOG)	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	III
C-01	Observational, multicenter study to describe the persistence in relapsing remitting multiple sclerosis naive patients with low-moderate activity treated with Ozanimod (Zeposia ®) in clinical practice in Spain (AppreZiate Study).	OBSERVATIONAL STUDIES WITH DRUGS	ANA MARÍA ALONSO TORRES	Not applicable
C-01	Estudio de fase II, de 2 partes, multicéntrico, aleatorizado, ciego y controlado con principio activo para evaluar de forma secuencial la seguridad y la eficacia de BIIB091 en monoterapia y del tratamiento combinado de BIIB091 con fumarato de diroximel en participantes con formas recidivantes de esclerosis múltiple	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	II
C-01	Medidas de seguridad y terapéuticas de la estimulación con corriente continua catódica transcraneal (TDCS) en pacientes con epilepsia focal resistente al tratamiento.	CLINICAL RESEARCH WITH MEDICAL DEVICES	PEDRO JESÚS SERRANO CASTRO	Not applicable

Group	Title	Subtype	LR Name	Phase
C-01	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y con fase de extensión para evaluar la eficacia y la seguridad de Dysport® en relación con la prevención de la migraña crónica en participantes adultos	CLINICAL TRIALS WITH DRUGS	LUCIA GARCIA TRUJILLO	III
C-01	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y con fase de extensión para evaluar la eficacia y la seguridad de Dysport® en relación con la prevención de la migraña crónica en participantes adultos	CLINICAL TRIALS WITH DRUGS	LUCIA GARCIA TRUJILLO	III
C-01	Un estudio de extensión multicéntrico y abierto para investigar a largo plazo seguridad de FAB122 en pacientes con esclerosis lateral amiotrófica. Adorexto	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	III
C-01	Estudio intervencionista de extensión en fase III para investigar la seguridad y la tolerabilidad a largo plazo de tolebrutinib en participantes con esclerosis múltiple recidivante, esclerosis múltiple primaria progresiva o esclerosis múltiple secundaria progresiva no recidivante.	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	III
C-01	MS-DETECT: Early detection of Multiple Sclerosis progression with MSCopilot® Detect	CLINICAL RESEARCH WITH MEDICAL DEVICES	ANA MARÍA ALONSO TORRES	Not applicable
C-01	Estudio transversal para evaluar la eficacia y seguridad de Ofatumumab (Kesimpta®) en pacientes con esclerosis múltiple recurrente en la práctica clínica española: estudio CRONOS-MS	OBSERVATIONAL STUDIES WITH DRUGS	ANA MARÍA ALONSO TORRES	Not applicable
C-01	Estudio de Fase III, aleatorizado, multicéntrico, doble ciego, controlado con placebo para evaluar la seguridad, la tolerabilidad y la eficacia de XEN1101 como terapia complementaria en las crisis convulsivas tónico-clónicas primarias generalizadas.	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase 3, doble ciego, aleatorizado, comparando la eficacia y seguridad de frexalimab (SAR441344) con placebo en participantes adultos con Esclerosis Múltiple Secundaria Progresiva sin recaídas.	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	III
C-01	Protocolo maestro de dos estudios en fase III, independientes, aleatorizados y doble ciegos que comparan la eficacia y la seguridad de frexalimab (SAR441344) con teriflunomida en participantes adultos con formas recidivantes de esclerosis múltiple	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	III
C-01	Protocolo maestro para tres estudios independientes, de reclutamiento continuo, con doble ciego, controlados con placebo, sobre la eficacia y la seguridad del ACP 204 en adultos con psicosis por enfermedad de Alzheimer	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de extensión en abierto de 52 semanas para evaluar el ACP-204 en adultos con psicosis por enfermedad de Alzheimer	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase 3, randomizado, doble ciego, multicéntrico para evaluar la eficacia y seguridad de Riliprubart (SAR445088) en comparación con inmunoglobulina intravenosa (IVIg) en participantes con polineuropatía desmielinizante inflamatoria crónica (CIDP)	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	III
C-01	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy.	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Real-life effectiveness of eptinezumab in migraine patients. Observational prospective study assessing the effectiveness in patients treated with eptinezumab as a preventive treatment for migraine in a real-world setting in Spain.	OBSERVATIONAL STUDIES WITH DRUGS	LUCIA GARCIA TRUJILLO	Not applicable
C-01	Estudio abierto, multicéntrico y a largo plazo para evaluar la seguridad, la tolerabilidad y la eficacia de XEN1101 en sujetos con diagnóstico de epilepsia	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension”	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de cohortes, observacional, prospectivo y con enfoque en la lesión hepática inducida por fármacos (LHIF), para evaluar la seguridad a largo plazo en los pacientes a quienes se les recetó Epidyolex®.	OBSERVATIONAL STUDIES WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio multicéntrico retrospectivo sobre la neurotoxicidad asociada a la terapia con células CART	OBSERVATIONAL STUDIES WITH DRUGS	PABLO CABEZUDO GARCÍA	Not applicable

Group	Title	Subtype	LR Name	Phase
C-01	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab, in Patients with Relapsing Multiple Sclerosis	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	II
C-01	Estudio de seguridad a largo plazo, de fase 2, global y multicéntrico diseñado para evaluar la seguridad y la tolerabilidad de BHV-7000 en sujetos con epilepsia de inicio focal refractaria	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	II
C-01	A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	II
C-01	A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus!(Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	III
C-02	Prevención universal de la depresión y ansiedad en población general mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayudas a las decisiones: Ensayo Aleatorio Controlado (Estudio PredictPlusPrevent)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JUAN ÁNGEL BELLÓN SAAMEÑO	Not applicable
C-02	Prevención de la depresión a través de una intervención personalizada basada en TICs, algoritmos predictivos de riesgo, y DSS para pacientes y médicos de familia: estudio e-predictD	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JUAN ÁNGEL BELLÓN SAAMEÑO	Not applicable
C-03	Estudio de extensión, abierto, de seguridad a largo plazo de esketamina en la depresión resistente al tratamiento. Seguridad y mantenimiento de la respuesta al tratamiento con esketamina con dosis repetidas en intervalos determinados por la gravedad de los síntomas (SUSTAIN-3).	COMMERCIAL CLINICAL TRIAL	FERMÍN MAYORAL CLERIES	III
C-03	Ensayo clínico aleatorizado, multicéntrico, para evaluar la seguridad y tolerabilidad de clozapina vs tratamiento de práctica clínica habitual en psicosis resistente a tratamiento en personas adolescentes y adultos jóvenes con discapacidad intelectual.	INDEPENDENT CLINICAL TRIAL	FERMÍN MAYORAL CLERIES	II
C-03	Estudio observacional, prospectivo, de cohorte, de 12 meses para analizar los cambios en el perfil cardiometabólico del cambio a lurasidona en pacientes con esquizofrenia. Estudio RESPECT.	COMMERCIAL POST-AUTHORIZATION STUDY	FERMÍN MAYORAL CLERIES	Not applicable
C-03	Estudio de fase II, de 6 semanas, multicéntrico, aleatorizado, doble ciego, doble enmascaramiento, controlado con placebo y de grupos paralelos, con un grupo de quetiapina para evaluar la eficacia, tolerabilidad y seguridad de BI 1358894 oral en pacientes con trastorno depresivo mayor con respuesta inadecuada a los antidepresivos.	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	II
C-03	Un estudio aleatorizado, doble ciego, multicéntrico, de grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de aticaprant 10 mg como tratamiento complementario en participantes adultos con trastorno depresivo mayor (TDM) con anhedonia moderada a grave y una respuesta insuficiente al tratamiento antidepresivo actual.	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	III
C-03	Un estudio abierto y a largo plazo para evaluar la seguridad y la eficacia de Aticaprant como tratamiento complementario en participantes adultos y de edad avanzada con trastorno depresivo mayor (TDM).	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	III
C-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de lcleptina una vez al día durante un periodo de tratamiento de 26 semanas en pacientes con esquizofrenia (CONNEX-2)	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	III
C-06	Características clínicas de los pacientes tratados con lurasidona en España: análisis retrospectivo de la información recogida en las historias clínicas electrónicas mediante el Procesamiento del Lenguaje Natural	COMMERCIAL POST-AUTHORIZATION STUDY	CARLOS GOMEZ SANCHEZ-LAFUENTE	Not applicable
C-06	Estudio de las características de la enfermedad y la eficacia del tratamiento habitual en la vida real en pacientes con trastorno depresivo mayor (TDM) con anhedonia y respuesta inadecuada al tratamiento antidepresivo actual, incluido un ISRS o un IRSN (VENTURA)	OBSERVATIONAL STUDIES WITH DRUGS	JESÚS HERRERA IMBRODA	Not applicable
C-06	Estudio de cohortes no intervencionista sobre el aerosol nasal de esketamina en la depresión resistente al tratamiento -ECHO.	OBSERVATIONAL STUDIES WITH DRUGS	JESÚS HERRERA IMBRODA	Not applicable

Group	Title	Subtype	LR Name	Phase
C-08	Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de eventos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación UMEC /VI por inhalación o UMEC por inhalación en comparación con tiotropio. (Estudio 201038)	COMMERCIAL POST-AUTHORIZATION STUDY	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Registro de pacientes con psoriasis y riesgo cardiovascular en Atención Primaria	NON-POST-AUTHORIZATION STUDY	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia analgésica y la seguridad de una combinación en dosis fijas por vía oral de dexketoprofeno trometamol y tramadol hidrocloreto en el dolor agudo de moderado a intenso en pacientes con lumbalgia aguda: estudio DANTE	COMMERCIAL CLINICAL TRIAL	LEOVIGILDO GINEL MENDOZA	IV
C-08	Estudio Observacional con Medicamento, para evaluar y documentar con monitorización continua de glucosa (MCG) la aparición de hipoglucemia en pacientes con diabetes mellitus tipo 2 (DM2) tratados con Glargina-100 en el ámbito de la Atención Primaria. Estudio GPDetect.	OBSERVATIONAL STUDIES WITH DRUGS	JUAN PABLO GARCÍA PAINE	Not applicable
C-08	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de bemnifosbuvir en pacientes ambulatorios de alto riesgo con COVID-19	CLINICAL TRIALS WITH DRUGS	LEOVIGILDO GINEL MENDOZA	III
C-08	A prospective study to evaluate the immune status in the elderly after receiving a booster dose under the Covid-19 vaccination program in Spain	OBSERVATIONAL STUDIES WITH DRUGS	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®	CLINICAL TRIALS WITH DRUGS	LEOVIGILDO GINEL MENDOZA	IV
C-08	Estudio observacional para evaluar el grado de control de la EPOC en la Atención Primaria de la Sanidad Española. Estudio AGORA	OBSERVATIONAL STUDIES WITH DRUGS	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Estudio observacional para evaluar el grado de control de la EPOC en la Atención Primaria de la Sanidad Española. Estudio AGORA.	OBSERVATIONAL STUDIES WITH DRUGS	MIGUEL DOMÍNGUEZ SANTAELLA	Not applicable
C-08	Eficacia de un Test Rápido Dual de Gripe y Covid-19 en la reducción de la prescripción antibiótica en Atención Primaria: Estudio RAPRIM	CLINICAL RESEARCH WITH MEDICAL DEVICES	LEOVIGILDO GINEL MENDOZA	Not applicable
C-11	Estudio nacional retrospectivo para evaluar la efectividad, tolerancia y seguridad del citrato de fentanilo sublingual en pacientes ancianos con dolor irruptivo oncológico. PODIO Study. Sponsor Code: FKAP-NIS-2001	COMMERCIAL POST-AUTHORIZATION STUDY	MARIANO FERNANDEZ BAENA	Not applicable
C-16	Estudio de observación multicéntrico, prospectivo y multinacional para evaluar la seguridad a largo plazo de Esmya, especialmente la seguridad endometrial, y los patrones de prescripción y gestión actuales de Esmya en el contexto de un tratamiento a largo plazo. Estudio PGL14-001.	COMMERCIAL POST-AUTHORIZATION STUDY	EMILIA VILLEGAS MUÑOZ	Not applicable
C-16	Estudio observacional, prospectivo y multicéntrico para evaluar el uso clínico de la prueba molecular GynEC-Dx para el descarte de cáncer de endometrio y posterior seguimiento en mujeres asintomáticas con formaciones polipoideas endometriales	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JESUS SALVADOR JIMENEZ LOPEZ	Not applicable
C-16	Estudio de extensión, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de linzagolix a largo plazo en pacientes con dolor asociado a endometriosis (Extensión del Edelweiss 3)	COMMERCIAL CLINICAL TRIAL	EMILIA VILLEGAS MUÑOZ	III
C-16	Ensayo clínico de fase 2, multicéntrico, abierto, aleatorizado, para evaluar la inhibición de la ovulación de tres dosificaciones de levonorgestrel (LNG) en un sistema de liberación vaginal (SLV), que se libera durante 28 días de manera continua, frente a desogestrel (Cerazet®).	COMMERCIAL CLINICAL TRIAL	JESUS SALVADOR JIMENEZ LOPEZ	II
C-16	Ensayo clínico aleatorizado, abierto, multicéntrico de grupos paralelos y con grupo control, para explorar la eficacia del gel vaginal papilocare® en la reparación de la mucosa cervical con lesiones causadas por virus papiloma humano de alto riesgo	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JESUS SALVADOR JIMENEZ LOPEZ	Not applicable

Group	Title	Subtype	LR Name	Phase
C-16	Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al Virus Respiratorio Sincitial (VRS), administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la Enfermedad vías respiratorias Bajas (EVRB) asociada al VRS en sus hijos hasta los 6 meses de edad. RSV-MAT-009	COMMERCIAL CLINICAL TRIAL	JESUS SALVADOR JIMENEZ LOPEZ	III
C-16	Estudio Fase IIIB, abierto, no aleatorizado, controlado, internacional para evaluar la seguridad, reactogenicidad e inmunogenicidad de una segunda dosis de 120 µg de la vacuna de GSK no adyuvada para inmunización materna frente al Virus Respiratorio Sincitial (VRS) durante embarazos subsiguientes en madres sanas de 18 a 49 años de edad, que hayan participado en estudios previos con esta vacuna. (RSV MAT-008)	COMMERCIAL CLINICAL TRIAL	JESUS SALVADOR JIMENEZ LOPEZ	III
C-16	Estudio de cohortes de fase 3b, no aleatorizado, abierto e internacional para describir la seguridad de las participantes que recibieron o la vacuna para inmunización materna RSVPreF3 (cualquier dosis) o el placebo (grupo control) en los estudios RSV MAT anteriores (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 y RSV MAT-039), durante cualquier embarazo posterior a la vacunación con la vacuna RSVPreF3 o el placebo.	CLINICAL TRIALS WITH DRUGS	JESUS SALVADOR JIMENEZ LOPEZ	III
CE-17	Un Ensayo de Fase III, Aleatorizado, Doble ciego y Controlado con placebo de?una solución para inhalación de acetato de flecainida?para la cardioversión de la fibrilación auricular sintomática de inicio reciente a ritmo sinusal (RESTORE-1)	CLINICAL TRIALS WITH DRUGS	FRANCISCO TEMBOURY RUIZ	III
CE-20	Evaluación de la eficacia y la seguridad de Vismed® Gel Multi 0,3% frente a Vismed® Multi 0,18% en el tratamiento de la sequedad ocular de moderada a grave	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MARINA RODRIGUEZ CALVO DE MORA	Not applicable
CE-20	Estudio de extensión para evaluar los resultados a largo plazo de los pacientes que recibieron tratamiento para la retinopatía del prematuro en el ensayo 20090	COMMERCIAL CLINICAL TRIAL	JULIA ESCUDERO GOMEZ	III
CE-20	Recopilación de datos a largo plazo del mundo real para obtener información clínica sobre Roche Productos de Oftalmología (Estudio Voyager).	OBSERVATIONAL STUDIES WITH DRUGS	ANA SOFÍA DELGADO FERNÁNDEZ	Not applicable
D-01	Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a dolutegravir más lamivudina en adultos infectados por el VIH 1 con supresión virológica	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	III
D-01	Estudio observacional para evaluar la tasa de reinfección en personas que se inyectan drogas (PID) infectadas con el virus de la hepatitis C (VHC) que se han sometido con éxito a un tratamiento para el VHC en España. LIVERate Study, Promtor Code: ID VEAP: 6375	COMMERCIAL POST-AUTHORIZATION STUDY	ROSARIO PALACIOS MUÑOZ	Not applicable
D-01	Estudio en fase III para evaluar el efecto de la pitavastatina para prevenir los acontecimientos vasculares en personas con infección por VIH-1. Estudio REPRIEVE	INDEPENDENT CLINICAL TRIAL	CRISTINA GOMEZ AYERBE	III
D-01	Ensayo clínico piloto, multicéntrico, para comparar la eficacia de RAL 1200 QD vs DRV-cb (800-150) QD ambos en combinación con TAF/FTC en pacientes con infección VIH y CD4<200 cel/microL	INDEPENDENT CLINICAL TRIAL	ROSARIO PALACIOS MUÑOZ	IV
D-01	Estudio de intervención quasi-experimental para la optimización del uso de nuevos antibióticos (Poyecto NEW_SAFE).	INDEPENDENT POST-AUTHORIZATION STUDY	GUILLERMO OJEDA BURGOS	Not applicable
D-01	Estudio de fase IV, multicéntrico, abierto y aleatorizado, para evaluar el impacto del cambio de tratamiento antirretroviral de terapia dual a terapia triple sobre la inflamación en pacientes con infección por VIH tipo 1	INDEPENDENT CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	IV
D-01	Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir (DOR/ISL) una vez al día en participantes con supresión virológica del VIH-1 con bictegravir/emtricitabina/tenofovir alafenamida(BIC/FTC/TAF)	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	III
D-01	Estudio clínico de fase 3, aleatorizado, doble ciego y comparativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir una vez al día en participantes infectados por el VIH-1 sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	III
D-01	Eficacia virológica de dolutegravir/lamivudina en personas virológicamente suprimidas con resistencia confirmada o sospechada a lamivudina. Estudio VOLVER	INDEPENDENT CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	II

Group	Title	Subtype	LR Name	Phase
D-01	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR	INDEPENDENT CLINICAL TRIAL	ROSARIO PALACIOS MUÑOZ	IV
D-01	Ensayo abierto multicéntrico aleatorizado y pragmático de Fase IV para evaluar la eficacia y seguridad de diferentes duraciones de tratamiento antimicrobiano de infecciones asociadas al material de osteosíntesis tras fractura de hueso largo. DURATIONIOM.	INDEPENDENT CLINICAL TRIAL	ENRIQUE NUÑO ÁLVAREZ	III
D-01	Estudio abierto, multicéntrico y aleatorizado para investigar el tratamiento antirretroviral con inhibidor de la integrasa frente al inhibidor de la proteasa potenciado para pacientes con enfermedad por el VIH avanzada. Estudio Late Presenter Treatment Optimisation (Optimización del tratamiento para pacientes con infección avanzada, LAPTOP).	INDEPENDENT CLINICAL TRIAL	CRISTINA GOMEZ AYERBE	III
D-01	FIS-PSE-2022-01 Estudio prospectivo de las infecciones del torrente sanguíneo por Pseudomonas aeruginosa en pacientes adultos: eficacia y seguridad de diferentes estrategias terapéuticas, en el contexto actual de resistencia a múltiples fármacos	COMMERCIAL POST-AUTHORIZATION STUDY	ANDREA PROLO ACOSTA	Not applicable
D-01	Estudio de fase IIIb, multicéntrico, no aleatorizado, de grupos paralelos, abierto, híbrido de tipo I que evalúa la eficacia, la seguridad, la efectividad de la implementación y los resultados comunicados por el paciente de dolutegravir/lamivudina por vía oral una vez al día como tratamiento de primera línea, seguido de un cambio opcional elegido por el participante a cabotegravir intramuscular de acción prolongada más rilpivirina cada dos meses para el mantenimiento de la supresión virológica en adultos con VIH-1 sin tratamiento antirretrovíricos	CLINICAL TRIALS WITH DRUGS	ROSARIO PALACIOS MUÑOZ	III
D-01	Eficacia y seguridad de la perfusión continua vs. perfusión intermitente de ampicilina y ceftriaxona para el tratamiento de endocarditis infecciosa por Enterococcus faecalis (Estudio DOBLEI).	CLINICAL TRIALS WITH DRUGS	GUILLERMO OJEDA BURGOS	IV
D-01	Prevalencia del VHD en pacientes coinfectados VIH/VHB en España.	OBSERVATIONAL STUDIES WITH DRUGS	ROSARIO PALACIOS MUÑOZ	Not applicable
D-01	Estudio de fases 2/3 operativamente sin interrupciones, aleatorizado y con control activo para evaluar la seguridad y la eficacia de una pauta semanal por vía oral de GS-1720 en combinación con GS-4182 en comparación con Biktarvy en personas con VIH-1 sin tratamiento previo	CLINICAL TRIALS WITH DRUGS	ROSARIO PALACIOS MUÑOZ	II
D-03	Evolución del Lupus Eritematoso Sistémico en España	NON-POST-AUTHORIZATION STUDY	ANTONIO FERNÁNDEZ NEBRO	Not applicable
D-03	Registro español de acontecimientos adversos de terapias dirigidas en enfermedades reumáticas (Fase III)	INDEPENDENT POST-AUTHORIZATION STUDY	SARA MANRIQUE ARIJA	Not applicable
D-03	Tratamiento precoz con terapia biológica en espondiloartritis axial: Efectividad a 5 años. Estudio TBSPA	INDEPENDENT POST-AUTHORIZATION STUDY	SARA MANRIQUE ARIJA	Not applicable
D-03	Estudio de extensión a largo plazo con dosis múltiples para demostrar la seguridad y la eficacia del tildrakizumab en sujetos con artritis psoriásica y espondilitis anquilosante o espondiloartritis axial no radiográfica que hayan completado previamente estudios con tildrakizumab	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio multicéntrico para caracterizar la seguridad y la eficacia a largo plazo de BMS-986165 en pacientes con lupus eritematoso sistémico	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de dapirolizumab pegol en participantes del estudio con lupus eritematoso sistémico de moderado a grave	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio observacional de la persistencia del tratamiento en la artritis psoriásica (Estudio PRO-SPIRIT, I1F-MC-B009)	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIO FERNÁNDEZ NEBRO	Not applicable
D-03	Registro de pacientes adultos jóvenes con diagnóstico de Artritis Idiopática Juvenil	INDEPENDENT POST-AUTHORIZATION STUDY	GISELA DÍAZ-CORDOVÉS REGO	Not applicable
D-03	Ensayo clínico en fase II, multicéntrico, aleatorizado, controlado con placebo, con doble enmascaramiento y con grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de MT-7117 en pacientes con esclerosis sistémica cutánea difusa	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II

Group	Title	Subtype	LR Name	Phase
D-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa I que habían recibido tratamiento previo con anti-TNF (INSPIRE 1)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Análisis del impacto del coste en pacientes con Artritis Reumatoide moderada severa que no responden a fármaco modificador de la enfermedad biológico (FAMEb) o a fármaco modificador de la enfermedad sintético convencional (FAMEsc). Sponsor Code: A3921325. Estudio CIARA	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIO FERNÁNDEZ NEBRO	Not applicable
D-03	Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos sobre la seguridad, tolerabilidad, farmacocinética y eficacia terapéutica de SAR441344 en pacientes adultos con síndrome de Sjögren primario (primary Sjögren's Syndrome, pSjS) phaethuSA	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Prevalencia de enfermedad Inflamatoria Intestinal no diagnosticada en pacientes con Espondiloartritis. Estudio EISER	INDEPENDENT POST-AUTHORIZATION STUDY	SARA MANRIQUE ARIJA	Not applicable
D-03	Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ABBV-154 en sujetos con artritis reumatoide activa moderada a grave con respuesta insuficiente a fármacos antirreumáticos modificadores de la enfermedad biológicos o sintéticos dirigidos (FARMEb/sd)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de fase IV, multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de guselkumab administrado por vía subcutánea en pacientes que no han recibido tratamiento biológico previo con artritis psoriásica axial activa.	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	IV
D-03	Estudio de extensión, abierto y multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de BIMEKIZUMAB en el tratamiento de sujetos con artritis psoriásica activa (BE VITAL).	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio de fase 3b, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de guselkumab administrado por vía subcutánea en la mejoría de los signos y síntomas clínicos y en la inhibición de la progresión radiográfica en participantes con artritis psoriásica activa.(APEX)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de PRA023 en sujetos con esclerosis sistémica asociada a enfermedad pulmonar intersticial (ES-EPI).	INDEPENDENT CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de fase 3B, multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y seguridad de Guselkumab administrado por vía subcutánea en participantes con artritis psoriásica activa que tuvieron una respuesta inadecuada y/o intolerancia a un tratamiento anterior de inhibición del factor de necrosis tumoral a	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Un estudio multinacional, no intervencionista de tofacitinib en pacientes tratados para la artritis psoriásica. TOPSATI Study. Sponsor Protocol Code: A3921332	OBSERVATIONAL STUDIES WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	Not applicable
D-03	Estudio de fase II, doble ciego, de rango de dosis, con grupos paralelos y de extensión a largo plazo para evaluar la seguridad y la eficacia de Enpatoran en participantes con lupus eritematoso cutáneo subagudo, lupus eritematoso discoide y/o lupus eritematoso sistémico que han completado el tratamiento del estudio WILLOW (MS200569_0003)	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de extensión, abierta y multicéntrico, para evaluar la seguridad y tolerabilidad a largo plazo del tratamiento con dapirolizumab pegol en participantes del estudio con lupus eritematoso sistémico	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio en fase II, aleatorizado, doble ciego, de búsqueda de dosis, controlado con placebo, de grupos paralelos y adaptativo para evaluar la eficacia y la seguridad de enpatoran en participantes con lupus eritematoso sistémico y con lupus eritematoso cutáneo (lupus eritematoso cutáneo subagudo o lupus eritematoso discoide) que toman el tratamiento de referencia.	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Registro Multicéntrico de Vasculitis Asociadas a ANCA (granulomatosis con poliangéitis, granulomatosis eosinofílica con poliangéitis y poliangéitis microscópica)	OBSERVATIONAL STUDIES WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	Not applicable
D-03	Estudio de fase 3, aleatorizado, en doble ciego, de grupos paralelos y controlado con principio activo, para comparar la eficacia, seguridad, farmacodinamia, farmacocinética e inmunogenia de denosumab de Enzene (ENZ215) y Prolia® en mujeres posmenopáusicas con osteoporosis (DANUBE)	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III

Group	Title	Subtype	LR Name	Phase
D-03	Estudio observacional ambispectivo para describir la persistencia de la secuenciación de guselkumab oTNFi como terapia de segunda línea para el tratamiento de la artritis psoriásica activa MANHATTAN	OBSERVATIONAL STUDIES WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	Not applicable
D-03	Estudio de extensión abierto para evaluar la seguridad y la eficacia a largo plazo de tildrakizumab en pacientes con artritis psoriásica.	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	I
D-03	Estudio multicéntrico, aleatorizado, con doble enmascaramiento y de comparación con placebo para evaluar la eficacia, la seguridad, la tolerabilidad, la farmacocinética y la farmacodinámica de GLPG3667 administrado por vía oral en pacientes adultos con lupus eritematoso sistémico activo	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Ensayo fase III, multicéntrico, aleatorizado, en grupos paralelos, doble ciego, de dos brazos, para evaluar la seguridad y eficacia de anifrolumab frente a placebo en pacientes entre 18 y 70 años con esclerosis sistémica (Estudio DAISY)	CLINICAL TRIALS WITH DRUGS	NATALIA MENA VAZQUEZ	III
D-03	INSPIRE 2 Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa II que no habían recibido tratamiento previo con anti-TNF (INSPIRE 2).	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de SAR441566 más metotrexato en adultos con artritis reumatoide de moderada a grave	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de Dapirolizumab Pegol en participantes del estudio con lupus eritematoso sistémico de moderado a grave.	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio fase 1, multicéntrico, abierto, de CC-97540 (BMS-986353), linfocitos T con receptor de antígeno quimérico (CAR) NEX-T dirigidos a CD19, en participantes con lupus eritematoso sistémico (LES) severo y refractario.	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	I
D-03	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de belimumab administrado por vía subcutánea en adultos con enfermedad pulmonar intersticial (EPI) asociada a enfermedad del tejido conectivo (ETC)	CLINICAL TRIALS WITH DRUGS	NATALIA MENA VAZQUEZ	III
D-03	Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de ianalumab.	CLINICAL TRIALS WITH DRUGS	NATALIA MENA VAZQUEZ	II
D-03	A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease ActivityA	CLINICAL TRIALS WITH DRUGS	SARA MANRIQUE ARIJA	III
D-03	Estudio fase 3 multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de JNJ-77242113 para el tratamiento de pacientes con artritis psoriásica activa sin tratamiento biológico previo.	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio fase 3 multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de JNJ-77242113 para el tratamiento de pacientes con artritis psoriásica activa con tratamiento biológico previo.	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-04	Estudio multicéntrico, aleatorizado, doble ciego, con control activo y placebo para investigar la eficacia y seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica espontánea (UCE) en adolescentes y adultos inadecuadamente controlados con antihistamínicos H1	COMMERCIAL CLINICAL TRIAL	FRANCISCA GÓMEZ PÉREZ	III
D-04	Estudio aleatorizado doble ciego controlado por placebo para evaluar la eficacia y mecanismos implicados en la inmunoterapia sublingual específica con Pru p 3 (Pru p 3-ITSL) en pacientes con alergia a nsLTP con síntomas graves en su respuesta frente a melocotón, cacahuete artemisia y olivo.	INDEPENDENT CLINICAL TRIAL	FRANCISCA GÓMEZ PÉREZ	III
D-04	Estudio de extensión multicéntrico, doble ciego y abierto para evaluar la eficacia y seguridad de ligelizumab como retratamiento, terapia autoadministrada y monoterapia en pacientes con urticaria crónica espontánea que han completado los estudios CQGE031C2302, CQGE031C2303, CQGE031C2202 o CQGE031C1301.	COMMERCIAL CLINICAL TRIAL	FRANCISCA GÓMEZ PÉREZ	III

Group	Title	Subtype	LR Name	Phase
D-04	Estudio de fase II para evaluar la tolerabilidad, seguridad y eficacia de la inmunoterapia sublingual en pacientes con alergia a los ácaros del polvo doméstico. (SULGEN Study)	COMMERCIAL CLINICAL TRIAL	CARMEN RONDÓN SEGOVIA	II
D-04	Reacciones de hipersensibilidad cruzada a Ibuprofeno y otros derivados Arilpropiónicos: entidades clínicas y mecanismos implícitos. Papel de la atopia e interacción fenotipo-genotipo SEAIC2018	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAÉN	Not applicable
D-04	Ensayo prospectivo multicéntrico aleatorizado, controlado con placebo y comparativo de la eficacia y la seguridad de la inmunoterapia subcutánea con mezcla de gramíneas y ácaros a dosis adecuadas frente a monoterapia, para el tratamiento de la alergia	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	BIOBADALER. Understanding similarities and differences of biological therapies for severe asthma	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAÉN	Not applicable
D-04	Estudio de 52 semanas de duración, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad, para evaluar la tasa de exacerbación, las mediciones adicionales de control del asma y la seguridad en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico tratados con GSK3511294 en comparación con mepolizumab o benralizumab	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	Estudio de 52 semanas, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y multicéntrico de la eficacia y la seguridad del tratamiento complementario con GSK3511294 en participantes adultos y adolescentes con asma grave no controlada con fenotipo eosinofílico	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	Protocolo maestro de dos estudios aleatorizados, controlados con placebo, doble ciegos, multicéntricos, de grupos paralelos de dupilumab en pacientes con urticaria crónica espontánea (UCE) que siguen siendo sintomática pesar del uso de tratamiento antihistamínico H1 en pacientes sin tratamiento previo con omalizumab y en pacientes intolerantes o con respuesta incompleta a omalizumab. (CUPID)	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	Ensayo de fase 3 de 3 partes, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para demostrar la eficacia y seguridad de Benralizumab en pacientes con Gastritis y/o Gastroenteritis eosinofílica (ensayo HUDSON GI)	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica inducible (CINDU) en adolescentes y adultos inadecuadamente controlados con antihistamínicos H1.	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	POLLINEX® GO: 600 SU/ml, 1.600 SU/ml, 4.000 SU/ml suspensión inyectable. Extracto alergénico modificado de pólenes: mezcla de gramíneas y olivo. Estudio GOL	COMMERCIAL POST-AUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAÉN	Not applicable
D-04	Similarities and differences of biological therapies for allergic diseases	REST OF OBSERVATIONAL STUDIES WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	Not applicable
D-04	Estudio de extensión, abierto, multicéntrico y de un solo grupo para evaluar la seguridad a largo plazo de GSK3511294 (depemokimab) en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico de los estudios 206713 o 213744	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	Ensayo clínico fase III multicéntrico, doble ciego, aleatorizado y controlado con placebo, en grupos paralelos, que evalúa la eficacia clínica y seguridad de la inmunoterapia con el alérgeno mayor purificado Cup a 1, en pacientes con rinoconjuntivitis alérgica moderada/ grave con o sin asma controlado, sensibilizados a Cupresáceas	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Ensayo clínico de eficacia y seguridad, prospectivo, aleatorizado, doble ciego, de doble simulación, controlado con placebo, multicéntrico, con inmunoterapia en pacientes con asma de leve a moderada controlada y rinitis/rinoconjuntivitis, alérgicos a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae	INDEPENDENT CLINICAL TRIAL	CARMEN RONDÓN SEGOVIA	III

Group	Title	Subtype	LR Name	Phase
D-04	Efectos de la combinación fija de dipropionato de beclometasona/fumarato de formoterol administrada con NEXT(haler) en un estudio en condiciones reales sobre la probabilidad de mejora del estado de control del asma después de 6 meses de tratamiento. Estudio NEWTON	OBSERVATIONAL STUDIES WITH DRUGS	IBON EGUILUZ GRACIA	Not applicable
D-04	Estudio de fase III, multicéntrico y abierto: monitorización ambulatoria de la presión arterial en pacientes adultos con urticaria crónica espontánea inadecuadamente controlada con antihistamínicos H1 y tratados con remibrutinib hasta 12 semanas	CLINICAL TRIALS WITH DRUGS	ALMUDENA TESTERA MONTES	III
D-04	Estudio doble ciego para participante e investigador de un mes de duración en el que se evalúan la eficacia y la seguridad de remibrutinib (LOU064) en varios niveles de dosis en participantes adultos con alergia al cacahuete.	CLINICAL TRIALS WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	II
D-04	Estudio de fase II de búsqueda de dosis, aleatorizado, doble ciego y controlado con un placebo, para evaluar la eficacia y la seguridad del CDX-0159 en pacientes con urticaria crónica espontánea	CLINICAL TRIALS WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	II
D-04	Estudio observacional prospectivo para evaluar la seguridad del tratamiento con “ALLERGOVAC® HIMENÓPTEROS” en pacientes sensibilizados a este veneno HIPNOS.	OBSERVATIONAL STUDIES WITH DRUGS	MARINA LABELLA ALVAREZ	Not applicable
D-04	Ensayo multicéntrico, prospectivo y no intervencionista que supervisa las vías terapéuticas de los pacientes con asma tratados con una triple terapia extrafina de un único inhalador con ICS/LABA/LAMA en condiciones reales y que caracteriza los efectos sobre los resultados relacionados con la salud	OBSERVATIONAL STUDIES WITH DRUGS	IBON EGUILUZ GRACIA	Not applicable
D-04	Estudio de extensión multicéntrico, abierto y doble ciego, controlado con placebo con retirada aleatorizada, seguido de ciclos de tratamiento abierto de larga duración para evaluar la eficacia, seguridad y tolerabilidad de remibrutinib (LOU064) en pacientes adultos con urticaria crónica espontánea que hayan completado los estudios anteriores de fase III de remibrutinib	CLINICAL TRIALS WITH DRUGS	ALMUDENA TESTERA MONTES	III
D-04	Estudio de fase II de búsqueda de dosis, aleatorizado, doble ciego y controlado con un placebo, para evaluar la eficacia y la seguridad del CDX-0159 en pacientes con urticaria crónica inducible	CLINICAL TRIALS WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	II
D-04	Estudio de fase IIb, multicéntrico, aleatorizado, doble ciego y controlado con placebo sobre la eficacia y la seguridad de brensocatib en participantes con rinosinusitis crónica sin polipos nasales - Estudio BIRCh	CLINICAL TRIALS WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	II
D-04	Estudio observacional, multicéntrico, prospectivo, para evaluar la efectividad y seguridad en vida real de Depigoid® DUO Gato- Dermatophagoides pteronyssinus (DPT) (100/100 DPP/ml) en pacientes con rinitis/rinoconjuntivitis persistente moderada-grave con o sin asma alérgica controlada en España”	OBSERVATIONAL STUDIES WITH DRUGS	CARMEN RONDÓN SEGOVIA	Not applicable
D-04	A 12-WEEK double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 PMDI 200/6/12.5 µg hfa-152a, compared to CHF5993 PMDI 200/6/12.5 µg hfa-134a, in subjects with asthma.	CLINICAL TRIALS WITH DRUGS	ALMUDENA TESTERA MONTES	III
D-04	Estudio pRagmático multinacional no intervEncioniSta y prospectivo para evaluar el mePOLizumab en pacientes con rinosinusitis crónica con poliposis Nasal y asma o aSma eosinofílico gravE y pólipos nasales. RESPONSE	OBSERVATIONAL STUDIES WITH DRUGS	ALMUDENA TESTERA MONTES	Not applicable
D-04	Evaluación de la tolerabilidad y la eficacia de la administración de inmunoterapia subcutánea en pauta clúster, en pacientes con rinoconjuntivitis y/o asma con sensibilización a olivo con o sin sensibilización a gramíneas: Pauta de inicio y primer año de tratamiento	OBSERVATIONAL STUDIES WITH DRUGS	ALMUDENA TESTERA MONTES	Not applicable
D-05	Registro no intervencionista de larga duración para evaluar la seguridad y la efectividad de HUMIRA® (adalimumab) en pacientes con colitis ulcerosa (CU) de actividad moderada a grave. P11-282, LEGACY	COMMERCIAL POST-AUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Estudio de fase 3, multicéntrico, aleatorizado, con doble enmascaramiento, a largo plazo y controlado con placebo para evaluar la seguridad y la eficacia del ácido obeticólico en sujetos con esteatohepatitis no alcohólica.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio Epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España.	NON-POST-AUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	Not applicable

Group	Title	Subtype	LR Name	Phase
D-05	Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio multicéntrico de Fase III aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del Etrolizumab como tratamiento de inducción y mantenimiento en pacientes con Enfermedad de Crohn activa de moderada a grave.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio abierto de extensión y supervisión de la seguridad de pacientes con Enfermedad de Crohn con actividad de moderada a grave previamente inscritos en el protocolo de Fase III con Etrolizumab, GA29144.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase III, multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo, para evaluar la eficacia y seguridad de cenicriviroc para el tratamiento de la fibrosis hepática en pacientes adultos con esteatohepatitis no alcohólica	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Suspensión del tratamiento anti-tnf en pacientes con enfermedad inflamatoria intestinal: ensayo clínico multicéntrico, prospectivo y aleatorizado.	INDEPENDENT CLINICAL TRIAL	RAQUEL CAMARGO CAMERO	IV
D-05	Estudio observacional de regorafenib en carcinoma hepatocelular. REFINE	COMMERCIAL POST-AUTHORIZATION STUDY	RAÚL J. ANDRADE BELLIDO	Not applicable
D-05	FLUID DAY. HTF-FLU-2018-01	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE AURELIO GÓMEZ LUQUE	Not applicable
D-05	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. GIS-DUMBO-2018	INDEPENDENT POST-AUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Evaluación integrada mecanística, diagnóstica y pronóstica en hepatotoxicidad	INDEPENDENT POST-AUTHORIZATION STUDY	RAÚL J. ANDRADE BELLIDO	Not applicable
D-05	Estudio abierto para evaluar la seguridad, actividad antiviral y farmacocinética de IMC-I109V en pacientes positivos para HLA-A*02:01 con infección crónica por VHB, no cirróticos, negativos para el antígeno e de hepatitis B y con carga viral suprimida	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio fase 2, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de múltiples dosis, para evaluar la eficacia y la seguridad de BMS-986263 en adultos con cirrosis compensada por esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de Seladelpar en pacientes con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico (UDCA).RESPONSE	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio doble ciego, aleatorizado, controlado con placebo y en fase II de búsqueda de dosis en el que se comparan distintas dosis de RhuDex gránulos con placebo en el tratamiento de la colangitis biliar primaria	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio abierto a largo plazo para evaluar la seguridad y la tolerabilidad de seladelpar en sujetos con colangitis biliar primaria (CBP). ASSURE	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	IV
D-05	Estudio prospectivo, multicéntrico (B-Sure) para evaluar la durabilidad a largo plazo de la respuesta virológica sostenida en participantes con hepatitis B crónica tratados y no tratados con nucleósidos/ nucleótidos, que recibieron GSK3228836 en un estudio de tratamiento previo y respondieron a dicho tratamiento	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	ASCEND-NASH: Estudio de fase IIB, aleatorizado, multicéntrico, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de CRV431 en sujetos adultos con esteatohepatitis no alcohólica y fibrosis hepática avanzada	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II

Group	Title	Subtype	LR Name	Phase
D-05	Ensayo doble ciego, aleatorizado, controlado con placebo, fase IIb sobre la eficacia y seguridad de comprimidos de ácido norursodesoxicólico en pacientes con esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	TRANSFORM: Ensayo clínico de fase IIb/III, adaptativo, doble ciego, aleatorizado, controlado con placebo y de 52 semanas de duración de setanaxib con una fase de extensión de 52 semanas en pacientes con colangitis biliar primaria (CBP) y rigidez hepática elevada	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Minimización de la 17b-hidroxiesteroide deshidrogenasa tipo 13 para el tratamiento de EHNA (HORIZON): Estudio Fase 2b, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de GSK4532990 en adultos con esteatohepatitis no alcohólica precirrótica.	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio de fase III aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de fazirsiran en el tratamiento de la enfermedad hepática asociada a la deficiencia de alfa-1 antitripsina con fibrosis en estadio F2 a F4 de METAVIR.	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio Fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de la administración de bepirovirsén en pacientes con Hepatitis B crónica HBeAg negativos y en tratamiento con análogos de nucleós(t)idos (B-Well 1)	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase II, aleatorizado, doble ciego, comparativo con placebo y de búsqueda de dosis para evaluar la eficacia y la seguridad de TAK-062 para el tratamiento de la celiaquía activa en participantes que siguen una dieta sin gluten	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio Multicéntrico, Aleatorizado, Doble Ciego y Controlado con Placebo para evaluar la eficacia y la seguridad de la rifaximina en comprimidos de Dispersión Sólida Soluble (SSD) para el retraso de la Descompensación de la Encefalopatía en la Cirrosis (Red-C)	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	Registro español de alteraciones hematológicas durante el tratamiento con siponimod. Estudio REALhES.	OBSERVATIONAL STUDIES WITH DRUGS	JUDITH ADRIANA SANABRIA CABRERA	Not applicable
D-05	A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants with Primary Biliary Cholangitis (PBC)	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	A randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the treatment of alpha-1 Antitrypsin Deficiency-Associated Liver Disease with METAVIR Stage F1 Fibrosi.	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños (registro DUMBO)	OBSERVATIONAL STUDIES WITH DRUGS	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Estudio en Fase II abierto para evaluar la seguridad y la eficacia de Bemnifosbuvir (BEM) y Ruzasvir (RZR) en sujetos con infección crónica por el virus de la Hepatitis c (VHC).	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Proof-of-concept Phase II study to evaluate the efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity and its mechanistic pathways through an integrative analysis: the DILICORT clinical trial.	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio en fase IIIb, aleatorizado, de grupos paralelos, con doble enmascaramiento, comparado con placebo y de dos grupos para evaluar la eficacia de elafibranor 80 mg en la normalización de la fosfatasa alcalina en participantes adultos con colangitis biliar primaria (CBP) y una respuesta inadecuada o intolerancia al ácido ursodesoxicólico	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio en fase IIa/b, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de amlitelimab subcutáneo en pacientes adultos con enfermedad celíaca sin respuesta de forma conjunta a una dieta sin	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II

Group	Title	Subtype	LR Name	Phase
D-05	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. Registro DUMBO 2.	OBSERVATIONAL STUDIES WITH DRUGS	RAQUEL CAMARGO CAMERO	Not applicable
DA-06	Estudio de prevalencia y adecuación del uso hospitalario de antimicrobianos en España.	INDEPENDENT POST-AUTHORIZATION STUDY	ELENA SANCHEZ YAÑEZ	Not applicable
DA-06	Factores asociados al descenso de densidad mineral ósea y a la incidencia de fracturas durante el periodo de descanso terapéutico con Bifosfonatos Sponsor Code: Vacaciones Terapéuticas	INDEPENDENT POST-AUTHORIZATION STUDY	BLANCA PANERO LAMOTHE	Not applicable
DA-06	Pautas de tratamiento con upadacitinib, consecución de los objetivos terapéuticos y mantenimiento de la respuesta en pacientes con artritis reumatoide de moderada a grave en la práctica real (Estudio UPHOLD, P20-095)	COMMERCIAL POST-AUTHORIZATION STUDY	ROSA MARIA GARCIA PORTALES	Not applicable
DA-06	Estudio observacional para evaluar la adherencia a TREMFYA (Guselkumab) en la práctica clínica en pacientes con psoriasis moderada a grave. ADHERENCE	OBSERVATIONAL STUDIES WITH DRUGS	ELENA SANCHEZ YAÑEZ	Not applicable
DA-06	Estudio multicéntrico, ambispectivo y observacional, en pacientes con psoriasis en placas de moderada a grave, para evaluar su satisfacción con el tratamiento con tildrakizumab.	OBSERVATIONAL STUDIES WITH DRUGS	ISABEL MOYA CARMONA	Not applicable
DA-06	Estudio observacional ambispectivo para describir la persistencia de la secuenciación de guselkumab o TNFi como terapia de segunda línea para el tratamiento de la artritis psoriásica activa.	OBSERVATIONAL STUDIES WITH DRUGS	ROSA MARIA GARCIA PORTALES	Not applicable
DA-06	A multinational, prospective, non-interventional study, to assess real world use of a tocilizumab biosimilar in rheumatoid arthritis patients.	OBSERVATIONAL STUDIES WITH DRUGS	ROSA MARIA GARCIA PORTALES	Not applicable
DA-06	Evaluación de los resultados reportados por el paciente con psoriasis tratado con un fármaco anti IL-17AF a través de un modelo de atención farmacéutica telemática.	OBSERVATIONAL STUDIES WITH DRUGS	ELENA SANCHEZ YAÑEZ	Not applicable
DE-02	Estudio Fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapiaantirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica.	COMMERCIAL CLINICAL TRIAL	MANUEL CASTAÑO CARRACEDO	III
DE-02	Estudio Fase IIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica	COMMERCIAL CLINICAL TRIAL	MANUEL CASTAÑO CARRACEDO	III
DE-02	Estudio Clínico, Farmacológico y Microbiológico del Tratamiento Optimizado con beta-lactámicos en combinación con colistina de la infección osteoarticular con y sin material ortopédico por bacilos gram-negativos resistentes a fluoroquinolonas. Estudio COLBETA-17	INDEPENDENT POST-AUTHORIZATION STUDY	BEATRIZ SOBRINO DIAZ	Not applicable
DE-02	Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por Enterobacteriaceae	INDEPENDENT CLINICAL TRIAL	ANTONIO PLATA CIEZAR	III
DE-02	Estudio comparativo en fase III, prospectivo, aleatorizado, multicéntrico, abierto pero enmascarado para el evaluador principal y de grupos paralelos para determinar la eficacia, seguridad y tolerabilidad de Aztreonam-Avibactam (ATM-AVI) ± Metronidazol (MTZ) en comparación con Meropenem ± Colistina (MER ± COL) en el tratamiento de infecciones graves por Bacterias Gramnegativas, incluidos los patógenos multirresistentes que producen Metallo-?-Lactamasa (MBL), para las que hay pocas o ninguna opción de tratamiento (REVISIT)	COMMERCIAL CLINICAL TRIAL	JOSÉ MARÍA REGUERA IGLESIAS	III
DE-02	Estudio de intervención quasi-experimental para la optimización del uso de nuevos antibióticos (Poyecto NEW_SAFE).	INDEPENDENT POST-AUTHORIZATION STUDY	LUCÍA VALIENTE DE SANTIS	Not applicable
DE-02	Estudio de cohortes, no intervencionista, en múltiples países, de la efectividad, seguridad, adherencia y calidad de vida relacionada con la salud en pacientes adultos infectados con el VIH-1 que reciben bictegravir/emtricitabina/tenofovir alafenamida (B/F/TAF). GS-EU-380-4472	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL CASTAÑO CARRACEDO	Not applicable

Group	Title	Subtype	LR Name	Phase
DE-02	Eficacia de fosfomicina intravenosa en la infección urinaria complicada con condiciones de vida real. Impacto de la CMI y de las mutaciones basales. Proyecto FOSFO-MIC	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MARÍA REGUERA IGLESIAS	Not applicable
DE-02	Temocilina vs Meropenem para el Tratamiento de la Bacteriemia por Enterobacteriales Resistentes a Cefalosporinas de Tercera Generación: Ensayo Aleatorizado y Pragmático.	INDEPENDENT CLINICAL TRIAL	LUCÍA VALIENTE DE SANTIS	III
DE-02	Temocilina vs Meropenem para el Tratamiento de la Bacteriemia por Enterobacteriales Resistentes a Cefalosporinas de Tercera Generación: Ensayo Aleatorizado y Pragmático.	INDEPENDENT CLINICAL TRIAL	CARMEN PEREZ LOPEZ	III
DE-02	Estudio Salutem: uso de hidroxiclороquina en profilaxis pre-exposición a la COVID-19 en trabajadores sanitarios	INDEPENDENT CLINICAL TRIAL	JUAN DIEGO RUIZ MESA	III
DE-02	Multicentre EuRopean study of MAJOR Infectious Disease Syndromes (MERMAIDS). Acute Respiratory Infections (MERMAIDS ARI) 2.0. Estudio RECoVER.	NON-POST-AUTHORIZATION STUDY	JOSÉ MARÍA REGUERA IGLESIAS	Not applicable
DE-02	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR	INDEPENDENT CLINICAL TRIAL	BEATRIZ SOBRINO DIAZ	IV
DE-02	Ensayo abierto multicéntrico aleatorizado y pragmático de Fase IV para evaluar la eficacia y seguridad de diferentes duraciones de tratamiento antimicrobiano de infecciones asociadas al material de osteosíntesis tras fractura de hueso largo.	INDEPENDENT CLINICAL TRIAL	BEATRIZ SOBRINO DIAZ	III
DE-02	Ensayo clínico aleatorizado, de superioridad, doble ciego, controlado con placebo, en fase ii, para demostrar la eficacia del trasplante de microbiota fecal en la descolonización intestinal selectiva de los pacientes colonizados por Enterobacterias productoras de carbapenemasa tipo KPC u OXA-48	INDEPENDENT CLINICAL TRIAL	JUAN DIEGO RUIZ MESA	II
DE-02	FIS-PSE-2022-01 Estudio prospectivo de las infecciones del torrente sanguíneo por Pseudomonas aeruginosa en pacientes adultos: eficacia y seguridad de diferentes estrategias terapéuticas, en el contexto actual de resistencia a múltiples fármac	COMMERCIAL POST-AUTHORIZATION STUDY	LUCÍA VALIENTE DE SANTIS	Not applicable
DE-02	Ensayo clínico aleatorizado de no inferioridad para evaluar la eficacia y seguridad del tratamiento corto de la bacteriemia enterocócica no complicada. INTENSE	INDEPENDENT CLINICAL TRIAL	ANTONIO PLATA CIEZAR	IV
DE-02	Clínica y Epidemiología del brote de infección por Monkeypox en España en el año 2022. ESTUDIO CEME 22	OBSERVATIONAL STUDIES WITH DRUGS	INES PEREZ CAMACHO	Not applicable
DE-02	Estudio de la función tubular renal y marcadores de remodelado óseo durante el tratamiento prolongado con entecavir y tenofovir en pacientes con infección crónica por el virus de la hepatitis B. Estudio MENTE	OBSERVATIONAL STUDIES WITH DRUGS	ANTONIO PLATA CIEZAR	Not applicable
DE-02	Estudio clínico traslacional en fase II multicéntrico, abierto, aleatorizado, controlado, en canasta y pragmático para determinar la eficacia y seguridad de la plitidepsina frente al control en pacientes adultos inmunodeprimidos con COVID-19 sintomática que necesitan asistencia hospitalaria (NEREIDA)	CLINICAL TRIALS WITH DRUGS	MARCIAL DELGADO FERNÁNDEZ	II
DE-02	CABO-CHANCE: Estudio en vida real sobre el uso de Cabotegravir/Rilpivirina de acción prolongada (CAB/RPV AP) en pacientes pretratados que viven con el VIH (PVVIH).	OBSERVATIONAL STUDIES WITH DRUGS	INES PEREZ CAMACHO	Not applicable
DE-02	Estudio en Fase IV con diseño de prueba negativa para evaluar la eficacia de una vacuna conjugada antineumocócica 20-valente contra la neumonía adquirida en la comunidad causada por serotipos vacunales confirmada radiológicamente en adultos ≥65 años.	CLINICAL TRIALS WITH DRUGS	ANTONIO PLATA CIEZAR	IV
DE-02	Eficacia y seguridad de la perfusión continua vs. perfusión intermitente de ampicilina y ceftriaxona para el tratamiento de endocarditis infecciosa por Enterococcus faecalis (Estudio DOBLEI).	CLINICAL TRIALS WITH DRUGS	ANTONIO PLATA CIEZAR	IV
DE-02	Estudio de fase 3b, abierto, aleatorizado, controlado con tratamiento estándar, multicéntrico, de superioridad para evaluar la eficacia, la seguridad y la tolerabilidad de CAB AP + RPV AP inyectable en participantes virémicos que viven con VIH-1 (CROWN).	CLINICAL TRIALS WITH DRUGS	MANUEL CASTAÑO CARRACEDO	III
DE-07	Tratamiento antiagregante en el síndrome coronario agudo. Seguridad y eficacia del cruce entre antiagregantes.	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE ANDRES ARBOLEDA SANCHEZ	Not applicable

Group	Title	Subtype	LR Name	Phase
DE-07	Tratamiento antiplaquetario en síndromes coronarios agudos. Seguridad y eficacia del cambio de antiplaquetario. Seguridad y eficacia de Tricagrelor VS Clopidogrel en pacientes con síndrome coronario agudo. Antiplatelet treatment in acute coronary syndromes. safety and efficacy of antiplatelet switching. Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients with Acute Coronary Syndrome.	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE ANDRES ARBOLEDA SANCHEZ	Not applicable
DE-07	Estudio exploratorio para evaluar la eficacia y seguridad de la administración en la nutrición de 1,5 g de proteína/kg/día frente a 1,0 g de proteína/kg/día en la fase catabólica del paciente crítico bajo ventilación mecánica.	INDEPENDENT CLINICAL TRIAL	JUAN FRANCISCO MARTINEZ CARMONA	IV
DE-07	Retrospective Analysis of Real-World Use of Cefiderocol in the Management of Gram-Negative Infections as part of the Early Access Program (PERSEUS Study).” // “Análisis retrospectivo del uso en la práctica real de cefiderocol para el tratamiento de infecciones por gramnegativos como parte del programa de acceso precoz (estudio PERSEUS).	OBSERVATIONAL STUDIES WITH DRUGS	CESAR ARAGON GONZALEZ	Not applicable
DE-07	Estudio retrospectivo de revisión de historias clínicas en el que se evalúa la práctica clínica, los patrones de tratamiento y los resultados relacionados con los concentrados de complejo de protrombina de 4 factores (4F-PCC) en pacientes tratados con inhibidores del factor Xa (FXa) antes de una cirugía o un procedimiento invasivo y en aquellos que precisan una neutralización a demanda por una hemorragia grave	OBSERVATIONAL STUDIES WITH DRUGS	MªDOLORES ARIAS VERDU	Not applicable
DE-07	Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)	CLINICAL TRIALS WITH DRUGS	MANUEL ENRIQUE HERRERA GUTIERREZ	IV
DE-08	Duodenopancreatectomía cefálica en tumores de páncreas y periampulares: abordaje inicial de la arteria mesentérica superior versus abordaje clásico. Estudio prospectivo, aleatorizado y multicéntrico.	NON-POST-AUTHORIZATION STUDY	JULIO SANTOYO SANTOYO	Not applicable
DE-08	Estudio Epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España.	NON-POST-AUTHORIZATION STUDY	RAUL VICENTE OLMEDO MARTIN	Not applicable
DE-08	Registro informatizado de pacientes con Patologías Pancreáticas	NON-POST-AUTHORIZATION STUDY	LETICIA MONGIL PONCE	Not applicable
DE-08	Eficacia del cambio de diana terapéutica en práctica clínica tras el fracaso del tratamiento con un primer fármaco antiTNF en la enfermedad de Crohn	INDEPENDENT POST-AUTHORIZATION STUDY	RAUL VICENTE OLMEDO MARTIN	Not applicable
DE-08	DICE INCIDENCE CAPTURE: Determinantes, Incidencia y Consecuencias del Exceso de corticoesteroides en EII	COMMERCIAL POST-AUTHORIZATION STUDY	PATRICIA ROMERO CARA	Not applicable
DE-08	Efectividad y seguridad de Ustekinumab en pacientes Bionaive con enfermedad de Chron moderada-grave refractaria a tratamiento convencional: un estudio retrospectivo observacional multicéntrico	INDEPENDENT POST-AUTHORIZATION STUDY	RAUL VICENTE OLMEDO MARTIN	Not applicable
DE-08	Estudio de fase 4, multicéntrico y observacional para evaluar la seguridad y la tolerabilidad de lenvatinib en pacientes con carcinoma hepatocelular avanzado o irresecable (STELLAR) E7080-M000-508	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL JIMÉNEZ PÉREZ	Not applicable
DE-08	Ensayo ABC-HCC: Ensayo en fase IIIb, aleatorizado, multicéntrico y abierto de atezolizumab más bevacizumab frente a quimioembolización transarterial (QETA) en carcinoma hepatocelular en estadio intermedio	CLINICAL TRIALS WITH DRUGS	MIGUEL JIMÉNEZ PÉREZ	III
DE-08	A Phase 3 Study to Evaluate the Efficacy and Safety of Pegzofermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.	CLINICAL TRIALS WITH DRUGS	MIGUEL JIMÉNEZ PÉREZ	III
DE-08	Proof-of-concept Phase II study to evaluate the efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity and its mechanistic pathways through an integrative analysis: the DILICORT clinical trial.	CLINICAL TRIALS WITH DRUGS	ROCÍO GONZÁLEZ GRANDE	II
DE-08	A Phase 3 Study to Evaluate the Efficacy and Safety of Pegzofermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)	CLINICAL TRIALS WITH DRUGS	MIGUEL JIMÉNEZ PÉREZ	III
DE-08	Registro AIRIS Crohn. Assessing the Impact of RISankizumab on clinical outcomes and biomarkers in Crohns Disease	OBSERVATIONAL STUDIES WITH DRUGS	RAUL VICENTE OLMEDO MARTIN	Not applicable

Group	Title	Subtype	LR Name	Phase
DE-10	Evaluación de una pauta de tratamiento extendida y proactiva en pacientes con degeneración macular asociada a la edad húmeda (DMAEh) sin tratamiento previo [Evaluation of an eXtended and proacTive dosing regimEn in treatment-Naïve patients with wet age-related macular Degeneration (wAMD)]	COMMERCIAL POST-AUTHORIZATION STUDY	ISABEL BAQUERO ARANDA	Not applicable
DE-10	Evaluación prospectiva de la eficacia y la seguridad del tratamiento tópico con hidrocortisona en los signos y síntomas clínicos de la xeroftalmia asociada a una disfunción moderada de las glándulas de Meibomio.	COMMERCIAL CLINICAL TRIAL	YOLANDA FERNANDEZ BARRIENTOS	IV
F-02	Registro clínico de pacientes diagnosticadas con cáncer ginecológico del Grupo Español de Investigación en Cáncer de Ovario (GEICO)	OBSERVATIONAL STUDIES WITH DRUGS	JOSÉ DAVID FERNÁNDEZ RODRÍGUEZ	Not applicable
FA-07	Estudio de extensión de fase III, abierto, para evaluar la seguridad y la eficacia a largo plazo de BMN 111 en pacientes pediátricos con acondroplasia	COMMERCIAL CLINICAL TRIAL	ANTONIO LEIVA GEA	III
FA-07	Ensayo clínico fase III, multicéntrico, aleatorizado, abierto, de comparación del tratamiento con células mesenquimales alogénicas frente a células mesenquimales autólogas y frente a control activo con ácido hialurónico en pacientes con artrosis de rodilla.	INDEPENDENT CLINICAL TRIAL	JUAN MIGUEL GOMEZ PALOMO	III
FA-07	Estudio de fase IIb, multicéntrico, aleatorizado, con doble enmascaramiento y comparativo con placebo, para evaluar la eficacia y la seguridad de un único implante de osteoblastos alogénicos (ALLOB®) en la fractura de tibia	COMMERCIAL CLINICAL TRIAL	ANTONIO LEIVA GEA	II
FA-07	Estudio de fase II, abierto, de escalada y expansión de dosis de Infigratinib, un inhibidor selectivo de la tirosina quinasa de los receptores del factor de crecimiento fibroblástico 1-3 (fgfr 1-3), en niños con acondroplasia: Propel 2.	COMMERCIAL CLINICAL TRIAL	FRANCISCO DE BORJA DELGADO RUFINO	II
FA-07	Estudio de extensión de fase II, abierto, a largo plazo de infigratinib, un inhibidor selectivo de la tirosina quinasa de los receptores del factor de crecimiento fibroblástico 1-3 (FGFR 1-3), en niños con acondroplasia: PROPEL OLE	COMMERCIAL CLINICAL TRIAL	FRANCISCO DE BORJA DELGADO RUFINO	II
FA-07	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3	CLINICAL TRIALS WITH DRUGS	ANTONIO LEIVA GEA	III
FE-18	Eficacia de un programa de rehabilitación cardiaca domiciliario de supervisión mixta mediante chaleco de monitorización modelo NUUBO en pacientes con cardiopatía isquémica de riesgo moderado	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	RAQUEL BRAVO ESCOBAR	Not applicable

ASSOCIATED GROUPS. CLINICAL STUDIES
ACTIVE IN 2024

Group	Title	Subtype	LR Name	Phase
AA-24	Influencia en práctica clínica real de dabigatrán y acenocumorol en la función renal de pacientes diabéticos de edad avanzada con fibrilación auricular no valvular y enfermedad renal crónica leve-moderada. Estudio Dadifarec.	INDEPENDENT POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	Not applicable
AA-24	Estudio de resultados cardiovasculares con semaglutida en pacientes con diabetes tipo 2	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	III
AA-24	Estudio ALCALOTIC: La ALCALOSis MeTabólica en la Insuficiencia Cardíaca descompensada: prevalencia e influencia en el pronóstico	NON-POST-AUTHORIZATION STUDY	JESUS OLMEDO LLANES	Not applicable
AA-24	Estudio de fase 3, aleatorizado, enmascarado para el observador y comparado con producto activo, para evaluar la seguridad y la eficacia de mRNA-1010, una vacuna experimental frente a la gripe estacional en adultos de 50 o más años.	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	III
AA-24	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisiran en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1)	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	III
AA-24	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	OBSERVATIONAL STUDIES WITH DRUGS	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	Not applicable
AA-24	Seguridad cardiovascular de 2,4 mg de cagrilintida s.c. en combinación con 2,4 mg de semaglutida s.c. (CagriSema 2,4 mg/2,4 mg s.c.) una vez a la semana en participantes con obesidad y enfermedad cardiovascular establecida	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	III
BA-14	Estudio Fase II, aleatorizado, para evaluar la incidencia de discontinuación debida a Diarrea en los 3 primeros ciclos de tratamiento en pacientes con Cáncer de Mama Precoz HER2 positivo (HER2+), Receptor Hormonal positivo (RH+), tratados con Neratinib más Loperamida versus Neratinib con escalada inicial de dosis más Loperamida (según necesidad) versus Neratinib más Loperamida más Colesevelam. “Estudio DIANER”	CLINICAL TRIALS WITH DRUGS	IRENE ZARCOS PEDRINACI	II
BA-14	Estudio fase II de un solo brazo la eficacia y la seguridad de la combinación de trastuzumab, TUCAtinib y viNorelbina en pacientes con cáncer de mama localmente avanzado no resecable o metastásico HER2-positivo. Estudio TrasTUCAN	CLINICAL TRIALS WITH DRUGS	IRENE ZARCOS PEDRINACI	II
BA-14	Estudio ambispectivo de pacientes con cáncer de mama triple negativo tratados con sacituzumab govitecan en el sur de España.	OBSERVATIONAL STUDIES WITH DRUGS	IRENE ZARCOS PEDRINACI	Not applicable
CA-14	Sustitución de Dolutegravir por Raltegravir 1200 mg QD en pacientes infectados con VIH que desarrollan síntomas neuropsiquiátricos tras iniciar triple terapia. Estudio clínico piloto.	INDEPENDENT CLINICAL TRIAL	XAVIER PEREZ STACHOWSKI	IV
CA-14	Ensayo clínico piloto, multicéntrico, para comparar la eficacia de RAL 1200 QD vs DRV-cb (800-150) QD ambos en combinación con TAF/FTC en pacientes con infección VIH y CD4<200 cel/microL	INDEPENDENT CLINICAL TRIAL	XAVIER PEREZ STACHOWSKI	IV
CA-14	Ensayo abierto multicéntrico aleatorizado y pragmático de Fase III para evaluar la eficacia y seguridad de diferentes duraciones de tratamiento antimicrobiano de infecciones asociadas al material de osteosíntesis tras fractura de hueso largo (DURATION).	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	III
CA-14	Ensayo clínico aleatorizado de no inferioridad para evaluar la eficacia y seguridad del tratamiento corto de la bacteriemia enterocócica no complicada. INTENSE	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	IV
CA-14	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR.	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	IV

Group	Title	Subtype	LR Name	Phase
CA-14	Estudio Fase I/II observador ciego, aleatorizado, internacional y controlado con placebo para evaluar la reactogenicidad, seguridad, respuesta inmune y eficacia de la vacuna frente al virus Herpes simplex (VHS) en sujetos sanos de 18 a 40 años o en pacientes de 18 a 60 años con herpes genital recurrente por VHS tipo 2.	INDEPENDENT CLINICAL TRIAL	JULIAN OLALLA SIERRA	II
CA-14	Ensayo clínico fase IV, aleatorizado, multicéntrico y doble ciego diseñado para evaluar la seguridad y la conveniencia del cambio de Dolutegravir/Lamivudina por Bictegravir/Emtricitabina/Tenofovir alafenamida en personas con VIH, buen control virológico y vulnerabilidades neuropsiquiátricas: Estudio MIND	INDEPENDENT CLINICAL TRIAL	JULIAN OLALLA SIERRA	IV
CA-14	Estudio ambispectivo y multicéntrico a largo plazo en práctica clínica habitual con semaglutida en pacientes con diabetes tipo 2 en España. Estudio SEMA-RWE	OBSERVATIONAL STUDIES WITH DRUGS	MARIA DOLORES GARCIA DE LUCAS	Not applicable
CA-14	Estudio FaseIIb, aleatorizado, con grupo control activo, parcialmente cegado, de búsqueda de dosis de GSK3640254 en comparación con un brazo control de dolutegravir, cada uno en combinación con inhibidores de la transcriptasa inversa análogos de nucleósidos, en adultos infectados con VIH-1 que no han recibido tratamiento antirretroviral previo.	CLINICAL TRIALS WITH DRUGS	JULIAN OLALLA SIERRA	II
CA-14	Estudio descriptivo, prospectivo, multinacional y multicéntrico para evaluar las variables relacionadas con la enfermedad genital causada por el virus herpes simple tipo 2 (VHS-2) según los resultados obtenidos a partir de cuestionarios de salud y muestras anogenitales realizados por pacientes = 18 años de edad en Estados Unidos y Europa mediante un proceso descentralizado	OBSERVATIONAL STUDIES WITH DRUGS	JULIAN OLALLA SIERRA	Not applicable
CA-14	Estudio de fase 2b, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de EDP-938 en adultos no hospitalizados con infección aguda por el virus respiratorio sincitial que tienen un riesgo alto de complicaciones.	CLINICAL TRIALS WITH DRUGS	JULIAN OLALLA SIERRA	II
CA-14	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de bemnifosbuvir en pacientes ambulatorios de alto riesgo con COVID-19	CLINICAL TRIALS WITH DRUGS	JULIAN OLALLA SIERRA	III
CA-14	DTG / 3TC frente a BIC / FTC / TAF como terapia de mantenimiento en personas que viven con VIH: ensayo clínico abierto y aleatorizado	CLINICAL TRIALS WITH DRUGS	XAVIER PEREZ STACHOWSKI	IV
CA-14	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisiran en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1 PREVENT).	CLINICAL TRIALS WITH DRUGS	JULIAN OLALLA SIERRA	III
CA-14	CABO-CHANCE: Estudio en vida real sobre el uso de Cabotegravir/Rilpivirine de acción prolongada (CAB/RPV AP) en pacientes pretratados que viven con el VIH (PVVIH).	OBSERVATIONAL STUDIES WITH DRUGS	JULIAN OLALLA SIERRA	Not applicable
CA-14	Estudio en fase II, de grupos paralelos, doble ciego y con tres grupos de tratamiento, para evaluar la eficacia y la seguridad de finerenona más empagliflozina en comparación con finerenona o empagliflozina en participantes con enfermedad renal crónica y diabetes tipo 2	CLINICAL TRIALS WITH DRUGS	Mª VICTORIA NÚÑEZ RODRÍGUEZ	II
CA-14	Implementation of Out-of-Hospital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infected patients from Spain. Acceptability, appropriateness, feasibility and satisfaction .. The HOLA Study	CLINICAL TRIALS WITH DRUGS	JULIAN OLALLA SIERRA	IV
CA-14	Estudio de fase IIIb, abierto, multicéntrico, aleatorizado, de grupos paralelos y de no inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad de la combinación de dolutegravir/lamivudina administrada por vía oral una vez al día como tratamiento de primera línea, en comparación con la combinación de bictegravir/emtricitabina/tenofovir alafenamida administrada por vía oral una vez al día, para la inhibición y el mantenimiento virológico en adultos con VIH sin tratamiento antirretroviral previo.	CLINICAL TRIALS WITH DRUGS	JULIAN OLALLA SIERRA	III
CA-14	Seguridad de edoxabán en pacientes con fibrilación auricular no valvular (FANV) y diabetes mellitus tipo 2 (DM2)	OBSERVATIONAL STUDIES WITH DRUGS	MARIA DOLORES GARCIA DE LUCAS	Not applicable
CA-19	Registro informatizado de la enfermedad tromboembólica (RIETE)	NON-POST-AUTHORIZATION STUDY	MONICA LORING CAFFARENA	Not applicable

ASSOCIATED GROUPS. PATENTS:

APPLICATION FOR INTERNATIONAL PATENT EXTENSIONS			
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES THROUGH THE BIOELECTRIC EFFECT	EP23815357.1	12/27/2024	FA-16

PATENT APPLICATIONS GRANTED 2020–2024		
TITLE	APPLICATION No.	GROUP IBIMA
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES THROUGH THE BIOELECTRIC EFFECT	P202230480	FA-16

